

There are 2347 publications

1 Phase III Randomized Study Of Sorafenib Plus Doxorubicin Versus Sorafenib In Patients With Advanced Hepatocellular Carcinoma (HCC)- CALGB 80802 (Alliance)

Ghassan K. Abou-Alfa, Donna Niedzwieski, Jennifer J. Knox, Andreas Kaubisch, James Posey, Benjam R. Tan Jr., Peter Kavan, Rakesh Goel, John J. Murray, Tanios S. Bekaii-Saab, Vincent Channing Tam, Lakshmi Rajde, Robin Kate Kelley, Abby Siegel, Jennifer Balletti, James J. Harding, Lawrence Howard Schartz, Richard M. Goldberg, Monica M. Bertagnolli, Alan P. Venook J Clin Oncol vol 34 (4s) abstr 192 2016
Abstract GI <http://meetinglibrary.asco.org/content/159480-173>

2 Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma

Ghassan K. Abou-Alfa, Qian Shi, Jennifer J. Knox, Andreas Kaubisch, Donna Niedzwiecki, James Posey, Benjamin R. Tan Jr., Petr Kavan, Rakesh Goel, Philip E. Lammers, Tanios S. Bekaii-Saab, Vincent C. Tam, Lakshmi Rajdev, Robin K. Kelley, Imane El Dika, Tyler Zemla, Ryan I. Potaracke, Jennifer Balletti, Anthony B. El-Khoueiry, James H. Harding, Jennifer M. Suga, Lawrence H. Schwartz, Richard M. Goldberg, Monica M. Bertagnolli, Jeffrey Meyerhardt, Eileen M. O'Reilly, Alan P. Venook JAMA Oncol vol 5 (11) 1582-8 2019
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/31486832>

3 Platelet count at baseline (Plt) and outcomes in patients (pts) with advanced hepatocellular carcinoma (HCC) treated with sorafenib (S) in CALGB 80802 (Alliance) (C8)

Ghassan K. Abou-Alfa, Qian Shi, Jennifer J. Knox, Andreas Kaubisch, James Posey, Benjamin R. Tan Jr., Petr Kavan, Rakesh Goel, Philip Lammers, Tanios S. Bekaii-Saab, Vincent C. Tam, Lakshmi Rajdev, Robin Kate Kelley, Abby Siegel, Tyler Zemla, Imane El Dika, Alan P. Venook, Monica M. Bertagnolli, Jeffrey Meyerhardt, Eileen M. O'Reilly J Clin Oncol vol 36 (15_suppl) e16107 2018
Abstract GI http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.e16107

4 Randomized Phase II/III Study of DA-EPOCH-R +/- Venetoclax in Previously Untreated Double Hit Lymphoma: Initial Results from Alliance A051701

Jeremy S. Abramson, Amy S. Ruppert, Sharmila Giri, Ann Hudson, Eric Hsi, Richard Little, Steven Gore, Anusha Vallurupalli, Daniel Landsburg, Brad Kahl, Jonathan Friedberg, Nancy L. Bartlett, John P. Leonard Blood vol 138 (Supplement 1) 523 2021
Abstract Lymphoma
<https://ashpublications.org/blood/article/138/Supplement%201/523/479349/Randomized-Phase-II-III-Stu>

5 A phase II second-line study of pemetrexed (pem) in combination with bevacizumab (bev) in patients with advanced non-small cell lung cancer (NSCLC): An NCCTG and SWOG study.

A. A. Adjei, S. J. Mandrekar, G. K. Dy, J. R. Molina, D. R. Gandara, K. L. Allen Ziegler, P. J. Stella, K. M. Rowland Jr, S. E. Schild, R. G. Zinner J Clin Oncol vol 26 (15s) abstr 8080 2008
Abstract Respiratory
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID

6 Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426

A. A. Adjei, S. J. Mandrekar, G. K. Dy, J. R. Molina, D. R. Gandara, K. L. Ziegler, P. J. Stella, K. M. Rowland Jr, S. E. Schild, R. G. Zinner J Clin Oncol vol 28 (4) 614-619 2010
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/19841321>

7 A front-line window of opportunity phase II study of sorafenib in patients with advanced non-small cell lung cancer.

A. A. Adjei, J. R. Molina, S. L. Hillman, R. F. Luyun, N. F. Reuter, K. M. Rowland Jr, J. R. Jett, S. J. Mandrekar, S. E. Schild J Clin Oncol vol 25 (18s) 396s abstr 7547 2007
Abstract Respiratory http://meeting.ascopubs.org/cgi/content/abstract/25/18_suppl/7547

8 Correlation between polymorphisms in the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer (NSCLC): An NCCTG N0026 based study. Abstract 198.

A. Adjei, O. Salavaggione, S. Mandrekar, G. Dy, K. Allen-Ziegler, C. Endo, J. Molina, S. Schild
2009
Abstract Respiratory

9 Genetic Predictors of Chemotherapy-Induced Peripheral Neuropathy from Paclitaxel, Carboplatin and Oxalipatin: NCCTG/Alliance N08C1, N08CA and N08CB Study

Araba A. Adjei, Camden L. Lopez, Daniel J. Schaid, Jeff A. Sloan, Jennifer G. Le-Rademacher, Charles L. Loprinzi, Aaron D. Norman, Janet E. Olson, Fergus J. Couch, Andreas S. Beutler, Celine M. Vachon, Kathryn J. Ruddy Cancers (Basel) vol 13 (5) 1084 2021
Manuscript Symptom Inter NCCTG-N08C1, NCCTG-N08CA, NCCTG-N08CB
<http://www.ncbi.nlm.nih.gov/pubmed/33802509>

10 Correlation between polymorphisms of the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer: a North Central Cancer Treatment Group-based exploratory study.

Araba A Adjei, Oreste E Salavaggione, Sumithra J Mandrekar, Grace K Dy, Katie L Allen Ziegler, Chiaki Endo, Julian R Molina, Steven E Schild, Alex A Adjei J Thorac Oncol vol 5 (9) 1346-53
2010
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/20651609>

11 Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia

Anjali S. Advani, Eric Larsen, Kristina Laumann, Selina M. Luger, Michaela Liedtke, Meenakshi Devidas, Zhiguo Chen, Jun Yin, Matthew C. Foster, David Claxton, Kristin Coffan, Martin S. Tallman, Frederick R. Appelbaum, Harry Erba, Richard M. Stone, Stephen P. Hunger, Jennifer L. McNeer, Mignon L. Loh, Elizabeth Raetz, Naomi Winick, William Carroll, Richard A. Larson, Wendy Stock Blood Adv vol 5 (2) 504-12 2021
Manuscript Leukemia COG-AALL0232 <http://www.ncbi.nlm.nih.gov/pubmed/33496745>

12 Frontline-Treatment Of Acute Lymphoblastic Leukemia (ALL) In Older Adolescents and Young Adults (AYA) Using a Pediatric Regimen Is Feasible: Toxicity Results of the Prospective US Intergroup Trial C10403 (Alliance)

Anjali S. Advani, Ben Sanford, Selina Luger, Meenakshi Devidas, Eric C. Larsen, Michaela Liedtke, Peter M. Voorhees, Matthew C. Foster, David F. Claxton, Susan Geyer, Edy Parker, Kristin Coffan, William L. Carroll, Naomi J. Winick, Steven E. Coutre, Martin S. Tallman, Frederick R. Appelbaum, Harry Paul Erba, Richard M. Stone, Stephen P. Hunger, Richard A. Larson, Wendy Stock Blood vol 122 (21) Abstract 3903 2013
Abstract Leukemia <http://bloodjournal.hematologylibrary.org/content/122/21/3903.abstract>

13 Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial

Pooja P. Advani, Karla V. Ballman, Travis J. Dockter, Gerardo Colon-Otero, Edith A. Perez J Clin Oncol vol 34 (6) 581-587 2016
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/26392097>

14 Long-term cardiac safety analysis of NCCTG (Alliance) N9831 adjuvant trastuzumab (H) trial.

Pooja Prem Advani, Karla V. Ballman, Travis J. Dockter, Gerardo Colon-Otero, Edith A. Perez J Clin

Oncol vol 32 (5s) (suppl; abstr 603) 2014

Abstract Breast http://abstracts.asco.org/144/AbstView_144_128009.html

15 Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E-IPI).

Ranjana H Advani, Haiyan Chen, Thomas M Habermann, Vicki A Morrison, Edie A Weller, Richard I Fisher, Bruce A Peterson, Randy D Gascoyne, Sandra J Horning Br J Haematol vol 151 (2) 143-51 2010

Manuscript Older Adult <http://www.ncbi.nlm.nih.gov/pubmed/20735398>

16 A phase 3 study of androgen annihilation in high-risk biochemically relapsed prostate cancer: an Alliance Foundation trial (AFT-19)

Rahul Aggarwal, Scott Eggener, Ronald Chen, Glenn Heller, Akash Patnaik, Han Xiao, Douglas Weckstein, James Mohler, Mark Watson, Mary-Ellen Taplin, Linda Skoog-Sluman, Meryl Pereji, Eunice Aikins-Afful, John Kellogg Parsons, Charles J. Ryan, Michael M. Morris J Clin Oncol vol 36 (15_suppl) abstr TPS5090 2018

Abstract GU http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.TPS5090

17 The Effect of Prior Androgen Synthesis Inhibition on Outcomes of Subsequent Therapy with Docetaxel in Patients with Metastatic Castrate Resistant Prostate Cancer: Results from a Retrospective Analysis of a Randomized Phase 3 Clinical Trial (CALGB 90401) (Alliance)

Rahul Aggarwal, Susan Halabi, William Kevin Kelly, Daniel George, John F. Mahoney, Frederick Millard, Walter M. Stadler, Michael J. Morris, Philip Kantoff, J. Paul Monk, Michael Carducci, Eric J. Small Cancer vol 119 (20) 3636-3643 2013

Manuscript GU <http://www.ncbi.nlm.nih.gov/pubmed/23913744>

18 Baseline Characteristics Associated with PSA Progression-Free Survival in Patients (pts) with High-Risk Biochemically Relapsed Prostate Cancer: Results from the Phase 3 PRESTO study (AFT-19)

Rahul Aggarwal, Glenn Heller, David Hillman, Han Xiao, Joel Picus, Mary-Ellen Taplin, Tanya Dorff, Leonard Appleman, Douglas Weckstein, Akash Patnaik, Alan Bryce, Daniel Shevrin, James Mohler, Daniel Anderson, Arpit Rao, Scott Tagawa, Alan Tan, Scott E. Eggener, Charles J. Ryan, Michael J. Morris J Clin Oncol vol 41 (6) 208 2023

Abstract GU https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.6_suppl.208?af=R

19 PRESTO: A Phase 3, Open-Label Study of Androgen Annihilation in Patients with High-Risk, Biochemically Relapsed Prostate Cancer (AFT-19)

Rahul Aggarwal, Glenn Heller, David Hillman, Han Xiao, Joel Picus, Jennifer Wang, Mary-Ellen Taplin, Tanya Dorff, Leonard Appleman, Douglas Weckstein, Akash Patnaik, Alan Bryce, Daniel Shevrin, James Mohler, Daniel Anderson, Arpit Rao, Scott Tagawa, Alan Tan, Scott E. Eggener, Michael J. Morris Ann Oncol vol 33 (57) abstr LBA63 2022

Abstract GU [https://www.annalsofncology.org/article/S0923-7534\(22\)03944-8/pdf](https://www.annalsofncology.org/article/S0923-7534(22)03944-8/pdf)

20 Performance of standard prognostic models in older patients with previously untreated chronic lymphocytic leukemia: a post hoc analysis of Alliance A041202 phase 3 trial

Inhye E. Ahn, Amy S. Ruppert, Adrian Wiestner, James Blachly, John C. Byrd, Richard M. Stone, Sumithra Mandrekar, Jennifer A. Woyach Blood vol 138 (Supplement 1) 2642 2021

Abstract Leukemia

<https://ashpublications.org/blood/article/138/Supplement%201/2642/478589/Performance-of-Standard-P>

21 A good prognosis of endocrine-dependent tumors among residual invasive cancer after anti-HER2 therapy: CALGB 40601 (Alliance) and validation studies

Sung Gwe Ahn, Aranzazu Fernandez-Martinez, Aleix Prat, Soong June Bae, Núria Chic, Fara Brasó-Maristany, Benedetta Conte, Seho Park, Valentina Guarneri, Maria Vittoria Dieci, Gaia Griguolo, PierFranco Conte, Joon Jeong, Lisa A Carey, Charles M. Perou *Cancer Res* vol 81 (4 Supplement) PS10-02 2020
Abstract Correl Sci NOS https://cancerres.aacrjournals.org/content/81/4_Supplement/PS10-02.short

22 Comparative analysis of outcomes in African American (AA) and white (W) patients (pts) with multiple myeloma (MM) treated with lenalidomide (LEN) or pomalidomide (POM)

Sikander Ailawadhi, Philip L. McCarthy, Sarah A. Holstein, Gail Larkins, Weiyuan Chung, Shankar Srinivasan, Amit Agarwal, Sagar Lonial *J Clin Oncol* vol 36 (Suppl) abstr 8050 2018
Abstract Transplant CALGB-100104, ECOG-E4A03, MM-002, MM-009
<https://meetinglibrary.asco.org/record/160715/abstract>

23 Management of Recurrent Prostate Cancer after Radiotherapy: Long-term results from CALGB 9687, a Contemporary Prospective Multi-institutional Salvage Prostatectomy Series

A Al-Daghmin, MH Sokoloff, S Halabi, BL Sanford, JA Eastham, PJ Walther, EJ Small, JL Mohler *J Urol* vol 191 (4s) e767, PD27-09 2014
Abstract GU <http://www.jurology.com/article/S0022-5347%2814%2902367-2/abstract>

24 Comparative Age-Based Prospective Multi-Institutional Observations from 12,367 Patients Enrolled to American College of Surgeons Oncology Group (ACOSOG Z901101) Trials (Alliance)

Waddah B. Al-Refaie, Paul A. Decker, Karla V. Ballman, Peter W.T. Pisters, Mitchell C. Posner, Kelly K. Hunt, Bryan Meyers, Armin D. Weinberg, Heidi Nelson, Lisa Newman, Angelina Tan, Jennifer Le-Rademacher, Arti Hurria, Aminah Jatoi *Ann Surg Oncol* vol 26 (13) 4213-21 2019
Manuscript Older Adult <http://www.ncbi.nlm.nih.gov/pubmed/31605327>

25 Attributes and Outcomes of Older Adults in Surgical Oncology Trials: Results from ACOSOG Z901101 (Alliance)

Waddah B. Al-Refaie, Paul A. Decker, Peter W.T. Pisters, Mitch Posner, Kelly K. Hunt, Bryan Meyers, Armin Weinberg, Heidi Nelson, Lisa Newman, Karla V. Ballman *Ann Surg Oncol* vol 22 (Suppl 1) 80 2015
Abstract Older Adult
<http://www.surgonc.orghttp://link.springer.com/article/10.1245%2Fs10434-015-4372-z>

26 Expression and polymorphism (rs4880) of mitochondrial superoxide dismutase (SOD2) and asparaginase induced hepatotoxicity in adult patients with acute lymphoblastic leukemia

Houda Alachkar, Noreen Fulton, Ben Sanford, Greg Malnassy, Martin Mutonga, Richard A. Larson, Clara D. Bloomfield, Guido Marcucci, Yusuke Nakamura, Wendy Stock *Pharmacogenomics J* vol 17 (3) 274-279 2017
Manuscript Leuk Corr Sci <http://www.ncbi.nlm.nih.gov/pubmed/27019981>

27 SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome

Houda Alachkar, Ramasamy Santhanam, Kati Maharry, Klaus H. Metzeler, Xiaomeng Huang, Jessica Kohlschmidt, Jason H. Mendler, Juliana M. Benito, Christopher Hickey, Paolo Neviani, Adrienne M. Dorrance, Mirela Anghelina, Jihane Khalife, Somayeh S. Tarighat, Stefano Volinia, Susan P. Whitman, Peter Paschka, Pia Hoellerbauer, Yue-Zhong Wu, Lina Han, Brad N. Bolon, William Blum, Krzysztof Mrózek, Andrew J. Carroll, Danilo Perrotti, Michael Andreeff, Michael A. Caligiuri, Marina Konopleva, Ramiro Garzon, Clara D. Bloomfield, Guido Marcucci *J Clin Invest* vol 124 (4) 1512-1524 2014
Manuscript Leuk Corr Sci CALGB-19808, CALGB-9621
<http://www.ncbi.nlm.nih.gov/pubmed/24590286>

28 Cisplatin-associated neuropathy characteristics compared to those associated with other

neurotoxic chemotherapy agents (Alliance A151724)

Costantine Albany, Travis Dockter, Eric Wolfe, Jennifer Le-Rademacher, Nina Wagner-Johnston, Lawrence Einhorn, Jackie Lafky, Ellen Smith, Deirdre Pachman, Nathan Staff, Cynthia Ma, Charles L. Loprinzi, Brian A. Costello Support Care Cancer vol 29 (2) 833-40 2021
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/32500206>

29 Efficacy and toxicity of cetuximab (C225) plus mFOLOFX6 in patients (pts) with nonoptimally resectable, colorectal metastases (MCRC) confined to the liver

S. R. Alberts, J. H. Donohue, M. R. Mahoney, G. D. Nelson, P. O. Schwarzenberger, J. W. Kugler, R. F. Morton, P. J. Flynn J Clin Oncol vol 26 (15s) abstr 15006 2008

Abstract GI

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID

30 NCCTG phase II trial (N044J) of AZD2171 for patients with hepatocellular carcinoma (HCC)--interim review of toxicity

S. R. Alberts, B. W. Morlan, G. P. Kim, H. C. Pitot, F. J. Quevedo, S. R. Dakhil, H. M. Gross, J. R. Merchan, L. R. Roberts Gastrointestinal Cancers Symposium abstr 186 2007

Abstract GI

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=45&abstractID

31 Adjuvant mFOLFOX6 +/- Cetuximab in KRAS Wild Type Patients With Resected Stage III Colon Cancer: NCCTG Intergroup Phase III Trial N0147.

S. R. Alberts, D. J. Sargent, T. C. Smyrk, A. F. Shields, E. Chan, R. M. Goldberg, S. Gill, M. S. Kahlenberg, S. N. Thibodeau, S. Nair J Clin Oncol vol 28 (18s) abstr CRA3507 2010

Abstract GI

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID

32 Influence of KRAS and BRAF mutational status and rash on disease-free survival (DFS) in patients with resected stage III colon cancer receiving cetuximab (Cmab): Results from NCCTG N0147.

S. R. Alberts, S. N. Thibodeau, D. J. Sargent, M. R. Mahoney, F. Sinicrope, A. F. Shields, E. Chan, R. M. Goldberg, S. Gill, M. S. Kahlenberg, J. T. Quesenberry, T. C. Smyrk, A. Grothey, S. G. Nair J Clin Oncol vol 29 (15s) abstr 3607 2011

Abstract Correl Sci NOS

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID

33 Systemic capecitabine and oxaliplatin administered with hepatic arterial infusion (HAI) of floxuridine (FUDR) following complete resection of colorectal metastases (M-CRC) confined to the liver.

S. Alberts, M. R. Mahoney, J. H. Donohue, M. S. Roh, E. M. Green, D. J. Sargent, L. D. Wagman, J. S. Bolton J Clin Oncol vol 25 (18s) abstr 4057 2007

Abstract GI

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID

34 Randomized phase II trial of extended versus standard neoadjuvant therapy for esophageal cancer, NCCTG (Alliance) trial N0849

S. Alberts, G. Soori, Q. Shi, D. Wigle, R. Sticca, R. Miller, J. Leenstra, P. Peller, T. Wu, H. Yoon, T. Drevyanko, S. Ko, B. Mattar, D. Nikcevich, R. Behrens, M. Khalil, G. Kim J Clin Oncol vol 31 (15 suppl) abstr 4026 2013

Abstract GI <http://meetinglibrary.asco.org/content/111984-132>

35 Cediranib (AZD2171) in Patients with Advanced Hepatocellular Carcinoma: A Phase II North Central Cancer Treatment Group (NCCTG) Clinical Trial

Steven R. Alberts, Tom R. Fitch, George P. Kim, Bruce W. Morlan, Shaker R. Dakhil, Howard M. Gross, Suresh Nair *Am J Clin Oncol* vol 35 (4) 329-333 2012
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/21422991>

36 Gemcitabine and Doxorubicin for Hepatocellular Carcinoma: A Phase II North Central Cancer Treatment Group (NCCTG) Clinical Trial

Steven R. Alberts, Joel M. Reid, Bruce W. Morlan, Gist H. Farr, John K. Camoriano, David B. Johnson, James R. Egner, Thomas E. Seay, George P. Kim *Am J Clin Oncol* vol 35 (5) 418-423 2012
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/21555932>

37 Alternating Systemic and Hepatic Artery Infusion Therapy for Resected Liver Metastases From Colorectal Cancer: A North Central Cancer Treatment Group (NCCTG)/ National Surgical Adjuvant Breast and Bowel Project (NSABP) Phase II Intergroup Trial, N9945/CI-66

Steven R. Alberts, Mark S. Roh, Michelle R. Mahoney, Michael J. O'Connell, David M. Nagorney, Lawrence Wagman, Thomas C. Smyrk, Timothy L. Weiland, Lily Lau Lai, Roderich E. Schwarz, Roy Molina, Todor Dentchev, John S. Bolton *J Clin Oncol* vol 28 (5) 853-858 2010
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/20048179>

38 Effect of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Cetuximab on Survival Among Patients With Resected Stage III Colon Cancer

Steven R. Alberts, Daniel J. Sargent, Suresh Nair, Michelle R. Mahoney, Margaret Mooney, Stephen N. Thibodeau, Thomas C. Smyrk, Frank A. Sinicrope, Emily Chan, Sharlene Gill, Morton S. Kahlenberg, Anthony F. Shields, James T. Quesenberry, Thomas A. Webb, Gist H. Farr, Barbara A. Pockaj, Axel Grothey, Richard M. Goldberg *JAMA* vol 307 (13) 1383-1393 2012
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/22474202>

39 Pemetrexed and gemcitabine for biliary tract and gallbladder carcinomas: a North Central Cancer Treatment Group (NCCTG) phase I and II Trial, N9943.

Steven R. Alberts, Jonathan R. Sande, Nathan R. Foster, Fernando J. Quevedo, Robert R. McWilliams, John W. Kugler, Tom R. Fitch, Anthony J. Jaslowski *J Gastrointest Cancer* vol 38 (2-4) 87-94 2007
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/19023677>

40 Use of KW-2189, a DNA minor groove-binding agent, in patients with hepatocellular carcinoma: a north central cancer treatment group (NCCTG) phase II clinical trial.

Steven R. Alberts, Vera J. Suman, Henry C. Pitot, John K. Camoriano, Joseph Rubin *J Gastrointest Cancer* vol 38 (1) 10-4 2007
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/19065716>

41 The impact of early PEG-asparaginase discontinuation in young adults with ALL: a post hoc analysis of the CALGB 10403 study

Ibrahim Aldoss, Jun Yin, Anna Wall, Krzysztof Mrózek, Michaela Liedtke, David F. Claxton, Matthew C. Foster, Frederick R. Appelbaum, Harry P. Erba, Mark R. Litzow, Martin S. Tallman, Richard M. Stone, Richard A. Larson, Anjali S. Advani, Wendy Stock, Selina M. Luger *Blood Adv* vol 7 (2) 196-204 2022
Manuscript Leukemia <http://www.ncbi.nlm.nih.gov/pubmed/36269846>

42 Computed tomography densitometry and morphology of radiofrequency ablated Stage IA non-small cell lung cancer: Results from the American College of Surgeons Oncology Group Z4033 (Alliance) trial

Erica S. Alexander, Lillian Xiong, Grayson L. Baird, Hiran Fernando, Damian E. Dupuy *J Vasc Interv Radiol* vol 31 (2) 286-93 2020
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/31902554>

- 43 Exercise and Dietary Change after Diagnosis and Cancer-related Symptoms in Long-term Survivors of Breast Cancer: CALGB 79804**
Catherine M. Alfano, Jeannette M. Day, Mira L. Katz, James E. Herndon, Marisa A. Bittoni, Jill M. Oliveri, Kathleen Donohue, Electra D. Paskett *Psycho-Oncol* vol 18 (2) 128-133 2009
Manuscript *Health Outcomes* <http://www.ncbi.nlm.nih.gov/pubmed/18536022>
- 44 Defining Priorities in Value-Based Cancer Care: Insights From the Alliance for Clinical Trials in Oncology National Cooperative Group Survey.**
Casey J Allen, Rebecca A Snyder, Danae Marie Horn, Matthew F Hudson, Anne Barber, Fabrice Smieliauskas, Patty A Spears, Stephen Edge, Rachel A Greenup *JCO Oncol Pract* OP2300159 2023
Manuscript *CCDR* <http://www.ncbi.nlm.nih.gov/pubmed/37651652>
- 45 ACOSOG Z0030 Study Group: Number of lymph nodes harvested from a mediastinal lymphadenectomy: results of the randomized, prospective ACOSOG Z0030 trial**
M. S. Allen, G. E. Darling, P. A. Decker, J. B. Putnam Jr, R. A. Malthaner, R. I. Inculet, D. R. Jones, R. J. Mckenna Jr, R. J. Landreneau, A. Z. S. Group *J Clin Oncol* vol 25 (18S) abstr 7555 2007
Abstract *Respiratory* http://meeting.ascopubs.org/cgi/content/short/25/18_suppl/7555
- 46 Perioperative mortality and Morbidity after Lobar versus Sublobar Resection for early stage lung cancer: A post-hoc analysis of an international randomized phase III trial (CALGB/Alliance 140503)**
Nasser K. Altorki, Xiaofei Wang, Dennis Wigle, Lin Gu, Gail Darling, Ahmad S Ashrafi, Rodney Landreneau, Daniel Miller, Moishe Liberman, David R Jones, Robert Keenan, Massimo Conti, Gavin Wright, Linda J Veit, Suresh S. Ramalingam, Mohamed Kamel, Harvey I. Pass, John D. Mitchell, Thomas Stinchcombe, Everett Vokes, Leslie J Kohman *Lancet Respir Med* vol 6 (12) 915-924 2018
Abstract *Respiratory* <http://www.ncbi.nlm.nih.gov/pubmed/30442588>
- 47 Perioperative mortality and Morbidity after Lobar versus Sublobar Resection for early stage lung cancer: A post-hoc analysis of an international randomized phase III trial (CALGB/Alliance 140503)**
Nasser K. Altorki, Xiaofei Wang, Dennis Wigle, Lin Gu, Gail Darling, Ahmad S Ashrafi, Rodney Landreneau, Daniel Miller, Moishe Liberman, David R Jones, Robert Keenan, Massimo Conti, Gavin Wright, Linda J Veit, Suresh S. Ramalingam, Mohamed Kamel, Harvey I. Pass, John D. Mitchell, Thomas Stinchcombe, Everett Vokes, Leslie J Kohman *Lancet Respir Med* vol 6 (12) 915-24 2018
Manuscript *Respiratory* <http://www.ncbi.nlm.nih.gov/pubmed/30442588>
- 48 CALGB 140503: Is it time to turn the page on LCSG 821?**
Nasser K Altorki, Oliver S Chow *J Thorac Cardiovasc Surg* 2023
Manuscript *Respiratory* <http://www.ncbi.nlm.nih.gov/pubmed/37597739>
- 49 Lobar or sub-lobar resection for peripheral clinical stage IA 2 cm non-small cell lung cancer (NSCLC): Results from an international randomized phase III trial (CALGB 140503 [Alliance])**
Nasser K Altorki, Xiaofei Wang, David Kozono, Colleen Watt, Rodney Landreneau, Dennis Wigle, Jeffrey Port, David R Jones, Robert Keenan, Thomas Bauer, Leslie J Kohman, Thomas Stinchcombe, Everett Vokes *Volume 17* vol 9 (Supplement) S1-S-2 2022
Abstract *Respiratory* [https://www.jto.org/article/S1556-0864\(22\)00353-7/fulltext](https://www.jto.org/article/S1556-0864(22)00353-7/fulltext)
- 50 Lobectomy, segmentectomy or wedge resection for peripheral clinical T1aN0 non-small cell lung cancer: a post-hoc analysis of CALGB 140503 (Alliance).**
Nasser Altorki, Xiaofei Wang, Bryce Damman, Jennifer Mentlick, Rodney Landreneau, Dennis Wigle, David R Jones, Massimo Conti, Ahmad S Ashrafi, Moishe Liberman, Marc de Perrot, John D Mitchell, Robert Keenan, Thomas Bauer, Daniel Miller, Thomas E Stinchcombe *J Thorac Cardiovasc Surg*

2023

Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/37473998>

51 Lobar or Sublobar Resection for Peripheral Stage IA Non–Small-Cell Lung Cancer

Nasser Altorki, Xiaofei Wang, David Kozono, Colleen Watt, Rodney Landrenau, Dennis Wigle, Jeffrey Port, David R. Jones, Massimo Conti, Ahmad S. Ashrafi, Moishe Liberman, Kazuhiro Yasufuku, Stephen Yang, John D. Mitchell, Harvey Pass, Robert Keenan, Thomas Bauer, Daniel Miller, Leslie J. Kohman, Thomas E. Stinchcombe, Everett Vokes *N Engl J Med* vol 388 (6) 489-98 2023

Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/36780674>

52 Par-4 Down-regulation Promotes Breast Cancer Recurrence by Preventing Multinucleation following Targeted Therapy

James V. Alvarez, Tien-chi Pan, Jason Ruth, Yi Feng, Alice Zhou, Dhruv Pant, Joshua S. Grimley, Thomas J. Wandless, Angela DeMichele, Lewis A. Chodosh *Cancer Cell* vol 24 (1) 2013

Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/23770012>

53 Clinical Utility of Metrics Based on Tumor Measurements in Phase II Trials to Predict Overall Survival Outcomes in Phase III Trials by Using Resampling Methods

Ming-Wen An, Yu Han, Jeffrey P. Meyers, Jan Bogaerts, Daniel J. Sargent, Sumithra J. Mandrekar *J Clin Oncol* vol 33 (34) 4048-4057 2015

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/26503199>

54 Exploring the statistical and clinical impact of two interim analyses on the phase II design with option for direct assignment

Ming-Wen An, Sumithra J. Mandrekar, Martin J. Edelman, Daniel J. Sargent *Contemp Clin Trials* vol 38 (2) 157-162 2014

Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/24768938>

55 Missing tumor measurement (TM) data in the search for alternative TM-based endpoints in cancer clinical trials

Ming-Wen An, Jun Tang, Axel Grothey, Daniel J. Sargent, Fang-Shu Ou, Sumithra J. Mandrekar *Contemp Clin Trials Commun* vol 17 100492 2020

Manuscript GI NCCTG-N0026, NCCTG-N9741 <http://www.ncbi.nlm.nih.gov/pubmed/31872158>

56 Molecular and Clinical Features of FLT3 Juxtamembrane Domain Point Mutations in Acute Myeloid Leukemia (AML) (Alliance

Nadeen Anabtawi, Jessica Kohlschmidt, Daelynn R. Buelow, Shelley J. Orwick, Kennedy Coleman, Krzysztof Mrózek, Jonathan E. Koliz, Bayard L. Powell, William G. Blum, Maria R. Baer, John C. Byrd, Wendy Stock, Geoffrey Uy, Ann-Kathrin Eisfeld, Sharyn D. Baker, James S. Blachly *Blood* vol 140 (suppl 1) 6244–6 2022

Abstract *Leuk Corr Sci* CALGB-20202, CALGB-8461, CALGB-9665

<https://ashpublications.org/blood/article/140/Supplement%201/6244/489271/Molecular-and-Clinical-Fea>

57 Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in High-Risk Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): a Subgroup Analysis of GRIFFIN (AFT-29)

Larry D. Anderson Jr., Jonathan L. Kaufman, Jacob Laubach, Douglas W. Sborov, Brandi Reeves, Cesar Rodriguez, Ajai Chari, Rebecca Silbermann, Luciano J. Costa, Nitya Nathwani, Nina Shah, Naresh Bumma, Sarah A. Holstein, Caitlin Costello, Andrzej Jakubowiak, Tanya M. Wildes, Robert Z. Orlowski, Kenneth H. Shain, Andrew J. Cowan, Huiling Pei, Annelore Cortoos, Sharmila Patel, Blake Bartlett, Jessica Vermeulen, Thomas S. Lin, Peter M. Voorhees, Paul G. Richardson *Blood* vol 138 (Supplement 1) 2723 2021

58 Single nucleotide polymorphisms (SNPs) and circulating endothelial cells (CECs) as outcome predictors in recurrent glioblastoma (rGBM) patients (pts) treated with bevacizumab (BEV) and sorafenib (SOR).

S. K. Anderson, J. M. Lafky, X. W. Carrero, T. K. Kimlinger, T. M. Halling, S. Kumar, P. J. Flynn, H. M. Gross, K. A. Jaeckle, J. C. Buckner J Clin Oncol vol 29 (15s) abstr 2019 2011

Abstract Neuro-Onc <http://meetinglibrary.asco.org/content/83751-102>

59 Validating RNAseq-Signatures of Vorinostat (VOR) Sensitivity and Resistance in Patients with Newly Diagnosed Glioblastoma (GBM) Treated with VOR, Temozolomide and Radiation Therapy From Alliance N0874/ABTC-0902.

S. Keith Anderson, C. Ryan Miller, Jann N. Sarkaria, Kurt A. Jaeckle, Jan C. Buckner, Keith L. Ligon, Karla V. Ballman, Dennis F. Moore Jr., Manmeet S. Ahluwalia, Eudocia Quant Lee, Elise Hovarth, Elizabeth Gerstner, Glenn J. Lesser, Michael Prados, Stuart A. Grossman, Caterina Giannini, Patrick Y. Wen, Evanthia Galanis J Clin Oncol vol 34 (suppl) abstr 2029 2016

Abstract Neuro-Onc ABTC-0902 <http://meetinglibrary.asco.org/content/164476-176>

60 Outcomes following adjuvant treatment (AT) for colon cancer (CC) 1978-1995 versus 1996-2007: Impact on recurrence rate, time from recurrence to death (TRD), and overall survival (OS) -- Findings from the ACCENT dataset.

T. Andre, Q. Shi, G. Yothers, B. Bot, D. Haller, E. Van Cutsem, J. Cassidy, J. Benedetti, M. O'Connell, D. Sargent J Clin Oncol vol 28 (15s) abstr 3616 2010

Abstract GI

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID

61 Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials

Thierry André, Jeffrey Meyerhardt, Timothy Iveson, Alberto Sobrero, Takayuki Yoshino, Ioannis Souglakos, Axel Grothey, Donna Niedzwiecki, Mark Saunders, Roberto Labianca, Takeharu

Yamanaka, Ioannis Boukovinas, Dewi Vernerey, Jeffrey Meyers, Andrea Harkin, Valter Torri, Eiji Oki, Vassilis Georgoulas, Julien Taieb, Anthony Shields, Qian Shi Lancet Oncol vol 21 (12) 1620-9 2020

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/33271092>

62 Phase II clinical trial of denileukin diftitox in combination with rituximab in previously untreated follicular B-cell non-Hodgkins lymphoma

S. M. Ansell, H. Tang, G. S. Nowakowski, D. A. Nikcevich, G. D. Nelson, C. E. Erlichman, T. E. Witzig 53rd ASH Annual Meeting and Exposition vol 116 abstr 2862 2010

Abstract Lymphoma <https://ash.confex.com/ash/2010/webprogram/Paper31618.html>

63 Low-Dose, Single-Agent Temsirolimus for Relapsed Mantle Cell Lymphoma

Stephen M. Ansell, David J. Inwards, Kendrith M. Rowland, Patrick J. Flynn, Roscoe F. Morton, Dennis F. Moore, Scott H. Kaufmann, Irene Ghobrial, Paul J. Kurtin, Matthew Maurer, Christine Allmer, Thomas E. Witzig Cancer vol 113 (3) 508-514 2008

Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/18543327>

64 Serum BLYS levels increase after rituximab as initial therapy in patients with follicular grade 1 non-Hodgkin lymphoma

Stephen M. Ansell, Anne J. Novak, Steven Ziesmer, Tammy Price-Troska, Betsy LaPlant, Stacey R. Dillon, Thomas E. Witzig Am J Hematol vol 84 (2) 71-73 2009

Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/19051265>

- 65 Temsirolimus and Rituximab in Patients with Relapsed or Refractory Mantle Cell Lymphoma: a multi-center Phase 2 Study**
Stephen M. Ansell, Hui Tang, Paul J. Kurtin, Patricia A. Koenig, David J. Inwards, Keith Shah, Steven C. Ziesmer, Andrew L. Feldman, Radha Rao, Mamta Gupta, Charles Erlichman, Thomas E. Witzig
Lancet Oncol vol 12 (4) 361-368 2011
Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/21440503>
- 66 Denileukin Diftitox in Combination with Rituximab for Previously Untreated Follicular B-cell Non-Hodgkin's Lymphoma**
Stephen M. Ansell, Hui Tang, Paul J. Kurtin, Patricia A. Koenig, Grzegorz S. Nowakowski, Daniel A. Nikcevich, Garth D. Nelson, Zhizhang Yang, Deanna M. Grote, Steven C. Ziesmer, Peter T. Silberstein, Charles Erlichman, Thomas E. Witzig
Leukemia vol 26 (5) 1046-1052 2012
Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/22015775>
- 67 Immune Checkpoint Profiles in Luminal B Breast Cancer (Alliance).**
Meenakshi Anurag, Mayanne Zhu, Chen Huang, Suhas Vasaikar, Junkai Wang, Jeremy Hoog, Samantha Burugu, Dongxia Gao, Vera Suman, Xiang H Zhang, Bing Zhang, Torsten Nielsen, Matthew J Ellis
J Natl Cancer Inst vol 112 (7) 737-46 2020
Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/31665365>
- 68 Effect of Vitamin D Supplementation on Breast Cancer Biomarkers: CALGB 70806 (Alliance) Study Design and Baseline Data**
Ogheneruona Apoe, Sin-Ho Jung, Heshan Liu, Drew K Seisler, Jayne Charlamb, Patricia Zekan, Lili X. Wang, Gary W. Unzeitig, Judy Garber, James Marshall, Marie Wood
Am J Hematol Oncol vol 12 (7) 4-9 2016
Manuscript Prevention <http://www.ncbi.nlm.nih.gov/pubmed/29081880>
- 69 Prognostic Model for Predicting Survival of Patients With Metastatic Urothelial Cancer Treated With Cisplatin-Based Chemotherapy**
Andrea B. Apolo, Irina Ostrovnaya, Susan Halabi, Alexia Iasonos, George K. Philips, Jonathan E. Rosenberg, Jamie Riches, Eric J. Small, Matthew I. Milowsky, Dean F. Bajorin
J Natl Cancer Inst vol 105 (7) 499-503 2013
Manuscript GU <http://www.ncbi.nlm.nih.gov/pubmed/23411591>
- 70 External validation of prognostic models for overall survival (OS) in patients (pts) with advanced cancer (UC) treated with cisplatin-based chemotherapy.**
Andrea Borghese Apolo, George Philips, Irina Ostrovnaya, Jonathan E. Rosenberg, Matthew I. Milowsky, Eric Jay Small, Dean F. Bajorin, Susan Halabi
J Clin Oncol vol 30 (15 suppl) abstr 4592 2012
Abstract GU
http://meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/4592?sid=b6130d1e-7db1-4a8a-b70c-2d7e
- 71 Alliance A031501: Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (MIBC) (AMBASSADOR) vs Observation**
Andrea Apolo, Jonathan Rosenberg, Michael Morris, Karla Ballman, Bishoy Faltas, Ronald Chen, Marissa Mallek, Colleen Watt, William Kim, Sandy Srinivasan, Guru Sonpavde
J Clin Oncol vol 37 (suppl 7S) abstr TPS504 2019
Abstract GU <https://meetinglibrary.asco.org/record/169792/abstract>
- 72 Surgical practice patterns following NCCTG N0338 Phase II trial of docetaxel and darboplatin administered every two weeks as induction therapy for stage II and stage III breast cancer.**

H. Apsey, V. Roy, B. Pockaj, D. Northfelt, R. Sticca, D. A. Nikcevich, B. Mattar, T. Fitch, E. A. Perez
J Clin Oncol vol 27 (15s) abstr 623 2009

Abstract Breast

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID

73 Molecular characteristics and clinical outcomes of patients with Neurofibromin 1-altered metastatic colorectal cancer

Hiroyuki Arai, Andrew Elliott, Joshua Millstein, Joanne Xiu, Fang-Shu Ou, Federico Innocenti, Jingyuan Wang, Francesca Battaglin, Priya Jayachandran, Natsuko Kawanishi, Shivani Soni, Wu Zhang, Davendra Sohal, Richard M. Goldberg, Michael J. Hall, Aaron J Scott, Mohd Khushman, Jimmy J. Hwang, Emil Lou, Benjamin A. Weinberg, Albert Craig Lockhart, Anthony Frank Shields, Jim P. Abraham, Daniel Magee, Phillip Stafford, Jian Zhang, Alan P Venook, W. Michael Korn, Heinz-Josef Lenz Oncogene vol 41 (2) 260-7 2022

Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/34728807>

74 Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer (mCRC) (Alliance)

Hiroyuki Arai, Yan Yang, Joshua Millstein, Tadamichi Denda, Fang-Shu Ou, Federico Innocenti, Hiroyuki Takeda, Ayako Doi, Yoshiki Horie, Kumiko Umemoto, Naoki Izawa, Jingyuan Wang, Francesca Battaglin, Natsuko Kawanishi, Priya Jayachandran, Shivani Soni, Wu Zhang, Alan P Venook, Yu Sunakawa, Heinz-Josef Lenz J Clin Oncol vol 40 (16_suppl) 3586-3586 2022

Abstract PPP CALGB-80405 https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.3586

75 Regularized Mixture Cure Models Identify a Gene Signature that Improves Risk Stratification Within the Favorable-Risk Group in 2017 European LeukemiaNet (ELN) Classification of Acute Myeloid Leukemia (Alliance)

Kellie J. Archer, Han Fu, Krzysztof Mrózek, Deedra Nicolet, Alice S. Mims, Geoffrey L. Uy, Wendy Stock, John C. Byrd, Ann-Kathrin Eisfeld Blood vol 140 (suppl 1) 1913-4 2022

Abstract Leuk Corr Sci CALGB-8721, CALGB-10503, CALGB-10603, CALGB-20202, CALGB-19808, CALGB-8461, CALGB-8525, CALGB-9222, CALGB-9621

<https://ashpublications.org/blood/article/140/Supplement%201/1913/490207/Regularized-Mixture-Cure->

76 Lymphedema symptoms and limb measurement changes in breast cancer survivors treated with neoadjuvant chemotherapy and axillary dissection: Results of ACOSOG (American College Of Surgeons Oncology Group) Z1071 (Alliance) Substudy

Jane M. Armer, Karla V. Ballman, Linda McCall, Nathan C. Armer, Yuanlu Sun, Tipparat Udmuangpia, Kelly K. Hunt, Elizabeth A. Mittendorf, David R. Byrd, Thomas B. Julian, Judy C. Boughey Support Care Cancer vol 27 (2) 495-503 2019

Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/29980907>

77 Factors Associated With Lymphedema in Women With Node-Positive Breast Cancer Treated With Neoadjuvant Chemotherapy and Axillary Dissection

Jane M. Armer, Karla V. Ballman, Linda McCall, Pamela L. Ostby, Eris Zagar, Henry M. Kuerer, Kelly K. Hunt, Judy C. Boughey JAMA Surg vol 154 (9) 800-9 2019

Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/31314062>

78 Lymphedema results of Alliance Z1071 (American College of Surgeons Oncology Group [ACOSOG]): Self-reported symptoms and limb volume changes for breast cancer survivors treated with neoadjuvant chemotherapy and axillary dissection

Jane M. Armer, Karla Ballman, Linda McCall, Vera Suman, Yuanlu Sun, Tipparat Udmuangpia, Kelly K. Hunt, Elizabeth A. Mittendorf, David R. Byrd, Thomas B. Julian, Judy C. Boughey 2018

Abstract Breast

- 79 Symptoms and limb changes for breast cancer survivors treated with neoadjuvant chemotherapy: Lymphedema results of ACOSOG Z1071 (Alliance)**
Jane M. Armer, Karla Ballman, Linda McCall, Vera Suman, Yuanlu Sun, Tipparat Udmuangpia, Elizabeth Mittendorf, Kelly K. Hunt, David R. Bryd, Thomas Julian, Judy C. Boughey Supportive Cancer Care vol 25 (Supplement 2) pp S128-S129 (eP179) 2017
Abstract Breast <https://link.springer.com/content/pdf/10.1007%2Fs00520-017-3704-x.pdf>
- 80 Effects of a lymphedema prevention intervention on range of motion among women receiving axillary node dissection for breast cancer treatment (Alliance) CALGB 70305**
Jane M Armer, Heshan Liu, Jill Oliveri, Drew Seisler, tbd, Jennifer Le-Rademacher, Jeffrey Sloan, Electra D Paskett J Clin Oncol vol 36 (15_suppl) 123-123 2018
Abstract Symptom Inter https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.7_suppl.123
- 81 Healthy Eating Index Scores are Associated with Inflammatory Markers in Breast Cancer Survivors**
Kristen Arnold, Rebecca Andridge, Amanda Logan, Lisa Yee, Maryam Lustberg, Tonya Orchard FASEB J vol 29 (1 supplement) LB267 2015
Abstract Symptom Inter
http://www.fasebj.org/gca?gca=fasebj%3B29%2F1_Supplement%2FLB267&allch=&submit=Go#abstr-
- 82 Challenges and Gaps in Clinical Trial Genomic Data Management**
Sarah Asad, Kathryn Kananen, Kurt R. Mueller, W. Fraser Symmans, Yujia Wen, Charles M. Perou, James S. Blachly, James Chen, Benjamin G. Vincent, Daniel G. Stover JCO Clin Cancer Inform vol 6 (1) e2100193 2022
Manuscript Translational Bioinformatics <http://www.ncbi.nlm.nih.gov/pubmed/35404674>
- 83 Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-line treatment of metastatic colorectal cancer.**
Amanda C Ashley, Daniel J Sargent, Steven R Alberts, Axel Grothey, Megan E Campbell, Roscoe F Morton, Charles S Fuchs, Ramesh K Ramanathan, Stephen K Williamson, Brian P Findlay, Henry C Pitot, Richard M Goldberg Cancer vol 110 (3) 670-7 2007
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/17559146>
- 84 Using the Skindex-16 and CTCAE to assess rash symptoms: Results of a pooled-analysis (N0993).**
P. Atherton, K. Burger, C. Loprinzi, R. Miller, A. Jatoi, J. Sloan J Clin Oncol vol 28 (15s) abstr 9015 2010
Abstract Symptom Inter
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID
- 85 Using the Skindex-16 and Common Terminology Criteria for Adverse Events to assess rash symptoms: results of a pooled-analysis (N0993)**
Pamela J. Atherton, Kelli N. Burger, Charles L. Loprinzi, Michelle A. Neben Wittich, Robert C. Miller, Aminah Jatoi, Jeff A. Sloan Support Care Cancer vol 20 (8) 1729-1735 2012
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/21922203>
- 86 Assessment of Patient-Reported Measures of Bowel Function Before and After Pelvic Radiotherapy: An Ancillary Study of the North Central Cancer Treatment Group Study N00CA**
Pamela J. Atherton, Michele Y. Halyard, Jeff A. Sloan, Robert C. Miller, Richard L. Deming, T. H. Patricia Tai, Kathy J. Stien, James A. Martenson Support Care Cancer vol 21 (4) 1193-1199 2013
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/23151649>
- 87 The Complementary Nature of Patient-Reported Outcomes (PROs) and Adverse Event Reporting in Cooperative Group Oncology Clinical Trials: A Pooled Analysis (NCCTG N0591)**

Pamela J. Atherton, Deborah W. Watkins-Bruner, Carolyn Gotay, Carol M. Moinpour, Daniel V. Satele, Kathryn A. Winter, Paul L. Schaefer, Benjamin Movsas, Jeff A. Sloan J Pain Symptom Manage vol 50 (4) 470-479.e9 2015
Manuscript Health Outcomes <http://www.ncbi.nlm.nih.gov/pubmed/26031708>

88 Patient Reported Outcomes Questionnaire Compliance in Cancer Cooperative Group Trials (Alliance N0992)

Pamela J Atherton, Kelli N Burger, Levi D Pederson, Suneetha Kaggal, Jeff A Sloan Clin Trials vol 13 (6) 612-620 2016
Manuscript Health Outcomes <http://www.ncbi.nlm.nih.gov/pubmed/27365012>

89 Clinician vs Patient Reporting of Baseline and Postbaseline Symptoms for Adverse Event Assessment in Cancer Clinical Trials

Thomas M. Atkinson, Amylou C. Dueck, Daniel V. Satele, Gita Thanarajasingam, Jacqueline M. Lafky, Jeff A. Sloan, Ethan Basch JAMA Oncol vol 6 (3) 437-9 2020
Manuscript Health Outcomes <http://www.ncbi.nlm.nih.gov/pubmed/31876902>

90 Measurement of Affective and Activity Pain Interference Using the Brief Pain Inventory (BPI): Cancer and Leukemia Group B 70903

Thomas M. Atkinson, Susan Halabi, Antonia V. Bennett, Lauren Rogak, Laura Sit, Yuelin Li, Ellen Kaplan, Ethan Basch Pain Med vol 13 (11) 1417-1424 2012
Manuscript Health Outcomes <http://www.ncbi.nlm.nih.gov/pubmed/23110676>

91 Comparison Between Clinician- and Patient-Reporting of Baseline (BL) and Post-BL Symptomatic Toxicities in Cancer Cooperative Group Clinical Trials (NCCTG N0591 [Alliance])

Thomas M. Atkinson, Daniel V. Satele, Jeff A. Sloan, Diana Mehedint, Jackie M. Lafky, Ethan Basch, Amylou C. Dueck J Clin Oncol vol 33 (suppl) abstr 9520 2015
Abstract Health Outcomes <http://meetinglibrary.asco.org/content/150688-156>

92 Lenalidomide (LEN) maintenance (MNTC) after high-dose melphalan and autologous stem cell transplant (ASCT) in multiple myeloma (MM): A meta-analysis (MA) of overall survival (OS) CALGB 100104 (Alliance)

Michel Attal, Antonio Palumbo, Sarah Holstein, Valérie Lauwers-Cances, Maria Teresa Petrucci, Paul Richardson, Cyrille Hulin, Patrizia Tosi, Kenneth C Anderson, Denis Caillot, Valeria Magarotto, Phillip Moreau, Zhinuan Yu, Philip L. McCarthy J Clin Oncol vol 34 (suppl) abstr 8001 2016
Abstract Myeloma http://abstract.asco.org/176/AbstView_176_168948.html

93 Phase II Study of Bortezomib Added to Standard Daunorubicin and Cytarabine Induction and Dose Escalation of Bortezomib with Intermediate-Dose Cytarabine Consolidation Therapy for Patients with Previously Untreated Acute Myeloid Leukemia Age 60–75 Years: Cancer and Leukemia Group B (CALGB) Study 10502

E. C. Attar, K. A. Donohue, P. C. Amrein, M. Wadleigh, D. J. Deangelo, J. E. Kolitz, B. L. Powell, P. M. Voorhees, E. S. Wang, W. Blum, A. Booth, R. M. Stone, B. K. Moser, R. Larson Blood vol 116 (abstr 331) 2010
Abstract Leukemia
<http://abstracts.hematologylibrary.org/cgi/content/abstract/116/21/331?maxtoshow=&hits=10&RESULT>

94 A phase II study of bortezomib added to standard daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine (Int-DAC) for consolidation in patients with previously untreated acute myeloid leukemia (AML) age 60-75 years: CALGB study 10502.

E. C. Attar, J. L. Johnson, P. C. Amrein, G. Lozanski, M. Wadleigh, D. J. Deangelo, J. E. Kolitz, B. L. Powell, P. M. Voorhees, E. S. Wang, W. G. Blum, G. Marcucci, C. D. Bloomfield, B. K. Moser, R. M. Stone, R. A. Larson J Clin Oncol vol 30 (suppl) abstr 6526 2012

95 Increased Expression of Macrophage Migration Inhibitory Factor (MIF) Receptor CD74 Is Associated with Inferior Outcome in Younger Patients (Pts) with Cytogenetically Normal Acute Myeloid Leukemia (CN-AML): a Cancer and Leukemia Group B (CALGB) Study

E. C. Attar, K. Maharry, K. Mrozek, M. D. Radmacher, S. P. Whitman, P. Paschka, C. Langer, K. B. Holland, B. L. Powell, J. E. Kolitz, A. J. Carroll, R. A. Larson, G. Marcucci, C. D. Bloomfield *Blood* vol 114 (22) 645-646 2009

Abstract *Leuk Corr Sci* CALGB-10502, CALGB-20202, CALGB-20502, CALGB-8461
<http://www.bloodjournal.org/content/114/22/1616>

96 Bortezomib Added to Daunorubicin and Cytarabine During Induction Therapy and to Intermediate-Dose Cytarabine for Consolidation in Patients With Previously Untreated Acute Myeloid Leukemia Age 60 to 75 Years: CALGB (Alliance) Study 10502

Eyal C. Attar, Jeffrey L. Johnson, Philip C. Amrein, Gerard Lozanski, Martha Wadleigh, Daniel J. DeAngelo, Jonathan E. Kolitz, Bayard L. Powell, Peter Voorhees, Eunice S. Wang, William Blum, Richard M. Stone, Guido Marcucci, Clara D. Bloomfield, Barry Moser, Richard A. Larson *J Clin Oncol* vol 31 (7) 923-929 2013

Manuscript *Leukemia* <http://www.ncbi.nlm.nih.gov/pubmed/23129738>

97 Small Cell Lung Cancer Exhibits Frequent Inactivating Mutations in the Histone Methyltransferase KMT2D/MLL2: CALGB 151111 (Alliance)

Arnaud Augert, Qing Zhang, Breanna Bates, Min Cui, Xiaofei Wang, Gary Wildey, Afshin Dowlati, David MacPherson *J Thorac Oncol* vol 12 (4) 704-13 2017

Manuscript *Correl Sci NOS* <http://www.ncbi.nlm.nih.gov/pubmed/28007623>

98 Cytarabine, daunorubicin and etoposide (ADE) chemotherapy in acute myeloid leukemia (AML) patients >= 60 years (CALGB 9720)

M. R. Baer, S. L. George, B. L. Sanford, S. M. Bothun, K. Mrozek, K. L. O'Loughlin, J. E. Kolitz, J. O. Moore, R. M. Stone, B. L. Powell, M. A. Caligiuri, C. D. Bloomfield, R. A. Larson *Blood* vol 110 (11) 94A-94A 2007

Abstract *Leukemia* CALGB-8461, CALGB-9720

<http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;110/11/296>

99 Treatment of older patients with de novo acute myeloid leukemia (AML) with one or more postremission chemotherapy courses: Analysis of four CALGB studies

M. R. Baer, S. L. George, B. L. Sanford, R. M. Stone, G. Marcucci, R. J. Mayer, R. A. Larson *J Clin Oncol* vol 28 (15s) abstr 6531 2010

Abstract *Leukemia* CALGB-8525, CALGB-10201, CALGB-8923, CALGB-9720

http://ascopubs.org/doi/abs/10.1200/jco.2010.28.15_suppl.6531

100 Cancer and Leukemia Group B studies of recombinant Interleukin-2 maintenance therapy in acute myeloid leukemia

M. R. Baer, J. E. Kolitz, S. L. George, M. A. Caligiuri, R. A. Larson *Ann Hematol* vol 87 (Supplement 1) S28-S29 2008

Abstract *Leukemia* <http://link.springer.com/content/pdf/10.1007%2Fs00277-008-0443-6>

101 Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720

MR Baer, SL George, BL Sanford, K Mrózek, JE Kolitz, JO Moore, RM Stone, BL Powell, MA Caligiuri, CD Bloomfield, RA Larson *Leukemia* vol 25 (5) 2011

Manuscript *Leukemia* <http://www.ncbi.nlm.nih.gov/pubmed/21321569>

102 Low-Dose Interleukin-2 Immunotherapy Does Not Improve Outcome of Patients Age 60 Years and Older With Acute Myeloid Leukemia in First Complete Remission: Cancer and Leukemia Group B Study 9720

Maria R. Baer, Stephen L. George, Michael A. Caligiuri, Ben L. Sanford, Sandra M. Bothun, Krzysztof Mrózek, Jonathan E. Kolitz, Bayard L. Powell, Joseph O. Moore, Richard M. Stone, John Anastasi, Clara D. Bloomfield, Richard A. Larson J Clin Oncol vol 26 (30) 4934-4939 2008
Manuscript Leukemia CALGB-8461, CALGB-9720
<http://www.ncbi.nlm.nih.gov/pubmed/18591543>

103 Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720

Maria R. Baer, Stephen L. George, Michael A. Caligiuri, Ben L. Sanford, Sandra M. Bothun, Krzysztof Mrózek, Jonathan E. Kolitz, Bayard L. Powell, Joseph R. Moore, Richard M. Stone, John Anastasi, Clara D. Bloomfield, Richard A. Larson J Clin Oncol vol 26 (30) 4934-4939 2008
Abstract Leukemia CALGB-10201, CALGB-10502, CALGB-10503, CALGB-10603, CALGB-19808, CALGB-8525, CALGB-8923, CALGB-9022, CALGB-9222, CALGB-9420, CALGB-9621, CALGB-9720 <http://jco.ascopubs.org/content/26/30/4934.abstract>

104 Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study—CALGB 30607 (Alliance)

Maria Q. Bagstrom, Mark A. Socinski, Xiaofei F. Wang, Lin Gu, Thomas E. Stinchcombe, Martin J. Edelman, Sherman Baker JR, Josephine Feliciano, Paul Novotny, Olwen Hahn, Jeffrey A. Crawford, Everett E. Vokes J Thorac Oncol vol 12 (5) 843-849 2017
Manuscript Respiratory CALGB-70701 <http://www.ncbi.nlm.nih.gov/pubmed/28161554>

105 Arsenic trioxide in recurrent urothelial cancer: a cancer and leukemia group B phase II trial (CALGB 99903).

Dean F Bajorin, Susan Halabi, Eric Small Clin Genitourin Cancer vol 7 (3) E66-70 2009
Manuscript GU <http://www.ncbi.nlm.nih.gov/pubmed/19815484>

106 A Genome-Wide Association Study Identifies Novel Loci for Paclitaxel-Induced Sensory Peripheral Neuropathy in CALGB 40101

R. Michael Baldwin, Kouros Owzar, Hitoshi Zembutsu, Aparna Chhibber, Michiaki Kubo, Chen Jiang, Dorothy Watson, Rachel J. Eclov, Joel Mefford, Howard L. McLeod, Paula N. Friedman, Clifford A. Hudis, Eric P. Winer, Eric M. Jorgenson, John S. Witte, Lawrence N. Shulman, Yusuke Nakamura, Mark J. Ratain, Deanna L. Kroetz Clin Cancer Res vol 18 (18) 5099-5109 2012
Manuscript PPP <http://www.ncbi.nlm.nih.gov/pubmed/22843789>

107 The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme

Karla V. Ballman, Jan C. Buckner, Paul D. Brown, Caterina Giannini, Patrick J. Flynn, Betsy R. LaPlant, Kurt A. Jaeckle Neuro-oncol vol 9 (1) 29-38 2007
Manuscript Neuro-Onc <http://www.ncbi.nlm.nih.gov/pubmed/17108063>

108 Transcriptional analysis of metastatic uveal melanoma survival nominates NRP1 as a therapeutic target

Riyue Bao, Oliver Surriga, Daniel J. Olson, Jacob B. Allred, Carrie A. Strand, Yuanyuan Zha, Timothy Carll, Brian W. Labadie, Bruno R. Bastos, Marcus Butler, David Hogg, Elgilda Musi, Grazia Ambrosini, Pamela Munster, Gary K. Schwartz, Jason J. Luke Melanoma Res vol 31 (1) 27-37 2021
Manuscript Experimental <http://www.ncbi.nlm.nih.gov/pubmed/33170593>

- 109 Adjuvant chemotherapy for resected stage II and III colon cancer: Comparison of widely used two prognostic calculators**
A. Bardia, C. Loprinzi, A. Grothey, G. Nelson, S. Alberts, S. Patiyil, S. Thome, S. Gill, D. Sargent J Clin Oncol vol 27 (15S) e15031 2009
Abstract GI
<http://jco.ascopubs.org/gca?allch=&submit=Go&gca=ascomtg%3B27%2F15S%2Fe15031>
- 110 Adjuvant Chemotherapy for Resected Stage II and III Colon Cancer: Comparison of Two Widely Used Prognostic Calculators**
Aditya Bardia, Charles Loprinzi, Axel Grothey, Garth Nelson, Steven Alberts, Smitha Menon, Stephan Thome, Sharlene Gill, Dan Sargent Semin Oncol vol 37 (1) 39-46 2010
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/20172363>
- 111 Age and the Risk of Paclitaxel-Induced Neuropathy in Women with Early-Stage Breast Cancer (Alliance A151411): Results from 1,881 Patients from Cancer and Leukemia Group B (CALGB) 40101**
Myra Barginear, Amylou C. Dueck, Jacob B. Allred, Craig Bunnell, Harvey J. Cohen, Rachel A. Freedman, Arti Hurria, Gretchen Kimmick, Jennifer G. LeRademacher, Stuart Lichtman, Hyman B. Muss, Lawrence N. Shulman, M. Sitiki Copur, David Biggs, Bhuvanewari Ramaswamy, Jacqueline M. Lafky, Aminah Jatoi Oncologist vol 24 (5) 617-23 2019
Manuscript Older Adult CALGB-40101, CALGB-70301
<http://www.ncbi.nlm.nih.gov/pubmed/30409792>
- 112 Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804.**
N L Bartlett, D Niedzwiecki, J L Johnson, J W Friedberg, K B Johnson, K van Besien, A D Zelenetz, B D Cheson, G P Canellos Ann Oncol vol 18 (6) 1071-9 2007
Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/17426059>
- 113 A phase I/II study of gemcitabine, vinorelbine, and liposomal doxorubicin for relapsed Hodgkin's disease: Preliminary results of CALGB 59804**
N. Bartlett, D. Niedzwiecki, J. Johnson, J. W. Friedberg, A. D. Zelenetz, G. P. Canellos Proc Am Soc Clin Oncol vol 22 abstr 2275 2003
Abstract Lymphoma
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=23&abstractID
- 114 Phase II Study of 9-aminocamptothecin in Previously Treated Lymphomas: Results of Cancer and Leukemia Group B 9551**
Nancy L. Bartlett, Jeffrey L. Johnson, Nina Wagner-Johnston, Mark J. Ratain, Bruce A. Peterson Cancer Chemother Pharmacol vol 63 (5) 793-798 2009
Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/18648813>
- 115 Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303**
Nancy L. Bartlett, Wyndham H. Wilson, Sin-Ho Jung, Eric D. Hsi, Matthew J. Maurer, Levi D. Pederson, Mei-Yin C. Polley, Brandelyn N. Pitcher, Bruce D. Cheson, Brad S. Kahl, Jonathan W. Friedberg, Louis M. Staudt, Nina D. Wagner-Johnston, Kristie A. Blum, Jeremy S. Abramson, Nishitha M. Reddy, Jane N. Winter, Julie E. Chang, Ajay K. Gopal, Amy Chadburn, Susan Mathew, Richard I. Fisher, Kristy L. Richards, Heiko Schöder, Andrew D. Zelenetz, John P. Leonard J Clin Oncol vol 37 (21) 1790-9 2019
Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/30939090>
- 116 The use of Valeriana officinalis (Valerian) in improving sleep in patients who are undergoing**

treatment for cancer: a phase III randomized, placebo-controlled, double-blind study (NCCTG Trial, N01C5)

D. L. Barton, P. J. Atherton, B. A. Bauer, D. F. Moore Jr, B. I. Mattar, B. I. Lavoiseur, K. M. Rowland Jr, R. T. Zon, N. A. Lelindqwister, G. G. Nagargoje, T. I. Morgenthaler, J. A. Sloan, C. L. Loprinzi J Support Oncol vol 9 (1) 24-31 2011
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/21399726>

117 Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9

D. L. Barton, B. I. Lavoiseur, J. A. Sloan, A. N. Stawis, K. A. Flynn, M. Dyar, D. B. Johnson, P. J. Atherton, B. Diekmann, C. L. Loprinzi J Clin Oncol vol 28 (20) 3278-3283 2010
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/20498389>

118 A phase III trial evaluating three doses of citalopram for hot flashes: NCCTG trial N05C9

D. L. Barton, B. Lavoiseur, J. A. Sloan, P. J. Stella, K. Flynn, M. Dyar, S. R. Dakhil, P. J. Atherton, B. Diekmann J Clin Oncol vol 26 (May 20 supplement) abstr 9538 2008
Abstract Symptom Inter
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID

119 Phase III evaluation of American ginseng (panax quinquefolius) to improve cancer-related fatigue: NCCTG trial N07C2

D. L. Barton, H. Liu, S. R. Dakhil, B. M. Linqvist, J. A. Sloan, C. R. Nichols, T. W. Mcginn, E. P. Balcueva, G. R. Seeger, C. L. Loprinzi J Clin Oncol vol 30 (15 supplement) abstr 9001, Oral Abstract Session, Patient and Survivor Care 2012
Abstract Symptom Inter
http://meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/3514?sid=0055954a-dce9-4db0-b477-d76e

120 Wisconsin ginseng (Panax quinquefolius) to improve cancer-related fatigue: A randomized, double-blind trial, N07C2

D. L. Barton, H. Liu, S. R. Dakhil, B. Linqvist, J. A. Sloan, C. R. Nichols, T. W. Mcginn, P. J. Stella, G. R. Seeger, A. Sood, C. L. Loprinzi J Natl Cancer Inst vol 105 (15) 1230-8 2013
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/23853057>

121 Long-acting methylphenidate for cancer-related fatigue: NCCTG trial N05C7

D. L. Barton, A. R. Moraska, A. Sood, J. A. Sloan, J. J. Suh, P. C. Griffin, D. B. Johnson, A. A. Ali, P. T. Silberstein, C. L. Loprinzi J Clin Oncol vol 28 (supplement) abstr 9004 2010
Abstract Symptom Inter
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID

122 Can gabapentin improve control of delayed nausea and vomiting (N/V)? A phase III placebo controlled trial, N08C3 (Alliance)

D. L. Barton, J. A. Sloan, P. J. Novotny, J. Fuloria, L. A. Kottschade, A. P. Lyss, A. J. Jaslowski, M. A. Mazurczak, S. C. Blair, S. A. Terstriep, C. L. Loprinzi Support Care Cancer vol 21 (suppl 1) abstr 0562 2013
Abstract Symptom Inter <http://link.springer.com/article/10.1007%2Fs00520-013-1798-3>

123 Does gabapentin prevent delayed chemotherapy-induced nausea and vomiting (N/V)? Results of a randomized placebo controlled trial, NCCTG N08C3 (Alliance)

D. L. Barton, J. A. Sloan, P. J. Novotny, J. Fuloria, L. A. Kottschade, A. P. Lyss, A. J. Jaslowski, M. Mazurczak, S. C. Blair, S. A. Terstriep, C. L. Loprinzi J Clin Oncol vol 31 (15, suppl) abstr 9513 2013
Abstract Symptom Inter <http://meetinglibrary.asco.org/content/111391-132>

- 124 A pilot, multi-dose, placebo-controlled evaluation of american ginseng (panax quinquefolius) to improve cancer-related fatigue: NCCTG trial N03CA**
D. L. Barton, G. S. Soori, B. Bauer, J. Sloan, P. A. Johnson, C. Figueras, S. Duane, S. Dakhil, H. Liu, C. L. Loprinzi J Clin Oncol vol 25 (18s) abstr 9001 2007
Abstract Symptom Inter http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID
- 125 A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA**
D. L. Barton, E. J. Wos, R. Qin, B. I. Mattar, N. B. Green, K. S. Lanier, J. D. Bearden 3rd, J. W. Kugler, K. L. Hoff, P. S. Reddy, K. M. Rowland Jr, M. Riepl, B. Christensen, C. L. Loprinzi Support Care Cancer vol 19 (6) 833-841 2011
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/20496177>
- 126 A randomized controlled trial evaluating a topical treatment for chemotherapy-induced neuropathy: NCCTG trial N06CA**
D. L. Barton, E. Wos, R. Qin, B. Mattar, N. Green, K. Lanier, J. Bearden, J. Kugler, K. Rowland Jr, C. Loprinzi J Clin Oncol vol 27 (15s) abstr 9531 2009
Abstract Symptom Inter http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID
- 127 Adiponectin: A novel biomarker for cancer-related fatigue?; NCCTG study N07C2 (Alliance)**
D. Barton, H. Liu, A. Tan, J. Sloan, C. Loprinzi Support Care Cancer vol 21 (suppl 1) abstr 0560 2013
Abstract Symptom Inter <http://link.springer.com/article/10.1007%2Fs00520-013-1798-3>
- 128 The use of Ginkgo biloba for the prevention of chemotherapy-related cognitive dysfunction in women receiving adjuvant treatment for breast cancer, N00C9**
Debra L. Barton, Kelli Burger, Paul J. Novotny, Tom R. Fitch, Sadhna Kohli, Gamini Soori, Mary Beth Wilwerding, Jeff A. Sloan, Lisa A. Kottschade, Kendrith M. Rowland, Shaker R. Dakhil, Daniel A. Nikcevich, Charles L. Loprinzi Support Care Cancer vol 21 (4) 1185-1192 2013
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/23150188>
- 129 Systemic and local effects of vaginal dehydroepiandrosterone (DHEA): NCCTG N10C1 (Alliance)**
Debra L. Barton, Lynne T. Shuster, Travis Dockter, Pamela J. Atherton, Jacqueline Thielen, Stephen N. Birrell, Richa Sood, Patricia Griffin, Shelby A. Terstriep, Bassam Mattar, Jacqueline M. Lafky, Charles L. Loprinzi Support Care Cancer vol 26 (4) 1335-43 2018
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/29164377>
- 130 Evaluating the efficacy of vaginal dehydroepiandrosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance)**
Debra L. Barton, Jeff A. Sloan, Lynne T. Shuster, Paula Gill, Patricia Griffin, Kathleen Flynn, Shelby A. Terstriep, Fauzia N. Rana, Travis Dockter, Pamela J. Atherton, Michaela Tsai, Keren Sturtz, Jacqueline M. Lafky, Mike Riepl, Jacqueline Thielen, Charles L. Loprinzi Support Care Cancer vol 26 (2) 643-650 2018
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/28921241>
- 131 Impact of vaginal dehydroepiandrosterone (DHEA) on vaginal symptoms in female cancer survivors: Trial N10C1 (Alliance)**
Debra L. Barton, Jeff A. Sloan, Lynne T Shuster, Paula Gill, James D. Bearden, David B Johnson, Philip J. Stella, Shelby A. Terstriep, Fauzia N. Rana, Daniel M. Anderson, Charles L. Loprinzi J Clin Oncol vol 32 (15_suppl) 9507 2014

132 Pilot study of *Panax quinquefolius* (American ginseng) to improve cancer-related fatigue: a randomized, double-blind, dose-finding evaluation: NCCTG trial N03CA

Debra L. Barton, Gamini S. Soori, Brent A. Bauer, Jeff A. Sloan, Patricia A. Johnson, Cesar Figueras, Steven Duane, Bassam Mattar, Heshan Liu, Pamela J. Atherton, Bradley Christensen, Charles L. Loprinzi Support Care Cancer vol 18 (2) 179-187 2010
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/19415341>

133 Phase III Double-Blind, Placebo-Controlled Study of Gabapentin for the Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy, NCCTG N08C3 (Alliance)

Debra L. Barton, Gita Thanarajasingam, Jeff A. Sloan, Brent Diekmann, Jyotsna Fuloria, Lisa A. Kottschade, Alan P. Lyss, Anthony J. Jaslowski, Mirosław A. Mazurczak, Scott C. Blair, Shelby Terstriep, Charles L. Loprinzi Cancer vol 120 (22) 3575-3583 2014
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/25043153>

134 A randomized phase II trial evaluating two non-pharmacologic interventions in cancer survivors for the treatment of sleep-wake disturbances: NCCTG N07C4 (Alliance)

Debra L Barton, Pamela J Atherton, Daniel V Satele, Rui Qin, Shaker Dakhil, Teri Pipe, Timothy Hobday, Kelli Fee-Schroeder, Charles L. Loprinzi Support Care Cancer vol 28 (12) 6085-94 2020
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/32307658>

135 Randomized controlled trial to evaluate transdermal testosterone in female cancer survivors with decreased libido; North Central Cancer Treatment Group protocol N02C3.

Debra L Barton, Donald B Wender, Jeff A Sloan, Robert J Dalton, Ernie P Balcueva, Pamela J Atherton, Albert M Bernath, Wanda L DeKrey, Tim Larson, James D Bearden, Paul C Carpenter, Charles L Loprinzi J Natl Cancer Inst vol 99 (9) 672-9 2007
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/17470735>

136 Addressing the Complexities of Sexual Health in Female Cancer Survivors: NCCTG N10C1 (Alliance)

Debra Barton, Travis Dockter, Pamela Atherton, Joanne Lester, Breanna Weisbrod, Jeff Sloan 2014
Abstract Symptom Inter
https://cans.memberclicks.net/assets/140915_sos%20onsite%20program_final%20lowres.pdf

137 Composite Grading Algorithm for the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

Ethan Basch, Claus Becker, Lauren J. Rogak, Deborah Schrag, Bryce B. Reeve, Patricia Spears, Mary Lou Smith, Mrinal M. Gounder, Michelle R. Mahoney, Gary K. Schwartz, Antonia V. Bennett, Tito R. Mendoza, Charles S. Cleeland, Jeff A. Sloan, Deborah Watkins Bruner, Gisela Schwab, Thomas M. Atkinson, Gita Thanarajasingam, Monica M. Bertagnolli, Amylou C. Dueck Clin Trials vol 18 (1) 104-14 2021
Manuscript Health Outcomes <http://www.ncbi.nlm.nih.gov/pubmed/33258687>

138 Development of a Composite Scoring Algorithm for the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) (Alliance)

Ethan Basch, Claus Becker, Lauren Rogak, Patricia Spears, Mary Lou Smith, Deborah Schrag, Mrinal Gounder, Michelle Mahoney, Gary Schwartz, Antonia Bennett, Tito Mendoza, Charles Cleeland, Jeff Sloan, Deborah Bruner, Gisela Schwab, Thomas Atkinson, Gita Thanarajasingam, Monica Bertagnolli, Amylou Dueck QUALITY OF LIFE RESEARCH vol 28 S43-S44 2019
Abstract Health Outcomes <https://www.isoqol.org/wp-content/uploads/2019/09/ac19-FP-web.pdf>

139 Patient-Reported Outcomes During and After Treatment for Locally Advanced Rectal Cancer in the PROSPECT Trial (Alliance N1048)

Ethan Basch, Amylou C. Dueck, Sandra A. Mitchell, Harvey Mamon, Martin Weiser, Leonard Saltz, Marc Gollub, Lauren Rogak, Brenda Ginos, Gina L. Mazza, Brian Colgrove, George Chang, Lori Minasian, Andrea Denicoff, Gita Thanarajasingam, Benjamin Musher, Thomas George, Alan Venook, Jeffrey Farma, Eileen O'Reilly, Jeffrey A. Meyerhardt, Qian Shi, Deborah Schrag J Clin Oncol vol 41 (21) 3724-34 2023

Manuscript Health Outcomes <http://www.ncbi.nlm.nih.gov/pubmed/37270691>

140 Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials

Ethan Basch, Amylou C. Dueck, Lauren J. Rogak, Lori M. Minasian, William Kevin Kelly, Ann M. O'Mara, Andrea M. Denicoff, Drew Seisler, Pamela J. Atherton, Electra Paskett, Lisa Carey, Maura Dickler, Rebecca S. Heist, Andrew Himelstein, Hope S. Rugo, William M. Sikov, Mark A. Socinski, Alan P. Venook, Douglas J. Weckstein, Diana E. Lake, David D. Biggs, Rachel A. Freedman, Charles Kuzma, Jeffrey J. Kirshner, Deborah Schrag JAMA Oncol vol 3 (8) 1043-50 2017

Manuscript Health Outcomes CALGB-30607, CALGB-30610, CALGB-40502, CALGB-40503, CALGB-40601, CALGB-70501, CALGB-70604, CALGB-80405, CALGB-90401
<http://www.ncbi.nlm.nih.gov/pubmed/28208174>

141 Feasibility of Implementing the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in a Multicenter Trial: NCCTG N1048

Ethan Basch, Amylou C. Dueck, Lauren J. Rogak, Sandra A. Mitchell, Lori M. Minasian, Andrea M. Denicoff, Jennifer K. Wind, Mary C. Shaw, Narre Heon, Qian Shi, Brenda Ginos, Garth D. Nelson, Jeffrey P. Meyers, George J. Chang, Harvey J. Mamon, Martin R. Weiser, Tatjana Kolevska, Bryce B. Reeve, Deborah Watkins Bruner, Deborah Schrag J Clin Oncol vol 36 (31) 3120-25 2018

Manuscript Health Outcomes <http://www.ncbi.nlm.nih.gov/pubmed/30204536>

142 Patient-reported adverse events in PROSPECT, a randomized trial of chemotherapy with selective use of pelvic chemoradiation to standard use of chemoradiation for neoadjuvant treatment of locally advanced rectal cancer (Alliance N1048)

Ethan Basch, Amylou Dueck, Sandra Mitchell, Lauren Rogak, Brenda Ginos, Martin Weiser, Harvey Mamon, Lenoard Saltz, George Chang, Lori Minasian, Andrea Denicoff, Gita Thanarajasingam, Doug Rubinson, Brian Colgrove, Rebecca Auer, Thomas George, Jeffrey Farma, Eileen O'Reilly, Jeffrey Meyerhardt, Qian Shi, Deborah Schrag J Clin Oncol vol 41 (supp 17) LBA2 2023

Abstract Health Outcomes <https://meetings.asco.org/abstracts-presentations/219804>

143 Effect of Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Metastatic Cancer

Ethan Basch, Deborah Schrag, Sydney Henson, Jennifer Jansen, Brenda Ginos, Angela M. Stover, Philip Carr, Patricia A. Spears, Mattias Jonsson, Allison M. Deal, Antonia V. Bennett, Gita Thanarajasingam, Lauren J. Rogak, Bryce B. Reeve, Claire Snyder, Deborah Bruner, David Cella, Lisa A. Kottschade, Jane Perlmutter, Cindy Geoghegan, Cleo A. Samuel-Ryals, Barbara Given, Gina L. Mazza, Robert Miller, Jon F. Strasser, Dylan M. Zylla, Anna Weiss, Victoria S. Blinder, Amylou C. Dueck JAMA vol 327 (24) 2413-22 2022

Manuscript Health Outcomes <http://www.ncbi.nlm.nih.gov/pubmed/35661856>

144 Digital symptom monitoring with patient-reported outcomes in community oncology practices: A U.S. national cluster randomized trial.

Ethan Basch, Deborah Schrag, Jennifer Jansen, Sydney Henson, Angela M. Stover, Patricia Spears, Mattias Jonsson, Allison Mary Deal, Antonia Vickery Bennett, Gita Thanarajasingam, Bryce Reeve, Claire Frances Snyder, Deborah Bruner, David Cella, Lisa A. Kottschade, Jane Perlmutter, Robert S.

Miller, Jon F. Strasser, Dylan M. Zylla, Amylou C. Dueck J Clin Oncol vol 39 (36_suppl) 349527. 2021

Abstract Health Outcomes https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.36_suppl.349527

145 Clinical Utility and User Perceptions of a Digital System for Electronic Patient-Reported Symptom Monitoring During Routine Cancer Care: Findings From the PRO-TECT Trial

Ethan Basch, Angela M. Stover, Deborah Schrag, Arlene Chung, Jennifer Jansen, Sydney Henson, Philip Carr, Brenda Ginos, Allison Deal, Patricia A. Spears, Mattias Jonsson, Antonia V. Bennett, Gita Mody, Gita Thanarajasingam, Lauren J. Rogak, Bryce B. Reeve, Claire Snyder, Lisa A. Kottschade, Marjory Charlot, Anna Weiss, Deborah Bruner, Amylou C. Dueck JCO Clin Cancer Inform vol 4 947-57 2020

Manuscript CCDR <http://www.ncbi.nlm.nih.gov/pubmed/33112661>

146 Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Patients with Hematologic Malignancies Who Relapse following Autologous Transplantation: A Multi-Institutional Prospective Study from the Cancer and Leukemia Group B (CALGB trial 100002)

Asad Bashey, Kouros Owzar, Jeffrey L. Johnson, Peggy S. Edwards, Michael Kelly, Lee-Ann Baxter-Lowe, Steven Devine, Sherif Farag, David Hurd, Edward Ball, Philip McCarthy, John Lister, Thomas C. Shea, Charles Linker Biol Blood Marrow Transplant vol 17 (4) 2011

Manuscript Transplant <http://www.ncbi.nlm.nih.gov/pubmed/20674758>

147 Myeloablative versus non-myeloablative consolidative chemotherapy for newly diagnosed primary central nervous system lymphoma: Results of induction therapy in CALGB 51101 (Alliance)

T Batchelor, S Giri, A Stark, N Bartlett, E Hsi, B Cheson, J L Nayak, John Leonard, J Rubenstein J Clin Oncol vol 38 (15_suppl) abst 8042 2020

Abstract Lymphoma https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.8042

148 Myeloablative versus non-myeloablative consolidative chemotherapy for newly diagnosed primary central nervous system lymphoma: Results of CALGB 51101 [Alliance]

Tracy T. Batchelor, Sharmila Giri, Amy S. Ruppert, Nancy L. Bartlett, Eric Hsi, Bruce D. Cheson, Lakshmi Nayak, John P. Leonard, James L. Rubenstein J Clin Oncol vol 39 (no. 15_suppl) 7506 2021

Abstract Lymphoma https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.7506

149 Myeloablative versus non-myeloablative consolidative chemotherapy for newly diagnosed primary central nervous system lymphoma: Results of CALGB 51101 [Alliance]

Tracy T. Batchelor, Sharmila Giri, Amy S. Ruppert, Nancy L. Bartlett, Eric Hsi, Bruce D. Cheson, Lakshmi Nayak, John P. Leonard, James L. Rubenstein 2021

Abstract Lymphoma

150 Her2 gene expression and not Her2 amplification is predictive and prognostic in patients (pts) with metastatic colorectal cancer (mCRC) enrolled in CALGB/SWOG 80405 (Alliance)

Francesca Battaglin, Fang-Shu Ou, Xueping Qu, Monica M. Bertagnolli, Howard S. Hochster, Donna Niedzwiecki, Richard M. Goldberg, Robert J. Mayer, Tyler Zemla, Charles D. Blanke, Alan P. Venook, Carlos Bias, Heinz Josef Lenz, Federico Innocenti J Clin Oncol vol 38 (15 suppl) abstr 4086 2020

Abstract Correl Sci NOS https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.4086

151 Sole Trisomy 8 In Patients (pts) with De Novo Acute Myeloid Leukemia (AML) Is Associated with Age-Independent Poor Outcome That Is Modified by Molecular Markers and with Unique Gene- and Microrna (miR)-Signatures: a Cancer and Leukemia Group B (CALGB) Study

H. Becker, K. Maharry, M. D. Radmacher, D. Margeson, K. Mrozek, S. P. Whitman, Y. Z. Wu, K. H. Metzeler, S. Schwind, K. B. Holland, J. E. Kolitz, A. J. Carroll, M. A. Caligiuri, M. R. Baer, R. A.

Larson, G. Marcucci, C. D. Bloomfield *Blood* vol 116 (21) 255-255 2010
Abstract *Leuk Corr Sci* CALGB-8525, CALGB-10201, CALGB-19808, CALGB-20202,
CALGB-20502, CALGB-8461, CALGB-8923, CALGB-9420, CALGB-9621, CALGB-9665,
CALGB-9720 <https://ash.confex.com/ash/2010/webprogram/Paper27627.html>

152 NPM1 mutations as an independent prognosticator for older cytogenetically normal acute myeloid leukemia (CN AML)

H. Becker, G. Marcucci, K. Maharry, D. Margeson, M. D. Radmacher, S. P. Whitman, K. Mrozek, M. R. Baer, R. A. Larson, C. D. Bloomfield, *Calgb J Clin Oncol* vol 27 (15) abstr 7000 2009
Abstract *Leuk Corr Sci* CALGB-10201, CALGB-20202, CALGB-8461, CALGB-9720
<http://meetinglibrary.asco.org/content/37032>

153 Comparison of Clinical and Biologic Significance of WT1 Mutations in Populations of Older (>= 60 years y) and Younger (< 60 y) Adult Patients (Pts) with Cytogenetically Normal (CN) De Novo Acute Myeloid Leukemia (AML): a Cancer and Leukemia Group B (CALGB) Study

H. Becker, G. Marcucci, K. Maharry, M. D. Radmacher, K. Mrozek, S. P. Whitman, P. Paschka, D. Margeson, Y. Z. Wu, S. Schwind, C. Langer, M. R. Baer, A. J. Carroll, M. A. Caligiuri, J. E. Kolitz, R. A. Larson, C. D. Bloomfield *Blood* vol 114 (22) 138-138 2009
Abstract *Correl Sci NOS* CALGB-8525, CALGB-10201, CALGB-19808, CALGB-20202,
CALGB-20502, CALGB-8461, CALGB-8923, CALGB-9420, CALGB-9621, CALGB-9665,
CALGB-9720
<http://abstracts.hematologylibrary.org/cgi/content/abstract/114/22/326?maxtoshow=&hits=10&RESULT>

154 CEBPA double mutations impact favorably on the outcome of older adults with wild-type NPM1 cytogenetically normal acute myeloid leukemia and are associated with distinct gene- and microRNA-expression patterns

H. Becker, G. Marcucci, K. Maharry, M. Radmacher, Y. Wu, K. Mrozek, S. Whitman, D. Margeson, K. Holland, S. Schwind, K. Metzeler, B. Powell, T. Carter, J. Kolitz, M. Wetzler, A. Carroll, M. Baer, J. O. Moore, M. Caligiuri, R. Larson, C. Bloomfield *Haematologica* vol 95(suppl. 2) 247 abstr 593 2010
Abstract *Leuk Corr Sci* CALGB-8525, CALGB-10201, CALGB-20202, CALGB-20502,
CALGB-8461, CALGB-8923, CALGB-9420, CALGB-9665, CALGB-9720
<http://online.haematologica.org/EHA15/browserecord.php?-action=browse&-recid=6663>

155 Prognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia with a sole trisomy 8

Heiko Becker, Kati Maharry, Krzysztof Mrózek, Stefano Volinia, Ann-Kathrin Eisfeld, Michael D. Radmacher, Jessica Kohlschmidt, Klaus H. Metzeler, Sebastian Schwind, Susan P. Whitman, Jason H. Mendler, Yue-Zhong Wu, Deedra Nicolet, Peter Paschka, Bayard L. Powell, Thomas H. Carter, Meir Wetzler, Jonathan E. Kolitz, Andrew J. Carroll, Maria R. Baer, Michael A. Caligiuri, Richard M. Stone, Guido Marcucci, Clara D. Bloomfield *Leukemia* vol 28 (8) 1754-1758 2014
Manuscript *Leuk Corr Sci* CALGB-8525, CALGB-10201, CALGB-10502, CALGB-10503,
CALGB-10603, CALGB-19808, CALGB-8923, CALGB-9022, CALGB-9222, CALGB-9420,
CALGB-9621, CALGB-9720 <http://www.ncbi.nlm.nih.gov/pubmed/24651097>

156 Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

Heiko Becker, Kati Maharry, Michael D. Radmacher, Krzysztof Mrózek, Klaus H. Metzeler, Susan P. Whitman, Sebastian Schwind, Jessica Kohlschmidt, Yue-Zhong Wu, Bayard L. Powell, Thomas H. Carter, Jonathan E. Kolitz, Meir Wetzler, Andrew J. Carroll, Maria R. Baer, Joseph O. Moore, Michael A. Caligiuri, Richard A. Larson, Guido Marcucci, Clara D. Bloomfield *Haematologica* vol 96 (10) 1488-95 2011

Manuscript Leuk Corr Sci CALGB-8525, CALGB-10201, CALGB-19808, CALGB-20202, CALGB-20502, CALGB-8461, CALGB-8923, CALGB-9420, CALGB-9621, CALGB-9665, CALGB-9720 <http://www.ncbi.nlm.nih.gov/pubmed/21659357>

157 Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

Heiko Becker, Guido Marcucci, Kati Maharry, Michael D. Radmacher, Krzysztof Mrózek, Dean Margeson, Susan P. Whitman, Peter Paschka, Kelsi B. Holland, Sebastian Schwind, Yue-Zhong Wu, Bayard L. Powell, Thomas H. Carter, Jonathan E. Kolitz, Meir Wetzler, Andrew J. Carroll, Maria R. Baer, Joseph O. Moore, Michael A. Caligiuri, Richard A. Larson, Clara D. Bloomfield *Blood* vol 116 (5) 788-792 2010

Manuscript Leuk Corr Sci CALGB-8525, CALGB-10201, CALGB-19808, CALGB-20202, CALGB-8461, CALGB-8923, CALGB-9420, CALGB-9621, CALGB-9665, CALGB-9720 <http://www.ncbi.nlm.nih.gov/pubmed/20442368>

158 Favorable Prognostic Impact of NPM1 Mutations in Older Patients With Cytogenetically Normal De Novo Acute Myeloid Leukemia and Associated Gene- and MicroRNA-Expression Signatures: A Cancer and Leukemia Group B Study

Heiko Becker, Guido Marcucci, Kati Maharry, Michael D. Radmacher, Krzysztof Mrózek, Dean Margeson, Susan P. Whitman, Yue-Zhong Wu, Sebastian Schwind, Peter Paschka, Bayard L. Powell, Thomas H. Carter, Jonathan E. Kolitz, Meir Wetzler, Andrew J. Carroll, Maria R. Baer, Michael A. Caligiuri, Richard A. Larson, Clara D. Bloomfield *J Clin Oncol* vol 28 (4) 596-604 2010

Manuscript Leuk Corr Sci CALGB-10201, CALGB-19808, CALGB-20202, CALGB-8461, CALGB-9720 <http://www.ncbi.nlm.nih.gov/pubmed/20026798>

159 Impact of therapy on genomics and transcriptomics in high-risk prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy

Himisha Beltran, Alexander W Wyatt, Edmund C Chedgy, Adam Donoghue, Matti Annala, Evan W Warner, Kevin Beja, Michael Sigouros, Fan Mo, Ladan Fazli, Colin C Collins, James Eastham, Michael Morris, Mary-Ellen Taplin, Andrea Sboner, Susan Halabi, Martin E Gleave *Clin Cancer Res* vol 23 (22) 6802-6811 2017

Manuscript GU <http://www.ncbi.nlm.nih.gov/pubmed/28842510>

160 Evaluation of mode equivalence of the MSKCC Bowel Function Instrument, LASA Quality of Life, and Subjective Significance Questionnaire items administered by Web, interactive voice response system (IVRS), and paper

Antonia V. Bennett, Kathleen Keenoy, Marwan Shouery, Ethan Basch, Larissa K. Temple *Qual Life Res* vol 25 (5) 1123-1130 2016

Manuscript Health Outcomes <http://www.ncbi.nlm.nih.gov/pubmed/26590838>

161 New strategies to improve drug development in carcinoid tumors (Alliance A021202)

Emily K. Bergsland, Susan M. Geyer, Michelle R. Mahoney, Timothy R. Asmis, Nathan Hall, Sanja Karovic, Michael Knopp, Priya Kumthekar, Andrew B. Nixon, Eileen Mary O'Reilly, Lawrence H Schwartz, Jonathan R. Strosberg, Jeffrey A. Meyerhardt, Michael L. Maitland 2020

Abstract GI <https://netrf.org/wp-content/uploads/2020/12/1605290615-3-bergsland-abstract.pdf>

162 New strategies to improve drug development in carcinoid tumors (Alliance A021202)

Emily K. Bergsland, Michelle R. Mahoney, Timothy R. Asmis, Nathan Hall, Sanja Karovic, Michael Knopp, Priya Kumthekar, Donna Niedzwiecki, Andrew B. Nixon, Eileen Mary O'Reilly, Lawrence H Schwartz, Jonathan R. Strosberg, Jeffrey A. Meyerhardt, Michael L. Maitland 2019

Abstract GI

<https://netrf.org/wp-content/uploads/2019/04/4-30-19-NET-Symposium-AgendaFinal.pdf>

- 163 Randomized phase II trial of pazopanib versus placebo in patients with progressive carcinoid tumors (CARC) (Alliance A021202).**
Emily K. Bergsland, Michelle R. Mahoney, Timothy R. Asmis, Nathan Hall, Priya Kumthekar, Michael L. Maitland, Donna Niedzwiecki, Andrew B. Nixon, Eileen Mary O'Reilly, Lawrence Howard Schwartz, Jeff A. Sloan, Jonathan Strosberg, Jeffrey A. Meyerhardt *J Clin Oncol* vol 37 (Suppl) abstr 4005 2019
Abstract GI http://abstracts.asco.org/239/AbstView_239_247995.html
- 164 Randomized phase II trial of pazopanib versus placebo in patients with progressive carcinoid tumors (CARC) (Alliance A021202).**
Emily K. Bergsland, Michelle R. Mahoney, Timothy R. Asmis, Nathan Hall, Priya Kumthekar, Michael L. Maitland, Donna Niedzwiecki, Andrew B. Nixon, Eileen Mary O'Reilly, Lawrence Howard Schwartz, Jeff Sloan, Jonathan R. Strosberg, Jeffrey A. Meyerhardt *Pancreas* 63-64 (1271-c6) 2019
Abstract GI
<https://nanets.org/abstracts-archive/2019/1271-c6-randomized-phase-ii-trial-of-pazopanib-versus-placebo>
- 165 Adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression: patient-reported outcomes in the TEXT and SOFT randomised trials**
Jürg Bernhard, Weixiu Luo, Karin Ribí, Marco Colleoni, Harold J. Burstein, Carlo Tondini, Graziella Pinotti, Simon Spazzapan, Thomas Ruhstaller, Fabio Puglisi, Lorenzo Pavesi, Vani Parmar, Meredith M. Regan, Olivia Pagani, Gini F. Fleming, Prudence A. Francis, Karen N. Price, Alan S. Coates, Richard D. Gelber, Aron Goldhirsch, Barbara A. Walley *Lancet Oncol* vol 16 (7) 848-58 2015
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/26092816>
- 166 High-dose chemotherapy with autologous stem-cell support versus standard-dose chemotherapy: meta-analysis of individual patient data from 15 randomized adjuvant breast cancer trials**
D. A. Berry, N. T. Ueno, M. M. Johnson, X. Lei, V. Lopez, J. Caputo, M. Bregni, T. Demirer *Breast Cancer Res Treat* vol 106 (S5-S5) 2007
Abstract Breast <http://www.springerlink.com/content/kx32107830v15316/fulltext.pdf>
- 167 High-Dose Chemotherapy With Autologous Stem-Cell Support As Adjuvant Therapy in Breast Cancer: Overview of 15 Randomized Trials**
Donald A. Berry, Naoto T. Ueno, Marcella M. Johnson, Xiudong Lei, Jean Caputo, Sjoerd Rodenhuis, William P. Peters, Robert C. Leonard, William E. Barlow, Martin S. Tallman, Jonas Bergh, Ulrike A. Nitz, Alessandro M. Gianni, Russell L. Basser, Axel R. Zander, R. Charles Coombes, Henri Roché, Yutaka Tokuda, Elisabeth G.E. de Vries, Gabriel N. Hortobagyi, John P. Crown, Paolo Pedrazzoli, Marco Bregni, Taner Demirer *J Clin Oncol* vol 29 (24) 3214-3223 2011
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/21768471>
- 168 Presence of 18q loss of heterozygosity (LOH) and disease-free and overall survival in stage II colon cancer: CALGB Protocol 9581**
M. M. Bertagnolli, D. Niedzwiecki, M. Hall, S. D. Jewell, R. J. Mayer, R. M. Goldberg, T. A. Colacchio, R. S. Warren, M. Redston *J Clin Oncol* vol 27 (15s) abstr 4012 2009
Abstract GI
http://www.asco.org/ASCOv2/Meetings/Abstracts?vmview=abst_detail_view&confID=65&abstractID=
- 169 What Happened to the US Cancer Cooperative Groups? A Status Update Ten Years After the IOM Report**
Monica M. Bertagnolli, Charles D. Blanke, Walter J. Curran Jr, Douglas S. Hawkins, Robert S. Mannel, Peter J. O'Dwyer, Mitchell D. Schnall, Norman Wolmark *Cancer* vol 126 (23) 5022-29 2020
Manuscript OGC funded--no committee <http://www.ncbi.nlm.nih.gov/pubmed/32970346>

- 170 Microsatellite Instability Predicts Improved Response to Adjuvant Therapy With Irinotecan, Fluorouracil, and Leucovorin in Stage III Colon Cancer: Cancer and Leukemia Group B Protocol 89803**
Monica M. Bertagnolli, Donna Niedzwiecki, Carolyn C. Compton, Hejin P. Hahn, Margaret Hall, Beatrice Damas, Scott D. Jewell, Robert J. Mayer, Richard M. Goldberg, Leonard B. Saltz, Robert S. Warren, Mark Redston J Clin Oncol vol 27 (11) 1814-1821 2009
Manuscript GI CALGB-89803 <http://www.ncbi.nlm.nih.gov/pubmed/19273709>
- 171 Microsatellite Instability and Loss of Heterozygosity at Chromosomal Location 18q: Prospective Evaluation of Biomarkers for Stages II and III Colon Cancer—A Study of CALGB 9581 and 89803**
Monica M. Bertagnolli, Mark Redston, Carolyn C. Compton, Donna Niedzwiecki, Robert J. Mayer, Richard M. Goldberg, Thomas A. Colacchio, Leonard B. Saltz, Robert S. Warren J Clin Oncol vol 29 (23) 3153-62 2011
Manuscript GI CALGB-89803, CALGB-9581 <http://www.ncbi.nlm.nih.gov/pubmed/21747089>
- 172 p27Kip1 in Stage III Colon Cancer: Implications for Outcome Following Adjuvant Chemotherapy in CALGB 89803**
Monica M. Bertagnolli, Robert S. Warren, Donna Niedzwiecki, Elke Mueller, Carolyn C. Compton, Mark Redston, Margaret Hall, Hejin P. Hahn, Scott D. Jewell, Robert J. Mayer, Richard M. Goldberg, Leonard B. Saltz, Massimo Loda Clin Cancer Res vol 15 2116-2122 2009
Manuscript GI CALGB-89803 <http://www.ncbi.nlm.nih.gov/pubmed/19276255>
- 173 Effect of age on the pharmacokinetics of busulfan (Bu): An Alliance study.**
J. H. Beumer, L. D. Lewis, K. Owzar, C. Jiang, J. L. Holleran, S. M. Christner, W. G. Blum, S. M. Devine, J. E. Kolitz, C. A. Linker, R. A. Larson, M. J. Ratain, M. J. Egorin J Clin Oncol vol 30 (15 suppl) abstr 2533 2012
Abstract PPP CALGB-10503, CALGB-19808, CALGB-100103
http://meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/2533?sid=5342c90d-7d4e-467b-ae5d-6d23
- 174 Effect of Age on the Pharmacokinetics of Busulfan in Patients Undergoing Hematopoietic Cell Transplantation; an Alliance study (CALGB 10503, 19808, and 100103)**
Jan H. Beumer, Kouros Owzar, Lionel D. Lewis, Chen Jiang, Julianne L. Holleran, Susan M. Christner, William Blum, Steven Devine, Jonathan E. Kolitz, Charles Linker, Ravi Vij, Edwin P Alyea, Richard A. Larson, Mark J. Ratain, Merrill J. Egorin Cancer Chemother Pharmacol vol 74 (5) 927-938 2014
Manuscript PPP CALGB-19808, CALGB-100103, CALGB-10503
<http://www.ncbi.nlm.nih.gov/pubmed/25163570>
- 175 Sequencing symptom control: Results from the Alliance N08C1 and N08CA genetics of chemotherapy neuropathy trials**
A. S. Beutler, A. Kulkarni, R. Kanwar, R. Qin, J. M. Cunningham, T. M. Therneau, C. L. Loprinzi AACR 2013 Annual Meeting abstr LB-196 2013
Abstract Symptom Inter NCCTG-N08C1, NCCTG-N08CA
<http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=d4332bf8-005b-4cb2-a378-921ae478208>
- 176 Sequencing of Charcot-Marie-Tooth disease genes in a toxic polyneuropathy**
Andreas S. Beutler, Amit A. Kulkarni, Rahul Kanwar, Christopher J. Klein, Terry M. Therneau, Rui Qin, Michaela S. Banck, Ganesh K. Boora, Kathryn J. Ruddy, Yanhong Wu, Regenia L. Smalley, Julie M. Cunningham, Nguyet Anh Le-Lindqwister, Peter Beyerlein, Gary P. Schroth, Anthony J. Windebank, Stephan Züchner, Charles L. Loprinzi Ann Neurol vol 76 (5) 727-737 2014
Manuscript Symptom Inter NCCTG-N08C1, NCCTG-N08CA
<http://www.ncbi.nlm.nih.gov/pubmed/25164601>

- 177 An intensive sequenced adjuvant chemotherapy regimen for breast cancer.**
S Bhardwaj, J F Holland, L Norton *Cancer Invest* vol 11 (1) 6-9 1993
Manuscript *Breast* <http://www.ncbi.nlm.nih.gov/pubmed/8422597>
- 178 Clinical features and gene- and microRNA-expression patterns in adult acute leukemia patients with t(11;19)(q23;p13.1) and t(11;19)(q23;p13.3)**
B Bhatnagar, JS Blachly, J Kohlschmidt, A-K Einfeld, S Volinia, D Nicolet, AJ Carroll, AW Block, JE Kolitz, RM Stone, K Mrózek, JC Byrd, CD Bloomfield *Leukemia* vol 30 (7) 1586-1589 2016
Manuscript *Leuk Corr Sci* CALGB-8461, CALGB-20202, CALGB-8525, CALGB-10102, CALGB-10201, CALGB-10503, CALGB-10603, CALGB-11002, CALGB-19808, CALGB-8923, CALGB-9120, CALGB-9222, CALGB-9621, CALGB-9720
<http://www.ncbi.nlm.nih.gov/pubmed/26669971>
- 179 Clinical and molecular characterization of patients with acute myeloid leukemia and sole trisomies of chromosomes 4, 8, 11, 13 or 21**
Bhavana Bhatnagar, Ann-Kathrin Einfeld, Jessica Kohlschmidt, Krzysztof Mrózek, Deedra Nicolet, Dimitrios Papaioannou, Christopher J. Walker, Shelley Orwick, James S. Blachly, Jonathan E. Kolitz, Bayard L. Powell, Andrew J. Carroll, Richard M. Stone, John C. Byrd, Clara D. Bloomfield
Leukemia vol 34 (2) 358-68 2020
Manuscript *Leuk Corr Sci* CALGB-8461, CALGB-9665, CALGB-20202
<http://www.ncbi.nlm.nih.gov/pubmed/31462731>
- 180 Acute myeloid leukemia (AML) patients with an isolated trisomy display increased frequency of spliceosome mutations CALGB 8461 and 20202 (Alliance)**
Bhavana Bhatnagar, Ann-Kathrin Einfeld, Krzysztof Mrózek, Jessica Kohlschmidt, Deedra Nicolet, Jonathan Kolitz, Bayard L. Powell, John C. Byrd, Clara D. Bloomfield *Blood* vol 130 (Suppl 1) 2691 2017
Abstract *Leuk Corr Sci* CALGB-20202, CALGB-8461
http://www.bloodjournal.org/content/130/Suppl_1/2691
- 181 Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia**
Bhavana Bhatnagar, Ann-Kathrin Einfeld, Deedra Nicolet, Krzysztof Mrózek, James S. Blachly, Shelley Orwick, David M. Lucas, Jessica Kohlschmidt, William Blum, Jonathan E. Kolitz, Richard M. Stone, Clara D. Bloomfield, John C. Byrd *Br J Haematol* vol 175 (2) 226-236 2016
Manuscript *Leuk Corr Sci* CALGB-20202, CALGB-10201, CALGB-10502, CALGB-10503, CALGB-10603, CALGB-19808, CALGB-9222, CALGB-9621, CALGB-9720
<http://www.ncbi.nlm.nih.gov/pubmed/27476855>
- 182 Poor Survival and Differential Impact of Genetic Features of Black Patients with Acute Myeloid Leukemia**
Bhavana Bhatnagar, Jessica Kohlschmidt, Krzysztof Mrózek, Qihong Zhao, James L. Fisher, Deedra Nicolet, Christopher J. Walker, Alice S. Mims, Christopher Oakes, Brian Giacomelli, Shelley Orwick, Isaiah Boateng, James S. Blachly, Sophia E. Maharry, Andrew J. Carroll, Bayard L. Powell, Jonathan E. Kolitz, Richard M. Stone, John C. Byrd, Electra D. Paskett, Albert de la Chapelle, Ramiro Garzon, Ann-Kathrin Einfeld *Cancer Discov* vol 11 (3) 626-37 2021
Manuscript *Leuk Corr Sci* CALGB-20202, CALGB-8461, CALGB-9665
<http://www.ncbi.nlm.nih.gov/pubmed/33277314>
- 183 Framework of clonal mutations concurrent with WT1 mutations in adults with acute myeloid leukemia: Alliance for Clinical Trials in Oncology study**
Bhavana Bhatnagar, Jessica Kohlschmidt, Shelley J. Orwick, Daelynn R. Buelow, Sydney Fobare,

Christopher C. Oakes, Jonathan E. Kolitz, Geoff Uy, Wendy Stock, Bayard L. Powell, Deedra Nicolet, Erin K. Hertlein, Krzysztof Mrózek, James S. Blachly, Ann-Kathrin Einfeld, Sharyn D. Baker, John C. Byrd *Blood Adv* vol 7 (16) 4671-5 2023

Manuscript *Leuk Corr Sci* CALGB-10201, CALGB-10502, CALGB-10503, CALGB-10603, CALGB-11002, CALGB-19808, CALGB-20202, CALGB-8461, CALGB-8525, CALGB-8923, CALGB-9022, CALGB-9120, CALGB-9222, CALGB-9621, CALGB-9665, CALGB-9720
<http://www.ncbi.nlm.nih.gov/pubmed/37603350>

184 Poor Treatment Outcomes of Young (<60 Years) African American Patients Diagnosed with Acute Myeloid Leukemia (AML) (Alliance)

Bhavana Bhatnagar, Qiuhong Zhao, Jay Fisher, Jessica Kohlschmidt, Krzysztof Mrózek, Deedra Nicolet, Shelley Orwick, James S. Blachly, Alice Mims, Christopher J. Walker, Andrew J. Carroll, Bayard L. Powell, Jonathan E. Kolitz, Electra D. Paskett, Clara D. Bloomfield, Richard M. Stone, John C. Byrd, Albert de la Chapelle, Ramiro Garzon, Ann-Kathrin Einfeld *Blood* vol 136 (Supplement 1) 5-7 2020

Abstract *Leuk Corr Sci* CALGB-20202, CALGB-8461, CALGB-9665

<https://ashpublications.org/blood/article/136/Supplement%201/5/470367/Poor-Treatment-Outcomes-of-1>

185 Outcomes of Older Adults With AML Treated in Community Versus Academic Centers: An Analysis of Alliance Trials

Vijaya Raj Bhatt, Angela M. Ulrich, Geoffrey L. Uy, Richard M. Stone, Wendy Stock, Michael O. Ojelabi, Jun Yin, Jessica Kohlschmidt, Ann-Kathrin Einfeld, Maria R. Baer, Selina Chow, Heidi Klepin, Jennifer Le-Rademacher, Aminah Jatoi *JCO Oncol Pract* vol 19 (6) e877-e891 2023

Manuscript *Older Adult* CALGB-10201, CALGB-11001, CALGB-11002, CALGB-9720

<http://www.ncbi.nlm.nih.gov/pubmed/37058684>

186 Discovery of SNPs associated with chemotherapy-induced peripheral neuropathy (CIPN) using model estimated parameters as phenotypes CALGB 40502 (Alliance)

Jiraganya Bhongsatiern, P. Carbonetto, Katherina C. Chua, S. Mehrotra, P.D. Evans, E.R. Gamazon, Hope Rugo, D.L. Kroetz, Jogarao V. Gobburu, Mark J. Ratain, N.J. Cox, Manish R. Sharma *CLINICAL PHARMACOLOGY & THERAPEUTICS* vol 103 (Suppl S1) S25 2018

Abstract *PPP* <https://ascpt.onlinelibrary.wiley.com/doi/epdf/10.1002/cpt.993>

187 Mutational Landscape and Clinical Outcome Associated with Different Rearrangements Involving 11q23/MLL in De Novo Acute Myeloid Leukemia (AML) CALB 8461 and 20202 (Alliance)

Marius Bill, Ann-Kathrin Einfeld, Krzysztof Mrózek, Jessica Kohlschmidt, Deedra Nicolet, Christopher J. Walker, James S. Blachly, Andrew J. Carroll, J Kolitz, Bayard L. Powell, Eunice S. Wang, Richard M. Stone, Albert de la Chapelle, John C. Byrd, Clara D. Bloomfield *Blood* vol 130 (Suppl 1) 3960 2017

Abstract *Leuk Corr Sci* CALGB-20202, CALGB-8461

http://www.bloodjournal.org/content/130/Suppl_1/3960

188 Differential Impact of Prognostically Significant Gene Mutations in Acute Myeloid Leukemia (AML) Patients (Pts) Older Than 70 Years (y) Treated With a Cytarabine-Based Induction Therapy (Alliance)

Marius Bill, Jessica Kohlschmidt, Krzysztof Mrózek, Deedra Nicolet, Christopher J. Walker, Dimitrios Papaioannou, James Blachly, Shelley Orwick, Eunice S. Wang, Jonathan E. Kolitz, Bayard L. Powell, Andrew J. Carroll, Ramiro Garzon, Richard M. Stone, John C Byrd, Clara D. Bloomfield, Ann-Kathrin Einfeld *Blood* vol 136 (Supplement 1) 40-1 2020

Abstract *Leuk Corr Sci* CALGB-20202, CALGB-8461, CALGB-9665

<https://ashpublications.org/blood/article/136/Supplement%201/40/472600/Differential-Impact-of-Progno>

189 Prognostic impact of the 2017 European Leukemianet (ELN) classification of adult patients (pts)

with acute myeloid leukemia (AML) treated on Cancer and Leukemia Group B (CALGB)/Alliance protocols

Marius Bill, K Mrózek, J. Kohlschmidt, D. Nicolet, A.-K. Einfeld, D. Papaioannou, J.E. Kolitz, B.L. Powell, A.J. Carroll, J.C. Byrd, C.D. Bloomfield *HemaSphere* vol 3 (S1) 68–9 2019
Abstract *Leuk Corr Sci* CALGB-8461, CALGB-20202, CALGB-9665
https://journals.lww.com/hemasphere/Fulltext/2019/06001/PROGNOSTIC_IMPACT_OF_THE_2017_E

190 Precision oncology in AML: validation of the prognostic value of the knowledge bank approach and suggestions for improvement

Marius Bill, Krzysztof Mrózek, Brian Giacomelli, Jessica Kohlschmidt, Deedra Nicolet, Dimitrios Papaioannou, Ann-Kathrin Einfeld, Jonathan E. Kolitz, Bayard L. Powell, Andrew J. Carroll, Richard M. Stone, Ramiro Garzon, John C. Byrd, Clara D. Bloomfield, Christopher C. Oakes *J Hematol Oncol* vol 14 2021
Manuscript *Leuk Corr Sci* CALGB-8461, CALGB-9665, CALGB-20202
<http://www.ncbi.nlm.nih.gov/pubmed/34229733>

191 Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23/KMT2A

Marius Bill, Krzysztof Mrózek, Jessica Kohlschmidt, Ann-Kathrin Einfeld, Christopher J. Walker, Deedra Nicolet, Dimitrios Papaioannou, James S. Blachly, Shelley Orwick, Andrew J. Carroll, Jonathan E. Kolitz, Bayard L. Powell, Richard M. Stone, Albert de la Chapelle, John C. Byrd, Clara D. Bloomfield *Proc Natl Acad Sci USA* vol 117 (42) 26340-6 2020
Manuscript *Leuk Corr Sci* CALGB-20202, CALGB-8461, CALGB-9665
<http://www.ncbi.nlm.nih.gov/pubmed/33020282>

192 Validation of the prognostic significance of the knowledge bank (KB) algorithm in adult acute myeloid leukemia (AML) patients (pts) treated on Cancer and Leukemia Group B (CALGB)/Alliance protocols and suggestions for improvements

Marius Bill, Krzysztof Mrózek, Jessica Kohlschmidt, Brian Giacomelli, Deedra Nicolet, Dimitrios Papaioannou, Ann-Kathrin Einfeld, Jonathan E. Kolitz, Bayard L. Powell, Andrew J. Carroll, Richard M. Stone, John C. Byrd, Ramiro Garzon, Christopher C. Oakes, Clara D. Bloomfield *EHA Library EP464* 2020
Abstract *Leuk Corr Sci* CALGB-20202, CALGB-8461, CALGB-9665
<https://library.ehaweb.org/eha/2020/eha25th/294383/marius.bill.validation.the.of.prognostic.significance>

193 Personalized Oncology in Acute Myeloid Leukemia (AML): Validation of the Prognostic Value of the Knowledge Bank Approach in Patients (Pts) Treated on Cancer and Leukemia Group B/Alliance Protocols

Marius Bill, Krzysztof Mrózek, Jessica Kohlschmidt, Deedra Nicolet, Brian Giacomelli, Christopher J. Walker, Dimitrios Papaioannou, Ann-Kathrin Einfeld, Jonathan E. Kolitz, Bayard L. Powell, Andrew J. Carroll, Richard M. Stone, John C. Byrd, Ramiro Garzon, Christopher C. Oakes, Clara D. Bloomfield *Blood* vol 134 (Supplement 1) 182 2019
Abstract *Leukemia* CALGB-20202, CALGB-8461, CALGB-9665
https://ashpublications.org/blood/article/134/Supplement_1/182/426230/Personalized-Oncology-in-Acute

194 A 17-gene leukemia stem cell (LSC) score in adult patients (pts) with acute myeloid leukemia (AML) reveals a distinct mutational landscape and refines current European Leukemianet (ELN) genetic risk stratification (Alliance)

Marius Bill, Deedra Nicolet, Ann-Kathrin Einfeld, Krzysztof Mrózek, Christopher J. Walker, Jessica Kohlschmidt, Dimitrios Papaioannou, Jonathan E. Kolitz, Bayard L. Powell, John C Byrd, Ramiro Garzon, Clara D. Bloomfield *Blood* vol 132 (Suppl 1) 289 2018
Abstract *Leuk Corr Sci* CALGB-20202, CALGB-8461
http://www.bloodjournal.org/content/132/Suppl_1/289

- 195 Mutations associated with a 17-gene leukemia stem cell score and the score's prognostic relevance in the context of the European LeukemiaNet classification of acute myeloid leukemia**
Marius Bill, Deedra Nicolet, Jessica Kohlschmidt, Christopher J. Walker, Krzysztof Mrózek, Ann-Kathrin Eisfeld, Dimitrios Papaioannou, Xiaoqing Rong-Mullins, Zachary Brannan, Jonathan E. Kolitz, Bayard L. Powell, Kellie J. Archer, Adrienne M. Dorrance, Andrew J. Carroll, Richard M. Stone, John C. Byrd, Ramiro Garzon, Clara D. Bloomfield *Haematologica* vol 105 (3) 721-729 2020
Manuscript *Leuk Corr Sci* CALGB-8621, CALGB-8461, CALGB-8721, CALGB-10201, CALGB-10502, CALGB-10503, CALGB-10603, CALGB-11001, CALGB-11002, CALGB-19808, CALGB-20202, CALGB-8525, CALGB-8821, CALGB-8923, CALGB-9022, CALGB-9120, CALGB-9222, CALGB-9420, CALGB-9621, CALGB-9665, CALGB-9720
<http://www.ncbi.nlm.nih.gov/pubmed/31413100>
- 196 Prognostic and biologic significance of transfer RNA-derived small RNAs(tsRNAs) expression in younger adult patients (pts) with cytogenetically normal acute myeloid leukemia (CN-AML)**
Marius Bill, Dario Veneziano, Jessica Kohlschmidt, Krzysztof Mrózek, Giovanni Nigita, Maria G. Krantz, Deedra Nicolet, Dimitrios Papaioannou, Allison E. Walker, Zachary Brannan, Bayard L. Powell, Richard M. Stone, Geoffrey L. Uy, Jonathan E. Kolitz, Eunice S. Wang, Adrienne M. Dorrance, John Byrd, Carlo M. Croce, Ramiro Garzon, Clara D. Bloomfield *Blood* vol 132 (Suppl 1) 89 2018
Abstract *Leuk Corr Sci* CALGB-8461, CALGB-9665, CALGB-20202
http://www.bloodjournal.org/content/132/Suppl_1/89?sso-checked=true
- 197 Perioperative Patient Reported Outcomes Predict Serious Postoperative Complications: A Secondary Analysis of the COST Trial**
Juliane Bingener, Jeff A. Sloan, Paul J. Novotny, Barbara A. Pockaj, Heidi Nelson *J Gastrointest Surg* vol 19 (1) 65-71 2015
Manuscript *Health Outcomes* <http://www.ncbi.nlm.nih.gov/pubmed/25091846>
- 198 Demonstrating the value of coincidence analysis for identifying successful implementation strategies**
Sarah A. Birken, Soohyun Hwang, Laura Viera, Emily Haines, Tamara Huson, Rebecca Whitaker, Lawrence Shulman, Deborah K. Mayer *IMPLEMENTATION SCIENCE* vol 15 1748-5908 2020
Abstract *CCDR*
<https://societyforimplementationresearchcollaboration.org/wp-content/uploads/2019/11/2019-SIRC-prog>
- 199 Induction (Ind) plus concurrent (Con) chemotherapy with high-dose (74 Gy) 3-dimensional (3-D) thoracic radiotherapy (TRT) in stage III non-small cell lung cancer (NSCLC): Preliminary report of Cancer and Leukemia Group B (CALGB) 30105**
A. W. Blackstock, M. A. Socinski, J. Bogart, L. Gu, X. Wang, M. Green, E. E. Vokes *J Clin Oncol* vol 24 (18s) abstr 7042 2006
Abstract *Respiratory* http://meeting.ascopubs.org/cgi/content/abstract/24/18_suppl/7042
- 200 Impact of young (Y) age on efficacy and safety in advanced colorectal cancer (aCRC): A pooled analysis examining 6,286 patients (pts) from nine first-line phase III chemotherapy (CT) trials**
C. D. Blanke, B. M. Bot, D. M. Thomas, A. Bleyer, C. Kohne, M. T. Seymour, A. De Gramont, R. M. Goldberg, D. J. Sargent, *LIVESTRONG Young Adult Alliance (LSYAA)* *J Clin Oncol* vol 28 (15s) abstr 3520 2010
Abstract *GI*
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID
- 201 Impact of Young Age on Treatment Efficacy and Safety in Advanced Colorectal Cancer: A Pooled Analysis of Patients From Nine First-Line Phase III Chemotherapy Trials**

Charles D. Blanke, Brian M. Bot, David M. Thomas, Archie Bleyer, Claus-Henning Kohne, Matthew T. Seymour, Aimery de Gramont, Richard M. Goldberg, Daniel J. Sargent J Clin Oncol vol 29 (20) 2781-2786 2011
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/21646604>

202 Meta-analyses of 22 randomized trials assessing the influence of chemotherapy in advanced/recurrent gastric cancer.

H. Bleiberg, D. J. Sargent J Clin Oncol vol 29 (suppl) abstr 4109 2011
Abstract GI NCCTG-79-41-51, NCCTG-83-41-51 <http://meetinglibrary.asco.org/content/83472-102>

203 Financial Toxicity Monitoring in a Randomized Controlled Trial of Patient-Reported Outcomes During Cancer Treatment (Alliance AFT-39).

Victoria S Blinder, Allison M Deal, Brenda Ginos, Jennifer Jansen, Amylou C Dueck, Gina L Mazza, Sydney Henson, Philip Carr, Lauren J Rogak, Anna Weiss, Anna Rapperport, Mattias Jonsson, Patricia A Spears, David Cella, Francesca Gany, Deborah Schrag, Ethan Basch J Clin Oncol JCO2202834 2023
Manuscript CCDR <http://www.ncbi.nlm.nih.gov/pubmed/37625107>

204 Alliance A071101: A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) Vaccine Given with Bevacizumab versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma

Orin Bloch, Qian Shi, S. Keith Anderson, Michael Knopp, Jeffrey Raizer, Jennifer Clarke, Allen Waziri, Howard Colman, Jeffrey Bruce, Jeffrey Olson, John Schwerkoske, Andrew Parsa, Joon Uhm, Priya Kumthekar, Evanthia Galanis, Ian Parney Neuro-oncology vol 19 (suppl 6) abst ATIM-14. 2017
Abstract Neuro-Onc
https://watermark.silverchair.com/nox168.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9

205 Cognitive Function and Discontinuation of Adjuvant Hormonal Therapy in Older Breast Cancer Survivors: CALGB 369901 (Alliance)

Shirley M. Bluethmann, Catherine M. Alfano, Jonathan D. Clapp, George Luta, Brent J. Small, Arti Hurria, Harvey J. Cohen, Steven Sugarman, Hyman Muss, Claudine Isaacs, Jeanne S. Mandelblatt Breast Cancer Res Treat vol 165 (3) 677-686 2017
Manuscript Older Adult <http://www.ncbi.nlm.nih.gov/pubmed/28653250>

206 Serious Pulmonary Toxicity with SGN-30 and Gemcitabine, Vinorelbine, and Liposomal Doxorubicin in Patients with Relapsed/Refractory Hodgkin Lymphoma (HL): Cancer and Leukemia Group B (CALGB) 50502

K. A. Blum, J. L. Johnson, S.-H. Jung, B. D. Cheson, N. L. Bartlett Blood vol 112 (11) 232 2008
Abstract Lymphoma <http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;112/11/232>

207 Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcRIIIa-158 V/F polymorphism

K. A. Blum, S.-H. Jung, J. L. Johnson, T. S. Lin, E. D. Hsi, D. M. Lucas, J. C. Byrd, B. D. Cheson, N. L. Bartlett Ann Oncol vol 21 (11) 2246-54 2010
Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/20423913>

208 Randomized phase 2 trial of ofatumumab and bendamustine versus ofatumumab, bendamustine and bortezomib induction and maintenance therapy in patients (pts) with previously untreated high risk follicular lymphoma (FL): results from CALGB 50904 (Alliance)

Kristie A. Blum, Sin-Ho Jung, Ian Barak, Eric D. Hsi, Nancy L. Bartlett, James N. Atkins, Nina Wagner-Johnston, Eric Hsi, Bruce D. Cheson, John P. Leonard Blood vol 130 (Suppl 1) 485 2017
Abstract Lymphoma http://www.bloodjournal.org/content/130/Suppl_1/485

209 Randomized Trial of Ofatumumab and Bendamustine versus Ofatumumab, Bendamustine and Bortezomib in previously untreated patients with highrisk follicular lymphoma: CALGB 50904 (Alliance)

Kristie A. Blum, Mei-Yin Polley, Sin-Ho Jung, Travis J. Dockter, Sarah Anderson, Eric D. Hsi, Nina Wagner-Johnston, Beth Christian, Jim Atkins, Bruce D. Cheson, John P. Leonard, Nancy L. Bartlett
Cancer vol 125 (19) 3378-89 2019
Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/31174236>

210 Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206.

Kristie A Blum, Jeffrey L Johnson, Donna Niedzwiecki, George P Canellos, Bruce D Cheson, Nancy L Bartlett
Leuk Lymphoma vol 48 (7) 1313-9 2007
Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/17613759>

211 Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin lymphoma: results of Cancer and Leukemia Group B Study 9153.

Kristie A Blum, Jeffrey L Johnson, Donna Niedzwiecki, Lawrence D Piro, Alan Saven, Bruce A Peterson, John C Byrd, Bruce D Cheson
Cancer vol 107 (12) 2817-25 2006
Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/17120198>

212 Challenges for conducting clinical trials evaluating maintenance chemotherapy in acute myeloid leukemia (AML): a Cancer and Leukemia Group B (CALGB) study

W. Blum, K. Donohue, G. Marcucci, D. J. Deangelo, G. L. Uy, B. L. Powell, W. Stock, M. Baer, J. E. Kolitz, M. Wetzler, E. Hoke, B. K. Moser, R. A. Larson
Blood vol 116 (21) 2176 2010
Abstract Leukemia <http://www.bloodjournal.org/content/116/21/2176>

213 Maintenance Therapy with Decitabine in Younger Adults with Acute Myeloid Leukemia (AML) in First Remission: A Phase II Cancer and Leukemia Group B Study (CALGB 10503, Alliance)

W. Blum, B. Sanford, R. B. Klisovic, D. J. Deangelo, G. Uy, B. L. Powell, W. Stock, M. R. Baer, J. E. Kolitz, M. Wetzler, E. Hoke, C. D. Bloomfield, S. Geyer, G. Marcucci, R. M. Stone, R. A. Larson
Blood vol 120 (21) -44 2012
Abstract Leukemia <http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;120/21/44>

214 Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B study (CALGB 10503)

William Blum, Ben L. Sanford, Rebecca Klisovic, Daniel J. DeAngelo, Geoffrey Uy, Bayard L. Powell, Wendy Stock, Maria R. Baer, Jonathan E. Kolitz, Eunice S. Wang, Eva Hoke, Krzysztof Mrózek, Jessica Kohlschmidt, Clara D. Bloomfield, Susan Geyer, Guido Marcucci, Richard M. Stone, Richard A. Larson
Leukemia vol 31 (1) 34-39 2017
Manuscript Leukemia <http://www.ncbi.nlm.nih.gov/pubmed/27624549>

215 Accelerated conformal radiotherapy for stage I non-small cell lung cancer (NSCLC) in patients with pulmonary dysfunction: A CALGB phase I study.

J. Bogart, D. Watson, S. Seagren, W. Blackstock, X Wang, R. Lenox, E. Vokes, A. T. Turrisi 3rd, M. R. Green
J Clin Oncol vol 25 (18S (June 20 Supplement)) 7556 2007
Abstract Respiratory
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID

216 Phase I Study of Accelerated Conformal Radiotherapy for Stage I Non-Small-Cell Lung Cancer in Patients With Pulmonary Dysfunction: CALGB 39904

Jeffrey A. Bogart, Lydia Hodgson, Stephen L. Seagren, A. William Blackstock, Xiaofei Wang, Robert Lenox, Andrew T. Turrisi, John Reilly, Ajeet Gajra, Everett E. Vokes, Mark R. Green
J Clin Oncol

217 Interruptions Of Once-Daily Thoracic Radiotherapy Do Not Correlate With Outcomes In Limited Stage Small Cell Lung Cancer: Analysis of CALGB Phase III Trial 9235

Jeffrey A. Bogart, Dorothy Watson, Edward F. McClay, Lisa Evans, James E. Herndon, Frances Laurie, Stephen L Seagren, T.J Fitzgerald, Everett Vokes, Mark R Green Lung Cancer vol 62 (1) 92-98 2008

Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/18367288>

218 High-Dose Once-Daily Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: CALGB 30610 (Alliance)/RTOG 0538

Jeffrey Bogart, Xiaofei Wang, Gregory Masters, Junheng Gao, Ritsuko Komaki, Laurie E. Gaspar, John Heymach, James Bonner, Charles Kuzma, Saiama Waqar, William Petty, Thomas E.

Stinchcombe, Jeffrey D. Bradley, Everett Vokes J Clin Oncol vol 41 (13) 2394-2402 2023

Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/36623230>

219 Impact of Stratification Factors on Outcomes in Limited-Stage Small Cell Lung Cancer: Analysis of CALGB 30610 (Alliance)/RTOG 0538

Jeffrey Bogart, Xiaofei Wang, Gregory Masters, Junheng Gao, Ritsuko Komaki, Laurie E. Gaspar, John Heymach, James Bonner, Charles Kuzma, Saiama Waqar, William Petty, Thomas E

Stinchcombe, Jeffrey D. Bradley, Everett Vokes Ann Oncol vol 33 (suppl 7) S1253-S1254 2022

Abstract Respiratory [https://www.annalsofoncology.org/article/S0923-7534\(22\)03491-3/fulltext](https://www.annalsofoncology.org/article/S0923-7534(22)03491-3/fulltext)

220 Short Communication: Interim toxicity analysis for patients with limited stage small cell lung cancer (LSCLC) treated on CALGB 30610 (Alliance) / RTOG 0538

Jeffrey Bogart, Xiaofei Wang, Gregory Masters, Junheng Gao, Ritsuko Komaki, Laurie E. Gaspar,

John Heymach, Michael Christian Dobelbower, Charles Kuzma, Tom Stinchcombe, Everett Vokes

Lung Cancer vol 156 68-71 2021

Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/33894496>

221 Phase III Comparison of High Dose Once-Daily (QD) Thoracic Radiotherapy (TRT) with Standard Twice-Daily (BID) TRT in limited stage small cell lung cancer (LSCLC): CALGB 30610 (Alliance) / RTOG 0538

Jeffrey Bogart, Xiaofei Wang, Gregory Masters, Junheng Gao, Ritsuko Komaki, Laurie E. Gaspar,

John Heymach, Michael Christian Dobelbower, Charles Kuzma, Saiama Waqar, William Jeffrey Petty,

Tom Stinchcombe, Jeffrey D. Bradley, Everett Vokes J Clin Oncol vol 39 (no. 15_suppl) 8505 2021

Abstract Respiratory <https://meetings.asco.org/abstracts-presentations/195952>

222 Mature outcomes of 61.2 Gy concomitant boost (CB) thoracic radiotherapy (TRT) in limited stage small cell lung cancer (LSCLC): CALGB 30610 (Alliance) / RTOG 0538

Jeffrey Bogart, Xiaofei Wang, Gregory Masters, Junheng Gao, Ritsuko Komaki, Laurie E. Gaspar,

John Heymach, Michael Christian Dobelbower, Charles Kuzma, Saiama Waqar, William Petty, Tom

Stinchcombe, Jeffrey D. Bradley, Everett Vokes International Journal of Radiation Oncology,

Biology, & Physics vol 111 (3 Supplement) S89 2021

Abstract Respiratory [https://www.redjournal.org/article/S0360-3016\(21\)01081-6/fulltext](https://www.redjournal.org/article/S0360-3016(21)01081-6/fulltext)

223 Interim toxicity analysis for patients with limited stage small cell lung cancer (LSCLC) treated on the experimental thoracic radiotherapy (TRT) arms of CALGB 30610 (Alliance) / RTOG 0538

Jeffrey Bogart, Xiaofei Wang, Gregory Masters, Han Zhu, Ritsuko Komaki, Laurie E. Gaspar, John

Heymach, Michael Christian Dobelbower, Charles Kuzma, Everett Vokes, Tom Stinchcombe Ann

Oncol vol 30 (5) v711 abstr 1737O 2019

Abstract Respiratory <https://www.sciencedirect.com/science/article/pii/S0923753419598714>

- 224 Hepatic arterial infusion and systemic chemotherapy after multiple metastasectomy in patients with colorectal carcinoma metastatic to the liver: a North Central Cancer Treatment Group (NCCTG) phase II study, 92-46-52**
J. S. Bolton, M. J. O'Connell, M. R. Mahoney, G. H. Farr Jr, T. R. Fitch, W. J. Maples, D. M. Nagorney, J. Rubin, J. Fuloria, P. D. Steen, S. R. Alberts Clin Colorectal Cancer vol 11 (1) 31-37 2012
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/21729678>
- 225 Laparoscopically assisted vs open colectomy for colon cancer: a meta-analysis.**
H Jacob Bonjer, Wim C J Hop, Heidi Nelson, Daniel J Sargent, Antonio M Lacy, Antoni Castells, Pierre J Guillou, Helen Thorpe, Julia Brown, Salvadora Delgado, Esther Kuhrij, Eva Haglind, Lars Pahlman Arch Surg vol 142 (3) 298-303 2007
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/17372057>
- 226 Testing of candidate single nucleotide variants associated with paclitaxel neuropathy in the trial NCCTG N08C1 (Alliance)**
Ganesh K. Boora, Rahul Kanwar, Amit A. Kulkarni, Alexej Abyzov, Jeff Sloan, Kathryn J. Ruddy, Michaela S. Banck, Charles L. Loprinzi, Andreas S. Beutler Cancer Med vol 5 (4) 631-639 2016
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/26763541>
- 227 Association of the Charcot-Marie-Tooth disease gene ARHGEF10 with paclitaxel induced peripheral neuropathy in NCCTG N08CA (Alliance)**
Ganesh K. Boora, Amit A. Kulkarni, Rahul Kanwar, Peter Beyerlein, Rui Qin, Michaela S. Banck, Kathryn J. Ruddy, Josef Pleticha, Cynthia A. Lynch, Robert J. Behrens, Stephan Zuchner, Charles L. Loprinzi, Andreas S. Beutler J Neurol Sci vol 357 (0) 35-40 2015
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/26143528>
- 228 Phase IB study of sorafenib + evofosfamide in patients with advanced hepatocellular carcinoma (HCC) and renal cell carcinoma NCCTG N1153 (Alliance)**
Mitesh J. Borad, Nathan R. Foster, Peter R. Martin, Steven Alberts, Joleen Hubbard, Alvin Silva, Thorvardur Halfdanarson, Charles Erlichman Ann Oncol vol 27 (2) abstr P-100 2016
Abstract Experimental http://annonc.oxfordjournals.org/content/27/suppl_2/ii29.4.short?rss=1
- 229 Comparative Outcomes and Molecular Response Predictors of IDH1/2-mutated Adult Acute Myeloid Leukemia (AML) Patients (Pts) after Frontline Treatment with Intensive Induction Chemotherapy (IC), Targeted Inhibitors, or Hypomethylating Agents (HMA) (Alliance)**
Uma Borate, Prapti Patel, Chetasi Talati, Jessica Kohlschmidt, Michael Ozga, Yazan Madanat, Luke Fletcher, Ravi Patel, Krzysztof Mrózek, Deedra Nicolet, Akriti Jain, Virginia Volpe, Fei Yang, Richard Press, Daniel Jones, James S. Blachly, Andrew J. Carroll, Guido Marcucci, Maria Baer, William G. Blum, Bayard L. Powell, Jonathan E. Kolitz, Richard M. Stone, John C. Byrd, Alice S. Mims, Kendra Sweet, Ann-Kathrin Eisfeld Blood vol 138 (Supplement 1) 226 2021
Abstract Leuk Corr Sci CALGB-20202, CALGB-8461, CALGB-9665
<https://www.sciencedirect.com/science/article/pii/S0006497121022230>
- 230 Activating Mutations in PIK3CA or AKT1 in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657)**
A. Boudreau, C. Yau, L. Petrillo, K. Stemke-Hale, G. Mills, J. W. Gray, D. M. Wolf, L. J. Van't Veer, L. J. Esserman Cancer Res vol 71 (24 Supplement 3) abstr P5-01-05 2011
Abstract Correl Sci NOS ACRIN-6657, CALGB-150007
http://cancerres.aacrjournals.org/content/71/24_Supplement/P5-01-05?cited-by=yes&legid=canres;71/24
- 231 Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for**

breast cancer patients enrolled in ACOSOG Z1071

J. C. Boughey, V. J. Suman, E. A. Mittendorf, G. M. Ahrendt, L. G. Wilke, B. Taback, A. Leitch, T. S. Flippo-Morton, D. R. Byrd, D. W. Ollila, T. B. Julian, S. A. McLaughlin, K. Hunt *Annals of Surgical Oncology* vol 20 (suppl 1) S8-S9 2013

Abstract Breast <http://www.annsurgoncol.org/journals/articlelist.html?v=20&j=10434&i=1&t=s>

232 The role of sentinel lymph node surgery in patients presenting with node positive breast cancer (T0-T4, N1-2) who receive neoadjuvant chemotherapy – results from the ACOSOG Z1071 trial

J. Boughey, V. Suman, E. Mittendorf, G. Ahrendt, L. Wilke, B. Taback, A. Leitch, T. Flippo-Morton, D. Byrd, D. Ollila, T. Julian, S. McLaughlin, L. McCall, W. Symmans, H. Le-Petross, B. Haffty, T. Buchholz, K. Hunt *Cancer Res* vol 72 (24 suppl) Abstract nr S2-1 2012

Abstract Breast

http://cancerres.aacrjournals.org/cgi/content/short/72/24_MeetingAbstracts/S2-1?rss=1

233 Axillary Ultrasound After Neoadjuvant Chemotherapy and Its Impact on Sentinel Lymph Node Surgery: Results From the American College of Surgeons Oncology Group Z1071 Trial (Alliance)

Judy C. Boughey, Karla V. Ballman, Kelly K. Hunt, Linda M. McCall, Elizabeth A. Mittendorf, Gretchen M. Ahrendt, Lee G. Wilke, Huong T. Le-Petross *J Clin Oncol* vol 33 (30) 3386-3393 2015
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/25646192>

234 Identification and resection of the clipped node decreases the false negative rate of sentinel lymph node surgery in patients presenting with node positive breast cancer (T0-T4, N1-2) who receive neoadjuvant chemotherapy – results from ACOSOG Z1071 (Alliance)

Judy C. Boughey, Karla V. Ballman, Huong T. Le-Petross, Linda M. McCall, Elizabeth A. Mittendorf, Gretchen M. Ahrendt, Lee G. Wilke, Bret Taback, Eric C. Feliberti, Kelly K. Hunt *Ann Surg* vol 263 (4) 802-807 2016

Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/26649589>

235 Tumor Biology and Response to Chemotherapy Impact Breast Cancer-Specific Survival in Node-Positive Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Long-term Follow-up from ACOSOG Z1071 (Alliance)

Judy C. Boughey, Karla V. Ballman, Linda M. McCall, Elizabeth A. Mittendorf, W. Fraser Symmans, Thomas B. Julian, David Byrd, Kelly K. Hunt *Ann Surg* vol 266 (4) 667-676 2017

Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/28657941>

236 Methods impacting the false negative rate of sentinel lymph node surgery in patients presenting with node positive breast cancer (T0-T4,N1-2) who receive neoadjuvant chemotherapy–results from a prospective trial–ACOSOG Z1071 (Alliance)

Judy C. Boughey, Karla V. Ballman, William F. Symmans, Linda M. McCall, Elizabeth A. Mittendorf, Gretchen M. Ahrendt, Lee G. Wilke, Bret Taback, Kelly K. Hunt *Cancer Res* vol 75 (9 Supplement) abstr P2-01-02 2015

Abstract Breast http://cancerres.aacrjournals.org/content/75/9_Supplement/P2-01-02.short?rss=1

237 Axillary Ultrasound after Neoadjuvant Chemotherapy in Patients Presenting with Node-Positive Breast Cancer (T0-T4, N1-2, M0) and its Impact on Sentinel Lymph Node Surgery in ACOSOG Z1071 (Alliance)

Judy C. Boughey, Karla Ballman, Kelly K. Hunt, Linda M. McCall, Elizabeth A. Mittendorf, Gretchen M. Ahrendt, Lee G. Wilke, Huong T. Le-Petross *Journal of the Senologic International Society* vol 2 (2) 40 (abstr SIS-0891) 2014

Abstract Breast <http://www.sisjournal.org/index.php/sisjournal/article/view/553>

238 Tumor biology and response to chemotherapy impact breast cancer specific survival in node positive breast cancer treated with neoadjuvant chemotherapy and axillary dissection: Results from

ACOSOG Z1071 (Alliance)

Judy C. Boughey, Karla Ballman, Linda McCall, David Byrd, Thomas Julian, Elizabeth Mittendorf, Kelly K. Hunt 2017
Abstract Breast <http://meeting.americansurgical.org/abstracts/2017/29.cgi>

239 Factors associated with lymphedema in patients/women with node positive breast cancer treated with neoadjuvant chemotherapy and axillary dissection on a prospective clinical trial (Alliance) ACOSOG Z1071

Judy C. Boughey, Karla Ballman, Linda McCall, Henry Kuerer, Kelly K. Hunt, Jane M. Armer J Clin Oncol vol 36 (no. 15_suppl) 513-513 2018
Abstract Breast https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.513

240 Predictors of locoregional recurrence after neoadjuvant chemotherapy and surgery for node positive breast cancer: Results from ACOSOG Z1071 (Alliance)

Judy C. Boughey, Karla Ballman, Linda McCall, Elizabeth Mittendorf, Kelly Hunt Cancer Res vol 77 (Suppl 4) Abstract nr P6-09-01 2017
Abstract Breast http://cancerres.aacrjournals.org/content/77/4_Supplement/P6-09-01

241 Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) prospective multicenter clinical trial

Judy C. Boughey, Linda M. McCall, Karla V. Ballman, Elizabeth A. Mittendorf, Gretchen M. Ahrendt, Lee G. Wilke, Bret Taback, A. Marilyn Leitch, Teresa Flippo-Morton, Kelly K. Hunt Ann Surg vol 260 (4) 608-616 2014
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/25203877>

242 Effect of the use of immediate reconstruction on the rates of bilateral mastectomy and adjuvant radiation therapy use in women with node-positive breast cancer treated with neoadjuvant chemotherapy on ACOSOG Z1071 (Alliance).

Judy C. Boughey, Linda McCall, Bruce Haffty, Tom Buchholz, Elizabeth A. Mittendorf, Karla Ballman, Kelly K. Hunt J Clin Oncol vol 33 (suppl) abstr 1060 2015
Abstract Breast http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/1060

243 Local Recurrence After Breast-Conserving Therapy in Patients With Multiple Ipsilateral Breast Cancer: Results From ACOSOG Z11102 (Alliance)

Judy C. Boughey, Kari M. Rosenkranz, Karla V. Ballman, Linda McCall, Bruce G. Haffty, Laurie W. Cuttino, Charlotte D. Kubicky, Huong T. Le-Petross, Armando E. Giuliano, Kimberly J. Van Zee, Kelly K. Hunt, Olwen M. Hahn, Lisa A. Carey, Ann H. Partridge J Clin Oncol vol 41 (17) 3184-93 2023
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/36977292>

244 Impact of the COVID-19 Pandemic on Cancer Clinical Trials

Judy C. Boughey, Rebecca A. Snyder, Olga Kantor, Linda Zheng, Akhil Chawla, Toan T. Nguyen, Shauna L. Hillman, Olwen M. Hahn, Sumithra J. Mandrekar, Christina L. Roland Ann Surg Oncol vol 28 (12) 7311-6 2021
Manuscript OGC funded--no committee <http://www.ncbi.nlm.nih.gov/pubmed/34236550>

245 Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071 (Alliance)

Judy C. Boughey, Vera J. Suman, Elizabeth A. Mittendorf, Gretchen M. Ahrendt, Lee G. Wilke, Bret Taback, A. Marilyn Leitch, Teresa S. Flippo-Morton, Henry M. Kuerer, Monet Bowling, Kelly K. Hunt Ann Surg vol 261 (3) 547-552 2015
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/25664534>

- 246 Sentinel Lymph Node Surgery after Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer: The American College of Surgeons Oncology Group (ACOSOG) Z1071 Clinical Trial**
Judy C. Boughey, Vera J. Suman, Elizabeth A. Mittendorf, Gretchen M. Ahrendt, Lee G. Wilke, Bret Taback, A. Marilyn Leitch, Henry M. Kuerer, Monet Bowling, Teresa S. Flippo-Morton, David R. Byrd, David W. Ollila, Thomas B. Julian, Sarah A. McLaughlin, Linda McCall, W. Fraser Symmans, Huong T. Le-Petross, Bruce G. Haffty, Thomas A. Buchholz, Heidi Nelson, Kelly K. Hunt JAMA vol 310 (14) 1455-1461 2013
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/24101169>
- 247 Detection of human telomerase reverse transcriptase mRNA in cells obtained by lavage of the pleura is not associated with worse outcome in patients with stage I/II non-small cell lung cancer; Results from CALGB 159902**
Alice M. Boylan, Xiaofei F Wang, Richard Ko, Patricia M Watson, Lin Gu, David Harpole, Raphael Bueno, Leslie Kohman, Robert Kratzke J Thorac Cardiovasc Surg vol 146 (1) 206-211 2013
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/23026566>
- 248 LACE-Bio: validation of prognostic role of tumour lymphocytic infiltration in resectable non small cell lung cancer**
E. Brambilla, C. Domerg, S. Lantuejoul, R. Kratzke, F.A. Sheperd, R. Pirker, J.Y. Douillard, T. Le Chevalier, A. Dunant, M Tsao J Thorac Oncol vol 7 (6) S29 2012
Abstract Respiratory <http://journals.lww.com/jto/Fulltext/2012/06001/Abstracts.6.aspx>
- 249 LACE-Bio: results of pooled analysis of prognostic and predictive values of histology and lymphocytic infiltration**
E. Brambilla, M. Tsao, E. Paris, S. Lantuejoul, S. L. Graziano, F. A. Shepherd, M. Filipits, R. Rosell, J. C. Soria, J. P. Pignon Ann Oncol vol 21 (suppl 8, viii130) abstr 388P 2010
Abstract Respiratory http://annonc.oxfordjournals.org/content/21/suppl_8/viii122.full.pdf+html
- 250 Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non-Small-Cell Lung Cancer**
Elisabeth Brambilla, Gwénaél Le Teuff, Sophie Marguet, Sylvie Lantuejoul, Ariane Dunant, Stephen Graziano, Robert Pirker, Jean-Yves Douillard, Thierry Le Chevalier, Martin Filipits, Rafael Rosell, Robert Kratzke, Helmut Popper, Jean-Charles Soria, Frances A. Shepherd, Lesley Seymour, Ming Sound Tsao J Clin Oncol vol 34 (11) 1223-1230 2016
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/26834066>
- 251 BRAF-MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas**
P.K. Brastianos, E. Twohy, S. Geyer, E.R. Gerstner, T.J. Kaufmann, S. Tabrizi, B. Kabat, J. Thierauf, M.W. Ruff, D.A. Bota, D.A. Reardon, A.L. Cohen, M.I. De La Fuente, G.J. Lesser, J. Campian, P.K. Agarwalla, P. Kumthekar, B. Mann, S. Vora, M. Knopp, A.J. Iafrate, W.T. Curry, D.P. Cahill, H.A. Shih, P.D. Brown, S. Santagata, F.G. Barker, E. Galanis N Engl J Med vol 389 (2) 118-126 2023
Manuscript Neuro-Onc <http://www.ncbi.nlm.nih.gov/pubmed/37437144>
- 252 Alliance A071401: Phase II trial of FAK inhibition in meningiomas with somatic NF2 mutations**
Priscilla K. Brastianos, Erin L. Twohy, Elizabeth R. Gerstner, Timothy J. Kaufmann, A. John Iafrate, Suriya Jeyapalan, David E. Piccioni, Mohammed M. Milhem, Andrew B. Lassman, Camilo E. Fadul, David Schiff, Jennie W. Taylor, Sajeel Akbar Chowdhary, Chetan Bettegowda, George Anstas, Frank S. Lieberman, Nicole Shonka, Thomas Kaley, Tara Morrison, Alissa A. Thomas, Mary R. Welch, Fabio Iwamoto, David Cachia, Adam L. Cohen, Priya Kumthekar, Ian Dunn, Jann Sarkaria, Susan Geyer, Xiomara W. Carrero, Maria Martinez-Lage, Paul D. Brown, Daniel P. Cahill, Caterina Giannini, Sandro Santagata, Frederick G. Barker, Evanthia Galanis J Clin Oncol vol 38 (15 suppl) 2502 2020

253 Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic NF2 Mutations

Priscilla K. Brastianos, Erin L. Twohy, Elizabeth R. Gerstner, Timothy J. Kaufmann, A. John Iafrate, Jochen Lennerz, Suriya Jeyapalan, David E. Piccioni, Varun Monga, Camilo E. Fadul, David Schiff, Jennie W. Taylor, Sajeel A. Chowdhary, Chetan Bettegowda, George Ansstas, Macarena De La Fuente, Mark D. Anderson, Nicole Shonka, Denise Damek, Jose Carrillo, Lara J. Kunschner-Ronan, Rekha Chaudhary, Kurt A. Jaeckle, Francis M. Senecal, Thomas Kaley, Tara Morrison, Alissa A. Thomas, Mary R. Welch, Fabio Iwamoto, David Cachia, Adam L. Cohen, Shivangi Vora, Michael Knopp, Ian F. Dunn, Priya Kumthekar, Jann Sarkaria, Susan Geyer, Xiomara W. Carrero, Maria Martinez-Lage, Daniel P. Cahill, Paul D. Brown, Caterina Giannini, Sandro Santagata, Frederick G. Barker II, Evanthia Galanis *J Clin Oncol* vol 41 (3) 618-28 2023
Manuscript Neuro-Onc <http://www.ncbi.nlm.nih.gov/pubmed/36288512>

254 Alliance A071601: Phase II trial of BRAF/MEK inhibition in newly diagnosed papillary craniopharyngiomas

Priscilla K. Brastianos, Erin Twohy, Susan Geyer, Elizabeth R. Gerstner, Timothy J. Kaufmann, Michael W. Ruff, Daniela Bota, David Reardon, Adam Cohen, Macarena De La Fuente, Glenn Lesser, Jian Campian, PK Agarwalla, Priya Kumthekar, Daniel P. Cahill, Helen A. Shih, Paul D. Brown, Sandro Santagata, Frederick G. Barker II, Evanthia Galanis *J Clin Oncol* vol 39 (no. 15_suppl) 2000 2021
Abstract Neuro-Onc https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.2000

255 Alliance A071601: Phase II trial of BRAF/MEK inhibition in newly diagnosed papillary craniopharyngiomas

Priscilla K. Brastianos, Erin Twohy, Susan Geyer, Elizabeth R. Gerstner, Timothy J. Kaufmann, Michael W. Ruff, Daniela Bota, David Reardon, Adam Cohen, Macarena De La Fuente, Glenn Lesser, Jian Campian, PK Agarwalla, Priya Kumthekar, Daniel P. Cahill, Helen A. Shih, Paul D. Brown, Sandro Santagata, Frederick G. Barker II, Evanthia Galanis *J Neurosurg* vol 135 (2) abstr 302 2021
Abstract Neuro-Onc <https://thejns.org/view/journals/j-neurosurg/135/2/article-p1.xml>

256 Alliance A071701: Genomically guided treatment trial in brain metastases

Priscilla Brastianos, Carey Anders, John Iafrate, Peter Kaufman, Justine Cohen, Rebecca Heist, Elizabeth Gerstner, Timothy Kaufmann, Erin Twohy, Susan M. Geyer, Laura Hoffman, Priya Kumthekar, Frederick Barker, Scott L. Carter, Paul D. Brown, Evanthia Galanis *J Clin Oncol* vol 38 (15_suppl) TPS2573 2020
Abstract Neuro-Onc https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.TPS2573

257 Development of Clinical Precision Medicine Approaches in Meningiomas: Alliance A071401.

Priscilla Brastianos, Qian Shi, Sandro Santagata, Keith Anderson, Suriya Jeyapalan, Dan Cahill, Elise Horvath, Fred Barker, Evanthia Galanis 2016
Abstract Neuro-Onc

258 Long term outcomes from intergroup NCCTG 86-72-51 (Alliance): Final report of a phase III prospective randomized trial of high dose versus low dose radiation therapy in adults with supratentorial low-grade glioma.

William G. Breen, S. Keith Anderson, Xiomara W Carrero, Paul D. Brown, Karla V. Ballman, Brian P. O'Neill, Walter J. Curran Jr., Ross Abrams, Nadia Laack, Ralph Levitt, Evanthia Galanis, Jan C. Buckner, Edward G. Shaw *Neuro-oncology* vol 2 (Supplement_6) vi13-vi14 2019
Abstract Neuro-Onc
https://www.researchgate.net/publication/337173070_ACTR-07_LONG-TERM_OUTCOMES_FROM_

- 259 Patterns of failure after stereotactic radiosurgery versus whole brain radiotherapy for resected brain metastases: central imaging review of the NCCTG N107C/CEC.3 (Alliance) phase III clinical trial**
William G. Breen, Katharine E. Dooley, Erin L. Twohy, Paul D. Brown, Karla V. Ballman, Jane H. Cerhan, James J. Urbanic, Anthony C. Whitton, Jeffrey Greenspoon, Ian F. Parney, Nadia N. Laack, Jean-Paul Bahary, Costas G. Hajipanayis, Fred G. Barker II, Deepak Khuntia, Caterina Giannini, Evanthis Galanis, David Roberge, Jonathan B. Ashman *International Journal of Radiation Oncology, Biology, & Physics* vol 114 (5) P1063-1064 2022
Abstract *Neuro-Onc* [https://www.redjournal.org/article/S0360-3016\(22\)03270-9/fulltext](https://www.redjournal.org/article/S0360-3016(22)03270-9/fulltext)
- 260 Final report from Intergroup NCCTG 86-72-51 (Alliance): a phase III randomized clinical trial of high-dose versus low-dose radiation for adult low-grade glioma**
William G Breen, S Keith Anderson, Xiomara W Carrero, Paul D Brown, Karla V Ballman, Brian P O'Neill, Walter J Curran, Ross A Abrams, Nadia N Laack, Ralph Levitt, Evanthis Galanis, Jan C Buckner, Edward G Shaw *Neuro-oncology* vol 22 (6) 830-7 2020
Manuscript *Neuro-Onc* <http://www.ncbi.nlm.nih.gov/pubmed/32002556>
- 261 Physical Activity in Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance)**
Justin C. Brown, Chao Ma, Qian Shi, Charles S. Fuchs, Jeffrey Meyer, Donna Niedzwiecki, Tyler Zemla, Felix Couture, Philip Kuebler, Pankaj Kumar, DeQuincy Lewis, Benjamin Tan, Smitha Krishnamurthi, Eileen M. O'Reilly, Anthony F. Shields, Jeffrey A. Meyerhardt *J Clin Oncol* vol 41 (2) 243-54 2023
Manuscript *GI* <http://www.ncbi.nlm.nih.gov/pubmed/35944235>
- 262 Physical activity in recurrent colon cancer: Cancer and Leukemia Group B/SWOG 80702 (Alliance).**
Justin C Brown, Chao Ma, Qian Shi, Tyler Zemla, Felix Couture, Philip Kuebler, Pankaj Kumar, Benjamin Tan, Smitha Krishnamurthi, Victor Chang, Richard M Goldberg, Alan P Venook, Charles D Blanke, Eileen M O'Reilly, Anthony F Shields, Jeffrey A Meyerhardt *Cancer* 2023
Manuscript *GI* <http://www.ncbi.nlm.nih.gov/pubmed/37651160>
- 263 Grain Intake and Clinical Outcome in Stage III Colon Cancer: Results From CALGB 89803 (Alliance)**
Justin C Brown, Sui Zhang, Donna Niedzwiecki, Leonard B Saltz, Robert J Mayer, Rex B Mowat, Renaud Whittom, Alexander Hantel, Al Benson III, Daniel Atienza, Michael Messino, Hedy Kindler, Alan Venook, Shuji Ogino, Yanping Li, Xuehong Zhang, Kimmie Ng, Walter C Willett, Edward L Giovannucci, Charles S Fuchs, Jeffrey A Meyerhardt *JNCI Cancer Spectr* vol 2 (2) pky017 2018
Manuscript *GI* <http://www.ncbi.nlm.nih.gov/pubmed/29877501>
- 264 Diabetes and Clinical Outcome in Patients With Metastatic Colorectal Cancer: CALGB 80405 (Alliance)**
Justin C Brown, Sui Zhang, Fang-Shu Ou, Alan P Venook, Donna Niedzwiecki, Heinz-Josef Lenz, Federico Innocenti, Bert H O'Neil, James E Shaw, Blase N Polite, Crystal S Denlinger, James N Atkins, Richard M Goldberg, Kimmie Ng, Robert J Mayer, Charles D Blanke, Eileen M O'Reilly, Charles S Fuchs, Jeffrey A Meyerhardt *JNCI Cancer Spectr* vol 4 (1) 2020
Manuscript *GI* <http://www.ncbi.nlm.nih.gov/pubmed/32259016>
- 265 Assessment of long-term rectal function in patients who received pelvic radiotherapy: a pooled North Central Cancer Treatment Group trial analysis, N09C1**
L. C. Brown, P. J. Atherton, M. A. Neben-Wittich, D. B. Wender, R. J. Behrens, T. F. Kozelsky, C. L. Loprinzi, M. G. Haddock, J. A. Martenson Jr *Support Care Cancer* vol 21 (10) 2869-77 2013
Manuscript *Health Outcomes* <http://www.ncbi.nlm.nih.gov/pubmed/23748483>

- 266 A phase II trial (N0177) of erlotinib and temozolomide (TMZ) combined with radiation therapy (RT) in glioblastoma multiforme (GBM)**
P. D. Brown, S. Krishnan, J. Sarkaria, W. Wu, P. Mischel, W. Yong, R. Arusell, R. Jenkins, J. Buckner, C. Giannini J Clin Oncol vol 26 (15s) abstr 2016 2008
Abstract Neuro-Onc
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID
- 267 Adult patients with supratentorial pilocytic astrocytoma: long-term follow-up of prospective multicenter clinical trial NCCTG-867251 (Alliance)**
Paul D. Brown, S. Keith Anderson, Xiomara W. Carrero, Brian P. O'Neill, Caterina Giannini, Eva Galanis, Sunjay A. Shah, Ross A. Abrams, Walter J. Curran, Jan C. Buckner, Edward G. Shaw
Neurooncol Pract vol 2 (4) 199-204 2015
Manuscript Neuro-Onc <http://www.ncbi.nlm.nih.gov/pubmed/26640699>
- 268 NCCTG N0574 (Alliance): A Phase III Randomized Trial of Whole Brain Radiation Therapy (WBRT) in Addition to Radiosurgery (SRS) in Patients with 1 to 3 Brain Metastases.**
Paul D. Brown, Anthony L. Asher, Karla V. Ballman, Elana Farace, Jane H. Cerhan, S. Keith Anderson, Xiomara W. Carrero, Fred G. Barker II, Richard Deming, Stuart H. Burri, Cynthia Menard, Caroline Chung, Volker W. Steiber, Richard, Bruce Pollock, Eva Galanis, Jan C. Buckner, Kurt Jaeckle Neuro Oncol vol 17 (suppl 5) v45-v46 2015
Abstract Neuro-Onc https://ascopubs.org/doi/abs/10.1200/jco.2015.33.18_suppl.lba4
- 269 NCCTG N0574 (Alliance): A Phase III Randomized Trial of Whole Brain Radiation Therapy (WBRT) in Addition to Radiosurgery (SRS) in Patients with 1 to 3 Brain Metastases**
Paul D. Brown, Anthony L. Asher, Karla V. Ballman, Elana Farace, Jane H. Cerhan, S. Keith Anderson, Xiomara W. Carrero, Fred Barker, Richard Deming, Stuart Burri, Bruce Pollock, Cynthia Menard, Caroline Chung, Volker W. Stieber, Eva Galanis, Jan C. Buckner, Kurt Jaeckle J Clin Oncol vol 33 (suppl) abstr LBA4 2015
Abstract Neuro-Onc <http://meetinglibrary.asco.org/content/146056-156>
- 270 N107C/CEC.3 (Alliance/NCIC): Phase III Trial of Post-Surgical Stereotactic Radiosurgery (SRS) Compared with Whole Brain Radiotherapy (WBRT) for Resected Metastatic Brain Disease**
Paul D. Brown, Karla V. Ballman, Jane H. Cerhan, S. Keith Anderson, Xiomara W. Carrero, Anthony C. Whitton, Jeffrey Greenspoon, Ian Parney, Nadia N.I. Laack, Jonathan Ashman, Jean-Paul Bahary, Costas G. Hadjipanayis, James Urbanic, Fred G. Barker II, Elana Farace, Deepak Khuntia, Caterina Giannini, Jan C. Buckner, Evanthia Galanis, David Roberge Int J Radiat Oncol Biol Phys vol 96 (5) 937, abstr LBA-1 2016
Abstract Neuro-Onc [http://www.redjournal.org/article/S0360-3016\(16\)33263-1/fulltext](http://www.redjournal.org/article/S0360-3016(16)33263-1/fulltext)
- 271 Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases**
Paul D. Brown, Kurt Jaeckle, Karla V. Ballman, Elana Farace, Jane H. Cerhan, S. Keith Anderson, Xiomara W. Carrero, Fred G. Barker, Richard Deming, Stuart H. Burri, Cynthia Ménard, Caroline Chung, Volker W. Stieber, Bruce E. Pollock, Evanthia Galanis, Jan C. Buckner, Anthony L. Asher
JAMA vol 316 (4) 401-409 2016
Manuscript Neuro-Onc <http://www.ncbi.nlm.nih.gov/pubmed/27458945>
- 272 Phase I/II Trial of Erlotinib and Temozolomide With Radiation Therapy in the Treatment of Newly Diagnosed Glioblastoma Multiforme: North Central Cancer Treatment Group Study N0177**
Paul D. Brown, Sunil Krishnan, Jann N. Sarkaria, Wenting Wu, Kurt A. Jaeckle, Joon H. Uhm, Francois J. Geoffroy, Robert Arusell, Gaspar Kitange, Robert B. Jenkins, John W. Kugler, Roscoe F. Morton, Kendrith M. Rowland, Paul Mischel, William H. Yong, Bernd W. Scheithauer, David Schiff, Caterina Giannini, Jan C. Buckner J Clin Oncol vol 26 (34) 5603-5609 2008

273 Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC-3): a multicentre, randomised, controlled, phase 3 trial

Paul D Brown, Karla V Ballman, Jane H Cerhan, S Keith Anderson, Xiomara W Carrero, Anthony C Whitton, Jeffrey Greenspoon, Ian F Parney, Nadia N I Laack, Jonathan B Ashman, Jean-Paul Bahary, Costas G Hadjipanayis, James J Urbanic, Fred G Barker, Elana Farace, Deepak Khuntia, Caterina Giannini, Jan C Buckner, Evanthia Galanis, David Roberge *Lancet Oncol* vol 18 (8) 1049-1060 2017

Manuscript Neuro-Onc <http://www.ncbi.nlm.nih.gov/pubmed/28687377>

274 Phase II Trial of Oral Topotecan and Intravenous Carboplatin With G-CSF Support in Previously Untreated Patients With Extensive Stage Small Cell Lung Cancer

Alan H. Bryce, Bassam Mattar, Shauna L. Hillman, Alex A. Adjei, John W. Kugler, Kendrith Rowland, Donald B. Wender, Gamini Soori, Edith A. Perez, James R. Jett *Am J Clin Oncol* vol 33 (4) 353-357 2010

Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/19935387>

275 Prognosis in patients with anaplastic oligoastrocytoma is associated with histologic grade.

Jan C Buckner, Judith R O'Fallon, Robert P Dinapoli, Paula J Schomberg, Gist Farr, Paul Schaefer, Caterina Giannini, Bernd W Scheithauer, Karla V Ballman *J Neurooncol* vol 84 (3) 279-86 2007

Manuscript Neuro-Onc <http://www.ncbi.nlm.nih.gov/pubmed/17431544>

276 Multi-institutional prospective validation of prognostic mRNA signatures in early stage squamous lung cancer (Alliance)

Raphael Bueno, William G. Richards, David H. Harpole, Karla V. Ballman, Ming-Sound Tsao, Zhengming Chen, Xiaofei Wang, Guoan Chen, Lucian R. Chirieac, M. Herman Chui, Wilbur A. Franklin, Thomas J. Giordano, Ramaswamy Govindan, Mary-Beth Joshi, Daniel T. Merrick, Christopher J. Rivard, Thomas Sporn, Adrie van Bokhoven, Hui Yu, Frances A. Shepherd, Mark A. Watson, David G. Beer, Fred R. Hirsch *J Thorac Oncol* vol 15 (11) 1748-57 2020

Manuscript Correl Sci NOS CALGB-140202 <http://www.ncbi.nlm.nih.gov/pubmed/32717408>

277 Fulvestrant with or without Lapatinib as Therapy for Hormone Receptor Positive Advanced Breast Cancer: A Double-Blinded, Placebo-Controlled, Randomized Phase III Study

H. J. Burstein, W. T. Barry, C. Cirrincione, H. K. Chew, S. Tolaney, D. Lake, T. Pluard, K. Blackwell, E. P. Winer, C. A. Hudis *Cancer Res* vol 70 (24 suppl 2) abstr PD05-01 2010

Abstract Breast

http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/70/24_MeetingAbstracts/PD05-01

278 Endocrine Therapy With or Without Inhibition of Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor 2: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Fulvestrant With or Without Lapatinib for Postmenopausal Women With Hormone Receptor–Positive Advanced Breast Cancer—CALGB 40302 (Alliance)

Harold J. Burstein, Constance T. Cirrincione, William T. Barry, Helen K. Chew, Sara M. Tolaney, Diana E. Lake, Cynthia Ma, Kimberly L. Blackwell, Eric P. Winer, Clifford A. Hudis *J Clin Oncol* vol 32 (35) 3959-3966 2014

Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/25348000>

279 Preliminary safety data of a randomized phase III trial comparing a preoperative regimen of FEC-75 alone followed by paclitaxel plus trastuzumab with a regimen of paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab in patients with HER2-positive operable breast cancer (ACOSOG Z1041)

A. U. Buzdar, F. Meric-Bernstam, J. C. Boughey, A. M. Leitch, G. Unzeitig, M. J. Ellis, M. Ewer, K.

K. Hunt J Clin Oncol vol 28 (15s) abtr 594 2010
Abstract Breast <http://meetinglibrary.asco.org/content/50348-74>

- 280 ACOSOG Z1041 (Alliance): Definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC -> P+T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P+T -> FEC+T) in HER2+ operable breast cancer**
A. Buzdar, V. Suman, F. Meric-Bernstam, M. Leitch, M. Ellis, J. Boughey, G. Unzeitig, M. Royce, K. Hunt J Clin Oncol vol 31 (15 suppl) abstr 502 2013
Abstract Breast http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/502?sid=505c7186-af8b-4515-a764-d88ee4
- 281 Disease-free (DFS) and overall survival (OS) data from ACOSOG Z1041 (Alliance) a randomized neoadjuvant trial comparing FEC followed by Paclitaxel plus Trastuzumab (FEC P+T) with Paclitaxel plus Trastuzumab followed by FEC plus Trastuzumab (P+T FEC+T) in HER2-positive operable breast cancer**
Aman U. Buzdar, Vera J. Suman, Funda Meric-Bernstam, Ann M. Leitch, Matthew J. Ellis, Judy C. Boughey, Gary W. Unzeitig, Melanie E. Royce, Michael S. Ewer, Kelly K. Hunt Cancer Res vol 76 (4 Suppl) P1-14-02 2016
Abstract Breast http://cancerres.aacrjournals.org/content/76/4_Supplement/P1-14-02.abstract
- 282 Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy**
Aman U. Buzdar, Vera J. Suman, Funda Meric-Bernstam, Ann Marilyn Leitch, Matthew J. Ellis, Judy C. Boughey, Gary W. Unzeitig, Melanie E. Royce, Kelly K. Hunt JAMA Oncol vol 5 (1) 45-50 2019
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/30193295>
- 283 Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial**
Aman U Buzdar, Vera J Suman, Funda Meric-Bernstam, A Marilyn Leitch, Matthew J Ellis, Judy C Boughey, Gary Unzeitig, Melanie Royce, Linda M McCall, Michael S Ewer, Kelly K Hunt Lancet Oncol vol 14 (13) 1317-1325 2013
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/24239210>
- 284 Disparities in Surveillance Imaging After Breast-Conserving Surgery for Primary DCIS (AFT-25)**
Danalyn Byng, Valeca P. Retèl, Wim H. van Harten, Christel N. Rushing, Samantha M. Thomas, Thomas Lynch, Anne McCarthy, Amanda B. Francescatti, Ann H. Partridge, Alastair M. Thompson, Lars Grimm, Terri Hyslop, E. Shelley Hwang, Marc D. Ryser J Clin Oncol vol 39 (15_suppl) 6516 2021
Abstract Breast https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.6516
- 285 Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance)**
John C. Byrd, Amy S. Ruppert, Nyla A. Heerema, Alese E. Halvorson, Eva Hoke, Mitchell R. Smith, John E. Godwin, Stephen Couban, Todd A. Fehniger, Michael J. Thirman, Martin S. Tallman, Frederick R. Appelbaum, Richard M. Stone, Sue Robinson, Julie E. Chang, Sumithra J. Mandrekar, Richard A. Larson Blood Adv vol 2 (14) 1705-18 2018
Manuscript Leukemia <http://www.ncbi.nlm.nih.gov/pubmed/30030269>
- 286 Fludarabine followed by alemtuzumab consolidation for previously untreated chronic**

lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901.

John C Byrd, Bercedis L Peterson, Kanti R Rai, David Hurd, Raymond Hohl, Michael C Perry, Jon Gockerman, Sreenivasa Nattam, Richard A Larson Leuk Lymphoma vol 50 (10) 1589-96 2009
Manuscript Leukemia <http://www.ncbi.nlm.nih.gov/pubmed/19863336>

287 TCR Sequencing to Identify Responders in Patients with Stage III NSCLC Treated with Atezoluzimab with Chemoradiation (AFT-16).

Woo Yul Byun, Helen Ross, David Kozono, James Urbanic, Ryan Robb, Tiffany Talabere, Filiz Oezkan, Daniel Spakowicz, David Carbone, Terence M. Williams J Thorac Oncol vol 16 (3_suppl) S645 2021
Abstract Respiratory [https://www.jto.org/article/S1556-0864\(21\)01222-3/fulltext](https://www.jto.org/article/S1556-0864(21)01222-3/fulltext)

288 Analysis of Transplant-eligible Patients (Pts) Who Received Front-line Daratumumab (DARA)-based Therapy for Treatment of Newly Diagnosed Multiple Myeloma (NDMM) With High-risk Cytogenetic Abnormalities (HRCA) in the GRIFFIN (AFT-29) and MASTER Studies

Natalie S. Callander, Rebecca Silbermann, Jonathan L. Kaufman, Kelly N. Godby, Jacob Laubach, Timothy Schmidt, Douglas W. Sborov, Eva Medvedova, Brandi Reeves, Binod Dhakal, Cesar Rodriguez, Saurabh Chhabra, Ajai Chari, Susan Bal, Larry D. Anderson Jr., Bhagirathbhai R Dholaria, Nitya Nathwani, Parameswaran Hari, Nina Shah, Naresh Bumma, Sarah A. Holstein, Caitlin Costello, Andrzej Jakubowiak, Tanya M. Wildes, Robert Z. Orlowski, Kenneth H. Shain, Andrew J. Cowan, Huiling Pei, Annelore Cortoos, Sharmila Patel, Thomas S. Lin, Smith Giri, Luciano J. Costa, Paul G. Richardson, Saad Z Usmani, Peter M. Voorhees Blood vol 140 (suppl 1) 10144-7 2022
Abstract Myeloma AFT-29 (GRIFFIN), MASTER
<https://ashpublications.org/blood/article/140/Supplement%201/10144/488521/Analysis-of-Transplant-El>

289 Comparison of Residual Cancer Burden, American Joint Committee on Cancer staging and Pathologic Complete Response in Breast Cancer after Neoadjuvant Chemotherapy: Results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)

Jeffrey I. Campbell, Christina Yau, Polina Krass, Dan Moore, Lisa A. Carey, Alfred Au, David Chhieng, Dilip Giri, Chad Livasy, Carolyn Mies, Joseph Rabban, Venetia R. Sarode, Baljit Singh, Laura Esserman, Yunn-Yi Chen Breast Cancer Res Treat vol 165 (1) 181-191 2017
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/28577078>

290 What is the added value of actual tumor measurements (TM) in predicting overall survival (OS)? The North Central Cancer Treatment Group (NCCTG) findings

M. E. Campbell, S. J. Mandrekar, S. L. Hillman, R. M. Goldberg, K. M. Rowland Jr, I. a. A. Adje, H. C. Pitot, A. Grothey, J. C. Buckner, D. J. Sargent J Clin Oncol vol 26 (15s) 342s abstr 6520 2008
Abstract GI NCCTG-N0026, NCCTG-N9741
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID

291 Waterfall plots provide detailed information on magnitude of response to conventional chemotherapy in advanced colorectal cancer (ACRC) - lessons learned from N9741.

M. Campbell, A. Grothey, D. Sargent, R. Goldberg J Clin Oncol vol 25 (18s) abstr 4080 2007
Abstract GI
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID

292 The Prognostic Implications of Macrophages Expressing Proliferating Cell Nuclear Antigen in Breast Cancer Depend on Immune Context

Michael J. Campbell, Denise Wolf, Rita A. Mukhtar, Vickram Tandon, Christina Yau, Alfred Au, Frederick Baehner, Laura van't Veer, Donald Berry, Laura J. Esserman PLoS ONE vol 8 (10) 2013
Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/24205370>

293 What is important to women considering fertility preservation before cancer treatment?

Comparing decision-making values with and without using the pathways patient decision aid website.

S. Campbell, A. Hoffman, J. Weston, L.C. Crocker, D. Holman, A. Houston, R. Volk, T. Woodard
Fertility and Sterility e140 (abstr P-183) vol 112 (3) e140 (abstr P-183). 2019
Abstract CCDCR [https://www.fertstert.org/article/S0015-0282\(19\)31091-X/fulltext](https://www.fertstert.org/article/S0015-0282(19)31091-X/fulltext)

294 AFT-50 EndoMAP: A phase IB/II multi-cohort study of targeted agents with atezolizumab (Atezo) for patients (pts) with recurrent or persistent endometrial cancer (EC).

Evelyn Cantillo, Tyler Zemla, John W. Moroney, Edwin A. Alvarez, Lauren Yauch, Yvonne G. Lin, Michelle Brockman, Gillian DiLallo, Joyce Liu, Angeles Alvarez Secord, Andrew B. Nixon, Sumithra Mandrekar, Ursula Matulonis, David Kozono, Brian M. Slomovitz Internat J Gynecol Cancer vol 32 (3) TP010/#242 2022
Abstract Experimental https://ijgc.bmj.com/content/32/Suppl_3

295 2-adrenergic receptor gene expression as a prognostic and predictive biomarker in HER2-positive early-stage breast cancer patients enrolled in the NCCTG-N9831 (Alliance) trial

Rafael Caparica, Yaohua Ma, Claudia De Angelis, François Richard, Christine Desmedt, Ahmad Awada, Martine Piccart, Edith A. Perez, Alvaro Moreno-Aspitia, Sunil Badve, E. Aubrey Thompson, Evandro de Azambuja Annals of Oncology vol 31 (Supplement 4) S310 2020
Abstract Breast [https://www.annalsofoncology.org/article/S0923-7534\(20\)40288-1/abstract](https://www.annalsofoncology.org/article/S0923-7534(20)40288-1/abstract)

296 Beta-2 adrenergic receptor gene (ADRB2) expression in HER2-positive early-stage breast cancer patients: a post-hoc analysis of the NCCTG-N9831 (Alliance) trial

Rafael Caparica, Yaohua Ma, Claudia De Angelis, François Richard, Christine Desmedt, Ahmad Awada, Martine Piccart, Edith A. Perez, Alvaro Moreno-Aspitia, Sunil Badve, E. Aubrey Thompson, Evandro de Azambuja Clin Breast Cancer vol 22 (4) 308-18 2022
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/34980541>

297 Prognostic and Predictive Impact of Beta-2 Adrenergic Receptor Expression in HER2-Positive Breast Cancer.

Rafael Caparica, François Richard, Mariana Brandão, Ahmad Awada, Christos Sotiriou, Evandro de Azambuja Clin Breast Cancer vol 20 (3) 262-73.e7 2020
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/32229175>

298 Impact of KRAS mutations on adjuvant carboplatin/paclitaxel in surgically resected stage IB NSCLC: CALGB 9633

M. Capelletti, X. F. Wang, L. Gu, S. L. Graziano, R. A. Kratzke, G. M. Strauss, M. Maddaus, M. R. Green, E. E. Vokes, P. A. Janne J Clin Oncol vol 28 (15s) abstr 7008 2010
Abstract Correl Sci NOS
http://hwmaint.meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/7008

299 Gene expression signatures in pre- and post-therapy (Rx) specimens from CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer (BrCa).

Lisa A. Carey, William Thomas Barry, Brandy Pitcher, Katherine A. Hoadley, Maggie Chon U. Cheang, Carey K. Anders, N. Lynn Henry, Sara M. Tolaney, Chau T. Dang, Ian E. Krop, Lyndsay Harris, Donald A. Berry, Charles M. Perou, Eric P. Winer, Clifford A. Hudis J Clin Oncol vol 32 (15_suppl) 506 2014
Abstract Breast http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/506

300 Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib

Lisa A. Carey, Donald A. Berry, Constance T. Cirincione, William T. Barry, Brandelyn N. Pitcher,

Lyndsay N. Harris, David W. Ollila, Ian E. Krop, Norah Lynn Henry, Douglas J. Weckstein, Carey K. Anders, Baljit Singh, Katherine A. Hoadley, Michael Iglesia, Maggie Chon U. Cheang, Charles M. Perou, Eric P. Winer, Clifford A. Hudis *J Clin Oncol* vol 34 (6) 542-549 2016
Manuscript *Breast* <http://www.ncbi.nlm.nih.gov/pubmed/26527775>

301 Clinical and translational results of CALGB 40601: A neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer

Lisa A. Carey, Donald A. Berry, David Ollila, Lyndsay Harris, Ian E. Krop, Douglas Weckstein, Norah Lynn Henry, Carey K. Anders, Constance Cirrincione, Eric P. Winer, Charles M. Perou, Clifford Hudis
J Clin Oncol vol 31 (15 suppl) abstr 500 2013
Abstract *Breast*
http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/500?sid=211d90d6-54e6-40ec-951b-49deb

302 Relationship between obesity and clinical outcome in adults with acute myeloid leukemia: A pooled analysis from four CALGB (Alliance) clinical trials

Jorge J. Castillo, Flora Mulkey, Susan Geyer, Jonathan E. Kolitz, William Blum, Bayard L. Powell, Stephen L. George, Richard A. Larson, Richard M. Stone *Am J Hematol* vol 91 (2) 199-204 2016
Manuscript *Leukemia* CALGB-9621, CALGB-9710, CALGB-10503, CALGB-19808
<http://www.ncbi.nlm.nih.gov/pubmed/26526191>

303 Obesity Is An Adverse Prognostic Factor For Overall and Disease-Free Survival In Adult Acute Promyelocytic Leukemia But Not In Acute Myeloid Leukemia: A Pooled Analysis From Four Alliance Prospective Studies

Jorge J. Castillo, Flora Mulkey, Susan Geyer, Jonathan E. Kolitz, William Blum, Bayard L. Powell, Richard A. Larson, Richard M. Stone *Blood* vol 122 (21) 832 2013
Abstract *Leukemia* CALGB-9621, CALGB-9710, CALGB-10503, CALGB-19808
<http://bloodjournal.hematologylibrary.org/content/122/21/832.short>

304 Teaching Health-Care Providers to Query Patients With Cancer About Sexual and Gender Minority (SGM) Status and Sexual Health

Elizabeth J. Cathcart-Rake, Carmen Radecki Breitkopf, Judith Kaur, Jennifer O'Connor, Jennifer L. Ridgeway, Aminah Jatoi *Am J Hosp Palliat Care* vol 36 (6) 533-7 2019
Manuscript *Disparities* <http://www.ncbi.nlm.nih.gov/pubmed/30599758>

305 Acquisition of Sexual Orientation and Gender Identity (SOGI) Data Among NCI Community Oncology Research Program (NCORP) Practice Groups

Elizabeth J. Cathcart-Rake, Tyler Zemla, Aminah Jatoi, Kathryn E. Weaver, Heather Neuman, Anne E. Kazak, Ruth Carlos, Lucy Gansauer, Joseph M. Unger, Nicholas M. Pajewski, Charles Kamen *Cancer* vol 125 (8) 1313-18 2019
Manuscript *Disparities* <http://www.ncbi.nlm.nih.gov/pubmed/30561776>

306 A randomized, double-blind, placebo-controlled trial of testosterone for treatment of postmenopausal women with aromatase inhibitor-induced arthralgias: Alliance study A221102

Elizabeth Cathcart-Rake, Paul Novotny, Roberto Leon-Ferre, Jennifer Le-Rademacher, Elizabeth M. Storricks, Araba A. Adjei, Shelby Terstriep, Rebecca Glaser, Armando Giuliano, William R. Mitchell, Seth Page, Colleen Austin, Richard L. Deming, Margaret A. Ferreira, Jacqueline M. Lafky, Stephen N. Birrell, Charles L. Loprinzi *Support Care Cancer* vol 29 (1) 387-96 2021
Manuscript *Symptom Inter* <http://www.ncbi.nlm.nih.gov/pubmed/32372176>

307 How (and Why) to Ask the Older Cancer Patient about Sexual Health and Sexual Minority Status

Elizabeth Cathcart-Rake, Jennifer M. O'Connor, Alison Jacobson, Lois McGuire, Aminah Jatoi *J Geriatr Oncol* vol 11 (4) 576-8 2020

308 Querying Cancer Patients About Sexual Health and Sexual and Gender Minority Status: A Qualitative Study of Healthcare Providers

Elizabeth Cathcart-Rake, Jennifer M. O'Connor, Jennifer L. Ridgeway, Carmen Radecki Breitkopf, Lois J Mc Guire, Eric A. Olson, Judith S. Kaur, Konstantinos Leventakos, Aminah Jatoi *Am J Hosp Palliat Care* vol 37 (6) 418-23 2020

Manuscript Disparities <http://www.ncbi.nlm.nih.gov/pubmed/31601116>

309 Patients' Perspectives and Advice on How to Discuss Sexual Orientation, Gender Identity, and Sexual Health in Oncology Clinics.

Elizabeth Cathcart-Rake, Jennifer O'Connor, Jennifer L Ridgeway, Carmen Radecki Breitkopf, Judith S Kaur, Jessica Mitchell, Konstantinos Leventakos, Aminah Jatoi *Am J Hosp Palliat Care* vol 37 (12) 1053-61 2020

Manuscript Disparities <http://www.ncbi.nlm.nih.gov/pubmed/32212925>

310 Examiner accuracy in cognitive testing in multisite brain-tumor clinical trials: an analysis from the Alliance for Clinical Trials in Oncology

Jane H Cerhan, S Keith Anderson, Alissa M Butts, Alyx B Porter, Kurt Jaeckle, Evanthia Galanis, Paul D Brown *Neurooncol Pract* vol 6 (4) 283-8 2019

Manuscript Health Outcomes NCCTG-N0577, Alliance-A221101, NCCTG-N0874, NCCTG-N107C <http://www.ncbi.nlm.nih.gov/pubmed/31386061>

311 Chemoradiation (CRT) Safety Analysis of ACOSOG Z6041: A Phase II Trial of Neoadjuvant (NEO) CRT followed by Local Excision (LE) in uT2 Rectal Cancer (RC)

E. Chan, Q. Shi, J. Garcia-Aguilar, B. G. Wolff, C. S. Johnson, B. Sanders, X. Carrero, M. C. Posner, D. M. Ota, C. R. Thomas Jr *Int J Radiat Oncol Biol Phys* vol 78 (3, Supplement) S53-S54 2010

Abstract GI <http://www.sciencedirect.com/science/article/pii/S0360301610011338>

312 Association of Family History with Cancer Recurrence and Survival Among Patients with Stage III Colon Cancer

Jennifer A. Chan, Jeffrey A. Meyerhardt, Donna Niedzwiecki, Donna Hollis, Leonard B. Saltz, Robert J. Mayer, James Thomas, Paul Schaefer, Renaud Whitton, Alexander Hantel, Richard M. Goldberg, Robert S. Warren, Monica Bertagnolli, Charles S. Fuchs *JAMA* vol 299 (21) 2515-2523 2008

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/18523220>

313 Innovative estimation of survival using log-normal survival modelling on ACCENT database

J W Chapman, C J O'Callaghan, N Hu, K Ding, G A Yothers, P J Catalano, Q Shi, R G Gray, M J O'Connell, D J Sargent *Br J Cancer* vol 108 (4) 784-790 2013

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/23385733>

314 Comparison of innovative estimation of efficacy to standard using the ACCENT database.

J. W. Chapman, C. O'Callaghan, N. Hu, K. Ding, G. A. Yothers, P. J. Catalano, Q. Shi, R. G. Gray, M. J. O'Connell, D. J. Sargent *J Clin Oncol* vol 29 (suppl) abstr 3616 2011

Abstract GI

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID

315 Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Final Analysis of GRIFFIN (AFT-29) Among Clinically Relevant Subgroups

Ajai Chari, Jonathan L. Kaufman, Jacob Laubach, Douglas W. Sborov, Brandi Reeves, Cesar Rodriguez, Rebecca Silbermann, Luciano J. Costa, Larry D. Anderson Jr., Nitya Nathwani, Nina Shah, Naresh Bumba, Sarah A. Holstein, Caitlin Costello, Andrzej Jakubowiak, Tanya M. Wildes, Robert Z.

Orlowski, Kenneth H. Shain, Andrew J. Cowan, Huiling Pei, Annelore Cortoos, Sharmila Patel, Thomas S. Lin, Paul G. Richardson, Saad Z Usmani, Peter M. Voorhees *Blood* vol 140 (suppl 1) 7278–81 2022
Abstract Myeloma
<https://ashpublications.org/blood/article/140/Supplement%201/7278/491805/Daratumumab-Plus-Lenalid>

316 Patient satisfaction with participation in phase II/III NCCTG clinical trials: Was it worth it? (N0392)

C. Chauhan, P. J. Atherton, D. Satele, A. C. Dueck, G. S. Soori, D. B. Johnson, S. J. Mandrekar, J. C. Buckner, J. A. Sloan *J Clin Oncol* vol 30 (suppl) abstr 6133 2012
Abstract Health Outcomes http://meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/6133

317 Phase 2 Trial of Pemetrexed Disodium and Carboplatin in Previously Untreated Extensive-Stage Small Cell Lung Cancer, N0423

Cheng E. Chee, James R. Jett, Albert M. Bernath, Nathan R. Foster, Garth D. Nelson, Julian Molina, Daniel A. Nikcevich, Preston D. Steen, Patrick J. Flynn, Kendrith M. Rowland *Cancer* vol 116 (10) 2382-2389 2010
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/20209614>

318 A multi-center phase II study of nivolumab +/- ipilimumab for patients with metastatic sarcoma (Alliance A091401), results of expansion cohorts

James Chen, Michelle Mahoney, Suzanne George, Cristina Antonescu, David Liebner, Brian Van Tine, Mohammad Milhelm, William Tap, Howard Streicher, Gary Schwartz, Sandra P. D'Angelo *J Clin Oncol* vol 38 (15_suppl) 11511-11511 2020
Abstract Experimental https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.11511

319 Quality-adjusted time without symptoms or toxicity (Q-TWiST): analysis of cabozantinib versus sunitinib in patients with advanced renal cell carcinoma of intermediate or poor risk (Alliance A031203)

RC Chen, M Feuilly, J Meng, J Lister, F Marteau, M Morris, D George, T Choueiri *J Clin Oncol* vol 36 (Suppl) abstr 4556 2018
Abstract GU <https://meetinglibrary.asco.org/record/165040/abstract>

320 Qualityadjusted survival with firstline cabozantinib or sunitinib for advanced renal cell carcinoma in the CABOSUN randomized clinical trial (Alliance)

Ronald C. Chen, Toni K. Choueiri, Marion Feuilly, Jie Meng, Johanna Lister, Florence Marteau, Aaron D. Falchook, Michael J. Morris, Daniel J. George, Darren R. Feldman *Cancer* vol 126 (24) 5311-8 2020
Manuscript GU <http://www.ncbi.nlm.nih.gov/pubmed/33022096>

321 Silencing of the inhibitor of DNA binding protein 4 (ID4) contributes to the pathogenesis of mouse and human CLL

S. S. Chen, R. Claus, D. M. Lucas, L. Yu, J. Qian, A. S. Ruppert, D. A. West, K. E. Williams, A. J. Johnson, F. Sablitzky, C. Plass, J. C. Byrd *Blood* vol 117 (3) 862-871 2011
Manuscript Leuk Corr Sci CALGB-9665, CALGB-20305, CALGB-9712
<http://www.ncbi.nlm.nih.gov/pubmed/21098398>

322 Bayesian Variable Selection with Joint Modeling of Categorical and Survival Outcomes: An Application to Individualizing Chemotherapy Treatment in Advanced Colorectal Cancer

Wei Chen, Debashis Ghosh, Trivellore E. Raghunathan, Daniel J. Sargent *Biometrics* vol 65 (4) 1030-1040 2009
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/19210736>

323 A randomized phase III double-blinded placebo-controlled trial of Aspirin as adjuvant therapy for Breast Cancer (Alliance A011502): The Aspirin after Breast Cancer (ABC) Trial

Wendy Chen, Karla V. Ballman, Eric P. Winer, Michelle Holmes, Carol Matyka, Margaret Carvan, Anna Weiss, Olwen Hahn, William Irvin Jr, Paula Pohlmann, Fred Briccetti, Ann Partridge, Linda McCall, Thomas Openshaw J Clin Oncol 360922 2022
Abstract Breast <https://meetings.asco.org/abstracts-presentations/206114>

324 Diet- and LifestyleBased Prediction Models to Estimate Cancer Recurrence and Death in Patients With Stage III Colon Cancer (CALGB 89803/Alliance)

En Cheng, Fang-Shu Ou, Chao Ma, Donna Spiegelman, Sui Zhang, Xin Zhou, Tiffany M. Bainter, Leonard B. Saltz, Donna Niedzwiecki, Robert J. Mayer, Renaud Whittom, Alexander Hantel, Al Benson III, Daniel Atienza, Michael Messino, Hedy Kindler, Edward L. Giovannucci, Erin L. Van Blarigan, Justin C. Brown, Kimmie Ng, Cary P. Gross, Jeffrey A. Meyerhardt, Charles S. Fuchs J Clin Oncol vol 40 (7) 740-51 2022
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/34995084>

325 Associations of Inflammatory Biomarkers with Survival Among Patients with Stage III Colon Cancer (CALGB/SWOG 80702 [Alliance])

En Cheng, Qian Shi, Anthony F. Shields, Elizabeth M. Cespedes Feliciano, Andrew B. Nixon, Ardaman P. Shegrill, Katherine A. Guthrie, Felix Couture, Philip Kuebler, Pankaj Kumar, Dequincy Lewis, Benjamin Tan, Eileen M. O'Reilly, Justin C. Brown, Philip A Philip, Bette J. Caan, Jeffrey A. Meyerhardt 2022
Abstract GI <https://www.abstractsonline.com/pp8/#!/10517/presentation/12395>

326 Association of Inflammatory Biomarkers With Survival Among Patients With Stage III Colon Cancer

En Cheng, Qian Shi, Anthony F. Shields, Andrew B. Nixon, Ardaman P. Shergill, Chao Ma, Katherine A. Guthrie, Felix Couture, Philip Kuebler, Pankaj Kumar, Benjamin Tan, Smitha S. Krishnamurthi, Kimmie Ng, Eileen M. O'Reilly, Justin C. Brown, Philip A. Philip, Bette J. Caan, Elizabeth M. Cespedes Feliciano, Jeffrey A. Meyerhardt JAMA Oncol vol 9 (3) :404-13 2023
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/36701146>

327 The Diet of Higher Insulinemic Potential Is Not Associated with Worse Survival in Patients with Stage III Colon Cancer (Alliance)

En Cheng, Sui Zhang, Fang-Shu Ou, Brian Mullen, Kimmie Ng, Leonard B. Saltz, Donna Niedzwiecki, Robert J. Mayer, Rex B. Mowat, Renaud Whittom, Alexander Hantel, Al Benson, Daniel Atienza, Michael Messino, Hedy Kindler, Edward L. Giovannucci, Erin L. Van Blarigan, Jeffrey A. Meyerhardt, Charles S. Fuchs Cancer Epidemiol Biomarkers Prev vol 29 (8) 1692-5 2020
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/32499312>

328 EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial

H Cheng, K Ballman, M Vassilakopoulou, A C Dueck, M M Reinholz, K Tenner, J Gralow, C Hudis, N E Davidson, G Fountzilas, A E McCullough, B Chen, A Psyrris, D L Rimm, E A Perez Br J Cancer vol 111 (6) 1065-1071 2014
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/25117817>

329 A prospective economic analysis of early outcome data from the Alliance A041202/ CCTG CLC.2 randomized phase III trial of bendamustine-rituximab compared with ibrutinib-based regimens in untreated older patients with chronic lymphocytic leukemia

Matthew C. Cheung, Nicole Mittmann, Carolyn Owen, Nizar Abdel-Samad, Graeme A. M. Fraser, Selay Lam, Michael Crump, Catherine Sperlich, Richard van der Jagt, Anca Prica, Stephen Couban, Jennifer A. Woyach, Amy S. Ruppert, Allison M. Booth, Sumithra J. Mandrekar, Gail McDonald, Lois

E. Shepherd, Hope Yen, Bingshu E. Chen, Annette E. Hay Clin Lymphoma Myeloma Leuk vol 21 (11) 766-74 2021

Manuscript Leukemia <http://www.ncbi.nlm.nih.gov/pubmed/34334330>

330 A prospective economic analysis of Canadian Cancer Trials Group CLC.2/Alliance A041202: A randomized phase III comparison of bendamustine-rituximab versus ibrutinib-based regimens in untreated older patients with chronic lymphocytic leukemia

Matthew C. Cheung, Nicole Mittmann, Carolyn Owen, Nizar Abdel-Samad, Graeme Fraser, Selay Lam, Michael Crump, Catherine Sperlich, Richard van der Jagt, Anca Prica, Stephen Couban, Jennifer A. Woyach, Amy Stark, Allison M. Booth, Sumithra J. Mandrekar, Gail McDonald, Lois E. Shepherd, Hope Yen, Bingshu E. Chen, Annette E. Hay Blood vol 136 (Supplement 1) 27-30 2020

Abstract Leukemia

<https://ashpublications.org/blood/article/136/Supplement%201/27/473098/A-Prospective-Economic-Ana>

331 Predictive and prognostic value of gender in early stage colon cancer: a pooled analysis of 33,345 patients from the ACCENT database.

W. Y. Cheung, Q. Shi, M. O'Connell, J. Cassidy, C. D. Blanke, D. J. Kerr, E. Van Cutsem, S. R. Alberts, A. Yothers, D. J. Sargent J Clin Oncol vol 29 (15s) abstr 3619 2011

Abstract GI

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID

332 The Predictive and Prognostic Value of Sex in Early-Stage Colon Cancer: A Pooled Analysis of 33,345 Patients from the ACCENT Database

Winson Y. Cheung, Qian Shi, Michael O'Connell, James Cassidy, Charles D. Blanke, David J. Kerr, Jeff Meyers, Eric Van Cutsem, Steven R. Alberts, Greg Yothers, Daniel J. Sargent Clin Colorectal Cancer vol 12 (3) 179-187 2013

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/23810482>

333 Use of a lidocaine patch in the management of postsurgical neuropathic pain in patients with cancer: a phase III double-blind crossover study (N01CB)

Andrea L. Cheville, Jeff A. Sloan, Donald W. Northfelt, Anand P. Jillella, Gilbert Y. Wong, James D. Bearden, Heshan Liu, Paul L. Schaefer, Benjamin T. Marchello, Bradley J. Christensen, Charles L. Loprinzi Support Care Cancer vol 17 (4) 451-460 2009

Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/19142669>

334 Stem Cell Collection with Daratumumab (DARA)-Based Regimens in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) in the Griffin and Master Studies

Saurabh Chhabra, Natalie S. Callander, Luciano J. Costa, Jonathan L. Kaufman, Jacob P. Laubach, Douglas W. Sborov, Brandi Reeves, Cesar Rodriguez, Ajai Chari, Rebecca W. Silbermann, Larry D. Anderson Jr, Jr., Nitya Nathwani, Nina Shah, Naresh Bumma, Sarah A. Holstein, Caitlin Costello, Andrzej Jakubowiak, Tanya M. Wildes, Robert Z. Orlowski, Kenneth H. Shain, Andrew J. Cowan, Bhagirathbhai Dholaria, Huiling Pei, Annelore Cortoos, Sharmila Patel, J Blake Bartlett, Jessica Vermeulen, Thomas S. Lin, Paul G. Richardson, Peter M. Voorhees Blood vol 138 (Supplement 1) 2852 2021

Abstract Myeloma

<https://ashpublications.org/blood/article/138/Supplement%201/2852/481347/Stem-Cell-Collection-with->

335 Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials.

Saurabh Chhabra, Natalie Callander, Nicole L Watts, Luciano J Costa, Bicky Thapa, Jonathan L Kaufman, Jacob Laubach, Douglas W Sborov, Brandi Reeves, Cesar Rodriguez, Ajai Chari, Rebecca Silbermann, Larry D Anderson, Susan Bal, Binod Dhakal, Nitya Nathwani, Nina Shah, Eva

Medvedova, Naresh Bumma, Sarah A Holstein, Caitlin Costello, Andrzej Jakubowiak, Tanya M Wildes, Timothy Schmidt, Robert Z Orłowski, Kenneth H Shain, Andrew J Cowan, Bhagirathbhai Dholaria, R Frank Cornell, James H Jerkins, Huiling Pei, Annelore Cortoos, Sharmila Patel, Thomas S Lin, Saad Z Usmani, Paul G Richardson, Peter M Voorhees *Transplant Cell Ther* vol 29 (3) 174.e1-174.e10 2023
Manuscript Myeloma AFT-29 (GRIFFIN), MASTER
<http://www.ncbi.nlm.nih.gov/pubmed/36494017>

336 Polygenic Inheritance of Paclitaxel-Induced Sensory Peripheral Neuropathy Driven by Axon Outgrowth Gene Sets in CALGB 40101 (Alliance)

Aparna Chhibber, Joel Mefford, Eli A. Stahl, Sarah A. Pendergrass, R. Michael Baldwin, Kouros Owzar, Megan Li, Eric P. Winer, Clifford A. Hudis, Hitoshi Zembutsu, Michiaki Kubo, Yusuke Nakamura, Howard L. McLeod, Mark J. Ratain, Lawrence N. Shulman, Marylyn D. Ritchie, Robert M. Plenge, John S. Witte, Deanna L. Kroetz *Pharmacogenomics J* vol 14 (4) 336-342 2014
Manuscript PPP <http://www.ncbi.nlm.nih.gov/pubmed/24513692>

337 Electronic Patient-Reported Outcome Data Collection Systems in Oncology Clinical Trials: A Survey of Clinical Research Professionals (an Alliance Study).

Youmin Cho, Ellen M Lavoie Smith, David Zahrieh, Selina L Chow, David A Williams, Denise Saint Arnault, Yun Jiang *JCO Clin Cancer Inform* vol 7 e2300007 2023
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/37677111>

338 PD-L1 status and clinical outcomes to cabozantinib, sunitinib and everolimus in patients with metastatic clear-cell RCC treated on CABOSUN and METEOR clinical trials

T.K. Choueiri, A. Flaifel, W. Xie, D. Braun, M. Ficial, R. Jennings, A. Nassar, B. Escudier, D.J. George, R.J. Motzer, M.J. Morris, T. Powles, E. Wang, Y. Huang, G. Freeman, S. Signoretti *Annal Oncol* vol 29 (suppl_8) Abstr LBA34 2018
Abstract GU
https://academic.oup.com/annonc/article/29/suppl_8/mdy424.040/5141786?searchresult=1

339 Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial

Toni K. Choueiri, Susan Halabi, Ben L. Sanford, Olwen Hahn, M. Dror Michaelson, Meghara K. Walsh, Darren R. Feldman, Thomas Olencki, Joel Picus, Eric J. Small, Shaker Dakhil, Daniel J. George, Michael J. Morris *J Clin Oncol* vol 35 (6) 591-597 2017
Manuscript GU <http://www.ncbi.nlm.nih.gov/pubmed/28199818>

340 CABOzantinib versus SUNitinib (CABOSUN) as initial targeted therapy for patients with metastatic renal cell carcinoma (mRCC) of poor and intermediate risk groups: results from ALLIANCE A031203 Trial.

Toni K. Choueiri, Susan Halabi, Ben L. Sanford, Olwen Hahn, M. Dror Michaelson, Meghara Walsh, Thomas Olencki, Joel Picus, Eric J. Small, Daniel George, Shaker Dakhil, Michael J. Morris 2016
Abstract GU
<http://www.esmo.org/Conferences/Past-Conferences/ESMO-2016-Congress/Press-Media/Cabozantinib-I>

341 Progression-free survival (PFS) by independent review results from ALLIANCE A031203 trial (CABOSUN): cabozantinib versus sunitinib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC)

Toni K. Choueiri, Colin Hessel, Susan Halabi, Ben Sanford, Olwen Hahn, Olenck T. Michaelson, Picus J, E.J. Small, S. Dakhi, George D.J. Scheffold C., M.J. Morris *Ann Oncol* vol 28 (suppl 5) mdx440.032, LBA38 2017
Abstract GU
https://academic.oup.com/annonc/article/28/suppl_5/mdx440.032/4109944?searchresult=1

- 342 Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update**
Toni K. Choueiri, Colin Hessel, Susan Halabi, Ben Sanford, M. Dror Michaelson, Olwen Hahn, Meghara Walsh, Thomas Olencki, Joel Picus, Eric J. Small, Shaker Dakhil, Darren R. Feldman, Milan Mangeshkar, Christian Scheffold, Daniel George, Michael J. Morris Eur J Cancer vol 94 115-25 2018
Manuscript GU <http://www.ncbi.nlm.nih.gov/pubmed/29550566>
- 343 Meta-analysis identifies variants in S1PR1 associated with microtubule targeting agent-induced sensory peripheral neuropathy CALGB 40101 and 40502 (Alliance)**
Katherina C. Chua, Carol Ho, Tasei Mushiroda, Chen Jiang, Flora Mulkey, Hope Rugo, Michiaki Kubo, Kouros Owzar, Lawrence N. Shulman, Deanna L. Kroetz Clinical Pharmacology & Therapeutics vol 103 (Suppl S1) S28 2018
Abstract Breast CALGB-40101, CALGB-40502
<https://ascpt.onlinelibrary.wiley.com/doi/epdf/10.1002/cpt.993>
- 344 Genome-Wide Meta-Analysis Validates a Role for S1PR1 in Microtubule Targeting Agent-Induced Sensory Peripheral Neuropathy**
Katherina C. Chua, Chenling Xiong, Carol Ho, Taisei Mushiroda, Chen Jiang, Flora Mulkey, Dongbing Lai, Bryan P. Schneider, Sara R. Rashkin, John S. Witte, Paula N. Friedman, Mark J. Ratain, Howard L. McLeod, Hope S. Rugo, Lawrence N. Shulman, Michiaki Kubo, Kouros Owzar, Deanna L. Kroetz Clin Pharmacol Ther vol 108 (3) 625-34 2020
Manuscript PPP CALGB-40101, CALGB-40502 <http://www.ncbi.nlm.nih.gov/pubmed/32562552>
- 345 Incidence of late recurrence in hormone receptor-positive or negative HER2-positive breast cancer receiving adjuvant trastuzumab: The combined analysis of the NCCTG (Alliance) N9831 and NSABP (NRG) B31 Trials**
Saranya Chumsri, Zhou Li, Daniel J. Serie, Afshin Mashadi-Hosseini, Gerardo Colon-Otero, Nan Song, Katherine L. Pogue-Geile, Patrick Gavin, Soon Paik, Alvaro Moreno-Aspitia, Edith A. Perez, E. Aubrey Thompson Cancer Res vol 79 (4_suppl) abstr PD3-02 2018
Abstract GI NCCTG-N9831, NSABP B-31
http://cancerres.aacrjournals.org/content/79/4_Supplement/PD3-02
- 346 Incidence of Late Relapses in Patients With HER2-Positive Breast Cancer Receiving Adjuvant Trastuzumab: Combined Analysis of NCCTG N9831 (Alliance) and NRG Oncology/NSABP B-31**
Saranya Chumsri, Zhuo Li, Daniel J. Serie, Afshin Mashadi-Hosseini, Gerardo Colon-Otero, Nan Song, Katherine L. Pogue-Geile, Patrick G. Gavin, Soonmyung Paik, Alvaro Moreno-Aspitia, Edith A. Perez, E. Aubrey Thompson J Clin Oncol vol 37 (35) 3425-35 2019
Manuscript Breast NCCTG-N9831, NSABP B-31 <http://www.ncbi.nlm.nih.gov/pubmed/31622131>
- 347 Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials**
Saranya Chumsri, Zhuo Li, Daniel J. Serie, Nadine Norton, Afshin Mashadi-Hosseini, Kathleen Tenner, Heather Ann Brauer, Sarah Warren, Patrick Danaher, Gerardo Colon-Otero, Ann H. Partridge, Lisa A. Carey, Florentine Hilbers, Veerle Van Dooren, Eileen Holmes, Serena Di Cosimo, Olena Werner, Jens Bodo Huober, Amylou C. Dueck, Christos Sotiriou, Cristina Saura, Alvaro Moreno-Aspitia, Keith L. Knutson, Edith A. Perez, E. Aubrey Thompson NPJ Breast Cancer vol 8 (1) 68 2022
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/35610260>
- 348 Outcome and Immune Landscape of HER2-positive Invasive Lobular Carcinoma in the North Central Cancer Treatment Group (NCCTG) N9831 (Alliance) Trial**

Saranya Chumsri, Zhuo Li, Tracy Shachner, Pooja Advani, Kostandinos Sideras, Alvaro Moreno-Aspitia, Gerardo Colon-Otero, Keith L. Knutson, Aziza Nassar, Edith A. Perez, E. Aubrey Thompson. *J Clin Oncol* vol 39 (no. 15_suppl) 535 2021
Abstract Breast https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.535

349 Effects of Age and Immune Landscape on Outcome in HER2-positive Breast Cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) Trials

Saranya Chumsri, Daniel J. Serie, Zhuo Li, Katherine L. Pogue-Geile, Aixa E. Soyano-Muller, Afshin Mashadi-Hosseini, Sarah Warren, Yanyan Lou, Gerardo Colon-Otero, Keith L. Knutson, Edith A. Perez, Alvaro Moreno-Aspitia, E. Aubrey Thompson *Clin Cancer Res* vol 25 (14) 4422-30 2019
Manuscript Breast NCCTG-N9831, NSABP B-31 <http://www.ncbi.nlm.nih.gov/pubmed/30808774>

350 Association between adaptive immune signature and outcome in HER2-positive breast cancer treated with trastuzumab and lapatinib in the NCCTG-N9831 (Alliance) and NeoALTTO trials

Saranya Chumsri, Daniel Serie, Afshin Mashadi-Hosseini, Jennifer M. Kachergus, Sarah Warren, Gerardo Colon-Otero, Ann H. Partridge, Lisa A. Carey, Florentine Hilbers, Veerle Van Doreen, Eileen Holmes, Serena Di Cosimo, Olena Werner, Jens Bodo Huober, Jose Baselga, Christos Sotiriou, Edith A. Perez, Amylou C. Dueck, Alvaro Moreno-Aspitia, E. Aubrey Thompson *J Clin Oncol* vol 36 (15 suppl) abstr 577 2018
Abstract GI http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.577

351 Functional tertiary lymphoid structure (TLS) and outcome in HER2-Positive Breast Cancer in the North Central Cancer Treatment Group (NCCTG) N9831 (Alliance) Trial

Saranya Chumsri, Tracy R. Shachner, Zhuo Li, Nadine Norton, Alvaro Moreno-Aspitia, Gerardo Colon-Otero, Edith A. Perez, E. Aubrey Thompson, Aziza Nassar, Keith L. Knutson *Cancer Res* vol 82 (12_Supplement) 5627 2022
Abstract Breast https://aacrjournals.org/cancerres/article/82/12_Supplement/5627/700032

352 High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance)

Saranya Chumsri, Jeff Sperinde, Heshan Liu, Joseph Gligorov, Jean-Philippe Spano, Martine Antoine, Alvaro Moreno Aspitia, Winston Tan, John Winslow, Christos J Petropoulos, Ahmed Chenna, Michael Bates, Jodi Marie Weidler, Weidong Huang, Amylou Dueck, Edith A. Perez *Clin Cancer Res* vol 24 (13) 3053-58 2018
Manuscript Correl Sci NOS NCCTG-N0337, NCCTG-N98-32-52
<http://www.ncbi.nlm.nih.gov/pubmed/29530935>

353 Correlation of high p95HER2:HER2 ratio with poor outcome in two phase II clinical trials of trastuzumab-treated HER2-positive metastatic breast cancer.

Saranya Chumsri, Jeff Sperinde, Heshan Liu, Joseph Gligorov, Jean-Philippe Spano, Alvaro Moreno-Aspitia, Sarah A. McLaughlin, John William Winslow, Christos J. Petropoulos, Ahmed Chenna, Michael Patrick Bates, Jodi Marie Weidler, Yolanda Lie, Weidong Huang, Edith A. Perez *J Clin Oncol* vol 34 (suppl) abstr 603 2016
Abstract Breast NCCTG-N0337, NCCTG-N98-32-52
<http://meetinglibrary.asco.org/content/168923-176>

354 Stereotactic Radiosurgery with or without Whole Brain Radiotherapy for Limited Brain Metastases: A Secondary Analysis of the NCCTG N0574 (Alliance) Randomized Controlled Trial

Thomas M. Churilla, Karla V. Ballman, Paul D. Brown, Erin L. Twohy, Kurt Jaeckle, Elana Farace, Jane H. Cerhan, S. Keith Anderson, Xiomara W. Carrero, Yolanda I. Garces, Fred G. Barker, Richard Deming, Jesse G. Dixon, Stuart H. Burri, Caroline Chung, Cynthia Ménard, Volker W. Stieber, Bruce E. Pollock, Evanthia Galanis, Jan C. Buckner, Anthony L. Asher *Int J Radiat Oncol Biol Phys* vol 99 (5) 1173-1178 2017

- 355 Methodological Considerations in the Design and Implementation of Clinical Trials**
Constance T. Cirincione, Ellen M. Lavoie Smith, Herbert Pang *Semin Oncol Nurs* vol 30 (1) 74-79
2014
Manuscript Onc Nursing <http://www.ncbi.nlm.nih.gov/pubmed/24559783>
- 356 Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.**
Marc L Citron, Donald A Berry, Constance Cirincione, Clifford Hudis, Eric P Winer, William J Gradishar, Nancy E Davidson, Silvana Martino, Robert Livingston, James N Ingle, Edith A Perez, John Carpenter, David Hurd, James F Holland, Barbara L Smith, Carolyn I Sartor, Eleanor H Leung, Jeffrey Abrams, Richard L Schilsky, Hyman B Muss, Larry Norton *J Clin Oncol* vol 21 (8) 1431-9
2003
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/12668651>
- 357 Sentinel Lymph Node Biopsy Accurately Stages the Regional Lymph Nodes for T1-T2 Oral Squamous Cell Carcinomas: Results of a Prospective Multi-Institutional Trial**
Francisco J. Civantos, Robert P. Zitsch, David E. Schuller, Amit Agrawal, Russell B. Smith, Richard Nason, Guy Petruzelli, Christine G. Gourin, Richard J. Wong, Robert L. Ferris, Adel El Naggar, John A. Ridge, Randal C. Paniello, Kouros Owzar, Linda McCall, Douglas B. Chepeha, Wendell G. Yarbrough, Jeffrey N. Myers *J Clin Oncol* vol 28 (8) 1395-1400 2010
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/20142602>
- 358 Pretreatment vitamin D level and response to neoadjuvant chemotherapy in women with breast cancer on the I-SPY trial (CALGB 150007/150015/ACRIN6657)**
Amy S Clark, Jinbo Chen, Shiv Kapoor, Claire Friedman, Carolyn Mies, Laura Esserman, Angela DeMichele *Cancer Med* vol 3 (3) 693-701 2014
Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/24719175>
- 359 Coagulation factors in citrated plasma predict for benefit from bevacizumab (B) in patients with advanced pancreatic cancer (APC): Results from CALGB 80303 (Alliance)**
Jeffrey M. Clarke, Herbert Pang, Mark D. Starr, Ace Hatch, Hedy L. Kindler, Federico Innocenti, Alan P. Venook, Herbert I. Hurwitz, Andrew B. Nixon *J Clin Oncol* vol 33 (suppl 3) abstr 306 2015
Abstract Correl Sci NOS
http://meeting.ascopubs.org/cgi/content/abstract/33/3_suppl/306?sid=36869157-2058-48a2-9fcd-80ab78
- 360 Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia**
R. Claus, D. M. Lucas, S. Stilgenbauer, A. S. Ruppert, L. Yu, M. Zucknick, D. Mertens, A. Buhler, C. C. Oakes, R. A. Larson, N. E. Kay, D. F. Jelinek, T. J. Kipps, L. Z. Rassenti, J. G. Gribben, H. Dohner, N. A. Heerema, G. Marcucci, C. Plass, J. C. Byrd *J Clin Oncol* vol 30 (20) 2483-2491 2012
Manuscript Leuk Corr Sci <http://www.ncbi.nlm.nih.gov/pubmed/22564988>
- 361 Combination trastuzumab and chemotherapy to induce immunity to multiple tumor antigens in patients with HER2-positive metastatic breast cancer: NCCTG (Alliance) studies N0337 and N98-32-52**
R. Clynes, K. L. Knutson, K. Ballman, C. L. Erskine, N. Norton, S. V. Sumrall, D. Northfelt, W. Tan, C. Calfa, M. Pegram, E. A. Perez *J Clin Oncol* vol 31 (15 suppl) abstr 521 2013
Abstract Breast NCCTG-N0337, NCCTG-N98-32-52
http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/521?sid=9c0743c8-049a-44b6-9683-a12b8
- 362 Impact of age, comorbidity and symptoms on physical function in long-term breast cancer**

survivors (CALGB 70803)

Harvey Jay Cohen, Lan Lan, Laura Archer, Alice B. Kornblith J Geriatr Oncol vol 3 (2) 82-89 2012
Manuscript Health Outcomes <http://www.ncbi.nlm.nih.gov/pubmed/22707996>

363 Combining tumor deposits with the number of lymph node metastases to improve the prognostic accuracy in stage III colon cancer: a post hoc analysis of the CALGB/SWOG 80702 phase III study (Alliance)

R. Cohen, Q. Shi, J. Meyers, Z. Jin, M. Svrcek, C. Fuchs, F. Couture, P. Kuebler, K.K. Ciombor, J. Bendell, A. De Jesus-Acosta, P. Kumar, D. Lewis, B. Tan, M.M. Bertagnolli, P. Philip, C. Blanke, E.M. O'Reilly, A. Shields, J.A. Meyerhardt Ann Oncol vol 32 (10) 1267-75 2021
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/34293461>

364 Prognostic value of tumor deposits in stage III colon cancer patients, a post hoc analysis of CALGB/SWOG 80702 phase III study

Romain Cohen, Qian Shi, Jeff Meyers, Zhaohui Jin, Magali Svrcek, Charles Fuchs, Felix Couture, Philip Kuebler, Johanna Bendell, Pankaj Kumar, Dequincy Lewis, Benjamin Tan, Monica Bertagnolli, Howard Hochster, Charles Blanke, Eileen O'Reilly, Anthony Shields, Jeffrey Meyerhardt J Clin Oncol vol 39 (3_suppl) 10 2021
Abstract GI https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.3_suppl.10

365 Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials

Romain Cohen, Julien Taieb, Jack Fiskum, Greg Yothers, Richard Goldberg, Takayuki Yoshino, Steven Alberts, Carmen Allegra, Aimery de Gramont, Jean-Francois Seitz, Michael O'Connell, Daniel Haller, Norman Wolmark, Charles Erlichman, Alberto Zaniboni, Sara Lonardi, Rachel Kerr, Axel Grothey, Frank A. Sinicrope, Thierry André, Qian Shi J Clin Oncol vol 39 (6) 642-51 2021
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/33356421>

366 Assessing financial difficulty in patients with multiple myeloma: preliminary results of Alliance study A231602CD

Rena Conti, Travis Dockter, Stacie Dusetzina, Bruce Rapkin, Elisa Weiss, Nisarg Desai, Philip A. Dy, Gabriela Gracia, Robert Behrens, Paul Richardson J Clin Oncol vol 39 (15_suppl) 8031 2021
Abstract CCDD https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.8031

367 Self-Reported Financial Difficulties Among Multiple Myeloma and Chronic Lymphocytic Leukemia Patients: An Alliance for Clinical Trials in Oncology Study

Rena Conti, Shaylene McCue, Travis Dockter, Stacie Dusetzina, Bruce Rapkin, Elisa Weiss, Gabriela Gracia, Robert Behrens, Paul Richardson J Clin Oncol vol 40 (16_suppl) 6602-6602 2022
Abstract Health Outcomes https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.6602

368 Acute Myeloid Leukemia (AML) with 9q aberrations occurring within a non-complex karyotype is highly associated with CEBPA and NPM1 mutations - A joint analysis of the German-Austrian AML Study Group (AMLSG) and Cancer and Leukemia Group B (CALGB)

A. Corbacioglu, S. Frohling, P. Paschka, G. Marcucci, A. Anhalt, K. Urlbauer, J. Krauter, R. A. Larson, K. Mrozek, A. S. Ruppert, A. Ganser, M. A. Caligiuri, H. Dohner, R. F. Schlenk, C. D. Bloomfield, K. Dohner Blood vol 110 (11) 762 2007
Abstract Leuk Corr Sci CALGB-19808, CALGB-8461, CALGB-9621, CALGB-9665
<http://www.bloodjournal.org/content/110/11/762?sso-checked=true>

369 Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): Results of the intergroup phase III trial ACOSOG Z9001

C. L. Corless, K. V. Ballman, C. Antonescu, C. D. Blanke, M. E. Blackstein, G. D. Demetri, M. Von

Mehren, R. G. Maki, P. W. Pisters, R. P. Dematteo J Clin Oncol vol 28 (15s) abstr 10006 2010
Abstract GI
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID

370 Pathologic and Molecular Features Correlate With Long-Term Outcome After Adjuvant Therapy of Resected Primary GI Stromal Tumor: The ACOSOG Z9001 Trial

Christopher L. Corless, Karla V. Ballman, Cristina R. Antonescu, Violetta Kolesnikova, Robert G. Maki, Peter W.T. Pisters, Martin E. Blackstein, Charles D. Blanke, George D. Demetri, Michael C. Heinrich, Margaret von Mehren, Shreyaskumar Patel, Martin D. McCarter, Kouros Owzar, Ronald P. DeMatteo J Clin Oncol vol 32 (15) 1563-1570 2014
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/24638003>

371 Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020.

Wendy R Cornett, Linda M McCall, Rebecca P Petersen, Merrick I Ross, Henry A Briele, R Dirk Noyes, Jeffrey J Sussman, William G Kraybill, John M Kane, H Richard Alexander, Jeffrey E Lee, Paul F Mansfield, James F Pingpank, David J Winchester, Richard L White, Vijaya Chadaram, James E Herndon, Douglas L Fraker, Douglas S Tyler J Clin Oncol vol 24 (25) 4196-201 2006
Manuscript Experimental <http://www.ncbi.nlm.nih.gov/pubmed/16943537>

372 ACOSOG Z0010: A multicenter prognostic study of sentinel node (SN) and bone marrow (BM) micrometastases in women with clinical T1/T2 N0 M0 breast cancer

R. Cote, A. E. Giuliano, D. Hawes, K. V. Ballman, P. W. Whitworth, P. W. Blumencranz, D. S. Reintgen, M. Morrow, A. M. Leitch, K. Hunt J Clin Oncol vol 28 (18s) abstr CRA504 2010
Abstract Breast <http://meetinglibrary.asco.org/content/50966-74>

373 Randomized comparison of a nicotine inhaler and bupropion for smoking cessation and relapse prevention.

Ivana T Croghan, Richard D Hurt, Shaker R Dakhil, Gary A Croghan, Jeff A Sloan, Paul J Novotny, Kendrith M Rowland, Albert Bernath, Mary L Loots, Nguyet A Le-Lindqwister, Loren K Tschetter, Stewart C Garneau, Kathleen A Flynn, Larry P Ebbert, Donald B Wender, Charles L Loprinzi Mayo Clin Proc vol 82 (2) 186-95 2007
Manuscript Prevention <http://www.ncbi.nlm.nih.gov/pubmed/17290726>

374 Effect of body mass index on tumor characteristics and disease-free survival in patients from the HER2-positive adjuvant trastuzumab trial N9831

J. A. Crozier, A. Moreno-Aspitia, K. V. Ballman, A. C. Dueck, B. A. Pockaj, E. A. Perez Cancer vol 119 (13) 2447-2454 2013
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/23585192>

375 N0436 (Alliance): A phase II trial of irinotecan plus cetuximab in patients with metastatic breast cancer previously exposed to anthracycline and/or taxane-containing therapy

Jennifer A. Crozier, Pooja P. Advani, Betsy LaPlant, Timothy Hobday, Anthony J. Jaslowski, Alvaro Moreno-Aspitia, Edith A. Perez Clin Breast Cancer vol 16 (1) 23-30 2016
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/26381420>

376 A pooled exploratory analysis of the effect of tumor size on survival benefit from adjuvant platinum-based chemotherapy (ACT) in node negative (N0) non-small cell lung cancer (NSCLC)

S. Cuffe, M. Ezzalfani, A. Bourredjem, S. L. Graziano, J. Pignon, E. Strevel, R. L. Burkes, F. Shepherd 2010
Abstract Respiratory

- 377 A Pooled Exploratory Analysis of the Impact of Tumor Size and KRAS Mutations on Survival Benefit from Adjuvant Platinum-Based Chemotherapy (ACT) in Node Negative (N0) Non-Small Cell Lung Cancer (NSCLC).**
S. Cuffe, S. Graziano, A. Bourredjem, J. P. Pignon, M. Ezzalfani, L. Seymour, E. Strevel, R. Burkes, M. Capelletti, P. A. Janne, M. S. Tsao, F. A. Shepherd J Thorac Oncol vol 6 (6) S462-463 2011
Abstract Respiratory <http://journals.lww.com/jto/toc/2011/06001>
- 378 A Pooled Exploratory Analysis of the Effect of Tumor Size and KRAS Mutations on Survival Benefit from Adjuvant Platinum-Based Chemotherapy in Node Negative Non-Small Cell Lung Cancer**
Sinead Cuffe, Abderrahmane Bourredjem, Stephen Graziano, Jean-Pierre Pignon, Caroline Domerg, Monia Ezzalfani, Lesley Seymour, Elizabeth Strevel, Ronald Burkes, Marzia Capelletti, Pasi A. Janne, Ming-Sound Tsao, Frances A. Shepherd J Thorac Oncol vol 7 (6) 963-972 2012
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/22588152>
- 379 Local Recurrence Rates are Low in High-Risk Neoadjuvant Breast Cancer in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657)**
Elizabeth L. Cureton, Christina Yau, Michael D. Alvarado, Helen Krontiras, David W. Ollila, Cheryl A. Ewing, Sindy Monnier, Laura J. Esserman Ann Surg Oncol vol 21 (9) 2889-2896 2014
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/24788555>
- 380 Multi-dimensional analysis of adult acute myeloid leukemia (AML) landscape cross-continent reveals age associated trends in mutations and outcomes (Alliance)**
Monica Cusan, Karilyn Larkin, Deedra Nicolet, Vindi Jurinovic, Krzysztof Mrózek, Aarif M. N. Batcha, Maja Rothenberg-Thurley, Stephanie Schneider, Maria Cristina Sauerland, Dennis Görlich, Utz Krug, Wolfgang E. Berdel, Bernhard J. Woermann, Wolfgang Hiddemann, Jan Braess, Karsten Spiekermann, Jessica Kohlschmidt, James S. Blachly, Alice S. Mims, Christopher J. Walker, Christopher Oakes, Shelley Orwick, Andrew J. Carroll, William E. Blum, Bayard L. Powell, Jonathan E. Kolitz, Joseph O. Moore, Robert J. Mayer, Richard M. Stone, John C. Byrd, Klaus H. Metzeler, Tobias Herold, Ann-Kathrin Eisfeld 2023
Abstract Leuk Corr Sci CALGB-20202, CALGB-8461, CALGB-9665
https://www.acute-leukemias.de/cms/upload/pdfXVIII/ISALXVIII_2023-PROGRAM_WEB-PDF.pdf
- 381 Multi-dimensional analysis of adult acute myeloid leukemia (AML) landscape cross-continent reveals age associated trends in mutations and outcomes (Alliance)**
Monica Cusan, Karilyn Larkin, Deedra Nicolet, Vindi Jurinovic, Krzysztof Mrózek, Aarif M. N. Batcha, Maja Rothenberg-Thurley, Stephanie Schneider, Maria Cristina Sauerland, Dennis Görlich, Utz Krug, Wolfgang E. Berdel, Bernhard J. Woermann, Wolfgang Hiddemann, Jan Braess, Karsten Spiekermann, Jessica Kohlschmidt, James S. Blachly, Alice S. Mims, Christopher J. Walker, Christopher Oakes, Shelley Orwick, Andrew J. Carroll, William E. Blum, Bayard L. Powell, Jonathan E. Kolitz, Joseph O. Moore, Robert J. Mayer, Richard M. Stone, John C. Byrd, Klaus H. Metzeler, Tobias Herold, Ann-Kathrin Eisfeld Blood vol 138 (Supplement 1) 685 2021
Abstract Leuk Corr Sci CALGB-20202, CALGB-8461, CALGB-9665
<https://ashpublications.org/blood/article/138/Supplement%201/685/479523>
- 382 Gene Expression Markers of Efficacy and Resistance to Cetuximab Treatment in Metastatic Colorectal Cancer: Results from CALGB 80203 (Alliance)**
Stephanie M. Cushman, Chen Jiang, Ace J. Hatch, Ivo Shterev, Alexander B. Sibley, Donna Niedzwiecki, Alan P. Venook, Kouros Owzar, Herbert I. Hurwitz, Andrew B. Nixon Clin Cancer Res vol 21 (5) 1078-1086 2015
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/25520391>
- 383 The Feasibility of Radiation Therapy after Breast-Conserving Surgery for Multiple Ipsilateral Breast Cancer: An Initial Report from ACOSOG Z11102 (Alliance) Trial**

Laurie W. Cuttino, Linda McCall, Charlotte Kubicky, Karla V. Ballman, Huong Le-Petross, Kelly K. Hunt, Bruce Haffty, Kari M. Rosenkranz, Judy C. Boughey Int J Radiat Oncol Biol Phys vol 112 (3) 636-42 2022

Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/34634438>

384 The Feasibility of Radiotherapy after Breast-Conserving Surgery for Multiple Ipsilateral Breast Cancer: An Initial Report from ACOSOG Z11102 (Alliance) Trial.

Laurie Cuttino, Linda McCall, C Kubicky, Karla Ballman, H. Carisa Le-Petross, Kelly K Hunt, Armando Giuliano, Kimberly Van Zee, Bruce Haffty, Kari M Rosenkranz, Judy C Boughey International Journal of Radiation Oncology • Biology • Physics vol 105 (1 Supplement) E20-E21 2019

Abstract Prevention [https://www.redjournal.org/article/S0360-3016\(19\)31497-X/fulltext](https://www.redjournal.org/article/S0360-3016(19)31497-X/fulltext)

385 Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness.

M S Czuczman, J P Leonard, S Jung, J L Johnson, E D Hsi, J C Byrd, B D Cheson Ann Oncol vol 23 (9) 2356-62 2012

Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/22357442>

386 A phase II trial of extended induction galiximab ([G] anti-CD80 monoclonal antibody) plus rituximab (R) in previously untreated follicular lymphoma (FL): Initial report of CALGB study 50402

M. S. Czuczman, J. L. Johnson, S. Jung, B. D. Cheson Ann Oncol vol 19 (suppl 4) abstr 143 2008

Abstract Lymphoma

http://annonc.oxfordjournals.org/content/19/suppl_4/iv129.full.pdf+html?sid=60de784d-8638-49b8-ba8c

387 FLIPI Score Is Applicable and Predictive of Response to Upfront Immunotherapy in CALGB 50402: Phase II Trial of Extended Induction Galiximab ([G] anti-CD80 monoclonal antibody) Plus Rituximab [R]

M. S. Czuczman, J. P. Leonard, J. L. Johnson, S.-H. Jung, E. Hsi, J. C. Byrd, B. D. Cheson Blood vol 112 (11) abstr 1003 2008

Abstract Lymphoma <https://ash.confex.com/ash/2008/webprogram/Paper6795.html>

388 Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901.

Myron S Czuczman, Pierluigi Porcu, Jeffrey Johnson, Donna Niedzwiecki, Michael Kelly, Eric D Hsi, James R Cook, George Canellos, Bruce D Cheson Leuk Lymphoma vol 48 (1) 97-103 2007

Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/17325852>

389 p53 Protein Expression Status and Recurrence in Men Treated With Radiation Therapy and Androgen Suppression Therapy for Higher Risk Prostate Cancer: A Prospective Phase II Cancer and Leukemia Group B Study

A. V. D'Amico, S. Halabi, R. Vollmer, M. Loffredo, E. McMahon, B. Sanford, L. Archer, N. J. Vogelzang, E. Small, P. Kantoff Int J Radiat Oncol Biol Phys vol 69 (3) S333 2007

Abstract GU CALGB-159807, CALGB-9682

<http://www.sciencedirect.com/science/article/pii/S0360301607026879>

390 Tumor volume changes on 1.5 tesla endorectal MRI during neoadjuvant androgen suppression therapy for higher-risk prostate cancer and recurrence in men treated using radiation therapy results of the phase II CALGB 9682 study

Anthony V. D'Amico, Susan Halabi, Clare Tempany, David Titelbaum, George K. Philips, Marian Loffredo, Elizabeth McMahon, Ben Sanford, Nicholas J. Vogelzang, Eric J. Small Int J Radiat Oncol Biol Phys vol 71 (1) 9-15 2008

391 p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II Cancer and Leukemia Group B Study (CALGB 9682).

Anthony V D'Amico, Susan Halabi, Robin Vollmer, Marian Loffredo, Elizabeth McMahon, Ben Sanford, Laura Archer, Nicholas J Vogelzang, Eric J Small, Philip W Kantoff *Urology* vol 71 (5) 933-7 2008

Manuscript GU CALGB-159807, CALGB-9682 <http://www.ncbi.nlm.nih.gov/pubmed/18291508>

392 Alliance A091103 a phase II study of the angiopoietin 1 and 2 peptibody trebananib for the treatment of angiosarcoma

Sandra P. D'Angelo, Michelle R. Mahoney, Brian A. Van Tine, Douglas R. Adkins, Maria T. Grosse Perdekamp, Mercedes M. Condy, Jason J. Luke, Eliza Woodward Hartley, Cristina R. Antonescu, William D. Tap, Gary K. Schwartz *Cancer Chemother Pharmacol* vol 75 (3) 629-638 2015

Manuscript Experimental <http://www.ncbi.nlm.nih.gov/pubmed/25672915>

393 A non-comparative multi-center randomized phase II study of nivolumab +/- ipilimumab for patients with metastatic sarcoma (Alliance A091401)

Sandra P. D'Angelo, Michelle R. Mahoney, Brian A. Van Tine, James Atkins, Mohammed M. Milhem, Balkrishna N. Jahagirdar, Cristina R. Antonescu, Elise Horvath, William D. Tap, Gary K. Schwartz, Howard Streicher *Lancet Oncol* vol 19 (3) 416-426 2018

Manuscript Experimental <http://www.ncbi.nlm.nih.gov/pubmed/29370992>

394 Alliance A091103: A multicenter phase II study of the angiopoietin-1 and -2 peptibody trebananib (AMG386) for the treatment of angiosarcoma (AS).

Sandra P. D'Angelo, Michelle R. Mahoney, Brian Andrew Van Tine, Douglas Adkins, Maria T. Grosse Perdekamp, Mercedes M. Condy, Eliza Woodward Hartley, Cristina R. Antonescu, Gary K. Schwartz, William D. Tap *J Clin Oncol* vol 32 (15_suppl) 10568 2014

Abstract Experimental http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/10568

395 A multi-center phase II study of nivolumab +/- ipilimumab for patients with metastatic sarcoma (Alliance A091401)

Sandra P. D'Angelo, Michelle R. Mahoney, Brian Van Tine, James Atkins, Mohammed M Milhem, William D. Tap, Cristina A. Antonescu, Priya U. Kumthekar, Gary K. Schwartz, Howard Streicher *J Clin Oncol* vol 35 (15 suppl) 11007 2017

Abstract Experimental http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.11007

396 The impact of occult micrometastases on survival following resection of stage I non-small cell lung cancer: Final analysis of CALGB 9761

J. D'Cunha, X. Wang, S. S. Groth, R. T. Vollmer, N. Z. Abraham, L. Gu, D. L. Herzan, D. H. Harpole, G. A. Patterson, M. R. Green, R. A. Kratzke, M. A. Maddaus *J Thorac Oncol* vol 4 (9) abstr PD12.11.13 2009

Abstract Respiratory

<http://www.docstoc.com/docs/66321124/Poster-Discussion-Sessions---On-Site-Programme---20090207->

397 Immunochemotherapy and Autologous Stem-Cell Transplantation for Untreated Patients With Mantle-Cell Lymphoma: CALGB 59909

Lloyd E. Damon, Jeffrey L. Johnson, Donna Niedzwiecki, Bruce D. Cheson, David D. Hurd, Nancy L. Bartlett, Ann S. LaCasce, Kristie A. Blum, John C. Byrd, Michael Kelly, Wendy Stock, Charles A. Linker, George P. Canellos *J Clin Oncol* vol 27 (36) 6101-6108 2009

Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/19917845>

398 Validation of EORTC Prognostic Factors for Adults with Low-Grade Glioma: a Report Utilizing Intergroup 86-72-511

Thomas B. Daniels, Paul D. Brown, Sara J. Felten, Wenting Wu, Jan C. Buckner, Robert M. Arusell, Walter J. Curran, Ross A. Abrams, David Schiff, Edward G. Shaw Int J Radiat Oncol Biol Phys vol 81 (1) 218-224 2011

Manuscript Neuro-Onc <http://www.ncbi.nlm.nih.gov/pubmed/21549518>

399 Is there a role for older-patient-specific trials? a pooled analysis of 2277 older patients in adjuvant breast cancer trials (Alliance A151715)

Dyda Dao, Tyler Zelma, Aminah Jatoi, Rachel Freedman, Arti Hurria, Hyman Muss, Harvey Cohen, Lawrence Shulman, Marc Citron, Budman, Ann Partridge, Lisa Carey, Jaqueline M. Lafky, Jennifer Le-Rademacher J Clin Oncol vol 36 (Suppl) abstr 10034 2018

Abstract Older Adult Alliance-A151715, CALGB-8541, CALGB-40101, CALGB-49907, CALGB-9344, CALGB-9741, NCCTG-N89-30-52, NCCTG-N9831

<https://meetinglibrary.asco.org/record/163279/abstract>

400 OlderPatientSpecific Cancer Trials: A Pooled Analysis of 2,277 Patients (A151715)

Dyda Dao, Tyler Zemla, Aminah Jatoi, Rachel A. Freedman, Arti Hurria, Hyman Muss, Harvey Jay Cohen, Lawrence N. Shulman, Marc Citron, Daniel Budman, Ryan McMurray, Ann Partridge, Lisa Carey, Mina S. Sedrak, Jacqueline M. Lafky, Jennifer G. LeRademacher Oncologist vol 24 (6) e284-e291 2019

Manuscript Older Adult CALGB-49907, CALGB-40401

<http://www.ncbi.nlm.nih.gov/pubmed/30975921>

401 Randomized Trial of Mediastinal Lymph Node Sampling versus Complete Lymphadenectomy During Pulmonary Resection in Patients with N0 or N1 (Less than Hilar) Non-Small Cell Carcinoma: Results of the ACOSOG Z0030 Trial

G. Darling, M. Allen, P. Decker, K. Ballman, R. Landreneau, R. McKenna, D. Jones, R. Inculet, V. Rusch, J. Putnam American Association for Thoracic Oncology 90th Annual Meeting, Toronto, ON, Canada abstract 2010

Abstract Respiratory <http://aats.org/annualmeeting/Abstracts/2010/1.cgi>

402 Number of Lymph Nodes Harvested From a Mediastinal Lymphadenectomy

Gail E. Darling, Mark S. Allen, Paul A. Decker, Karla Ballman, Richard A. Malthaner, Richard I. Inculet, David R. Jones, Robert J. McKenna, Rodney J. Landreneau, Joe B. Putnam Chest vol 139 (5) 1124-1129 2011

Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/20829340>

403 Randomized Trial of Mediastinal Lymph Node Sampling Versus Complete Lymphadenectomy During Pulmonary Resection in the Patient with N0 or N1 (Less Than Hilar) Non-Small Cell Carcinoma: Results of the ACOSOG Z0030 Trial

Gail E. Darling, Mark S. Allen, Paul A. Decker, Karla Ballman, Richard A. Malthaner, Richard

Inculet, David R. Jones, Robert J. McKenna, Rodney J. Landreneau, Valerie W. Rusch, Joe B. Putnam J Thorac Cardiovasc Surg vol 141 (3) 662-670 2011

Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/21335122>

404 Causal modeling of CALGB/SWOG 80405 (Alliance) identifies primary (1°) side-related angiogenic drivers of metastatic colorectal cancer (mCRC)

Rahul K Das, Leon Furchtgott, Jeffrey A. Meyerhardt, Andrew B. Nixon, Federico Innocenti, Daniel Cunha, Kelly Rich, Heinz-Josef Lenz, Donna Niedzwiecki, Eileen Mary O'Reilly, Fang-Shu Ou, Jeanne Latourelle, Diane Wuest, Boris Hayete, Iya Khalil, Alan P. Venook Ann Oncol vol 29 (suppl_8) abstr 458PD 2018

Abstract GI

405 Bayesian machine learning on CALGB/SWOG 80405 (Alliance) and PEAK data identifies heterogeneous landscape of clinical predictors of overall survival (OS) in different populations of metastatic colorectal cancer (mCRC)

Rahul K Das, Fang-Shu Ou, Cecilia Washburn, Andrew B. Nixon, Federico Innocenti, Heinz-Josef Lenz, Charles Blanke, Donna Niedzwiecki, Eileen Mary O'Reilly, Iya Khalil, Boris Hayete, Alan P. Venook *Annals of Oncology* vol 30 (Supplement_4) mdz156.019 2019

Abstract GI https://academic.oup.com/annonc/article/30/Supplement_4/mdz156.019/5526583

406 A phase II study of estramustine, docetaxel, and exisulind in patients with hormone- refractory prostate cancer: results of cancer and leukemia group B trial 90004.

Nancy A Dawson, Susan Halabi, San-San Ou, David D Biggs, Anne Kessinger, Nicholas Vogelzang, Gerald H Clamon, David M Nanus, W Kevin Kelly, Eric J Small *Clin Genitourin Cancer* vol 6 (2) 110-6 2008

Manuscript GU <http://www.ncbi.nlm.nih.gov/pubmed/18824434>

407 A Pilot Randomized, Placebo Controlled, Double Blind Study of Omega-3 Fatty Acids to Prevent Paclitaxel Associated Acute Pain Syndrome

Zoneddy Dayao, Ursa Brown-Glabermann, Lu Chen, Shane Pankratz, Jacqueline M. Lafky, Charles L. Loprinzi, Debra Barton *J Clin Oncol* vol 38 (15_suppl) e24115 2020

Abstract Symptom Inter https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.e24115

408 Association between 3 year (yr) disease free survival (DFS) and overall survival (OS) delayed with improved survival after recurrence (REC) in patients receiving cytotoxic adjuvant therapy for colon cancer: Updated findings from the 20,800 patient (Pt) ACCENT dataset

A. De Gramont, D. Sargent *J Clin Oncol* vol 26 (May 20 suppl) abstr 4007 2008

Abstract GI

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID

409 Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801

Daniel J. DeAngelo, Daohai Yu, Jeffrey L. Johnson, Steven E. Coutre, Richard M. Stone, Alison T. Stopeck, Jon P. Gockerman, Beverly S. Mitchell, Frederick R. Appelbaum, Richard A. Larson *Blood* vol 109 (12) 5136-5142 2007

Manuscript Leukemia <http://www.ncbi.nlm.nih.gov/pubmed/17344466>

410 Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665

Rebecca DeBoer, Gregory Koval, Flora Mulkey, Meir Wetzler, Steven Devine, Guido Marcucci, Richard M. Stone, Richard A. Larson, Clara D. Bloomfield, Susan Geyer, Charles G. Mullighan, Wendy Stock *Leuk Lymphoma* vol 57 (10) 2298-306 2016

Manuscript Leuk Corr Sci CALGB-9665, CALGB-10001

<http://www.ncbi.nlm.nih.gov/pubmed/26892479>

411 Clinical impact of ABL1 kinase and IKZF1 mutations in adults with Philadelphia chromosome-positive (PH+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB 10001 and 9665 (Alliance)

Rebecca DeBoer, Flora Mulkey, Gregory Koval, Meir Wetzler, Guido Marcucci, Richard M. Stone, Richard A. Larson, Susan Geyer, Charles Mullighan, Wendy Stock *Haematologica* vol 99s (1) 152 (abstract S723) 2014

Abstract Leuk Corr Sci CALGB-10001, CALGB-9665

412 Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor (GIST): ACOSOG Z9000 (Alliance) intergroup phase 2 trial

Ronald P. DeMatteo, Karla V. Ballman, Cristina R. Antonescu, Christopher Corless, Violetta Kolesnikova, Margaret von Mehren, Martin D. McCarter, Jeffrey Norton, Robert G. Maki, Peter W.T. Pisters, George D. Demetri, Murray F. Brennan, Kouros Owzar *Ann Surg* vol 258 (3) 422-429 2013
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/23860199>

413 Placebo-Controlled Randomized Trial of Adjuvant Imatinib Mesylate Following the Resection of Localized, Primary Gastrointestinal Stromal Tumor (GIST)

Ronald P. DeMatteo, Karla V. Ballman, Cristina R. Antonescu, Robert G. Maki, Peter W.T. Pisters, George D. Demetri, Martin E. Blackstein, Charles D. Blanke, Margaret von Mehren, Murray F. Brennan, Shreyaskumar Patel, Martin D. McCarter, Jonathan A. Polikoff, Benjamin R. Tan, Kouros Owzar *Lancet* vol 373 (9669) 1097-1104 2009
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/19303137>

414 Adjuvant Palbociclib for ER+ Breast Cancer (PALLAS Trial (ABCSG-42/AFT-05/BIG-14-13): A Preplanned Analysis of the Stage IIA cohort

Angela DeMichele, Amylou Dueck, Dominik Hlauschek, Miguel Martin, Hal Burstein, Georg Pfeiler, Nick Zdenkowski, Antonio Wolff, Meritxell Bellet-Ezquerria, Eric Winer, Marija Balic, Kathy Miller, Marco Colleoni, Diana Lake, Gabor Rubovsky, David Cameron, Justin Balko, Christian Singer, Zbigniew Nowecki, Hiroji Iwata, Norman Wolmark, Kepa Amilano Parraga, Hope Rugo, Guenther G. Steger, Tiffany Traina, Gustavo Werutsky, Dorota Czajkowska, Otto Metzger, Sarra El-Abed, Kathy Puyana Theall, Ray Dongrui Lu, Patrick O'Brien, Christian Fesl, Erica Mayer, Michael Gnant *J Clin Oncol* vol 40 (36 suppl) 390216 2022
Abstract Breast https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.36_suppl.390216

415 Breast lymphedema following breast conservation surgery and radiation for multiple ipsilateral breast cancer: Data from the Alliance Z11102 Study

Amy C. Degnim, Karla V. Ballman, Linda McCall, Tanya L. Hoskin, Kari M. Rosenkranz, Judy C. Boughey *The American Society of Breast Surgeons' Official Proceedings* vol XXI (suppl) 159-160 (#786294) 2020
Abstract Breast <https://www.breastsurgeons.org/education/virtual/proceedings.pdf#page=159>

416 The Breast Cancer Weight Loss (BWEL) Trial (Alliance A011401): A Description and Evidence for the Lifestyle Intervention

Linda M. Delahanty, Thomas A. Wadden, Pamela J. Goodwin, Catherine M. Alfano, Cynthia A. Thomson, Melinda L. Irwin, Marian L. Neuhouser, Tracy E. Crane, Elizabeth Frank, Patricia A. Spears, Bonnie P. Gillis, Dawn L. Hershman, Electra D. Paskett, Judith Hopkins, Vanessa Bernstein, Vered Stearns, Julia White, Clifford Hudis, Eric P. Winer, Lisa A. Carey, Ann H. Partridge, Jennifer A. Ligibel *Obesity (Silver Spring)* vol 30 (1) 28-38 2022
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/34932888>

417 Efficacy of adjuvant imatinib mesylate following complete resection of localized, primary gastrointestinal stromal tumor (GIST) at high risk of recurrence: The U.S. Intergroup phase II trial ACOSOG Z9000

R. P. Dematteo, K. Owzar, C. R. Antonescu, R. Maki, G. D. Demetri, M. Mccarter, M. Von Mehren, P. Pisters, M. F. Brennan, K. V. Ballman *Gastrointestinal Cancers Symposium abstr* 8 2008
Abstract GI
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=53&abstractID

418 Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely

resected localized primary gastrointestinal stromal tumor (GIST): North American Intergroup Phase III trial ACOSOG Z9001

R. Dematteo, K. Owzar, R. Maki, P. Pisters, M. Blackstein, C. Antonescu, C. Blanke, G. Demetri, M. Von Mehren, K. Ballman ASCO Annual Meeting Oral abstract 2007

Abstract GI

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID

419 Loss of p27 expression and response to neoadjuvant chemotherapy: Results from the I-SPY Trial (CALGB150007/150012, ACRIN6657)

A. Demichele, L. Dunn, P. Gimotty, C. Livasy, C. Perou, L. Carey, L. Esserman J Clin Oncol vol 27 (15s) abstr 11091 2009

Abstract Correl Sci NOS <http://meetinglibrary.asco.org/content/35378-65>

420 Comparison of community and central Her2 assessment on outcome of neoadjuvant chemotherapy in the I-SPY trial (CALGB 150007/150012, ACRIN 6657)

A. Demichele, C. Yau, J. Zhu, J. Wuhfkuhle, M. E. Lenburg, M. B. Buxton, S. E. Davis, C. Livasy, K. Chin, L. A. Carey, L. J. Esserman, E. F. Petricoin 3rd Cancer Res vol 71 (24) P1-06-11 2011

Abstract Correl Sci NOS ACRIN-6657, CALGB-150007

http://cancerres.aacrjournals.org/content/71/24_Supplement/P1-06-11

421 In-dwelling catheters are superior to talc pleurodesis in the management of malignant pleural effusions

T. L. Demmy, L. Gu, J. Burkhalter, E. M. Toloza, T. A. D'Amico, S. L. Sutherland, X. Wang, L. E. Archer, L. Veit, L. J. Kohman J Clin Oncol vol 28 (15s) abstr 9031 2010

Abstract Respiratory

http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/9031?sid=45271217-8e1e-4915-9c79-c3f21

422 Hypothetical double-consent design intervention

T. L. Demmy, L. J. Kohman, X. Wang 2010

Abstract Respiratory CALGB-30102, CALGB-9334

423 Optimal Management of Malignant Pleural Effusions (Results of CALGB 30102)

Todd L. Demmy, Lin Gu, Jack E. Burkhalter, Eric M. Toloza, Thomas A. D'Amico, Susan Sutherland, Xiaofei Wang, Laura Archer, Linda J. Veit, Leslie Kohman J Natl Compr Canc Netw vol 10 (8) 975-982 2012

Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/22878823>

424 Radiomic signatures to predict survival in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib +/- doxorubicin: Correlative Science from CALGB 80802

Laurent Derle, Susan Geyer, Andrew Nixon, Federico Innocenti, Qian Shi, Sawyer B. Jacobson, Lyndon Luk, Andrew Liu, Hao Yang, Yujia Wen, Binsheng Zhao, Monica M. Bertagnolli, Jeffrey Meyerhardt, Eileen M. O'Reilly, Alan P. Venook, Lawrence H. Schwartz, Ghassan K. Abou-Alfa J Clin Oncol vol 39 (3_suppl) 343 2021

Abstract GI https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.3_suppl.343

425 Perceived Risk for Cancer Progression and Psychological Status in Chronic Lymphocytic Leukemia Patients: CALGB 70603 (Alliance)

Teresa Deshields, Amylou C. Dueck, Kerry Rogers, Jennifer R. Brown, Tait Shanafelt, David Mintzer, John C. Byrd Leuk Lymphoma vol 60 (10) 2580-3 2019

Manuscript Health Outcomes CALGB-10501 <http://www.ncbi.nlm.nih.gov/pubmed/30916608>

426 A Phase II Study of Allogeneic Transplantation for Older Patients with AML in First Complete Remission Using a Reduced Intensity Conditioning Regimen: Results From CALGB 100103/BMT

CTN 0502

S. M. Devine, K. Owzar, W. Blum, D. Deangelo, R. M. Stone, J. W. Hsu, R. E. Champlin, Y.-B. A. Chen, R. Vij, J. L. Slack, R. J. Soiffer, R. A. Larson, T. C. Shea, V. Hars, E. Bennett, S. Spangle, S. A. Giralt, S. L. Carter, M. M. Horowitz, C. Linker, E. P. Alyea 3rd ASH Annual Meeting Abstracts vol 120 (21) -230 2012
Abstract Transplant <http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;120/21/230>

427 Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502

Steven M. Devine, Kouros Owzar, William Blum, Flora Mulkey, Richard M. Stone, Jack W. Hsu, Richard E. Champlin, Yi-Bin Chen, Ravi Vij, James Slack, Robert J. Soiffer, Richard A. Larson, Thomas C. Shea, Vera Hars, Alexander B. Sibley, Sergio Giralt, Shelly Carter, Mary M. Horowitz, Charles Linker, Edwin P. Alyea J Clin Oncol vol 33 (35) 4167-4175 2015
Manuscript Transplant <http://www.ncbi.nlm.nih.gov/pubmed/26527780>

428 Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B.

Michael P DiGiovanna, David F Stern, Susan Edgerton, Gloria Broadwater, Lynn G Dressler, Daniel R Budman, I Craig Henderson, Larry Norton, Edison T Liu, Hyman B Muss, Donald A Berry, Daniel F Hayes, Ann D Thor J Clin Oncol vol 26 (14) 2364-72 2008
Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/18390970>

429 Influence of dietary insulin scores on survival in patients with metastatic colorectal cancer (mCRC): Findings from CALGB (Alliance) 80405

Katherine W. DiNardo, Sui Zhang, Fang-Shu Ou, Chen Yuan, Brendan Guercio, Vicente Morales-Oyarvide, Erin L. Van Blarigan, Donna Niedzwiecki, I-Wen Chang, Heinz-Josef Lenz, Charles D. Blanke, Alan P. Venook, Robert J. Mayer, Charles S. Fuchs, Federico Innocenti, Andrew Nixon, Richard Goldberg, Eileen M. O'Reilly, Jeffrey A. Meyerhardt, Kimmie Ng J Clin Oncol vol 39 (no. 15_suppl) 3568 2021
Abstract GI https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.3568

430 Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor–Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance)

Maura N. Dickler, William T. Barry, Constance T. Cirrincione, Matthew J. Ellis, Mary Ellen Moynahan, Federico Innocenti, Arti Hurria, Hope S. Rugo, Diana E. Lake, Olwen Hahn, Bryan P. Schneider, Debasish Tripathy, Lisa A. Carey, Eric P. Winer, Clifford A. Hudis J Clin Oncol vol 34 (22) 2602-2609 2016
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/27138575>

431 Phase III Trial Evaluating the Addition of Bevacizumab to Letrozole As First-line Endocrine Therapy for Treatment of Hormone-receptor Positive Advanced Breast Cancer: CALGB 40503 (Alliance)

Maura N. Dickler, William Thomas Barry, Constance T. Cirrincione, Matthew James Ellis, Mary Ellen Moynahan, Federico Innocenti, Arti Hurria, Hope S. Rugo, Diana Lake, Olwen M Hahn, Bryan P. Schneider, Debu Tripathy, Eric P. Winer, Clifford A. Hudis J Clin Oncol vol 33 (suppl) abstr 501 2015
Abstract Breast <http://meetinglibrary.asco.org/content/143639-156>

432 Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma†

M. A. Dickson, M. R. Mahoney, W. D. Tap, S. P. D'Angelo, M. L. Keohan, B. A. Van Tine, M. Agulnik, L. E. Horvath, J. S. Nair, G. K. Schwartz *Ann Oncol* vol 27 (10) 1855-1860 2016
Manuscript Experimental <http://www.ncbi.nlm.nih.gov/pubmed/27502708>

- 433 Alliance A091102: Phase II study of MLN8237 (alisertib) in advanced/metastatic sarcoma**
Mark Andrew Dickson, Michelle R. Mahoney, Benjamin T. Marchello, Mercedes M. Condy, William D. Tap, Gary K. Schwartz *J Clin Oncol* vol 31 (15 suppl) abstr TPS10594 2013
Abstract Experimental http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/10527
- 434 Features Associated with Successful Recruitment of Diverse Patients onto Cancer Clinical Trials: Report from the American College of Surgeons Oncology Group**
Kathleen M. Diehl, Erin M. Green, Armin Weinberg, Wayne A. Frederick, Dennis R. Holmes, Bettye Green, Arden Morris, Henry M. Kuerer, Robert A. Beltran, Jane Mendez, Venus Gines, David M. Ota, Heidi Nelson, Lisa A. Newman *Ann Surg Oncol* vol 18 (13) 3544-3550 2011
Manuscript Disparities <http://www.ncbi.nlm.nih.gov/pubmed/21681382>
- 435 Alliance/CALGB 80802 impact of hepatitis C (HCV) on doxorubicin (D) + sorafenib (S) vs. s in patients (pts) advanced HCC (aHCC)**
Imane El Dika, Susan M. Geyer, Andrew Nixon, Federico Innocenti, Qian Shi, Sawyer B. Jacobson, Amin Yaqubie, Juan Lopez, Binhui Huang, Yi-Wei Tang, Yujia Wen, Lawrence H. Schwartz, Monica M. Bertagnolli, Jeffrey Meyerhardt, Eileen M. O'Reilly, Alan P. Venook, Ghassan K. Abou-Alfa *J Clin Oncol* vol 39 (3_suppl) 325 2021
Abstract GI https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.3_suppl.325
- 436 Impact of trial development time on accruals at CCOPs: The case of the MARVEL trial.**
D. M. Dilts, A. A. Adjei, S. J. Mandrekar, J. C. Buckner, L. M. Minasian, M. Rienzo, R. Ledsky, H. Massett *J Clin Oncol* vol 28 (15s) abstr e16505 2010
Abstract Respiratory <http://meetinglibrary.asco.org/content/53642-74>
- 437 Allosteric Akt inhibitor MK2206 synergizes with bendamustine in promoting the apoptosis of chronic lymphocytic leukemia cells and selectively targets B-cell receptor mediated cytokine production**
W. Ding, T. D. Shanafelt, C. Lesnick, T. Sassoon, C. Secreto, C. Erlichman, J. Leis, T. G. Call, D. Bowen, S. K. Kumar, N. E. Kay *Blood* vol 120 (21) abstr 3928 2012
Abstract Leukemia <https://ash.confex.com/ash/2012/webprogram/Paper48588.html>
- 438 Akt Inhibitor MK2206 Selectively Targets CLL B-cell Receptor Induced Cytokines, Mobilizes Lymphocytes and Synergizes with Bendamustine to Induce CLL Apoptosis**
Wei Ding, Tait D. Shanafelt, Connie E. Lesnick, Charles Erlichman, Jose F. Leis, Charla Secreto, Traci R. Sassoon, Timothy G. Call, Deborah A. Bowen, Michael Conte, Shaji Kumar, Neil E. Kay *Br J Haematol* vol 164 (1) 146-150 2014
Manuscript Leukemia <http://www.ncbi.nlm.nih.gov/pubmed/24111951>
- 439 The AKT Inhibitor MK2206 In Combination With Rituximab and Bendamustine Is Tolerable and Active In Relapsed Or Refractory Chronic Lymphocytic Leukemia: Results From a Phase 1 Study (NCCTG N1087 Alliance)**
Wei Ding, Tait D. Shanafelt, Clive S. Zent, Jose F. Leis, Betsy R. LaPlant, Timothy G. Call, Curtis A. Hanson, Charles Erlichman, Thomas M. Habermann, Craig Reeder, Daniel Nikceovich, Deborah Bowen, Michael J. Conte, Justin Boysen, Charla Secreto, Connie Lesnick, Renee C. Tschumper, Diane F. Jelinek, Neil E. Kay *Blood* vol 122 (21) Abstract 2882 2013
Abstract Leukemia <http://bloodjournal.hematologylibrary.org/content/122/21/2882.abstract>
- 440 Sublobar Resection and Iodine-125 Brachytherapy for Stage 1 NSCLC, Initial Quality**

Assurance Review of ACOSOG Z-4032

T. A. Dipetrillo, D. E. Heron, R. J. Landreneau, D. Logan, C. Briggs, T. J. Fitzgerald, C. R. Thomas Jr, J. B. J. Putnam, B. F. Meyers, F. C. Nichols 3rd, H. C. Fernando Int J Radiat Oncol Biol Phys vol 75 (3s) S61 2009

Abstract Respiratory <http://www.redjournal.org/article/S0360-3016%2809%2901201-2/fulltext>

441 Clinical and Genome Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer

M. Eileen Dolan, Omar El Charif, Heather E. Wheeler, Eric R. Gamazon, Shirin Ardeshir-Rouhani-Fard, Patrick Monahan, Darren R. Feldman, Robert J. Hamilton, David J. Vaughn, Clair J. Beard, Chunkit Fung, Jeri Kim, Sophie D. Fossa, Daniel L Hertz, Taisei Mushiroda, Michiaki Kubo, Lawrence H. Einhorn, Nancy J. Cox, Lois B. Travis Clin Cancer Res vol 23 (19) 5757-68 2017

Manuscript PPP <http://www.ncbi.nlm.nih.gov/pubmed/28611204>

442 Phase III Intergroup Study of Talc Poudrage vs Talc Slurry Sclerosis for Malignant Pleural Effusion

Carolyn M. Dresler, Jemi Olak, James E. Herndon, William G. Richards, Ernest Scalzetti, Stewart B. Fleishman, Kemp H. Kernstine, Todd Demmy, David M. Jablons, Leslie Kohman, Thomas M. Daniel, George B. Haasler, David J. Sugarbaker Chest vol 127 (3) 909-915 2005

Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/15764775>

443 Participation in cancer pharmacogenomic studies in 8,456 patients registered to Cancer and Leukemia Group B (Alliance) clinical trials

L. G. Dressler, A. M. Deal, D. Watson, D. Hollis, K. Owzar, K. Donohue, P. N. Friedman, M. J. Ratain, H. L. Mcleod J Clin Oncol vol 31 (15 suppl) abstr 6501 2013

Abstract Health Outcomes CALGB-40101, CALGB-50303, CALGB-80203, CALGB-80303, CALGB-80405, CALGB-90401

http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/6501?sid=e2b09ffa-e28f-45c1-afb9-2f6e54

444 Participation in Cancer Pharmacogenomic Studies: A Study of 8456 Patients Registered to Clinical Trials in the Cancer and Leukemia Group B (Alliance)

Lynn G. Dressler, Allison M. Deal, Kouros Owzar, Dorothy Watson, Kathleen Donahue, Paula N. Friedman, Mark J. Ratain, Howard L. McLeod J Natl Cancer Inst vol 107 (10) 2015

Manuscript Health Outcomes CALGB-40101, CALGB-50303, CALGB-80101, CALGB-80203, CALGB-80303, CALGB-80405, CALGB-90401 <http://www.ncbi.nlm.nih.gov/pubmed/26160883>

445 N0675: NCCTG phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma (MM)

R. Dronca, D. Perez, J. Allred, W. Maples, E. Creagan, B. Pockaj, J. Kaur, J. Kuebler, B. Marchello, S. Markovic J Clin Oncol vol 28 (15s) abstr 8572 2010

Abstract Experimental

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID

446 Phase II Study of Temozolomide (TMZ) and Everolimus (RAD001) Therapy for Metastatic Melanoma

Roxana S. Dronca, Jacob B. Allred, Domingo G. Perez, Wendy K. Nevala, Elizabeth A.T. Lieser, Michael Thompson, William J. Maples, Edward T. Creagan, Barbara A. Pockaj, Judith S. Kaur, Timothy D. Moore, Benjamin T. Marchello, Svetomir N. Markovic Am J Clin Oncol vol 37 (4) 369-376 2014

Manuscript Experimental <http://www.ncbi.nlm.nih.gov/pubmed/23357973>

447 CALGB 150905 (Alliance): Rituximab broadens the anti-lymphoma response by activating

unlicensed NK cells

Juan Du, Sandra Lopez-Verges, Brandelyn N. Pitcher, Jeffrey Johnson, Sin-Ho Jung, Lili Zhou, Katharine Hsu, Myron S. Czuczman, Bruce Cheson, Lawrence Kaplan, Lewis L. Lanier, Jeffrey M. Venstrom *Cancer Immunol Res* vol 2 (9) 878-889 2014
Manuscript Lymphoma CALGB-50402, CALGB-50701
<http://www.ncbi.nlm.nih.gov/pubmed/24958280>

448 A phase II study of sorafenib in malignant mesothelioma: results of CALGB 30307

Sarita Dubey, Pasi A. Jänne, Lee Krug, Herbert Pang, Xiaofei Wang, Robin Heinze, Colleen Watt, Jeff Crawford, Robert Kratzke, Everett Vokes, Hedy Lee Kindler *J Thorac Oncol* vol 5 (10) 2010
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/20736856>

449 CALGB 30601: A phase II study of dasatinib (D) in patients (pts) with previously treated malignant mesothelioma (MM)

A. Z. Dudek, H. L. Kindler, G. A. Otterson, H. Pang, R. A. Kratzke, E. E. Vokes *J Clin Oncol* vol 28 (15s) abstr 7037 2010
Abstract Respiratory
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID

450 Phase II study of dasatinib in patients with previously treated malignant mesothelioma (Cancer and Leukemia Group B 30601): a brief report

A. Z. Dudek, H. Pang, R. A. Kratzke, G. A. Otterson, L. Hodgson, E. E. Vokes, H. L. Kindler *J Thorac Oncol* vol 7 (4) 755-759 2012
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/22425926>

451 Randomized Study of Maintenance Pemetrexed versus Observation for Treatment of Malignant Pleural Mesothelioma: CALGB 30901

Arkadiusz Z. Dudek, Xiaofei Wang, Lin Gu, Stephanie Duong, Thomas E. Stinchcombe, Robert Kratzke, Hossein Borghaei, Everett E. Vokes, Hedy L. Kindler *Clin Lung Cancer* vol 21 (6) 553-561.e1 2020
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/32727707>

452 Randomized phase 2 study of maintenance pemetrexed versus observation for patients (pts) with malignant pleural mesothelioma (MPM) without progression after first-line chemotherapy: Cancer and Leukemia Group B (CALGB/Alliance) 30901

Arkadiusz Z. Dudek, Xiaofei Wang, Lin Gu, Thomas Stinchcombe, Robert Kratzke, Everett E. Vokes, Hedy L Kindler *J Clin Oncol* vol 37 (Suppl) abstr 8517 2019
Abstract Respiratory
https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.8517?journalCode=jco&volume=37&year=

453 Rates of Ipsilateral Local-regional Recurrence in High-risk Patients Undergoing Immediate Post-mastectomy Reconstruction (AFT-01).

Christina M Dudley, Alyssa A Wiener, Trista J Stankowski-Drengler, Jessica R Schumacher, Amanda B Francescatti, Samuel O Poore, Caprice C Greenberg, Heather B Neuman *Clin Breast Cancer* vol 21 (5) 433-9 2021
Manuscript CCDD <http://www.ncbi.nlm.nih.gov/pubmed/34103255>

454 Validity and reliability of the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).

A. C. Dueck, T. R. Mendoza, S. A. Mitchell, B. B. Reeve, K. M. Castro, A. Denicoff, A. M. O'Mara, L. J. Rogak, S. B. Clauser, D. M. Bryant, T. A. Gillis, J. D. Bearden 3rd, R. D. Siegel, J. K. Harness, D. B. Paul, C. S. S. Cleeland, J. A. Sloan, D. Schrag, L. M. Minasian, E. M. Basch *J Clin Oncol* vol 30 (15 suppl) abstr 9047 2012

455 Endpoint comparison for bone mineral density measurements in North Central Cancer Treatment Group cancer clinical trials N02C1 and N03CC (Alliance)

A. C. Dueck, J. Singh, P. Atherton, H. Liu, P. Novotny, S. Hines, C. L. Loprinzi, E. A. Perez, A. Tan, K. Burger, X. Zhao, B. Diekmann, J. A. Sloan *Osteoporos Int* vol 26 (7) 1971-1977 2015

Manuscript Health Outcomes NCCTG-N02C1, NCCTG-N03CC

<http://www.ncbi.nlm.nih.gov/pubmed/25749740>

456 Calibrating clinically significant effects in survival and response endpoints in cancer clinical trials.

A. Dueck, D. Sargent, P. Novotny, P. Decker, H. Nelson, R. Qin, J. Sloan *J Clin Oncol* vol 29 (15 supplement) Abstract 6130 2011

Abstract Health Outcomes <http://meetinglibrary.asco.org/content/85098-102>

457 Composite Grading Algorithm for the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

Amylou C. Dueck, Claus Becker, Lauren J. Rogak, Deborah Schrag, Bryce B. Reeve, Patricia Spears, Mary Lou Smith, Mrinal M. Gounder, Michelle R. Mahoney, Gary K. Schwartz, Antonia V. Bennett, Tito R. Mendoza, Charles S. Cleeland, Jeff A. Sloan, Deborah Watkins Bruner, Gisela Schwab, Thomas M. Atkinson, Gita Thanarajasingam, Monica M. Bertagnolli, Ethan Basch *J Clin Oncol* vol 38 (15_suppl) 7018 2020

Abstract Health Outcomes Alliance-A091105, COMET-2

https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.7018

458 Quality of life (QOL) among patients (pts) with HER2+ breast cancer (bc) treated with adjuvant lapatinib and/or trastuzumab in the ALTTO study (BIG 2-06, Alliance N063D).

Amylou C. Dueck, David W. Hillman, Lisa A. Kottschade, Michele Y. Halyard, Jeff A. Sloan, Lynn M. Flickinger, Antonio C. Wolff, Lyndsay Harris, Julie Gralow, Kathleen I. Pritchard, Susan Ellard, Nguyet Le-Lindqwister, Frances M. Boyle, Evandro de Azambuja, Wortia J. McCaskill-Stevens, Jo

Anne Zujewski, Martine J. Piccart-Gebhart, Edith A. Perez *J Clin Oncol* vol 32 (5s) (suppl; abstr 647) 2014

Abstract Breast http://abstracts.asco.org/144/AbstView_144_134049.html

459 Validity and Reliability of the U.S. National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

Amylou C. Dueck, Tito R. Mendoza, Sandra A. Mitchell, Bryce B. Reeve, Kathleen M. Castro, Lauren J. Rogak, Thomas M. Atkinson, Antonia V. Bennett, Andrea M. Denicoff, Ann M. O'Mara, Yuelin Li, Steven B. Clauser, Donna M. Bryant, James D. Bearden, Theresa A. Gillis, Jay K. Harness, Robert D.

Siegel, Diane B. Paul, Charles S. Cleeland, Deborah Schrag, Jeff A. Sloan, Amy P. Abernethy, Deborah W. Bruner, Lori M. Minasian, Ethan Basch *JAMA Oncol* vol 1 (8) 1051-1059 2015

Manuscript Health Outcomes <http://www.ncbi.nlm.nih.gov/pubmed/26270597>

460 A cluster-randomized study of clinician-patient shared vs standard reporting of symptomatic adverse events using PRO-CTCAE nested in a multicenter trial of multimodal therapy for rectal cancer (Alliance N1048 PROSPECT)

Amylou C. Dueck, S.A. Mitchell, Lauren I. Rogak, Brenda Ginos, Daniel J. Sargent, Qian Shi, J.M. Farma, C. Crane, H. Kennecke, A.M O'Mara, L.M. Minasian, Deborah Schrag, Ethan Basch *Qual Life Res* vol 24 (Suppl 1) 1-191 (abstract 2) 2015

Abstract GI

<http://download.springer.com/static/pdf/824/art%253A10.1007%252Fs11136-015-1078-4.pdf?originUrl=>

- 461 Impact of c-MYC Protein Expression on Outcome of Patients with Early-Stage HER2+ Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831**
Amylou C. Dueck, Monica M. Reinholz, Xochiquetzal J. Geiger, Kathleen Tenner, Karla Ballman, Robert B. Jenkins, Darren Riehle, Beiyun Chen, Ann E. McCullough, Nancy E. Davidson, Silvana Martino, George W. Sledge, Peter A. Kaufman, Leila A. Kutteh, Julie Gralow, Lyndsay N. Harris, James N. Ingle, Wilma L. Lingle, Edith A. Perez Clin Cancer Res vol 19 (20) 5798-5807 2013
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/23965903>
- 462 Patient-reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in NCCTG (Alliance) N1031 (Randomized Phase II Study of Two Doses of Pixantrone in Patients with Metastatic Breast Cancer)**
Amylou C. Dueck, Kostandinos Sideras, Jeff Sloan, Brenda F. Ginos, Shaker R. Dakhil, Ethan Basch, Edith A. Perez Quality of Life Research vol 22 (1 Supplement) 81-82 (abstr 1086) 2013
Abstract Breast <http://link.springer.com/journal/11136/22/1/suppl/page/1>
- 463 Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial.**
David B Duggan, Gina R Petroni, Jeffrey L Johnson, John H Glick, Richard I Fisher, Joseph M Connors, George P Canellos, Bruce A Peterson J Clin Oncol vol 21 (4) 607-14 2003
Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/12586796>
- 464 Attitudes of Clinicians about Screening Head and Neck Cancer Survivors for Lung Cancer Using Low-Dose Computed Tomography**
Kimberly Dukes, Aaron T. Seaman, Richard M. Hoffman, Alan J. Christensen, Nicholas Kendell, Andrew L. Sussman, Miriam Vélez-Bermúdez, Robert J. Volk, Nitin A. Pagedar Ann Otol Rhinol Laryngol vol 129 (1) 23-31 2020
Manuscript Prevention <http://www.ncbi.nlm.nih.gov/pubmed/31409114>
- 465 Radiofrequency ablation of stage Ia NSCLC in medically inoperable patients: Results from ACOSOG Z4033 (Alliance) an NCI funded multicenter trial**
D. E. Dupuy, H. Fernando, S. Hillman, T. Ng, A. D. Tan, J.-A. Shepard, W. Rilling, K. Hong, J. B. Putnam Jr Chest vol 144 (4) 86A 2013
Abstract Respiratory
<http://journal.publications.chestnet.org/article.aspx?articleid=1739584&resultClick=1>
- 466 Radiofrequency Ablation of Stage IA NSCLC in Medically Inoperable Patients: Results from the ACOSOG Z4033 (Alliance) Trial**
Damian E. Dupuy, Hiran C. Fernando, Shauna Hillman, Thomas Ng, Angelina D. Tan, Amita Sharma, William S. Rilling, Kelvin Hong, Joe B. Putnam Cancer vol 121 (19) 3491-3498 2015
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/26096694>
- 467 Personality, coping, and social support as predictors of long-term quality-of-life trajectories in older breast cancer survivors: CALGB protocol 369901 (Alliance)**
Estrella Durá-Ferrandis, Jeanne S. Mandelblatt, Jonathan Clapp, George Luta, Leigh Anne Faul, Gretchen Kimmick, Harvey Jay Cohen, Rachel L. Yung, Arti Hurria Psycho-Oncol vol 26 (11) 1914-1921 2017
Manuscript Older Adult <http://www.ncbi.nlm.nih.gov/pubmed/28219113>
- 468 A randomized phase II study of gemcitabine (G) and carboplatin (C) with or without cediranib (AZD2171 [CED]) as first-line therapy in advanced non-small cell lung cancer (NSCLC).**
G. K. Dy, S. J. Mandrekar, G. D. Nelson, H. J. Ross, R. H. Ansari, A. P. Lyss, P. J. Stella, S. E. Schild, J. R. Molina, A. A. Adjei J Clin Oncol vol 28 (15s) abstr 7603 2010
Abstract Respiratory

- 469 N0821: A phase II first-line study of a combination of pemetrexed (P), carboplatin (C), and bevacizumab (B) in elderly patients with good performance status (PS < 2)**
G. K. Dy, J. Molina, Y. Qi, R. H. Ansari, S. Thomas, H. J. Ross, J. Meyers, S. Mandrekar, A. A. Adjei
J Clin Oncol vol 30 (15 suppl) abstr 7555 2012
Abstract Respiratory
http://meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/7555?sid=292ba759-a9d8-45c0-8f1f-2ab66
- 470 A Front-Line “Window of Opportunity” Phase II Study of Sorafenib in Patients with Advanced Non-small Cell Lung Cancer (NSCLC)– A North Central Cancer Treatment Group Study N03261**
Grace K. Dy, Shauna L. Hillman, Kendrith M. Rowland, Julian R. Molina, Preston D. Steen, Donald B. Wender, Suresh Nair, Sumithra Mandrekar, Steven E. Schild, Alex A. Adjei Cancer vol 116 (24) 5686-5693 2010
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/21218460>
- 471 Long-Term Survivors of Metastatic Colorectal Cancer Treated with Systemic Chemotherapy Alone: A North Central Cancer Treatment Group Review of 3811 Patients, N0144**
Grace K. Dy, Timothy J. Hobday, Garth Nelson, Harold E. Windschitl, Michael J. O'Connell, Steven R. Alberts, Richard M. Goldberg, Daniel A. Nikcevich, Daniel J. Sargent Clin Colorectal Cancer vol 8 (2) 88-93 2009
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/19739269>
- 472 A Randomized Phase II Study of Gemcitabine and Carboplatin With or Without Cediranib as First-Line Therapy in Advanced Non-Small Cell Lung Cancer: North Central Cancer Treatment Group Study N0528**
Grace K. Dy, Sumithra J. Mandrekar, Garth D. Nelson, Jeffrey P. Meyers, Araba A. Adjei, Helen J. Ross, Rafat H. Ansari, Alan P. Lyss, Philip J. Stella, Steven E. Schild, Julian R. Molina, Alex A. Adjei
J Thorac Oncol vol 8 (1) 79-88 2013
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/23232491>
- 473 NCCTG N0821 (Alliance): A phase II first-line study of pemetrexed, carboplatin and bevacizumab in elderly patients with advanced nonsquamous non-small cell lung cancer with good performance status**
Grace K. Dy, Julian R. Molina, Yingwei Qi, Rafat Ansari, Sachdev Thomas, Helen J. Ross, Gamini Soori, Daniel Anderson, Marie Christine Aubry, Jeffrey Meyers, Araba A. Adjei, Sumithra Mandrekar, Alex A. Adjei J Thorac Oncol vol 9 (8) 1146-1153 2014
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/25157767>
- 474 Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741.**
Grace K Dy, James E Krook, Erin M Green, Daniel J Sargent, Thierry Delaunoit, Roscoe F Morton, Charles S Fuchs, Ramesh K Ramanathan, Stephen K Williamson, Brian P Findlay, Barbara A Pockaj, Robert P Sticca, Steven R Alberts, Henry C Pitot, Richard M Goldberg J Clin Oncol vol 25 (23) 3469-74 2007
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/17687151>
- 475 Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia**
Konstanze Döhner, Christian Thiede, Nikolaus Jahn, Ekaterina Panina, Agnes Gambietz, Richard A. Larson, Thomas W. Prior, Guido Marcucci, Dan Jones, Jürgen Krauter, Michael Heuser, Maria Teresa Voso, Tiziana Ottone, Josep F. Nomdedeu, Sumithra J. Mandrekar, Rebecca B. Klisovic, Andrew H. Wei, Jorge Sierra, Miguel A. Sanz, Joseph M. Brandwein, Theo de Witte, Joop H. Jansen, Dieterger

Niederwieser, Frederick R. Appelbaum, Bruno C. Medeiros, Martin S. Tallman, Richard F. Schlenk, Arnold Ganser, Hubert Serve, Gerhard Ehninger, Sergio Amadori, Insa Gathmann, Axel Benner, Celine Pallaud, Richard M. Stone, Hartmut Döhner, Clara D. Bloomfield *Blood* vol 135 (5) 371-80 2020

Manuscript *Leuk Corr Sci* <http://www.ncbi.nlm.nih.gov/pubmed/31826241>

476 Prognostic and predictive impact of NPM1/FLT3-ITD genotypes as defined by 2017 European LeukemiaNet (ELN) risk categorization from randomized patients with acute myeloid leukemia (AML) treated within the International RATIFY Study (ALLIANCE 10603)

Konstanze Döhner, Christian Thiede, Nikolaus Jahn, Ekaterina Panina, Agnes Gambietz, Thomas W Prior, Guido Marcucci, Dan Jones, Jürgen Krauter, Michael Heuser, Francesco Lo Coco, Tiziana Ottone, Josep Nomdedeu, Sumithra J Mandrekar, Ben L. Sanford, Kristine Laumann, Susan M. Geyer, Rebecca B. Klisovic, Andrew Wei, Jorge Sierra, Miguel A. Sanz, Joseph M. Brandwein, T. M. M de Witte, Joop H. Jansen, Dietger Niederwieser, Frederick R. Appelbaum, Bruno C Medeiros, Martin S. Tallman, Richard F. Schlenk, Arnold Ganser, Hubert Serve, Gerhard Ehninger, Sergio Amadori, Insa Gathmann, Axel Benner, Celine Pallaud, Richard A. Larson, Richard M. Stone, Hartmut Döhner, Clara D. Bloomfield *HemaSphere* vol 3 (Issue) 81–82 2019

Abstract *Leukemia*

https://journals.lww.com/hemasphere/Fulltext/2019/06001/PROGNOSTIC_AND_PREDICTIVE_IMPA

477 Prognostic impact of NPM1/FLT3-ITD genotypes from randomized patients treated within the RATIFY/CALGB 10603 (Alliance) Study

Konstanze Döhner, Christian Thiede, Richard A. Larson, Thomas W. Prior, Guido Marcucci, Jürgen Krauter, Michael Heuser, Francesco Lo-Coco, Josep F. Nomdedeu, Sumithra Mandrekar, Ben L. Sanford, Kristine Laumann, Susan Geyer, Rebecca B. Klisovic, Andrew Wei, Jorge Sierra, Miguel Sanz, Joseph M. Brandwein, Theo de Witte, Dietger Niederwieser, Frederick R. Appelbaum, Bruno C. Medeiros, Martin S. Tallman, Richard F. Schlenk, Arnold Ganser, Hubert Serve, Gerhard Ehninger, Sergio Amadori, Yuan Cheng, Celine Pallaud, Richard M. Stone, Hartmut Döhner, Clara D. Bloomfield *Blood* vol 130 (Suppl 1) 467 2017

Abstract *Leukemia* http://www.bloodjournal.org/content/130/Suppl_1/467

478 CALGB 90203 (Alliance): Radical Prostatectomy with or without neoadjuvant chemohormonal therapy in men with clinically localized, high risk prostate cancer

J.A. Eastham, G. Heller, S. Halabi, J. P. Monk, H. Beltran, M. Gleave, C.P. Evans, Steven Clinton, Russell Szmulewitz, Jonathan Coleman, David Hillman, Colleen Watt, O. Hahn, M. E. Taplin, E. Small, J. Mohler, M. J. Morris *J Clin Oncol* vol 37 (15_suppl) 5079 2019

Abstract *GU* https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.5079

479 CALGB 90203 (Alliance): Radical Prostatectomy with or without neoadjuvant chemohormonal therapy in men with clinically localized, high risk prostate cancer.

J.A. Eastham, G. Heller, S. Halabi, J. P. Monk, H. Beltran, M. Gleave, C.P. Evans, Steven Clinton, Russell Szmulewitz, Jonathan Coleman, David Hillman, Colleen Watt, O. Hahn, M. E. Taplin, E. Small, J. Mohler, M. J. Morris *Journal of Urology* vol 201 (Suppl 4) e997 2019

Abstract *GU* <https://www.auajournals.org/doi/abs/10.1097/01.JU.0000557504.00464.d6>

480 Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer

James A. Eastham, Glenn Heller, Susan Halabi, J. Paul Monk III, Himisha Beltran, Martin Gleave, Christopher P. Evans, Steven K. Clinton, Russell Z. Szmulewitz, Jonathan Coleman, David W. Hillman, Colleen R. Watt, Saby George, Martin G. Sanda, Olwen M. Hahn, Mary-Ellen Taplin, J. Kellogg Parsons, James L. Mohler, Eric J. Small, Michael J. Morris *J Clin Oncol* vol 38 (26) 3042-50 2020

Manuscript *GU* <http://www.ncbi.nlm.nih.gov/pubmed/32706639>

- 481 Baseline testosterone levels in men with clinically localized high-risk prostate cancer treated with radical prostatectomy with or without neoadjuvant chemohormonal therapy (Alliance)**
James A. Eastham, Glenn Heller, David W. Hillman, Olwen M. Hahn, J. Kellogg Parsons, James L. Mohler, Eric J. Small, Michael Morris J Urol vol 206 (2) 319-24 2021
Manuscript GU <http://www.ncbi.nlm.nih.gov/pubmed/33780276>
- 482 Serum VEGF and COX-2/5LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304**
M. J. Edelman, L. D. Hodgson, X. Wang, R. H. Christenson, E. E. Vokes, R. A. Kratzke J Clin Oncol vol 28 (15s) abstr 7614 2010
Abstract Respiratory
http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/7614?sid=378de8b3-c266-4aa9-9277-0f441
- 483 Eicosanoid modulation in advanced non-small cell lung cancer (NSCLC): CALGB 30203**
M. J. Edelman, D. M. Watson, X. Wang, R. A. Kratzke, A. M. Mauer, M. R. Green, E. E. Vokes, S. L. Graziano, G. A. Masters, M. M. Bedor J Clin Oncol vol 24 (18s) abst 7025 2006
Abstract Respiratory
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=40&abstractID
- 484 CYFRA 21-1 as a prognostic and predictive marker in advanced non-small cell lung cancer in a prospective trial: CALGB 150304**
Martin J. Edelman, Lydia Hodgson, Paula Y. Rosenblatt, Robert H. Christenson, Everett Vokes, Xiaofei Wang, Robert Kratzke J Thorac Oncol vol 7 (4) 649-654 2012
Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/22425913>
- 485 Serum Vascular Endothelial Growth Factor and COX-2/5-LOX Inhibition in Advanced Non-small Cell Lung Cancer: Cancer and Leukemia Group B 150304**
Martin J. Edelman, Lydia Hodgson, Xiaofei Wang, Robert Christenson, Scott Jewell, Everett Vokes, Robert Kratzke J Thorac Oncol vol 6 (11) 1902-1906 2011
Manuscript Respiratory CALGB-30203 <http://www.ncbi.nlm.nih.gov/pubmed/21964530>
- 486 Final Results of a phase III trial of celecoxib (C) in addition to standard chemotherapy for advanced NSCLC with COX- 2 overexpression: CALGB 30801 (Alliance)**
Martin J. Edelman, Xiaofei Wang, Lydia Hodgson, Richard T. Cheney, Maria Q. Baggstrom, Thomas Sachdev, Ajeet Gajra, Erin Bertino, Karen L. Reckamp, Julian Molina, Joan Schiller, Kisha Mitchell-Richards, Paula N. Friedman, Jon Ritter, Ginger Milne, Olwen Hahn, Thomas Stinchcombe, Everett E. Vokes Int J Radiat Oncol Biol Phys vol 98 (1) 220-1 2017
Abstract Respiratory [http://www.redjournal.org/article/S0360-3016\(17\)30057-3/abstract](http://www.redjournal.org/article/S0360-3016(17)30057-3/abstract)
- 487 Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance)**
Martin J. Edelman, Xiaofei Wang, Lydia Hodgson, Richard T. Cheney, Maria Q. Baggstrom, Sachdev P. Thomas, Ajeet Gajra, Erin Bertino, Karen L. Reckamp, Julian Molina, Joan H. Schiller, Kisha Mitchell-Richards, Paula N. Friedman, Jon Ritter, Ginger Milne, Olwen M. Hahn, Thomas E. Stinchcombe, Everett E. Vokes J Clin Oncol vol 35 (19) 2184-2192 2017
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/28489511>
- 488 Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.**
Martin J Edelman, Dee Watson, Xiaofei Wang, Carl Morrison, Robert A Kratzke, Scott Jewell, Lydia Hodgson, Ann M Mauer, Ajeet Gajra, Gregory A Masters, Michelle Bedor, Everett E Vokes, Mark J

489 Cytogenetic, Molecular and Clinical Features Associated with Rare CFBF-MYH11 Fusion Transcripts in Patients (Pts) with Acute Myeloid Leukemia (AML) and inv(16)/t(16;16)

C. G. Edwards, K. Maharry, K. Mrozek, S. Schwind, P. Paschka, D. Nicolet, J. Kohlschmidt, T. W. Prior, Y.-Z. Wu, J. E. Kolitz, W. Blum, M. J. Pettenati, P. D. Cin, A. J. Carroll, M. A. Caligiuri, R. A. Larson, G. Marcucci, C. D. Bloomfield *Blood* vol 118 (21) 2514 2011
Abstract *Leuk Corr Sci* CALGB-10503, CALGB-19808, CALGB-9621
<http://www.bloodjournal.org/content/118/21/2514>

490 Long-term cardiac outcomes of HER2+ breast cancer patients treated in the ALTTO trial

D. Eiger, N. F. Ponde, D. Agbor-Tarh, Alvaro Moreno-Aspitia, Martine Piccart, Richard Rodeheffer, Michael Ewers, Thomas Suter, E. de Azambuja *Annals of Oncology* vol 30 (Supplement_3) iii65–iii71 2019
Abstract *Breast ALTTO*
https://academic.oup.com/annonc/article/30/Supplement_3/mdz101/5488368

491 Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial

Daniel Eiger, Noam F. Pondé, Dominique Agbor-Tarh, Alvaro Moreno-Aspitia, Martine Piccart, Florentine S. Hilbers, Olena Werner, Saranya Chumsri, Amylou Dueck, Judith R. Kroep, Henry Gomez, István Láng, Richard J. Rodeheffer, Michael S. Ewer, Thomas Suter, Evandro de Azambuja *Br J Cancer* vol 122 (10) 1453-60 2020
Manuscript *Breast NCCTG-N063D* <http://www.ncbi.nlm.nih.gov/pubmed/32203207>

492 The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia

A-K Eifeld, K Mrózek, J Kohlschmidt, D Nicolet, S Orwick, C J Walker, K W Kroll, J S Blachly, A J Carroll, J E Kolitz, B L Powell, E S Wang, R M Stone, A de la Chapelle, J C Byrd, C D Bloomfield *Leukemia* vol 31 (10) 2211-18 2017
Manuscript *Leuk Corr Sci* CALGB-20202, CALGB-8461, CALGB-9665
<http://www.ncbi.nlm.nih.gov/pubmed/28321123>

493 Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged <60 years

Ann-Kathrin Eifeld, Jessica Kohlschmidt, Alice Mims, Deedra Nicolet, Christopher J. Walker, James S. Blachly, Andrew J. Carroll, Dimitrios Papaioannou, Jonathan E. Kolitz, Bayard E. Powell, Richard M. Stone, Albert de la Chapelle, John C. Byrd, Krzysztof Mrózek, Clara D. Bloomfield *Leukemia* vol 34 (12) 3215-27 2020
Manuscript *Leuk Corr Sci* CALGB-10503, CALGB-10603, CALGB-19808, CALGB-8525, CALGB-8821, CALGB-9022, CALGB-9222, CALGB-9621
<http://www.ncbi.nlm.nih.gov/pubmed/32461631>

494 Adult acute myeloid leukemia with trisomy 11 as the sole abnormality is characterized by the presence of five distinct gene mutations: MLL-PTD, DNMT3A, U2AF1, FLT3-ITD and IDH2

Ann-Kathrin Eifeld, Jessica Kohlschmidt, Krzysztof Mrózek, James S. Blachly, Deedra Nicolet, Karl Kroll, Shelley Orwick, Andrew J. Carroll, Richard M. Stone, Albert de la Chapelle, John C. Byrd, Clara D. Bloomfield *Leukemia* vol 30 (11) 2254-2258 2016
Manuscript *Leuk Corr Sci* CALGB-20202, CALGB-8461
<http://www.ncbi.nlm.nih.gov/pubmed/27435003>

495 Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or

older who respond favorably to standard chemotherapy: an analysis of Alliance studies

Ann-Kathrin Eisfeld, Jessica Kohlschmidt, Krzysztof Mrózek, James S. Blachly, Christopher J. Walker, Deedra Nicolet, Shelley Orwick, Sophia E. Maharry, Andrew J. Carroll, Richard M. Stone, Albert de la Chapelle, Eunice S. Wang, Jonathan E. Kolitz, Bayard L. Powell, John C. Byrd, Clara D. Bloomfield *Leukemia* vol 32 (6) 1338-48 2018
Manuscript *Leuk Corr Sci* CALGB-8525, CALGB-8821, CALGB-9665, CALGB-10201, CALGB-10502, CALGB-11001, CALGB-11002, CALGB-20202, CALGB-8461, CALGB-8923, CALGB-9420, CALGB-9720 <http://www.ncbi.nlm.nih.gov/pubmed/29563537>

496 NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome

Ann-Kathrin Eisfeld, Jessica Kohlschmidt, Krzysztof Mrózek, Alice Mims, Christopher J. Walker, James S. Blachly, Deedra Nicolet, Shelley Orwick, Sophia E. Maharry, Andrew J. Carroll, Bayard L. Powell, Jonathan E. Kolitz, Eunice S. Wang, Richard M. Stone, Albert de la Chapelle, John C. Byrd, Clara D. Bloomfield *Leukemia* vol 32 2536-45 2018
Manuscript *Leuk Corr Sci* CALGB-8525, CALGB-8821, CALGB-9022, CALGB-9621, CALGB-9720, CALGB-10201, CALGB-10502, CALGB-10503, CALGB-10603, CALGB-19808, CALGB-8923 <http://www.ncbi.nlm.nih.gov/pubmed/29872168>

497 Additional gene mutations refine the 2017 European Leukemianet (ELN) classification of adult patients (pts) with de novo acute myeloid leukemia (AML) aged <60 years: An analysis of Alliance studies

Ann-Kathrin Eisfeld, Jessica Kohlschmidt, Krzysztof Mrózek, Alice Mims, Christopher J. Walker, Deedra Nicolet, James S. Blachly, Andrew J. Carroll, Jonathan E. Kolitz, Bayard E. Powell, Richard M. Stone, Albert De La Chapelle, John C. Byrd, Clara D. Bloomfield *Blood* vol 132 (Suppl 1) 2740 2018
Abstract *Leuk Corr Sci* CALGB-8461, CALGB-20202
http://www.bloodjournal.org/content/132/Suppl_1/2740

498 Mutations in genes associated with familial predisposition to myeloid neoplasms: their frequency and associations with pretreatment characteristics in adult patients (pts) with presumably sporadic de novo acute myeloid leukemia (AML) (Alliance)

Ann-Kathrin Eisfeld, Jessica Kohlschmidt, Krzysztof Mrózek, Alice Mims, Christopher J. Walker, Deedra Nicolet, James S. Blachly, Luke Genutis, Andrew J. Carroll, Bayard L. Powell, Jonathan E. Kolitz, Richard M. Stone, Albert De La Chapelle, John C. Byrd, Clara D. Bloomfield *Blood* vol 132 (Suppl 1) 1478 2018
Abstract *Leuk Corr Sci* CALGB-8461, CALGB-20202
http://www.bloodjournal.org/content/132/Suppl_1/1478

499 The 2017 European LeukemiaNet Genetic Risk Classification performs poorly in elderly Acute Myeloid Leukemia (AML) patients and should be refined to enable identification of patients requiring additional or alternative treatment (Alliance)

Ann-Kathrin Eisfeld, Jessica Kohlschmidt, Krzysztof Mrózek, Deedra Nicolet, Dimitrios Papaioannou, Christopher J. Walker, James S. Blachly, Sophia E. Maharry, Andrew J. Carroll, Richard M. Stone, Albert De La Chapelle, Eunice S. Wang, Jonathan E. Kolitz, Bayard L. Powell, John C. Byrd, Clara D. Bloomfield *Blood* vol 134 (Supplement 1) 2681 2019
Abstract *Leukemia* CALGB-20202, CALGB-8461, CALGB-9665
https://ashpublications.org/blood/article/134/Supplement_1/2681/423274/The-2017-European-Leukemia

500 Mutational landscape and gene-expression patterns in adult acute myeloid leukemias with monosomy 7 as a sole abnormality

Ann-Kathrin Eisfeld, Jessica Kohlschmidt, Krzysztof Mrózek, Stefano Volinia, James S. Blachly, Deedra Nicolet, Christopher Oakes, Karl Kroll, Shelley Orwick, Andrew J. Carroll, Richard M. Stone, John C. Byrd, Albert de la Chapelle, Clara D. Bloomfield *Cancer Res* vol 77 (1) 207-18 2017

Manuscript Leuk Corr Sci CALGB-10201, CALGB-10503, CALGB-10603, CALGB-11002, CALGB-19808, CALGB-20202, CALGB-8461, CALGB-8525, CALGB-9222, CALGB-9420, CALGB-9621 <http://www.ncbi.nlm.nih.gov/pubmed/27784745>

501 Mutations in the CCND1 and CCND2 genes are frequent events in adult patients with t(8;21)(q22;q22) acute myeloid leukemia

Ann-Kathrin Eisfeld, Jessica Kohlschmidt, Sebastian Schwind, Deedra Nicolet, James S. Blachly, Shelley Orwick, Chandni Shah, Maryam Bainazar, Karl W. Kroll, Christopher J. Walker, Andrew J. Carroll, Bayard L. Powell, Richard M. Stone, Jonathan E. Kolitz, Maria R. Baer, Albert de la Chapelle, Krzysztof Mrózek, John C. Byrd, Clara D. Bloomfield *Leukemia* vol 31 (6) 1278-1285 2017
Manuscript Leuk Corr Sci CALGB-20202, CALGB-8461, CALGB-9665
<http://www.ncbi.nlm.nih.gov/pubmed/27843138>

502 Heritable polymorphism predisposes to high expression of BAALC in cytogenetically normal acute myeloid leukemia (CN-AML)

Ann-Kathrin Eisfeld, G. Marcucci, S. Liyanarachchi, K. Döhner, S. Schwind, K. Maharry, D. Nicolet, M. D. Radmacher, H. Döhner, S. M. Tanner, C. D. Bloomfield, A. De La Chapelle *AACR Annual Meeting abstr* 1307 2012
Abstract Leuk Corr Sci
http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/72/8_MeetingAbstracts/1307

503 MiR-3151, a novel microRNA embedded in BAALC, is only weakly co-expressed with its host gene and independently impacts on the clinical outcome of older patients (pts) with de novo cytogenetically normal acute myeloid leukemia (CN-AML)

Ann-Kathrin Eisfeld, G. Marcucci, K. Maharry, S. Schwind, M. D. Radmacher, D. Nicolet, H. Becker, S. P. Whitman, K. H. Metzeler, K. Mrozek, Y.-Z. Wu, M. R. Baer, B. L. Powell, T. H. Carter, J. O. Moore, J. E. Kolitz, M. Wetzler, M. A. Caligiuri, R. A. Larson, S. M. Tanner, A. De La Chapelle, C. D. Bloomfield *Blood* vol 118 (21) 1462 2011
Abstract Leuk Corr Sci CALGB-8525, CALGB-10201, CALGB-8923, CALGB-9420, CALGB-9720 <http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;118/21/1462>

504 Heritable polymorphism predisposes to high BAALC expression in acute myeloid leukemia

Ann-Kathrin Eisfeld, Guido Marcucci, Sandya Liyanarachchi, Konstanze Döhner, Sebastian Schwind, Kati Maharry, Benjamin Leffel, Hartmut Döhner, Michael D. Radmacher, Clara D. Bloomfield, Stephan M. Tanner, Albert de la Chapelle *Proc Natl Acad Sci USA* vol 109 (17) 6668-6673 2012
Manuscript Leuk Corr Sci <http://www.ncbi.nlm.nih.gov/pubmed/22493267>

505 miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia

Ann-Kathrin Eisfeld, Guido Marcucci, Kati Maharry, Sebastian Schwind, Michael D. Radmacher, Deedra Nicolet, Heiko Becker, Krzysztof Mrózek, Susan P. Whitman, Klaus H. Metzeler, Jason H. Mendler, Yue-Zhong Wu, Sandya Liyanarachchi, Ravi Patel, Maria R. Baer, Bayard L. Powell, Thomas H. Carter, Joseph O. Moore, Jonathan E. Kolitz, Meir Wetzler, Michael A. Caligiuri, Richard A. Larson, Stephan M. Tanner, Albert de la Chapelle, Clara D. Bloomfield *Blood* vol 120 (2) 249-258 2012
Manuscript Leuk Corr Sci <http://www.ncbi.nlm.nih.gov/pubmed/22529287>

506 Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma

Benjamin M Ellingson, Lauren E Abrey, Sarah J Nelson, Timothy J Kaufmann, Josep Garcia, Olivier Chinot, Frank Saran, Ryo Nishikawa, Roger Henriksson, Warren P Mason, Wolfgang Wick, Nicholas Butowski, Keith L Ligon, Elizabeth R Gerstner, Howard Colman, John de Groot, Susan Chang, Ingo Mellinghoff, Robert J Young, Brian M Alexander, Rivka Colen, Jennie W Taylor, Isabel

Arrillaga-Romany, Arnav Mehta, Raymond Y Huang, Whitney B Pope, David Reardon, Tracy Batchelor, Michael Prados, Evanthia Galanis, Patrick Y Wen, Timothy F Cloughesy Neuro-oncology vol 20 (9) 1240-50 2018
Manuscript Neuro-Onc <http://www.ncbi.nlm.nih.gov/pubmed/29660006>

- 507 ACOSOG Z1031: A randomized phase II trial comparing exemestane, letrozole, and anastrozole in postmenopausal women with clinical stage II/III estrogen receptor-positive breast cancer**
M. J. Ellis, A. U. Buzdar, G. W. Unzeitig, L. J. Esserman, A. M. Leitch, K. Deshryver, D. C. Allred, V. Suman, K. K. Hunt, J. Olson J Clin Oncol vol 28 (18s) abstr LBA513 2010
Abstract Breast http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID
- 508 Whole-genome analysis informs breast cancer response to aromatase inhibition**
M. J. Ellis, L. Ding, D. Shen, J. Q. Luo, V. J. Suman, J. W. Wallis, B. A. Van Tine, J. Hoog, R. J. Goiffon, T. C. Goldstein, S. Ng, L. Lin, R. Crowder, J. Snider, K. Ballman, J. Weber, K. Chen, D. C. Koboldt, C. Kandoth, W. S. Schierding, J. F. McMichael, C. A. Miller, C. Lu, C. C. Harris, M. D. McLellan, M. C. Wendl, K. Deschryver, D. C. Allred, L. Esserman, G. Unzeitig, J. Margenthaler, G. V. Babiera, P. K. Marcom, J. M. Guenther, M. Leitch, K. Hunt, J. Olson, Y. Tao, C. A. Maher, L. L. Fulton, R. S. Fulton, M. Harrison, B. Oberkfell, F. Y. Du, R. Demeter, T. L. Vickery, A. Elhammali, H. Piwnica-Worms, S. McDonald, M. Watson, D. J. Dooling, D. Ota, L. W. Chang, R. Bose, T. J. Ley, D. Piwnica-Worms, J. M. Stuart, R. K. Wilson, E. R. Mardis Nature vol 486 (7403) 353-360 2012
Manuscript PPP <http://www.ncbi.nlm.nih.gov/pubmed/22722193>
- 509 Z1031B neoadjuvant aromatase inhibitor trial: A Phase 2 study of triage to chemotherapy based on 2 to 4 week Ki67 level >10%**
M. J. Ellis, V Suman, L. McCall, R. Luo, J. Hoog, A. Brink, M. Watson, C. Ma, G. Unzeitig, T. Pluard, P. Whitworth, G. Babiera, M. Guenther, Z. Dayao, M. Leitch, D. Ota, J. Olson, K. Hunt, C. Allred Cancer Res vol 72 (24 suppl) PD07-01 2012
Abstract Breast http://cancerres.aacrjournals.org/content/72/24_Supplement/PD07-01.short
- 510 Tumor Ki67 Proliferation Index within 4 Weeks of Initiating Neoadjuvant Endocrine Therapy for Early Identification of Non-Responders**
M. Ellis, J. Luo, Y. Tao, J. Hoog, J. Snider, K. DeSchryver, C. Allred, S. Davies, K. Hunt, J. Olson, V. Suman, C. Perou, T. Nielsen, M. Cheang, I. Smith, R. A'Hern, M. Dowsett Cancer Research vol 69 (24) 2009
Abstract Correl Sci NOS http://cancerres.aacrjournals.org/content/69/24_Supplement/78
- 511 The effect of intrinsic subtype on inhibition of tumor growth by anastrozole vs. fulvestrant vs. the combination: Results from the Alliance neoadjuvant endocrine therapy (NET) ALTERNATE trial.**
Matthew J. Ellis, Meenakshi Anurag, Jeremy Hoog, Aranzazu Fernandez-Martinez, Cheng Fan, Richard Gibbs, Souzan Sanati, Kiran Vij, Travis Dockter, Olwen Hahn, Joseph Guenther, Abigail Caudle, Erika Crouch, Amy Tiersten, Monica Mita, Wajeeha Razaq, Tina J. Hieken, Yang Wang, A. Marilyn Leitch, Gary W. Unzeitig, Eric Winer, Anna Weiss, Kelly Hunt, Ann H. Partridge, Charles M. Perou, Cynthia X. Ma, Vera Suman, Lisa A Carey 2022
Abstract Breast
- 512 Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)**
Matthew J. Ellis, Vera J. Suman, Jeremy Hoog, Rodrigo Goncalves, Souzan Sanati, Chad J. Creighton, Katherine DeSchryver, Erika Crouch, Amy Brink, Mark Watson, Jingqin Luo, Yu Tao, Michael Barnes, Mitchell Dowsett, G. Thomas Budd, Eric Winer, Paula Silverman, Laura Esserman, Lisa Carey, Cynthia X. Ma, Gary Unzeitig, Timothy Pluard, Pat Whitworth, Gilda Babiera, J. Michael

Guenther, Zoneddy Dayao, David Ota, Marilyn Leitch, John A. Olson, D. Craig Allred, Kelly Hunt J Clin Oncol vol 35 (10) 1061-1069 2017
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/28045625>

513 Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031

Matthew J. Ellis, Vera J. Suman, Jeremy Hoog, Li Lin, Jacqueline Snider, Aleix Prat, Joel S. Parker, Jingqin Luo, Katherine DeSchryver, D. Craig Allred, Laura J. Esserman, Gary W. Unzeitig, Julie Margenthaler, Gildy V. Babiera, P. Kelly Marcom, Joseph M. Guenther, Mark A. Watson, Marilyn Leitch, Kelly Hunt, John A. Olson J Clin Oncol vol 29 (17) 2342-2349 2011
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/21555689>

514 Validation of a predictive model for potential response to neoadjuvant endocrine therapy (NET) in postmenopausal women with clinical stage II or III Estrogen Receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC): an Alliance ALTERNATE trial analysis. (Alliance)

Matthew J. Ellis, Vera Suman, A. Marilyn Leitch, Souzan Sanati, Kiran Vij, Gary W. Unzeitig, Jeremy Hoog, Mark Watson, Olwen Hahn, Joseph Guenther, Abigail Caudle, Erika Crouch, Horacio Maluf, Mitch Dowsett, Amy Tiersten, Monica Mita, Wajeeha Razaq, Tina J. Hieken, Yang Wang, Travis Dockter, Jo Anne Zujewski, Anna Weiss, Clifford Hudis, Eric P. Winer, Kelly Hunt, Ann H. Partridge, Cynthia X. Ma, Lisa A. Carey Cancer Res vol 81 (4 Supplement) PD2-10 2020
Abstract Breast https://cancerres.aacrjournals.org/content/81/4_Supplement/PD2-10.short

515 Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer

Matthew J Ellis, Li Lin, Robert Crowder, Yu Tao, Jeremy Hoog, Jacqueline Snider, Sherri Davies, Katherine DeSchryver, Dean B Evans, Jutta Steinseifer, Raj Bandaru, WeiHua Liu, Humphrey Gardner, Vladimir Semiglazov, Mark Watson, Kelly Hunt, John Olson, José Baselga Breast Cancer Res Treat vol 119 (2) 379-390 2010
Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/19844788>

516 Effectiveness of a Multimedia Educational Intervention to Improve Understanding of the Risks and Benefits of Palliative Chemotherapy in Patients With Advanced Cancer

Andrea C. Enzinger, Hajime Uno, Nadine McCleary, Elizabeth Frank, Hanna Sanoff, Katherine Van Loon, Khalid Matin, Andrea Bullock, Christine Cronin, Heather Cibotti, Janet Bagley, Deborah Schrag JAMA Oncol vol 6 (8) 1-6 2020
Manuscript Health Outcomes <http://www.ncbi.nlm.nih.gov/pubmed/32672806>

517 The effect of disclosing life expectancy information on patients' prognostic understanding: secondary outcomes from a multicenter randomized trial of a palliative chemotherapy educational intervention.

Andrea Enzinger, Hajime Uno, Nadine McCleary, Elizabeth Frank, Hanna Sanoff, Katherine Van Loon, Khalid Matin, Andrea Bullock, Christine Cronin, Janet Bagley, Deborah Schrag J Pain Symptom Manage vol 61 (1) 1-11 2021
Manuscript Health Outcomes <http://www.ncbi.nlm.nih.gov/pubmed/32777456>

518 CALGB 80403/ECOG 1206: A randomized phase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer

P. C. Enzinger, B. Burtness, D. R. Hollis, D. Niedzwiecki, D. H. Ilson, A. B. Benson 3rd, R. J. Mayer, R. M. Goldberg J Clin Oncol vol 28 (15s) abstr 4006 2010
Abstract GI <http://meetinglibrary.asco.org/content/44487-74>

- 519 CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers**
Peter C. Enzinger, Barbara Ann Burtness, Donna Niedzwiecki, Xing Ye, Kathe Douglas, David H. Ilson, Victoria Meucci Villaflor, Steven J. Cohen, Robert J. Mayer, Alan Venook, Al Bowen Benson III, Richard M. Goldberg J Clin Oncol vol 34 (23) 2736-2742 2016
Manuscript GI ECOG-1206 <http://www.ncbi.nlm.nih.gov/pubmed/27382098>
- 520 Effect of additional cytogenetic abnormalities on survival in arsenic trioxide-treated acute promyelocytic leukemia**
Zachary D. Epstein-Peterson, Andriy Derkach, Susan Geyer, Krzysztof Mrózek, Jessica Kohlschmidt, Jae H. Park, Sridevi Rajeeve, Eytan M. Stein, Yanming Zhang, Harry Iland, Lynda J. Campbell, Richard A. Larson, Xavier Poiré, Bayard L. Powell, Wendy Stock, Richard M. Stone, Martin S. Tallman Blood Adv vol 6 (11) 3433-9 2022
Manuscript Leukemia CALGB-9710 <http://www.ncbi.nlm.nih.gov/pubmed/35349669>
- 521 Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657**
L. J. Esserman, D. A. Berry, A. Demichele, L. Carey, S. E. Davis, M. Buxton, C. Hudis, J. W. Gray, C. Perou, C. Yau, C. Livasy, H. Krontiras, L. Montgomery, D. Tripathy, C. Lehman, M. C. Liu, O. I. Olopade, H. S. Rugo, J. T. Carpenter, L. Dressler, D. Chhieng, B. Singh, C. Mies, J. Rabban, Y. Y. Chen, D. Giri, L. van't Veer, N. Hylton J Clin Oncol vol 30 (26) 3242-3249 2012
Manuscript Correl Sci NOS CALGB-150007, CALGB-150012, ACRIN-6657
<http://www.ncbi.nlm.nih.gov/pubmed/22649152>
- 522 Breast cancer molecular profiles and tumor response of neoadjuvant doxorubicin and paclitaxel: The I-SPY Trial (CALGB 150007/150012, ACRIN 6657)**
L. J. Esserman, C. M. Perou, M. Cheang, A. Demichele, L. A. Carey, L. J. Van't Veer, J. W. Gray, E. Petricoin, K. M. Conway, D. A. Berry J Clin Oncol vol 27 (18s) abstr LBA515 2009
Abstract Correl Sci NOS ACRIN-6657, CALGB-150007
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID
- 523 Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)**
Laura J. Esserman, Donald A. Berry, Maggie C. U. Cheang, Christina Yau, Charles M. Perou, Lisa Carey, Angela DeMichele, Joe W. Gray, Kathleen Conway-Dorsey, Marc E. Lenburg, Meredith B. Buxton, Sarah E. Davis, Laura J. van't Veer, Clifford Hudis, Koei Chin, Denise Wolf, Helen Krontiras, Leslie Montgomery, Debu Tripathy, Constance Lehman, Minetta C. Liu, Olufunmilayo I. Olopade, Hope S. Rugo, John T. Carpenter, Chad Livasy, Lynn Dressler, David Chhieng, Baljit Singh, Carolyn Mies, Joseph Rabban, Yunni-Yi Chen, Dilip Giri, Alfred Au, Nola Hylton Breast Cancer Res Treat vol 132 (3) 1049-1062 2012
Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/22198468>
- 524 Centralized adequacy assessment of DCIS samples for the COMET study (AFT-25)**
Rachel Factor, Stuart Schnitt, Robert West, Terry Hyslop, Thomas Lynch, Deborah Collyar, Desiree Basila, Lars Grimm, Lorraine King, Jeffrey Marks, Sunil Badve, Mark Watson, Marc Ryser, Anna Rapperport, Linda McCall, Huong Le-Petross, Ann Partridge, Shelley Hwang, Alastair Thompson Cancer Res vol 83 (5_Supplement) P6-04-13 2022
Abstract Breast https://aacrjournals.org/cancerres/article/83/5_Supplement/P6-04-13/718132
- 525 Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance)**
Temidayo Fadelu, Sui Zhang, Donna Niedzwiecki, Xing Ye, Leonard B. Saltz, Robert J. Mayer, Rex B. Mowat, Renaud Whittom, Alexander Hantel, Al B. Benson, Daniel M. Atienza, Michael Messino,

Hedy L. Kindler, Alan Venook, Shuji Ogino, Kimmie Ng, Kana Wu, Walter Willett, Edward Giovannucci, Jeffrey Meyerhardt, Ying Bao, Charles S. Fuchs *J Clin Oncol* vol 36 (11) 1112-20 2018
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/29489429>

526 Nut Consumption and Survival in Stage III Colon Cancer Patients: Results from CALGB 89803 (Alliance)

Temidayo Fadelu, Sui Zhang, Donna Niedzwiecki, Xing Ye, Leonard B. Saltz, Robert J. Mayer, Rex B. Mowat, Renaud Whittom, Alexander Hantel, Al Benson III, Daniel Atienza, Michael Messino, Heather B. Hedy Kindler, Alan Venook, Shuji Ogino, Kimmie Ng, Edward L. Giovannucci, Jeffrey A. Meyerhardt, Ying Bao, Charles S. Fuchs *J Clin Oncol* vol 35 (15 suppl) abstr 3517 2017
Abstract GI http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.3517

527 A Prospective Multicenter Phase II Trial of Pentostatin in Adult Patients with Steroid-Refractory Chronic Graft-Versus-Host Disease (cGvHD): A Cancer and Leukemia Group B/Eastern Cooperative Oncology Group Study

S. Farag, K. Owzar, V. Hars, H. M. Lazarus, E. A. Stadtmauer, S. M. Devine, K. V. Besien, C. Linker *Blood* vol 114 (22) 2238 2009
Abstract Transplant <http://www.bloodjournal.org/content/114/22/2238?sso-checked=true>

528 Comparison of Reduced-Intensity Hematopoietic Cell Transplantation with Chemotherapy in Patients Aged 60–70 Years with Acute Myeloid Leukemia in First Remission

Sherif S. Farag, Kati Maharry, Mei-Jie Zhang, Waleska S. Pérez, Stephen L. George, Krzysztof Mrózek, John DiPersio, Donald W. Bunjes, Guido Marcucci, Maria R. Baer, Mitchell Cairo, Edward Copelan, Corey S. Cutler, Luis Isola, Hillard M. Lazarus, Mark R. Litzow, David I. Marks, Olle Ringdén, David A. Rizzieri, Robert Soiffer, Richard A. Larson, Martin S. Tallman, Clara D. Bloomfield, Daniel J. Weisdorf *Biol Blood Marrow Transplant* vol 17 (12) 2011
Manuscript Leukemia CALGB-9720, CALGB-10201
<http://www.ncbi.nlm.nih.gov/pubmed/21699879>

529 Lymphatic Drainage Patterns in Oral Squamous Cell Carcinoma: Findings of the ACOSOG Z0360 (Alliance) Study

Roger W. Farmer, Linda McCall, Francisco J. Civantos, Jeffrey N. Myers, Wendell G. Yarbrough, Barbara Murphy, Miriam O'Leary, Robert Zitsch, Barry A. Siegel *Otolaryngol Head Neck Surg* vol 152 (4) 673-677 2015
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/25749001>

530 Associations among survivorship care plans, experiences of survivorship care, and functioning in older breast cancer survivors: CALGB/Alliance 369901

Leigh Anne Faul, Gheorghe Luta, Vanessa Sheppard, Claudine Isaacs, Harvey J. Cohen, Hyman B. Muss, Rachel Yung, Jonathan D. Clapp, Eric Winer, Clifford Hudis, Michelle Tallarico, Julhy Wang, William T. Barry, Jeanne S. Mandelblatt *J Cancer Surviv* vol 8 (4) 627-637 2014
Manuscript Older Adult <http://www.ncbi.nlm.nih.gov/pubmed/24917307>

531 ECOG score analysis as a proxy for health-related quality of life assessment in patients with poor or intermediate risk metastatic renal cell carcinoma from the CABOSUN trial (Alliance A031203)

D Feldman, M Feuilly, J Meng, J Lister, F Marteau, MJ Morris, D George, T Choueiri *J Clin Oncol* vol 36 (Suppl) abstr e18690 2018
Abstract GU <https://meetinglibrary.asco.org/record/159636/abstract>

532 Do Older Patients with Metastatic Non-Small Cell Lung Cancer Also Benefit from First-Line Platinum-Based Doublet Chemotherapy?

Josephine L. Feliciano, Jennifer G. Le-Rademacher, Ajeet Gajra, Martin J. Edelman, Tyler Zemla,

Ryan McMurray, Hongbin Chen, Arti Hurria, Hyman Muss, Harvey J. Cohen, Rogerio Lilenbaum, Aminah Jatoi J Geriatr Oncol vol 9 (5) 501-6 2018
Manuscript Older Adult CALGB-30203, CALGB-30801, CALGB-9730
<http://www.ncbi.nlm.nih.gov/pubmed/29848457>

533 Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer

Aranzazu Fernandez-Martinez, Ian E. Krop, David W. Hillman, Mei-Yin Polley, Joel S. Parker, Lucas Huebner, Katherine A. Hoadley, Jonathan Shepherd, Sara Tolaney, N. Lynn Henry, Chau Dang, Lyndsay Harris, Donald Berry, Olwen Hahn, Clifford Hudis, Eric Winer, Ann Partridge, Charles M. Perou, Lisa A. Carey J Clin Oncol vol 38 (35) 4184-93 2020
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/33095682>

534 Prognostic value of immune gene-expression signatures (iGES) vs. tumor-infiltrating lymphocytes (TILs) in early-stage HER2+ breast cancer: a combined analysis of CALGB 40601 (Alliance) and PAMELA trials.

Aranzazu Fernandez-Martinez, Tomás Pascual, Baljit Singh, Paolo Nuciforo, Katherine A. Hoadley, Naim U. Rashid, Patricia A. Spears, Ian Krop, David Hillman, Ann Partridge, Aleix Prat, Lisa Carey, Charles Perou Annals of Oncology vol 32 (suppl_5) 120MO, p 409 S407-S446 2021
Abstract Correl Sci NOS <https://www.sciencedirect.com/science/article/pii/S0923753421026302>

535 Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer

Aranzazu Fernandez-Martinez, Tomás Pascual, Baljit Singh, Paolo Nuciforo, Naim U. Rashid, Karla V. Ballman, Jordan D. Campbell, Katherine A. Hoadley, Patricia A. Spears, Laia Pare, Fara Brasó-Maristany, Nuria Chic, Ian Krop, Ann Partridge, Javier Cortés, Antonio Llombart-Cussac, Aleix Prat, Charles M. Perou, Lisa A. Carey JAMA Oncol vol 9 (4) 490-9 2023
Manuscript Correl Sci NOS CALGB-40601, PAMELA
<http://www.ncbi.nlm.nih.gov/pubmed/36602784>

536 Prognostic and predictive implications of the intrinsic subtypes and gene expression signatures in early-stage HER2+ breast cancer: a pooled analysis of CALGB 40601 (Alliance), NeoALTTO and NSABP B-41 trials

Aranzazu Fernandez-Martinez, Mattia Rediti, Gong Tang, Tomás Pascual, Katherine A. Hoadley, David Venet, Naim U. Rashid, Patricia A. Spears, Md N. Islam, David Goerlitz, Rong Hu, Peter Lucas, Sandra M. Swain, Christos Sotiriou, Charles M. Perou, Lisa A. Carey J Clin Oncol vol 40 (16_suppl) 509-509 2022
Abstract Breast CALGB-40601, NeoALTTO, NSABP B-41
https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.509

537 Genomic predictive biomarkers to anti-HER2 targeted therapies: a combined analysis of CALGB 40601 (Alliance) and PAMELA clinical trials

Aranzazu Fernandez-Martinez, Maki Tanioka, Cheng Fan, Joel S. Parker, Katherine A. Hoadley, Ian Krop, Javier Cortes, Antonio Llombart-Cussac, Paolo Nuciforo, Patricia Galván, Tomás Pascual, Ann Partridge, Aleix Prat, Charles Perou, Lisa Carey J Clin Oncol vol 37 (15_suppl) 571-571 2019
Abstract Breast https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.571

538 Predictive and prognostic value of B-cell gene-expression signatures and B-cell receptor (BCR) repertoires in HER2-positive breast cancer: a correlative analysis of the CALGB 40601 (Alliance) clinical trial.

Aranzazu Fernandez-Martinez, Maki Tanioka, Cheng Fan, Joel S. Parker, Katherine A. Hoadley, Ian Krop, Ann Partridge, Lisa Carey, Charles Perou Ann Oncol vol 30 (5) v55 abst 174O 2019
Abstract Breast <https://www.sciencedirect.com/science/article/pii/S0923753419584009>

539 Thirty and Ninety Day Outcomes After Sublobar Resection of High-risk Patients with Non-small cell lung cancer (NSCLC); Results from a multicenter phase III study

H. C. Fernando, R. J. Landreneau, S. Mandraker, S. Hillman, F. Nichols, T. A. Dipetrillo, D. E. Heron, B. F. Meyers, D. R. Jones, S. Starnes, J. B. Putnam Jr American Association of Thoracic Surgery 91st Annual Meeting abstr 2011
Abstract Respiratory <http://www.aats.org/annualmeeting/Abstracts/2011/55.cgi>

540 The Impact of Adjuvant Brachytherapy with Sublobar Resection on Pulmonary Function and Dyspnea: Preliminary Results from ACOSOG Z4032 Trial

H. C. Fernando, R. Landreneau, S. Mandraker, S. Hillman, F. Nichols, B. Meyers, T. A. Dipetrillo, D. E. Heron, J. B. Putnam Jr American Association of Thoracic Surgery 90th Annual Meeting abstr 2010
Abstract Respiratory <http://aats.org/annualmeeting/Abstracts/2010/15.cgi>

541 Impact of brachytherapy on local recurrence after sublobar resection: Results from ACOSOG Z4032 (Alliance), a phase III randomized trial for high-risk operable non-small cell lung cancer (NSCLC)

H. Fernando, R. Landreneau, S. Mandrekar, F. Nichols, S. Hillman, D. Heron, B. Meyers, T. Dipetrillo, D. Jones, S. Starnes, A. Tan, B. Daly, J. Putnam J Clin Oncol vol 31 (15 suppl) abstr 7502 2013
Abstract Respiratory
http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/7502?sid=40c2cbc2-3313-4c9e-8f07-89c7f

542 Impact of Brachytherapy on Local Recurrence Rates After Sublobar Resection: Results From ACOSOG Z4032 (Alliance), a Phase III Randomized Trial for High-Risk Operable Non-Small-Cell Lung Cancer

Hiran C. Fernando, Rodney J. Landreneau, Sumithra J. Mandrekar, Francis C. Nichols, Shauna L. Hillman, Dwight E. Heron, Bryan F. Meyers, Thomas A. DiPetrillo, David R. Jones, Sandra L. Starnes, Angelina D. Tan, Benedict D.T. Daly, Joe B. Putnam Jr J Clin Oncol vol 32 (23) 2456-2462 2014
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/24982457>

543 American College of Surgeons Oncology Group Z4099/Radiation Therapy Oncology Group 1021: A randomized study of sublobar resection compared with stereotactic body radiotherapy for high-risk stage I non-small cell lung cancer

Hiran C. Fernando, Robert Timmerman J Thorac Cardiovasc Surg vol 144 (3) S35-S38 2012
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/22795435>

544 The Impact of Adjuvant Brachytherapy with Sublobar Resection on Pulmonary Function and Dyspnea in High-risk Operable Patients; Preliminary results from the ACOSOG Z4032 Trial

Hiran C Fernando, Rodney J Landreneau, Sumithra J Mandrekar, Shauna L Hillman, Francis C Nichols, Bryan Meyers, Thomas A DiPetrillo, Dwight Heron, David R Jones, Benedict D T Daly, Sandra L Starnes, Jeffrey E Hatter, Joe B Putnam J Thorac Cardiovasc Surg vol 142 (3) 554-562 2011
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/21724195>

545 Analysis of longitudinal quality of life data in high-risk operable patients with lung cancer: Results from ACOSOG Z4032 (Alliance) a multicenter randomized trial

Hiran C Fernando, Rodney J Landreneau, Sumithra J Mandrekar, Francis C Nichols, Thomas A DiPetrillo, Bryan F Meyers, Dwight E Heron, Shauna Hillman, David R Jones, Sandra L Starnes, Angelina D Tan, Benedict D T Daly, Joe B Putnam J Thorac Cardiovasc Surg vol 149 (3) 718-726 2015
Manuscript Health Outcomes <http://www.ncbi.nlm.nih.gov/pubmed/25500100>

- 546 Factors contributing to cancer screening in African Americans**
C. E. Ferrans, C. Ryan, L. E. Archer, S. Freels, L. Lan, E. Paskett, R. Molokie, D. D. Hurd, A. B. Kornblith J Clin Oncol vol 26 (May 20 suppl) abstr 6514 2008
Abstract Health Outcomes
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID
- 547 Dose intensified daunorubicin induction and consolidation plus combined modality maintenance therapy for children with newly diagnosed acute promyelocytic leukemia (APL): North American Intergroup study C9710**
J. Feusner, J. Gregory, B. K. Moser, V. Hars, B. L. Powell, R. A. Larson J Clin Oncol vol 25 (15s) abstr 9510 2010
Abstract Leukemia
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID
- 548 Validation of the lung cancer staging system revisions using a large prospective clinical trial database (ACOSOG Z0030)**
J. J. Fibla, S. D. Cassivi, P. A. Decker, M. S. Allen, G. E. Darling, R. J. Landreneau, R. W. Mckenna, D. R. Jones, R. I. Incelet, J. B. Putnam Jr J Clin Oncol vol 28 (15s) abstr 7021 2010
Abstract Respiratory <http://meetinglibrary.asco.org/content/54130-74>
- 549 Re-evaluation of the prognostic value of visceral pleura invasion in Stage IB non-small cell lung cancer using the prospective multicenter ACOSOG Z0030 trial data set**
Juan J. Fibla, Stephen D. Cassivi, Alessandro Brunelli, Paul A. Decker, Mark S. Allen, Gail E. Darling, Rodney J. Landreneau, Joe B. Putnam Lung Cancer vol 78 (3) 259-262 2012
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/23040416>
- 550 Validation of the lung cancer staging system revisions using a large prospective clinical trial database (ACOSOG Z0030)**
Juan J. Fibla, Stephen D. Cassivi, Paul A. Decker, Mark S. Allen, Gail E. Darling, Rodney J. Landreneau, Robert J. McKenna, Joe B. Putnam Eur J Cardiothorac Surg vol 43 (5) 911-914 2013
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/23014970>
- 551 Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer**
Otto Metzger Filho, Daniel G. Stover, Sarah Asad, Peter J. Ansell, Mark Watson, Sibylle Loibl, Charles E. Geyer Jr., Junu Bae, Katharine Collier, Mathew Cherian, Joyce O'Shaughnessy, Michael Untch, Hope S. Rugo, Jens B. Huober, Mehra Golshan, William M. Sikov, Gunter von Minckwitz, Priya Rastogi, David Maag, Norman Wolmark, Carsten Denkert, W. Fraser Symmans JAMA Oncol vol 7 (4) 1-6 2021
Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/33599688>
- 552 Randomized comparison of adjuvant tamoxifen (T) plus ovarian function suppression (OFS) versus tamoxifen in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Update of the SOFT trial**
Gini F Fleming, Prudence A Francis, István Láng, Eva M Ciruelos, Meritxell Bellet, Hervé R Bonnefoi, Miguel A Climent, Lorenzo Pavesi, Harold J Burstein, Silvana Martino, Nancy E Davidson, Charles E Geyer, Jr, Barbara A Walley, Robert E Coleman, Pierre Kerbrat, Stefan Buchholz, James N Ingle, Manuela Rabaglio-Poretti, Marco Colleoni, Meredith M Regan Ann Oncol vol 28 (9) 2225-2232 2017
Abstract Breast <https://academic.oup.com/annonc/article/28/9/2225/4080725>
- 553 Five year results from the COST trial testing laparoscopic versus open colectomy for colon cancer**

J. Fleshman, D. Sargent, E. Green, M. Anvari, S. Stryker, R. Beart, M. Hellinger, R. Flanagan, W. Peters, H. Nelson EJC Supplement vol 5 (4) 12 abstr 31 2007
Abstract GI
<http://download.journals.elsevierhealth.com/pdfs/journals/1359-6349/PIIS1359634907701453.pdf>

554 Disease Free Survival and Local Recurrence for Laparoscopic Resection Compared to Open Resection of Stage II-III Rectal Cancer: Follow up Results of the ACOSOG Z6051 Randomized Controlled Trial

J Fleshman, ME Branda, DJ Sargent, AM Boller, VV George, MA Abbas, WR Peters Jr, DC Maun, GJ Chang, A Herline, A Fichera, MG Mutch, SD Wexner, MH Whiteford, J Marks, E Birnbaum, DA Margolin, DW Larson, PW Marcello, MC Posner, TE Read, JRT Monson, SM Wren, PWT Pisters, H Nelson Ann Surg vol 269 (4) 589-95 2019
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/30080730>

555 Effect of Laparoscopic-Assisted Resection vs Open Resection of Stage II or III Rectal Cancer on Pathologic Outcomes

James Fleshman, Megan Branda, Daniel J. Sargent, Anne Marie Boller, Virgilio George, Maher Abbas, Walter R. Peters, Dipen Maun, George Chang, Alan Herline, Alessandro Fichera, Matthew Mutch, Steven Wexner, Mark Whiteford, John Marks, Elisa Birnbaum, David Margolin, David Larson, Peter Marcello, Mitchell Posner, Thomas Read, John Monson, Sherry M. Wren, Peter W. T. Pisters, Heidi Nelson JAMA vol 314 (13) 1346-1355 2015
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/26441179>

556 Laparoscopic colectomy for cancer is not inferior to open surgery based on 5-year data from the COST Study Group trial.

James Fleshman, Daniel J Sargent, Erin Green, Mehran Anvari, Steven J Stryker, Robert W Beart, Michael Hellinger, Richard Flanagan, Walter Peters, Heidi Nelson Ann Surg vol 246 (4) 655-62; discussion 662-4 2007
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/17893502>

557 Identification of PTPN11 mutations as early events in the development of acute myeloid leukemia (Alliance)

Sydney Fobare, Jessica Kohlschmidt, Shelley Orwick, Ben Wronowski, Tom Sesterhenn, Megan Johnstone, Andrew J. Carroll, Richard M. Stone, Eunice S. Wang, Jonathan E. Kolitz, Bayard L. Powell, Ann-Kathrin Eisfeld, Erin Hertlein, John C. Byrd Blood vol 140 (suppl 1) 743-4 2022
Abstract Leuk Corr Sci CALGB-20202, CALGB-8461, CALGB-9665
<https://ashpublications.org/blood/article/140/Supplement%201/743/488676/Identification-of-PTPN11-m>

558 Molecular, clinical, and prognostic implications of PTPN11 mutations in acute myeloid leukemia

Sydney Fobare, Jessica Kohlschmidt, Hatice Gulcin Ozer, Krzysztof Mrózek, Deedra Nicolet, Alice S. Mims, Ramiro Garzon, James S. Blachly, Shelley Orwick, Andrew J. Carroll, Richard M. Stone, Eunice S. Wang, Jonathan E. Kolitz, Bayard L. Powell, Christopher C. Oakes, Ann-Kathrin Eisfeld, Erin Hertlein, John C. Byrd Blood Adv vol 6 (5) 1371-80 2022
Manuscript Leuk Corr Sci CALGB-20202, CALGB-8461, CALGB-9665
<http://www.ncbi.nlm.nih.gov/pubmed/34847232>

559 Clinical and Prognostic Implications of PTPN11 Mutations in Acute Myeloid Leukemia

Sydney Fobare, Jessica Kohlschmidt, Hatice Gulcin Ozer, Krzysztof Mrózek, Deedra Nicolet, Alice Mims, Ramiro Garzon, James S. Blachly, Shelley Orwick, Andrew J. Carroll, Richard M. Stone, Eunice S. Wang, Jonathan E. Kolitz, Bayard L. Powell, Christopher C. Oakes, Ann-Kathrin Eisfeld, Erin Hertlein, John C. Byrd Blood vol 36 (Supplement 1) 20-21 2020
Abstract Leuk Corr Sci CALGB-20202, CALGB-8461, CALGB-9583
<https://ashpublications.org/blood/article/136/Supplement%201/20/470922/Clinical-and-Prognostic-Impli>

- 560 Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin**
Elisa Fontana, Jeff Meyers, Alberto Sobrero, Timothy Iveson, Anthony F. Shields, Julien Taieb, Takayuki Yoshino, Ioannis Souglakos, Elizabeth C. Smyth, Florian Lordick, Markus Moehler, Anne Giraut, Andrea Harkin, Roberto Labianca, Jeffrey Meyerhardt, Thierry André, Ioannis Boukovinas, Sara Lonardi, Mark Saunders, Dewi Vernerey, Eiji Oki, Vassilis Georgoulas, Irit Ben-Aharon, Qian Shi J Clin Oncol vol 39 (36) 4009-19 2021
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/34752136>
- 561 Early-Onset Stage II/III Colorectal Adenocarcinoma in the IDEA database: Treatment Adherence, Toxicities and Outcomes from Adjuvant Fluoropyrimidine and Oxaliplatin**
Elisa Fontana, Jeffrey P. Meyers, Alberto F. Sobrero, Timothy Iveson, Anthony Frank Shields, Julien Taieb, Takayuki Yoshino, Ioannis Souglakos, Elizabeth Catherine Smyth, Florian Lordick, Markus H. Moehler, Andrea Harkin, Roberto Labianca, Jeffrey A. Meyerhardt, Thierry Andre, Takeharu Yamanaka, Ioannis Boukovinas, Axel Grothey, Irit Ben-Aharon, Qian Shi J Clin Oncol vol 39 (15_suppl) 3517-3517 2021
Abstract GI https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.3517
- 562 Genomic integration of adult and pediatric acute myeloid leukemia reveals age dependent risk association (Alliance)**
Maarten Fornerod, Deedra Nicolet, Krzysztof Mrózek, Jonathan E. Kolitz, William E. Blum, Joseph O. Moore, Robert J. Mayer, Richard M. Stone, Geoffrey Uy, Wendy Stock, John C. Byrd, Ann-Kathrin Einfeld, Tanja Gruber Blood vol 140 (suppl 1) 9165-6 2022
Abstract Leuk Corr Sci CALGB-20202, CALGB-8461, CALGB-9665
<https://ashpublications.org/blood/article/140/Supplement%201/9165/488765/Genomic-Integration-of-Ad>
- 563 Comparative “Nocebo Effects” in Older Patients Enrolled in Cancer Therapeutic Trials: Observations From a 446-Patient Cohort**
Jared C. Foster, Jennifer G. Le-Rademacher, Josephine L. Feliciano, Ajeet Gajra, Drew K. Seisler, Ronald DeMatteo, Jacqueline M. Lafky, Arti Hurria, Hyman B. Muss, Harvey J. Cohen, Aminah Jatoi Cancer vol 123 (21) 4193-98 2017
Manuscript Older Adult ACOSOG-Z9001, NCCTG-97-24-51
<http://www.ncbi.nlm.nih.gov/pubmed/28700816>
- 564 Comparative nocebo findings in older patients enrolled in cancer therapeutic trials: observations from a 446-patient cohort (Alliance A151602)**
Jared C. Foster, Jennifer G. Le-Rademacher, Josephine L. Feliciano, Ajeet Gajra, Drew K. Seisler, Ronald DeMatteo, Jacqueline M. Lafky, Arti Hurria, Hyman B. Muss, Harvey J. Cohen, Aminah Jatoi J Clin Oncol vol 35 (15 suppl) e21545 2017
Abstract Older Adult Alliance-A151602, ACOSOG-Z9001, NCCTG-97-24-51
http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.e21545
- 565 Age, Gender, Performance Status and Stage Outperformed Stage alone in Predicting Overall Survival (OS) in Patients with Small Cell Lung Cancer: A Pooled Analysis of 1623 patients from the North Central Cancer Treatment Group.**
N. R. Foster, S. J. Mandrekar, S. E. Schild, G. D. Nelson, J. R. Jett, A. A. Adjei J Clin Oncol vol 25 (18s) abstr 7223 2007
Abstract Respiratory
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID
- 566 Prognostic importance of performance status (PS) in small cell lung cancer (SCLC): A North Central Cancer Treatment Group (NCCTG) investigation.**

N. R. Foster, S. J. Mandrekar, S. E. Schild, G. D. Nelson, K. M. Rowland Jr, R. L. Deming, T. F. Kozelsky, J. R. Jett, R. S. Marks, A. A. Adjei J Clin Oncol vol 26 (18s) 19041 2008
Abstract Respiratory
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID

567 Comparison of progression-free survival (PFS) and tumor response as endpoints for predicting overall survival (OS) in untreated extensive-stage small cell lung cancer (ED-SCLC): Findings based on North Central Cancer Treatment Group (NCCTG) trials.

N. R. Foster, Y. Qi, J. E. Krook, J. W. Kugler, S. A. Kuross, J. R. Jett, J. R. Molina, S. E. Schild, A. A. Adjei, S. J. Mandrekar J Clin Oncol vol 27 (15s) abstr 8085 2009
Abstract Respiratory
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID

568 Tumor response and progression-free survival (PFS) as potential surrogate endpoints for overall survival (OS) in extensive-stage small cell lung cancer (ES-SCLC): Findings based on North Central Cancer Treatment Group (NCCTG) trials.

N. R. Foster, Y. Qi, Q. Shi, J. E. Krook, J. W. Kugler, J. R. Jett, J. R. Molina, S. E. Schild, A. A. Adjei, S. J. Mandrekar J Clin Oncol vol 28 (15 (May 20 Supplement)) 7637 2010
Abstract Respiratory http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/7637

569 Multitrial evaluation of progression-free survival (PFS) as a surrogate endpoint for overall survival (OS) in previously untreated extensive-stage small cell lung cancer (ES-SCLC): An Alliance-led analysis

N. R. Foster, L. A. Renfro, S. E. Schild, M. W. Redman, X. F. Wang, S. E. Dahlberg, K. Ding, P. A. Bradbury, S. S. Ramalingam, D. R. Gandara, E. E. Vokes, A. A. Adjei, S. J. Mandrekar J Clin Oncol vol 31 (15 suppl) abstr 7510 2013
Abstract Respiratory Comprehensive, CALGB-9033, CALGB-9732, CALGB-30103, NCCTG-862051, NCCTG-892051, NCCTG-932053, ECOG-1500, ECOG-7593, JCOG-9511, NCIC-BR4, NCIC-BR8, SWOG-S0124
http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/7510?sid=af1f40b1-fe3e-4dff-9005-91e48c

570 Body mass index (BMI) and DNA mismatch repair status in colon cancers from patients treated in adjuvant therapy trials.

N. R. Foster, F. Sinicrope, G. Yothers, C. Allegra, D. Sargent J Clin Oncol vol 29 (suppl) abstr 10590 2011
Abstract GI
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID

571 Prognostic factors differ by tumor stage for Small Cell Lung Cancer: A Pooled Analysis of North Central Cancer Treatment Group (NCCTG) Trials

Nathan R. Foster, Sumithra J. Mandrekar, Steven E. Schild, Garth D. Nelson, Kendrith M. Rowland, Richard L. Deming, Timothy F. Kozelsky, Randolph S. Marks, James R. Jett, Alex A. Adjei Cancer vol 115 (12) 2721-2731 2009
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/19402175>

572 Tumor Response and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Extensive-Stage Small Cell Lung Cancer (ES-SCLC): Findings Based on North Central Cancer Treatment Group (NCCTG) Trials

Nathan R. Foster, Yingwei Qi, Qian Shi, James E. Krook, John W. Kugler, James R. Jett, Julian R. Molina, Steven E. Schild, Alex A. Adjei, Sumithra J. Mandrekar Cancer vol 117 (6) 1262-1271 2011
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/20960500>

573 Multi-Trial Evaluation of Progression-Free Survival (PFS) as a Surrogate Endpoint for Overall

Survival (OS) in First-Line Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

Nathan R. Foster, Lindsay A. Renfro, Steven E. Schild, Mary W. Redman, Xiaofei F. Wang, Suzanne E. Dahlberg, Keyue Ding, Penelope A. Bradbury, Suresh S. Ramalingam, David R. Gandara, Taro Shibata, Nagahiro Saijo, Everett E. Vokes, Alex A. Adjei, Sumithra J. Mandrekar J Thorac Oncol vol 10 (7) 1099-106 2015

Manuscript Respiratory CALGB-30103, NCCTG-N0424, NCCTG-932053

<http://www.ncbi.nlm.nih.gov/pubmed/26134227>

574 Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer

P. A. Francis, O. Pagani, G. F. Fleming, B. A. Walley, M. Colleoni, I. Láng, H. L. Gómez, C. Tondini, E. Ciruelos, H. J. Burstein, H. R. Bonnefoi, M. Bellet, S. Martino, C. E. Geyer Jr, M. P. Goetz, V. Stearns, G. Pinotti, F. Puglisi, S. Spazzapan, M. A Climent, L. Pavesi, T. Ruhstaller, N. E. Davidson, R. Coleman, M. Debled, S. Buchholz, J. N. Ingle, E. P. Winer, R. Maibach, M. RabaglioPoretti, B. Ruepp, A. Di Leo, A. S. Coates, R. D. Gelber, A. Goldhirsch, M.M. Regan N Engl J Med vol 379 (2) 122-37 2018

Manuscript Breast IBCSG-24-02 (SOFT-TEXT), IBCSG-25-02 (TEXT), SWOG-S0002

<http://www.ncbi.nlm.nih.gov/pubmed/29863451>

575 Adjuvant Ovarian Suppression in Premenopausal Breast Cancer

Prudence A. Francis, Meredith M. Regan, Gini F. Fleming, István Láng, Eva Ciruelos, Meritxell Bellet, Hervé R. Bonnefoi, Miguel A. Climent, Gian Antonio Da Prada, Harold J. Burstein, Silvana Martino, Nancy E. Davidson, Charles E. Geyer, Barbara A. Walley, Robert Coleman, Pierre Kerbrat, Stefan Buchholz, James N. Ingle, Eric P. Winer, Manuela Rabaglio-Poretti, Rudolf Maibach, Barbara Ruepp, Anita Giobbie-Hurder, Karen N. Price, Marco Colleoni, Giuseppe Viale, Alan S. Coates, Aron Goldhirsch, Richard D. Gelber N Engl J Med vol 372 (5) 436-46 2015

Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/25495490>

576 Long-Term Follow-Up of TEXT and SOFT Trials of Adjuvant Endocrine Therapies for Premenopausal Women with HR+ Early Breast Cancer

Prue Francis, Gini Fleming, Meredith Regan, Olivia Pagani, Barb Walley Cancer Res vol 77 (4 Suppl) Abstract nr OT3-02-0 2017

Abstract Breast http://cancerres.aacrjournals.org/content/77/4_Supplement/OT3-02-03

577 Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of NCCTGs phase III trials N9741 and N9841.

J. Franko, Q. Shi, C. D. Goldman, B. A. Pockaj, G. D. Nelson, R. M. Goldberg, H. C. Pitot, A. Grothey, S. R. Alberts, D. J. Sargent J Clin Oncol vol 29 (suppl) abstr 3571 2011

Abstract GI NCCTG-N9841, NCCTG-N9741

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID

578 Treatment of Colorectal Peritoneal Carcinomatosis With Systemic Chemotherapy: A Pooled Analysis of North Central Cancer Treatment Group Phase III Trials N9741 and N9841

Jan Franko, Qian Shi, Charles D. Goldman, Barbara A. Pockaj, Garth D. Nelson, Richard M. Goldberg, Henry C. Pitot, Axel Grothey, Steven R. Alberts, Daniel J. Sargent J Clin Oncol vol 30 (3) 263-267 2012

Manuscript GI NCCTG-N9841, NCCTG-N9741 <http://www.ncbi.nlm.nih.gov/pubmed/22162570>

579 Changes in Cognitive Function in Older Women With Breast Cancer Treated with Standard Chemotherapy and Capecitabine within CALGB 49907

R. Freedman, B. Pitcher, N. Keating, W. Barry, K. Ballman, A. Kornblith, J. Mandelblatt, G. Kimmick, A. Hurria, E. Winer, C. Hudis, H. Cohen, H. Muss Cancer Res vol 72 (24 suppl) Abstract nr P6-08-05 2012

Abstract Older Adult

580 Promoting Accrual of Older Patients with Cancer to Clinical Trials: An Alliance for Clinical Trials in Oncology Member Survey (A171602)

Rachel A. Freedman, Travis J. Dockter, Jacqueline M. Lafky, Arti Hurria, Hyman J. Muss, Harvey J. Cohen, Aminah Jatoi, M. Margaret Kemeny, Kathryn J. Ruddy *Oncologist* vol 23 (9) 1016-23 2018
Manuscript Older Adult <http://www.ncbi.nlm.nih.gov/pubmed/29674441>

581 Accrual of Older Patients With Breast Cancer to Alliance Systemic Therapy Trials Over Time: Protocol A151527

Rachel A. Freedman, Jared C. Foster, Drew K. Seisler, Jacqueline M. Lafky, Hyman B. Muss, Harvey J. Cohen, Jeanne Mandelblatt, Eric P. Winer, Clifford A. Hudis, Ann H. Partridge, Lisa A. Carey, Constance Cirrincione, Alvaro Moreno-Aspitia, Gretchen Kimmick, Aminah Jatoi, Arti Hurria *J Clin Oncol* vol 35 (4) 421-431 2017
Manuscript Older Adult ACOSOG-Z1031, ACOSOG-Z1041, CALGB-8541, CALGB-9344, CALGB-9741, CALGB-40101, CALGB-40302, CALGB-40502, CALGB-40503, CALGB-40601, CALGB-40603, CALGB-49907, CALGB-9342, CALGB-9840, NCCTG-N89-30-52, NCCTG-N9831
<http://www.ncbi.nlm.nih.gov/pubmed/27992272>

582 Cognitive function in older women with breast cancer treated with standard chemotherapy and capecitabine on Cancer and Leukemia Group B 49907

Rachel A. Freedman, Brandelyn Pitcher, Nancy L. Keating, Karla V. Ballman, Jeanne Mandelblatt, Alice B. Kornblith, Gretchen G. Kimmick, Arti Hurria, Eric P. Winer, Clifford A. Hudis, Harvey Jay Cohen, Hyman B. Muss *Breast Cancer Res Treat* vol 139 (2) 607-616 2013
Manuscript Older Adult CALGB-49907 <http://www.ncbi.nlm.nih.gov/pubmed/23681403>

583 Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511)

Rachel A. Freedman, D. K. Seisler, J. C. Foster, J. A. Sloan, J. M. Lafky, G. G. Kimmick, A. Hurria, H. J. Cohen, E. P. Winer, C. A. Hudis, A. H. Partridge, L. A. Carey, A. Jatoi, H. D. Klepin, M. Citron, D. A. Berry, L. N. Shulman, A. U. Buzdar, V. J. Suman, H. B. Muss *Breast Cancer Res Treat* vol 161 (2) 363-373 2017
Manuscript Older Adult CALGB-40101, CALGB-49907, CALGB-9344, CALGB-9741
<http://www.ncbi.nlm.nih.gov/pubmed/27866278>

584 Accrual of Older Breast Cancer Patients to Alliance Systemic Therapy Protocols over Time: Alliance A151527

Rachel A Freedman, Drew K. Seisler, Jared C. Foster, Jacqueline Lafky, Gretchen Kimmick, Aminah Jatoi, Hyman B. Muss, Harvey J. Cohen, Eric P. Winer, Clifford A. Hudis, Arti Hurria *J Clin Oncol* vol 34 (suppl) abstr 1024 2016
Abstract Older Adult ACOSOG-Z1031, ACOSOG-Z1041, CALGB-8541, CALGB-9344, CALGB-9741, CALGB-40101, CALGB-40302, CALGB-40502, CALGB-40503, CALGB-40601, CALGB-40603, CALGB-49907, CALGB-9342, CALGB-9840, NCCTG-N89-30-52, NCCTG-N9831
http://abstract.asco.org/176/AbstView_176_163808.html

585 Model-based prediction of defective DNA mismatch repair using clinicopathological variables in stage II and III colon cancers.

A. French, F. Sinicrope, N. Foster, S. Thibodeau, D. Sargent, M. O'Connell *J Clin Oncol* vol 27 (15s) 11093 2009
Abstract GI
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID

- 586 Prognostic Significance of Defective Mismatch Repair and BRAF-V600E in Patients with Colon Cancer**
Amy J. French, Daniel J. Sargent, Lawrence J. Burgart, Nathan R. Foster, Brian F. Kabat, Richard Goldberg, Lois Shepherd, Harold E. Windschitl, Stephen N. Thibodeau Clin Cancer Res vol 14 (11) 3408-3415 2008
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/18519771>
- 587 Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma multiforme: a north central cancer treatment group study.**
B. B. Friday, J. Buckner, S. K. Anderson, C. Giannini, J. Kugler, M. Mazurczak, P. Flynn, H. Gross, E. Pajon, K. Jaeckle, E. Galanis 15th Annual Meeting of the Society for Neuro-Oncology (SNO) vol 12 (suppl 4) 70 2010
Abstract Neuro-Onc
http://neuro-oncology.oxfordjournals.org/content/12/suppl_4/iv69.full.pdf+html
- 588 Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study**
Bret B. Friday, S. Keith Anderson, Jan Buckner, Chunrong Yu, Caterina Giannini, Francois Geoffroy, John Schwerkoske, Mirosław Mazurczak, Howard Gross, Eduardo Pajon, Kurt Jaeckle, Evanthia Galanis Neuro Oncol vol 14 (2) 215-221 2012
Manuscript Neuro-Onc <http://www.ncbi.nlm.nih.gov/pubmed/22090453>
- 589 Controlled variable selection in Weibull mixture cure models for high-dimensional data.**
Han Fu, Deedra Nicolet, Krzysztof Mrózek, Richard M Stone, Ann-Kathrin Einfeld, John C Byrd, Kellie J Archer Stat Med vol 41 (22) 4340-66 2022
Manuscript Leuk Corr Sci CALGB-20202, CALGB-8461, CALGB-9665
<http://www.ncbi.nlm.nih.gov/pubmed/35792553>
- 590 Dietary and lifestyle determinants of colon cancer recurrence and survival**
C. S. Fuchs, J. A. Meyerhardt, K. Ng, D. Niedzwiecki, D. R. Hollis, S. Ogino, A. T. Chan, B. M. Wolpin, M. M. Bertagnolli, E. Giovannucci, R. M. Goldberg 2008
Abstract GI
- 591 KRAS mutation, cancer recurrence and patient survival in stage III colon cancer: Findings from CALGB 89803**
C. S. Fuchs, S. Ogino, J. A. Meyerhardt, N. Irahara, D. Niedzwiecki, D. R. Hollis, L. B. Saltz, R. J. Mayer, M. M. Bertagnolli J Clin Oncol vol 27 (15s) abstr 4037 2009
Abstract GI
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID
- 592 Postoperative adjuvant chemoradiation for gastric or gastroesophageal (GE) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (RT): Results from Intergroup trial CALGB 80101**
C. S. Fuchs, J. E. Tepper, D. Niedzwiecki, D. R. Hollis, H. Mamon, R. S. Swanson, D. G. Haller, T. Dragovich, S. Alberts, G. A. Bjarnason, C. Willett, R. M. Goldberg, A. P. Venook, R. J. Mayer J Clin Oncol vol 29 (15s) abstr 4003 2011
Abstract GI
http://meeting.ascopubs.org/cgi/content/abstract/29/15_suppl/4003?sid=9616a22c-422f-42c7-8a99-d222
- 593 Plasma Insulin-like Growth Factors, Insulin-like Binding Protein-3, and Outcome in Metastatic Colorectal Cancer: Results from Intergroup Trial N9741**
Charles S. Fuchs, Richard M. Goldberg, Daniel J. Sargent, Jeffrey A. Meyerhardt, Brian M. Wolpin, Erin M. Green, Henry C. Pitot, Michael Pollak Clin Cancer Res vol 14 (24) 8263-8269 2008

594 Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance)

Charles S. Fuchs, Donna Niedzwiecki, Harvey J. Mamon, Joel E. Tepper, Xing Ye, Richard S. Swanson, Peter C. Enzinger, Daniel G. Haller, Tomislav Dragovich, Steven R. Alberts, Georg A. Bjarnason, Christopher G. Willett, Leonard L. Gunderson, Richard M. Goldberg, Alan P. Venook, David Ilson, Eileen O'Reilly, Kristen Ciombor, David J. Berg, Jeffrey Meyerhardt, Robert J. Mayer J Clin Oncol vol 35 (32) 3671-77 2017

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/28976791>

595 Predicted vitamin D status and colon cancer recurrence and mortality in CALGB 89803 (Alliance)

M. A. Fuchs, C. Yuan, K. Sato, D. Niedzwiecki, X. Ye, L. B. Saltz, R. J. Mayer, R. B. Mowat, R. Whittom, A. Hantel, A. Benson, D. Atienza, M. Messino, H. Kindler, A. Venook, F. Innocenti, R. S. Warren, M. M. Bertagnolli, S. Ogino, E. L. Giovannucci, E. Horvath, J. A. Meyerhardt, K. Ng Ann Oncol vol 28 (6) 1359-67 2017

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/28327908>

596 Sugar-Sweetened Beverage Intake and Cancer Recurrence and Survival in CALGB 89803 (Alliance)

Michael A. Fuchs, Kaori Sato, Donna Niedzwiecki, Xing Ye, Leonard B. Saltz, Robert J. Mayer, Rex B. Mowat, Renaud Whittom, Alexander Hantel, Al Benson, Daniel Atienza, Michael Messino, Hedy Kindler, Alan Venook, Shuji Ogino, Kana Wu, Walter C. Willett, Edward L. Giovannucci, Jeffrey A. Meyerhardt PLoS ONE vol 9 (6) e99816 2014

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/24937507>

597 Minimal Residual Disease (MRD) Status Following Induction Chemo-Immunotherapy Predicts Progression-Free Survival In Mantle Cell Lymphoma (MCL): CALGB 50403 (Alliance)

Noreen Fulton, Jeffrey Johnson, Lawrence D. Kaplan, Greg Koval, Greg Malnassy, Sin-Ho Jung, Steve Devine, Thomas C. Shea, John P. Leonard, Bruce D. Cheson, Wendy Stock Blood vol 122 (21) Abstract 3002 2013

Abstract Lymphoma <http://bloodjournal.hematologylibrary.org/content/122/21/3002.abstract>

598 Statistical modeling of CALGB 80405 (Alliance) to identify influential factors in metastatic colorectal cancer (CRC) dependent on primary tumor side.

Leon Furchtgott, David Swanson, Boris Hayete, Iya Khalil, Diane Wuest, Kelly Rich, Andrew B. Nixon, Donna Niedzwiecki, Jeffrey A. Meyerhardt, Eileen Mary O'Reilly, Fang-Shu Ou, Heinz-Josef Lenz, Federico Innocenti, Alan P. Venook J Clin Oncol vol 35 (15 suppl) abstr 3528 2017

Abstract GI http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.3528

599 A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254

Richard R. Furman, Michael L. Grossbard, Jeffrey L. Johnson, Andrew L. Pecora, Peter A. Cassileth, Sin-Ho Jung, Bruce A. Peterson, Lee M. Nadler, Arnold Freedman, Ruthee-Lu Bayer, Nancy L. Bartlett, David D. Hurd, Bruce D. Cheson Leuk Lymphoma vol 52 (4) 587-596 2011

Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/21275630>

600 Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104)

T. F. Gajewski, A. K. Salama, D. Niedzwiecki, J. Johnson, G. Linette, C. Bucher, M. A. Blaskovich, S. M. Sebti, F. Haluska J Transl Med vol 10 246 2012

- 601 Association of patient preference for adjuvant chemotherapy (chemo) at baseline (BL) with toxicity, mental health, function, quality of life (QoL) and survival in older women with early stage breast cancer (ESBC) [CALGB 49907 Alliance]**
Ajeet Gajra, Linda McCall, Hyman B. Muss, Harvey J. Cohen, A Jatoi, Karla V. Ballman, AH Partridge, L. Sutton, BA Parker, G. Magrinat, JM Lafky, Arti Hurria *Cancer Res* vol 75 (9 Supplement) abstr P5-15-07 2015
Abstract Breast http://cancerres.aacrjournals.org/content/75/9_Supplement/P5-15-07.short?rss=1
- 602 The Preference to Receive Chemotherapy and Cancer-related Outcomes in Older Adults with Breast Cancer CALGB 49907 (Alliance)**
Ajeet Gajra, Linda McCall, Hyman B. Muss, Harvey J Cohen, Aminah Jatoi, Karla V Ballman, Ann H Partridge, Linda Sutton, Barbara A Parker, Gustav Magrinat, Heidi D Klepin, Jacqueline M Lafky, Arti Hurria *J Geriatr Oncol* vol 9 (3) 221-7 2018
Manuscript Older Adult <http://www.ncbi.nlm.nih.gov/pubmed/29602735>
- 603 Time-to-Treatment-Failure and Related Outcomes among 1000+ Advanced Non-Small Cell Lung Cancer Patients: Comparisons Between Older Versus Younger Patients (Alliance A151711)**
Ajeet Gajra, Tyler J. Zemla, Aminah Jatoi, Josephine L. Feliciano, Melisa L. Wong, Hongbin Chen, Ronald Maggiore, Ryan P. McMurray, Arti Hurria, Hyman B. Muss, Harvey J. Cohen, Jacqueline Lafky, Martin J. Edelman, Rogerio Lilenbaum, Jennifer G. Le-Rademacher *J Thorac Oncol* vol 13 (7) 996-1003 2018
Manuscript Older Adult CALGB-30203, CALGB-30801, CALGB-9730
<http://www.ncbi.nlm.nih.gov/pubmed/29608967>
- 604 NCCTG phase II trial of bevacizumab in combination with sorafenib (BEV/SOR) in recurrent glioblastoma (RGBM).**
E. Galanis, S. K. Anderson, J. M. Lafky, T. J. Kaufmann, J. H. Uhm, C. Giannini, S. K. Kumar, D. W. Northfelt, P. J. Flynn, K. A. Jaeckle, J. C. Buckner *Neuro-oncology* vol 13 (3) 62 Abstract NO-93 2011
Abstract Neuro-Onc
http://neuro-oncology.oxfordjournals.org/content/13/suppl_3/iii41.full.pdf+html
- 605 Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial**
E. Galanis, S. K. Anderson, J. M. Lafky, J. Uhm, C. Giannini, S. K. Kumar, T. Kimlinger, D. W. Northfelt, P. J. Flynn, K. Jaeckle, T. J. Kaufmann, J. C. Buckner *Clin Cancer Res* vol 19 (17) 4816-23 2013
Manuscript Neuro-Onc <http://www.ncbi.nlm.nih.gov/pubmed/23833308>
- 606 N047B: NCCTG phase II trial of vorinostat (suberoylanilide hydroxamic acid) in recurrent glioblastoma multiforme (GBM)**
E. Galanis, K. A. Jaeckle, M. J. Maurer, J. M. Reid, M. M. Ames, C. Giannini, J. S. Hardwick, D. F. Moore Jr, J. A. Zwiebel, J. C. Buckner *J Clin Oncol* vol 25 (18s) abstr 2004 2007
Abstract Neuro-Onc http://meeting.ascopubs.org/cgi/content/short/25/18_suppl/2004
- 607 NCCTG phase II trial of bevacizumab in combination with sorafenib in recurrent GBM.**
E. Galanis, K. Jaeckle, S. Anderson, T. Kaufmann, J. Uhm, C. Giannini, S. Kumar, D. Northfelt, P. Flynn, J. Buckner *J Clin Oncol* vol 28 (15s) abstr 2018 2010
Abstract Neuro-Onc <http://meetinglibrary.asco.org/content/42461-74>
- 608 Vorinostat in glioblastoma multiforme (Gbm): updated results from phase I and II trials**

provide the rationale for further clinical development.

E. Galanis, K. Jaeckle, J. Buckner, M. Maurer, J. Hardwick, V. Puduvalli, K. Lamborn, J. Kuhn, M. Prados, P. Wen *Ann Oncol* vol 19 (Suppl 8) 249-250 abstr 806PD 2008
Abstract *Neuro-Onc* http://annonc.oxfordjournals.org/content/19/suppl_8/viii249.full.pdf+html

609 Phase I/II trial of vorinostat combined with temozolomide (TMZ) and radiation therapy (RT) for newly diagnosed glioblastoma (GBM) (N0874-ABTC0902, Alliance): Final results of the phase I trial

E. Galanis, J. Sarkaria, K. Anderson, W. Wu, K. Jaeckle, C. Giannini, J. Buckner, P. Wen *J Clin Oncol* vol 31 (15 suppl) abstr 2046 2013
Abstract *Neuro-Onc* <http://meetinglibrary.asco.org/content/112936-132>

610 Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02

Evanthia Galanis, S Keith Anderson, C Ryan Miller, Jann N Sarkaria, Kurt Jaeckle, Jan C Buckner, Keith L Ligon, Karla V Ballman, Dennis F Moore, Michael Nebozhyn, Andrey Loboda, David Schiff, Manmeet Singh Ahluwalia, Eudocia Q Lee, Elizabeth R Gerstner, Glenn J Lesser, Michael Prados, Stuart A Grossman, Jane Cerhan, Caterina Giannini, Patrick Y Wen *Neuro-oncology* vol 20 (4) 546-56 2018
Manuscript *Neuro-Onc* <http://www.ncbi.nlm.nih.gov/pubmed/29016887>

611 Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance)

Evanthia Galanis, S Keith Anderson, Erin Twohy, Nicholas A Butowski, Adilia Hormigo, David Schiff, Antonio Omuro, Kurt A Jaeckle, Shaji Kumar, Timothy J Kaufmann, Susan Geyer, Priya U Kumthekar, Jian Campian, Caterina Giannini, Jan C Buckner, Patrick Y Wen *Neurooncol Adv* vol 4 (1) 2022
Manuscript *Neuro-Onc* <http://www.ncbi.nlm.nih.gov/pubmed/35664553>

612 NCCTG N0872 (Alliance): A Randomized Placebo-Controlled Phase II Trial of Bevacizumab Plus Dasatinib in Patients with Recurrent Glioblastoma (GBM)

Evanthia Galanis, S. Keith Anderson, Panagiotis Z. Anastasiadis, David Tran, Suriya A. Jeyapalan, Daniel M. Anderson, Tim Kaufmann, Caterina Giannini, Jan C. Buckner, David Schiff *J Clin Oncol* vol 33 (suppl) abstr 2004 2015
Abstract *Neuro-Onc* http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/2004?sid=163ebdc1-978e-4e50-b1e8-e2b1

613 NCCTG N1174: Phase I/Comparative Randomized Phase II Trial of TRC105 plus Bevacizumab versus Bevacizumab in Bevacizumab-Naïve Patients with Recurrent Glioblastoma Multiforme (Alliance)

Evanthia Galanis, S. Keith Anderson, Nicholas Butowski, Adilia MV Hormingo, David Schiff, David. D. Tran, Antonio M. Omuro, Kurt A. Jaeckle, Shaji Kumar, Timothy Kaufmann, Caterina Giannini, Erin Twohy, Patrick Y. Wen *J Clin Oncol* vol 35 (15 suppl) abstr 2023 2017
Abstract *Neuro-Onc* http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.2023

614 Phase II trial of vorinostat (VOR) combined with temozolomide (TMZ) and radiation therapy (RT) for newly diagnosed glioblastoma (GBM) (Alliance N0874/ABTC-0902)

Evanthia Galanis, S. Keith Anderson, C. Ryan Miller, Jann Nagina Sarkaria, Kurt A. Jaeckle, Jan C. Buckner, Keith L. Ligon, Karla V. Ballman, Dennis Frederic Moore, Manmeet Singh Ahluwalia, Eudocia Quant Lee, Elizabeth Robins Gerstner, Glenn Jay Lesser, Michael Prados, Stuart A. Grossman, Caterina Giannini, Patrick Y. Wen *J Clin Oncol* vol 32 (5s) (suppl); abstr 2030 2014
Abstract *Neuro-Onc* http://abstracts.asco.org/144/AbstView_144_133770.html

615 A Phase I and Randomized Placebo-Controlled Phase II Trial of Bevacizumab plus Dasatinib in Patients with Recurrent Glioblastoma (GBM): Alliance/NCCTG N0872

Evanthia Galanis, S. Keith Anderson, Erin L. Twohy, Xiomara W. Carrero, Jesse G. Dixon, David Dinh Tran, Suriya A. Jeyapalan, Daniel M. Anderson, Timothy J. Kaufmann, Ryan W. Feathers, Caterina Giannini, Jan C. Buckner, Panos Z. Anastasiadis, David Schiff *Cancer* vol 125 (21) 3790-800 2019
Manuscript *Neuro-Onc* <http://www.ncbi.nlm.nih.gov/pubmed/31290996>

616 Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study

Evanthia Galanis, Kurt A. Jaeckle, Matthew J. Maurer, Joel M. Reid, Matthew M. Ames, James S. Hardwick, John F. Reilly, Andrey Loboda, Michael Nebozhyn, Valeria R. Fantin, Victoria M. Richon, Bernd Scheithauer, Caterina Giannini, Patrick J. Flynn, Dennis F. Moore, James Zwiebel, Jan C. Buckner *J Clin Oncol* vol 27 (12) 2052-2058 2009
Manuscript *Neuro-Onc* <http://www.ncbi.nlm.nih.gov/pubmed/19307505>

617 Treatment-influenced associations of PML-RARalpha mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia

R. E. Gallagher, B. K. Moser, J. Racevskis, X. Poire, C. D. Bloomfield, A. J. Carroll, R. P. Ketterling, D. Roulston, E. Schachter-Tokarz, D. C. Zhou, I. M. Chen, R. Harvey, G. Koval, D. A. Sher, J. H. Feusner, M. S. Tallman, R. A. Larson, B. L. Powell, F. R. Appelbaum, E. Paietta, C. L. Willman, W. Stock *Blood* vol 120 (10) 2098-2108 2012
Manuscript *Leuk Corr Sci* <http://www.ncbi.nlm.nih.gov/pubmed/22734072>

618 Clonal Markers In Relapsed Acute Promyelocytic Leukemia (APL): Clinicopathological Associations and Relation to All-Trans Retinoic Acid (ATRA) Treatment on Intergroup Phase III Trial C9710

R. E. Gallagher, B. K. Moser, J. Racevskis, X. Poire, C. D. Bloomfield, A. J. Carroll, R. Ketterling, D. Ralston, E. Schachter-Tokarz, D. Zhou, I.-M. L. Chen, R. Harvey, G. Koval, D. A. Sher, J. H. Feusner, M. S. Tallman, F. R. Appelbaum, R. A. Larson, B. L. Powell, E. Paietta, C. L. Willman, W. Stock *Blood* vol 116 (21) 1038 2010
Abstract *Leuk Corr Sci* <http://www.bloodjournal.org/content/116/21/1038>

619 Comparison of quality of life in patients randomized to high-dose once daily (QD) thoracic radiotherapy (TRT) with standard twice daily (BID) TRT in limited stage small cell lung cancer (LS-SCLC) on CALGB 30610 (CALGB 70702) Alliance

Apar K. Ganti, Amylou C. Dueck, Briant Fruth, Andreas Rimmer, Saiama Waqar, Michael Mix, W. Jeffrey Petty, Jeffrey Bogart *J Clin Oncol* vol 40 (16_suppl) 8504-8504 2022
Abstract *Health Outcomes CALGB-30610*
https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.8504

620 Factor V Leiden Mutation and Thromboembolism Risk in Women Receiving Adjuvant Tamoxifen for Breast Cancer

Judy E. Garber, Susan Halabi, Sara M. Tolaney, Ellen Kaplan, Laura Archer, James N. Atkins, Stephen Edge, Charles L. Shapiro, Lynn Dressler, Electra M. Paskett, Gretchen Kimmick, James Orcutt, Anthony Scalzo, Eric Winer, Ellis Levine, Nasir Shahab, Nancy Berliner *J Natl Cancer Inst* vol 102 (13) 942-949 2010
Manuscript *Breast* <http://www.ncbi.nlm.nih.gov/pubmed/20554945>

621 Phase I North Central Cancer Treatment Group Trial-N9923 of escalating doses of twice-daily thoracic radiation therapy with amifostine and with alternating chemotherapy in limited stage small-cell lung cancer.

Yolanda I Garces, Scott H Okuno, Steven E Schild, Sumithra J Mandrekar, Brian M Bot, John M

Martens, Donald B Wender, Gamini S Soori, Dennis F Moore, Timothy F Kozelsky, James R Jett Int J Radiat Oncol Biol Phys vol 67 (4) 995-1001 2007
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/17336213>

622 Pathologic complete response (pCR) to neoadjuvant chemoradiation (CRT) and local excision (LE) for uT2uN0 rectal cancer (RC): results of the ACOSOG Z6041 trial

J. Garcia-Aguilar, Q. Shi, C. R. Thomas Jr, E. Chan, P. Cataldo, J. Marcet, D. Medich, A. Pigazzi, S. Oommen, M. C. Posner J Clin Oncol vol 28 (15s) abstr 3510 2010

Abstract GI

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID

623 Organ preservation for clinical t2n0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision: results of a multicenter phase 2 study

Julio Garcia-Aguilar, Lindsay A. Renfro, Oliver S. Chow, Qian Shi, Xiomara W. Carrero, Patricio B. Lynn, Charles R. Thomas, Emily Chan, Peter A. Cataldo, Jorge E. Marcet, David S. Medich, Craig S. Johnson, Samuel C. Oommen, Bruce G. Wolff, Alessio Pigazzi, Shane M. McNevin, Roger K. Pons, Ronald Bleday Lancet Oncol vol 16 (15) 1537-1546 2015

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/26474521>

624 A Phase II Trial of Neoadjuvant Chemoradiation and Local Excision for T2N0 Rectal Cancer: Preliminary Results of the ACOSOG Z6041 Trial

Julio Garcia-Aguilar, Qian Shi, Charles R. Thomas, Emily Chan, Peter Cataldo, Jorge Marcet, David Medich, Alessio Pigazzi, Samuel Oommen, Mitchell C. Posner Ann Surg Oncol vol 19 (2) 384-391 2012

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/21755378>

625 Expression and prognostic impact of lncRNAs in acute myeloid leukemia

Ramiro Garzon, Stefano Volinia, Dimitrios Papaioannou, Deedra Nicolet, Jessica Kohlschmidt, Pearly S. Yan, Krzysztof Mrózek, Donna Bucci, Andrew J. Carroll, Maria R. Baer, Meir Wetzler, Thomas H. Carter, Bayard L. Powell, Jonathan E. Kolitz, Joseph O. Moore, Ann-Kathrin Einfeld, James S. Blachly, William Blum, Michael A. Caligiuri, Richard M. Stone, Guido Marcucci, Carlo M. Croce, John C. Byrd, Clara D. Bloomfield Proc Natl Acad Sci USA vol 111 (52) 18679-18684 2014

Manuscript Leuk Corr Sci <http://www.ncbi.nlm.nih.gov/pubmed/25512507>

626 RasGRP1 is a potential biomarker for stratifying anti-EGFR therapy response in colorectal cancer

Oghenekevwe M. Gbenedio, Caroline Bonnans, Delphine Grun, Chih-Yang Wang, Ace J. Hatch, Michelle R. Mahoney, David Barras, Mary Matli, Yi Miao, K. Christopher Garcia, Sabine Tejpar, Mauro Delorenzi, Alan P. Venook, Andrew B. Nixon, Robert S. Warren, Jeroen P. Roose, Philippe Depeille JCI Insight vol 4 (15) e127552 2019

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/31237864>

627 Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial

Daniel J. George, Colin Hessel, Susan Halabi, M. Dror Michaelson, Olwen Hahn, Meghara Walsh, Joel Picus, Eric J. Small, Shaker Dakhil, Darren R. Feldman, Milan Mangeshkar, Christian Scheffold, Michael J. Morris, Toni K. Choueiri Oncologist vol 24 (11) 1497-1501 2019

Manuscript GU <http://www.ncbi.nlm.nih.gov/pubmed/31399500>

628 The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from Cancer and Leukemia Group B 9480.

Daniel J George, Susan Halabi, Timothy F Shepard, Ben Sanford, Nicholas J Vogelzang, Eric J Small, Philip W Kantoff Clin Cancer Res vol 11 (5) 1815-20 2005

629 Association of on-treatment plasma HGF levels with overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (INF) +/- bevacizumab (BEV): Results from CALGB 90206 (Alliance)

Daniel J. George, Susan Halabi, Andrew B. Nixon, Mark D. Starr, J. Chris Brady, Herbert I. Hurwitz, Ian Barak, M. Morris, Brian I. Rini, Eric Small, Won Kim, Mary-ellen Taplin *J Clin Oncol* vol 35 (15 suppl) abstr 4522 2017

Abstract Correl Sci NOS http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.4522

630 Cabozantinib versus sunitinib for previously untreated patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk: subgroup analysis of progression-free survival (PFS) and objective response rate (ORR) in the Alliance A031203 CABOSUN trial

Daniel George, Colin Hessel, Susan Halabi, Ben Sanford, M. Dror Michaelson, Olwen Hahn, Meghara Walsh, Thomas Olencki, Joel Picus, Eric J. Small, Shaker Dakhil, Darren Feldman, Milan Mangeshkar, Christian Scheffold, Michael J. Morris, Toni K. Choueiri *J Clin Oncol* vol 36 (suppl 6S) abstr 582 2018

Abstract GU <https://meetinglibrary.asco.org/record/156873/abstract>

631 Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial.

C E Geyer, W M Sikov, J Huober, H S Rugo, N Wolmark, J O'Shaughnessy, D Maag, M Untch, M Golshan, J Ponce Lorenzo, O Metzger, M Dunbar, W F Symmans, P Rastogi, J H Sohn, R Young, G S Wright, C Harkness, K McIntyre, D Yardley, S Loibl *Ann Oncol* vol 33 (4) 384-94 2022

Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/35093516>

632 Discordance between central vs. local response assessments in neuroendocrine tumor (NET) patients enrolled in A021202.

Susan M. Geyer, Michelle R. Mahoney, Timothy R. Asmis, Nathan Hall, Sanja Karovic, Michael Knopp, Priya Kumthekar, Andrew B. Nixon, Eileen Mary O'Reilly, Lawrence H Schwartz, Jonathan R. Strosberg, Jeffrey A. Meyerhardt, Michael L. Maitland, Emily K Bergsland *J Clin Oncol* vol 39 (3_suppl) 361 2021

Abstract GI https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.3_suppl.361

633 Epigenetic phenocopying expands molecular risk assessment in acute myeloid leukemia (Alliance)

Brian Giacomelli, Salma Abdelbaky, Kyoko Yamaguchi, Jessica Kohlschmidt, Krzysztof Mrózek, Ada Cleary, Yue-Zhong Wu, Shelley Orwick, Deedra Nicolet, Kevin R. Coombes, James S. Blachly, Bayard L. Powell, Jonathan E. Kolitz, William G. Blum, Maria R. Baer, Richard M. Stone, Ann-Kathrin Einfeld, Clara D. Bloomfield, John C. Byrd, Christopher C. Oakes *Blood* vol 138 (Supplement 1) 803 2021

Abstract Leuk Corr Sci CALGB-20202, CALGB-8461, CALGB-9665
<https://www.sciencedirect.com/science/article/pii/S0006497121027919>

634 Central Pathology Review by Whole Slide Imaging in Glioblastoma Clinical Trials

Caterina Giannini, Ryan Miller, Keith Ligon, Helen Tollefson, Mark Korinek, Justin Koepplin, David Holmes, Sarah Jenkins, Jan Buckner *J Neuropathol Expl Neurol* vol 74 (6) 595, abstr 26 2015

Abstract Neuro-Onc NCCTG-N0872, NCCTG-N0877

<https://academic.oup.com/jnen/article/74/6/588/2614402#46637304>

635 Analysis of prognostic (prog) Web-based models for stage II and III colon cancer (CC): A population-based validation of Numeracy (NUM) and ADJUVANT! Online (ADJ!).

S. Gill, C. Loprinzi, H. Kennecke, A. Grothey, G. Nelson, R. Woods, C. Speers, S. Alberts, A. Bardia, D. Sargent *J Clin Oncol* vol 27 (15s) 4044 2009
Abstract GI
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID

636 Prognostic Web-based Models for Stage II and III Colon Cancer: a Population and Clinical Trials-based Validation of Numeracy and Adjuvant! Online

Sharlene Gill, Charles Loprinzi, Hagen Kennecke, Axel Grothey, Garth Nelson, Ryan Woods, Caroline Speers, Steven R. Alberts, Aditya Bardia, Michael J. O'Connell, Daniel J. Sargent *Cancer* vol 117 (18) 4155-4165 2011
Manuscript GI NCCTG-89-46-51, NCCTG-914653 <http://www.ncbi.nlm.nih.gov/pubmed/21365628>

637 Local and Regional Control in Breast Cancer after Sentinel Node Biopsy without Axillary Lymph Node Dissection: Results from a Randomized Trial

A. E. Giuliano, L. McCall, P. Beitsch, P. W. Whitworth, P. Blumencranz, A. M. Leitch, S. Saha, K. K. Hunt, M. Morrow, K. V. Ballman *American Surgical Association 130th Annual Meeting* 43-44 2010
Abstract Breast <http://www.americansurgical.info/files/2010/ASA10-Program-Book-for-Web.pdf>

638 ACOSOG Z0011: A randomized trial of axillary node dissection in women with clinical T1 - 2 N0 M0 breast Cancer who have a positive sentinel node

A. E. Giuliano, L. McCall, P. Beitsch, P. Whitworth, M. Morrow, P. Blumencranz, A. M. Leitch, S. Saha, K. K. Hunt, K. V. Ballman *J Clin Oncol* vol 28 (18s) abstr CRA506 2010
Abstract Breast <http://meetinglibrary.asco.org/content/47842-74>

639 Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis

Armando E. Giuliano, Karla V. Ballman, Linda McCall, Peter D. Beitsch, Meghan B. Brennan, Pond R. Kelemen, David W. Ollila, Nora M. Hansen, Pat W. Whitworth, Peter W. Blumencranz, A. Marilyn Leitch, Sukamal Saha, Kelly K. Hunt, Monica Morrow *JAMA* vol 318 (10) 918-26 2017
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/28898379>

640 Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients with Sentinel Lymph Node Metastases: Long-Term Follow-Up from the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized Trial

Armando E. Giuliano, Karla Ballman, Linda McCall, Peter Beitsch, Pat W. Whitworth, Peter Blumencranz, A. Marilyn Leitch, Sukamal Saha, Monica Morrow, Kelly K. Hunt *Ann Surg* vol 264 (3) 413-420 2016
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/27513155>

641 Association of occult metastases in sentinel lymph nodes and bone marrow with survival of women with early-stage invasive breast cancer

Armando E. Giuliano, Debra Hawes, Karla V. Ballman, Pat W. Whitworth, Peter W. Blumencranz, Douglas S. Reintgen, Monica Morrow, A. Marilyn Leitch, Kelly K. Hunt, Linda M. McCall, Andrea Abati, Richard Cote *JAMA* vol 306 (4) 385-393 2011
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/21791687>

642 Ten-Year Survival Results of ACOSOG Z0011 (Alliance)

Armando E. Giuliano, Kelly K. Hunt, Karla V. Ballman, Peter D. Beitsch, Pat W. Whitworth, Peter W. Blumencranz, A. Marilyn Leitch, Sukamal Saha, Linda M. McCall, Monica Morrow *J Clin Oncol* vol 34 (suppl) abstr 1007 2016
Abstract Breast <http://meetinglibrary.asco.org/content/170337-176>

643 Sentinel Lymph Node Dissection With and Without Axillary Dissection in Women With Invasive

Breast Cancer and Sentinel Node Metastasis: A Randomized Clinical Trial

Armando E. Giuliano, Kelly K. Hunt, Karla. V. Ballman, Peter D. Beitsch, Pat W. Whitworth, Peter W. Blumencranz, A. Marilyn Leitch, Sukamal Saha, Linda M. McCall, Monica Morrow JAMA vol 305 (6) 569-575 2011

Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/21304082>

644 Locoregional Recurrence after Sentinel Lymph Node Dissection with or without Axillary Dissection in Patients with Sentinel Lymph Node Metastases: The American College of Surgeons Oncology Group Z0011 Randomized Trial

Armando E Giuliano, Linda McCall, Peter Beitsch, Pat W Whitworth, Peter Blumencranz, A. Marilyn Leitch, Sukamal Saha, Kelly K Hunt, Monica Morrow, Karla Ballman Ann Surg vol 252 (3) 426-433 2010

Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/20739842>

645 Locoregional Recurrence after Sentinel Lymph Node Dissection with or without Axillary Dissection in Patients with Sentinel Lymph Node Metastases: Long-term follow-up from the American College of Surgeons Oncology Group (Alliance) Z0011 Randomized Trial

Armando E Giuliano, Linda McCall, Peter Beitsch, Pat W Whitworth, Peter Blumencranz, A. Marilyn Leitch, Sukamal Saha, Kelly K Hunt, Monica Morrow, Karla Ballman 2016

Abstract Breast <http://meeting.americansurgical.org/abstracts/2016/1.cgi>

646 Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03).

Michael Gnant, Amylou C Dueck, Sophie Frantal, Miguel Martin, Hal J Burstein, Richard Greil, Peter Fox, Antonio C Wolff, Arlene Chan, Eric P Winer, Georg Pfeiler, Kathy D Miller, Marco Colleoni, Jennifer M Suga, Gabor Rubovsky, Judith M Bliss, Ingrid A Mayer, Christian F Singer, Zbigniew Nowecki, Olwen Hahn, Jacqui Thomson, Norman Wolmark, Kepa Amillano, Hope S Rugo, Guenther G Steger, Blanca Hernando Fernández de Aránguiz, Tufia C Haddad, Antonia Perelló, Meritxell Bellet, Hannes Fohler, Otto Metzger Filho, Anita Jallitsch-Halper, Kadine Solomon, Céline Schurmans, Kathy P Theall, Dongrui R Lu, Kathleen Tenner, Christian Fesl, Angela DeMichele, Erica L Mayer J Clin Oncol vol 40 (3) 282-93 2022

Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/34874182>

647 Adjuvant Palbociclib for Early Breast Cancer – the PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)

Michael Gnant, Amylou Dueck, Sophie Frantal, Miguel Martin, Hal Burstein, Richard Greil, Peter Fox, Antonio Wolff, Arlene Chan, Eric Winer, Christian Singer, Kathy Miller, Marco Colleoni, Michelle Naughton, Gabor Rubovsky, Judith Bliss, Ingrid Mayer, Guenther G. Steger, Zbigniew Nowecki, Olwen Hahn, Norman Wolmark, Hope Rugo, Georg Pfeiler, Hannes Fohler, Otto Metzger, Kathleen Tenner, Christian Fesl, Angela DeMichele, Erica L Mayer J Clin Oncol vol 40 (3) pp. 282-293(12) 2022

Abstract Breast

<https://www.ingentaconnect.com/content/wk/jco/2022/00000040/00000003/art00009>

648 The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer.

Ajay Goel, Takeshi Nagasaka, Christian N Arnold, Toru Inoue, Cody Hamilton, Donna Niedzwiecki, Carolyn Compton, Robert J Mayer, Richard Goldberg, Monica M Bertagnolli, C Richard Boland Gastroenterology vol 132 (1) 127-38 2007

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/17087942>

649 Role of SULT1A1 copy number in tamoxifen treated breast cancer: findings from the North Central Cancer Treatment Group (NCCTG) adjuvant trial 89-30-52.

M. P. Goetz, A. M. Moyer, R. M. Weinshilboum, V. A. Suman, S. J. Hebbing, M. M. Ames, J. C. Berg, C. Reynolds, E. A. Perez, J. N. Ingle J Clin Oncol vol 26 (15s) 22041 2008
Abstract PPP http://hwmain.meeting.ascopubs.org/cgi/content/abstract/26/15_suppl/22041

650 Use of gene expression profiling to identify responsive patients treated with carboplatin (Carb), paclitaxel (Pac), and everolimus as first-line treatment for cancer of unknown primary (CUP): NCCTG N0871 (Alliance)

M. Goetz, N. Foster, J. Meyers, P. Steen, D. Visscher, H. Yoon, R. Pillai, D. Prow, C. Reynolds, B. Marchello, R. Mowat, B. Mattar, C. Erlichman J Clin Oncol vol 31 (15 suppl) abstr 2562 2013
Abstract Experimental <http://meetinglibrary.asco.org/content/113055-132>

651 Tamoxifen Pharmacogenetics of CYP2D6, CYP2C19, and SULT1A1: Long Term Follow-up of the North Central Cancer Treatment Group 89-30-52 Adjuvant Trial.

M. Goetz, V. Suman, M. Ames, J. Black, S. Safgren, M. Kuffel, R. Avula, A. Moyer, R. Weinshilboum, C. Reynolds, E. Perez, J. Ingle Cancer Res vol 69 (2, suppl 1) abstr SABCS-6037 2009
Abstract PPP
http://cancerres.aacrjournals.org/content/69/2_Supplement/6037.abstract?sid=d7929468-5cd6-4de4-8cfa

652 CYP2D6 and HOXB13/IL17BR: Combining inherited and tumor gene markers for prediction of tamoxifen resistance

Matthew P. Goetz, Vera J. Suman, Fergus J. Couch, Matthew M. Ames, James M. Rae, Mark G. Erlander, Xiao-Jun Ma, Dennis C. Sgroi, Carol A. Reynolds, Wilma L. Lingle, Richard M. Weinshilboum, David A. Flockhart, Zeruesenay Desta, Edith A. Perez, James N. Ingle Clin Cancer Res vol 14 (18) 5864-5868 2008
Manuscript PPP <http://www.ncbi.nlm.nih.gov/pubmed/18794098>

653 Alliance A011203: A randomized phase II trial of tamoxifen versus Z-endoxifen HCL in postmenopausal women with metastatic estrogen receptor positive, HER2 negative breast cancer

Matthew P. Goetz, Vera J Suman, Joel M. Reid, Mary Kuffel, Sarah A. Buhrow, Renee M. McGovern, John Black, Travis Dockter, Carrie Strand, William F. Symmans, Minetta C. Liu, John R. Hawse, James Doroshov, Jerry M. Collins, Howard Streicher, Anna Maria Vita Storniolo, Matthew M. Ames, James N. Ingle, Ann Partridge, Lisa Carey Cancer Res vol 80 (4 Supplement) Abstract PD7-06 2020
Abstract Breast https://cancerres.aacrjournals.org/content/80/4_Supplement/PD7-06

654 Loss of Heterozygosity at the CYP2D6 Locus in Breast Cancer: Implications for Germline Pharmacogenetic Studies

Matthew P. Goetz, James X. Sun, Vera J. Suman, Grace O. Silva, Charles M. Perou, Yusuke Nakamura, Nancy J. Cox, Philip J. Stephens, Vincent A. Miller, Jeffrey S. Ross, David Chen, Stephanie L. Safgren, Mary J. Kuffel, Matthew M. Ames, Krishna R. Kalari, Henry L. Gomez, Ana M. Gonzalez-Angulo, Octavio Burgues, Hiltrud B. Brauch, James N. Ingle, Mark J. Ratain, Roman Yelensky J Natl Cancer Inst vol 107 (2) 2014
Manuscript PPP <http://www.ncbi.nlm.nih.gov/pubmed/25490892>

655 The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen.

Matthew P Goetz, Stacey K Knox, Vera J Suman, James M Rae, Stephanie L Safgren, Matthew M Ames, Daniel W Visscher, Carol Reynolds, Fergus J Couch, Wilma L Lingle, Richard M Weinshilboum, Emily G Barr Fritcher, Andrea M Nibbe, Zeruesenay Desta, Anne Nguyen, David A Flockhart, Edith A Perez, James N Ingle Breast Cancer Res Treat vol 101 (1) 113-21 2007
Manuscript PPP <http://www.ncbi.nlm.nih.gov/pubmed/17115111>

656 A pooled safety and efficacy analysis examining the effect of performance status (PS) on outcomes in 9 first line treatment (rx) trials (cts) of 6,286 patients (pts) with metastatic colorectal

cancer (MCRC).

R. M. Goldberg, C. H. Kohne, M. T. Seymour, A. De Gramont, R. Porschen, L. Saltz, P. Rougier, C. Tournigand, A. Grothey, D. J. Sargent J Clin Oncol vol 25 (18s) abstr 4011 2007
Abstract GI NCCTG-N0545, NCCTG-N9741
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID

657 Adjuvant mFOLFOX6 +/- Cetuximab in Patients With KRAS Mutant Resected Stage III Colon Cancer: NCCTG Intergroup Phase III Trial N0147.

R. Goldberg, D. Sargent, S. Thibodeau, M. Mahoney, A. Shields, E. Chan, S. Gill, M. Kahlenberg, S. Nair, S. Alberts J Clin Oncol vol 28 (15s) abstr 3508 2010
Abstract GI
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID

658 A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

Richard M Goldberg, Daniel J Sargent, Roscoe F Morton, Charles S Fuchs, Ramesh K Ramanathan, Stephen K Williamson, Brian P Findlay, Henry C Pitot, Steven R Alberts J Clin Oncol vol 22 (1) 23-30 2004
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/14665611>

659 Variability of Pelvic MRI Performance in a Prospective Multicenter Rectal Cancer Trial NCCTG N1048 (Alliance)

Marc J. Gollub, Qian Shi, Stephanie Nougaret, Preethi Subramanian, Jun Zhang, Michael Knopp, Deborah Schrag, Gregory Nyman, Lawrence Schwartz J Clin Oncol vol 36 (Suppl) abstr e18783 2018
Abstract GI <https://meetinglibrary.asco.org/record/159550/abstract>

660 Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant paclitaxel followed by doxorubicin and cyclophosphamide on breast conservation rates: Surgical results from CALGB 40603 (Alliance).

Mehra Golshan, Constance T. Cirrincione, Donald A. Berry, William M. Sikov, Sara Jasinski, Tracey F. Weisberg, George Somlo, Eric P. Winer, Clifford Hudis, David W. Ollila 2015
Abstract Breast <http://meeting.americansurgical.org/abstracts/2015/3.cgi>

661 Impact of Neoadjuvant Therapy on Breast Conservation Rates in Triple- Negative and HER2-positive breast cancer: Combined results of CALGB 40603 and 40601 (Alliance)

Mehra Golshan, Constance T. Cirrincione, Donald Berry, Lisa Carey, William Sikov, Norah Henry, George Somlo, Elisa Port, Eric Winer, Clifford A. Hudis, David Ollila J Clin Oncol vol 33 (suppl) abstr 1007 2015
Abstract Breast CALGB-40601, CALGB-40603
http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/1007?sid=dea30587-a124-4651-a1b8-66b0

662 Impact of Neoadjuvant Chemotherapy in Stage II–III Triple Negative Breast Cancer on Eligibility for Breast-conserving Surgery and Breast Conservation Rates

Mehra Golshan, Constance T. Cirrincione, William M. Sikov, Donald A. Berry, Sara Jasinski, Tracey F. Weisberg, George Somlo, Clifford Hudis, Eric Winer, David W. Ollila Ann Surg vol 262 (3) 434-439 2015
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/26222764>

663 Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II–III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance)

Mehra Golshan, Constance T. Cirrincione, William M. Sikov, Lisa A. Carey, Donald A. Berry, Beth Overmoyer, Nora L. Henry, George Somlo, Elisa Port, Harold J. Burstein, Clifford Hudis, Eric Winer,

David W. Ollila Breast Cancer Res Treat vol 160 (2) 297-304 2016
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/27704226>

- 664 Breast Conservation After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer**
Mehra Golshan, Sibylle Loibl, Stephanie M. Wong, Jens Bodo Houber, Joyce O'Shaughnessy, Hope S. Rugo, Norman Wolmark, Mark D. McKee, David Maag, Danielle M. Sullivan, Otto Metzger-Filho, Gunter Von Minckwitz, Charles E. Geyer Jr., William M. Sikov, Michael Untch JAMA Surg vol 155 (3) 2020
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/31913413>
- 665 Sentinel node biopsy performed in the neoadjuvant setting for Breast Cancer: Results from the CALGB 150007 & 150012/ACRIN 6657 I-SPY TRIAL**
R. Gomez, J. Zakhireh, D. Moore, A. Demichelle, J. Przewoznik, D. W. Ollila, J. Frank, H. Krontiras, L. L. Montgomery, V. Sarode, G. Broadwater, L. J. Esserman Cancer Res vol 69 (2 suppl 1) 2020
2009
Abstract Correl Sci NOS ACRIN-6657, CALGB-150007
http://cancerres.aacrjournals.org/content/69/2_Supplement/202
- 666 Patient and Tumor Characteristics and BRAF and KRAS Mutations in Colon Cancer, NCCTG/Alliance N0147**
Wilson I. Gonsalves, Michelle R. Mahoney, Daniel J. Sargent, Garth D. Nelson, Steven R. Alberts, Frank A. Sinicrope, Richard M. Goldberg, Paul J. Limburg, Stephen N. Thibodeau, Axel Grothey, Joleen M. Hubbard, Emily Chan, Suresh Nair, Jeffrey L. Berenberg, Robert R. McWilliams J Natl Cancer Inst vol 106 (7) 2014
Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/24925349>
- 667 Survival Outcomes from CALGB 80803 (Alliance): A Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy for Esophageal Cancer**
Karyn A. Goodman, Nathan Hall, Tanios Bekaii-Saab, Fang-Shu Ou, Erin Twohy, Michael Meyers, Daniel Boffa, Kristen Ciombor, Wendy Frankel, Alan Venook, Eileen O'Reilly, David Ilson J Clin Oncol vol 36 (15_suppl) 4012-4012 2018
Abstract GI https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.4012
- 668 Initial results of CALGB 80803: A randomized phase II trial of pet scan-directed combined modality therapy for esophageal cancer (Alliance)**
Karyn A. Goodman, Donna Niedzwiecki, Nathan Hall, Tanios Bekaii-Saab, Xing Ye, Michael Meyers, Daniel Boffa, Wendy Frankel, Alan Venook, Howard Hochster, Christopher Crane, Eileen O'Reilly, David Ilson J Clin Oncol vol 35 (suppl 4S) abstr 1 2017
Abstract GI http://abstracts.asco.org/195/AbstView_195_176998.html
- 669 Randomized Phase II Study of PET Response-Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial**
Karyn A. Goodman, Fang-Shu Ou, Nathan C. Hall, Tanios Bekaii-Saab, Briant Fruth, Erin Twohy, Michael O. Meyers, Daniel J. Boffa, Kisha Mitchell, Wendy L. Frankel, Donna Niedzwiecki, Anne Noonan, Yelena Y. Janjigian, Paul J. Thurmes, Alan P. Venook, Jeffrey A. Meyerhardt, Eileen M. O'Reilly, David H. Ilson J Clin Oncol vol 39 (25) 2803-2815 2021
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/34077237>
- 670 Predictors of accrual success for cooperative group trials: The Cancer and Leukemia Group B (Alliance) experience**
David Gordon, Qianying Liu, Benjamin Kleinman, Theodore Karrison, Michael Kelly, Gini Fleming J Clin Oncol vol 31 (15) abstr TPS6645 2013
Abstract Health Outcomes

671 New validated prognostic models and prognostic calculators in patients with low-grade gliomas diagnosed by central pathology review: a pooled analysis of EORTC/RTOG/NCCTG phase III clinical trials

Thierry Gorlia, Wenting Wu, Meihua Wang, Brigitta G. Baumert, Minesh Mehta, Jan C. Buckner, Edward Shaw, Paul Brown, Roger Stupp, Evanthia Galanis, Denis Lacombe, Martin J. van den Bent
Neuro-oncology vol 15 (11) 1568-1579 2013

Manuscript Neuro-Onc <http://www.ncbi.nlm.nih.gov/pubmed/24049111>

672 Sorafenib for Advanced and Refractory Desmoid Tumors

Mrinal M. Gounder, Michelle R. Mahoney, Brian A. Van Tine, Vinod Ravi, Steven Attia, Hari A. Deshpande, Abha A. Gupta, Mohammed M. Milhem, Robert M. Conry, Sujana Movva, Michael J. Pishvaian, Richard F. Riedel, Tarek Sabagh, William D. Tap, Natally Horvat, Ethan Basch, Lawrence H. Schwartz, Robert G. Maki, Narasimhan P. Agaram, Robert A. Lefkowitz, Yousef Mazaheri, Rikiya Yamashita, John J. Wright, Amylou C. Dueck, Gary K. Schwartz
N Engl J Med vol 379 (25) 2417-28 2018

Manuscript Experimental <http://www.ncbi.nlm.nih.gov/pubmed/30575484>

673 Phase III, randomized, double blind, placebo (P)-controlled trial of sorafenib (S) in desmoid tumor, (DT) (ALLIANCE A091105)

Mrinal M. Gounder, Michelle R. Mahoney, Brian Andrew Van Tine, Vinod Ravi, Steven Attia, Hari Anant Deshpande, Abha A. Gupta, Mohammed M. Milhem, Robert Martin Conry, Sujana Movva, Michael J. Pishvaian, Jeffrey Crawford, Tarek Sabagh, Robert G. Maki, William D. Tap, Robert A. Lefkowitz, Narasimhan P. Agaram, John Joseph Wright, Amylou C. Dueck, Gary K. Schwartz
J Clin Oncol vol 36 (no. 15_suppl) 11500-11500 2018

Abstract Experimental https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.11500

674 Phase II study of pemetrexed, carboplatin and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small cell lung cancer: CALGB 30407

R. Govindan, J. A. Bogart, X. Wang, L. D. Hodgson, R. A. Kratzke, E. E. Vokes
J Clin Oncol vol 27 (15s) abstr 7505 2009

Abstract Respiratory

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID

675 A phase II study of pemetrexed, carboplatin and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non small cell lung cancer: CALGB 30407 early evaluation of feasibility and toxicity

R. Govindan, J. A. Bogart, X. Wang, D. Liu, R. A. Kratzke, E. E. Vokes
J Clin Oncol vol 26 (May 20 suppl) abstr 7518 2008

Abstract Respiratory

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID

676 Randomized Phase II Study of Pemetrexed, Carboplatin, and Thoracic Radiation With or Without Cetuximab in Patients With Locally Advanced Unresectable Non-Small-Cell Lung Cancer: Cancer and Leukemia Group B Trial 30407

Ramaswamy Govindan, Jeffrey Bogart, Thomas Stinchcombe, Xiaofei Wang, Lydia Hodgson, Robert Kratzke, Jennifer Garst, Timothy Brotherton, Everett E. Vokes
J Clin Oncol vol 29 (23) 3120-3125 2011

Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/21747084>

677 ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early Stage Non-Small Cell Lung Cancer

Ramaswamy Govindan, Sumithra J. Mandrekar, David E. Gerber, Geoffrey R. Oxnard, Suzanne E. Dahlberg, Shakun Malik, Margaret Mooney, Jeffrey S. Abrams, Pasi A. Jänne, David R. Gandara, Suresh S. Ramalingam, Everett E. Vokes Clin Cancer Res vol 21 (24) 5439-5444 2015
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/26672084>

678 A phase II study of carboplatin, etoposide, and exisulind in patients with extensive small cell lung cancer: CALGB 30104.

Ramaswamy Govindan, Xiaofei Wang, Maria Q Bagstrom, Susan Burdette-Radoux, Lydia Hodgson, Everett E Vokes, Mark R Green J Thorac Oncol vol 4 (2) 220-6 2009
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/19179900>

679 Combination Biologic Therapy as Initial Treatment for Follicular Lymphoma: Initial Results From CALGB 50701 - a Phase II Trial of Extended Induction Epratuzumab (anti-CD22) and Rituximab (anti-CD20)

B. Grant, J. P. Leonard, J. L. Johnson, L. Kostakoglu, E. Hsi, J. C. Byrd, J. A. Jones, S.-H. Jung, B. D. Cheson Blood vol 116 (21) -427 2010
Abstract Lymphoma <http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;116/21/427>

680 A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701.

Barbara W Grant, Sin-Ho Jung, Jeffrey L Johnson, Lale Kostakoglu, Eric Hsi, John C Byrd, Jeffrey Jones, John P Leonard, S Eric Martin, Bruce D Cheson Cancer vol 119 (21) 3797-804 2013
Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/23922187>

681 Menstrual Cycle and Surgical Treatment of Breast Cancer: Findings From the NCCTG N9431 Study

Clive S. Grant, James N. Ingle, Vera J. Suman, Daniel A. Dumesic, D. Lawrence Wickerham, Richard D. Gelber, Patrick J. Flynn, Lorna M. Weir, Mattia Intra, Wayne O. Jones, Edith A. Perez, Lynn C. Hartmann J Clin Oncol vol 27 (22) 3620-3626 2009
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/19487378>

682 Prognostic significance of molecular markers and clinical factors in stage IB non-small cell lung cancer (NSCLC): A laboratory companion study to CALGB 9633

S. L. Graziano, L. Gu, X. Wang, A. Tatum, R. T. Vollmer, G. M. Strauss, R. A. Kratzke, M. R. Green, E. E. Vokes J Thorac Oncol vol 2 (8) S403 2007
Abstract Correl Sci NOS CALGB-9633
http://journals.lww.com/jto/Fulltext/2007/08001/Prognostic_significance_of_molecular_markers_and.36

683 Cross-validation analysis of the prognostic significance of mucin expression in patients with resected non-small cell lung cancer (NSCLC) treated with adjuvant chemotherapy: Results from IALT, JBR.10 and ANITA

S. L. Graziano, J. P. Pignon, R. T. Vollmer, R. A. Kratzke, V. Soriano, M. Tsao, R. Rosell J Thorac Oncol vol 4 (9 suppl 1) abstr PD7.3.2 2009
Abstract Respiratory [http://www.jto.org/article/S1556-0864\(15\)33608-X/fulltext](http://www.jto.org/article/S1556-0864(15)33608-X/fulltext)

684 Dose-dense weekly paclitaxel (P) in extensive stage small cell lung cancer (ES-SCLC): Cancer and Leukemia Group B (CALGB) 39901

S. L. Graziano, M. A. Socinski, J. E. Herndon 2nd, D. M. Watson, M. R. Green Proc Am Soc Clin Oncol vol 22 Abstr 2598 2003
Abstract Respiratory
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=23&abstractID

685 LACE-Bio pooled analysis of the prognostic and predictive value of p53 mutations and

expression by Immunohistochemistry (IHC) in patients with resected Non-Small Cell Lung Cancer (NSCLC).

S. Graziano, E. Paris, X. Ma, J. Pignon, P. Hainaut, M. Taron, M. Tsao, B. Brambilla, J. Soria Ann Oncol vol 21 ((suppl 8): viii122-viii161) abstract 389P 2010
Abstract Respiratory http://annonc.oxfordjournals.org/content/21/suppl_8/viii122.full.pdf+html

686 Prognostic Significance of Mucin and p53 Expression in Stage IB Non-Small Cell Lung Cancer: A Laboratory Companion Study to CALGB 9633

Stephen L. Graziano, Lin Gu, Xiaofei Wang, Arthur H. Tatum, Robin T. Vollmer, Gary M. Strauss, Robert Kratzke, Arkadiusz Z. Dudek, Everett E Vokes, Mark R. Green J Thorac Oncol vol 5 (6) 810-817 2010
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/20521348>

687 Cross-validation analysis of the prognostic significance of mucin expression in patients with resected non-small cell lung cancer treated with adjuvant chemotherapy: results from IALT, JBR.10 and ANITA

Stephen L. Graziano, Benjamin Lacas, Robin Vollmer, Robert Kratzke, Helmut Popper, Martin Filipits, Lesley Seymour, Frances A. Shepherd, Rafael Rosell, Anne Sophie Veillard, Miquel Taron, Jean-Pierre Pignon Lung Cancer vol 82 (1) 149-155 2013
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/23920379>

688 Phase II trial of weekly dose-dense paclitaxel in extensive-stage small cell lung cancer: cancer and leukemia group B study 39901.

Stephen L Graziano, James E Herndon, Mark A Socinski, Xiaofei Wang, Dorothy Watson, Everett Vokes, Mark R Green J Thorac Oncol vol 3 (2) 158-62 2008
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/18303437>

689 Phase II randomized study of dose-dense docetaxel (Doc) and cisplatin (Cis) every two weeks with pegfilgrastim (Pfil) and darbepoetin alfa (Darb) with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (NSCLC)

M. R. Green, A. A. Miller, X. Wang, L. Gu, E. E. Vokes J Clin Oncol vol 25 (18s) abstr 7617 2007
Abstract Respiratory
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID

690 Local excision of distal rectal cancer: An update of Cancer and Leukemia Group B 8984

J. A. Greenberg, D. Shibata, J. E. Herndon 2nd, G. D. Steele Jr, R. J. Mayer, R. Bleday Am Soc Colon Rectal Surg vol 51 (8) abstr 8984 2008
Abstract GI
http://journals.lww.com/dcrjournal/Abstract/2008/51080/Local_Excision_of_Distal_Rectal_Cancer__An

691 Local excision of distal rectal cancer: an update of cancer and leukemia group B 8984.

Jacob A Greenberg, David Shibata, James E Herndon, Glenn D Steele, Robert Mayer, Ronald Bleday Dis Colon Rectum vol 51 (8) 1185-91; discussion 1191-4 2008
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/18536973>

692 Evaluating Treatment Tolerability in Cancer Clinical Trials Using the Toxicity Index

Gillian Gresham, Márcio A Diniz, Zahra S Razaee, Michael Luu, Sungjin Kim, Ron D Hays, Steven Piantadosi, Mourad Tighiouart, Greg Yothers, Patricia A Ganz, André Rogatko J Natl Cancer Inst vol 112 (12) 1266-74 2020
Manuscript Health Outcomes <http://www.ncbi.nlm.nih.gov/pubmed/32091598>

693 Treatment of Myelodysplastic Syndrome with Two Schedules and Doses of Oral Topotecan: A Randomized Phase II Trial by the Cancer and Leukemia Group B (CALGB 19803)

David L. Grinblatt, Daohai Yu, Vera Hars, James W. Vardiman, Bayard L. Powell, Sreenivasa Nattam, Lewis R. Silverman, Carlos de Castro, Richard M. Stone, Clara D. Bloomfield, Richard A. Larson
Cancer vol 115 (1) 84-93 2009
Manuscript Leukemia <http://www.ncbi.nlm.nih.gov/pubmed/19025972>

694 Accuracy of FDG-PET to diagnose lung cancer in the ACOSOG Z4031 trial

E. Grogan, S. Deppen, K. Ballman, G. Andrade, F. Verdail, M. Aldrich, H. Chen, P. Decker, D. Harpole, R. Cerfolio, R. Keenan, D. Jones, T. D'Amico, J. Shrager, B. Meyers, J. Putnam J Clin Oncol vol 30 (suppl) abstr 7008 2012
Abstract Respiratory <https://meetinglibrary.asco.org/content/94453-114>

695 Accuracy of FDG-PET within the clinical practice of the ACOSOG Z4031 trial to diagnose clinical stage I NSCLC

Eric L. Grogan, Stephen A. Deppen, Karla V. Ballman, Gabriela M. Andrade, Francys C. Verdial, Melinda C. Aldrich, Chiu L. Chen, Paul A. Decker, David H. Harpole, Rrobert J. Cerfolio, Robert J. Keenan, David R. Jones, Thomas A. D'Amico, Joseph B. Shrager, Bryan F. Meyers, Joe B. Putnam Ann Thorac Surg vol 97 (4) 1142-1148 2014
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/24576597>

696 New lesions vs. growth of existing disease: does it impact prognosis?

A. Grothey, J. M. Heun, M. Branda, R. M. Goldberg, D. J. Sargent J Clin Oncol vol 29 (suppl) abstr 2579 2011
Abstract GI <http://meetinglibrary.asco.org/content/82873-102>

697 Dual VEGF inhibition with sorafenib and bevacizumab (BEV) as salvage therapy in metastatic colorectal cancer (mCRC): results of the phase II North Central Cancer Treatment Group Study N054C

A. Grothey, J. M. Lafky, B. W. Morlan, P. J. Stella, S. R. Dakhil, P. D. Steen, W. S. Loui, B. M. Bot, S. R. Alberts, J. T. Reynolds J Clin Oncol vol 28 (15s) abstr 3549 2010
Abstract GI <http://meetinglibrary.asco.org/content/51133-74>

698 Baseline quality of life (QOL) is a strong and performance status (PS)-independent prognostic factor for overall survival (OS) in patients with metastatic colorectal cancer (mCRC)

A. Grothey, D. J. Sargent, W. Szydlo, X. Zhao, M. Campbell, R. M. Goldberg, J. Sloan Gastrointestinal Cancers Symposium abstr 334 2008
Abstract GI
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=53&abstractID

699 Duration of Adjuvant Chemotherapy for Stage III Colon Cancer

A. Grothey, A.F. Sobrero, A.F. Shields, T. Yoshino, J. Paul, J. Taieb, J. Souglakos, Q. Shi, R. Kerr, R. Labianca, J.A. Meyerhardt, D. Vernerey, T. Yamanaka, I. Boukovinas, J.P. Meyers, L.A. Renfro, D. Niedzwiecki, T. Watanabe, V. Torri, M. Saunders, D.J. Sargent, T. Andre, T. Iveson N Engl J Med vol 378 (13) 1177-88 2018
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/29590544>

700 Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107.

Axel Grothey, Eric E Hedrick, Robert D Mass, Somnath Sarkar, Sam Suzuki, Ramesh K Ramanathan, Herbert I Hurwitz, Richard M Goldberg, Daniel J Sargent J Clin Oncol vol 26 (2) 183-9 2008
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/18182660>

701 Intravenous Calcium and Magnesium for Oxaliplatin-Induced Sensory Neurotoxicity in Adjuvant Colon Cancer: NCCTG N04C7

Axel Grothey, Daniel A. Nikcevich, Jeff A. Sloan, John W. Kugler, Peter T. Silberstein, Todor Dentchev, Donald B. Wender, Paul J. Novotny, Umesh Chitale, Steven R. Alberts, Charles L. Loprinzi *J Clin Oncol* vol 29 (4) 421-427 2011
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/21189381>

702 Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration

Axel Grothey, Alberto F. Sobrero, Jeffrey A. Meyerhardt, Takayuki Yoshino, James Paul, Julien Taieb, Ioannis Souglakos, Rachel Kerr, Roberto Labianca, Anthony F. Shields, Franck Bonnetain, Toshiaki Watanabe, Ioannis Boukovinas, Qian Shi, Lindsay A. Renfro, Donna Niedzwiecki, Valter Torri, Daniel J. Sargent, Thierry Andre, Timothy Iveson *Annals of Oncology* vol 28 (suppl_5) v605-v649 2017
Abstract GI CALGB-80702
<http://oncologypro.esmo.org/Meeting-Resources/ESMO-2017-Congress/Prospective-pooled-analysis-of->

703 Determination of Utility Scores for Control of Chemotherapy-Induced Nausea or Vomiting—CALGB 309801

S. M. Grunberg, J. Weeks, W. F. Magnan, J. Herndon 2nd, M. L. Naughton, K. L. Blackwell, M. E. Wood, D. L. Christian, M. C. Perry, E. C. Dees, E. Reed, M. E. Marshall *J Support Oncol* vol 7 (5) W17 - W22 2009
Manuscript Disparities

704 Electronic Geriatric Assessment: Is It Feasible in a Multi-Institutional Study That Included a Notable Proportion of Older African American Patients? (Alliance A171603)

Emily Guerard, Andrew B. Dodge, Jennifer G. Le-Rademacher, M. Margaret Kemeny, Michael Ojelabi, Mina S. Sedrak, Judith Hopkins, Armin Shahrokni, Elizabeth Harlos, Hyman Muss, Harvey Jay Cohen, Jacqueline Lafky, Jeff Sloan, Aminah Jatoi, Arti Hurria *JCO Clin Cancer Inform* vol 5 435-41 2021
Manuscript Older Adult <http://www.ncbi.nlm.nih.gov/pubmed/33852323>

705 Coffee Intake, Recurrence, and Mortality in Stage III Colon Cancer: Results From CALGB 89803 (Alliance)

Brendan J. Guercio, Kaori Sato, Donna Niedzwiecki, Xing Ye, Leonard B. Saltz, Robert J. Mayer, Rex B. Mowat, Renaud Whittom, Alexander Hantel, Al Benson, Daniel Atienza, Michael Messino, Hedy Kindler, Alan Venook, Frank B. Hu, Shuji Ogino, Kana Wu, Walter C. Willett, Edward L. Giovannucci, Jeffrey A. Meyerhardt, Charles S. Fuchs *J Clin Oncol* vol 33 (31) 3598-3607 2015
Manuscript Prevention <http://www.ncbi.nlm.nih.gov/pubmed/26282659>

706 Associations of Physical Activity with Survival and Progression in Metastatic Colorectal Cancer: Results from CALGB 80405 (Alliance)

Brendan J. Guercio, Alan P. Venook, Donna Niedzwiecki, Sui Zhang, Kaori Sato, Charles Fuchs, Heinz-Josef Lenz, Federico Innocenti, Michelle R. Mahoney, Bert H. O'Neil, James Edward Shaw, Blase N. Polite, Howard S. Hochster, James Norman Atkins, Richard M. Goldberg, Robert J. Mayer, Monica M. Bertagnolli, Charles D. Blanke, Jeffrey A. Meyerhardt *J Clin Oncol* vol 35 (suppl 4S) abstr 659 2017
Abstract GI http://abstracts.asco.org/195/AbstView_195_175855.html

707 Associations of Insulin-Like Growth Factor Binding Proteins and Adiponectin with Disease Progression and Mortality in Metastatic Colorectal Cancer: Results from CALGB/SWOG 80405 (Alliance)

Brendan J. Guercio, Alan P. Venook, Sui Zhang, Fang-Shu Ou, Donna Niedzwiecki, Heinz-Josef Lenz, Federico Innocenti, Michael Pollak, Andrew Nixon, Michelle R. Mahoney, Bert H. O'Neil, James E. Shaw, Blase N. Polite, Crystal Denlinger, James N. Atkins, Richard M. Goldberg, Robert J. Mayer,

Charles D. Blanke, Charles S. Fuchs, Jeffrey A. Meyerhardt J Clin Oncol vol 37 (15_suppl) 3035-3035 2019

Abstract GI https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.3035

708 Associations of artificially sweetened beverage intake with disease recurrence and mortality in stage III colon cancer: Results from CALGB 89803 (Alliance)

Brendan J. Guercio, Sui Zhang, Donna Niedzwiecki, Yanping Li, Ana Babic, Vicente Morales-Oyarvide, Leonard B. Saltz, Robert J. Mayer, Rex B. Mowat, Renaud Whittom, Alexander Hantel, Al Benson III, Daniel Atienza, Michael Messino, Hedy Kindler, Alan Venook, Shuji Ogino, Emilie S. Zoltick, Meir Stampfer, Kimmie Ng, Kana Wu, Walter C. Willett, Edward L. Giovannucci, Jeffrey A. Meyerhardt, Charles S. Fuchs PLoS ONE vol 13 (7) e0199244 2018
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/30024889>

709 Body mass index, weight loss, and progression and mortality in metastatic colorectal cancer (Alliance)

Brendan J. Guercio, Sui Zhang, Alan P. Venook, Fang-Shu Ou, Donna Niedzwiecki, Heinz-Josef Lenz, Federico Innocenti, Michelle R. Mahoney, Bert H. O'Neil, James E. Shaw, Blase N. Polite, Howard S. Hochster, James N. Atkins, Richard M. Goldberg, Robert J. Mayer, Charles D. Blanke, Charles S. Fuchs, Jeffrey A. Meyerhardt Cancer Res vol 79 (13) abst 3285 2019
Abstract GI https://cancerres.aacrjournals.org/content/79/13_Supplement/3285

710 Associations of Physical Activity With Survival and Progression in Metastatic Colorectal Cancer: Results From Cancer and Leukemia Group B (Alliance)/SWOG 80405.

Brendan J Guercio, Sui Zhang, Fang-Shu Ou, Alan P Venook, Donna Niedzwiecki, Heinz-Josef Lenz, Federico Innocenti, Bert H O'Neil, James E Shaw, Blase N Polite, Howard S Hochster, James N Atkins, Richard M Goldberg, Kaori Sato, Kimmie Ng, Erin Van Blarigan, Robert J Mayer, Charles D Blanke, Eileen M O'Reilly, Charles S Fuchs, Jeffrey A Meyerhardt J Clin Oncol vol 37 (29) 2620-31 2019
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/31408415>

711 IGF-Binding Proteins, Adiponectin, and Survival in Metastatic Colorectal Cancer: Results From CALGB (Alliance)/SWOG 80405

Brendan J Guercio, Sui Zhang, Fang-Shu Ou, Alan P Venook, Donna Niedzwiecki, Heinz-Josef Lenz, Federico Innocenti, Michael N Pollak, Andrew B Nixon, Brian C Mullen, Bert H O'Neil, James E Shaw, Blase N Polite, Al Bowen Benson III, James N Atkins, Richard M Goldberg, Justin C Brown, Eileen M O'Reilly, Robert J Mayer, Charles D Blanke, Charles S Fuchs, Jeffrey A Meyerhardt JNCI Cancer Spectr vol 5 (1) 2020
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/33426464>

712 Body Mass Index and Weight Loss in Metastatic Colorectal Cancer in CALGB (Alliance)/SWOG 80405

Brendan J Guercio, Sui Zhang, Alan P Venook, Fang-Shu Ou, Donna Niedzwiecki, Heinz-Josef Lenz, Federico Innocenti, Brian C Mullen, Bert H O'Neil, James E Shaw, Blase N Polite, Howard S Hochster, James N Atkins, Richard M Goldberg, Justin C Brown, Eileen M O'Reilly, Robert J Mayer, Charles D Blanke, Charles S Fuchs, Jeffrey A Meyerhardt JNCI Cancer Spectr vol 4 (3) 2020
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/33134818>

713 A Phase II Study of the Oral VEGF Receptor Tyrosine Kinase Inhibitor Vatalanib (PTK787/ZK222584) in Myelodysplastic Syndrome: Cancer and Leukemia Group B Study 10105 (Alliance)

Pankaj Gupta, Flora Mulkey, Robert P. Hasserjian, Ben L. Sanford, Ravi Vij, David D. Hurd, Olatoyosi M. Odenike, Clara D. Bloomfield, Kouros Owzar, Richard M. Stone, Richard A. Larson Invest New Drugs vol 31 (5) 1311-1320 2013

714 MAIN-CAV: Phase III randomized trial of maintenance cabozantinib (CABO) and avelumab versus Avelumab after first-line platinum-based chemotherapy in patients with metastatic urothelial cancer (mUC) (Alliance A032001).

Shilpa Gupta, Matthew D. Galsky, Michael J. Morris, Karla V. Balman, Ronald Chen, Timothy M. Chan, Laurent Derclé, Tareq Al-Baghdadi, Srikala Sridhar, Aihua Edward Yen, Petros Grivas, Shiva Baghaie, Alan Tan, Jonathan E. Rosenberg *J Clin Oncol* vol 40 (16_suppl) TPS4607 2022

Abstract GU https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.TPS4607

715 Dual Epigenetic Control of CCAAT/Enhancer Binding Protein {alpha} (C/EBP{alpha}) Expression in Acute Myeloid Leukemia

B. Hackanson, K. L. Bennett, R. M. Brena, J. Jiang, K. Maharry, S. P. Whitman, T. D. Schmittgen, M. Luebbert, G. Marcucci, C. D. Bloomfield, C. Plass *Blood* vol 110 (11) 2116 2007

Abstract *Leuk Corr Sci* CALGB-19808, CALGB-20502, CALGB-8461, CALGB-9621, CALGB-9665 <http://www.bloodjournal.org/content/110/11/2116>

716 Epigenetic modification of CCAAT/enhancer binding protein alpha expression in acute myeloid leukemia.

Björn Hackanson, Kristi L Bennett, Romulo M Brena, Jinmai Jiang, Rainer Claus, Shih-Shih Chen, Nadya Blagitko-Dorfs, Katie Maharry, Susan P Whitman, Thomas D Schmittgen, Michael Lübbert, Guido Marcucci, Clara D Bloomfield, Christoph Plass *Cancer Res* vol 68 (9) 3142-51 2008

Manuscript *Leuk Corr Sci* CALGB-8461, CALGB-9665
<http://www.ncbi.nlm.nih.gov/pubmed/18451139>

717 Persistent Fatigue in Hematopoietic Stem Cell Transplantation Survivors

Eileen Danaher Hacker, Anne M. Fink, Tara Peters, Chang Park, Giamila Fantuzzi, Damiano Rondelli *Cancer Nurs* vol 40 (3) 174-183 2017

Manuscript *Symptom Inter* <http://www.ncbi.nlm.nih.gov/pubmed/27333126>

718 Persistent Fatigue in Stem Cell Transplant Survivors: A Biobehavioral Perspective

Eileen Danaher Hacker, Anne Fink, Tara Peters, Chang Park, Giamila Fantuzzi, Damiano Rondelli *Biol Blood Marrow Transplant* vol 21 (2) S126 2015

Abstract *Symptom Inter* [http://www.bbmt.org/article/S1083-8791\(14\)00875-1/pdf](http://www.bbmt.org/article/S1083-8791(14)00875-1/pdf)

719 Real-Time Fatigue and Free-Living Physical Activity in Hematopoietic Stem Cell Transplantation Cancer Survivors and Healthy Controls: A Preliminary Examination of the Temporal, Dynamic Relationship

Eileen Danaher Hacker, Inah Kim, Chang Park, Tara Peters *Cancer Nurs* vol 40 (4) 259-268 2017

Manuscript *Health Outcomes* <http://www.ncbi.nlm.nih.gov/pubmed/27922918>

720 Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and Chemotherapy: NCCTG N0733 (Alliance)

Tufia C. Haddad, Jun He, Ciara C. O'Sullivan, Beiyun Chen, Donald Northfelt, Amylou C. Dueck, Karla V. Ballman, Kathleen S. Tenner, Hannah Linden, Joseph A. Sparano, Judith O. Hopkins, Chamath De Silva, Edith A. Perez, Paul Haluska, Matthew P. Goetz *Breast Cancer Res Treat* vol 188 (2) 477-87 2021

Manuscript *Breast* <http://www.ncbi.nlm.nih.gov/pubmed/33852121>

721 Phase II study of oxaliplatin, 5-FU and RT followed by gemcitabine in patients with unresectable pancreatic cancer.

M. Haddock, G. Kim, N. Foster, J. Bollinger, P. Stella, J. Kugler, S. Dakhil, S. Alberts

722 Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: results of the North Central Cancer Treatment Group Phase II Study N9942.

Michael G Haddock, Revathi Swaminathan, Nathan R Foster, Mark D Hauge, James A Martenson, John K Camoriano, Philip J Stella, Richard C Tenglin, Paul L Schaefer, Dennis F Moore, Steven R Alberts J Clin Oncol vol 25 (18) 2567-72 2007

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/17577035>

723 Impact of radiation on local regional control in women with node positive breast cancer treated with neoadjuvant chemotherapy and axillary lymph node dissection: Results from ACOSOG 1071 Clinical Trial

Bruce G. Haffty, Linda M. McCall, Karla V. Ballman, Thomas A. Buchholz, Kelly K. Hunt, Judy C. Boughey Int J Radiat Oncol Biol Phys vol 105 (1) 174-82 2019

Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/31085287>

724 Radiation use and field design in women with node positive breast cancer treated with preoperative systemic therapy and breast surgery including axillary dissection on a prospective clinical trial ACOSOG Z1071 [Alliance]

Bruce G. Haffty, Linda M. McCall, Karla V. Ballman, Kelly K. Hunt, Thomas A. Buchholz, Judy C. Boughey Int J Radiation Biol Physics vol 93 (3) abstr S136 2015

Abstract Breast <http://www.redjournal.org/article/S0360-3016%2815%2901055-X/abstract>

725 Patterns of local-regional management following neoadjuvant chemotherapy in breast cancer: Results from ACOSOG Z1071 (Alliance)

Bruce G. Haffty, Linda M. McCall, Karla V. Ballman, Sarah McLaughlin, Reshma Jagsi, David W. Ollila, Kelly K. Hunt, Thomas A. Buchholz, Judy C. Boughey Int J Radiat Oncol Biol Phys vol 94 (3) 493-502 2016

Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/26867878>

726 Impact of radiation on local regional control in women with node positive breast cancer treated with neoadjuvant chemotherapy (NAC) and axillary lymph node dissection (ALND); results from ACOSOG Z1071 (Alliance)

Bruce Haffty, Karla Ballman, Kelly Hunt, Linda McCall, Judy C. Boughey Int J Radiat Oncol Biol Phys vol 96 (2 suppl) S144 2016

Abstract Breast [http://www.redjournal.org/article/S0360-3016\(16\)30676-9/abstract](http://www.redjournal.org/article/S0360-3016(16)30676-9/abstract)

727 Optimal Two-Stage Dynamic Treatment Regimes from a Classification Perspective with Censored Survival Data

Rebecca Hager, Anastasios A. Tsiatis, Marie Davidian Biometrics vol 74 (4) 1180-92 2018

Manuscript Leukemia <http://www.ncbi.nlm.nih.gov/pubmed/29775203>

728 LACE-Bio Pooled Analysis of the Prognostic and Predictive Value of TP53 mutations in Completely Resected Non Small Cell Lung Cancer (NSCLC)

P. Hainaut, X. Ma, B. Lacas, M. Tsao, J.-Y. Douillard, V. Rousseau, A. Dunant, L. Seymour, M. Filipits, S. Graziano 2012

Abstract Respiratory

729 Relationship of opioid analgesic (OA) use at 3 months and overall survival in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

S. Halabi, W. K. Kelly, E. B. Kaplan, E. J. Small J Clin Oncol vol 30 (suppl 5) abstr 200 2012

730 A novel intermediate endpoint for predicting overall survival in men with metastatic castration-recurrent prostate cancer (CRPC)

S. Halabi, S. Ou, N. J. Vogelzang, H. I. Scher, E. J. Small J Clin Oncol vol 25 (18s) 5113 2007
Abstract GU

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=46&abstractID

731 Is progression free survival a predictor of overall survival in men with castration recurrent prostate cancer (CRPC)?

S. Halabi, S. Ou, N. J. Vogelzang, E. J. Small 2008

Abstract GU CALGB-9181, CALGB-9182, CALGB-90004, CALGB-90006, CALGB-9583, CALGB-9680, CALGB-9780, CALGB-99813, INT-0159

732 Use of progression-free survival (PFS) to predict overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)

S. Halabi, B. I. Rini, W. M. Stadler, L. E. Archer, E. J. Small J Clin Oncol vol 28 (15s) abstr 4525 2010

Abstract GU

http://jco.ascopubs.org/gca?gca=ascomtg%3B28%2F15_suppl%2F4525&allch=&submit=Go

733 Pain interference scores at 6-weeks from baseline and overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC)

S. Halabi, N. J. Vogelzang, A. B. Kornblith, L. E. Archer, P. W. Kantoff, N. A. Dawson, E. J. Small Genitourinary Cancers Symposium abstr 168 2009

Abstract GU CALGB-9181, CALGB-9182, INT-0159

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=64&abstractID

734 Identification of prognostic and predictive biomarkers of overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with docetaxel, prednisone (DP) +/- bevacizumab (B) in CALGB 90401 (Alliance)

S Halabi, Q. Yang, Mark D Starr, John C Brady, A.J. Armstrong, D. George, WK Kelly, H Beltran, M. Morris, AB Nixon J Clin Oncol vol 39 (6_suppl) 154 2021

Abstract GU https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.6_suppl.154

735 Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer

Susan Halabi, William Kevin Kelly, Hua Ma, Haojin Zhou, Nicole C. Solomon, Karim Fizazi, Catherine M. Tangen, Mark Rosenthal, Daniel P. Petrylak, Maha Hussain, Nicholas J. Vogelzang, Ian M. Thompson, Kim N. Chi, Johann de Bono, Andrew J. Armstrong, Mario A. Eisenberger, Abderrahim Fandi, Shaoyi Li, John C. Araujo, Christopher J. Logothetis, David I. Quinn, Michael J. Morris, Celestia S. Higano, Ian F. Tannock, Eric J. Small J Clin Oncol vol 34 (14) 1652-1659 2016
Manuscript GU <http://www.ncbi.nlm.nih.gov/pubmed/26951312>

736 The site of visceral metastases (mets) to predict overall survival (OS) in castration-resistant prostate cancer (CRPC) patients (pts): A meta-analysis of five phase III trials.

Susan Halabi, William Kevin Kelly, Haojin Zhou, Andrew J. Armstrong, David Quinn, Karim Fizazi, Nicole C Solomon, Ian Tannock, Daniel Peter Petrylak, Michael J. Morris, Eric Jay Small J Clin Oncol vol 32 (5s) (suppl; abstr 5002) 2014

Abstract GU CALGB-90401, SWOG-S9916

http://abstracts.asco.org/144/AbstView_144_129874.html

737 Updated Prognostic Model for Predicting Overall Survival in First-Line Chemotherapy for

Patients With Metastatic Castration-Resistant Prostate Cancer

Susan Halabi, Chen-Yen Lin, W. Kevin Kelly, Karim S. Fizazi, Judd W. Moul, Ellen B. Kaplan, Michael J. Morris, Eric J. Small *J Clin Oncol* vol 32 (7) 671-677 2014
Manuscript GU <http://www.ncbi.nlm.nih.gov/pubmed/24449231>

738 A prognostic model for predicting overall survival in metastatic castrate-resistant prostate cancer (mCRPC) men treated with second-line chemotherapy

Susan Halabi, Chen-Yen Lin, Eric J. Small, Andrew J. Armstrong, Ellen B. Kaplan, Daniel P. Petrylak, Cora N. Sternberg, Liji Shen, Stephane Oudard, Johann S. De Bono, Sartor A. Oliver *J Clin Oncol* vol 31 (suppl, abstr 5011) 2013
Abstract GU <http://meetinglibrary.asco.org/content/110602-132>

739 Inverse correlation between body mass index and clinical outcomes in men with advanced castration-recurrent prostate cancer.

Susan Halabi, San-San Ou, Nicholas J Vogelzang, Eric J Small *Cancer* vol 110 (7) 1478-84 2007
Manuscript GU CALGB-9181, CALGB-9182, CALGB-90004, CALGB-90006, CALGB-9583, CALGB-9680, CALGB-9780, CALGB-99813 <http://www.ncbi.nlm.nih.gov/pubmed/17665494>

740 Progression-Free Survival (PFS) as a Surrogate Endpoint of Overall Survival (OS) in Patients with Metastatic Renal Cell Carcinoma (mRCC)

Susan Halabi, Brian Rini, Bernard Escudier, Walter M. Stadler, Eric J. Small *Cancer* vol 120 (1) 2014
Manuscript GU <http://www.ncbi.nlm.nih.gov/pubmed/24347384>

741 Progression-Free Survival as a Predictor of Overall Survival in Men With Castrate-Resistant Prostate Cancer

Susan Halabi, Nicholas J. Vogelzang, San-San Ou, Kouros Owzar, Laura Archer, Eric J. Small *J Clin Oncol* vol 27 (17) 2766-2771 2009
Manuscript GU <http://www.ncbi.nlm.nih.gov/pubmed/19380448>

742 Pain predicts overall survival in men with metastatic castration-refractory prostate cancer.

Susan Halabi, Nicholas J Vogelzang, Alice B Kornblith, San-San Ou, Philip W Kantoff, Nancy A Dawson, Eric J Small *J Clin Oncol* vol 26 (15) 2544-9 2008
Manuscript GU CALGB-9181, CALGB-9182 <http://www.ncbi.nlm.nih.gov/pubmed/18487572>

743 The impact of prior radical prostatectomy in men with metastatic castration recurrent prostate cancer: a pooled analysis of 9 Cancer and Leukemia Group B Trials.

Susan Halabi, Nicholas J Vogelzang, San-San Ou, Eric J Small *J Urol* vol 177 (2) 531-4 2007
Manuscript GU CALGB-9181, CALGB-9182, CALGB-90004, CALGB-9000, CALGB-9583, CALGB-9680, CALGB-9780, CALGB-99813, INT-0159
<http://www.ncbi.nlm.nih.gov/pubmed/17222627>

744 A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance)

Thorvardur R. Halfdanarson, Nathan R. Foster, George P. Kim, Jeffrey P. Meyers, Thomas C. Smyrk, Ann E. McCullough, Matthew M. Ames, Jeffrey P. Jaffe, Steven R. Alberts *Oncologist* vol 24 (5) 589-e160 2019
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/30679315>

745 N064A (Alliance): Phase II Study of Panitumumab, Chemotherapy, and External Beam Radiation in Patients with Locally Advanced Pancreatic Adenocarcinoma

Thorvardur R Halfdanarson, Nathan R Foster, George P Kim, Michael G Haddock, Shaker R Dakhil,

- 746 N0733: Phase II trial of capecitabine and lapatinib +/- cixutumumab in HER2 positive breast cancer**
P. Haluska, M. M. Reinholz, A. C. Dueck, H. M. Linden, W. L. Lingle, A. M. Bernath Jr, M. C. Arbushites, H. Youssoufian, H. X. Chen, E. A. Perez J Clin Oncol vol 28 (15s) abstr TPS129 2010
Abstract Breast http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID
- 747 Randomized phase II trial of capecitabine and lapatinib with or without cixutumumab in patients with HER2+ breast cancer previously treated with trastuzumab and an anthracycline and/or a taxane: NCCTG N0733 (Alliance).**
Paul Haluska, Albert M. Bernath, Karla V. Ballman, Amylou C. Dueck, Hannah M. Linden, Matthew P. Goetz, Donald W. Northfelt, Xiaonan Hou, Kathleen S. Tenner, Piyawan Tienchaiananda, Lynn M. Flickinger, Beiyun Chen, Helen X. Chen, Wilma L. Lingle, Christine M. Pellegrino, Robert W. Sponzo, Monica Madden Reinholz, Edith A. Perez J Clin Oncol vol 32 (5s) suppl; abstr 632) 2014
Abstract Breast <http://meetinglibrary.asco.org/content/132004-144>
- 748 Impact of Adjuvant Trastuzumab on Local Regional Recurrence; Data from the NCCTG N9831 study.**
M. Y. Halyard, A. C. Dueck, T. M. Pisansky, S. A. Mclaughlin, L. J. Pierce, L. B. Marks, L. J. Solon, B. A. Pockaj, E. A. Perez Cancer Res vol 70 (24) abstr P5-13-02 2010
Abstract Breast http://cancerres.aacrjournals.org/content/70/24_Supplement/P5-13-02
- 749 Assessing the clinical significance of real-time Quality of Life (QOL) data in cancer patients treated with radiation therapy**
M. Y. Halyard, A. D. Tan, M. D. Callister, J. B. Ashman, S. A. Vora, W. Wong, S. E. Schild, P. J. Atherton, J. A. Sloan J Clin Oncol vol 28 (15s) abstr 9107 2010
Abstract Health Outcomes <http://meetinglibrary.asco.org/content/53556-74>
- 750 Changes in left ventricular function after radiation therapy and trastuzumab: analysis of North Central Cancer Treatment Group Phase III Trial N9831.**
M. Halyard, T. M. Pisansky, L. J. Pierce, L. J. Solin, L. B. Marks, K. S. Tenner, A. C. Dueck, E. A. Perez Int J Radiat Oncol Biol Phys vol 75 (3s) S50 2009
Abstract Breast [http://www.redjournal.org/article/S0360-3016\(09\)01178-X/abstract](http://www.redjournal.org/article/S0360-3016(09)01178-X/abstract)
- 751 Radiotherapy and Adjuvant Trastuzumab in Operable Breast Cancer: Tolerability and Adverse Event Data From the NCCTG Phase III Trial N9831**
Michele Y. Halyard, Thomas M. Pisansky, Amylou C. Dueck, Vera Suman, Lori Pierce, Larry Solin, Larry Marks, Nancy Davidson, Silvana Martino, Peter Kaufman, Leila Kutteh, Shaker R. Dakhil, Edith A. Perez J Clin Oncol vol 27 (16) 2638-2644 2009
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/19349549>
- 752 Local control after resection and adjuvant radiosurgery compared to radiosurgery alone for brain metastasis: Exploratory analysis of Alliance NCCTG N107C**
Chase C. Hansen, Karla V. Ballman, S. Keith Anderson, Paul D. Brown, Xiomara W. Carrero, Jane H. Cerhan, Anthony C. Whitton, Jeffrey Greenspoon, Ian F. Parney, Nadia N. Laack, Jonathan B. Ashman, Jean-Paul Bahary, Costas G. Hadjipanayis, James J. Urbanic, Fred G. Barker II, Elana Farace, Deepak Khuntia, Caterina Giannini, Jan C Buckner, Evanthis Galanis, David Roberge, Stephanie E. Weiss Int J Radiation Biol Physics vol 108 (Supplement) e749-e750 2020
Abstract Neuro-Onc [https://www.redjournal.org/article/S0360-3016\(20\)31586-8/abstract](https://www.redjournal.org/article/S0360-3016(20)31586-8/abstract)

- 753 Race-Ethnic Enrollment Disparities over 15 Years of Alliance/CALGB Acute Myeloid Leukemia Clinical Trials, Biobanks, and Correlative Science Protocols**
Andrew Hantel, Jessica Kohlschmidt, Ann-Kathrin Eisfeld, Wendy Stock, Sawyer Jacobson, Sumithra J Mandrekar, Richard M. Stone, Daniel J. DeAngelo, John C. Byrd, Gregory A. Abel Blood vol 138 (suppl 1) abstr 111 2021
Abstract Leuk Corr Sci CALGB-10001, CALGB-10101, CALGB-10201, CALGB-10403, CALGB-10502, CALGB-10503, CALGB-10603, CALGB-10701, CALGB-10801, CALGB-11002, CALGB-8461, CALGB-9665, CALGB-9720
<https://ashpublications.org/blood/article/138/Supplement%201/111/478061/Race-Ethnic-Enrollment-Dis>
- 754 Inequities in Alliance Acute Leukemia Clinical Trial and Biobank Participation: Defining Targets for Intervention**
Andrew Hantel, Jessica Kohlschmidt, Ann-Kathrin Eisfeld, Wendy Stock, Sawyer Jacobson, Sumithra Mandrekar, Richard A. Larson, Richard M. Stone, Christopher S. Lathan, Daniel J. DeAngelo, John C. Byrd, Gregory A. Abel J Clin Oncol vol 40 (32) 3709-18 2022
Manuscript Leuk Corr Sci CALGB-10001, CALGB-10102, CALGB-10201, CALGB-10403, CALGB-10502, CALGB-10603, CALGB-10701, CALGB-10801, CALGB-11001, CALGB-11002, CALGB-19801, CALGB-19802, CALGB-9720, CALGB-19808, CALGB-8461, CALGB-9665
<http://www.ncbi.nlm.nih.gov/pubmed/35696629>
- 755 Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer.**
Svasti Haricharan, Nindo Punturi, Purba Singh, Kimberly R Holloway, Meenakshi Anurag, Jacob Schmelz, Cheryl Schmidt, Jonathan T Lei, Vera Suman, Kelly Hunt, John A Olson, Jeremy Hoog, Shunqiang Li, Shixia Huang, Dean P Edwards, Shyam M Kavuri, Matthew N Bainbridge, Cynthia X Ma, Matthew J Ellis Cancer Discov vol 7 (10) 1168-83 2017
Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/28801307>
- 756 Proteomic analysis for detection of NSCLC: Results of ACOSOG Z4031**
D. Harpole, K. V. Ballman, A. L. Oberg, G. Whiteley, R. Cerfolio, R. Keenan, D. R. Jones, T. A. D'Amico, J. Shrager, J. B. Putnam Jr, American College of Surgeons Oncology Group J Clin Oncol vol 29 (15_suppl) 7003 2011
Abstract Respiratory http://meeting.ascopubs.org/cgi/content/abstract/29/15_suppl/7003
- 757 Genome-wide profiling of archived material from CALGB 9840 and 9342 for paclitaxel (P) and trastuzumab (T) response biomarkers using gene expression and copy number analysis**
L. N. Harris, J. R. Parker, G. Broadwater, V. Schulz, K. T. Halligan, K. Geyda, A. D. Seidman, D. A. Berry, E. P. Winer, C. A. Hudis, M. J. Ellis, A. Kraznitz, J. Hicks, D. Tuck, C. M. Perou Cancer Res vol 69 (24, suppl 3) abstr SABCS-09-4032 2009
Abstract PPP CALGB-9342, CALGB-9840, CALGB-159806
http://cancerres.aacrjournals.org/cgi/content/abstract/69/24_MeetingAbstracts/4032
- 758 Topoisomerase II Amplification Does Not Predict Benefit From Dose-Intense Cyclophosphamide, Doxorubicin, and Fluorouracil Therapy in HER2-Amplified Early Breast Cancer: Results of CALGB 8541/150013**
Lyndsay N. Harris, Gloria Broadwater, Maysa Abu-Khalaf, David Cowan, Ann D. Thor, Daniel Budman, Constance T. Cirrincione, Donald A. Berry, Eric P. Winer, Clifford A. Hudis, Daniel F. Hayes, Paula Friedman, Matthew Ellis, Lynn Dressler J Clin Oncol vol 27 (21) 3430-3436 2009
Manuscript Correl Sci NOS CALGB-8541 <http://www.ncbi.nlm.nih.gov/pubmed/19470942>
- 759 Evaluating the effect of tobacco on prostate cancer outcomes with VEGF-targeted therapy**
A. L. Harzstark, S. Halabi, W. K. Kelly, M. J. Morris, P. G. Febbo, E. J. Small J Clin Oncol vol 30 (suppl 5) abstr 129 2012

Abstract GU

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=116&abstractID

760 Hypertension is associated with clinical outcome for patients (Pts) with metastatic renal cell carcinoma (RCC) treated with interferon and bevacizumab on CALGB 90206

A. L. Harzstark, S. Halabi, W. M. Stadler, D. A. Vaena, J. N. Atkins, J. Picus, P. Czakowski, J. Dutcher, B. I. Rini, E. J. Small Genitourinary Cancers Symposium abstr 351 2010

Abstract GU

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=73&abstractID

761 Application of 2008 WHO classification criteria for myelodysplastic syndromes (MDS) without excess blasts: Observations from Cancer and Leukemia Group B Study 10105

R. Hasserjian, P. Gupta, K. A. Donohue, K. Owzar, R. A. Larson, F. K. Racke, C. D. Bloomfield United States and Canadian Academy of Pathology Annual Meeting vol 22 (suppl 1) abstr 1208 2009

Abstract Leuk Corr Sci http://www.abstracts2view.com/uscap09/view.php?nu=USCAP09L_1208

762 A comparison of two methodologies to quantify Thymidylate synthase for predicting survival in patients with colorectal cancer treated on CALGB 89803

R. M. Hasson, D. Niedzwiecki, M. M. Bertagnoli Cancer Res vol 72 (8, Supplement 1) Abstract 4514 2012

Abstract GI http://cancerres.aacrjournals.org/content/72/8_Supplement/4514.short

763 On-treatment changes of plasma protein biomarkers in CALGB/SWOG 80405 (Alliance)

Ace J. Hatch, Fang-Shu Ou, Tyler Zemla, Liu, Mark D. Star, J. Chris Brady, Yingmiao, Federico Innocenti, Michael Morris, Jeffrey A. Meyerhardt, Eileen O'Reilly, Heinz-Josef Lenz, Herbert I. Hurwitz, Alan Venook, Andrew B. Nixon J Clin Oncol vol 37 (4 suppl) 588 2019

Abstract GI https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.4_suppl.588

764 Bloodbased markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance)

Ace J. Hatch, Alexander B. Sibley, Mark D. Starr, J. Chris Brady, Chen Jiang, Jingquan Jia, Daniel L. Bowers, Herbert Pang, Kouros Owzar, Donna Niedzwiecki, Federico Innocenti, Alan P. Venook, Herbert I. Hurwitz, Andrew B. Nixon Cancer Med vol 5 (9) 2249-2260 2016

Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/27465221>

765 Prognostic and predictive blood-based biomarkers of overall survival (OS) in patients (pts) with advanced colorectal cancer (CRC) treated with cetuximab (C): Results from CALGB 80203 (Alliance).

Ace Joseph Hatch, Herbert Pang, Mark D. Starr, John C. Brady, Jingquan Jia, Chen Jiang, Alexander Sibley, Kouros Owzar, Donna Niedzwiecki, Alan P. Venook, Stephanie M. Cushman, Herbert Hurwitz, Andrew B. Nixon J Clin Oncol vol 32 (5s) (suppl; abstr 11022) 2014

Abstract GI http://abstracts.asco.org/144/AbstView_144_129964.html

766 Genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer

Christos Hatzis, Lajos Pusztai, Vicente Valero, Daniel J. Booser, Laura Esserman, Ana Lluch, Tatiana Vidaurre, Frankie Holmes, Eduardo Souchon, Miguel Martin, José Cotrina, Henry Gomez, Rebekah Hubbard, J. Ignacio Chacón, Jaime Ferrer-Lozano, Richard Dyer, Meredith Buxton, Yun Gong, Yun Wu, Nuhad Ibrahim, Eleni Andreopoulou, Naoto T. Ueno, Kelly Hunt, Wei Yang, Arlene Nazario, Angela DeMichele, Joyce O'Shaughnessy, Gabriel N. Hortobagyi, W. Fraser Symmans JAMA vol 305 (18) 1873-1881 2011

Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/21558518>

767 Implications of the miR-10 family in chemotherapy response of NPM1-mutated AML

Violaine Havelange, Parvathi Ranganathan, Susan Geyer, Deedra Nicolet, Xiaomeng Huang, Xueyan Yu, Stefano Volinia, Steven M. Kornblau, Michael Andreeff, Carlo M. Croce, Guido Marcucci, Clara D. Bloomfield, Ramiro Garzon Blood vol 123 (15) 2412-2415 2014
Manuscript Leuk Corr Sci CALGB-8525, CALGB-9720, CALGB-10201, CALGB-8923, CALGB-9420 <http://www.ncbi.nlm.nih.gov/pubmed/24596420>

768 Improving patient-centered communication in breast cancer: a study protocol for a multilevel intervention of a shared treatment deliberation system (SharES) within the NCI community oncology research program (NCORP) (Alliance A231901CD)

Sarah T. Hawley, Kelley Kidwell, David Zahrieh, Anne McCarthy, Rachel Wills, Aaron Rankin, Timothy Hofer, Selina Chow, Reshma Jagsi, Heather Neuman Trials vol 24 (1) 16 2023
Manuscript CCDR <http://www.ncbi.nlm.nih.gov/pubmed/36609349>

769 Implementing a multi-level cancer care delivery intervention within the NCI Community Oncology Research Program (NCORP) (Alliance A231901CD)

Sarah Hawley, Aaron Rankin, Anne McCarthy, Rachel Wills, Selina Chow, Heather Neuman 2022
Abstract CCDR
<https://academyhealth.confex.com/academyhealth/2022di/meetingapp.cgi/Paper/55201>

770 HER2 and response to paclitaxel in node-positive breast cancer.

Daniel F Hayes, Ann D Thor, Lynn G Dressler, Donald Weaver, Susan Edgerton, David Cowan, Gloria Broadwater, Lori J Goldstein, Silvana Martino, James N Ingle, I Craig Henderson, Larry Norton, Eric P Winer, Clifford A Hudis, Matthew J Ellis, Donald A Berry N Engl J Med vol 357 (15) 1496-506 2007
Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/17928597>

771 Outcomes for FOLFIRI plus bevacizumab (BEV) or cetuximab (CET) in patients previously treated with oxaliplatin-based adjuvant therapy: A combined analysis of data from FIRE-3 and CALGB 80405

Volker Heinemann, Donna Niedzwiecki, Rachel Pearline, Heinz-Josef Lenz, Federico Innocenti, Howard S. Hochster, Axel Grothey, Richard M. Goldberg, Robert J. Mayer, Richard L. Schilsky, Monica M. Bertagnolli, Charles D. Blanke, Alan P. Venook, Sebastian Stinzing, Bert H. O'Neil J Clin Oncol vol 33 (suppl) abstr 3585 2015
Abstract GI <http://meetinglibrary.asco.org/content/150067-156>

772 Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group

Michael C. Heinrich, Kouros Owzar, Christopher L. Corless, Donna Hollis, Ernest C. Borden, Christopher D.M. Fletcher, Christopher W. Ryan, Margaret von Mehren, Charles D. Blanke, Cathryn Rankin, Robert S. Benjamin, Vivien H. Bramwell, George D. Demetri, Monica M. Bertagnolli, Jonathan A. Fletcher J Clin Oncol vol 26 (33) 5360-5367 2008
Manuscript PPP <http://www.ncbi.nlm.nih.gov/pubmed/18955451>

773 CALGB 30704: A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small cell lung cancer (NSCLC)

R. C. Suk Heist, X. Wang, L. D. Hodgson, G. A. Otterson, T. E. Stinchcombe, M. A. Socinski J Clin Oncol vol 30 (suppl) abstr 7513 2012
Abstract Respiratory
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID

774 A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib or Pemetrexed

Plus Sunitinib in the Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer

Rebecca S. Heist, Xiaofei Wang, Lydia Hodgson, Gregory A. Otterson, Thomas E. Stinchcombe, Leena Gandhi, Miguel A. Villalona-Calero, Peter Watson, Everett E. Vokes, Mark A. Socinski J Thorac Oncol vol 9 (2) 214-221 2014

Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/24419419>

775 Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

I Craig Henderson, Donald A Berry, George D Demetri, Constance T Cirrincione, Lori J Goldstein, Silvana Martino, James N Ingle, M Robert Cooper, Daniel F Hayes, Katherine H Tkaczuk, Gini Fleming, James F Holland, David B Duggan, John T Carpenter, Emil Frei, Richard L Schilsky, William C Wood, Hyman B Muss, Larry Norton J Clin Oncol vol 21 (6) 976-83 2003

Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/12637460>

776 Alliance Foundation Trial 09: A Randomized, Multicenter, Phase 2 Trial Evaluating Two Sequences of Pembrolizumab and Standard Platinum-Based Chemotherapy in Patients With Metastatic NSCLC

Thomas A. Hensing, Xiaofei Wang, Thomas E. Stinchcombe, Junheng Gao, Michael V. Knopp, Mark Watson, Arkadiusz Z. Dudek, Stephen L. Graziano, Jyoti D. Patel, Bryan A. Faller, Konstantin H. Dragnev, David Kozono, Everett E. Vokes JTO Clin Res Rep vol 2 (8) 2021

Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/34590049>

777 Randomized multicenter phase II trial evaluating the sequencing of PD-1 inhibition with pembrolizumab (ppembro) and standard platinum-based chemotherapy (chemo) in patients (pts) with metastatic non-small cell lung cancer (NSCLC) AFT-09 (Alliance)

Thomas Hensing, Xiaofei Wang, David Kozono, Arkadiusz Dudek, Stephen Graziano, Jyoti Patel, Bryan Faller, Konstantin Dragnev, Everett Vokes, Thomas Stinchcombe J Clin Oncol vol 37 (15_suppl) 2019

Abstract Respiratory https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.9088

778 Effect of socioeconomic status as measured by education level on survival in breast cancer clinical trials

J. E. Herndon, A. B. Kornblith, J. C. Holland, E. D. Paskett Psycho-Oncol vol 22 (2) 315-23 2013

Manuscript Disparities CALGB-9141, CALGB-9741, CALGB-9082, CALGB-9140, CALGB-9342, CALGB-9142, CALGB-9343, CALGB-9840 <http://www.ncbi.nlm.nih.gov/pubmed/22021121>

779 Patient Education Level As a Predictor of Survival In Lung Cancer Clinical Trials

James E. Herndon, Alice B. Kornblith, Jimmie C. Holland, Electra D. Paskett J Clin Oncol vol 26 (25) 4116-23 2008

Manuscript Health Outcomes CALGB-8831, CALGB-8931, CALGB-9130, CALGB-9033, CALGB-9235, CALGB-9532, CALGB-9430, CALGB-9431, CALGB-9534, CALGB-9730, CALGB-9731 <http://www.ncbi.nlm.nih.gov/pubmed/18757325>

780 A genome-wide association study (GWAS) of docetaxel-induced peripheral neuropathy in CALGB 90401 (Alliance)

D. L. Hertz, K. Owzar, S. Halabi, W. K. Kelly, H. Zembutsu, C. Jiang, J. Patel, D. Watson, I. Shterev, D. L. Kroetz, P. N. Friedman, J. F. Mahoney, M. A. Carducci, M. L. J. Kelley, E. J. Small, P. G. Febbo, Y. Nakamura, M. Kubo, M. J. Ratain, H. L. Mcleod J Clin Oncol vol 31 (15 suppl) abstr 11053 2013

Abstract PPP CALGB-90401

http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/11053?sid=cddda47f-d3d5-4c90-8bbc-1f7t

781 Association of CEP72 rs924607 with vincristine-induced peripheral neuropathy in patients with

diffuse large B-cell lymphoma on Alliance/CALGB 50303

Daniel L. Hertz, Nicholas Larson, Timothy M Pierpont, Shaun Riska, Kristy L. Richards J Clin Oncol vol 38 (15_suppl) e13535 2020
Abstract PPP https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.e13535

782 Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism That Increases Risk of Docetaxel-Induced Neuropathy

Daniel L. Hertz, Kouros Owzar, Sherrie Lessans, Claudia Wing, Chen Jiang, William Kevin Kelly, Jai Patel, Susan Halabi, Yoichi Furukawa, Heather E. Wheeler, Alexander B. Sibley, Cameron Lassiter, Lois Weisman, Dorothy Watson, Stefanie D. Krens, Flora Mulkey, Cynthia L. Renn, Eric J. Small, Phillip G. Febbo, Ivo Shterev, Deanna L. Kroetz, Paula N. Friedman, John F. Mahoney, Michael A. Carducci, Michael J Kelley, Yusuke Nakamura, Michiaki Kubo, Susan G. Dorsey, M. Eileen Dolan, Michael J. Morris, Mark J. Ratain, Howard L. McLeod Clin Cancer Res vol 22 (19) 4890-900 2016
Manuscript PPP CALGB-90401 <http://www.ncbi.nlm.nih.gov/pubmed/27143689>

783 Neuropathy Severity at the Time of Oxaliplatin Treatment Alteration in Patients with Colon Cancer (Alliance A151912)

Daniel L Hertz, Travis J Dockter, Daniel V Satele, Charles L. Loprinzi, Jennifer Le-Rademacher Support Care Cancer vol 29 (12) 7855-7863 2021
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/34176021>

784 Neuropathy Severity at the Time of Oxaliplatin Treatment Alteration in Patients with Colon Cancer (Alliance A151912)

Daniel Louis Hertz, Travis Dockter, Daniel V. Satele, Charles L. Loprinzi, Jennifer Le-Rademacher J Clin Oncol vol 9 (15_suppl) 12090 2021
Abstract Symptom Inter NCCTG-N08CB
https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.12090

785 A genome-wide association study (GWAS) of docetaxel-induced neutropenia in CALGB 90401/60404 (Alliance).

Daniel Louis Hertz, Chen Jiang, Kouros Owzar, Susan Halabi, William Kevin Kelly, Flora Mulkey, Jai Narendra Patel, Michael Anthony Carducci, Michael J. Kelley, Walter Michael Stadler, Mohamed K. Mohamed, Michael J. Morris, Yusuke Nakamura, Hitoshi Zembutsu, Mark J. Ratain, Howard L. McLeod J Clin Oncol vol 32 (15_suppl) 9612 2014
Abstract PPP CALGB-90401 <http://meetinglibrary.asco.org/content/126788-144>

786 Tumor Status at 12 Weeks Predicts Survival in Advanced Colorectal Cancer: Findings from NCCTG N9741

James M. Heun, Axel Grothey, Megan E. Branda, Richard M. Goldberg, Daniel J. Sargent Oncologist vol 16 (6) 859-867 2011
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/21632455>

787 Lenalidomide-mediated enhanced translation of C/EBP-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia

Christopher J. Hickey, Sebastian Schwind, Hanna S. Radomska, Adrienne M. Dorrance, Ramasamy Santhanam, Anjali Mishra, Yue-Zhong Wu, Houda Alachkar, Kati Maharry, Deedra Nicolet, Krzysztof Mrózek, Alison Walker, Anna M. Eiring, Susan P. Whitman, Heiko Becker, Danilo Perrotti, Lai-Chu Wu, Xi Zhao, Todd A. Fehniger, Ravi Vij, John C. Byrd, William Blum, L. James Lee, Michael A. Caligiuri, Clara D. Bloomfield, Ramiro Garzon, Guido Marcucci Blood vol 121 (1) 159-169 2013
Manuscript Leuk Corr Sci CALGB-9621, CALGB-19808
<http://www.ncbi.nlm.nih.gov/pubmed/23100311>

788 Evaluation of the value of attribution in the interpretation of adverse event data: a North

Central Cancer Treatment Group and American College of Surgeons Oncology Group investigation

S. L. Hillman, S. J. Mandrekar, B. Bot, R. P. Dematteo, E. A. Perez, K. V. Ballman, H. Nelson, J. C. Buckner, D. J. Sargent J Clin Oncol vol 28 (18) 3002-7 2010
Manuscript Respiratory ACOSOG-Z9001, NCCTG-97-24-51
<http://www.ncbi.nlm.nih.gov/pubmed/20479400>

789 Questionable value of attribution when interpreting adverse event data: A joint evaluation by North Central Cancer Treatment Group (NCCTG) and American College of Surgeons Oncology Group (ACOSOG).

SL Hillman, DJ Sargent, BM Bot, DeMatteo RP, EA Perez, KV Ballman, SJ Mandrekar J Clin Oncol vol 25 (18S) abst 6511 2007
Abstract GI
https://www.researchgate.net/publication/339758986_Questionable_value_of_attribution_when_interpre

790 Evaluation of the Optimal Number of Lesions Needed for Tumor Evaluation Using the Response Evaluation Criteria in Solid Tumors: A North Central Cancer Treatment Group Investigation

Shauna L. Hillman, Ming-Wen An, Michael J. O'Connell, Richard M. Goldberg, Paul Schaefer, Jan C. Buckner, Daniel J. Sargent J Clin Oncol vol 27 (19) 3205-3210 2009
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/19414682>

791 Rates of and Factors Associated With Patient Withdrawal of Consent in Cancer Clinical Trials

Shauna L. Hillman, Aminah Jatoi, Carrie A. Strand, Jane Perlmutter, Suzanne George, Sumithra J. Mandrekar JAMA Oncol vol 9(8):1041-1047. (8) 1041-7 2023
Manuscript SDMC NOS <http://www.ncbi.nlm.nih.gov/pubmed/37347469>

792 Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases

Andrew L. Himmelstein, Jared C. Foster, James L. Khatcheressian, John D. Roberts, Drew K. Seisler, Paul J. Novotny, Rui Qin, Ronald S. Go, Stephen S. Grubbs, Tracey O'Connor, Mario R. Velasco, Douglas Weckstein, Ann O'Mara, Charles L. Loprinzi, Charles L. Shapiro JAMA vol 317 (1) 48-58 2017
Manuscript Symptom Inter CALGB-70604, CALGB-150804
<http://www.ncbi.nlm.nih.gov/pubmed/28030702>

793 CALGB 70604 (Alliance): A randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer

Andrew L. Himmelstein, Rui Qin, Paul J. Novotny, Drew K. Seisler, James L. Khatcheressian, John D. Roberts, Stephen S. Grubbs, Tracey O'Connor, Douglas Weckstein, Charles L. Loprinzi, Charles L. Shapiro J Clin Oncol vol 33 (suppl) abstr 9501 2015
Abstract Symptom Inter http://meeting.ascopubs.org/cgi/content/short/33/15_suppl/6011?rss=1

794 Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC

Stephanie L. Hines, Betty Mincey, Todor Dentchev, Jeff A. Sloan, Edith A. Perez, David B. Johnson, Paul L. Schaefer, Steve Alberts, Heshan Liu, Stephen Kahanic, Mirosław A. Mazurczak, Daniel A. Nikcevich, Charles L. Loprinzi Breast Cancer Res Treat vol 117 (3) 603-609 2009
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/19214743>

795 Alliance A022101: A pragmatic randomized phase III trial evaluating total ablative therapy for patients with limited metastatic colorectal cancer - evaluating radiation, ablation, and surgery (ERASur)

Kathryn E. Hitchcock, Paul B. Romesser, Qian Shi, Jesse G. Dixon, Sepideh Gholami, Sarah B. White, Christina Wu, Christopher C. Goulet, Kyung-Wook Jee, Chadwick L. Wright, Rona Yaeger, Ardaman

Shergill, Theodore S. Hong, Thomas J. George, Eileen M. O'Reilly, Jeffrey A. Meyerhardt, Eric D. Miller *J Clin Oncol* vol 41 (16 suppl) TPS3629 2023
Abstract GI https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.TPS3629

796 Phase II Study of Enzalutamide for Patients With Androgen Receptor–Positive Salivary Gland Cancers (Alliance A091404)

Alan L. Ho, Nathan R. Foster, Alex J. Zoroufy, Jordan D. Campbell, Francis Worden, Katharine Price, Douglas Adkins, Daniel W. Bowles, Hyunseok Kang, Barbara Burtness, Eric Sherman, Roscoe Morton, Luc G.T. Morris, Zaineb Nadeem, Nora Katabi, Pamela Munster, Gary K. Schwartz *J Clin Oncol* vol 40 (36) 4240-9 2022
Manuscript Experimental <http://www.ncbi.nlm.nih.gov/pubmed/35867947>

797 Alliance A091104: A Phase II Trial of MK-2206 in patients with progressive, recurrent/metastatic adenoid cystic carcinoma

Alan L Ho, Nathan R. Foster, Jeffrey P. Meyers, Shyamprasad Deraje Vasudeva, Nora Katabi, Cristina R. Antonescu, L. Elise Horvath, Charles Erlichman, Gary K. Schwartz *J Clin Oncol* vol 33 (suppl) abstr 6039 2015
Abstract Experimental http://hwmaint.meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/6039

798 Alliance A091404: a phase II study of enzalutamide (nsc# 766085) for patients with androgen receptor positive salivary cancers

Alan Loh Ho, Nathan R. Foster, Alex J. Zoroufy, Francis Worden, Katharine Price, Douglas Adkins, Daniel W. Bowles, Hyunseok Kang, Barbara Burtness, Eric Sherman, Roscoe Morton, Nora Katabi, Pamela Munster, Gary K. Schwartz *J Clin Oncol* vol 37 (15_suppl) 6020-6020 2019
Abstract Experimental https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.6020

799 Mutational analysis of CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without +/- lapatinib (L) for HER2-positive breast cancer

Katherine A. Hoadley, William T. Barry, Brandelyn N. Pitcher, Joel S. Parker, Matthew D. Wilkerson, William Irvin, N. Lynn Henry, Sara M. Tolaney, Chau Dang, Ian E. Krop, Donald A. Berry, Elaine R. Mardis, Charles M. Perou, Eric P. Winer, Clifford A. Hudis, Lisa A. Carey *Cancer Res* vol 75 (9 Supplement) abstr S3-06 2015
Abstract Breast http://cancerres.aacrjournals.org/content/75/9_Supplement/S3-06

800 Multivariate Analysis of Subtype and Gene Expression Signatures Predictive of Pathologic Complete Response (pCR) in Triple-Negative Breast Cancer (TNBC): CALGB 40603 (Alliance)

Katherine A. Hoadley, Terry Hyslop, Cheng Fan, Donald A. Berry, Olwen Hahn, Sara Tolaney, William M. Sikov, Charles M. Perou, Lisa Carey *Cancer Res* vol 77 (4 suppl) Abstract nr PD1-03 2017
Abstract Correl Sci NOS http://cancerres.aacrjournals.org/content/77/4_Supplement/PD1-03

801 Mutational Analysis of Triple-Negative Breast Cancer (TNBC): CALGB 40603 (Alliance)

Katherine A. Hoadley, Bradford C. Powell, Dona Kanavy, David Marron, Lisle E. Mose, Terry Hyslop, Donald A. Berry, Olwen Hahn, Sara M. Tolaney, William M. Sikov, Charles M. Perou, Lisa A. Carey *Cancer Res* vol 80 (4) suppl, abstr P4-05-03 2019
Abstract Correl Sci NOS https://cancerres.aacrjournals.org/content/80/4_Supplement/P4-05-03

802 N0436: A phase II trial of irinotecan plus cetuximab in patients with metastatic breast cancer and prior anthracycline and/or taxane-containing therapy

T. J. Hobday, P. J. Stella, T. R. Fitch, A. Jaslowski, B. Laplant, M. M. Ames, M. P. Goetz, E. A. Perez *J Clin Oncol* vol 26 (May 20 suppl; abstr 1081) General Poster Session, Breast Cancer - Metastatic Abstract 1081 2008
Abstract Breast

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID

803 A North Central Cancer Treatment Group (NCCTG) Phase II Trial of VEGF Trap in Patients With Metastatic Breast Cancer (MBC) Previously Treated with an Anthracycline and/or a Taxane.

T. Hobday, K. Rowland Jr, A. Dueck, D. Northfelt, W. Lingle, R. Morton, T. Fitch, D. Nikcevich, E. Perez Breast Cancer Symposium abstr 164 2008

Abstract Breast

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=58&abstractID

804 Pathways: a fertility preservation patient decision aid website for women with cancer – effectiveness and feasibility of dissemination to newly-diagnosed women in community cancer centers.

A.S. Hoffman, J. Weston, S. Campbell, L. Crocker, D. Holman, A. J. Houston, R. J. Volk, T. L.

Woodard Medical Decision Making vol 40 (1) E380-E402 (abst PS 384-314) 2020

Abstract CCDR <https://journals.sagepub.com/doi/pdf/10.1177/0272989X19890544>

805 Are we assuming too much with our statistical assumptions? Lessons learned from the ALTTO trial

E M Holmes, I Bradbury, L S Williams, L Korde, E de Azambuja, D Fumagalli, A Moreno-Aspitia, J

Baselga, M Piccart-Gebhart, A C Dueck, R D Gelber Ann Oncol vol 30 (9) 1507-13 2019

Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/31240310>

806 Updated analysis of CALGB 100104 (Alliance): a randomised phase III study evaluating lenalidomide vs placebo maintenance after single autologous stem cell transplant for multiple myeloma

Sarah A. Holstein, Sin-Ho Jung, Paul G. Richardson, Craig C. Hofmeister, David D. Hurd, Hani Hassoun, Sergio Giralt, Edward A. Stadtmauer, Daniel J. Weisdorf, Ravi Vij, Jan S. Moreb, Natalie S. Callander, Koen van Besien, Teresa G. Gentile, Luis Isola, Richard T Maziarz, Asad Bashey, Heather Landau, Thomas Martin, Muzaffar H Qazilbash, Cesar Rodriguez, Brian McClune, Robert L. Schlossman, Scott E. Smith, Vera Hars, Kouros Owzar, Chen Jiang, Molly Boyd, Chelsea Schultz, Marcia Wilson, Parameswaran Hari, Marcelo C. Pasquini, Mary M. Horowitz, Thomas C. Shea, Steven M. Devine, Charles Linker, Kenneth C. Anderson, Philip L. McCarthy Lancet Haematol vol 4 (9) e431-e442 2017

Manuscript Myeloma <http://www.ncbi.nlm.nih.gov/pubmed/28826616>

807 Updated analysis of CALGB 100104: lenalidomide (Len) vs. placebo maintenance therapy after single autologous stem cell transplant (ASCT) for multiple myeloma (MM).

Sarah A. Holstein, Kouros Owzar, Paul G. Richardson, Chen Jiang, Craig C. Hofmeister, Hani Hassoun, David D. Hurd, Edward A. Stadtmauer, Sergio Giralt, Steven M. Devine, Vera Hars, John Postiglione, Daniel J. Weisdorf, Ravi Vij, Jan S. Moreb, Natalie S. Callander, Marcelo C. Pasquini, Thomas C. Shea, Kenneth Anderson, Philip L. McCarthy J Clin Oncol vol 33 (suppl) abstr 8523 2015

Abstract Myeloma http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/8523

808 Long-term follow-up of CALGB (Alliance) 100001: Autologous followed by non-myeloablative allogeneic transplant for multiple myeloma

Sarah A. Holstein, Vera J. Suman, Kouros Owzar, Katelyn Santo, Don M. Benson, Thomas C. Shea Jr., Thomas Martin, Margarida Silverman, Luis Isola, Ravi Vij, Bruce D. Cheson, Charles Linker, Kenneth C. Anderson, Paul G. Richardson, Philip L. McCarthy Biol Blood Marrow Transplant vol 26 (8) 1414-24 2020

Manuscript Myeloma <http://www.ncbi.nlm.nih.gov/pubmed/32325171>

809 Gemcitabine (G) and irinotecan (CPT-11) as first-line therapy for carcinoma (ca) of unknown primary (CUP): An NCCTG phase II trial

S. G. Holtan, N. R. Foster, C. E. Erlichman, M. Aubry, M. M. Ames, S. Safgren, P. D. Steen, R. F.

Morton, D. Graham, M. P. Goetz J Clin Oncol vol 26 (suppl) abstr 13525 2008
Abstract Experimental
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID

810 Gemcitabine and Irinotecan as First-Line Therapy for Carcinoma of Unknown Primary: Results of a Multicenter Phase II Trial

Shernan G. Holtan, Preston D. Steen, Nathan R. Foster, Charles Erlichman, Fabiola Medeiros, Matthew M. Ames, Stephanie L. Safgren, David L. Graham, Robert J. Behrens, Matthew P. Goetz
PLoS ONE vol 7 (7) e39285 2012
Manuscript Experimental <http://www.ncbi.nlm.nih.gov/pubmed/22815703>

811 Public Health and Cooperative Group Partnership: A Colorectal Cancer Educational Intervention for Breast Cancer Survivors

Homan, G Sherri Semin Oncol Nurs vol 30 (1) 61-73 2014
Manuscript Onc Nursing <http://www.ncbi.nlm.nih.gov/pubmed/24559782>

812 Lymphedema, Musculoskeletal Events and Arm Function in Older Patients Receiving Adjuvant Chemotherapy for Breast Cancer (Alliance A171302)

Judith O. Hopkins, Jake Allred, Arti Hurria, Aminah Jatoi, Jacqueline M. Lafky, Harvey Cohen, Clifford Hudis, Eric Winer, Jeanne Mandelblatt, Ann Partridge, Lisa Carey, Hyman B. Muss Breast Cancer Res Treat vol 166 (3) 793-808 2017
Manuscript Older Adult CALGB-49907 <http://www.ncbi.nlm.nih.gov/pubmed/28825227>

813 Irinotecan-induced neutropenia and UGT1A1*28: Does dose matter?

J. M. Hoskins, R. M. Goldberg, H. L. McLeod J Clin Oncol vol 25 (18s) abstr 4023 2007
Abstract PPP
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID

814 UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters.

Janelle M Hoskins, Richard M Goldberg, Pingping Qu, Joseph G Ibrahim, Howard L McLeod J Natl Cancer Inst vol 99 (17) 1290-5 2007
Manuscript PPP <http://www.ncbi.nlm.nih.gov/pubmed/17728214>

815 Biologic Prognostic Markers in Diffuse Large B-Cell Lymphoma Patients Treated with Dose Adjusted EPOCH-R: a CALGB 50103 Correlative Science Study

E. D. Hsi, J. Said, J. L. Johnson, S. Jung, R. Lai, D. Jones, A. Chadburn, B. D. Cheson, W. H. Wilson
Blood vol 112 (11) abstr 476 2008
Abstract Correl Sci NOS <http://www.bloodjournal.org/content/112/11/476>

816 Ki67 and PIM1 expression in aggressively treated mantle cell lymphoma (MCL): A Cancer and Leukemia Group B (CALGB) 59909 correlative science study

E. Hsi, S. Jung, R. Lai, J. Johnson, J. Cook, D. Jones, S. Devos, B. D. Cheson, L. E. Damon, J. Said J Clin Oncol vol 26 (May 20 suppl) abstr 8560 2008
Abstract Lymphoma
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID

817 Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study

Eric D. Hsi, Sin-Ho Jung, Raymond Lai, Jeffrey L. Johnson, James R. Cook, Dan Jones, Sven Devos, Bruce D. Cheson, Lloyd E. Damon, Jonathan Said Leuk Lymphoma vol 49 (11) 2081-2090 2008
Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/19021050>

- 818 Pilot experience with adjuvant FOLFIRI with or without cetuximab in patients with resected stage III colon cancer: NCCTG Intergroup N0147**
J. Huang, D. J. Sargent, M. R. Mahoney, A. F. Shields, E. Chan, R. M. Goldberg, S. Gill, M. S. Kahlenberg, J. T. Quesenberry, T. C. Smyrk, A. Grothey, F. Sinicrope, S. G. Nair, S. R. Alberts *J Clin Oncol* vol 29 (Suppl 1) abstr 3522 2011
Abstract GI
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID
- 819 Adjuvant FOLFIRI with or without cetuximab in patients with resected stage III colon cancer: NCCTG Intergroup phase III trial N0147**
J. Huang, D. J. Sargent, M. R. Mahoney, S. N. Thibodeau, T. C. Smyrk, F. Sinicrope, G. D. Alberts, S. R. Nelson *J Clin Oncol* 29, No 4_suppl (February vol 29 (4s) abstr 363 2011
Abstract GI http://meeting.ascopubs.org/cgi/content/abstract/29/4_suppl/363
- 820 Comparison of FOLFIRI With or Without Cetuximab in Patients With Resected Stage III Colon Cancer; NCCTG (Alliance) Intergroup Trial N0147**
Jocelin Huang, Suresh G. Nair, Michelle R. Mahoney, Garth D. Nelson, Anthony F. Shields, Emily Chan, Richard M. Goldberg, Sharlene Gill, Morton S. Kahlenberg, James T. Quesenberry, Stephen N. Thibodeau, Thomas C. Smyrk, Axel Grothey, Frank A. Sinicrope, Thomas A. Webb, Gist H. Farr, Barbara A. Pockaj, Jeffrey L. Berenberg, Margaret Mooney, Daniel J. Sargent, Steven R. Alberts *Clin Colorectal Cancer* vol 13 (2) 100-109 2014
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/24512953>
- 821 Phase I evaluation of sorafenib (SOR) & bevacizumab (BEV) in first-line therapy in hepatocellular cancer (HCC): North Central Cancer Treatment Group Trial N0745**
J. Hubbard, S. Alberts, W. Loui, M. Mahoney, L. Roberts, T. Smyrk, Z. Gatalica, S. Kumar, S. Dakhil, P. Flynn, M. Bury *J Clin Oncol* vol 29 (suppl) abstr 4116 2011
Abstract GI
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID
- 822 Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group trial N0745 (Alliance)**
Joleen M. Hubbard, Michelle R. Mahoney, William S. Loui, Lewis R. Roberts, Thomas C. Smyrk, Zoran Gatalica, Mitesh Borad, Shaji Kumar, Steven R. Alberts *Target Oncol* vol 12 (2) 201-209 2017
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/27943153>
- 823 Benefits and Adverse Events in Younger Versus Older Patients Receiving Adjuvant Chemotherapy for Colon Cancer: Findings From the Adjuvant Colon Cancer Endpoints Data Set**
Joleen Hubbard, David M. Thomas, Greg Yothers, Erin Green, Charles Blanke, Michael J. O'Connell, Roberto Labianca, Qian Shi, Archie Bleyer, Aimery de Gramont, Daniel Sargent *J Clin Oncol* vol 30 (19) 2334-2339 2012
Manuscript GI ACCENT, CALGB-89803 <http://www.ncbi.nlm.nih.gov/pubmed/22614981>
- 824 Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer**
K. S. Hughes, L. Schnaper, C. T. Cirrincione, D. A. Berry, B. McCormick, C. A. Hudis, E. P. Winer *J Clin Oncol* vol 28 (15s) abstr 507 2010
Abstract Breast
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID
- 825 Lumpectomy Plus Tamoxifen With or Without Irradiation in Women Age 70 Years or Older**

With Early Breast Cancer: Long-Term Follow-Up of CALGB 9343

Kevin S. Hughes, Lauren A. Schnaper, Jennifer R. Bellon, Constance T. Cirrincione, Donald A. Berry, Beryl McCormick, Hyman B. Muss, Barbara L. Smith, Clifford A. Hudis, Eric P. Winer, William C. Wood *J Clin Oncol* vol 31 (19) 2382-2387 2013
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/23690420>

826 Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer.

Kevin S Hughes, Lauren A Schnaper, Donald Berry, Constance Cirrincione, Beryl McCormick, Brenda Shank, Judith Wheeler, Lorraine A Champion, Thomas J Smith, Barbara L Smith, Charles Shapiro, Hyman B Muss, Eric Winer, Clifford Hudis, William Wood, David Sugarbaker, I Craig Henderson, Larry Norton *N Engl J Med* vol 351 (10) 971-7 2004
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/15342805>

827 Safety and tolerability of lapatinib ditosylate given concurrently with docetaxel, carboplatin, and trastuzumab (TCHL) as part of adjuvant therapy for patients with HER2+ breast cancer: Pilot data from the North Central Cancer Treatment Group Trial N083E.

C. Bueno Hume, A. Moreno-Aspitia, D. Hillman, B. Chen, A. Perez, R. Jenkins, A. C. Dueck, D. B. Johnson, R. Carolla, E. Perez *J Clin Oncol* vol 28 (15s) abstr 565 2010
Abstract Breast
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID

828 Statins and Left Ventricular Ejection Fraction Following Doxorubicin Treatment

W. Gregory Hundley, Ralph D'Agostino, Teresa Crotts, Karen Craver, Mary Helen Hackney, Jennifer H. Jordan, Bonnie Ky, Lynne I. Wagner, David M. Herrington, Joseph Yeboah, Kerryn W. Reding, Amy C. Ladd, Stephen R. Rapp, Sandra Russo, Nathaniel O'Connell, Kathryn E. Weaver, Emily V. Dressler, Yaorong Ge, Susan A. Melin, Vinay Gudena, Glenn J. Lesser *NEJM Evid* vol 1 (9) 2022
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/36908314>

829 A phase II study evaluating the role of sentinel lymph node surgery and axillary lymph node dissection following preoperative chemotherapy in women with node-positive breast cancer (T1-4, N1-2, M0) at initial diagnosis: ACOSOG Z1071

K. Hunt, H. T. Le-Petross, V. Suman, B. G. Haffty, A. M. Leitch, D. Ollila, D. R. Byrd, T. A. Bucholz, W. F. Symmans, J. C. Boughey *J Clin Oncol* vol 28 (15s) abstr TPS118 2010
Abstract Breast
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID

830 Factors Associated with Local-Regional Recurrence Following a Negative Sentinel Node Dissection: Results of the ACOSOG Z0010 Trial

Kelly K. Hunt, Karla V. Ballman, Linda M. McCall, Judy C. Boughey, Elizabeth A. Mittendorf, Charles E. Cox, Pat W. Whitworth, Peter D. Beitsch, A. Marilyn Leitch, Thomas A. Buchholz, Monica A. Morrow, Armando E. Giuliano *Ann Surg* vol 256 (3) 428-436 2012
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/22868365>

831 Local-regional recurrence (LRR) following neoadjuvant endocrine therapy: Data from ACOSOG Z1031 (Alliance), a randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer versus chemotherapy.

Kelly K. Hunt, Vera J. Suman, Ann M. Leitch, Gary Unzeitig, Judy Boughey, Funda Meric-Bernstam, John Olson, Matthew J. Ellis *Ann Surg Oncol* vol 27 (Suppl 1) S5 2020
Abstract Breast
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222983/pdf/10434_2020_Article_8278.pdf

832 Local-Regional Recurrence (LRR) Data from the American College of Surgeons Oncology Group (ACOSOG) Z1041 (Alliance): A Randomized Neoadjuvant Trial of Sequential Versus Concurrent Anthracycline with Trastuzumab and Paclitaxel Plus Trastuzumab in HER2-Positive (HER2+) Breast Cancer (BC)

Kelly K. Hunt, Vera J. Suman, Funda Meric-Bernstam, Ann M. Leitch, Matthew J. Ellis, Judy C. Boughey, Gary W. Unzeitig, Melanie E. Royce, Aman U. Buzdar Ann Surg Oncol vol 26 (suppl 1) S5 abstr 1 2019
Abstract Breast <http://expo.jspargo.com/exhibitor/web/SSO2019ASOAbstractSupplement.pdf>

833 Local-regional recurrence following neoadjuvant endocrine therapy: Data from ACOSOG Z1031 (Alliance), a randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor–positive clinical stage 2 to 3 breast cancer

Kelly K. Hunt, Vera J. Suman, Hannah F. Wingate, A. Marilyn Leitch, Gary Unzeitig, Judy C. Boughey, Funda Meric-Bernstam, Matthew J. Ellis, John Olson Ann Surg Oncol vol 30 (4) 2111-8 2023
Manuscript Breast Alliance-A011106 <http://www.ncbi.nlm.nih.gov/pubmed/36653664>

834 Association of circulating markers with cognitive decline after radiation therapy for brain metastasis

Kristin Huntoon, S Keith Anderson, Karla V Ballman, Erin Twohy, Katharine Dooley, Wen Jiang, Yi An, Jing Li, Christina von Roemeling, Yaqing Qie, Owen A Ross, Jane H Cerhan, Anthony C Whitton, Jeffrey N Greenspoon, Ian F Parney, Jonathan B Ashman, Jean-Paul Bahary, Constantinos Hadjipanayis, James J Urbanic, Elana Farace, Deepak Khuntia, Nadia N Laack, Paul D Brown, David Roberge, Betty Y S Kim Neuro Oncol vol 25 (6) 1123-31 2023
Manuscript Correl Sci NOS NCCTG-N107C <http://www.ncbi.nlm.nih.gov/pubmed/36472389>

835 Implementing a Geriatric Assessment in Cooperative Group Clinical Cancer Trials: CALGB 360401

Arti Hurria, Constance T. Cirrincione, Hyman B. Muss, Alice B. Kornblith, William Barry, Andrew S. Artz, Linda Schmieder, Rafat Ansari, William P. Tew, Douglas Weckstein, Jeffrey Kirshner, Kayo Togawa, Kurt Hansen, Vani Katheria, Richard Stone, Ilene Galinsky, John Postiglione, Harvey Jay Cohen J Clin Oncol vol 29 (10) 1290-1296 2011
Manuscript GU CALGB-99809 <http://www.ncbi.nlm.nih.gov/pubmed/21357782>

836 Functional Decline and Resilience among Older Women Receiving Adjuvant Chemotherapy for Breast Cancer

Arti Hurria, Enrique Soto-Perez-de-Celis, Jacob B. Allred, Harvey Jay Cohen, Anait Arsenyan, Karla Ballman, Jennifer Le-Rademacher, Aminah Jatoui, Julie Filo, Jeanne Mandelblatt, Jacqueline M. Lafky, Gretchen Kimmick, Heidi D. Klepin, Rachel A. Freedman, Harold Burstein, Julie Gralow, Antonio C. Wolff, Gustav Magrinat, Myra Barginear, Hyman Muss J Am Geriatr Soc vol 67 (5) 920-7 2019
Manuscript Older Adult CALGB-49907 <http://www.ncbi.nlm.nih.gov/pubmed/30146695>

837 Tumor markers of efficacy and resistance to cetuximab (C) treatment in metastatic colorectal cancer (mCRC): Results from CALGB 80203 (Alliance)

H. Hurwitz, S. Cushman, C. Jiang, I. Shterev, M. R. Mahoney, D. Niedzwiecki, R. J. Mayer, A. P. Venook, K. Owzar, A. B. Nixon J Clin Oncol vol 31 (15 suppl) abstr 11011 2013
Abstract GI
http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/11011?sid=8da84e74-5d65-4c40-a3e7-7ac

838 Combination external beam radiation and brachytherapy boost with androgen deprivation for treatment of intermediate-risk prostate cancer: long-term results of CALGB 99809

M. D. Hurwitz, S. Halabi, L. Archer, L. S. McGinnis, M. R. Kuettel, S. J. Dibiase, E. J. Small Cancer

- 839 Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate cancer: an initial report of CALGB 99809.**
Mark D Hurwitz, Susan Halabi, San-San Ou, Lamar S McGinnis, Michael R Keuttel, Steven J Dibiase, Eric J Small *Int J Radiat Oncol Biol Phys* vol 72 (3) 814-9 2008
Manuscript GU <http://www.ncbi.nlm.nih.gov/pubmed/18407435>
- 840 A pooled analysis of quality of life measures and adverse events data in north central cancer treatment group lung cancer clinical trials.**
Mashele M Huschka, Sumithra J Mandrekar, Paul L Schaefer, James R Jett, Jeff A Sloan *Cancer* vol 109 (4) 787-95 2007
Manuscript Respiratory NCCTG-N0021, NCCTG-N0022, NCCTG-95-20-53, NCCTG-95-24-51, NCCTG-95-24-52, NCCTG-97-24-51, NCCTG-98-24-52
<http://www.ncbi.nlm.nih.gov/pubmed/17211864>
- 841 The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS)**
E Shelley Hwang, Terry Hyslop, Thomas Lynch, Elizabeth Frank, Donna Pinto, Desiree Basila, Deborah Collyar, Antonia Bennett, Celia Kaplan, Shoshana Rosenberg, Alastair Thompson, Anna Weiss, Ann Partridge *BMJ Open* vol 9 (3) e026797 2019
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/30862637>
- 842 Primary endocrine therapy for ER-positive ductal carcinoma in situ (DCIS) (Alliance) CALGB 40903**
E. Shelley Hwang, Stephanie Duong, Isabelle Bedrosian, Jacob Allred, Dorota Wisner, Terry Hyslop, Abigail Caudle, Tina Hieken, Joseph Guenther, Laura Esserman, Nola Hylton *Cancer Res* vol 78 (4 Supplement) GS5-05 2017
Abstract Breast http://cancerres.aacrjournals.org/content/78/4_Supplement/GS5-05
- 843 Phase II Single-Arm Study of Preoperative Letrozole for Estrogen Receptor-Positive Postmenopausal Ductal Carcinoma In Situ: CALGB 40903 (Alliance)**
E. Shelley Hwang, Terry Hyslop, Laura H. Hendrix, Stephanie Duong, Isabelle Bedrosian, Elissa Price, Abigail Caudle, Tina Hieken, Joseph Guenther, Clifford A. Hudis, Eric Winer, Alan P. Lyss, Diana Dickson-Witmer, Richard Hofer, David W. Ollila, Timothy Hardman, Jeffrey Marks, Yunn-Yi Chen, Gregor Krings, Laura Esserman, Nola Hylton *J Clin Oncol* vol 38 (12) 1284-92 2020
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/32125937>
- 844 Identifying Strategies for Robust Survivorship Program Implementation: A Qualitative Analysis of Cancer Programs**
Soohyun Hwang, Burcu Bozkurt, Tamara Huson, Sarah Asad, Lauren Richardson, Joseph Amarachi Ogbansiegbe, Laura Viera, Caroline Buse, Ted A. James, Deborah K. Mayer, Lawrence N. Shulman, Sarah A. Birken *JCO Oncol Pract* vol 18 (3) e304-e312 2022
Manuscript CCCR <http://www.ncbi.nlm.nih.gov/pubmed/34606296>
- 845 Characterization of Survival Outcomes and Clinical and Molecular Modulators in Adult Patients with Core-Binding Factor Acute Myeloid Leukemia (CBF-AML): An Alliance Legacy Study**
Jonathon Hyak, Deedra Nicolet, Jessica Kohlschmidt, Kellie J. Archer, James S. Blachly, Bayard L. Powell, Jonathan E. Kolitz, Maria R. Baer, William G. Blum, Geoffrey Uy, Wendy Stock, John C. Byrd, Krzysztof Mrózek, Ann-Kathrin Eisfeld#, Alice S. Mims *Blood* vol 140 (suppl 1) 1284-5 2022
Abstract *Leuk Corr Sci* CALGB-20202, CALGB-8461, CALGB-9665

846 MRI Assessment of Breast Cancer Response to Neoadjuvant Chemotherapy: Preliminary Findings of the American College of Radiology Imaging Network (ACRIN) Trial 6657

N. M. Hylton, J. Blume, W. Bernreuter, E. Pisano, M. Rosen, E. Morris, P. Weatherall, C. Lehman, S. Polin, G. Newstead, H. Marques, M. Schnall, L. J. Esserman Radiological Society of North America 94th Scientific Assembly and Annual Meeting abstr 6006524 2008
Abstract Breast http://rsna2008.rsna.org/event_display.cfm?em_id=6006524

847 Comparison of MRI endpoints for assessing breast cancer response to neoadjuvant treatment: preliminary findings of the American College of Radiology Imaging Network (ACRIN) trial 6657

N. M. Hylton, J. Blume, W. Bernreuter, E. Pisano, M. Rosen, E. Morris, P. Weatherall, C. Lehman, S. Polin, G. Newstead, H. Marques, M. Schnall, L. J. Esserman Cancer Res vol 69 (2 Suppl) Abstr 6043 2009
Abstract Breast http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/69/2_MeetingAbstracts/6043?sid=004eb34

848 MRI tumor volume for predicting response to neoadjuvant chemotherapy in locally advanced breast cancer: Findings from ACRIN trial 6657/CALGB 150007

N. M. Hylton, J. Blume, C. Gastonis, R. Gomez, W. Bernreuter, E. Pisano, M. Rosen, H. Marques, L. J. Esserman, M. Schnall J Clin Oncol vol 27 (15s) abstr 529 2009
Abstract Breast ACRIN-6657, CALGB-150007
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID

849 Locally Advanced Breast Cancer: MR Imaging for Prediction of Response to Neoadjuvant Chemotherapy—Results from ACRIN 6657/I-SPY TRIAL

Nola M. Hylton, Jeffrey D. Blume, Wanda K. Bernreuter, Etta D. Pisano, Mark A. Rosen, Elizabeth A. Morris, Paul T. Weatherall, Constance D. Lehman, Gillian M. Newstead, Sandra Polin, Helga S. Marques, Laura J. Esserman, Mitchell D. Schnall Radiology vol 263 (3) 663-672 2012
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/22623692>

850 Neoadjuvant Chemotherapy for Breast Cancer: Functional Tumor Volume by MR Imaging Predicts Recurrence-free Survival—Results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL

Nola M. Hylton, Constantine A. Gatsonis, Mark A. Rosen, Constance D. Lehman, David C. Newitt, Savannah C. Partridge, Wanda K. Bernreuter, Etta D. Pisano, Elizabeth A. Morris, Paul T. Weatherall, Sandra M. Polin, Gillian M. Newstead, Helga S. Marques, Laura J. Esserman, Mitchell D. Schnall Radiology vol 279 (1) 44-55 2016
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/26624971>

851 Reproducibility of Random Periareolar Fine Needle Aspiration in a Multi-Institutional Cancer and Leukemia Group B (CALGB) Cross-Sectional Study

Catherine Ibarra-Drendall, Lee G. Wilke, Carola Zalles, Victoria Scott, Laura E. Archer, Siya Lem, Lisa D. Yee, Joanne Lester, Swati Kulkarni, Christine Murekeyisoni, Marie Wood, Karen Wilson, Judy Garber, Carleen Gentry, April Stouder, Gloria Broadwater, Joseph C. Baker, Shauna N. Vasilatos, Elizabeth Owens, Sarah Rabiner, Abbey C. Barron, Victoria L. Seewaldt Cancer Epidemiol Biomarkers Prev vol 18 (5) 1379-1385 2009
Manuscript Prevention <http://www.ncbi.nlm.nih.gov/pubmed/19383884>

852 Impact of Tumor-Infiltrating B-Cell Clonal Diversity on Response to Neoadjuvant Therapy in Triple Negative and HER2+ Breast Cancer Treated on CALGB (Alliance) 40601 and 40603

Michael D. Iglesia, Benjamin G. Vincent, Jonathan S. Serody, Lisa A. Carey, William T. Barry, William M. Sikov, Clifford Hudis, Eric M. Winer, Charles M. Perou Cancer Res vol 75 (9_supplement) abstr PD1-2 2014

Abstract Breast CALGB-40601, CALGB-40603
http://cancerres.aacrjournals.org/content/75/9_Supplement/PD1-2.short

- 853 Can a Gastric Cancer Risk Survey Identify High-Risk Patients for Endoscopic Screening? A Pilot Study**
Haejin In, Marisa Langdon-Embry, Lauren Gordon, Clyde B. Schechter, Judith Wylie-Rosett, Philip E. Castle, M. Margaret Kemeny, Bruce D. Rapkin *J Surg Res* vol 227 246-56 2018
Manuscript Health Outcomes <http://www.ncbi.nlm.nih.gov/pubmed/29622399>
- 854 A Pilot Case Control Study: Could a Gastric Cancer Risk Screening Tool Help Identify High Risk Patients for Endoscopic Screening in the US?**
Haejin In, Marisa Langdon-Embry, Lauren Gordon, Clyde Schechter, Judith Wylie-Rosett, Philip Castle, Margaret Kemeny, Bruce Rapkin *J Clin Oncol* vol 36 (supplement 4S) abstr 64 2018
Abstract Disparities https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.4_suppl.64
- 855 A Pilot Case Control Study: Could a Gastric Cancer Risk Screening Tool Help Identify High Risk Patients for Endoscopic Screening in the US?**
Haejin In, Marisa Langdon-Embry, Lauren Gordon, Clyde Schechter, Judith Wylie-Rosett, Philip Castle, Margaret Kemeny, Bruce Rapkin *Ann Surg Oncol* vol 25 (Suppl 1) S200 2018
Abstract Disparities <http://expo.jspargo.com/exhibitor/web/Abstracts18.pdf>
- 856 Utilizing Cultural and Ethnic Variables in Screening Models to Identify Individuals at High Risk for Gastric Cancer: A Pilot Study**
Haejin In, Ian Solsky, Philip E. Castle, Clyde B. Schechter, Michael Parides, Patricia Friedmann, Judith Wylie-Rosett, M. Margaret Kemeny, Bruce D. Rapkin *Cancer Prev Res (Phila)* vol 13 (8) 687-98 2020
Manuscript Disparities <http://www.ncbi.nlm.nih.gov/pubmed/32409594>
- 857 A Randomized Phase II Study of MLN0128 (M) vs. Pazopanib (P) in Pts with Advanced Sarcoma (Alliance A091304)**
M Ingham, M Mahoney, F Remotti, Sandra D'Angelo, A Shergill, M Dickson, S Attia, R. Riedel, V Villalobos, AD Elias, D Liebner, M Agulnik, K Thornton, V Monga, GK Schwartz, W Tap *J Clin Oncol* vol 38 (15_suppl) 11562 2020
Abstract Experimental https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.11562
- 858 Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52.**
James N Ingle, Vera J Suman, James A Mailliard, John W Kugler, James E Krook, John C Michalak, Thomas M Pisansky, Lester E Wold, John H Donohue, Matthew P Goetz, Edith A Perez *Breast Cancer Res Treat* vol 98 (2) 217-22 2006
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/16538529>
- 859 Heritable interleukin-17F (IL17F) gene variation is associated with overall survival (OS) in pancreatic cancer patients: Results from a genome-wide association study (GWAS) in CALGB 80303**
F. Innocenti, K. Owzar, N. J. Cox, P. Evans, M. Kubo, D. R. Hollis, T. Mushiroda, H. L. Kindler, Y. Nakamura, M. J. Ratain *J Clin Oncol* vol 27 (15s) abstr 4531 2009
Abstract PPP
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID
- 860 A genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients**
F Innocenti, C Jiang, A B Sibley, S Denning, A S Etheridge, D Watson, D Niedzwiecki, A J Hatch, H Hurwitz, A Nixon, Y Furukawa, M Kubo, D J Crona, H Kindler, H L McLeod, M J Ratain, K Owzar

861 An Initial Genetic Analysis of Gemcitabine-Induced High-Grade Neutropenia in Pancreatic Cancer Patients in CALGB 80303 (Alliance)

Federico Innocenti, Chen Jiang, Alexander B. Sibley, Stefanie Denning, Amy S. Etheridge, Dorothy Watson, Donna Niedzwiecki, Ace J. Hatch, Herbert I. Hurwitz, Andrew B. Nixon, Yoichi Furukawa, Michiaki Kubo, Daniel J. Crona, Hedy L. Kindler, Howard L. McLeod, Mark J. Ratain, Kouros Owzar
Pharmacogenet Genomics vol 29 (6) 123-31 2019

Manuscript PPP <http://www.ncbi.nlm.nih.gov/pubmed/30889042>

862 Genetic variation determines VEGF-A plasma levels in cancer patients

Federico Innocenti, Chen Jiang, Alexander B. Sibley, Amy S. Etheridge, Ace J. Hatch, Stefanie Denning, Donna Niedzwiecki, Ivo D. Shterev, Jiaying Lin, Yoichi Furukawa, Michiaki Kubo, Hedy L. Kindler, J. Todd Auman, Alan P. Venook, Herbert I. Hurwitz, Howard L. McLeod, Mark J. Ratain, Raluca Gordan, Andrew B. Nixon, Kouros Owzar
Sci Rep vol 8 16332 2018

Manuscript PPP <http://www.ncbi.nlm.nih.gov/pubmed/30397360>

863 Genetic prediction of VEGF-A plasma levels in cancer patients CALGB 80303 (Alliance)

Federico Innocenti, Chen Jiang, Alexander Sibley, Amy S Etheridge, Yoichi Furukawa, Michiaki Kubo, Hedy L Kindler, Alan P Venook, Herbert Hurwitz, Andrew Nixon, Kouros Owzar
Cancer Res vol 76 (14 suppl) abstr 3388 2016

Abstract PPP http://cancerres.aacrjournals.org/content/76/14_Supplement/3388

864 Causal modeling of CALGB 80405 (Alliance) identifies network drivers of metastatic colorectal cancer (CRC)

Federico Innocenti, Heinz-Josef Lenz, Jeffrey Meyerhardt, Donna Niedzwiecki, Andrew Nixon, Eileen O'Reilly, Fang-Shu Ou, Alan Venook, Rahul K. Das, Leon Furchtgott, Daniel Cunha, Kelly Rich, Jeanne Latourelle, Diane Wuest, Boris Hayete, Iya Khalil
J Clin Oncol vol 36 (Suppl) abstr 3570 2018

Abstract GI <https://meetinglibrary.asco.org/record/158938/abstract>

865 Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome

Federico Innocenti, Fang-Shu Ou, Xueping Qu, Tyler J. Zemla, Donna Niedzwiecki, Rachel Tam, Shilpi Mahajan, Richard M. Goldberg, Monica M. Bertagnolli, Charles D. Blanke, Hanna Sanoff, James Atkins, Blasé Polite, Alan P. Venook, Heinz-Josef Lenz, Omar Kabbarah
J Clin Oncol vol 37 (14) 1217-27 2019

Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/30865548>

866 Somatic DNA mutations, mutational load (ML), and MSI status: association with overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC) of CALGB/SWOG 80405 (Alliance)

Federico Innocenti, Fang-Shu Ou, Tyler Zemla, Donna Niedzwiecki, Xueping Qu, Rachel Tam, Shilpi Mahajan, Richard Goldberg, Robert Mayer, Monica Bertagnolli, Howard S. Hochster, Charles David Blanke, Alan P. Venook, Heinz-Josef Lenz, Hanna Sanoff, Omar Kabbarah
J Clin Oncol vol 35 (15 suppl) abstr 3504 2017

Abstract Correl Sci NOS http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.3504

867 A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303

Federico Innocenti, Kouros Owzar, Nancy L. Cox, Patrick Evans, Michiaki Kubo, Hitoshi Zembutsu, Chen Jiang, Donna Hollis, Taisei Mushiroda, Liang Li, Paula Friedman, Liewei Wang, Dylan Glubb,

Herbert Hurwitz, Kathleen M. Giacomini, Howard L. McLeod, Richard M. Goldberg, Richard L. Schilsky, Hedy L. Kindler, Yusuke Nakamura, Mark J. Ratain Clin Cancer Res vol 18 (2) 577-584 2012

Manuscript PPP CALGB-80303 <http://www.ncbi.nlm.nih.gov/pubmed/22142827>

868 The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients:

Genomic analysis and experimental validation

Federico Innocenti, Kouros Owzar, Chen Jiang, Amy S. Etheridge, Raluca Gordân, Alexander B. Sibley, Flora Mulkey, Donna Niedzwiecki, Dylan Glubb, Nicole Neel, Mark S. Talamonti, David J. Bentrem, Eric Seiser, Jen Jen Yeh, Katherine Van Loon, Howard McLeod, Mark J. Ratain, Hedy L. Kindler, Alan P. Venook, Yusuke Nakamura, Michiaki Kubo, Gloria M. Petersen, William R. Bamlet, Robert R. McWilliams PLoS ONE vol 13 (8) e0202272 2018

Manuscript PPP <http://www.ncbi.nlm.nih.gov/pubmed/30107003>

869 The vitamin D receptor gene is a determinant of survival in advanced pancreatic cancer patients

Federico Innocenti, Kouros Owzar, Chen Jiang, Eric Seiser, Amy Etheridge, Raluca Gordan, Dylan Glubb, Katherine Van Loon, Hedy L Kindler, Alan P Venook, Yusuke Nakamura, Michiaki Kubo, Gloria M Petersen, William R Bamlet, Robert R McWilliams 2015

Abstract GI [http](http://meetinglibrary.asco.org/content/151613-156)

870 A genome-wide association study (GWAS) of overall survival (OS) in 609 metastatic colorectal cancer (mCRC) patients treated with chemotherapy and biologics in CALGB 80405

Federico Innocenti, Kouros Owzar, Chen Jiang, Alexander B. Sibley, Donna Niedzwiecki, Heinz-Josef Lenz, Monica M. Bertagnolli, Paula N. Friedman, Yoichi Furukawa, Michiaki Kubo, Mark J. Ratain, Charles David Blanke, Alan P. Venook, Howard McLeod J Clin Oncol vol 33 (suppl) abstr 3599 2015

Abstract PPP <http://meetinglibrary.asco.org/content/151613-156>

871 A genome-wide association study (GWAS) of overall survival (OS) in 609 metastatic colorectal cancer (mCRC) patients treated with chemotherapy and biologics in CALGB 80405

Federico Innocenti, Kouros Owzar, Chen Jiang, Alexander B. Sibley, Donna Niedzwiecki, Heinz-Josef Lenz, Monica M. Bertagnolli, Yoichi Furukawa, Michiaki Kubo, Mark J. Ratain, Alan P. Venook, Howard McLeod Eur J Cancer vol 41 (suppl 3) S329–S330 2015

Abstract PPP [http://www.ejccancer.com/article/S0959-8049\(16\)30932-7/abstract](http://www.ejccancer.com/article/S0959-8049(16)30932-7/abstract)

872 A Genome-Wide Association Study (GWAS) Of Survival In Metastatic Breast Cancer (MBC) Patients Treated With Letrozole (L) With Or Without Bevacizumab (B) In CALGB 40503 (Alliance)

Federico Innocenti, Kouros Owzar, Chen Jiang, Alexander B Sibley, Flora Mulkey, Lisa Carey, Debu Tripathy, Bryan Schneider, William T Barry, Eric P Winer, Clifford A Hudis, Howard L McLeod, Maura N Dickler J Clin Oncol vol 34 (suppl) abstr 538 2016

Abstract PPP <http://meetinglibrary.asco.org/content/166252-176>

873 Next-generation sequencing (NGS) in patients (pts) with metastatic colorectal cancer (mCRC): novel mutated genes and differential response to therapy (Alliance)

Federico Innocenti, Naim Rashid, Wancen Mu, Fang-Shu Ou, Xueping Qu, Stefanie Denning, Monica Bertagnolli, Charles David Blanke, Alan P. Venook, Omar Kabbarah, Heinz-Josef Lenz Annals of Oncology vol 30 (Supplement_5) v198–v199 2019

Abstract GI [https://www.annalsofoncology.org/article/S0923-7534\(19\)58745-2/pdf](https://www.annalsofoncology.org/article/S0923-7534(19)58745-2/pdf)

874 Genomic analysis of germline variation associated with survival of colorectal cancer patients treated with chemotherapy plus biologics in CALGB/SWOG 80405 (Alliance)

Federico Innocenti, Alexander B. Sibley, Sushant A. Patil, Amy S. Etheridge, Chen Jiang, Fang-Shu Ou, Stefanie D. Howell, Sarah J Plummer, Graham Casey, Monica M. Bertagnolli, Howard L.

McLeod, James T. Auman, Charles D. Blanke, Yoichi Furukawa, Alan P. Venook, Michiaki Kubo, Heinz-Josef Lenz, Joel S. Parker, Mark J. Ratain, Kouros Owzar Clin Cancer Res vol 27 (1) 267-75 2021

Manuscript PPP <http://www.ncbi.nlm.nih.gov/pubmed/32958699>

875 Bevacizumab-induced hypertension and proteinuria: A genome-wide analysis of more than 1,000 patients (Alliance)

Federico Innocenti, Jin Wang, Alexander B. Sibley, Chen Jiang, Amy S. Etheridge, Fei Shen, Jai N. Patel, Daniel L. Hertz, Elizabeth Claire Dees, Howard L. McLeod, Monica Bertagnolli, Hope Rugo, Hedy L. Kindler, William Kevin Kelly, Mark J. Ratain, Deanna L. Kroetz, Kouros Owzar, Bryan Schneider, Danyu Lin, Júlia C.F. Quintanilha. European Journal of Cancer vol 138 (Supplement 2) S9-S10 2020

Abstract PPP CALGB-40502, CALGB-40503, CALGB-80303, CALGB-90401

[https://www.ejancer.com/article/S0959-8049\(20\)31090-X/abstract](https://www.ejancer.com/article/S0959-8049(20)31090-X/abstract)

876 Immune signatures to affect overall survival (OS) and response to bevacizumab (Bev) or cetuximab (Cet) in patients (pts) with metastatic colorectal cancer (mCRC) of CALGB/SWOG 80405 (Alliance)

Federico Innocenti, Akram Yazdani, Xueping Qu, Fang-Shu Ou, Scott Van Buren, Omar Kabbarah, Charles David Blanke, Alan P. Venook, Heinz-Josef Lenz, Benjamin Garrett Vincent J Clin Oncol vol 39 (15_suppl) 3515 2021

Abstract GI <https://meetings.asco.org/abstracts-presentations/195974>

877 Tumor Immunogenomic Features Determine Outcomes in Patients with Metastatic Colorectal Cancer Treated with Standard-of-Care Combinations of Bevacizumab and Cetuximab.

Federico Innocenti, Akram Yazdani, Naim Rashid, Xueping Qu, Fang-Shu Ou, Scott Van Buren, Monica M Bertagnolli, Omar Kabbarah, Charles David Blanke, Alan P Venook, Heinz-Josef Lenz, Benjamin G Vincent Clin Cancer Res vol 28 (8) 1690-1700 2022

Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/35176136>

878 Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphoma.

D J Inwards, P A Fishkin, B R LaPlant, M T Drake, P J Kurtin, D A Nikcevich, D B Wender, B S Lair, T E Witzig Ann Oncol vol 25 (10) 2020-4 2014

Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/25057177>

879 Phase I Trial of Rituximab, Cladribine and Temsirolimus (RCT) for Initial Therapy of Mantle Cell Lymphoma

D. J. Inwards, P. Fishkin, B. R. Laplant, M. T. Drake, P. Kurtin, D. Nikcevich, D. Wender, B. Lair, T. E. Witzig ASH Annual Meeting Abstracts vol 120 (21) -3661 2012

Abstract Lymphoma <http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;120/21/3661>

880 Long-term Results of the Treatment of Patients With Mantle Cell Lymphoma With Cladribine (2-CDA) Alone (95-80-53) or 2-CDA and Rituximab (N0189) in the North Central Cancer Treatment Group

David J. Inwards, Paul A. S. Fishkin, David W. Hillman, David W. Brown, Stephen M. Ansell, Paul J. Kurtin, Rafael Fonseca, Roscoe F. Morton, Michael H. Veeder, Thomas E. Witzig Cancer vol 113 (1) 108-116 2008

Manuscript Lymphoma NCCTG-N0189, NCCTG-95-80-53

<http://www.ncbi.nlm.nih.gov/pubmed/18470909>

881 Enrollment Patterns and Site Level Predictors of Black Participant Recruitment to a Multisite Randomized Clinical Trial of Endocrine Therapy Adherence Support (Alliance)

Joannie Ivory, Heather Gunn, Stephanie B Wheeler, Sarah Drier, Electra Paskett, Michelle Naughton, Shaylene McCue, Rachel Wills, Kayla Swetel, Selina Chow, Katherine Reeder-Hayes J Clin Oncol vol 40 (28) 68 2022
Abstract Disparities https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.28_suppl.068

882 A Phase II Study of Gemcitabine Plus Cisplatin Chemotherapy in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for those Patients whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations (Alliance A031701)

Gopa Iyer, Karla V. Ballman, Pamela Atherton, Katie Murray, Young Kwok, Preston Steen, Shiva Baghaie, Jonathan E. Rosenberg, Michael J. Morris J Clin Oncol vol 40 (16_suppl) TPS4615-TPS4615 2022
Abstract GU https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.TPS4615

883 Association of DNA damage repair (DDR) mutations (mts) and clinical outcomes in CALGB 90601 (Alliance)

Gopa Iyer, Susan Halabi, Bin Luo, Woonyoung Choi, Hikmat Al-Ahmadie, Jack Mountain, Ashley Regazzi, Megan Fong, Kent Mouw, Eli Van Allen, David M McConkey, Yujia Wen, Linda McCart, Karla Ballman, Misha Beltran, Michael Morris, Jonathan E Rosenberg J Clin Oncol vol 40 (16_suppl) 4521-4521 2022
Abstract GU https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.4521

884 Mucolytic N-Acetylcysteine vs Placebo Rinses for Mucositis during Head and Neck Chemoradiotherapy

J.C.Rwigema, T.Sio, M.Blanchard, P.Novotny, S.Patel, L.Pederson, M.Gamez, G.Seeger J.Martenson, Y.Grover, R.Foote, R.Miller, M.Halyard 2018
Abstract Symptom Inter
<https://d11x47257n5xt.cloudfront.net/257060/data/common/downloads/publication.pdf?uni=2.19.4&data>

885 The impact of smoking on cancer recurrence and survival in patients with stage III colon cancer: Findings from Intergroup trial CALGB 89803

N. A. Jackson, C. S. Fuchs, D. Niedzwiecki, D. R. Hollis, L. B. Saltz, R. J. Mayer, J. A. Meyerhardt J Clin Oncol vol 26 (May 20 suppl) abstr 4039 2008
Abstract GI
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID

886 Transformation of low grade glioma and correlation with outcome: an NCCTG database analysis.

K A Jaeckle, P A Decker, K V Ballman, P J Flynn, C Giannini, B W Scheithauer, R B Jenkins, J C Buckner J Neurooncol vol 104 (1) 253-9 2011
Manuscript Neuro-Onc Comprehensive, NCCTG-85-72-51, NCCTG-86-03-51, NCCTG-88-72-02, NCCTG-88-72-52, NCCTG-90-72-01, NCCTG-91-72-01, NCCTG-92-72-03, NCCTG-93-72-02, NCCTG-93-72-52, NCCTG-88-72-51, NCCTG-89-72-51, NCCTG-89-72-52, NCCTG-91-72-51, NCCTG-92-72-51, NCCTG-93-72-51, NCCTG-95-72-53, NCCTG-98-72-54, NCCTG-N997B, NCCTG-84-72-51, NCCTG-86-72-02, NCCTG-86-72-53, NCCTG-N0074, NCCTG-N0272, NCCTG-98-72-52, NCCTG-86-72-51, NCCTG-98-72-51, NCCTG-96-72-51
<http://www.ncbi.nlm.nih.gov/pubmed/21153680>

887 NCCTG N0272: phase II trial of imatinib mesylate; (gleevec; sti571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma: a north central cancer treatment group study.

K. A. Jaeckle, S. K. Anderson, M. Kosel, J. Sarkaria, P. Brown, P. J. Flynn, J. C. Buckner, E. Galanis Neuro-oncology vol 13 (3) 89 2011
Abstract Neuro-Onc http://neuro-oncology.oxfordjournals.org/content/13/suppl_3/iii85.abstract

888 NCCTG N0572 phase I/II trial of sorafenib and temsirolimus in patients with recurrent glioblastoma: A North Central Cancer Treatment Group study

K. A. Jaeckle, D. Schiff, S. K. Anderson, E. Galanis, P. J. Stella, P. J. Flynn, J. N. Sarkaria, B. W. Scheithauer, B. J. Erickson, J. C. Buckner J Clin Oncol vol 29 (suppl) abstr 2033 2011
Abstract Neuro-Onc <http://meetinglibrary.asco.org/content/80655-102>

889 Correlation of response with survival endpoints in patients with newly diagnosed and recurrent glioblastoma (GBM) treated on prospective North Central Cancer Treatment Group (NCCTG) clinical trials

K. A. Jaeckle, W. Wu, M. Kosel, P. J. Flynn, J. C. Buckner J Clin Oncol vol 26 (15s, pt I) 95s abstr 2024 2008
Abstract Neuro-Onc
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID

890 Phase I/II trial of sorafenib and CCI-779 in patients with recurrent glioblastoma (GBM)

K. Jaeckle, K. Anderson, J. Sarkaria, P. Decker, J. Buckner, E. Galanis, J. Dancy, C. Giannini, P. Brown, M. Wiesenfeld, D. Schiff 2008
Abstract Neuro-Onc

891 Results of a phase II trial of vorinostat in patients with recurrent glioblastoma: Evidence of post-treatment histone acetylation in tumor tissue and pharmacokinetic analysis: North Central Cancer Treatment Group (NCCTG) study N047B

K. Jaeckle, M. Maurer, J. Reid, M. Ames, C. Giannini, D. Moore, J. Zwiebel, J. Buckner, E. Galanis 2007
Abstract Neuro-Onc

892 NCCTG (Alliance) N0572: A phase II trial of sorafenib and temsirolimus in recurrent glioblastoma (GBM) patients who progress following prior RT/temozolomide (TMZ) and VEGF inhibitors (VEGFi)

K. Jaeckle, D. Schiff, S. Anderson, E. Galanis, P. Stella, P. Flynn, J. Sarkaria, C. Giannini, B. Erickson, J. Buckner J Clin Oncol vol 31 (15 suppl) abstr 2014 2013
Abstract Neuro-Onc
http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/2014?sid=165fe81a-424a-4104-aacf-b90d5

893 Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North Central Cancer Treatment Group study N0272 (Alliance/NCCTG)

Kurt A. Jaeckle, S K. Anderson, Erin L. Twohy, Jesse G. Dixon, Caterina Giannini, Robert Jenkins, Merrill J. Egorin, Jann N. Sarkaria, Paul D. Brown, P J. Flynn, John Schwerkoske, Jan C. Buckner, Eva Galanis J Neurooncol vol 143 (3) 573-81 2019
Manuscript Neuro-Onc <http://www.ncbi.nlm.nih.gov/pubmed/31119479>

894 CODEL: Phase III study of RT alone, RT plus temozolomide, or temozolomide alone for newly diagnosed 1P/19Q codeleted anaplastic oligodendroglioma patients. Updated analysis from the initial study design (NCCTG N0577, Alliance)

Kurt A. Jaeckle, Karla V. Ballman, Martin van den Bent, Caterina Giannini, Evanthia Galanis, Paul D. Brown, Robert B. Jenkins, J Gregory Cairncross, Wolfgang Wick, Michael Weller, Kenneth D. Aldape, Jesse G. Dixon, S. Keith Anderson, Jane H. Cerhan, Jeffrey S. Wefel, Martin Klein, Stuart A. Grossman, David Schiff, Frederick Dhermain, Donald G. Nordstrom, Patrick J. Flynn, Michael A. Vogelbaum Neuro-oncology vol 22 (2) NP CTNI-29. 2020
Abstract Neuro-Onc
https://academic.oup.com/neuro-oncology/article/22/Supplement_2/NP/5960537

- 895 Correlation of enzyme-inducing anticonvulsant use with outcome of patients with glioblastoma**
Kurt A. Jaeckle, Karla Ballman, Alfred Furth, Jan C. Buckner *Neurology* vol 73 (15) 1207-1213
2009
Manuscript *Neuro-Onc* <http://www.ncbi.nlm.nih.gov/pubmed/19822870>
- 896 CODEL: phase III study of RT, RT+ TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design**
Kurt A Jaeckle, Karla V Ballman, Martin van den Bent, Caterina Giannini, Evanthia Galanis, Paul D Brown, Robert B Jenkins, J Gregory Cairncross, Wolfgang Wick, Michael Weller, Kenneth D Aldape, Jesse G Dixon, S Keith Anderson, Jane H Cerhan, Jeffrey S Wefel, Martin Klein, Stuart A Grossman, David Schiff, Jeffrey J Raizer, Frederick Dhermain, Donald G Nordstrom, Patrick J Flynn, Michael A Vogelbaum *Neuro Oncol* vol 23 (3) 457-67 2020
Manuscript *Neuro-Onc* <http://www.ncbi.nlm.nih.gov/pubmed/32678879>
- 897 CODEL (Alliance-N0577; EORTC-26081/22086; NRG-1071; NCIC-CEC-2): Phase III randomized study of RT vs. RT+TMZ vs. TMZ for newly diagnosed 1p/19q-codeleted anaplastic glioma. Analysis of patients treated on the original protocol design**
Kurt Jaeckle, Michael Vogelbaum, Karla Ballman, S. Keith Anderson, Caterina Giannini, Kenneth Aldape, Jane Cerhan, Jeffrey Wefel, Donald Nordstrom, Robert Jenkins, Martin Klein, Jeffrey Raizer, Martin van den Bent, Wolfgang Wick, Patrick Flynn, Frederick Dhermain, Gregory Cairncross, Paul Brown *Neurology* vol 86 (16 suppl) abstr PL02.005 2016
Abstract *Neuro-Onc*
http://www.neurology.org/content/86/16_Supplement/PL02.005.short?sid=e537ffeb-b9f7-4182-beb0-68
- 898 CODEL (Alliance N0577; EORTC 26081/22086 ; NRG 1071; NCIC CEC-2): A Phase III Randomized Intergroup Study for patients (pts) with newly diagnosed 1p/19q codeleted anaplastic glioma. Preliminary analysis of patients treated on the original protocol design with RT vs. RT + concomitant/adjuvant TMZ vs. TMZ alone**
Kurt Jaeckle, Michael Voglebaum, Karla Ballman, Caterina Giannini, Ken Aldape, Jane Cerhan, Jeffrey Wefel, Donald Nordstrom, Robert Jenkins, Martin Klein, Jeffrey Raizer, Martin van den Bent, Wolfgang Wick, Patrick Flynn, Frederick Dhermain, Gregory Cairncross, Paul Brown *Neuro Oncol* vol 17 (suppl 5) v4-v5 abstr ATCT-16 2015
Abstract *Neuro-Onc*
http://neuro-oncology.oxfordjournals.org/content/17/suppl_5/v4.4.full?sid=5a186658-2b60-4272-94f5-31
- 899 Radiation field design on the ACOSOG Z0011 trial**
R. Jagsi, K. Ballman, M. Chadha, J. Moni, F. Laurie, T. A. Buchholz, B. G. Haffty, A. Giuliano *Cancer Res* vol 73 (24 Suppl) Abstract P5-14-19 2013
Abstract *Breast* http://cancerres.aacrjournals.org/content/73/24_Supplement/P5-14-19
- 900 Radiation Field Design in the ACOSOG Z0011 (Alliance) Trial**
Reshma Jagsi, Manjeet Chadha, Janaki Moni, Karla Ballman, Fran Laurie, Thomas A. Buchholz, Armando Giuliano, Bruce G. Haffty *J Clin Oncol* vol 32 (32) 3600-3606 2014
Manuscript *Breast* <http://www.ncbi.nlm.nih.gov/pubmed/25135994>
- 901 Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107).**
Thierry Jahan, Lin Gu, Robert Kratzke, Arkadiusz Dudek, Gregory A Otterson, Xiaofei Wang, Mark Green, Everett E Vokes, Hedy Lee Kindler *Lung Cancer* vol 76 (3) 393-6 2012
Manuscript *Respiratory* <http://www.ncbi.nlm.nih.gov/pubmed/22197613>
- 902 Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial**

Nikolaus Jahn, Ekaterina Jahn, Maral Saadati, Lars Bullinger, Richard A. Larson, Tiziana Ottone, Sergio Amadori, Thomas W. Prior, Joseph M. Brandwein, Frederick R. Appelbaum, Bruno C. Medeiros, Martin S. Tallman, Gerhard Ehninger, Michael Heuser, Arnold Ganser, Celine Pallaud, Insa Gathmann, Julia Krzykalla, Axel Benner, Clara D. Bloomfield, Christian Thiede, Richard M. Stone, Hartmut Döhner, Konstanze Döhner *Leukemia* vol 36 (9) 2218-27 2022
Manuscript *Leuk Corr Sci* <http://www.ncbi.nlm.nih.gov/pubmed/35922444>

903 Genetic landscape of FLT3-mutated acute myeloid leukemia (AML) patients treated within the ratify trial (Alliance C10603)

Nikolaus Jahn, Ekaterina Panina, Lars Bullinger, Anna Dolnik, Julia Herzig, Tamara J. Blätte, Axel Benner, Julia Krzykalla, Insa Gathmann, Richard A. Larson, Francesco Lo-Coco, Sergio Amadori, Thomas W. Prior, Joseph M. Brandwein, Frederick R. Appelbaum, Bruno C. Medeiros, Martin S. Tallman, Eva Tiecke, Celine Pallaud, Gerhard Ehninger, Michael Heuser, Arnold Ganser, Richard M. Stone, Christian Thiede, Hartmut Döhner, Clara D. Bloomfield, Konstanze Döhner *HemaSphere* vol 3 (Issue) 436 2019
Abstract *Leuk Corr Sci*
https://journals.lww.com/hemasphere/Fulltext/2019/06001/GENETIC_LANDSCAPE_OF_FLT3_MUT/

904 Comprehensive molecular profiling of FLT3-mutated acute myeloid leukemia (AML) patients treated within the RATIFY trial (Alliance)

Nikolaus Jahn, Ekaterina Panina, Lars Bullinger, Anna Dolnik, Julia Herzig, Tamara J. Blätte, Axel Benner, Julia Krzykalla, Insa Gathmann, Richard A. Larson, Francesco Lo-Coco, Sergio Amadori, Thomas W. Prior, Joseph M. Brandwein, Frederick R. Appelbaum, Bruno C. Medeiros, Martin S. Tallman, Eva Tiecke, Celine Pallaud, Gerhard Ehninger, Michael Heuser, Arnold Ganser, Richard M. Stone, Christian Thiede, Hartmut Döhner, Clara D. Bloomfield, Konstanze Döhner *Blood* vol 132 (Suppl 1) 1534 2018
Abstract *Leuk Corr Sci* http://www.bloodjournal.org/content/132/Suppl_1/1534

905 Prospective phase II trial of preresection thoracoscopic mediastinal restaging after neoadjuvant therapy for IIIA (N2) non-small cell lung cancer: Results of CALGB Protocol 39803

M. T. Jaklitsch, L. Gu, T. Demmy, D. H. Harpole, T. A. D'Amico, R. J. Mckenna Jr, M. J. Krasna, L. J. Kohman, S. J. Swanson, M. M. Decamp, X. Wang, S. Barry, D. J. Sugarbaker *J Thorac Cardiovasc Surg* vol 146 (1) 9-16 2013
Manuscript *Respiratory* <http://www.ncbi.nlm.nih.gov/pubmed/23768804>

906 Prospective Phase II Trial of Pre-Resection Thoracoscopic (VATS) Restaging Following Neoadjuvant Therapy For IIIA(N2) Non-small Cell Lung Cancer (NSCLC): Results of CALGB 39803

M. T. Jaklitsch, L. Gu, D. H. Harpole, T. A. D'Amico, R. J. Mckenna Jr, M. J. Krasna, L. J. Kohman, S. J. Swanson, M. M. Decamp, D. J. Sugarbaker *J Clin Oncol* vol 23 (16s) abstr 7065 2005
Abstract *Respiratory*
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=34&abstractID

907 Randomized phase II trial of erlotinib (E) alone or in combination with carboplatin/paclitaxel (CP) in never or light former smokers with advanced lung adenocarcinoma: CALGB 30406

P. A. Janne, V. A. Miller, X. Wang, M. A. Socinski, J. Crawford, M. Capelletti, M. J. Edelman, M. A. Villalona-Calero, R. A. Kratzke, E. E. Vokes *J Clin Oncol* vol 28 (15s) abstr 7503 2010
Abstract *Respiratory*
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID

908 Sorafenib in malignant mesothelioma (MM): A phase II trial of the Cancer and Leukemia Group B (CALGB 30307)

P. A. Janne, X. F. Wang, L. M. Krug, L. Hodgson, E. E. Vokes, H. L. Kindler *J Clin Oncol* vol 25 (18s) abstr 7707 2007

909 Randomized Phase II Trial of Erlotinib Alone or With Carboplatin and Paclitaxel in Patients Who Were Never or Light Former Smokers With Advanced Lung Adenocarcinoma: CALGB 30406 Trial

P. A. Janne, X. F. Wang, M. A. Socinski, J. Crawford, T. E. Stinchcombe, L. Gu, M. Capelletti, M. J. Edelman, M. A. Villalona-Calero, R. Kratzke, E. E. Vokes, V. A. Miller J Clin Oncol vol 30 (17) 2063-2069 2012

Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/22547605>

910 Outcome of advanced NSCLC patients with EGFR exon 19 and 21 mutations treated with erlotinib (E) alone or in combination with carboplatin/paclitaxel (CP) in CALGB 30406

P. A. Janne, X. Wang, M. A. Socinski, J. Crawford, L. Gu, M. Capelletti, M. J. Edelman, M. A. Villalona-Calero, R. A. Kratzke, E. E. Vokes, V. A. Miller J Thorac Oncol vol 6 (suppl 2) abstr O39.01 2011

Abstract Respiratory <http://journals.lww.com/jto/toc/2011/06001#1986296615>

911 Prognostic and Predictive Values of KRAS in EGFR-based Subgroups and Combined with P53 in Completely Resected Non-Small Cell Lung Cancer (NSCLC): a LACE-Bio Study

P. Janne, F. Shepherd, C. Domerg, G. Le Teuff, R. Kratzke, P. Hainaut, J. Pignon, R. Rosell, J. Soria, M. Tsao Ann Oncol vol 23 ((suppl 9): ix73-ix94.) abstract 1670 2012

Abstract Respiratory

http://annonc.oxfordjournals.org/content/23/suppl_9/ix73.abstract?sid=f3d4d421-30a0-497a-8e9e-bb1b9

912 Family history of colorectal cancer and its impact on survival in patients with resected stage III colon cancer: results from NCCTG Trial N0147 (Alliance)

Claire L. Jansson-Knodell, Nathan R. Foster, Daniel J. Sargent, Paul J. Limburg, Stephen N. Thibodeau, Thomas C. Smyrk, Frank A. Sinicrope, Balkrishna Jahagirdar, Richard M. Goldberg, Steven R. Alberts J Gastrointest Oncol vol 8 (1) 1-11 2017

Manuscript Prevention <http://www.ncbi.nlm.nih.gov/pubmed/28280603>

913 Elderly patients with metastatic esophageal/gastric cancer: a pooled analysis of age-based outcomes from 8 consecutive North Central Cancer Treatment Group (NCCTG) therapeutic trials

A. Jatoi, N. R. Foster, J. Egner, P. Burch, P. J. Stella, J. Rubin, S. R. Dakhil, D. J. Sargent, B. Murphy, S. R. Alberts J Clin Oncol vol 26 (15s abstr 9507) 503s 2008

Abstract GI http://ascopubs.org/doi/abs/10.1200/jco.2008.26.15_suppl.9507

914 A phase II study of cetuximab and radiation in elderly and/or poor performance status patients with locally advanced non-small-cell lung cancer (N0422)

A. Jatoi, S. E. Schild, N. Foster, G. T. Henning, K. J. Dornfeld, P. J. Flynn, T. R. Fitch, S. R. Dakhil, K. M. Rowland Jr, P. J. Stella, G. S. Soori, A. A. Adjei Ann Oncol vol 21 (10) 2040-4 2010

Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/20570832>

915 A double-blind, placebo-controlled randomized trial of creatine for the cancer anorexia/weight loss syndrome (N02C4): an Alliance trial.

A Jatoi, P D Steen, P J Atherton, D F Moore, K M Rowland, N A Le-Lindqwister, C S Adonizio, A J Jaslowski, J Sloan, C Loprinzi Ann Oncol vol 28 (8) 1957-63 2017

Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/28475678>

916 A tomato-based, lycopene-containing intervention for androgen-independent prostate cancer: results of a Phase II study from the North Central Cancer Treatment Group.

Aminah Jatoi, Patrick Burch, David Hillman, Joanne M Vanyo, Shaker Dakhil, Daniel Nikcevich,

Kendrith Rowland, Roscoe Morton, Patrick J Flynn, Charles Young, Winston Tan Urology vol 69 (2) 289-94 2007

Manuscript GU <http://www.ncbi.nlm.nih.gov/pubmed/17320666>

917 Bortezomib, Paclitaxel, and Carboplatin as a First-Line Regimen for Patients with Metastatic Esophageal, Gastric, and Gastroesophageal Cancer: Phase II Results from the North Central Cancer Treatment Group (N044B)1

Aminah Jatoi, Shaker R. Dakhil, Nathan R. Foster, Cynthia Ma, Kendrith M. Rowland, Dennis F. Moore, Anthony J. Jaslowski, Sachdev P. Thomas, Mark D. Hauge, Patrick J. Flynn, Philip J. Stella, Steven R. Alberts J Thorac Oncol vol 3 (5) 516-520 2008

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/18449005>

918 Prophylactic Tetracycline Does Not Diminish the Severity of Epidermal Growth Factor Receptor (EGFR) Inhibitor Induced Rash: Results from the North Central Cancer Treatment Group (Supplementary N03CB)1

Aminah Jatoi, Shaker R. Dakhil, Jeff A. Sloan, John W. Kugler, Kendrith M. Rowland, Paul L. Schaefer, Paul J. Novotny, Donald B. Wender, Howard M. Gross, Charles L. Loprinzi Support Care Cancer vol 19 (10) 1601-1607 2011

Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/20820817>

919 Older versus younger patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and stomach: A pooled analysis of eight consecutive North Central Cancer Treatment Group (NCCTG) trials

Aminah Jatoi, Nathan R. Foster, James R. Egner, Patrick A. Burch, Philip J. Stella, Joseph Rubin, Shaker R. Dakhil, Daniel J. Sargent, Brian R. Murphy, Steven R. Alberts Int J Oncol vol 36 (3) 601-606 2010

Manuscript Experimental <http://www.ncbi.nlm.nih.gov/pubmed/20126980>

920 Clinical Predictors of Severe Cetuximab-Induced Rash: Observations from 933 Patients Enrolled in North Central Cancer Treatment Group Study N0147

Aminah Jatoi, Erin M. Green, Kendrith M. Jr. Rowland, Daniel J. Sargent, Steven R. Alberts Oncology vol 77 (2) 120-123 2009

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/19622902>

921 Is social support associated with improved clinical outcomes in geriatric lung cancer patients? Observations from North Central Cancer Treatment Group Studies N9921 and N0222

Aminah Jatoi, Shauna L Hillman, Katie L Allen Ziegler, Philip J Stella, Gamini S Soori, Kendrith M Rowland Cancer Manag Res vol 1 61-8 2009

Manuscript Respiratory NCCTG-N0222, NCCTG-N9921
<http://www.ncbi.nlm.nih.gov/pubmed/21188124>

922 Paclitaxel, carboplatin, 5-fluorouracil, and radiation for locally advanced esophageal cancer: phase II results of preliminary pharmacologic and molecular efforts to mitigate toxicity and predict outcomes: North Central Cancer Treatment Group (N0044).

Aminah Jatoi, James A Martenson, Nathan R Foster, Howard L McLeod, Bradley S Lair, Frank Nichols, Loren K Tschetter, Dennis F Moore, Tom R Fitch, Steven R Alberts Am J Clin Oncol vol 30 (5) 507-13 2007

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/17921712>

923 Social Support and Its Implications in Older, Early-Stage Breast Cancer Patients in CALGB 49907 (Alliance A171301)

Aminah Jatoi, Hyman Muss, Jake B. Allred, Harvey J. Cohen, Karla Ballman, Judith O. Hopkins, Ajeet Gajra, Jacqueline Lafky, Antonio Wolff, Lisa Kottschade, Julie Gralow, Arti Hurria

- 924 Interleukin-1 genetic polymorphisms and their relationship to the cancer anorexia/weight loss syndrome in metastatic gastric and gastroesophageal junction adenocarcinoma.**
Aminah Jatoi, Phuong L Nguyen, Nathan Foster, David Sun, Philip J Stella, Megan Campbell, Loren K Tschetter, Shaker R Dakhil, James A Mailliard, Daniel A Nikcevich *J Support Oncol* vol 5 (1) 41-6 2007
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/17265786>
- 925 A Pilot Study of Long-Acting Octreotide for Symptomatic Malignant Ascites (N04C2)**
Aminah Jatoi, Jorge J. Nieva, Rui Qin, Charles L. Loprinzi, Edward J. Wos, Paul J. Novotny, Dennis F. Moore, Rex B. Mowat, Naftali Bechar, Eduardo R. Pajon, Lynn C. Hartmann *Oncology* vol 82 (6) 315-320 2012
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/22572824>
- 926 A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9).**
Aminah Jatoi, Howard L Ritter, Amylou Dueck, Phuong L Nguyen, Daniel A Nikcevich, Ronnie F Luyun, Bassam I Mattar, Charles L Loprinzi *Lung Cancer* vol 68 (2) 234-9 2010
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/19665818>
- 927 Tetracycline to Prevent Epidermal Growth Factor Receptor Inhibitor-Induced Skin Rashes: Results of a Placebo-Controlled Trial from the North Central Cancer Treatment Group (N03CB)1**
Aminah Jatoi, Kendrith Rowland, Jeff A. Sloan, Howard M. Gross, Paul A. Fishkin, Stephen P. Kahanic, Paul J. Novotny, Paul L. Schaefer, David B. Johnson, Loren K. Tschetter, Charles L. Loprinzi *Cancer* vol 113 (4) 847-853 2008
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/18543329>
- 928 Phase II Study of Preoperative Pemetrexed, Carboplatin, and Radiation Followed by Surgery for Locally Advanced Esophageal Cancer and Gastroesophageal Junction Tumors**
Aminah Jatoi, Gamini Soori, Nathan R. Foster, Bradley Hiatt, James A. Knost, Tom R. Fitch, Matthew D. Callister, Francis C. Nichols, Tim M. Husted, Steven R. Alberts *J Thorac Oncol* vol 5 (12) 1994-1998 2010
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/20975604>
- 929 Does Sunscreen Prevent Epidermal Growth Factor Receptor (EGFR) Inhibitor-Induced Rash? Results of a Placebo-Controlled Trial from the North Central Cancer Treatment Group (N05C4)**
Aminah Jatoi, Abby Thrower, Jeff A. Sloan, Patrick J. Flynn, Nicole Lea Wentworth-Hartung, Shaker R. Dakhil, Bassam I. Mattar, Daniel A. Nikcevich, Paul Novotny, Aleksandar Sekulic, Charles L. Loprinzi *Oncologist* vol 15 (9) 1016-1022 2010
Manuscript Prevention <http://www.ncbi.nlm.nih.gov/pubmed/20798191>
- 930 A phase I/II trial adding the poly(ADP-ribose) polymerase (PARP) inhibitor veliparib to induction carboplatin-paclitaxel in patients with locoregionally advanced squamous cell carcinoma of the head and neck (HNSCC) Alliance A091101**
Michael J. Jelinek, Nathan R. Foster, Alex J. Zoroufy, Jonas A. DeSouza, Gary K. Schwartz, Pamela Munster, Tanguy Seiwert, Everett E. Vokes *J Clin Oncol* vol 36 (15 suppl) 6031 2018
Abstract Experimental https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.6031
- 931 A Phase I Trial Adding Poly(ADP-ribose) Polymerase Inhibitor Veliparib to Induction Carboplatin-Paclitaxel in Patients with Head and Neck Squamous Cell Carcinoma: Alliance A091101**
Michael J. Jelinek, Nathan R. Foster, Alex J. Zoroufy, Gary K. Schwartz, Pamela N. Munster, Tanguy

- 932 Impact of physical activity after cancer diagnosis on survival in patients with recurrent colon cancer: Findings from CALGB 89803 / ALLIANCE**
Justin Jeon, Kaori Sato, Donna Niedzwiecki, Xing Ye, Leonard B. Saltz, Robert J. Mayer, Rex B. Mowat, Renaud Whittom, Alexander Hantel, Al Benson, Devin S. Wigler, Daniel Atienza, Michael Messino, Hedy Kindler, Alan Venook, Charles S. Fuchs, Jeffrey A. Meyerhardt Clin Colorectal Cancer vol 12 (4) 2013
Manuscript Prevention <http://www.ncbi.nlm.nih.gov/pubmed/24035029>
- 933 Phase II trial of pemetrexed (P) and carboplatin (C) in previously untreated extensive stage disease small cell lung cancer (ED-SCLC): A NCCTG Study**
J. R. Jett, A. Bernath Jr, N. Foster, J. Molina, D. Nikcevich, P. Steen, P. Flynn, K. Rowland Jr, T. Fitch, A. Adjei J Clin Oncol vol 26 (suppl) abstr 8066 2008
Abstract Respiratory
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID
- 934 The Effect of Atorvastatin on Breast Cancer Biomarkers in High-Risk Women**
YongLi Ji, Tiffany Rounds, Abigail Crocker, Betsy Sussman, Russell C. Hovey, Fonda Kingsley, Hyman B. Muss, Judy E. Garber, Marie E. Wood Cancer Prev Res (Phila) vol 9 (5) 379-384 2016
Manuscript Prevention <http://www.ncbi.nlm.nih.gov/pubmed/26908565>
- 935 Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib**
Heikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, Jörg T Hartmann, Daniel Pink, Jochen Schütte, Giuliano Ramadori, Peter Hohenberger, Justus Duyster, Salah-Eddin Al-Batran, Marcus Schlemmer, Sebastian Bauer, Eva Wardelmann, Maarit Sarlomo-Rikala, Bengt Nilsson, Harri Sihto, Karla V Ballman, Mika Leinonen, Ronald P DeMatteo, Peter Reichardt Cancer vol 120 (15) 2325-2333 2014
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/24737415>
- 936 Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer (NSCLC) after completion of initial therapy (NCCTG 97-24-51).**
Elizabeth A Johnson, Randolph S Marks, Sumithra J Mandrekar, Shauna L Hillman, Mark D Hauge, Mitchel D Bauman, Edward J Wos, Dennis F Moore, John W Kugler, Harold E Windschitl, David L Graham, Albert M Bernath, Tom R Fitch, Gamini S Soori, James R Jett, Alex A Adjei, Edith A Perez Lung Cancer vol 60 (2) 200-7 2008
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/18045731>
- 937 Geriatric assessment measures are predictive of outcomes in chronic lymphocytic leukemia.**
P Connor Johnson, Jennifer A Woyach, Angela Ulrich, Veronique Marcotte, Ryan D Nipp, Daniel E Lage, Ashley M Nelson, Richard A Newcomb, Julia Rice, Mitchell W Lavoie, Christine S Ritchie, Nancy Bartlett, Deborah M Stephens, Wei Ding, Carolyn Owen, Richard Stone, Amy S Ruppert, Sumithra J Mandrekar, John C Byrd, Areej El-Jawahri, Jennifer Le-Rademacher, Ashley Rosko J Geriatr Oncol vol 14 (6) 101538 2023
Manuscript Older Adult <http://www.ncbi.nlm.nih.gov/pubmed/37329769>
- 938 ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer**
Radia M. Johnson, Xueping Qu, Chu-Fang Lin, Ling-Yuh Huw, Avinashnarayan Venkatanarayan, Ethan Sokol, Fang-Shu Ou, Nnamdi Ihuegbu, Oliver A. Zill, Omar Kabbarah, Lisa Wang, Richard Bourgon, Felipe de Sousa e Melo, Chris Bolen, Anneleen Daemen, Alan P. Venook, Federico Innocenti, Heinz-Josef Lenz, Carlos Bais Nat Commun vol 13 (1) 5478 2022

- 939 ARID1A mutations induce an EGFR-like gene expression signature and confer intrinsic and acquired resistance to cetuximab treatment in first line metastatic CRC (Alliance)**
Radia M. Johnson, Xueping Qu, Joshua Thomas, Yvonne Kschonsak, Ling Huw, Fang-Shu Ou, Ethan Sokol, Nnamdi Ihuegbu, Oliver A. Zill, Omar Kabbarah, Anneleen Daemen, Richard Bourgon, Alan Venook, Federico Innocenti, Heinz-Josef Lenz, Felipe de Sousa e Melo, Carlos Bais *Cancer Res* vol 80 ((16 Supplement)) LB-063-LB-063 2020
Abstract Correl Sci NOS
<https://cancerres.aacrjournals.org/search/Radia%20jcode%3Acanres%20volume%3A80%20issue%3A16>
- 940 Everolimus plus R-CHOP-21 is Safe and Highly Effective for New Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results of the Phase I Trial NCCTG N1085 (Alliance)**
Patrick B. Johnston, Betsy R. LaPlant, Ellen D. McPhail, Thomas M. Habermann, David J. Inwards, Ivana Micallef, Joseph Colgan, Grzegorz Nowakowski, Stephen M. Ansell, Thomas E. Witzig *Blood* vol 126 (23) abstr 813 2015
Abstract Lymphoma <http://www.bloodjournal.org/content/126/23/813>
- 941 Combination of everolimus with R-CHOP (ever R-CHOP) as an initial therapy for diffuse large B cell lymphoma (DLBCL): NCCTG N1085 (Alliance) phase I and feasibility study**
Patrick B. Johnston, Betsy R. LaPlant, Grzegorz S. Nowakowski, Ivana N.M. Micallef, Stephen M. Ansell, Thomas H. Habermann, Joseph, P. Colgan, Thomas E. Witzig *J Clin Oncol* vol 33 (suppl) abstr 8518 2015
Abstract Lymphoma <http://meetinglibrary.asco.org/content/147348-156>
- 942 Everolimus plus R-CHOP as initial therapy for DLBCL: a phase I/feasibility study (NCCTG N1085 [Alliance])**
Patrick B. Johnston, Betsy R. LaPlant, Grzegorz S. Nowakowski, Ivana N.M. Micallef, Stephen M. Ansell, Thomas H. Habermann, Joseph, P. Colgan, Thomas E. Witzig *Hematol Oncol* vol 33 (suppl S2) p 241, abstr 282 2015
Abstract Lymphoma <http://onlinelibrary.wiley.com/doi/10.1002/hon.2228/epdf>
- 943 The mTORC1 Inhibitor Everolimus Combined with R-CHOP-21 for New Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Safety and Efficacy Results of a Phase I and Feasibility Trial NCCTG 1085 (Alliance)**
Patrick B. Johnston, Betsy LaPlant, Ellen McPhail, Thomas M. Habermann, David J. Inwards, Ivana N. Micallef, Joseph P. Colgan, Grzegorz S. Nowakowski, Stephen M. Ansell, Thomas E. Witzig *Lancet Haematol* vol 3 (7) e309-e316 2016
Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/27374464>
- 944 Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101**
J. A. Jones, A. S. Ruppert, W. Zhao, T. S. Lin, K. Rai, B. Peterson, R. A. Larson, G. Marcucci, N. A. Heerema, J. C. Byrd *Leuk Lymphoma* vol 54 (12) 2654-9 2013
Manuscript Leukemia CALGB-19901, CALGB-10101
<http://www.ncbi.nlm.nih.gov/pubmed/23547837>
- 945 Alemtuzumab Consolidation Does Not Improve Outcome for CLL Patients with High Risk Genomic Features on Successive CALGB Trials**
J. A. Jones, A. Stark, W. Zhao, T. S. Lin, K. R. Rai, G. Marcucci, B. Peterson, R. A. Larson, N. A. Heerema, J. C. Byrd *Blood* vol 118 (21) -1791 2011
Abstract Leukemia CALGB-10101, CALGB-19901

946 Peak Oxygen Consumption and Long-Term All-Cause Mortality in Non-Small Cell Lung Cancer

Lee W. Jones, Dorothy Watson, James E. Herndon, Neil D. Eves, Benjamin E. Haithcock, Gregory Loewen, Leslie Kohman *Cancer* vol 116 (20) 4825-32 2010
Manuscript Respiratory CALGB-140803 <http://www.ncbi.nlm.nih.gov/pubmed/20597134>

947 Quantitation of Cabozantinib in Human Plasma by LC-MS/MS

Reyna Jones, Julianne Holleran, Robert A Parise, Michelle A Rudek, Jennifer Chan, Yujia Wen, Joga Gobburu, Lionel D Lewis, Jan H Beumer *J Chromatogr Sci* vol 60 (3) 274-9 2021
Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/34240176>

948 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer

K. Kalinsky, W.E. Barlow, J.R. Gralow, F. Meric-Bernstam, K.S. Albain, D.F. Hayes, N.U. Lin, E.A. Perez, L.J. Goldstein, S.K.L. Chia, S. Dhesy-Thind, P. Rastogi, E. Alba, S. Delaloge, M. Martin, C.M. Kelly, M. Ruiz-Borrego, M. Gil-Gil, C.H. Arce-Salinas, E.G.C. Brain, E.-S. Lee, J.-Y. Pierga, B. Bermejo, M. Ramos-Vazquez, K.-H. Jung, J.-M. Ferrero, A.F. Schott, S. Shak, P. Sharma, D.L. Lew, J. Miao, D. Tripathy, L. Pusztai, G.N. Hortobagyi *N Engl J Med* vol 385 (25) 2336-47 2021
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/34914339>

949 Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study.

P W Kantoff, S Halabi, M Conaway, J Picus, J Kirshner, V Hars, D Trump, E P Winer, N J Vogelzang *J Clin Oncol* vol 17 (8) 2506-13 1999
Manuscript GU <http://www.ncbi.nlm.nih.gov/pubmed/10561316>

950 Bortezomib maintenance (BM) vs consolidation (BC) following aggressive immunochemotherapy and autologous stem cell transplant (ASCT) for untreated mantle cell (MCL): CALGB 50403 (Alliance).

L. D. Kaplan, S. H. Jung, N. C. Bartlett, J. Johnson, J. Byrd, K. Blum, W. Stock, A. S. Lacasce, E. Hsi, D. Hurd, M. S. Czuczman, B. D. Cheson *Hematol Oncol* vol 31 (suppl 1) abstr 089 2013
Abstract Lymphoma <http://onlinelibrary.wiley.com/doi/10.1002/hon.2057/pdf>

951 A randomized phase II trial of maintenance vs consolidation bortezomib therapy following aggressive chemo-immunotherapy and autologous stem cell transplant for previously untreated mantle cell lymphoma (MCL): CALGB 50403

L. D. Kaplan, S. Jung, J. L. Johnson, C. Linker, J. C. Byrd, W. Stock, B. D. Cheson *J Clin Oncol* vol 28 (15s) abstr TPS306 2010
Abstract Lymphoma <http://meetinglibrary.asco.org/content/41656-74>

952 Bortezomib Consolidation or Maintenance Following Immunochemotherapy and Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: CALGB/Alliance 50403

Lawrence D. Kaplan, Matthew J. Maurer, Wendy Stock, Nancy L. Bartlett, Noreen Fulton, Adam Pettinger, John C. Byrd, Kristie A. Blum, Ann S. LaCasce, Eric D. Hsi, Yi Tian Liu, David W. Scott, David Hurd, Amy S. Ruppert, Francisco Hernandez-Ilizaliturri, John P. Leonard, Bruce. D. Cheson *Am J Hematol* vol 95 (6) 583-93 2020
Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/32170769>

953 Bortezomib maintenance (BM) or consolidation (BC) following aggressive immunochemotherapy and autologous stem cell transplant (ASCT) for untreated mantle cell lymphoma (MCL): 8-year follow-up of CALGB 50403 (Alliance)

Lawrence D. Kaplan, Matthew Maurer, Wendy Stock, Noreen Fulton, Nancy Bartlett, Adam Pettinger,

John Byrd, Kristie A. Blum, Anne S. LaCasce, Eric D. Hsi, David Hurd, Amy Ruppert, John P. Leonard, Bruce. D. Cheson Blood vol 132 (suppl 1) 146 2018
Abstract Lymphoma http://www.bloodjournal.org/content/132/Suppl_1/146

954 Bortezomib Maintenance (Bm) Versus Consolidation (Bc) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (Asct) For Untreated Mantle Cell Lymphoma (Mcl): CALGB 50403

Lawrence D. Kaplan, Wendy Stock, Sin-Ho Jung, Nancy Bartlett, Brandy Pitcher, John Byrd, Kristie A. Blum, Ann S. LaCasce, Eric D. Hsi, David Hurd, Myron Czuczman, John P. Leonard, Bruce. D. Cheson Blood vol 126 (23) abstr 337 2015
Abstract Lymphoma <http://www.bloodjournal.org/content/126/23/337.abstract?sso-checked=true>

955 Pemetrexed, Carboplatin, and Concomitant Radiation followed by Surgery for Locally Advanced Esophageal Cancer: Results of a Planned Interim Toxicity Analysis of North Central Cancer Treatment Group Study N044E

Rajini Katipamula, Aminah Jatoi, Nathan R. Foster, Francis Nichols, Joseph Rubin, Matthew Callister, Leonard Gunderson, Steven Alberts Clin Med Oncol vol 2 223-225 2008
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/21892283>

956 Standardization and documentation of surgical and pathologic variables in a multi-institutional trial of adjuvant therapy for pancreatic cancer: Results from ACOSOG Z5031

M. H. Katz, N. B. Merchant, S. Brower, M. Campbell, M. C. Posner, L. W. Traverso, R. A. Abrams, V. J. Picozzi, P. W. Pisters SSO Annual Meeting abstr Z5031 2010
Abstract GI
http://www.surgonc.org/media/88503/sso_annual_cancer_symposium_abstract_supplement_to_annals_o

957 The role of patient advocates in clinical trials: Perspectives from investigators and advocates in the Cancer and Leukemia Group B (CALGB)

M. L. Katz, L. E. Archer, J. M. Peppercorn, S. Kereakoglow, D. Collyar, H. J. Burstein, R. L. Schilsky, A. H. Partridge J Clin Oncol vol 28 (15s) abstr 6148 2010
Abstract Patient Adv
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID

958 Standardization of Surgical and Pathologic Variables is Needed in Multicenter Trials of Adjuvant Therapy for Pancreatic Cancer: Results from the ACOSOG Z5031 Trial

Matthew H. G. Katz, Nipun B. Merchant, Steven Brower, Megan Branda, Mitchell C. Posner, L. William Traverso, Ross A. Abrams, Vincent J. Picozzi, Peter W. T. Pisters Ann Surg Oncol vol 18 (2) 337-344 2011
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/20811779>

959 Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas

Matthew H. G. Katz, Fang-Shu Ou, Joseph M. Herman, Syed A. Ahmad, Brian Wolpin, Robert Marsh, Spencer Behr, Qian Shi, Michael Chuong, Lawrence H. Schwartz, Wendy Frankel, Eric Collisson, Eugene J. Koay, JoLeen M. Hubbard, James L. Leenstra, Jeffrey Meyerhardt, Eileen O'Reilly BMC Cancer vol 17 505 2017
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/28750659>

960 Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer

Matthew H. G. Katz, Qian Shi, Syed A. Ahmad, Joseph M. Herman, Robert de W. Marsh, Eric Collisson, Lawrence Schwartz, Wendy Frankel, Robert Martin, William Conway, Mark Truty, Hedy

Kindler, Andrew M. Lowy, Tanios Bekaii-Saab, Philip Philip, Mark Talamonti, Dana Cardin, Noelle LoConte, Perry Shen, John P. Hoffman, Alan P. Venook JAMA Surg vol 151 (8) e161137 2016
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/27275632>

961 Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas

Matthew H. G. Katz, Qian Shi, Jeff Meyers, Joseph M. Herman, Michael Chuong, Brian M. Wolpin, Syed Ahmad, Robert Marsh, Larry Schwartz, Spencer Behr, Wendy L. Frankel, Eric Collisson, James Leenstra, Terence M. Williams, Gina Vaccaro, Alan Venook, Jeffrey A. Meyerhardt, Eileen M. O'Reilly JAMA Oncol vol 8 (9) 1263-70 2022
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/35834226>

962 Preoperative modified FOLFIRINOX (mFOLFIRINOX) followed by chemoradiation (CRT) for borderline resectable (BLR) pancreatic cancer (PDAC): Initial results from Alliance Trial A021101.

Matthew H.G. Katz, Qian Shi, Syed Ahmad, Joseph Herman, Robert Marsh, Eric Collisson, Lawrence Schwartz, Robert Martin, William Conway, Mark Truty, Hedy Kindler, Andrew M. Lowy, Tanios Bekaii-Saab, Dana Cardin, Noelle LoConte, Alan P. Venook J Clin Oncol vol 33 (suppl) abstr 4008 2015
Abstract GI <http://meetinglibrary.asco.org/content/147695-156>

963 Borderline resectable pancreatic cancer: Need for Standardization and Methods for Optimal Clinical Trial Design

Matthew HG Katz, Robert Marsh, Joseph M. Herman, Qian Shi, Eric Collison, Alan Venook, Hedy Kindler, Steven Alberts, Philip Philip, Andrew M. Lowy, Peter Pisters, Mitchell Posner, Jordan Berlin, Syed A. Ahmad Ann Surg Oncol vol 20 (8) 2787-2795 2013
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/23435609>

964 Nomogram-Based Estimate of Axillary Nodal Involvement in ACOSOG Z0011 (Alliance): Validation and Association with Radiation Protocol Variations and Outcomes

Matthew S. Katz, Linda McCall, Karla Ballman, Bruce G. Haffty, Reshma Jagsi, Armando E. Giuliano Int J Radiat Oncol Biol Phys vol 102 (3 suppl) S228-9 2018
Abstract Breast [https://www.redjournal.org/article/S0360-3016\(18\)31566-9/fulltext](https://www.redjournal.org/article/S0360-3016(18)31566-9/fulltext)

965 Nomogram-based estimate of axillary nodal involvement in ACOSOG Z0011 (Alliance): validation and association with radiation protocol variations

Matthew S. Katz, Linda McCall, Karla Ballman, Reshma Jagsi, Bruce G. Haffty, Armando E. Giuliano Breast Cancer Res Treat vol 180 (2) 429-36 2020
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/32043193>

966 Alliance for clinical trials in oncology trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas

Matthew Katz, Joseph M. Herman, Fang-Shu Ou, Robert Marsh, Michael Chuong, Brian Wolpin, Lawrence H. Schwarz, James L. Leenstra, Eileen O'Reilly, Jeffrey Meyerhardt, Syed Ahmad J Clin Oncol vol 35 (15 suppl) TPS4151 2017
Abstract GI http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.TPS4151

967 Alliance trial A021501: Preoperative mFOLFIRINOX or mFOLFIRINOX plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the pancreas

Matthew Katz, Qian Shi, Jeff Meyers, Joseph M. Herman, Michael Chuong, Brian Wolpin, Syed Ahmad, Robert Marsh, Lawrence Schwartz, Spencer Behr, Wendy Frankel, Eric Collisson, James Leenstra, Terence Williams, Gina Vaccaro, Alan Venook, Jeff Meyerhardt, Eileen O'Reilly J Clin Oncol vol 39 (suppl 3) abstr 419 2021

968 Cancer Surveillance Behaviors and Psychosocial Factors Among Long-Term Survivors of Breast Cancer

Mira L. Katz, Kathleen A. Donohue, Catherine M. Alfano, Jeannette M. Day, James E. Herndon, Electra D. Paskett *Cancer* vol 115 (3) 480-488 2009
Manuscript *Breast* <http://www.ncbi.nlm.nih.gov/pubmed/19133656>

969 Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of GRIFFIN After 12-months of Maintenance Therapy (AFT-29)

Jonathan L. Kaufman, Jacob Laubach, Douglas W. Sborov, Brandi Reeves, Cesar Rodriguez, Ajai Chari, Rebecca Silbermann, Luciano J. Costa, Larry D. Anderson Jr, Nitya Nathwani, Nina Shah, Yvonne A. Efebera, Sarah A. Holstein, Caitlin Costello, Andrzej Jakubowiak, Tanya M. Wildes, Robert Z. Orlowski, Kenneth H. Shain, Andrew J. Cowan, Yana Lutska, Cynthia Haines, Huiling Pei, Jon Ukropec, Jessica Vermeulen, Thomas S. Lin, Paul G. Richardson, Peter M. Voorhees *Blood* vol 36 (Supplement 1) 45-46 2020
Abstract *Myeloma*
<https://ashpublications.org/blood/article/136/Supplement%201/45/470279/Daratumumab-DARA-Plus-Lc>

970 CALGB 150002: Correlation of HER-2 and chromosome 17 (ch17) copy number with trastuzumab (T) efficacy in CALGB 9840: Paclitaxel (P) +/-T in HER-2(+) and (-) metastatic breast cancer (MBC)

P. A. Kaufman, G. Broadwater, K. A. Lezon-Geyda, L. G. Dressler, M. J. Ellis, E. P. Winer, C. A. Hudis, A. D. Seidman, L. N. Harris *J Clin Oncol* vol 25 (18s) abstr 1009 2007
Abstract *Correl Sci NOS*
http://jco.ascopubs.org/gca?allch=&submit=Go&gca=ascomtg%3B25%2F18_suppl%2F1009

971 Improved outcome in recurrent glioblastoma (RGBM) patients treated with bevacizumab (BEV) and sorafenib (SOR) is predicted by a greater drop in apparent diffusion coefficient (ADC) on MRI imaging.

T. J. Kaufmann, S. K. Anderson, K. A. Jaeckle, J. H. Uhm, D. W. Northfelt, P. J. Flynn, J. C. Buckner, E. Galanis 16th Annual Scientific Meeting of the Society for Neuro-Oncology in Conjunction with the AANS/CNS Section on Tumors vol 13 (suppl 3) 138 2011
Abstract *Neuro-Onc* http://neuro-oncology.oxfordjournals.org/content/13/suppl_3/iii136.abstract

972 Regional Differences In Breast Cancer Biomarkers In American Indian And Alaska Native Women

Judith S Kaur, Robert A. Vierkant, Timothy Hobday, Daniel Visscher *Cancer Epidemiol Biomarkers Prev* vol 23 (3) 409-415 2014
Manuscript *Disparities* <http://www.ncbi.nlm.nih.gov/pubmed/24609850>

973 Osteoporosis prevention in prostate cancer patients receiving androgen ablation therapy: placebo-controlled double-blind study of estradiol and risedronate: N01C8

Ann E. Kearns, Donald W. Northfelt, Amylou C. Dueck, Pamela J. Atherton, Shaker R. Dakhil, Kendrith M. Rowland, Jyotsna Fuloria, Patrick J. Flynn, Todor Dentchev, Charles L. Loprinzi *Support Care Cancer* vol 18 (3) 321-8 2010
Manuscript *Symptom Inter* <http://www.ncbi.nlm.nih.gov/pubmed/19468757>

974 Rates of guideline-concordant surgery and adjuvant chemotherapy among patients in the U.S. ALCHEMIST study (Alliance)

Kenneth L. Kehl, David M. Zahrieh, Ping Yang, Shauna L. Hillman, Angelina D. Tan, Jacob M. Sands, Geoffrey R. Oxnard, Erin Alexis Gillaspie, Dennis Wigle, Malik Shakun, Thomas Stinchcombe,

Suresh Ramalingam, Karen L. Kelly, Sumithra J. Mandrekar, Raymond Osarogiagbon, David E.

Kozono 2021

Abstract Respiratory

https://library.iaslc.org/conference-program?product_id=24&author=kehl&category=&date=&session_ty

975 Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients With Early-Stage Lung Cancer in the US ALCHEMIST Study (Alliance A151216)

Kenneth L. Kehl, David Zahrieh, Ping Yang, Shauna L. Hillman, Angelina D. Tan, Jacob M. Sands, Geoffrey R. Oxnard, Erin A. Gillaspie, Dennis Wigle, Shakun Malik, Thomas E. Stinchcombe, Suresh S. Ramalingam, Karen Kelly, Ramaswamy Govindan, Sumithra J. Mandrekar, Raymond U.

Osarogiagbon, David Kozono JAMA Oncol vol 8 (5) 717-28 2022

Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/35297944>

976 Phase II Study of Induction Cisplatin and Irinotecan Followed by Concurrent Carboplatin, Etoposide, and Thoracic Radiotherapy for Limited-Stage Small-Cell Lung Cancer, CALGB 30206

M. J. Kelley, J. A. Bogart, L. D. Hodgson, R. H. Ansari, J. N. Atkins, H. Pang, M. R. Green, E. E.

Vokes J Thorac Oncol vol 8 (1) 102-108 2013

Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/23196276>

977 CALGB 30206: Phase II study of induction cisplatin (P) and irinotecan (I) followed by combination carboplatin (C), etoposide (E), and thoracic radiotherapy for limited stage small cell lung cancer

M. J. Kelley, J. A. Bogart, L. D. Hodgson, R. H. Ansari, J. N. Atkins, X Wang, M. R. Green, E. E.

Vokes J Clin Oncol vol 25 (18s) abstr 7565 2007

Abstract Respiratory http://meeting.ascopubs.org/cgi/content/abstract/25/18_suppl/7565

978 Five-year follow-up of a multicenter phase II study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin (TEC) plus androgen-deprivation therapy (ADT) prior to radiation therapy in patients with unfavorable-risk localized prostate cancer: CALGB 99811

W. K. Kelly, S. Halabi, L. E. Archer, J. A. Bogart, M. J. Zelefsky, E. J. Small Genitourinary Cancers Symposium abstr 123 2010

Abstract GU

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=73&abstractID

979 Liver metastases (LM) to predict for short overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts)

W. K. Kelly, S. Halabi, M. A. Carducci, D. J. George, J. F. Mahoney, W. M. Stadler, M. J. Morris, P.

W. Kantoff, J. P. Monk, E. J. Small J Clin Oncol vol 30 (Supplement) abstr 4655 2012

Abstract GU http://hwmain.meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/4655

980 A randomized double-blind placebo controlled phase III trial comparing docetaxel, prednisone and placebo with docetaxel prednisone and bevacizumab in men with metastatic castrate resistant prostate cancer (metCRPC): Survival results of CALGB 90401

W. K. Kelly, S. Halabi, D. J. George, W. M. Stadler, P. W. Kantoff, M. J. Morris, P. J. Monk, E. H. Leung, E. J. Small J Clin Oncol vol 28 (15s) abstr 4511 2010

Abstract GU

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID

981 Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401

William Kevin Kelly, Susan Halabi, Michael Carducci, Daniel George, John F. Mahoney, Walter M. Stadler, Michael Morris, Philip Kantoff, J. Paul Monk, Ellen Kaplan, Nicholas J. Vogelzang, Eric J.

982 Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: results of Cancer and Leukemia Group B 99811.

William Kevin Kelly, Susan Halabi, Aymen Elfiky, San-San Ou, Jeff Bogart, Michael Zelefsky, Eric Small Cancer vol 113 (11) 3137-45 2008

Manuscript GU <http://www.ncbi.nlm.nih.gov/pubmed/18989865>

983 Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481).

Nancy E Kemeny, Donna Niedzwiecki, Donna R Hollis, Heinz-Josef Lenz, Robert S Warren, Michelle J Naughton, Jane C Weeks, Elin R Sigurdson, James E Herndon, Chunfeng Zhang, Robert J Mayer J Clin Oncol vol 24 (9) 1395-403 2006

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/16505413>

984 Factors impacting oncologic outcomes after sublobar pulmonary resection: Results from ACOSOG Z4032 (Alliance), a randomized trial for high-risk operable non-small cell lung cancer (NSCLC)

M. Kent, R. Landreneau, S. Mandrekar, F. Nichols, T. Dipetrillo, B. Meyers, D. Heron, J. Putnam, D. Jones, S. Starnes, B. Daly, A. Tan, H. Fernando J Clin Oncol vol 31 (15 suppl) abstr 7524 2013
Abstract Respiratory

http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/7524?sid=468ed2a2-4b64-4195-a8fd-8ef48

985 Impact of Sublobar Resection on Pulmonary Function: Long-term Results from ACOSOG Z4032 (Alliance)

Michael S. Kent, Sumithra J. Mandrekar, Rodney Landreneau, Francis Nichols, Thomas A. DiPetrillo, Bryan Meyers, Dwight E. Heron, David R. Jones, Angelina D. Tan, Sandra Starnes, Joe B. Putnam, Hiran C. Fernando Ann Thorac Surg vol 102 (1) 230-238 2016

Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/27101728>

986 A Nomogram to Predict Recurrence and Survival of High-Risk Patients Undergoing Sublobar Resection for Lung Cancer: An Analysis of a Multicenter Prospective Study (ACOSOG Z4032)

Michael S. Kent, Sumithra J. Mandrekar, Rodney Landreneau, Francis Nichols, Nathan R. Foster, Thomas A. DiPetrillo, Bryan Meyers, Dwight E. Heron, David R. Jones, Angelina D. Tan, Sandra Starnes, Joe B. Putnam, Hiran C Fernando Ann Thorac Surg vol 102 (1) 239-246 2016

Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/27101729>

987 Impact of Sublobar Resection on pulmonary function; Long-term results from Z4032 (Alliance), a randomized phase III trial

Michael Kent, Hiran C Fernando, Sumithra Mandrekar, Rodney Landreneau, Francis Nichols, Thomas A DiPetrillo, Bryan Meyers, Dwight Heron, David R Jones, Angelina D Tan, Sandra Starnes, Joe B Putnam Ann Thorac Surg vol 102 (1) 230-238 2016

Abstract Respiratory [http://www.annalsthoracicsurgery.org/article/S0003-4975\(16\)00082-5/abstract](http://www.annalsthoracicsurgery.org/article/S0003-4975(16)00082-5/abstract)

988 Development of a Nomogram for Predicting Outcomes after Sublobar Resection for lung cancer; An Analysis from ACOSOG Z4032 (Alliance) a Randomized Trial

Michael Kent, Sumithra Mandrekar, Rodney Landreneau, Francis Nichols, Nathan Foster, Thomas A DiPetrillo, Bryan Meyers, Dwight Heron, David R Jones, Angelina D Tan, Sandra Starnes, Joe B Putnam, Hiran C Fernando 2015

Abstract Respiratory <http://aats.org/annualmeeting/program-books/2015/70.cgi>

- 989 A variant allele of Growth Factor Independence 1 (GFI1) is associated with acute myeloid leukemia**
C. Khandanpour, C. Thiede, P. J. Valk, E. Sharif-Askari, H. Nuckel, D. Lohmann, B. Horsthemke, W. Siffert, A. Neubauer, K. H. Grzeschik, C. D. Bloomfield, G. Marcucci, K. Maharry, M. L. Slovak, B. A. Van Der Reijden, J. H. Jansen, H. K. Schackert, K. Afshar, S. Schnittger, J. K. Peeters, F. Kroschinsky, G. Ehninger, B. Lowenberg, U. Duhrsen, T. Moroy *Blood* vol 115 (12) 2462-2472 2010
Manuscript *Leuk Corr Sci CALGB-9665, CALGB-8461*
<http://www.ncbi.nlm.nih.gov/pubmed/20075157>
- 990 North Central Cancer Treatment Group phase II study of panitumumab (Pmab), chemotherapy, and external beam radiation (Chemo-RT) in patients with locally advanced (LA) pancreatic cancer**
G. P. Kim, N. R. Foster, M. G. Haddock, S. R. Dakhil, R. J. Behrens, P. J. Flynn, S. R. Alberts *J Clin Oncol* vol 30 (suppl 4) abstr 271 2012
Abstract GI http://meeting.ascopubs.org/cgi/content/abstract/30/4_suppl/271
- 991 Randomized phase II trial of panitumumab (P), erlotinib (E), and gemcitabine (G) versus erlotinib-gemcitabine in patients with untreated, metastatic pancreatic adenocarcinoma**
G. P. Kim, N. R. Foster, M. Salim, P. J. Flynn, D. F. Moore Jr, R. Zon, R. B. Mowat, M. Wiesenfeld, A. E. McCullough, S. R. Alberts *J Clin Oncol* vol 29 (suppl 4) abstr 238 2011
Abstract GI <http://meetinglibrary.asco.org/content/71370-103>
- 992 Phase II study of oxaliplatin (OX), 5-fluorouracil (5-FU) and radiation therapy (RT) followed by gemcitabine (GEM) in patients with unresectable pancreatic cancer**
G. P. Kim, M. G. Haddock, N. Foster, J. Bollinger, P. Stella, J. Kugler, S. Alberts, J. Martenson
Gastrointestinal Cancers Symposium abstr 144 2008
Abstract GI
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=53&abstractID
- 993 Phase II study of oxaliplatin (OX), 5-fluorouracil (5-FU), and radiation therapy (RT) followed by gemcitabine (GEM) in patients with unresectable pancreatic cancer**
G. P. Kim, M. Haddock, N. R. Foster, J. Bollinger, P. J. Stella, J. W. Kugler, S. R. Alberts, J. Martenson *J Clin Oncol* vol 26 (15s) abstr 15553 2008
Abstract GI
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID
- 994 Analysis of time-dependent patterns of treatment effect and failure to explain the predictive role of deficient mismatch repair (dMMR) in stage II and III colon cancer (CC)**
G. P. Kim, S. Marsoni, G. Monges, C. J. Allegra, S. N. Thibodeau, S. R. Hamilton, B. Kabat, G. A. Yothers, S. Gallinger, D. J. Sargent *J Clin Oncol* vol 28 (15s) abstr 3518 2010
Abstract GI
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID
- 995 Phase II of bevacizumab, gemcitabine, oxaliplatin in patients with metastatic pancreatic adenocarcinoma**
G. P. Kim, A. L. Oberg, N. R. Foster, A. Jaslowski, P. J. Flynn, D. Campbell, E. Hedrick, L. Gray, A. Grothey, S. Alberts *J Clin Oncol* vol 25 (18s) abstr 4553 2007
Abstract GI http://meeting.ascopubs.org/cgi/content/short/25/18_suppl/4553
- 996 Time-dependent patterns of treatment effect and failure as an explanation for the predictive role of deficient mismatch repair (dMMR) in colon cancer.**
G. Kim, S. Marsoni, G. Monges, C. Allegra, S. N. Thibodeau, S. Hamilton, B. F. Kabat, G. Yothers, S.

Gallinger, D. Sargent Gastrointestinal Cancers Symposium abstr 342 2010

Abstract GI

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=72&abstractID

997 Phase III Noninferiority Trial Comparing Irinotecan With Oxaliplatin, Fluorouracil, and Leucovorin in Patients With Advanced Colorectal Carcinoma Previously Treated With Fluorouracil: N9841

George P. Kim, Daniel J. Sargent, Michelle R. Mahoney, Kendrith M. Rowland, Philip A. Philip, Edith Mitchell, Abraham P. Mathews, Tom R. Fitch, Richard M. Goldberg, Steven R. Alberts, Henry C. Pitot
J Clin Oncol vol 27 (17) 2848-2854 2009

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/19380443>

998 A Molecular Model for Predicting Overall Survival in Patients with Metastatic Clear Cell Renal Carcinoma: Results from CALGB 90206 (Alliance)

Hyung L. Kim, Susan Halabi, Ping Li, Greg Mayhew, Jeff Simko, Andrew B. Nixon, Eric J. Small, Brian Rini, Michael J. Morris, Mary-Ellen Taplin, Daniel George EBioMedicine vol 2 (11) 1814-20 2015

Manuscript GU CALGB-90206 <http://www.ncbi.nlm.nih.gov/pubmed/26870806>

999 A prognostic model for overall survival in patients with metastatic clear cell renal carcinoma: Results from CALGB 90206 (Alliance)

Hyung L. Kim, Susan Halabi, Ping Li, Greg Mayhew, Jeff Simko, Andrew Nixon, Eric Small, Brian Rini, Michael Morris, Mary-Ellen Taplin, Daniel George J Urol vol 193 (4S) abstr MP44-01 2015

Abstract GU <http://www.jurology.com/article/S0022-5347%2815%2901854-6/abstract>

1000 Simultaneous quantitation of abiraterone, enzalutamide, N-desmethyl enzalutamide, and bicalutamide in human plasma by LC-MS/MS

Kyu-pyo Kim, Robert A. Parise, Julianne L. Holleran, Lionel D. Lewis, Leonard Appleman, Nielka van Erp, Michael J. Morris, Jan H. Beumer J Pharm Biomed Anal vol 138 197-205 2017

Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/28219796>

1001 Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944)

G. G. Kimmick, C. Cirrincione, D. B. Duggan, K. Bhalla, N. Robert, D. Berry, L. Norton, S. Lemke, I. C. Henderson, C. Hudis, E. Winer Breast Cancer Res Treat vol 113 (3) 479-490 2009

Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/18306034>

1002 Using ePrognosis to Estimate 2-year All-Cause Mortality in Older Women with Breast Cancer: Cancer and Leukemia Group B (CALGB) 49907 and 369901 (Alliance A151503)

Gretchen G Kimmick, Brittany Major, Jonathan Clapp, Jeff Sloan, Brandelyn Pitcher, Karla Ballman, Myra Barginear, Rachel A Freedman, Andrew Artz, Heidi D Klepin, Jacqueline M Lafky, Judith Hopkins, Eric Winer, Clifford Hudis, Hyman Muss, Harvey Cohen, Aminah Jatoui, Arti Hurria, Jeanne Mandelblatt Breast Cancer Res Treat vol 163 (2) 391-98 2017

Manuscript Older Adult CALGB-369901, CALGB-49907

<http://www.ncbi.nlm.nih.gov/pubmed/28283904>

1003 Musculoskeletal side effects over time and the association of side effects and adherence in women taking neoadjuvant letrozole for estrogen receptor positive DCIS (CALGB 40903)

Gretchen Kimmick, Amylou C. Dueck, Rebecca Shelby, Michelle Naughton, Briant Fruth, E. Shelley Hwang Cancer Res vol 80 (4) Suppl abstr P5-14-17 2020

Abstract Health Outcomes <https://www.abstractsonline.com/pp8/#!/7946/presentation/1551>

1004 Determining All-Cause Survival Estimates using ePrognosis in Older Women with Breast Cancer in CALGB 49907 and 369901 (Alliance A151503)

Gretchen Kimmick, Brandelyn Pitcher, Jeanne Mandelblatt, Jonathan Clapp, Myra Barginear, Rachel Freedman, Heidi Klepin, Jacqueline Lafky, Eric Winer, Clifford Hudis, Hyman Muss, Harvey Cohen, Aminah Jatoi, Arti Hurria *Cancer Res* vol 76 (4 Suppl) P6-09-10 2016
Abstract Older Adult CALGB-369901, CALGB-49907
http://cancerres.aacrjournals.org/content/76/4_Supplement/P6-09-10.short?rss=1

1005 A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B (CALGB)

H. L. Kindler, D. Niedzwiecki, D. R. Hollis, E. A. Oraefo, D. Schrag, H. I. Hurwitz, H. L. Mcleod, M. Mulcahy, R. L. Schilsky, R. M. Goldberg *J Clin Oncol* vol 25 (18s) abstr 4508 2007
Abstract GI
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID

1006 Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)

Hedy Lee Kindler, Donna Niedzwiecki, Donna Hollis, Susan Sutherland, Deborah Schrag, Herbert Hurwitz, Federico Innocenti, Mary Frances Mulcahy, Eileen O'Reilly, Timothy F. Wozniak, Joel Picus, Pankaj Bhargava, Robert J. Mayer, Richard L. Schilsky, Richard M. Goldberg *J Clin Oncol* vol 28 (22) 3617-3622 2010
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/20606091>

1007 Comorbidity, chemotherapy toxicity, and outcomes among older women receiving adjuvant chemotherapy for breast cancer (BC)

H. D. Klepin, B. Pitcher, K. V. Ballman, G. G. Kimmick, A. B. Kornblith, H. J. Cohen, A. Hurria, E. P. Winer, C. Hudis, H. B. Muss *J Clin Oncol* vol 30 (Supplement May) abstr 6015 2012
Abstract Older Adult CALGB-49907
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID

1008 Comorbidity, Chemotherapy Toxicity, and Outcomes Among Older Women Receiving Adjuvant Chemotherapy for Breast Cancer on a Clinical Trial: CALGB 49907 and CALGB 361004 (Alliance)

Heidi D. Klepin, Brandelyn N. Pitcher, Karla V. Ballman, Alice B. Kornblith, Arti Hurria, Eric P. Winer, Clifford Hudis, Harvey J. Cohen, Hyman B. Muss, Gretchen G. Kimmick *J Oncol Pract* vol 10 (5) e285-e292 2014
Manuscript Older Adult CALGB-49907 <http://www.ncbi.nlm.nih.gov/pubmed/25074878>

1009 Feasibility of geriatric assessment for older adults with acute myeloid leukemia (AML) receiving intensive chemotherapy on a cooperative group trial: CALGB 361006 (Alliance).

Heidi D. Klepin, Ellen K. Ritchie, Ben L. Sanford, Guido Marcucci, Weiqiang Zhao, Susan Michelle Geyer, Karla V. Ballman, Bayard L. Powell, Maria R. Baer, Wendy Stock, Harvey Jay Cohen, Richard M. Stone, Richard A. Larson, Geoffrey L. Uy *J Clin Oncol* vol 32 (15_suppl) 7102 2014
Abstract Older Adult http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/7102

1010 Geriatric assessment among older adults receiving intensive therapy for acute myeloid leukemia: Report of CALGB 361006 (Alliance).

Heidi D Klepin, Ellen Ritchie, Brittny Major-Elechi, Jennifer Le-Rademacher, Drew Seisler, Libby Storrick, Ben L Sanford, Guido Marcucci, Weiqiang Zhao, Susan A Geyer, Karla V Ballman, Bayard L Powell, Maria R Baer, Wendy Stock, Harvey Jay Cohen, Richard M Stone, Richard A Larson, Geoffrey L Uy *J Geriatr Oncol* vol 11 (1) 107-13 2020
Manuscript Older Adult <http://www.ncbi.nlm.nih.gov/pubmed/31668825>

- 1011 Nursing contributions in Community Clinical Oncology Research Programs.**
Kathy Klinger, Cesar Figueras, Kathleen M Beney, Jane M Armer, Sharon Levy Semin Oncol Nurs
vol 30 (1) 38-43 2014
Manuscript Onc Nursing <http://www.ncbi.nlm.nih.gov/pubmed/24559779>
- 1012 Prognostic and predictive tumor-based biomarkers in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (IFN) with or without bevacizumab (Bev): Results from CALGB (Alliance) 90206**
Harriet M. Kluger, Susan Halabi, Nicole C Solomon, Lucia Jilaveanu, Christopher Zito, Joshua Sznol, Andrew B. Nixon, Brian I. Rini, Eric Jay Small, Daniel J. George J Clin Oncol vol 32 (5s) (suppl; abstr 4532) 2014
Abstract GU http://abstracts.asco.org/144/AbstView_144_132556.html
- 1013 Generation of adaptive HER2-specific immunity in HER2 breast cancer patients by addition of trastuzumab to chemotherapy in the adjuvant setting: NCCTG (Alliance) study N9831**
K. L. Knutson, E. A. Perez, K. Ballman, C. L. Erskine, N. Fox, C.-A. Mccarl, N. Norton, S. V. Sumrall, D. Northfelt, W. Tan, C. Calfa, M. Pegram, R. Clynes J Clin Oncol vol 31 (15 suppl) abstr 522 2013
Abstract Breast <http://meetinglibrary.asco.org/content/110646-132>
- 1014 Improved survival of HER2+ breast cancer patients treated with trastuzumab and chemotherapy is associated with host antibody immunity against the HER2 intracellular domain**
Keith L. Knutson, Raphael Clynes, Barath Shreeder, Patrick Yeramian, Kathleen P. Kemp, Karla Ballman, Kathleen S. Tenner, Courtney L. Erskine, Nadine Norton, Donald Northfelt, Winston Tan, Carmen Calfa, Mark Pegram, Elizabeth A. Mittendorf, Edith A. Perez Cancer Res vol 76 (13) 3702-3710 2016
Manuscript Breast NCCTG-N0337, NCCTG-N98-32-52, NCCTG-N0938
<http://www.ncbi.nlm.nih.gov/pubmed/27197192>
- 1015 Associations of HER2-Specific Immunity with Survival During Treatment with Trastuzumab and Chemotherapy in Breast Cancer**
Keith L. Knutson, Raphael Clynes, Patrick Yeramian, Kathleen P. Kemp, Barath Shreeder, Karla Ballman, Kathleen S. Tenner, Courtney L. Erskine, Nadine Norton, Donald Northfelt, Winston Tan, Mark Pegram, Carmen Calfa, Elizabeth A. Mittendorf, Edith A. Perez J Clin Oncol vol 33 (suppl) abstr 587 2015
Abstract Breast NCCTG-N0337, NCCTG-N98-32-52, NCCTG-N0938
<http://meetinglibrary.asco.org/content/143678-156>
- 1016 Association between cardiorespiratory fitness and overall survival in operable lung cancer patients: Ancillary analysis of protocol 9238**
L. J. Kohman, D. M. Watson, J. E. Herndon 2nd, N. Eves, B. E. Haithcock, G. M. Loewen, L. W. Jones J Clin Oncol vol 27 (15s) abstr 7518 2009
Abstract Respiratory CALGB-9238
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID
- 1017 Biopsy first: Lessons learned from CALGB 140503**
Leslie J. Kohman, Lin Gu, Nasser Altorki, Ernest Scalzetti, Linda J. Veit, Jason M. Wallen, Xiaofei Wang J Thorac Cardiovasc Surg vol 153 (6) 1592-7 2017
Manuscript Respiratory CALGB-140503, CALGB-580602
<http://www.ncbi.nlm.nih.gov/pubmed/28274562>
- 1018 Surgeon Error In Predicting Stage I Non-Small Cell Lung Cancer (NSCLC) Is A Major Factor**

Precluding Randomization In CALGB 140503 (Alliance)

Leslie J. Kohman, Lin Gu, Nasser Altorki, Linda J. Veit, Xiaofei Wang 2016

Abstract Respiratory

http://aats.org/aatsimis/AATS/Meetings/Past_AATS_Meetings/2016/AATS_96th_Annual_Meeting_.asp

1019 Gene Expression of Vitamin D (VitD) Pathway Markers and Survival in Patients (Pts) with Metastatic Colorectal Cancer (mCRC): Findings from CALGB/SWOG 80405 (Alliance)

Christine G. Kohn, Fang-Shu Ou, Chao Ma, Nicholas B. Larson, Tyler J. Zemla, Chen Yuan, Donna Niedzwiecki, Bruce W. Hollis, Andrew B. Nixon, Heinz-Josef Lenz, Charles D. Blanke, Richard M. Goldberg, Robert J. Mayer, Alan P. Venook, Eileen O'Reilly, Jeffrey A. Meyerhardt, Kimmie Ng J Clin Oncol vol 40 (16_suppl) 3553-3553 2022

Abstract PPP https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.3553

1020 Phase III Trial of Immunotherapy with Recombinant Interleukin-2 (rIL-2) Versus Observation in Patients < 60 Years with Acute Myeloid Leukemia (AML) in First Remission (CR1): Preliminary Results from Cancer and Leukemia Group B (CALGB) 19808

J. E. Kolitz, V. Hars, D. J. Deangelo, S. L. Allen, T. C. Shea, R. Vij, E. Hoke, C. D. Bloomfield, M. A. Caligiuri, S. L. George, R. A. Larson Blood vol 110 (11) 157 2007

Abstract Leukemia CALGB-19808, CALGB-8461, CALGB-9665

<http://www.bloodjournal.org/content/110/11/157>

1021 Recombinant Interleukin-2 in Patients Aged Younger Than 60 Years With Acute Myeloid Leukemia in First Complete Remission

Jonathan E. Kolitz, Stephen L. George, Don M. Benson, Kati Maharry, Guido Marcucci, Ravi Vij, Bayard L. Powell, Steven L. Allen, Daniel J. DeAngelo, Thomas C. Shea, Wendy Stock, Courtney E. Bakan, Vera Hars, Eva Hoke, Clara D. Bloomfield, Michael A. Caligiuri, Richard A. Larson Cancer vol 120 (7) 1010-1017 2014

Manuscript Leukemia <http://www.ncbi.nlm.nih.gov/pubmed/24382782>

1022 P-glycoprotein inhibition using valsopodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808

Jonathan E. Kolitz, Stephen L. George, Guido Marcucci, Ravi Vij, Bayard L. Powell, Steven L. Allen, Daniel J. DeAngelo, Thomas C. Shea, Wendy Stock, Maria R. Baer, Vera Hars, Kati Maharry, Eva Hoke, James W. Vardiman, Clara D. Bloomfield, Richard A. Larson Blood vol 116 (9) 1413-1421 2010

Manuscript Leukemia CALGB-8461 <http://www.ncbi.nlm.nih.gov/pubmed/20522709>

1023 Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials.

Edward L Korn, Ping-Yu Liu, Sandra J Lee, Judith-Anne W Chapman, Donna Niedzwiecki, Vera J Suman, James Moon, Vernon K Sondak, Michael B Atkins, Elizabeth A Eisenhauer, Wendy Parulekar, Svetomir N Markovic, Scott Saxman, John M Kirkwood J Clin Oncol vol 26 (4) 527-34 2008

Manuscript Experimental <http://www.ncbi.nlm.nih.gov/pubmed/18235113>

1024 Quality of life of early stage breast cancer patients 65 years old or older randomized to standard chemotherapy or capecitabine (CALGB 49907)

A. B. Kornblith, L. E. Archer, L. Lan, G. G. Kimmick, A. H. Partridge, R. A. Casey, S. Bennett, C. A. Hudis, E. P. Winer, H. J. Cohen, H. B. Muss Cancer Res vol 69 (24, suppl 3) abstr SABCS-09-5035 2009

Abstract Breast http://cancerres.aacrjournals.org/cgi/content/abstract/69/24_MeetingAbstracts/5035

1025 Quality of Life of Older Patients With Early-Stage Breast Cancer Receiving Adjuvant

Chemotherapy: A Companion Study to Cancer and Leukemia Group B 49907

Alice B. Kornblith, Lan Lan, Laura Archer, Ann Partridge, Gretchen Kimmick, Clifford Hudis, Eric Winer, Rebecca Casey, Samantha Bennett, Harvey Jay Cohen, Hyman B. Muss J Clin Oncol vol 29 (8) 1022-1028 2011

Manuscript Health Outcomes CALGB-49907 <http://www.ncbi.nlm.nih.gov/pubmed/21300923>

1026 Interim FDG PET Imaging in CALGB 50203 Trial of Stage I/II Non-Bulky Hodgkin Lymphoma: Would Using Combined PET and CT Criteria Better Predict Response Than Each Test Alone?

L. Kostakoglu, H. Schoder, N. C. Hall, D. J. Straus, J. L. Johnson, L. Schwartz, A. S. Lacasce, S. Jung, N. L. Bartlett, G. P. Canellos, B. D. Cheson ASH Annual Meeting Abstracts vol 118 (21) abstr 3644 2011

Abstract Lymphoma <http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;118/21/3644>

1027 Validation of the International Harmonization Project (IHP) Guidelines in Early Stage Hodgkin Lymphoma (HL) Treated with Adriamycin, Vinblastine and Gemcitabine (AVG) (CALGB 50203): Early Results

L. Kostakoglu, D. J. Straus, H. Schoder, A. S. Lacasce, N. L. Bartlett, N. C. Hall, J. L. Johnson, S. Jung, G. P. Canellos, L. H. Schwartz, B. D. Cheson ASH Annual Meeting Abstracts vol 112 (11) abstr 1460 2008

Abstract Lymphoma <http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;112/11/1460>

1028 Interim [(18)F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone?

Lale Kostakoglu, Heiko Schöder, Jeffrey L Johnson, Nathan C Hall, Lawrence H Schwartz, David J Straus, Ann S LaCasce, Sin-Ho Jung, Nancy L Bartlett, George P Canellos, Bruce D Cheson Leuk Lymphoma vol 53 (11) 2143-50 2012

Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/22421007>

1029 Prognostic association of PTGS2 (COX-2) over-expression according to BRAF mutation status in colorectal cancer: results from two prospective cohorts and CALGB 89803 Alliance) trial

Keisuke Kosumi, Tsuyoshi Hamada, Sui Zhang, Li Liu, Annacarolina da Silva, Hideo Koh, Tyler S. Twombly, Kosuke Mima, Teppei Morikawa, Mingyang Song, Jonathan A. Nowak, Reiko Nishihara, Leonard B. Saltz, Donna Niedzwiecki, Fang-Shu Ou, Tyler Zemla, Robert J. Mayer, Hideo Baba, Kimmie Ng, Marios Giannakis, Xuehong Zhang, Kana Wu, Edward L. Giovannucci, Andrew T. Chan, Charles S. Fuchs, Jeffrey A. Meyerhardt, Shuji Ogino Eur J Cancer vol 111 82-93 2019

Manuscript Correl Sci NOS CALGB-89803 <http://www.ncbi.nlm.nih.gov/pubmed/30826660>

1030 A phase II trial of carboplatin and ABI-007 in patients with unresectable stage IV melanoma, N057E.

L. Kottschade, V. Suman, T. Amatruda, R. McWilliams, S. Dakhil, D. Nikcevich, R. Morton, T. Fitch, A. Jaslowski, S. Markovic J Clin Oncol vol 26 (May 20 suppl) abstr 9044 2008

Abstract Experimental

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID

1031 A randomized phase II trial of temozolomide (TMZ) and bevacizumab (BEV) or nab-paclitaxel (nab-P)/carboplatin (CBDCA) and bevacizumab (BEV) in patients with unresectable stage IV metastatic melanoma: A North Central Cancer Treatment Group Study (N0775)

L. Kottschade, V. Suman, D. Perez, R. McWilliams, J. Kaur, T. Amatruda, F. Geoffroy, H. Gross, T. Fitch, A. Jaslowski, M. Kosel, S. Markovic J Clin Oncol vol 29 (suppl) abstr 8532 2011

Abstract Experimental <http://meetinglibrary.asco.org/content/77235-102>

- 1032 The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase III clinical trial**
Lisa A. Kottschade, Jeff A. Sloan, Mirosław A. Mazurczak, David B. Johnson, Bronagh P. Murphy, Kendrith M. Rowland, DeAnne A. Smith, Alan R. Berg, Philip J. Stella, Charles L. Loprinzi Support Care Cancer vol 19 (11) 1769-1777 2011
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/20936417>
- 1033 A randomized phase II study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma: A North Central Cancer Treatment Group Study, N0775**
Lisa A. Kottschade, Vera J. Suman, Domingo G. Perez, Robert R. McWilliams, Judith S. Kaur, Thomas T. Amatruda, Francois J. Geoffroy, Howard M. Gross, Peter A. Cohen, Anthony J. Jaslowski, Matthew L. Kosel, Svetomir N. Markovic Cancer vol 119 (3) 586-592 2013
Manuscript Experimental <http://www.ncbi.nlm.nih.gov/pubmed/22915053>
- 1034 Nursing's presence in the changing cooperative group setting.**
Lisa A Kottschade, Jennifer Bell, Kathy Klinger, Ellen M Lavoie Smith Semin Oncol Nurs vol 30 (1) 32-7 2014
Manuscript Onc Nursing <http://www.ncbi.nlm.nih.gov/pubmed/24559778>
- 1035 A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma- A North Central Cancer Treatment Group Study, N057E1**
Lisa A Kottschade, Vera J. Suman, Thomas Amatruda, Robert R. McWilliams, Bassam I. Mattar, Daniel A Nikcevich, Robert Behrens, Tom R Fitch, Anthony J Jaslowski, Svetomir N Markovic Cancer vol 117 (8) 2011
Manuscript Experimental <http://www.ncbi.nlm.nih.gov/pubmed/21472717>
- 1036 A randomized phase II study of paclitaxel (P), carboplatin (C), bevacizumab (B) +/- everolimus (E) in metastatic melanoma (MM): secondary analysis of outcomes in patients who harbor an NRAS mutation NCCTG N0879 (Alliance).**
Lisa Kottschade, Jacob Allred, K. Rumila, Svetomir Markovic, Matthew Block, Robert McWilliams 2017
Abstract Experimental
<https://www.professionalabstracts.com/melanoma2017/programme-melanoma2017.pdf>
- 1037 Chemotherapy-induced nausea and vomiting: incidence and characteristics of persistent symptoms and future directions NCCTG N08C3 (Alliance)**
Lisa Kottschade, Paul Novotny, Alan Lyss, Mirosław Mazurczak, Charles Loprinzi, Debra Barton Support Care Cancer vol 24 (6) 2661-2667 2016
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/26768436>
- 1038 Abl Kinase Domain Mutations Leading to Relapse of Ph+ Acute Lymphoblastic Leukemia (ALL) Occur Commonly and Can Be Detected At Initial Diagnosis: Molecular Results From CALGB 10001**
G. Koval, M. Wetzler, D. Watson, K. Owzar, C. D. Bloomfield, G. Malnassy, D. A. Sher, R. A. Larson, W. Stock Blood vol 118 (21) 2541 2011
Abstract Leuk Corr Sci <http://www.bloodjournal.org/content/118/21/2541>
- 1039 Tolerability of veliparib (V) in combination with carboplatin (C)/paclitaxel (P) - based chemoradiotherapy (CRT) in subjects with stage III non-small cell lung cancer (NSCLC).**
David E. Kozono, Joseph Kamel Salama, Tom Stinchcombe, Jeffrey Bogart, William J. Petty, Michael J. Guarino, Lyudmila Bazhenova, James Mitchell Larner, Jared Weiss, Thomas A. DiPetrillo, Steven J. Feigenberg, Tu Xu, Beibei Hu, Silpa Nuthalapati, Lindsey Rosenwinkel, Lindsey Bensman, Eric Feral

Johnson, Mark D. McKee, Everett E. Vokes J Clin Oncol vol 35 (15 suppl) abstr 8546 2017
Abstract Respiratory http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.8546

1040 Veliparib (Vel) in Combination with Chemoradiotherapy (CRT) of Carboplatin/Paclitaxel (C/P) Plus Radiation in Patients With Stage III Non-Small Cell Lung Cancer (NSCLC) (AFT-07).

David E. Kozono, Thomas Stinchcombe, Joseph K. Salama, Jeffery Bogart, William J. Petty, Michael J. Guarino, Lyudmila Bazhenova, James M. Lerner, Jared Weiss, Thomas A. Di Petrillo, Steven J. Feigenberg, Beibei Hu, Silpa Nuthalapati, Yan Luo, Everett E. Vokes J Clin Oncol vol 37 (15_suppl) 8510-8510 2019
Abstract Respiratory https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.8510

1041 Veliparib in combination with carboplatin/paclitaxel-based chemoradiotherapy in patients with stage III non-small cell lung cancer.

David E Kozono, Thomas E Stinchcombe, Joseph K Salama, Jeffrey Bogart, W Jeffrey Petty, Michael J Guarino, Lyudmila Bazhenova, James M Lerner, Jared Weiss, Thomas A DiPetrillo, Steven J Feigenberg, Xin Chen, Zhaowen Sun, Silpa Nuthalapati, Lindsey Rosenwinkel, Eric F Johnson, Bruce A Bach, Yan Luo, Everett E Vokes Lung Cancer vol 159 56-65 2021
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/34311345>

1042 Alliance A151804: Establishment of a national biorepository to advance studies of immune-related adverse events

David Kozono, Elad Sharon, Jennifer Le-Rademacher, Erin Twohy, Tyler Zemla, Yujia Wen, Mark Watson, Elie Dib, John Kirkwood, Gary Lyman, Jarushka Naidoo, Andrew Nixon, Elizabeth Mittendorf J Clin Oncol vol 38 (suppl) abstr TPS3154 2020
Abstract Immuno-Onc 9767 <https://meetinglibrary.asco.org/record/191799/abstract>

1043 Alliance A151804: Establishment of a National Biorepository to Advance Studies of Immune-related Adverse Events

David Kozono, Tyler Zemla, Elie Dib, Mark Watson, Yujia Wen, Frank Keller, John Kirkwood, Gary H. Lyman, Jarushka Naidoo, Barb Mulhern, Laura Hoffman, Jennifer Le-Rademacher, Andrew Nixon, Elad Sharon J Immunotherapy Cancer vol 10 (suppl 2) 1244 2022
Abstract Immuno-Onc https://jitc.bmj.com/content/10/Suppl_2/A1290

1044 Does positron emission tomography prevent nontherapeutic pulmonary resections for clinical stage IA lung cancer?

Benjamin D Kozower, Bryan F Meyers, Carolyn E Reed, David R Jones, Paul A Decker, Joe B Putnam Ann Thorac Surg vol 85 (4) 1166-9; discussion 1169-70 2008
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/18355490>

1045 Response to the methylation inhibitor dihydro-5-azacytidine in mesothelioma is not associated with methylation of p16INK4a: results of cancer and leukemia group B 159904.

Robert A Kratzke, Xiaofei Wang, Long Wong, Marian G Kratzke, Mark R Green, Everett E Vokes, Nicholas J Vogelzang, Hedy L Kindler, Jeffrey A Kern J Thorac Oncol vol 3 (4) 417-21 2008
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/18379362>

1046 Inherited genetic variation in EPHA5, FGD4 and NRDG1 and paclitaxel (P) induced peripheral neuropathy (PN): Results from a genome-wide association study (GWAS) in CALGB 40101

D. L. Kroetz, R. Baldwin, K. Owzar, C. Jiang, H. Zembutsu, M. Kubo, C. A. Hudis, E. P. Winer, E. Nakamura, L. N. Shulman, M. J. Ratain J Clin Oncol vol 28 (15s) abstr 3021 2010
Abstract PPP CALGB-40101
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID

1047 Increasing Adherence to Adjuvant Hormone Therapy among Breast Cancer Patients: A Smart

Phone App-Based Pilot Study

Jessica L. Krok-Schoen, Michelle J. Naughton, Gregory S. Young, Jennifer Moon, Electra D. Paskett, Douglas M. Post J Clin Oncol vol 36 (Suppl) abstr e12523 2018
Abstract Health Outcomes <https://meetinglibrary.asco.org/record/163105/abstract>

1048 Increasing Adherence to Adjuvant Hormone Therapy Among Patients With Breast Cancer: A Smart Phone App-Based Pilot Study

Jessica L. Krok-Schoen, Michelle J. Naughton, Gregory S. Young, Jennifer Moon, Ming Poi, Susan A. Melin, Marie E. Wood, Judith O. Hopkins, Electra D. Paskett, Douglas M. Post Cancer Control vol 26 (1) 2019
Manuscript Health Outcomes <http://www.ncbi.nlm.nih.gov/pubmed/31736324>

1049 Invasive disease-free survival and gene expression signatures in CALGB (Alliance) 40601, a randomized phase III neoadjuvant trial of dual HER2-targeting with lapatinib added to chemotherapy plus trastuzumab

Ian E. Krop, David Hillman, Mei Polley, Maki Tanioka, Joel S. Parker, Lucas Huebner, N. Lynn Henry, Sara Tolaney, Chau Dang, Lyndsay Harris, Donald A. Berry, Charles M. Perou, Ann Partridge, Lisa A. Carey Cancer Res vol 78 (4 Supplement) GS3-02 2018
Abstract Breast http://cancerres.aacrjournals.org/content/78/4_Supplement/GS3-02

1050 RWDD3 and TECTA variants not linked to paclitaxel induced peripheral neuropathy in North American trial N08C1

Amit A. Kulkarni, Ganesh Boora, Rahul Kanwar, Kathryn J. Ruddy, Michaela S. Banck, Nguyet Le-Lindqwister, Terry M. Therneau, Charles L. Loprinzi, Andreas S. Beutler Acta Oncol vol 54 (8) 1227-1229 2015
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/25549536>

1051 Randomized Phase II Study of Everolimus (E) versus Everolimus plus Bevacizumab (E+B) in Patients (Pts) with Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors (pNET), CALGB 80701 (Alliance)

Matthew H. Kulke, Donna Niedzwiecki, Nathan R. Foster, Briant Fruth, Pamela L. Kunz, Hagen Kennecke, Edward M. Woli, Alan P. Venook Pancreas vol 45 (3) abstr C23 2016
Abstract GI https://www.nanets.net/nanets_cd/2015/Browse_NET_Abstracts.html

1052 Randomized Phase II Study of Everolimus Alone (E) versus Everolimus plus Bevacizumab (E+B) in Patients with Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors, CALGB 80701 (Alliance)

Matthew H. Kulke, Donna Niedzwiecki, Nathan R. Foster, Bryant Fruth, Pamela L. Kunz, Hagen Kennecke, Edward M. Wolin, Alan P. Venook J Clin Oncol vol 33 (suppl) abstr 4005 2015
Abstract GI <http://meetinglibrary.asco.org/content/150169-156>

1053 Everolimus With or Without Bevacizumab in Advanced pNET: CALGB 80701 (Alliance)

Matthew H. Kulke, Fang-Shu Ou, Donna Niedzwiecki, Lucas Huebner, Pamela Kunz, Hagen F. Kennecke, Edward M. Wolin, Jennifer A Chan, Eileen M. O'Reilly, Jeffrey A. Meyerhardt, Alan Venook Endocr Relat Cancer vol 29 (6) 335-44 2022
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/35324465>

1054 Randomized Phase II Study of Gemcitabine Administered at a Fixed Dose Rate or in Combination With Cisplatin, Docetaxel, or Irinotecan in Patients With Metastatic Pancreatic Cancer: CALGB 89904

Matthew H. Kulke, Margaret A. Tempero, Donna Niedzwiecki, Donna R. Hollis, Hedy L. Kindler, Michael Cusnir, Peter C. Enzinger, Stefan M. Gorsch, Richard M. Goldberg, Robert J. Mayer J Clin Oncol vol 27 (33) 5506-5512 2009

1055 Subcutaneous interleukin-4 (IL-4) for relapsed and resistant non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group, NCCTG 91-78-51.

David M Kurtz, Loren K Tschetter, Jacob B Allred, Susan M Geyer, Paul J Kurtin, Wesley D Putnam, Kendrith M Rowland, Martin Wiesenfeld, Gamini S Soori, Richard C Tenglin, Albert M Bernath, Thomas E Witzig *Leuk Lymphoma* vol 48 (7) 1290-8 2007
Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/17613756>

1056 FLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: a report from the Children's Oncology Group

M. A. Kutny, B. K. Moser, K. Laumann, J. H. Feusner, A. Gamis, J. Gregory, R. A. Larson, B. L. Powell, W. Stock, C. L. Willman, W. G. Woods, S. Meshinchi *Pediatr Blood Cancer* vol 59 (4) 662-667 2012
Manuscript Leuk Corr Sci <http://www.ncbi.nlm.nih.gov/pubmed/22378655>

1057 Outcome for Pediatric Acute Promyelocytic Leukemia Patients at Children's Oncology Group Sites on the Leukemia Intergroup Study CALGB 9710 (Alliance)

Matthew A. Kutny, Susan Geyer, Kristina M Laumann, John Gregory, Cheryl L. Willman, Wendy Stock, Richard A. Larson, Bayard L. Powell, James H. Feusner *Pediatr Blood Cancer* vol 66 (3) e27542 2019
Manuscript Leukemia <http://www.ncbi.nlm.nih.gov/pubmed/30393935>

1058 A Comparison of Outcomes between Adolescents and Young Adults (AYA) and Children with Acute Promyelocytic Leukemia: North American Intergroup Study CALGB 9710 (Alliance)

Matthew A. Kutny, Susan Geyer, Kristina M Laumann, John Gregory, Cheryl L. Willman, Wendy Stock, Richard A. Larson, Bayard L. Powell, James H. Feusner *Blood* vol 124 (21) 2306 2014
Abstract Leukemia <http://www.bloodjournal.org/content/124/21/2306?sso-checked=true>

1059 Effect of young Age on Outcomes in Pediatric Acute Promyelocytic Leukemia: North American Intergroup Study CALGB 9710 (Alliance)

Matthew A. Kutny, John Gregory, Susan Geyer, Kristina Laumann, Cheryl L. Willman, Wendy Stock, Richard A. Larson, Bayard L. Powell, James H. Feusner *Blood* vol 124 (21) 2301 2014
Abstract Leukemia <http://www.bloodjournal.org/content/124/21/2301?sso-checked=true>

1060 A correlative study of cardiac biomarkers and left ventricular ejection fraction (LVEF) from N9831, a phase III randomized trial of chemotherapy and trastuzumab as adjuvant therapy for HER2 positive breast cancer

L.A. Kutteh, T. J. Hobday, A. S. Jaffe, B. R. Laplant, D. W. Hillman, P. Kaufman, N. Davidson, S. Martino, A. Moreno, E. A. Perez *J Clin Oncol* vol 25 (18s) abstr 579 2007
Abstract Breast http://meeting.ascopubs.org/cgi/content/short/25/18_suppl/579

1061 High expression of IGFBP2 is associated with chemoresistance in adult acute myeloid leukemia

Andrea Kühnl, Martin Kaiser, Martin Neumann, Lars Fransecky, Sandra Heesch, Michael Radmacher, Guido Marcucci, Clara D Bloomfield, Wolf-Karsten Hofmann, Eckhard Thiel, Claudia D Baldus *Leuk Res* vol 35 (12) 1585-1590 2011
Manuscript Leuk Corr Sci CALGB-9665, CALGB-20202, CALGB-9621, CALGB-8461
<http://www.ncbi.nlm.nih.gov/pubmed/21899885>

1062 Positron Emission Tomography-Adapted Therapy in Bulky Stage I/II Classic Hodgkin Lymphoma: CALGB 50801 (Alliance)

Ann S. LaCasce, Travis Dockter, Amy S. Ruppert, Lale Kostakoglu, Heiko Schöder, Eric Hsi, Jeffrey Bogart, Bruce Cheson, Nina Wagner-Johnston, Jeremy Abramson, Kristie Blum, John P. Leonard,

1063 Alliance 50801: PET adapted therapy in bulky stage I/II classic Hodgkin lymphoma

Ann LaCasce, Travis Dockter, Amy S. Ruppert, Lale Kostakoglu, Heiko Schöder, Eric Hsi, Jeffrey Bogart, Bruce Cheson, John Leonard, Nancy L. Bartlett J Clin Oncol vol 39 (no. 15_suppl) 7507 2021

Abstract Lymphoma https://ascopubs.org/doi/10.1200/JCO.2021.39.15_suppl.7507

1064 Alliance 50801: PET adapted therapy in bulky stage I/II classic Hodgkin lymphoma

Ann LaCasce, Travis Dockter, Amy S. Ruppert, Lale Kostakoglu, Heiko Schöder, Eric Hsi, Jeffrey Bogart, Bruce Cheson, John Leonard, Nancy L. Bartlett Hematological Oncology vol 39 (S2 Supplemental) 120 2021

Abstract Lymphoma https://onlinelibrary.wiley.com/doi/10.1002/hon.72_2879

1065 Phase I randomized phase II trial of either dasatinib or placebo combined with standard chemoradiotherapy for newly diagnosed glioblastoma multiforme (GBM): Final results of phase I study

N. N. Laack, E. Galanis, C. Leinweber, J. C. Buckner, C. Giannini, F. J. Geoffroy, K. A. Jaeckle, J. N. Sarkaria J Clin Oncol vol 30 (15 suppl) abstr 2032 2012

Abstract Neuro-Onc

http://meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/2032?sid=2b49f5ee-cb83-4a46-8d0a-2505c

1066 CHOD/BVAM Chemotherapy and Whole-Brain Radiotherapy for Newly Diagnosed Primary Central Nervous System Lymphoma

Nadia N. Laack, Brian Patrick O'Neill, Karla V. Ballman, Judith Rich O'Fallon, Xiomara W. Carrero, Paul J. Kurtin, Bernd W. Scheithauer, Paul D. Brown, Thomas M. Habermann, Joseph P. Colgan, Mark R. Gilbert, Roland B. Hawkins, Roscoe F. Morton, Harry E. Windschitl, Tom R. Fitch, Eduardo R. Pajon Int J Radiat Oncol Biol Phys vol 81 (2) 476-482 2011

Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/20800387>

1067 Randomized Placebo-Controlled Phase II Study of Dasatinib with Standard Chemo-Radiotherapy for Newly Diagnosed Glioblastoma (GBM), N0877

Nadia Laack, Eva Galanis, S. Keith Anderson, Clinton Leinweber, Jan Buckner, Caterina Giannini, Francois Geoffroy, Derek R. Johnson, Glenn J. Lesser, Kurt Jaeckle, Jann Sarkaria J Clin Oncol vol 33 (suppl) abstr 2013 2015

Abstract Neuro-Onc <http://meetinglibrary.asco.org/content/151649-156>

1068 Genetic predictors of severe skin toxicity in stage III colon cancer patients treated with cetuximab: NCCTG N0147 (Alliance)

Julia D. Labadie, Xinwei Hua, Tabitha A. Harrison, Barbara L. Banbury, Jeroen R. Huyghe, Wei Sun, Qian Shi, Greg Yothers, Steven R. Alberts, Frank A. Sinicrope, Richard M. Goldberg, Thomas J. George, Kathryn L. Penney, Amanda I. Phipps, Stacey A. Cohen, Ulrike Peters, Andrew T. Chan, Polly A. Newcomb Cancer Epidemiol Biomarkers Prev vol 30 (2) 404-11 2021

Manuscript PPP NCCTG-N0147 <http://www.ncbi.nlm.nih.gov/pubmed/33203692>

1069 Utility of circulating biomarkers as outcome predictors in metastatic colorectal cancer and recurrent glioblastoma multiforme patients treated with bevacizumab/sorafenib

J. M. Lafky, S. K. Anderson, B. W. Morlan, G. D. Nelson, X. W. Carrero, S. Kumar, J. T. Reynolds, P. J. Stella, S. R. Dakhil, W. S. Loui, S. R. Alberts, P. J. Flynn, H. M. Gross, K. A. Jaeckle, J. C. Buckner, E. Galanis, A. Grothey Cancer Res vol 72 (8) abstr 5562 2012

Abstract GI http://cancerres.aacrjournals.org/content/72/8_Supplement/5562.short

- 1070 Circulating endothelial cells (CECs) in metastatic colorectal cancer (mCRC) patients treated with bevacizumab (BEV) and sorafenib**
J. M. Lafky, B. M. Bot, B. W. Morlan, S. K. Anderson, S. K. Kumar, T. K. Kimlinger, J. T. Reynolds, P. J. Stella, S. R. Dakhil, W. S. Loui, S. R. Alberts, A. Grothey J Clin Oncol vol 29 (suppl) abstr e 14063 2011
Abstract GI <http://meetinglibrary.asco.org/content/83471-102>
- 1071 Genetic variant associations with treatment outcome and safety in metastatic colorectal cancer patients treated with sorafenib and bevacizumab (BEV) as salvage therapy**
J. Lafky, B. Bot, B. Morlan, A. Grothey Proc Am Assoc Can Res vol 71 (8 Suppl) 382, abstr nr 4131 2011
Abstract GI http://cancerres.aacrjournals.org/content/71/8_Supplement/4131.short
- 1072 Deficit Accumulation Frailty Index (DAFI) Scores and Acute Myeloid Leukemia Outcomes (Alliance A152124)**
Catherine Lai, Olivia Conway, Minji Lee, Jennifer Le-Rademacher, Jeanne Mandelblatt, Heidi Klepin J Clin Oncol vol 40 (16_suppl) 12040-12040 2022
Abstract Older Adult CALGB-11001, CALGB-11002, CALGB-361006, CALGB-361101
https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.12040
- 1073 High expression of nucleoside transporter protein hENT1 in Reed-Sternberg cells is associated with treatment failure in relapsed/refractory Hodgkin lymphoma patients treated with gemcitabine, vinorelbine and liposomal doxorubicin - a CALGB 59804 correlative study.**
Raymond Lai, Nancy L Bartlett, John R Mackey, Sin-Ho Jung, Jeffrey L Johnson, James R Cook, Dan Jones, Carol E Cass, James D Young, Jonathan Said, Bruce Cheson, Eric D Hsi Leuk Lymphoma vol 49 (6) 1202-5 2008
Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/18452103>
- 1074 Utilization of receptor targeted technetium Tc 99m Tilmanocept (lymphoseek injection) to identify and evaluate the pathological status of sentinel lymph nodes vs. elective neck dissection in patients with intraoral squamous cell carcinoma: A preliminary performance evaluation against technetium Tc 99m sulfur colloid in the ACOSOG-Z0360 study**
S. Y. Lai, A. Agrawal, F. J. Civantos Ann Surg Oncol vol 20 (1 suppl) abstr P226-S108 2013
Abstract GI <http://link.springer.com/article/10.1245/s10434-013-2877-x>
- 1075 Joint NABTC + NCCTG prognostic factors analysis for high grade recurrent glioma**
K. Lamborn, W. Wu, M. Prados, K. Jaeckle, S. Chang, P. Novotny, J. Buckner J Clin Oncol vol 25 (18S) abstr 2075 2007
Abstract Neuro-Onc
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID
- 1076 Differences in clinical trial patient attributes and outcomes according to trial enrollment setting: Analyses from 10 CALGB lung cancer trials**
E. B. Lamont, L. E. Archer, L. Lan, E. E. Vokes, B. J. Mcneil, N. L. Keating, M. Landrum J Clin Oncol vol 26 (May 20 suppl) abstr 6517 2008
Abstract Disparities
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID
- 1077 Survival of clinical trial subjects vs elderly Medicare patients with extensive stage small cell lung cancer following treatment with cisplatin and etoposide**
E. B. Lamont, Y. He, L. Lan, S. Joffe J Geriatr Oncol vol 2 (Supplement 1) S24 2011
Abstract Disparities
http://ac.els-cdn.com/S1879406811000683/1-s2.0-S1879406811000683-main.pdf?_tid=71e546da-26be-

- 1078 Measuring clinically significant chemotherapy-related toxicities using Medicare claims from CALGB breast and lung cancer trial participants**
E. B. Lamont, J. E. Herndon 2nd, J. C. Weeks, I. C. Henderson, R. C. Lilenbaum, R. L. Schilsky, N. A. Christakis J Clin Oncol vol 25 (18s) abstr 6595 2007
Abstract Breast CALGB-70101, CALGB-9730, INT-0148
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&c
- 1079 Sensitivity of Medicare Claims Data for Measuring Use of Standard Multiagent Chemotherapy Regimens**
E. B. Lamont, L. Lan Med Care vol 52 (3) e15-20 2014
Manuscript Health Outcomes CALGB-9344, CALGB-9730, CALGB-9235, CALGB-9732, CALGB-80203, CALGB-89803 <http://www.ncbi.nlm.nih.gov/pubmed/22410411>
- 1080 Measuring Clinically Significant Chemotherapy-Related Toxicities Using Medicare Claims From Cancer and Leukemia Group B (CALGB) Trial Participants**
Elizabeth B. Lamont, James E. Herndon, Jane C. Weeks, I. Craig Henderson, Rogerio Lilenbaum, Richard L. Schilsky, Nicholas A. Christakis Med Care vol 46 (3) 303-308 2008
Manuscript Health Outcomes <http://www.ncbi.nlm.nih.gov/pubmed/18388845>
- 1081 Differences in Clinical Trial Patient Attributes and Outcomes According to Enrollment Setting**
Elizabeth B. Lamont, Mary Beth Landrum, Nancy L. Keating, Laura Archer, Lan Lan, Gary M. Strauss, Rogerio Lilenbaum, Harvey B. Niell, L. Herbert Maurer, Michael P. Kosty, Antonius A. Miller, Gerald H. Clamon, Anthony D. Elias, Edward F. McClay, Everett E. Vokes, Barbara J. McNeil J Clin Oncol vol 28 (2) 215-221 2010
Manuscript Disparities <http://www.ncbi.nlm.nih.gov/pubmed/19933919>
- 1082 Generalizability of Trial Results to Elderly Medicare Patients with Advanced Solid Tumors (Alliance 70802)**
Elizabeth B. Lamont, Richard L. Schilsky, Yulei He, Hyman Muss, Harvey Jay Cohen, Arti Hurria, Ashley Meilleur, Hedy L. Kindler, Alan Venook, Rogerio Lilenbaum, Harvey Niell, Richard M. Goldberg, Steven Joffe J Natl Cancer Inst vol 107 (1) 2014
Manuscript Health Outcomes <http://www.ncbi.nlm.nih.gov/pubmed/25432408>
- 1083 Hospital-based health care use correlates with incidence of adverse events among elderly Medicare patients treated in adjuvant chemotherapy trials (Alliance 70802)**
Elizabeth B. Lamont, Menggang Yu, Yulei He, Leonard Saltz, Hyman Muss, Alan M. Zaslavsky J Geriatr Oncol vol 5 (3) 230-237 2014
Manuscript Health Outcomes <http://www.ncbi.nlm.nih.gov/pubmed/24594119>
- 1084 Multicenter I-SPY 1 TRIAL (CALGB 150007/150012): Breast cancer stem cells are associated with intrinsic chemoresistance and worse survival**
M. Landis, C. Yau, V. Neumeister, D. Rimm, L. Esserman, J. Chang Cancer Res vol 72 (24 suppl) Abstract nr P2-10-06 2012
Abstract Correl Sci NOS CALGB-150007, CALGB-150012
http://cancerres.aacrjournals.org/cgi/content/short/72/24_MeetingAbstracts/P2-10-06?rss=1
- 1085 Low Meningioma 1 (MN1) gene expression to predict outcome in cytogenetically normal acute myeloid leukemia (CN-AML): A Cancer and Leukemia Group B (CALGB) study**
C. Langer, K. S. Maharry, K. A. Mrozek, P. Paschka, S. P. Whitman, J. E. Kolitz, R. A. Larson, G. Marcucci, C. D. Bloomfield J Clin Oncol vol 26 (May 20 suppl) abstr 7011 2008
Abstract Leuk Corr Sci CALGB-19808, CALGB-20502, CALGB-9621
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID

1086 High BAALC expression associates with other molecular prognostic markers, poor outcome and a distinct gene expression signature in cytogenetically normal acute myeloid leukemia (CN AML): A Cancer and Leukemia Group B (CALGB) study

C. Langer, A. S. Ruppert, M. D. Radmacher, S. P. Whitman, P. Paschka, C. Baldus, K. A. Mrozek, J. E. Kolitz, G. Marcucci, C. D. Bloomfield J Clin Oncol vol 25 (18s) abstr 7013 2007
Abstract Leuk Corr Sci CALGB-19808, CALGB-20502, CALGB-8461, CALGB-9621, CALGB-9665
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID

1087 Prognostic Importance of MN1 Transcript Levels, and Biologic Insights From MN1-Associated Gene and MicroRNA Expression Signatures in Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

Christian Langer, Guido Marcucci, Kelsi B. Holland, Michael D. Radmacher, Kati Maharry, Peter Paschka, Susan P. Whitman, Krzysztof Mrózek, Claudia D. Baldus, Ravi Vij, Bayard L. Powell, Andrew J. Carroll, Jonathan E. Kolitz, Michael A. Caligiuri, Richard A. Larson, Clara D. Bloomfield J Clin Oncol vol 27 (19) 3198-3204 2009
Manuscript Leuk Corr Sci CALGB-19808, CALGB-20502, CALGB-8461, CALGB-9621, CALGB-9665 <http://www.ncbi.nlm.nih.gov/pubmed/19451432>

1088 High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study

Christian Langer, Michael D. Radmacher, Amy S. Ruppert, Susan P. Whitman, Peter Paschka, Krzysztof Mrózek, Claudia D. Baldus, Tamara Vukosavljevic, Chang-Gong Liu, Mary E. Ross, Bayard L. Powell, Albert de la Chapelle, Jonathan E. Kolitz, Richard A. Larson, Guido Marcucci, Clara D. Bloomfield Blood vol 111 (11) 5371-5379 2008
Manuscript Leuk Corr Sci CALGB-19808, CALGB-20502, CALGB-8461, CALGB-9621, CALGB-9665 <http://www.ncbi.nlm.nih.gov/pubmed/18378853>

1089 Early relapse of follicular lymphoma after rituximab-based biologic doublet upfront therapy is associated with increased risk of death: a combined analysis from CALGB/Alliance Studies 50402, 50701 and 50803

Frederick Lansigan, Ian Barak, Brandelyn Pitcher, Sin-Ho Jung, Bruce Cheson, Myron Czuczman, Barbara Grant, Peter Martin, Eric Hsi, Heiko Schroder, Nancy Bartlett, John P. Leonard, Kristie A. Blum Blood vol 128 (22) abstr 2953 2016
Abstract Lymphoma CALGB-50402, CALGB-50701, CALGB-50803
<http://www.bloodjournal.org/content/128/22/2953>

1090 The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: A combined analysis of 3 CALGB trials

Frederick Lansigan, Ian Barak, Brandelyn Pitcher, SinHo Jung, Bruce D. Cheson, Myron Czuczman, Peter Martin, Eric Hsi, Heiko Schöder, Scott Smith, Nancy L. Bartlett, John P. Leonard, Kristie A. Blum Cancer Med vol 8 (1) 165-73 2018
Manuscript Lymphoma CALGB-50402, CALGB-50701, CALGB-50803
<http://www.ncbi.nlm.nih.gov/pubmed/30575311>

1091 p53 Expression in Node Positive Breast Cancer Patients: Results from the Cancer and Leukemia Group B (CALGB) 9344 Trial (159905)

Jonathan F. Lara, Ann D. Thor, Lynn G. Dressler, Gloria Broadwater, Ira J. Bleiweiss, Susan Edgerton, David Cowan, Lori J. Goldstein, Silvana Martino, James N. Ingle, I. Craig Henderson, Larry Norton, Eric P. Winer, Clifford A. Hudis, Matthew J. Ellis, Donald A. Berry, Daniel F. Hayes Clin Cancer Res vol 17 (15) 5170-5178 2011

1092 High Early Death Rates, Treatment Resistance and Short Survival of Very Young Black Adolescent and Young Adults (AYAs) with Acute Myeloid Leukemia (AML) (Alliance)

Karilyn T. Larkin, Deedra Nicolet, Ben Kelly, Krzysztof Mrózek, Katie Miller, Saranga Wijeratne, Stephanie LaHaye, Jessica Kohlschmidt, James S. Blachly, Alice S. Mims, Christopher J. Walker, Christopher C. Oakes, Shelley Orwick, Isaiah Boateng, Jill Buss, Adrienne Heyrosa, Andrew J. Carroll, William Blum, Bayard L. Powell, Jonathan E. Kolitz, Joseph O. Moore, Robert J. Mayer, Richard M. Stone, Electra D. Paskett, John C. Byrd, Elaine Mardis, Ann-Kathrin Einfeld *Blood Adv* vol 6 (19) 5570–5581 2022

Abstract *Leuk Corr Sci* CALGB-20202, CALGB-8461, CALGB-9665

<https://ashpublications.org/bloodadvances/article/6/19/5570/485729/High-early-death-rates-treatment-res>

1093 High early death rates, treatment resistance, and short survival of Black adolescents and young adults with AML

Karilyn T. Larkin, Deedra Nicolet, Benjamin J. Kelly, Krzysztof Mrózek, Stephanie LaHaye, Katherine E. Miller, Saranga Wijeratne, Gregory Wheeler, Jessica Kohlschmidt, James S. Blachly, Alice S. Mims, Christopher J. Walker, Christopher C. Oakes, Shelley Orwick, Isaiah Boateng, Jill Buss, Adrienne Heyrosa, Helee Desai, Andrew J. Carroll, William Blum, Bayard L. Powell, Jonathan E. Kolitz, Joseph O. Moore, Robert J. Mayer, Richard A. Larson, Richard M. Stone, Electra D. Paskett, John C. Byrd, Elaine R. Mardis, Ann-Kathrin Einfeld *Blood Adv* vol 6 (19) 5570-81 2022

Manuscript *Leuk Corr Sci* CALGB-20202, CALGB-8461, CALGB-9665

<http://www.ncbi.nlm.nih.gov/pubmed/35788257>

1094 Surgeon volume does not predict outcomes in the setting of technical credentialing: results from a randomized trial in colon cancer.

David W Larson, Peter W Marcello, Sergio W Larach, Steven D Wexner, Adrian Park, John Marks, Anthony J Senagore, Alan G Thorson, Tonia M Young-Fadok, Erin Green, Daniel J Sargent, Heidi Nelson *Ann Surg* vol 248 (5) 746-50 2008

Manuscript *GI* <http://www.ncbi.nlm.nih.gov/pubmed/18948801>

1095 What Determines the Outcome for Adolescents and Young Adults With Acute Lymphoblastic Leukemia?

R. A. Larson, W. Stock *Ann Hematol* vol 87 (Suppl 1) S67-S69 2008

Abstract *Leukemia* CALGB-8811, CALGB-9331, CALGB-19802, CALGB-8461

<http://www.springerlink.com/content/u34p00527070m826/>

1096 Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial

Richard A. Larson, Sumithra J. Mandrekar, Lucas J. Huebner, Ben L. Sanford, Kristina Laumann, Susan Geyer, Clara D. Bloomfield, Christian Thiede, Thomas W. Prior, Konstanze Döhner, Guido Marcucci, Maria Teresa Voso, Rebecca B. Klisovic, Ilene Galinsky, Andrew H. Wei, Jorge Sierra, Miguel A. Sanz, Joseph M. Brandwein, Theo de Witte, Dietger Niederwieser, Frederick R. Appelbaum, Bruno C. Medeiros, Martin S. Tallman, Jürgen Krauter, Richard F. Schlenk, Arnold Ganser, Hubert Serve, Gerhard Ehninger, Sergio Amadori, Insa Gathmann, Hartmut Döhner, Richard M. Stone *Leukemia* vol 35 (9) 2539-51 2021

Manuscript *Leukemia* <http://www.ncbi.nlm.nih.gov/pubmed/33654204>

1097 An Analysis of Maintenance Therapy and Post-Midostaurin Outcomes in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603/RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with FLT3 Mutations

Richard A. Larson, Sumithra Mandrekar, Ben L Sanford, Kristine Laumann, Susan Geyer, Clara D. Bloomfield, Christian Thiede, T W Prior, Konstanze Dohner, Guido Marcucci, Francesco Lo-Coco,

Rebecca B. Klisovic, Andrew Wei, Jorge Sierra, Miguel A. Sanz, Joseph M. Brandwein, Theo de Witte, Dietger Niederwieser, Frederick R. Appelbaum, Bruno C. Medeiros, Martin S Tallman, Jurgen Krauter, *Richard F. Schlenk, Arnold Ganser, Hubert Serve, Gerhard Ehninger, Sergio Amadori, Hartmut Dohner, Richard M. Stone *Blood* vol 130 (Suppl 1) 145 2017
Abstract Leukemia http://www.bloodjournal.org/content/130/Suppl_1/145

1098 Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) with Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of GRIFFIN After 24 Months of Maintenance (AFT-29)

Jacob Laubach, Johnathan L. Kaufman, Douglas W. Sborov, Brandi Reeves, Cesar Rodriguez, Ajai Chari, Rebecca Silbermann, Luciano J. Costa, Larry D. Anderson Jr., Nitya Nathwani, Nina Shah, Yvonne A. Efebera, Sarah A. Holstein, Caitlin Costello, Andrzej Jakubowiak, Tanya M. Wildes, Robert Z. Orlowski, Kenneth H. Shain, Andrew J. Cowan, Huiling Pei, Annelore Cortoos, Sharmila Patel, Blake Bartlett, Jessica Vermeulen, Thomas S. Lin, Paul G. Richardson, Peter M. Voorhees
Blood vol 138 (Supplement 1) 79 2021
Abstract Myeloma
<https://ashpublications.org/blood/article/138/Supplement%201/79/477547/Daratumumab-DARA-Plus-Lc>

1099 Psychometric Testing of the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-CIPN20 Using Pooled Chemotherapy-Induced Peripheral Neuropathy Outcome Measures Standardization (CI-PeriNomS) and Alliance for Clinical Trials in Oncology (Alliance) A151408 Study Data

Ellen M. Lavoie Smith, Tanima Banerjee, James J. Yang, Celia M. Bridges, Paola Alberti, Jeff A. Sloan, Charles Loprinzi *Cancer Nurs* vol 42 (3) 179-89 2019
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/29649081>

1100 Central review versus local review of axillary ultrasound prior to and after neoadjuvant chemotherapy: Results from the American College of Surgeons Oncology Group Z1071 trial (Alliance)

H. Carisa Le-Petross, Linda M. McCall, Kelly K. Hunt, Karla V. Ballman, Judy C. Boughey 2019
Abstract Breast

1101 Role of axillary ultrasound after neoadjuvant chemotherapy in women with node-positive breast cancer (T1-4, N1-2, M0) at initial diagnosis (ACOSOG Z1071)

H. T. Le-Petross, L. Mccall, K. Hunt, E. A. Mittendorf, G. Ahrendt, L. Wilke, M. Leitch, B. Taback, J. C. Boughey *J Clin Oncol* vol 30 (15 suppl) abstr 1107 2012
Abstract Breast
http://meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/1107?sid=09cfdc8b8-739c-4acc-849e-43718

1102 Axillary Ultrasound Identifies Residual Nodal Disease After Chemotherapy: Results From the American College of Surgeons Oncology Group Z1071 Trial (Alliance)

Huong T. Le-Petross, Linda M. McCall, Kelly K. Hunt, Elizabeth A. Mittendorf, Gretchen M. Ahrendt, Lee G. Wilke, Karla V. Ballman, Judy C. Boughey *AJR Am J Roentgenol* vol 210 (3) 669-76 2018
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/29381381>

1103 Comparison of results from three different density assessment methods on mammographic density (MD) in a screening patients receiving vitamin D (Vit D): Results of CALGB 70806 (Alliance)

Huong T. Le-Petross, Drew K. Seisler, Despina Kontos, Sin-Ho Jung, Jayne Charlamb, James Marshall, Marie Wood 2018
Abstract Prevention <http://archive.rsna.org/2018/18004859.pdf>

1104 Adverse Event Burden Score—A Versatile Summary Measure for Cancer Clinical Trials

Jennifer G. Le-Rademacher, Shauna Hillman, Elizabeth Storrick, Michelle R. Mahoney, Peter F. Thall, Aminah Jatoi, Sumithra J. Mandrekar *Cancers (Basel)* vol 12 (11) 2020

1105 Neurological Safety of Oxaliplatin in Patients with Uncommon Variants in Charcot-Marie-Tooth Disease Genes

Jennifer G. Le-Rademacher, Camden L. Lopez, Rahul Kanwar, Brittny Major, Alexej Abyzov, Michaela S. Banck, Terry M. Therneau, Jeff A. Sloan, Charles L. Loprinzi, Andreas S. Beutler J Neurol Sci vol 411 116687 2020

Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/32018185>

1106 Application of multi-state models in cancer clinical trials

Jennifer G Le-Rademacher, Ryan A Peterson, Terry M Therneau, Ben L Sanford, Richard M Stone, Sumithra J Mandrekar Clin Trials vol 15 (5) 489-98 2018

Manuscript Leukemia CALGB-10603 <http://www.ncbi.nlm.nih.gov/pubmed/30035644>

1107 Association Between Patient Perception of Oncology Clinical Trial Participation and Survival: NCCTG N0392 (Alliance)

Jennifer Le-Rademacher, Amylou Dueck, Cynthia Chauhan, Daniel Satele, Jeff Sloan J Clin Oncol vol 34 (suppl) abstr e18122 2016

Abstract Health Outcomes <http://meetinglibrary.asco.org/content/168067-176>

1108 Association Between Patient Perception of Oncology Clinical Trial Participation and Survival: NCCTG N0392 (Alliance)

Jennifer Le-Rademacher, Amylou Dueck, Cynthia Chauhan, Daniel Satele, Jeff Sloan 2016

Abstract Health Outcomes

<http://mascc2016.kenes.com/PublishingImages/scientific-information/abstract-journal/MASCC%202016>

1109 Patient-Reported (EORTC QLQ-CIPN20) Versus Physician-Reported (CTCAE) Quantification of Oxaliplatin- and Paclitaxel/Carboplatin-Induced Peripheral Neuropathy in NCCTG/Alliance Clinical Trials

Jennifer Le-Rademacher, Rahul Kanwar, Drew Seisler, Deirdre R. Pachman, Rui Qin, Alexej Abyzov, Kathryn J. Ruddy, Michaela S. Banck, Ellen M. Lavoie Smith, Susan G. Dorsey, Neil K. Aaronson, Jeff Sloan, Charles L. Loprinzi, Andreas S. Beutler Support Care Cancer vol 25 (11) 3537-44 2017

Manuscript Symptom Inter NCCTG-N08CA, NCCTG-N08CB

<http://www.ncbi.nlm.nih.gov/pubmed/28634656>

1110 Trial Design Considerations to Increase Older Adult Accrual to National Cancer Institute Clinical Trials

Jennifer Le-Rademacher, Supriya Mohile, Joseph Unger, Matthew F Hudson, Jared Foster, Stuart Lichtman, Jane Perlmutter, Efrat Dotan, Martine Extermann, Kevin Dodd, William Tew, Heidi Klepin, Tanya M Wildes, Mina S Sedrak, Aminah Jatoui, Richard F Little J Natl Cancer Inst Monogr vol 2022 (60) 135-41 2022

Manuscript Older Adult <http://www.ncbi.nlm.nih.gov/pubmed/36519818>

1111 NCCTG N08CA (Alliance): The use of Glutathione for Prevention of Paclitaxel/Carboplatin Induced Peripheral Neuropathy: A Phase III Randomized, Double-Blind Placebo-Controlled Study

Alexis D. Leal, Rui Qin, Pamela J. Atherton, Paul Haluska, Robert J. Behrens, Charles Tiber, Patanit Watanaboonyakhet, Matthias Weiss, Paul T. Adams, Travis Dockter, Charles L. Loprinzi Cancer vol 120 (12) 1890-1897 2014

Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/24619793>

1112 Validation of DPYD variants DPYD*2A, I560S, and D949V as predictors of 5-fluorouracil (5-FU)-related toxicity in stage III colon cancer (CC) patients from adjuvant trial NCCTG N0147

A. Lee, Q. Shi, E. Pavey, D. J. Sargent, S. R. Alberts, F. A. Sinicrope, J. Berenberg, R. Goldberg, R. B. Diasio J Clin Oncol vol 31 (15 suppl) abstr 3510 2013
Abstract Correl Sci NOS
http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/3510?sid=2f408d27-7862-4e30-bca6-bee5f

1113 HapB3 and the deep intronic variant c.1129-5923 C>G of the dihydropyrimidine dehydrogenase gene (DPYD) as predictors of toxicity in Stage III colon cancer (CC) patients (pts) (NCCTG N0147) (Alliance)

Adam M. Lee, Qian Shi, Steven R. Alberts, Daniel J. Sargent, Frank A. Sinicrope, Jeffrey L. Berenberg, Richard M. Goldberg, Robert B. Diasio J Clin Oncol vol 33 (3 suppl) 508 2015
Abstract Correl Sci NOS
http://meeting.ascopubs.org/cgi/content/abstract/33/3_suppl/508?sid=32dbef88-d682-4247-8ef8-39e3a68

1114 Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance)

Adam M. Lee, Qian Shi, Steven R. Alberts, Daniel J. Sargent, Frank A. Sinicrope, Jeffrey L. Berenberg, Axel Grothey, Blase Polite, Emily Chan, Sharlene Gill, Morton S. Kahlenberg, Suresh G. Nair, Anthony F. Shields, Richard M. Goldberg, Robert B. Diasio Pharmacogenet Genomics vol 26 (3) 133-137 2016
Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/26658227>

1115 DPYD Variants as Predictors of 5-fluorouracil Toxicity in Adjuvant Colon Cancer Treatment (NCCTG N0147)

Adam M. Lee, Qian Shi, Emily Pavey, Steven R. Alberts, Daniel J. Sargent, Frank A. Sinicrope, Jeffrey L. Berenberg, Richard M. Goldberg, Robert B. Diasio J Natl Cancer Inst vol 106 (12) 2014
Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/25381393>

1116 Analysis of tumor microenvironmental features to refine prognosis by T, N risk group in patients with stage III colon cancer (NCCTG N0147) (Alliance)

H. Lee, D. Sha, N. R. Foster, Q. Shi, S. R. Alberts, T. C. Smyrk, F. A. Sinicrope Ann Oncol vol 31 (4) 487-94 2020
Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/32165096>

1117 Association of micropapillary architecture and high tumor budding with prognosis in patients with stage III colon cancer from a FOLFOX-based adjuvant chemotherapy trial: NCCTG N0147 (Alliance)

Hee Eun Lee, Qian Shi, Nate Foster, Emily Chan, Sharlene Gill, Monrton Kahlenberg, Suresh Nair, Anthony F Shields, Richard M Goldberg, Steven R. Alberts, Frank A. Sinicrope, Thomas C. Smyrk Mod Pathol vol 30 (S2) 181A 2017
Abstract Correl Sci NOS
<https://www.nature.com/modpathol/journal/v30/n2s/pdf/modpathol2016249a.pdf>

1118 Potential Mediators of Oxaliplatin-Induced Peripheral Neuropathy From Adjuvant Therapy in Stage III Colon Cancer: Findings From CALGB (Alliance)/SWOG 80702

Seohyuk Lee, Chao Ma, Qian Shi, Pankaj Kumar, Felix Couture, Philip Kuebler, Smitha Krishnamurthi, DeQuincy Lewis, Benjamin Tan, Richard M. Goldberg, Alan Venook, Charles Blanke, Eileen M. O'Reilly, Anthony F. Shields, Jeffrey A. Meyerhardt J Clin Oncol vol 41 (5) 1079-91 2023
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/36367997>

1119 Sleep and cancer recurrence and survival in patients with resected Stage III colon cancer: findings from CALGB/SWOG 80702 (Alliance)

Seohyuk Lee, Chao Ma, Qian Shi, Jeffrey Meyers, Pankaj Kumar, Felix Couture, Philip Kuebler,

Smitha Krishnamurthi, DeQuincy Lewis, Benjamin Tan, Eileen M. O'Reilly, Anthony F. Shields, Jeffrey A. Meyerhardt *Br J Cancer* vol 129 (2) 283-90 2023
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/37179438>

1120 Marital Status, Living Arrangement, and Cancer Recurrence and Survival in Patients with Stage III Colon Cancer: Findings from CALGB 89803 (Alliance)

Seohyuk Lee, Chao Ma, Sui Zhang, Fang-Shu Ou, Tiffany M Bainter, Donna Niedzwiecki, Leonard B Saltz, Robert J Mayer, Renaud Whittom, Alexander Hantel, Al Benson III, Daniel Atienza, Hedy Kindler, Cary P Gross, Melinda L Irwin, Jeffrey A Meyerhardt, Charles S Fuchs *Oncologist* vol 27 (6) e494-e505 2022
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/35641198>

1121 Race, Income, and Survival in Stage III Colon Cancer: CALGB 89803 (Alliance).

Seohyuk Lee, Sui Zhang, Chao Ma, Fang-Shu Ou, Eric G Wolfe, Shuji Ogino, Donna Niedzwiecki, Leonard B Saltz, Robert J Mayer, Rex B Mowat, Renaud Whittom, Alexander Hantel, Al Benson III, Daniel Atienza, Michael Messino, Hedy Kindler, Alan Venook, Cary P Gross, Melinda L Irwin, Jeffrey A Meyerhardt, Charles S Fuchs *JNCI Cancer Spectr* vol 5 (3) 2021
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/34104867>

1122 Doxepin Rinse Versus Placebo in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Head and Neck Radiotherapy With or Without Chemotherapy: A Phase III, Randomized, Double-Blind Trial (NCCTG-N09C6 [Alliance])

James L. Leenstra, Robert C. Miller, Rui Qin, James A. Martenson, Kenneth J. Dornfeld, James D. Bearden, Dev R. Puri, Philip J. Stella, Miroslaw A. Mazurczak, Marie D. Klish, Paul J. Novotny, Robert L. Foote, Charles L. Loprinzi *J Clin Oncol* vol 32 (15) 1571-1577 2014
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/24733799>

1123 Impact of Lung and Heart Radiation Dose during Preoperative Chemoradiation on Overall Survival – A Secondary Analysis of CALGB 80803 (Alliance)

Eric J. Lehrer, Susan Geyer, Austin Goodrich, David Ilson, Vishruta Dumane, Karyn A. Goodman *International Journal of Radiation Oncology, Biology, & Physics* vol 114 (3 Supplemental) S13 2022
Abstract GI [https://www.redjournal.org/article/S0360-3016\(22\)01075-6/fulltext](https://www.redjournal.org/article/S0360-3016(22)01075-6/fulltext)

1124 Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer

Jonathan T. Lei, Jieya Shao, Jin Zhang, Michael Iglesia, Doug W. Chan, Jin Cao, Meenakshi Anurag, Purba Singh, Xiaping He, Yoshimasa Kosaka, Ryoichi Matsunuma, Robert Crowder, Jeremy Hoog, Chanpheng Phommaly, Rodrigo Goncalves, Susana Ramalho, Raquel Mary Rodrigues Peres, Nindo Punturi, Cheryl Schmidt, Alex Bartram, Eric Jou, Vaishnavi Devarakonda, Kimberly R. Holloway, W. Victoria Lai, Oliver Hampton, Anna Rogers, Ethan Tobias, Poojan A. Parikh, Sherri R. Davies, Shunqiang Li, Cynthia X. Ma, Vera J. Suman, Kelly K. Hunt, Mark A. Watson, Katherine A. Hoadley, E. Aubrey Thompson, Xi Chen, Shyam M. Kavuri, Chad J. Creighton, Christopher A. Maher, Charles M. Perou, Svasti Haricharan, Matthew J. Ellis *Cell Rep* vol 24 (6) 1434-44.e7 2018
Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/30089255>

1125 CALGB/SWOG 80405: PHASE III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with expanded RAS analyses untreated metastatic adenocarcinoma of the colon

H. Lenz, D. Niedzwiecki, F. Innocenti, C. Blanke, M. Mahoney, B. O'Neil, J. Shaw, B. Polite, H. Hochster, J. Atkins, R. Goldberg, R. Mayer, R. Schilsky, M. Bertagnolli, A. Venook *Ann Oncol* vol 25 (suppl 4) 5010 2014
Abstract GI http://annonc.oxfordjournals.org/content/25/suppl_4/mdu438.13

1126 Impact of Consensus Molecular Subtyping (CMS) on overall survival (OS) and Progression

Free Survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB / SWOG 80405 (Alliance).

Heinz-Josef Lenz, Fang-Shu Ou, Alan P. Venook, Howard S. Hochster, Donna Niedzwiecki, Richard Goldberg, Robert Mayer, Monica Bertagnolli, Charles David Blanke, Tyler Zemla, Xueping Qu, Omar Kabbarah, Federico Innocenti J Clin Oncol vol 35 (15 suppl) abstr 3511 2017
Abstract Correl Sci NOS http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.3511

1127 Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance).

Heinz-Josef Lenz, Fang-Shu Ou, Alan P Venook, Howard S Hochster, Donna Niedzwiecki, Richard M Goldberg, Robert J Mayer, Monica M Bertagnolli, Charles D Blanke, Tyler Zemla, Xueping Qu, Pratyaksha Wirapati, Sabine Tejpar, Federico Innocenti, Omar Kabbarah J Clin Oncol vol 37 (22) 1876-85 2019
Manuscript Correl Sci NOS CALGB-80405 <http://www.ncbi.nlm.nih.gov/pubmed/31042420>

1128 A randomized, double-blind, placebo-controlled trial of testosterone (T) for aromatase inhibitor-induced arthralgias (AIA) in postmenopausal women: Alliance study A221102

Roberto A. Leon-Ferre, Paul Novotny, Shelby Terstriep, Rebecca Glaser, Debra L. Barton, Jennifer Le-Rademacher, Armando Giuliano, Sibel Blau, Cheryl Jones, Seth PageWilliam Mitchell, Stephen N. Birrell, Charles L. Loprinzi Cancer Res vol 79 (4 suppl) abstr P4-16-01 2019
Abstract Symptom Inter https://cancerres.aacrjournals.org/content/79/4_Supplement/P4-16-01

1129 N083E (Alliance): Long-term outcomes of patients treated in a pilot phase II study of docetaxel, carboplatin, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer

Roberto A. Leon-Ferre, Edith A Perez, David W Hillman, Celyne Bueno, Alejandra T Perez, Beiyun Chen, Robert B Jenkins, Donald W Northfelt, David B Johnson, Robert L Carolla, Robin T Zon, Alvaro Moreno-Aspitia Breast Cancer Res Treat vol 182 (3) 613-622 2020
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/32504284>

1130 CALGB 50401: A randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma.

J. Leonard, S.-H. Jung, J. L. Johnson, N. L. Bartlett, K. A. Blum, B. D. Cheson J Clin Oncol vol 30 (15 suppl) abstr 80000 2012
Abstract Lymphoma <http://meetinglibrary.asco.org/content/93509-114>

1131 Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance)

John P. Leonard, Sin-Ho Jung, Jeffrey Johnson, Brandelyn N. Pitcher, Nancy L. Bartlett, Kristie A. Blum, Myron Czuczman, Jeffrey K. Giguere, Bruce D. Cheson J Clin Oncol vol 33 (31) 3635-3640 2015
Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/26304886>

1132 Alliance A051202: A Phase I Trial of Lenalidomide, Rituximab and GS-1101 (Idelalisib) in recurrent follicular lymphoma

John P. Leonard, Sin-ho Jung, Bruce D. Cheson Hematol Oncol vol 31 (51) 271-278 (abstr 563) 2013
Abstract Lymphoma <http://onlinelibrary.wiley.com/doi/10.1002/hon.2084/full>

1133 A mentored cooperative group pilot study: atrophic vaginitis.

Joanne L Lester, Chandler Jarvis, Deborah Bartholomew, Lisa Yee Semin Oncol Nurs vol 30 (1) 53-60 2014
Manuscript Onc Nursing <http://www.ncbi.nlm.nih.gov/pubmed/24559781>

- 1134 Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy—results from the ACOSOG Z1041 (Alliance) trial**
R. Lesurf, O. L. Griffith, M. Griffith, J. Hundal, L. Trani, M. A. Watson, R. Aft, M. J. Ellis, D. Ota, V. J. Suman, F. Meric-Bernstam, A. M. Leitch, J. C. Boughey, G. Unzeitig, A. U. Buzdar, K. K. Hunt, E. R. Mardis *Ann Oncol* vol 28 (5) 1070-77 2017
Manuscript PPP <http://www.ncbi.nlm.nih.gov/pubmed/28453704>
- 1135 The genomics of response to neoadjuvant trastuzumab in HER2-positive breast cancer – results from the ACOSOG Z1041 (Alliance) trial**
Robert Lesurf, Malachi Griffith, Obi Griffith, Mark A. Watson, Jeremy Hoog, Matthew J. Ellis, David Ota, Vera J. Suman, Funda Meric-Bernstam, A. Marilyn Leitch, Judy C. Boughey, Gary Unzeitig, Aman U. Buzdar, Kelly K. Hunt, Elaine R. Mardis *Cancer Res* vol 76 (4 Suppl) PD6-02 2016
Abstract PPP http://cancerres.aacrjournals.org/content/76/4_Supplement/PD6-02.short
- 1136 The genomics of response to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer - results from the ACOSOG Z1041 (Alliance) trial**
Robert Lesurf, Obi Griffith, Malachi Griffith, Lee Trani, Mark A. Watson, Matthew J. Ellis, David Ota, Vera J. Suman, Funda Meric--Bernstam, A. Marilyn Leitch, Judy C. Boughey, Gary Unzeitig, Aman U. Buzdar, Kelly K. Hunt, Elaine R. Mardis 2016
Abstract PPP
http://pccradiumhospital.org/content/text_8ef111f1-5736-4092-8487-6601340066bb/1456755424010/pc
- 1137 The nurse liaison role in the cooperative group setting.**
Sharon Levy, Kathy Klinger, Ilene Galinsky, Wanda DeKrey, Joanne Lester *Semin Oncol Nurs* vol 30 (1) 11-6 2014
Manuscript *Onc Nursing* <http://www.ncbi.nlm.nih.gov/pubmed/24559775>
- 1138 The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance)**
L. D. Lewis, A. A. Miller, K. Owzar, R. R. Bies, S. Markova, C. Jiang, D. L. Kroetz, M. J. Egorin, H. L. Mcleod, M. J. Ratain *Pharmacogenet Genomics* vol 23 (1) 29-33 2013
Manuscript PPP <http://www.ncbi.nlm.nih.gov/pubmed/23188068>
- 1139 The pharmacokinetics and pharmacodynamics of docetaxel (DCTX) in caucasian and African American patients with solid tumors**
L. D. Lewis, G. L. Rosner, A. A. Miller, M. J. Egorin, M. V. Relling, H. Kastrissios, R. Bies, M. J. Ratain *J Clin Oncol* vol 22 (14s) abstr 2043 2004
Abstract PPP
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=26&abstractID
- 1140 A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871.**
Lionel D Lewis, Antonius A Miller, Gary L Rosner, Jonathan E Dowell, Manuel Valdivieso, Mary V Relling, Merrill J Egorin, Robert R Bies, Donna R Hollis, Ellis G Levine, Gregory A Otterson, Frederick Millard, Mark J Ratain *Clin Cancer Res* vol 13 (11) 3302-11 2007
Manuscript *Experimental* <http://www.ncbi.nlm.nih.gov/pubmed/17545536>
- 1141 DNMT3A mutations in acute myeloid leukemia**
T. J. Ley, L. Ding, M. J. Walter, M. D. Mclellan, T. Lamprecht, D. E. Larson, C. Kandoth, J. E. Payton, J. Baty, J. Welch, C. C. Harris, C. F. Lichti, R. R. Townsend, R. S. Fulton, D. J. Dooling, D. C. Koboldt, H. Schmidt, Q. Zhang, J. R. Osborne, L. Lin, M. O'Laughlin, J. F. Mcmichael, K. D. Delehaunty, S. D. Mcgrath, L. A. Fulton, V. J. Magrini, T. L. Vickery, J. Hundal, L. L. Cook, J. J.

Conyers, G. W. Swift, J. P. Reed, P. A. Alldredge, T. Wylie, J. Walker, J. Kalicki, M. A. Watson, S. Heath, W. D. Shannon, N. Varghese, R. Nagarajan, P. Westervelt, M. H. Tomasson, D. C. Link, T. A. Graubert, J. F. Dipersio, E. R. Mardis, R. K. Wilson *N Engl J Med* vol 363 (25) 2424-2433 2010
Manuscript *Leuk Corr Sci* CALGB-9665, CALGB-8461
<http://www.ncbi.nlm.nih.gov/pubmed/21067377>

1142 DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome

T. J. Ley, E. R. Mardis, L. Ding, B. Fulton, M. D. McLellan, K. Chen, D. Dooling, B. H. Dunford-Shore, S. Mcgrath, M. Hickenbotham, L. Cook, R. Abbott, D. E. Larson, D. C. Koboldt, C. Pohl, S. Smith, A. Hawkins, S. Abbott, D. Locke, L. W. Hillier, T. Miner, L. Fulton, V. Magrini, T. Wylie, J. Glasscock, J. Conyers, N. Sander, X. Shi, J. R. Osborne, P. Minx, D. Gordon, A. Chinwalla, Y. Zhao, R. E. Ries, J. E. Payton, P. Westervelt, M. H. Tomasson, M. Watson, J. Baty, J. Ivanovich, S. Heath, W. D. Shannon, R. Nagarajan, M. J. Walter, D. C. Link, T. A. Graubert, J. F. Dipersio, R. K. Wilson *Nature* vol 456 (7218) 66-72 2008
Manuscript *Leuk Corr Sci* CALGB-9665, CALGB-8461
<http://www.ncbi.nlm.nih.gov/pubmed/18987736>

1143 Weight loss over time and survival: a landmark analysis of 1000+ prospectively treated and monitored lung cancer patients

Jennifer LeRademacher, Camden Lopez, Eric Wolfe, Nathan R. Foster, Sumithra J. Mandrekar, Xiaofei Wang, Rajiv Kumar, Alex Adjei, Aminah Jatoi *J Cachexia Sarcopenia Muscle* vol 11 (6) 1501-8 2020
Manuscript *Health Outcomes* <http://www.ncbi.nlm.nih.gov/pubmed/32940014>

1144 Comparative Effects of CT Imaging Measurement on RECIST End Points and Tumor Growth Kinetics Modeling

CH Li, RR Bies, Y Wang, MR Sharma, S Karovic, L Werk, MJ Edelman, AA Miller, EE Vokes, A Oto, MJ Ratain, LH Schwartz, ML Maitland *Clin Transl Sci* vol 9 (1) 43-50 2016
Manuscript *PPP* CALGB-30203, CALGB-30303, CALGB-9730
<http://www.ncbi.nlm.nih.gov/pubmed/26790562>

1145 Identifying Risk Factors For Toxicity In Patients With Hormone-Receptor Positive Advanced Breast Cancer Treated With Bevacizumab Plus Letrozole: A CALGB 40503 (Alliance) Correlative Study

Daneng Li, Maura N. Dickler, Linda M. McCall, Olwen M Hahn, Clifford A. Hudis, Harvey J. Cohen, Hyman B. Muss, Karla V. Ballman, Eric P. Winer, Debu Tripathy, Bryan Schneider, Constance Cirrincione, William Barry, Arti Hurria *J Clin Oncol* vol 34 (suppl) abstr 10047 2016
Abstract *Older Adult* <http://meetinglibrary.asco.org/content/168148-176>

1146 Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: A CALGB 40503 (Alliance) correlative study.

Daneng Li, Linda M. McCall, Olwen M Hahn, Clifford A. Hudis, Harvey J. Cohen, Hyman B. Muss, Aminah Jatoi, Jacqueline M. Lafky, Karla V. Ballman, Eric P. Winer, Debu Tripathy, Bryan Schneider, William Barry, Maura N. Dickler, Arti Hurria *Breast Cancer Res Treat* vol 171 (2) 325-34 2018
Manuscript *Older Adult* <http://www.ncbi.nlm.nih.gov/pubmed/29789969>

1147 RANK expression in primary tumor tissue at the time of diagnosis correlates with risk of subsequent bone metastases in the I-SPY 1 trial (CALGB 150007/150012; ACRIN 6657)

J. Li, C. Yau, M. Campbell, J. W. Park, H. S. Rugo *Cancer Res* vol 71 (24, suppl 3) abstr SABC11-P15-14-04 2011
Abstract *Correl Sci NOS* ACRIN-6657, CALGB-150007
http://cancerres.aacrjournals.org/content/71/24_Supplement/P5-14-04

1148 Identification of a Genomic Region Between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance)

Megan Li, Flora Mulkey, Chen Jiang, Bert H. O'Neil, Bryan P. Schneider, Fei Shen, Paula N. Friedman, Yukihide Momozawa, Michiaki Kubo, Donna Niedzwiecki, Howard S. Hochster, Heinz-Josef Lenz, James N. Atkins, Hope S. Rugo, Susan Halabi, William Kevin Kelly, Howard L. McLeod, Federico Innocenti, Mark J. Ratain, Alan P. Venook, Kouros Owzar, Deanna L. Kroetz Clin Cancer Res vol 24 (19) 4734-44 2018
Manuscript PPP CALGB-40502, CALGB-80405, CALGB-90401, ECOG-E5103
<http://www.ncbi.nlm.nih.gov/pubmed/29871907>

1149 Association of Variants with Bevacizumab-Induced Hypertension Identified by Exome Sequencing CALGB-80405 (Alliance)

Megan Li, Flora Mulkey, Chen Jiang, Alan P. Venook, Kouros Owzar, Deanna L. Kroetz 2016
Abstract GI
<http://www.ascp.org/Portals/8/docs/Meetings/2016%20Annual%20Meeting/Final%20Program.pdf>

1150 Effect of MR Imaging Contrast Thresholds on Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes: A Subgroup Analysis of the ACRIN 6657/I-SPY 1 TRIAL

Wen Li, Vignesh Arasu, David C. Newitt, Ella F. Jones, Lisa Wilmes, Jessica Gibbs, John Kornak, Bonnie N. Joe, Laura J. Esserman, Nola M. Hylton Tomography vol 2 (4) 378-387 2016
Manuscript Breast ACRIN 6657, CALGB-150007 <http://www.ncbi.nlm.nih.gov/pubmed/28066808>

1151 Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML

Z. Li, H. Huang, Y. Li, X. Jiang, P. Chen, S. Arnovitz, M. D. Radmacher, K. Maharry, A. Elkahlon, X. Yang, C. He, M. He, Z. Zhang, K. Dohner, M. B. Neilly, C. Price, Y. A. Lussier, Y. Zhang, R. A. Larson, M. M. Le Beau, M. A. Caligiuri, L. Bullinger, P. J. Valk, R. Delwel, B. Lowenberg, P. P. Liu, G. Marcucci, C. D. Bloomfield, J. D. Rowley, J. Chen Blood vol 119 (10) 2314-2324 2012
Manuscript Leuk Corr Sci <http://www.ncbi.nlm.nih.gov/pubmed/22251480>

1152 Activation of a Mir-181-Targeting HOXA-PBX3 Homeobox Gene Signature Is Associated with Adverse Prognosis of Cytogenetically Abnormal Acute Myeloid Leukemia

Z. Li, H. Huang, Y. Li, X. Jiang, P. Chen, S. Arnovitz, M. D. Radmacher, K. Maharry, A. Elkahlon, X. Yang, C. He, C. O. Price, K. Dohner, Z. Zhang, C. Shen, M. B. Neilly, Y. A. Lussier, Y. Zhang, R. A. Larson, M. M. Le Beau, M. A. Caligiuri, L. Bullinger, P. Valk, R. Delwel, B. Lowenberg, P. P. Liu, G. Marcucci, C. D. Bloomfield, J. D. Rowley, J. Chen ASH Annual Meeting Abstracts vol 118 (21) 236 2011
Abstract Leuk Corr Sci
<http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;118/21/236>

1153 Identification of a 24-Gene Prognostic Signature That Improves the European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: An International Collaborative Study

Zejuan Li, Tobias Herold, Chunjiang He, Peter J.M. Valk, Ping Chen, Vindi Jurinovic, Ulrich Mansmann, Michael D. Radmacher, Kati S. Maharry, Miao Sun, Xinan Yang, Hao Huang, Xi Jiang, Maria-Cristina Sauerland, Thomas Büchner, Wolfgang Hiddemann, Abdel Elkahlon, Mary Beth Neilly, Yanming Zhang, Richard A. Larson, Michelle M. Le Beau, Michael A. Caligiuri, Konstanze Döhner, Lars Bullinger, Paul P. Liu, Ruud Delwel, Guido Marcucci, Bob Lowenberg, Clara D. Bloomfield, Janet D. Rowley, Stefan K. Bohlander, Jianjun Chen J Clin Oncol vol 31 (9) 1172-1181 2013
Manuscript Leukemia CALGB-19808, CALGB-9222, CALGB-9621, CALGB-9710, CALGB-9720
<http://www.ncbi.nlm.nih.gov/pubmed/23382473>

1154 Effect of renal function (RF) on outcomes in the adjuvant treatment of older women with

breast cancer (>65 years): CALGB/CTSUS 49907 (CC) ancillary data study

S. M. Lichtman, C. Cirrincione, A. Hurria, A. Jatoi, M. Theodoulou, A. C. Wolff, J. Gralow, D. Morganstern, G. Magrinat, H. J. Cohen, H. B. Muss J Clin Oncol vol 31 (15 suppl) abstr 9515 2013
Abstract Older Adult CALGB-49907
http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/9515?sid=959c7a05-11ee-43ff-be27-1377e

1155 Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB 9342 and 9840

S. M. Lichtman, A. Hurria, C. T. Cirrincione, A. D. Seidman, E. Winer, C. Hudis, H. J. Cohen, H. B. Muss Ann Oncol vol 23 (3) 632-8 2012
Manuscript Breast CALGB-9342, CALGB-9840 <http://www.ncbi.nlm.nih.gov/pubmed/21693770>

1156 Paclitaxel in older women with breast cancer. Combined analysis of CALGB 9342 and 9840 with a focus on age

S. M. Lichtman, A. Hurria, C. T. Cirrincione, A. D. Seidman, E. Winer, C. Hudis, H. J. Cohen, H. B. Muss Cancer Res vol 69 (2 (supplement)) 6112 2009
Abstract Older Adult CALGB-360701, CALGB-9342, CALGB-9840
http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/69/2_MeetingAbstracts/6112

1157 Effect of Pretreatment Renal Function on Treatment and Clinical Outcomes in the Adjuvant Treatment of Older Women With Breast Cancer: Alliance A171201, an Ancillary Study of CALGB/CTSUS 49907

Stuart M. Lichtman, Constance T. Cirrincione, Arti Hurria, Aminah Jatoi, Maria Theodoulou, Antonio C. Wolff, Julie Gralow, Daniel E. Morganstern, Gustav Magrinat, Harvey Jay Cohen, Hyman B. Muss J Clin Oncol vol 34 (7) 699-705 2016
Manuscript Older Adult Alliance-A171201, CALGB-49907
<http://www.ncbi.nlm.nih.gov/pubmed/26755510>

1158 Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762).

Stuart M Lichtman, Donna Hollis, Antonius A Miller, Gary L Rosner, Chris A Rhoades, Eric P Lester, Frederick Millard, John Byrd, Stephen A Cullinan, D Marc Rosen, Robert A Parise, Mark J Ratain, Merrill J Egorin J Clin Oncol vol 24 (12) 1846-51 2006
Manuscript Experimental <http://www.ncbi.nlm.nih.gov/pubmed/16567769>

1159 Body mass index (BMI), tumor subtype, and relapse-free survival (RFS) in CALGB 9741 (Alliance)

J. A. Ligibel, C. Cirrincione, M. Liu, M. Citron, J. Ingle, W. Gradishar, S. Martino, W. M. Sikov, R. A. Michaelson, C. Hudis, E. Winer, W. Barry J Clin Oncol vol 31 (15 suppl) abstr 1032 2013
Abstract Disparities
http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/1032?sid=c5d6e4ba-d61c-4dcd-ae36-d571

1160 The Breast Cancer Weight Loss (BWEL) Trial: Randomized Phase III Trial Evaluating The Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer (Alliance A011401)

Jennifer A. Ligibel, William T. Barry, Catherine Alfano, Dawn L. Hershman, Melinda Irwin, Marian Neuhaus, Cynthia A. Thomson, Linda Delahanty, Elizabeth Frank, Patty Spears, Electra D. Paskett, Judith Hopkins, Vanessa Bernstein, Vered Stearns, Julia White, The BWEL Investigators Group, Thomas A. Wadden, Pamela J. Goodwin, Lisa A. Carey, Ann H. Partridge, Eric P. Winer J Clin Oncol vol 36 (Suppl) abstr TPS598 2018
Abstract Breast <https://meetinglibrary.asco.org/record/165229/abstract>

1161 Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of

overweight and obese women with early breast cancer (Alliance A011401): study design

Jennifer A. Ligibel, William T. Barry, Catherine Alfano, Dawn L. Hershman, Melinda Irwin, Marian Neuhaus, Cynthia A. Thomson, Linda Delahanty, Elizabeth Frank, Patty Spears, Electra D. Paskett, Judith Hopkins, Vanessa Bernstein, Vered Stearns, Julia White, Olwen Hahn, Clifford Hudis, Eric P. Winer, Thomas A. Wadden, Pamela J. Goodwin NPJ Breast Cancer vol 3 37 2017
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/28948213>

1162 Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance)

Jennifer A. Ligibel, Constance T. Cirincione, Minetta Liu, Marc Citron, James N. Ingle, William Gradishar, Silvana Martino, William Sikov, Richard Michaelson, Elaine Mardis, Charles M. Perou, Matthew Ellis, Eric Winer, Clifford A. Hudis, Donald Berry, William T. Barry J Natl Cancer Inst vol 107 (9) 2015
Manuscript Breast CALGB-9741, CALGB-40902 <http://www.ncbi.nlm.nih.gov/pubmed/26113580>

1163 Impact of a Telephone-Based Physical Activity Intervention upon Exercise Behaviors and Fitness in Cancer Survivors Enrolled in a Cooperative Group Setting

Jennifer A. Ligibel, Jeffrey Meyerhardt, John P. Pierce, Julie Najita, Laura Shockro, Nancy Campbell, Vicky A. Newman, Leslie Barbier, Eileen Hacker, Marie Wood, James Marshall, Electra Paskett, Charles Shapiro Breast Cancer Res Treat vol 132 (1) 205-13 2012
Manuscript Prevention <http://www.ncbi.nlm.nih.gov/pubmed/22113257>

1164 Physical Activity, Weight, and Outcomes in Patients Receiving Chemotherapy for Metastatic Breast Cancer (C40502/Alliance)

Jennifer A Ligibel, Luke Huebner, Hope S Rugo, Harold J Burstein, Debra L Toppmeyer, Carey K Anders, Cynthia Ma, William T Barry, Vera Suman, Lisa A Carey, Ann H Partridge, Clifford A Hudis, Eric P Winer JNCI Cancer Spectr vol 5 (3) pkab025 2021
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/33981951>

1165 Physical Activity, Weight and Outcomes in Patients Receiving First-Line Chemotherapy for Metastatic Breast Cancer: Results from CALGB 40502 (Alliance)

LJ Ligibel, JA Heubner, HS Rugo, H Burstein, DL Toppmeyer, CK Anders, C Ma, CA Hudis, EP Winer, WT Barry Cancer Res vol 78 (4 Supplement) P1-07-04 2018
Abstract Breast http://cancerres.aacrjournals.org/content/78/4_Supplement/P1-07-04

1166 Phase II randomized trial of docetaxel plus cetuximab or bortezomib in patients with advanced NSCLC and performance status (PS) 2: CALGB 30402

R. C. Lilenbaum, X. Wang, L. Gu, J. Kirshner, E. E. Vokes J Clin Oncol vol 25 (18s) abstr 7595 2007
Abstract Respiratory
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID

1167 A Phase II Study Of Induction Chemotherapy Followed By Thoracic Radiotherapy (TRT) And Erlotinib In Poor-risk Stage III Non-small Cell Lung Cancer (NSCLC): Initial Results Of CALGB 30605 And RTOG 0972

R. Lilenbaum, M. Samuels, F. Kong, X. Wang, P. Janne, G. Masters, J. Bogart, J. Bradley, E. Vokes J Thorac Oncol vol 7 (15) abstract 153 2012
Abstract Respiratory <http://journals.lww.com/jto/Fulltext/2012/09004/Abstracts.5.aspx>

1168 Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: The Cancer and Leukemia Group B (study 9730).

Rogério C Lilenbaum, James E Herndon, Marcy A List, Chris Desch, Dorothy M Watson, Antonius A Miller, Stephen L Graziano, Michael C Perry, Wayne Saville, Philippe Chahinian, Jane C Weeks,

Jimmie C Holland, Mark R Green J Clin Oncol vol 23 (1) 190-6 2005
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/15625373>

1169 A phase II study of induction chemotherapy followed by thoracic radiotherapy and erlotinib in poor risk stage III non-small cell lung cancer: Results of CALGB 30605 (Alliance)/RTOG 0972 (NRG)

Rogério Lilenbaum, Michael Samuels, Xiaofei Wang, Feng Ming Kong, Pasi A. Jänne, Gregory Masters, Sreedhar Katragadda, Lydia Hodgson, Jeffrey Bogart, Jeffrey Bradley, Everett Vokes J Thorac Oncol vol 10 (1) 143-147 2015

Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/25384173>

1170 Randomized Phase II Trial of Docetaxel Plus Cetuximab or Docetaxel Plus Bortezomib in Patients With Advanced Non-Small-Cell Lung Cancer and a Performance Status of 2: CALGB 30402

Rogério Lilenbaum, Xiaofei Wang, Lin Gu, Jeffrey Kirshner, Keith Lerro, Everett Vokes J Clin Oncol vol 27 (27) 4487-4491 2009

Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/19704058>

1171 Detection of locally advanced breast cancer in the I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657) in the interval between routine screening

C. Lin, D. Moore, A. Demichele, D. W. Ollila, L. L. Montgomery, M. C. Liu, H. Krontiras, R. Gomez, L. J. Esserman J Clin Oncol vol 27 (15s) abstr 1503 2009

Abstract Correl Sci NOS

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID

1172 Locally advanced breast cancers are more likely to present as Interval Cancers: results from the I-SPY 1 TRIAL (CALGB 150007/150012, ACRIN 6657, InterSPORE Trial)

Cheryl Lin, Meredith Becker Buxton, Dan Moore, Helen Krontiras, Lisa Carey, Angela DeMichele, Leslie Montgomery, Debasish Tripathy, Constance Lehman, Minetta Liu, Olufunmilayo Olapade, Christina Yau, Donald Berry, Laura J. Esserman Breast Cancer Res Treat vol 132 (3) 871-879 2012

Manuscript Breast CALGB-150007, CALGB-150012

<http://www.ncbi.nlm.nih.gov/pubmed/21796368>

1173 Consolidation Therapy with Subcutaneous (SC) Alemtuzumab After Fludarabine and Rituximab (FR) Induction Therapy Improves the Complete Response (CR) Rate in Chronic Lymphocytic Leukemia (CLL) and Eradicates Minimal Residual Disease (MRD) but Is Associated with Severe Infectious Toxicity: Final Analysis of CALGB Study 10101

T. S. Lin, K. A. Donohue, J. C. Byrd, M. S. Lucas, E. Hoke, E. M. Bengtson, J. N. Atkins, B. K. Link, K. R. Rai, R. A. Larson Blood vol 114 (22) -210 2009

Abstract Leukemia <http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;114/22/210>

1174 Consolidation Therapy with Subcutaneous (SC) Alemtuzumab Results in Severe Infectious Toxicity in Previously Untreated CLL Patients Who Achieve a Complete Response (CR) after Fludarabine and Rituximab (FR) Induction Therapy: Interim Safety Analysis of the CALGB Study 10101

T. S. Lin, K. A. Donohue, M. S. Lucas, J. C. Byrd, E. M. Bengtson, B. L. Peterson, R. A. Larson Blood vol 110 (11) 755 2007

Abstract Leukemia <http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;110/11/755>

1175 Consolidation Therapy With Subcutaneous Alemtuzumab After Fludarabine and Rituximab Induction Therapy for Previously Untreated Chronic Lymphocytic Leukemia: Final Analysis of CALGB 10101

Thomas S. Lin, Kathleen A. Donohue, John C. Byrd, Margaret S. Lucas, Eva E. Hoke, Elizabeth M. Bengtson, Kanti R. Rai, James N. Atkins, Brian K. Link, Richard A. Larson J Clin Oncol vol 28 (29) 4500-4506 2010

1176 Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia

Daniel C. Link, Ghada Kunter, Yumi Kasai, Yu Zhao, Tracie Miner, Michael D. McLellan, Rhonda E. Ries, Deepak Kapur, Rakesh Nagarajan, David C. Dale, Audrey Anna Bolyard, Laurence A. Boxer, Karl Welte, Cornelia Zeidler, Jean Donadieu, Christine Bellanné-Chantelot, James W. Vardiman, Michael A. Caligiuri, Clara D. Bloomfield, John F. DiPersio, Michael H. Tomasson, Timothy A. Graubert, Peter Westervelt, Mark Watson, William Shannon, Jack Baty, Elaine R. Mardis, Richard K. Wilson, Timothy J. Ley *Blood* vol 110 (5) 1648-1655 2007

Manuscript *Leuk Corr Sci* CALGB-8461, CALGB-9665
<http://www.ncbi.nlm.nih.gov/pubmed/17494858>

1177 Auto-SCT for AML in second remission: CALGB study 9620.

C A Linker, K Owzar, B Powell, D Hurd, L E Damon, L E Archer, R A Larson *Bone Marrow Transplant* vol 44 (6) 353-9 2009

Manuscript *Leukemia* <http://www.ncbi.nlm.nih.gov/pubmed/19289999>

1178 Semi-quantitative protein analysis of HER2 and ER levels in human breast cancer reveals broad expression ranges within HER2+ and ER+ phenotypes

L. Liotta, M. Pierobon, J. Wulfkuhle, J. Laird, C. Livasy, V. Espina, L. J. Esserman, E. Petricoin *J Clin Oncol* vol 27 (15s) abstr 11014 2009

Abstract *Correl Sci NOS* <http://meetinglibrary.asco.org/content/35157-65>

1179 Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer

Esther H. Lips, Rita A. Mukhtar, Christina Yau, Jorma J. de Ronde, Chad Livasy, Lisa A. Carey, Claudette E. Loo, Marie-Jeanne T.F.D. Vrancken-Peeters, Gabe S. Sonke, Donald A. Berry, Laura J. van 't Veer, Laura J. Esserman, Jelle Wesseling, Sjoerd Rodenhuis, E. Shelley Hwang *Breast Cancer Res Treat* vol 136 (1) 35-43 2012

Manuscript *Correl Sci NOS* <http://www.ncbi.nlm.nih.gov/pubmed/22961065>

1180 Role of age, BMI, and tumor subtype in racial/ethnic disparities in breast cancer survival: A pooled analysis of four Alliance adjuvant clinical trials.

Marla Lipsyc-Sharf, Karla V. Ballman, Jordan D. Campbell, Hyman B. Muss, Lawrence N. Shulman, Edith A. Perez, Lisa A. Carey, Ann H. Partridge, Erica T. Warner *Cancer Res* vol 82 (12_Supplement) 494 2022

Abstract *Breast* CALGB-40101, CALGB-49907, CALGB-9741, NCCTG-N9831
https://aacrjournals.org/cancerres/article/82/12_Supplement/494/700680

1181 Survival in Young-Onset Metastatic Colorectal Cancer: Findings From Cancer and Leukemia Group B (Alliance)/SWOG 80405

Marla Lipsyc-Sharf, Sui Zhang, Fang-Shu Ou, Chao Ma, Nadine Jackson McCleary, Donna Niedzwiecki, I-Wen Chang, Heinz-Josef Lenz, Charles D Blanke, Sorbarikor Piawah, Katherine Van Loon, Tiffany M Bainter, Alan P Venook, Robert J Mayer, Charles S Fuchs, Federico Innocenti, Andrew B Nixon, Richard Goldberg, Eileen M O'Reilly, Jeffrey A Meyerhardt, Kimmie Ng *J Natl Cancer Inst* vol 114 (3) 427-35 2021

Manuscript *GI* <http://www.ncbi.nlm.nih.gov/pubmed/34636852>

1182 Intraoperative sentinel node mapping with technitium-99 in lung cancer: results of CALGB 140203 multicenter phase II trial.

Michael J Liptay, Thomas A D'amico, Chumy Nwogu, Todd L Demmy, Xiaofei F Wang, Lin Gu, Virginia R Litle, Scott J Swanson, Leslie J Kohman *J Thorac Oncol* vol 4 (2) 198-202 2009

Manuscript *Respiratory* <http://www.ncbi.nlm.nih.gov/pubmed/19179896>

- 1183 Comparing and validating simple measures of patient-reported peripheral neuropathy (PRPN) for NCCTG Clinical Trials: A pooled analysis of 2,440 patients (pts)**
H. Liu, A. D. Tan, A. Grothey, P. L. Schaefer, J. C. Buckner, C. L. Loprinzi, R. F. Morton, J. A. Sloan
J Clin Oncol vol 26 (May 20 supplement) abstr 9534 2008
Abstract Symptom Inter
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID
- 1184 Comparing and Validating Simple Measures of Patient-Reported Peripheral Neuropathy for Oncology Clinical Trials: NCCTG N0897 (Alliance) A Pooled Analysis of 2440 Patients**
Heshan Liu, Angelina D. Tan, Rui Qin, Daniel J. Sargent, Axel Grothey, Jan C. Buckner, Paul L. Schaefer, Jeff A. Sloan SOJ Anesthesiol Pain Manag vol 2 (2) 2015
Manuscript Health Outcomes <http://www.ncbi.nlm.nih.gov/pubmed/26526218>
- 1185 Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909**
Hongtao Liu, Jeffrey L. Johnson, Greg Koval, Greg Malnassy, Dorie Sher, Lloyd E. Damon, Eric D. Hsi, Donna Marie Bucci, Charles A. Linker, Bruce D. Cheson, Wendy Stock Haematologica vol 97 (4) 579-585 2012
Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/22102709>
- 1186 PAM50 gene signature is prognostic for breast cancer patients treated with adjuvant anthracycline and taxane based chemotherapy**
M. Liu, B. Pitcher, E. Mardis, S. Davies, J. Snider, T. Vickery, J. Reed, K. Deschryver, B. Singh, P. Friedman, W. Gradishar, E. Perez, S. Martino, M. Citron, L. Norton, E. Winer, C. Hudis, C. Perou, M. Ellis, W. Barry Cancer Res vol 72 (24 supplement) abstract P2-10-01 2012
Abstract Correl Sci NOS
http://cancerres.aacrjournals.org/content/72/24_Supplement/P2-10-01?cited-by=yes&legid=canres;72/24
- 1187 Circulating tumor cell (CTC) enumeration and HER2 assessment as predictors of breast cancer outcomes in the ALTTO (BIG 2-06, Alliance N063D) Trial**
M.C. Liu, B. Rack, A.C. Dueck, D.W. Hillman, M.B. Campion, M.M. Reinholz, K.C. Halling, C. Sotiriou, F. Rothé, M. Maetens, G. Rouas, W. Janni, A.C. Wolff, L.N. Harris, J.R. Gralow, K.I. Pritchard, S. Ellard, N.A. Le-Lindqwister, F. Boyle, E. de Azambuja, M.J. Piccart-Gebhart, M. Ignatiadis, E.A. Perez Cancer Res vol 75 (9_Supplement) abstr P4-01-01 2015
Abstract Breast http://cancerres.aacrjournals.org/content/75/9_Supplement/P4-01-01.short
- 1188 Dose-escalation of filgrastim does not improve efficacy: Clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel**
Minetta C. Liu, George D. Demetri, Donald A. Berry, Larry Norton, Gloria Broadwater, Nicholas J. Robert, David Duggan, Daniel F. Hayes, I.Craig Henderson, Alan Lyss, Judith Hopkins, Peter A. Kaufman, P. Kelly Marcom, Jerry Younger, Nancy Lin, Katherine Tkaczuk, Eric P. Winer, Clifford A. Hudis Cancer Treat Rev vol 34 (3) 223-230 2008
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/18234424>
- 1189 PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance)**
Minetta C Liu, Brandelyn N Pitcher, Elaine R Mardis, Sherri R Davies, Paula N Friedman, Jacqueline E Snider, Tammi L Vickery, Jerry P Reed, Katherine DeSchryver, Baljit Singh, William J Gradishar, Edith A Perez, Silvana Martino, Marc L Citron, Larry Norton, Eric P Winer, Clifford A Hudis, Lisa A Carey, Philip S Bernard, Torsten O Nielsen, Charles M Perou, Matthew J Ellis, William T Barry NPJ Breast Cancer vol 2 15023 2016

1190 Sp1/NFB/HDAC/miR-29b Regulatory Network in KIT-driven Myeloid Leukemia

Shujun Liu, Lai-Chu Wu, Jiuxia Pang, Ramasamy Santhanam, Sebastian Schwind, Yue-Zhong Wu, Christopher Hickey, Jianhua Yu, Heiko Becker, Kati Maharry, Michael D Radmacher, Chenglong Li, Susan P. Whitman, Anjali Mishra, Nicole Stauffer, Anna M. Eiring, Roger Briesewitz, Robert A. Baiocchi, Kenneth K. Chan, Peter Paschka, Michael A. Caligiuri, John C. Byrd, Carlo M Croce, Clara D. Bloomfield, Danilo Perrotti, Ramiro Garzon, Guido Marcucci *Cancer Cell* vol 17 (4) 333-347 2010

Manuscript Leuk Corr Sci <http://www.ncbi.nlm.nih.gov/pubmed/20385359>

1191 Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation.

Ting Xi Liu, Michael W Becker, Jaroslav Jelinek, Wen-Shu Wu, Min Deng, Natallia Mikhalkovich, Karl Hsu, Clara D Bloomfield, Richard M Stone, Daniel J DeAngelo, Ilene A Galinsky, Jean-Pierre Issa, Michael F Clarke, A Thomas Look *Nat Med* vol 13 (1) 78-83 2007

Manuscript Leuk Corr Sci CALGB-8461, CALGB-9665
<http://www.ncbi.nlm.nih.gov/pubmed/17159988>

1192 Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab

Y. Liu, M. D. Starr, A. Bulusu, H. Pang, N. S. Wong, W. Honeycutt, A. Amara, H. I. Hurwitz, A. B. Nixon *Cancer Med* vol 2 (2) 234-242 2013

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/23634291>

1193 Validation of Single-Item Linear Analog Scale Assessment of Quality of Life in Neuro-Oncology Patients

Dona E.C. Locke, Paul A. Decker, Jeff A. Sloan, Paul D. Brown, James F. Malec, Matthew M. Clark, Teresa A. Rummans, Karla V. Ballman, Paul L. Schaefer, Jan C. Buckner *J Pain Symptom Manage* vol 34 (6) 628-638 2007

Manuscript Neuro-Onc NCCTG-N0074, NCCTG-98-72-51, NCCTG-98-72-52
<http://www.ncbi.nlm.nih.gov/pubmed/17703910>

1194 Phase II study of neoadjuvant therapy with docetaxel, cisplatin, panitumumab, and radiation therapy followed by surgery in patients with locally advanced adenocarcinoma of the distal esophagus (ACOSOG Z4051).

A C Lockhart, C E Reed, P A Decker, B F Meyers, M K Ferguson, A R Oeltjen, J B Putnam, S D Cassivi, A J Montero, T E Schefter *Ann Oncol* vol 25 (5) 1039-44 2014

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/24562448>

1195 Preoperative exercise VO2 measurement for lung resection candidates: results of Cancer and Leukemia Group B Protocol 9238.

Gregory M Loewen, Dorothy Watson, Leslie Kohman, James E Herndon II, Hani Shennib, Kemp Kernstine, Jemi Olak, M Jeffery Mador, David Harpole, David Sugarbaker, Mark Green *J Thorac Oncol* vol 2 (7) 619-25 2007

Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/17607117>

1196 Efficacy and safety of veliparib plus carboplatin or carboplatin alone with neoadjuvant chemotherapy (NAC) in triple-negative breast cancer (TNBC) after 4 years of follow-up: BrightNess, a randomized, Phase 3 trial

Sibylle Loibl, Mehra Golshan, Jens Huober, Otto Metzger, Joyce O'Shaughnessy, Hope Rugo, William Sikov, Fraser Symmans, Michael Untch, Norman Wolmark, David Maag, Martin Dunbar, Charles E Geyer Jr *Ann Oncol* vol 32 (5) abstr S408 2021

1197 A phase III randomized, double-blind, placebo-controlled study of pilocarpine for vaginal dryness: NCCTG study N04CA

C. L. Loprinzi, E. P. Balcueva, H. Liu, L. A. Kottschade, P. J. Stella, M. D. Carlson, D. F. Moore Jr, R. Zon, R. Levitt, J. A. Sloan J Clin Oncol vol 28 (15s) abstr 9024 2010

Abstract Symptom Inter

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID

1198 A phase III randomized, double-blind, placebo-controlled study of pilocarpine for vaginal dryness: North Central Cancer Treatment Group study N04CA

C. L. Loprinzi, E. P. Balcueva, H. Liu, J. A. Sloan, L. A. Kottschade, P. J. Stella, M. D. Carlson, D. F. Moore Jr, R. T. Zon, R. Levitt, A. J. Jaslawski J Support Oncol vol 9 (3) 105-112 2011

Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/21702402>

1199 Gabapentin for hot flashes in men: NCCTG trial N00CB

C. L. Loprinzi, B. S. Khoyratty, A. Dueck, D. L. Barton, S. Jafar, K. M. Rowland Jr, P. J. Atherton, G. W. Marsa, J. Krook, L. Kottschade J Clin Oncol vol 25 (June 20 Supplement) abstr 9005 2007

Abstract Symptom Inter

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID

1200 Phase III randomized, placebo (PL)-controlled, double-blind study of intravenous calcium/magnesium (CaMg) to prevent oxaliplatin-induced sensory neurotoxicity (sNT), N08CB: An Alliance for Clinical Trials in Oncology study

C. L. Loprinzi, R. Qin, S. R. Dakhil, L. Fehrenbacher, P. J. Stella, P. Atherton, D. Seisler, R. Qamar, G. C. Lewis, A. Grothey J Clin Oncol vol 31 (15 suppl) abstr 3501 2013

Abstract Symptom Inter

http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/3501?sid=afb15112-3f62-4e22-9fb1-e2c23

1201 Pregabalin for hot flashes in women: NCCTG trial N07C1

C. L. Loprinzi, R. Qin, P. J. Stella, K. M. Rowland Jr, D. L. Graham, N. Erwin, S. R. Dakhil, D. J. Jurgens, K. N. Burger J Clin Oncol vol 27 (15s) abstr 9513 2009

Abstract Symptom Inter

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID

1202 Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1

C. L. Loprinzi, B. N. Reeves, S. R. Dakhil, J. A. Sloan, S. L. Wolf, K. N. Burger, A. Kamal, N. A. Le-Lindqwister, G. S. Soori, A. J. Jaslawski, P. J. Novotny, D. H. Lachance J Clin Oncol vol 29 (11) 1472-1478 2011

Manuscript Health Outcomes <http://www.ncbi.nlm.nih.gov/pubmed/21383290>

1203 Phase III, Randomized, Double-Blind, Placebo-Controlled Evaluation of Pregabalin for Alleviating Hot Flashes, N07C1

Charles L. Loprinzi, Rui Qin, Ernie P. Baclueva, Kathleen A. Flynn, Kendrith M. Rowland, David L. Graham, Nancy K. Erwin, Shaker R. Dakhil, Donald J. Jurgens, Kelli N. Burger J Clin Oncol vol 28 (4) 641-647 2010

Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/19901102>

1204 Phase III Randomized, Placebo-Controlled, Double-Blind Study of Intravenous Calcium and Magnesium to Prevent Oxaliplatin-Induced Sensory Neurotoxicity (N08CB/Alliance)

Charles L. Loprinzi, Rui Qin, Shaker R. Dakhil, Louis Fehrenbacher, Kathleen A. Flynn, Pamela Atherton, Drew Seisler, Rubina Qamar, Grant C. Lewis, Axel Grothey J Clin Oncol vol 32 (10)

1205 Phase III trial of gabapentin alone or in conjunction with an antidepressant in the management of hot flashes in women who have inadequate control with an antidepressant alone: NCCTG N03C5.

Charles L Loprinzi, John W Kugler, Debra L Barton, Amylou C Dueck, Loren K Tschetter, Robert A Nelimark, Ernie Porteza Balcueva, Kelli N Burger, Paul J Novotny, Mark D Carlson, Steven Fletcher Duane, Steven W Corso, David B Johnson, Anthony J Jaslowski J Clin Oncol vol 25 (3) 308-12 2007

Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/17146104>

1206 The genetic landscape of mutations in Burkitt lymphoma

Cassandra Love, Zhen Sun, Dereje Jima, Guojie Li, Jenny Zhang, Rodney Miles, Kristy L Richards, Cherie H Dunphy, William W L Choi, Gopesh Srivastava, Patricia L Lugar, David A Rizzieri, Anand S Lagoo, Leon Bernal-Mizrachi, Karen P Mann, Christopher R Flowers, Kikkeri N Naresh, Andrew M Evens, Amy Chadburn, Leo I Gordon, Magdalena B Czader, Javed I Gill, Eric D Hsi, Adrienne Greenough, Andrea B Moffitt, Matthew McKinney, Anjishnu Banerjee, Vladimir Grubor, Shawn Levy, David B Dunson, Sandeep S Dave Nat Genet vol 44 (12) 1321-1325 2012

Manuscript Leuk Corr Sci <http://www.ncbi.nlm.nih.gov/pubmed/23143597>

1207 Quantitative Measurement of CD52 Expression and Alemtuzumab Binding in Adult Acute Lymphoblastic Leukemia (ALL): Correlation with Immunophenotype and Cytogenetics in Patients (Pts) Enrolled on a Phase I/II Trial from the Cancer and Leukemia Group B (CALGB 10102)

G. Lozanski, B. Sanford, K. Mrozek, C. Edwards, R. Pearson, C. D. Bloomfield, R. A. Larson, W. Stock Blood vol 110 (11) 2386 2007

Abstract Leuk Corr Sci CALGB-10102, CALGB-8461, CALGB-9665, CALGB-9862

<http://www.bloodjournal.org/content/110/11/2386?sso-checked=true>

1208 Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study

Gerard Lozanski, Amy S. Ruppert, Nyla A. Heerema, Arletta Lozanski, David M. Lucas, Amber Gordon, John G. Gribben, Vicki A. Morrison, Kanti M. Rai, Guido Marcucci, Richard A. Larson, John C. Byrd Leuk Lymphoma vol 53 (9) 1743-1748 2012

Manuscript Leuk Corr Sci CALGB-9712, CALGB-9665

<http://www.ncbi.nlm.nih.gov/pubmed/22369572>

1209 Development of a Conditional Event-Free Survival Tool in Diffuse Large B-Cell Lymphoma (Alliance)

Danny Luan, Zhengming Chen, Lasse Jakobsen, Matthew Maurer, Tarek El-Galaly, Loretta Nastoupil, James Cerhan, Christopher Flowers, Brian Link, Izidore Lossos, Deborah Stephens, Thomas Habermann, Grzegorz Nowakowski, Nancy Bartlett, Jonathan Friedberg, Brad Kahl, John Leonard, Karin Smedby, Mats Jerkeman, Peter Martin Blood vol 140 (Supplement) 1921-23. 2022

Abstract Lymphoma CALGB-50303, ECOG-E1412, ECOG-E4494, SWOG-S1001

<https://ashpublications.org/blood/article/140/Supplement%201/1921/492547/Development-of-a-Condition>

1210 Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011.

Anthony Lucci, Linda Mackie McCall, Peter D Beitsch, Patrick W Whitworth, Douglas S Reintgen, Peter W Blumencranz, A Marilyn Leitch, Sukumal Saha, Kelly K Hunt, Armando E Giuliano J Clin Oncol vol 25 (24) 3657-63 2007

Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/17485711>

1211 Randomized phase II study comparing the met inhibitor cabozantinib to temozolomide (tmz) or dacarbazine (dtic) in ocular melanoma - A091201

Jason J. Luke, Jacob B. Allred, Laura E. Horvath, Bruno R. Bastos, Charles Erlichman, Gary K. Schwartz J Clin Oncol vol 33 (suppl) abstr TPS9087 2015
Abstract Experimental <http://meetinglibrary.asco.org/content/149141-156>

1212 Randomized phase II trial and tumor mutational spectrum analysis from cabozantinib versus chemotherapy in metastatic uveal melanoma (Alliance A091201)

Jason J. Luke, Daniel J. Olson, Jacob B. Allred, Carrie A. Strand, Riyue Bao, Yuanyuan Zha, Timothy Carll, Brian W. Labadie, Bruno R. Bastos, Marcus Butler, Davide Hogg, Pamela Munster, Gary K. Schwartz Clin Cancer Res vol 26 (4) 804-11 2020
Manuscript Experimental <http://www.ncbi.nlm.nih.gov/pubmed/31558480>

1213 A randomized phase II study of anti-PD-1 antibody [MK-3475 (pembrolizumab)] alone versus anti-PD1 antibody plus stereotactic body radiation therapy in advanced Merkel cell carcinoma (Alliance A091605)

Jason Luke, Steven Chmura, Joseph Salama, Hania Al-Hallaq, Charles Hsu, Sue Yom, Mark Kozloff, Jacob Allred, Pamela Munster, Gary Schwartz J Clin Oncol vol 36 (15_suppl) TPS9599-TPS9599 2018
Abstract Experimental https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.TPS9599

1214 An mRNA Gene Expression–Based Signature to Identify FGFR1-Amplified Estrogen Receptor–Positive Breast Tumors

Jingqin Luo, Shuzhen Liu, Samuel Leung, Alejandro A. Gru, Yu Tao, Jeremy Hoog, Julie Ho, Sherri R. Davies, D. Craig Allred, Andrea L. Salavaggione, Jacqueline Snider, Elaine R. Mardis, Torsten O. Nielsen, Matthew J. Ellis J Mol Diagn vol 19 (1) 147-161 2017
Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/27993329>

1215 Prevention of aromatase inhibitor (AI)-induced joint symptoms with omega-3 fatty acid supplementation: A randomized placebo-controlled pilot study

M.B. Lustberg, T. Orchard, X. Pan, R. Reinbolt, A. Logan, J. Lester, R.M. Layman, E. Macrae, E. Mrozek, B. Ramaswamy, R. Wesolowski, M. Berger, M. Knopp, C. Loprinzi, C.L. Shapiro, L. Yee Cancer Res vol 75 (suppl 9) abstr P1-09-03 2015
Abstract Symptom Inter http://cancerres.aacrjournals.org/content/75/9_Supplement/P1-09-03

1216 Randomized Placebo-Controlled Pilot Trial of Omega 3 Fatty Acids for Prevention of Aromatase Inhibitor-Induced Musculoskeletal Pain

Maryam B Lustberg, Tonya S. Orchard, Raquel Reinbolt, Rebecca Andridge, Xueliang Pan, Martha Belury, Rachel Cole, Amanda Logan, Rachel Layman, Bhuvaneswari Ramaswamy, Robert Wesolowski, Michael Berger, Elaine Patterson, Charles Loprinzi, Charles L. Shapiro, Lisa Yee Breast Cancer Res Treat vol 167 (3) 709-18 2018
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/29101597>

1217 Comparing an Operation to Monitoring, with or without Endocrine Therapy (COMET): a prospective randomized trial for low-risk DCIS

T. Lynch, A. Partridge, A. Thompson, E. Frank, D. Pinto, D. Collyar, D. Basila, L. Davies, J. Donovan, T. Hyslop, L. McCall, M.D. Ryser, T. O'Donnell, A. Weiss, S. Hwang Cancer Res vol 81 (4 Supplement) OT-08-02 2020
Abstract Breast https://cancerres.aacrjournals.org/content/81/4_Supplement/OT-08-02.short

1218 Effectiveness of an online decision support tool in communicating information about treatment options and related risks for ductal carcinoma in situ (DCIS) (AFT-25)

Thomas Lynch, Ann Partridge, Shelley Hwang, Alastair Thompson, Elizabeth Frank, Donna Pinto, Deborah Collyar, Desiree Basila, Terry Hyslop, Marc Ryser, Anna Rapperport, Rinaa Punglia, Elissa Ozanne 2022

Abstract Breast <https://aacr.ent.box.com/s/puexiax6rwtjhj3hj0top3eup3ae1yy5>

1219 Chemoradiation and Local Excision Versus Total Mesorectal Excision for T2N0 Rectal Cancer

Patricio B. Lynn, Maxime J. M. Van der Valk, Yvette H. M. Claassen, Qian Shi, Maria Widmar, Ester Bastiaannet, Cornelis J. H. Van de Velde, Julio Garcia-Aguilar Ann Surg 2021

Manuscript GI ACOSOG-Z6041 <http://www.ncbi.nlm.nih.gov/pubmed/34225302>

1220 PAM50 intrinsic subtype and risk of recurrence score (ROR) for the prediction of endocrine (ET) sensitivity and pathologic response to chemotherapy in postmenopausal women with clinical stage II/III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC) in the ALTERNATE trial (Alliance A011106)

Cynthia X. Ma, Meenakshi Anurag, Travis Dockter, Jeremy Hoog, Aranzazu Fernandez-Martinez, Cheng Fan, Richard Gibbs, Souzan Sanati, Kiran Vij, Mark Watson, Olwen Hahn, Joseph Guenther, Abigail Caudle, Erika Crouch, Amy Tiersten, Monica Mita, Wajeeha Razaq, Tina J. Hieken, Yang Wang, A. Marilyn Leitch, Gary W. Unzeitig, Anna Weiss, Eric P. Winer, Kelly Hunt, Ann H. Partridge, Lisa A Carey, Charles M. Perou, Matthew J. Ellis, Vera Suman Cancer Res vol 82 (4_supplement) abstr PD9-03. 2022

Abstract Breast

https://aacrjournals.org/cancerres/article/82/4_Supplement/PD9-03/681493/Abstract-PD9-03-Pam50-intr

1221 Alliance A011106: ALTERNATE approaches for clinical stage II or III Estrogen Receptor positive breast cancer Neoadjuvant Treatment (ALTERNATE) in postmenopausal women: A Phase III Study

Cynthia X. Ma, Vera Suman, A. Marilyn Leitch, Souzan Sanati, Katherine DeSchryver, Gary W. Unzeitig, Paul Haluska, Mark Watson, Olwen Hahn, Jo Anne Zujewski, Kelly Hunt, Eric P. Winer, Clifford A. Hudis, Matthew J. Ellis Cancer Res vol 75 (9 Supplement) abstr OT2-1-04 2015

Abstract Breast http://cancerres.aacrjournals.org/content/75/9_Supplement/OT2-1-04.short

1222 Neoadjuvant chemotherapy (NCT) response in postmenopausal women with clinical stage II or III Estrogen Receptor positive and HER2 negative breast cancer resistant to endocrine therapy (ET) in the ALTERNATE trial (Alliance A011106)

Cynthia X. Ma, Vera Suman, A. Marilyn Leitch, Souzan Sanati, Kiran Vij, Gary W. Unzeitig, Jeremy Hoog, Mark Watson, Olwen Hahn, Joseph Guenther, Abigail Caudle, Erika Crouch, Horacio Maluf, Amy Tiersten, Monica Mita, Wajeeha Razaq, Tina J. Hieken, Yang Wang, Travis Dockter, Jo Anne Zujewski, Anna Weiss, Kelly Hunt, Clifford Hudis, Eric P. Winer, Matthew J. Ellis, Lisa A. Carey, Ann H. Partridge Cancer Res vol 81 (4 Supplement) GS4-05 2020

Abstract Breast https://cancerres.aacrjournals.org/content/81/4_Supplement/GS4-05.short

1223 ALTERNATE: Neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III Estrogen Receptor positive HER2 negative breast cancer (ER+ HER2- BC) in postmenopausal (PM) women: Alliance A011106

Cynthia X. Ma, Vera Suman, A. Marilyn Leitch, Souzan Sanati, Kiran Vij, Gary W. Unzeitig, Jeremy Hoog, Mark Watson, Olwen Hahn, Joseph Guenther, Abigail Caudle, J. Michael Guenther, Travis Dockter, Larissa Korde, Anna Weiss, Kelly Hunt, Clifford Hudis, Eric P. Winer, Ann Partridge, Lisa Carey, Matthew J. Ellis J Clin Oncol vol 38 (15_suppl) 504 2020

Abstract Breast https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.504

1224 NCCTG N057K phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: A North Central Cancer Treatment Group trial.

D. Ma, E. Galanis, D. Schiff, W. Wu, P. J. Peller, C. Giannini, P. D. Brown, J. H. Uhm, S. McGraw, K. A. Jaeckle, P. J. Flynn, J. C. Buckner, J. N. Sarkaria J Clin Oncol vol 30 (15 suppl) abstr 2031 2012

1225 A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K

Daniel J. Ma, Evanthia Galanis, S. Keith Anderson, David Schiff, Timothy J. Kaufmann, Patrick J. Peller, Caterina Giannini, Paul D. Brown, Joon H. Uhm, Steven McGraw, Kurt A. Jaeckle, Patrick J. Flynn, Keith L. Ligon, Jan C. Buckner, Jann N. Sarkaria *Neuro-oncology* vol 17 (9) 1261-1269 2015
Manuscript *Neuro-Onc* <http://www.ncbi.nlm.nih.gov/pubmed/25526733>

1226 Prognostic and Predictive Effect of TP53 Mutations in Patients with Non-Small Cell Lung Cancer from Adjuvant Cisplatin-Based Therapy Randomized Trials: A LACE-Bio Pooled Analysis.

Xiaoli Ma, Gwénaél Le Teuff, Benjamin Lacas, Ming Sound Tsao, Stephen Graziano, Jean-Pierre Pignon, Jean-Yves Douillard, Thierry Le Chevalier, Lesley Seymour, Martin Filipits, Robert Pirker, Pasi A Jänne, Frances A Shepherd, Elisabeth Brambilla, Jean-Charles Soria, Pierre Hainaut *J Thorac Oncol* vol 11 (6) 850-61 2016
Manuscript *Respiratory* CALGB-9633 <http://www.ncbi.nlm.nih.gov/pubmed/26899019>

1227 Association of Coffee Intake With Survival in Patients With Advanced or Metastatic Colorectal Cancer

Christopher Mackintosh, Chen Yuan, Fang-Shu Ou, Sui Zhang, Donna Niedzwiecki, I-Wen Chang, Bert H. O'Neil, Brian C. Mullen, Heinz-Josef Lenz, Charles D. Blanke, Alan P. Venook, Robert J. Mayer, Charles S. Fuchs, Federico Innocenti, Andrew B. Nixon, Richard M. Goldberg, Eileen M. O'Reilly, Jeffrey A. Meyerhardt, Kimmie Ng *JAMA Oncol* vol 6 (11) 1713-21 2020
Manuscript *GI* <http://www.ncbi.nlm.nih.gov/pubmed/32940631>

1228 Genome-wide copy number analysis of circulating tumor cells from patients (pts) with metastatic breast cancer (MBC)

M. M. Magbanua, E. V. Sosa, L. E. Eisenbud, J. Scott, A. Olshen, D. Pinkel, H. S. Rugo, J. W. Park *J Clin Oncol* vol 29 (suppl 27) abstr 9 2011
Abstract *PPP*
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=111&abstractID

1229 Serial analysis of circulating tumor cells identifies four prognostic groups for novel risk-stratification in metastatic breast cancer (CALGB 40502/NCCTG N063H) (Alliance)

Mark Jesus M. Magbanua, Laura H. Hendrix, Terry Hyslop, William T. Barry, Eric P. Winer, Clifford Hudis, Deborah Toppmeyer, Lisa Anne Carey, Anne Partridge, Jean-Yves Pierga, Tanja Fehm, José Vidal-Martínez, Dimitrios Mavroudis, Jose A. Garcia-Saenz, Justin Stebbing, Paola Gazzaniga, Luis Manso, Rita Zamarchi, María Luisa Antelo, Leticia De Mattos-Arruda, Daniele Generali, Carlos Caldas, Elisabetta Munzone, Luc Dirix, Amy L. Delson, Harold Burstein, Misbah Qadir, Cynthia Ma, Janet H. Scott, François-Clément Bidard, John W. Park, Hope S. Rugo 2020
Abstract *Correl Sci NOS* http://cancer.ucsf.edu/_docs/BOP2020_PosterHandout.pdf

1230 Trajectory patterns of circulating tumor cells (CTC) in chemotherapy-treated metastatic breast cancer (MBC) patients predict poor clinical outcomes: CALGB 40502 / NCCTG N063H (Alliance)

Mark Jesus M. Magbanua, Laura Hendrix, Terry Hyslop, William Barry, Eric P. Winer, Clifford Hudis, Deborah Toppmeyer, Harold Burstein, Misbah Qadir, Cynthia Ma, Janet H. Scott, John W. Park, Hope S. Rugo *Cancer Res* vol 78 (4 Supplement) P2-01-01 2017
Abstract *Correl Sci NOS* http://cancerres.aacrjournals.org/content/78/4_Supplement/P2-01-01

1231 Expanded genomic profiling of circulating tumor cells in metastatic breast cancer patients to assess biomarker status and biology over time (CALGB 40502 and CALGB 40503, Alliance)

Mark Jesus M. Magbanua, Hope S. Rugo, Denise M. Wolf, Louai Hauranieh, Ritu Roy, Praveen

Pendyala, Eduardo V. Sosa, Janet H. Scott, Jin Sun Lee, Brandelyn Pitcher, Terry Hyslop, William T. Barry, Steven J. Isakoff, Maura Dickler, Laura van't Veer, John W. Park Clin Cancer Res vol 24 (6) 1486-99 2018

Manuscript Correl Sci NOS CALGB-40502, CALGB-40503

<http://www.ncbi.nlm.nih.gov/pubmed/29311117>

1232 Clinical significance of circulating tumor cells in hormone receptor-positive metastatic breast cancer patients who received letrozole with or without bevacizumab

Mark Jesus M. Magbanua, Oleksandr Savenkov, Erik J. Asmus, Karla V. Ballman, Janet H. Scott, John W. Park, Maura Dickler, Ann Partridge, Lisa Carey, Eric Winer, Hope S. Rugo Clin Cancer Res vol 26 (18) 4911-20 2020

Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/32586939>

1233 Clinical significance of circulating tumor cells (CTCs) in hormone receptor-positive (HR+) metastatic breast cancer (MBC) patients receiving letrozole or letrozole plus bevacizumab: CALGB 40503 (Alliance)

Mark Jesus M. Magbanua, Oleksandr Savenkov, Erik J. Asmus, Karla V. Ballman, Janet H. Scott, John W. Park, Maura Dickler, Ann Partridge, Lisa Carey, Eric Winer, Hope S. Rugo J Clin Oncol vol 37 (15_suppl) 1049-1049 2019

Abstract Breast https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.1049

1234 Genomic profiling of isolated circulating tumor cells from metastatic breast cancer patients

Mark Jesus M. Magbanua, Eduardo V. Sosa, Ritu Roy, Lauren E. Eisenbud, Janet H. Scott, Adam Olshen, Dan Pinkel, Hope Rugo, John W. Park Cancer Res vol 73 (1) 30-40 2013

Manuscript PPP CALGB-40502, CALGB-40503 <http://www.ncbi.nlm.nih.gov/pubmed/23135909>

1235 Serial expression analysis of breast tumors during neoadjuvant chemotherapy reveals changes in cell cycle and immune pathways associated with recurrence and response

Mark Jesus M. Magbanua, Denise M. Wolf, Christina Yau, Sarah E. Davis, Julia Crothers, Alfred Au, Christopher M. Haqq, Chad Livasy, Hope S. Rugo, Laura Esserman, John W. Park, Laura J. van 't Veer Breast Cancer Res vol 17 (1) 2015

Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/26021444>

1236 Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy

Mark Jesus M Magbanua, Laura H Hendrix, Terry Hyslop, William T Barry, Eric P Winer, Clifford Hudis, Deborah Toppmeyer, Lisa Anne Carey, Ann H Partridge, Jean-Yves Pierga, Tanja Fehm, José Vidal-Martínez, Dimitrios Mavroudis, Jose A Garcia-Saenz, Justin Stebbing, Paola Gazzaniga, Luis Manso, Rita Zamarchi, María Luisa Antelo, Leticia De Mattos-Arruda, Daniele Generali, Carlos Caldas, Elisabetta Munzone, Luc Dirix, Amy L Delson, Harold J Burstein, Misbah Qadir, Cynthia Ma, Janet H Scott, François-Clément Bidard, John W Park, Hope S Rugo J Natl Cancer Inst vol 113 (4) 443-52 2020

Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/32770247>

1237 Toxicity and Survival Outcomes in Older Adults Receiving Concurrent or Sequential Chemoradiation for Stage III Non-Small Cell Lung Cancer in Alliance Trials (Alliance A151812)

Ronald J. Maggiore, David Zahrieh, Ryan P. McMurray, Josephine L. Feliciano, Pamela Samson, Pranshu Mohindra, Hongbin Chen, Melisa L. Wong, Jacqueline M. Lafky, Aminah Jatoi, Jennifer G. Le-Rademacher J Geriatr Oncol vol 12 (4) 563-71 2021

Manuscript Older Adult CALGB-8433, CALGB-8813, CALGB-9130, CALGB-30106, CALGB-30407, CALGB-39801 <http://www.ncbi.nlm.nih.gov/pubmed/32950428>

1238 Endpoints for validation of tumor markers for recurrence risk: Recurrence-free interval (RFI),

disease-free survival (DFS), overall survival (OS), and colon-cancer specific survival (CCSS) in CALGB 9581

N. N. Mahmoud, M. Lopatin, M. Lee, K. Clark-Langone, D. Niedzwiecki, A. P. Venook Eur J Cancer vol 47 (Suppl 1) S172 2011
Abstract GI
<http://www.ejancer.info/article/abstracts?terms1=CALGB+9581&terms2=&terms3=&terms4=>

1239 Quality assessment metrics for whole genome gene expression profiling of paraffin embedded samples

D. W. Mahoney, T. M. Therneau, S. K. Anderson, J. Jen, J. P. Kocher, M. M. Reinholz, E. A. Perez, J. E. Eckel-Passow BMC Res Notes vol 6 33 2013
Manuscript PPP <http://www.ncbi.nlm.nih.gov/pubmed/23360712>

1240 Quality of life (QOL) for patients treated with FOLFOX+/-cetuximab (Cmab) following complete resection of colorectal cancer (CRC): Results from North Central Cancer Treatment Group (NCCTG) Phase III Trial N0147

M. R. Mahoney, J. A. Sloan, J. M. Hubbard, H. Liu, A. F. Shields, E. Chan, R. M. Goldberg, S. Gill, M. S. Kahlenberg, S. G. Nair, D. J. Sargent, S. R. Alberts J Clin Oncol vol 29 (suppl) abstr 3541 2011
Abstract GI
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=

1241 The Clinical Significance of Effect Sizes for Survival and Tumor Response Endpoints Using Empirical Rule Effect Size

BT Major-Elechi, JA Sloan, PJ Novotny, DJ Sargent, A Grothey, JM Lafky, AC Dueck J Biom Biostat vol 10 (5) 433 2019
Manuscript Health Outcomes

1242 Combining Survival and Toxicity Effect Sizes from Clinical Trials: NCCTG 89-20-52 (Alliance)

Brittney T. Major-Elechi, Paul J. Novotny, Jasvinder A. Singh, James A. Bonner, Amylou C. Dueck, Daniel J. Sargent, Axel Grothey, Jeff A. Sloan Int J Stat Med Res vol 7 (4) 137-46 2018
Manuscript Health Outcomes NCCTG-89-20-52 <http://www.ncbi.nlm.nih.gov/pubmed/31396297>

1243 Rural and urban disparities based on zip code of residence: Analyses of 834 and 2159 patients in NCCTG N9741 and CALGB 80405 (Alliance) trials respectively

Midhun Malla, Luke J Huebner, Sorbarikor Piawah, Heinz-Josef Lenz, Jeffrey Meyerhardt, Eileen O'Reilly, Charles D. Blanke, Qian Shi, Alan P Venook, Richard M Goldberg JCO vol 38 (no. 15_suppl) e16076 2020
Abstract GI CALGB-80405, NCCTG-N9741
https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.e16076

1244 Comparison Of Deep Sequencing and Allele-Specific Oligonucleotide PCR Methods For MRD Quantitation In Acute Lymphoblastic Leukemia and Mantle Cell Lymphoma: CALGB 10403 and CALGB 59909 (Alliance)

Greg Malnassy, Susan Geyer, Noreen Fulton, Greg Koval, Donna Niedzwiecki, Victoria Carlton, Li Weng, Lawrence D. Kaplan, Guido Marcucci, Lloyd E. Damon, Richard A. Larson, Richard M. Stone, Bruce D. Cheson, Malek Faham, Wendy Stock Blood vol 122 (21) 2547 2013
Abstract Leuk Corr Sci CALGB-10403, CALGB-59909
<http://bloodjournal.hematologylibrary.org/content/122/21/2547.abstract?sid=ae1b6fda-d137-4533-b41c-c>

1245 Preliminary Analysis of Cancer and Leukemia Group B (CALGB) 80003: A Phase II Trial of Gemcitabine, 5-Fluorouracil (5FU), and Radiation Therapy (RT) in Locally Advanced Non-Metastatic Pancreatic Adenocarcinoma

H. J. Mamon, D. Niedzwiecki, D. R. Hollis, B. Tan, J. Smith, A. W. Blackstock, J. E. Tepper, R. M. Goldberg, R. J. Mayer, C. S. Fuchs *Int J Radiat Oncol Biol Phys* vol 63 (S13) 0360-3016 2005
Abstract GI <http://linkinghub.elsevier.com/retrieve/pii/S0360301605011958?showall=true>

1246 A Phase II Trial of Gemcitabine, 5-Fluorouracil, and Radiation Therapy in Locally Advanced Non-Metastatic Pancreatic Adenocarcinoma: Cancer and Leukemia Group B (CALGB) 80003

Harvey J. Mamon, Donna Niedzwiecki, Donna Hollis, Benjamin R. Tan, Robert J. Mayer, Joel E. Tepper, Richard M. Goldberg, A. William Blackstock, Charles S. Fuchs *Cancer* vol 117 (12) 2620-2628 2011
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/21656739>

1247 Patient and physician decision styles and breast cancer chemotherapy use in older women: Cancer and Leukemia Group B protocol 369901

J. S. Mandelblatt, L. A. Faul, G. Luta, S. B. Makgoeng, C. Isaacs, K. Taylor, V. B. Sheppard, M. Tallarico, W. T. Barry, H. J. Cohen *J Clin Oncol* vol 30 (21) 2609-2614 2012
Manuscript Older Adult <http://www.ncbi.nlm.nih.gov/pubmed/22614985>

1248 Patient preference as a determinant of breast cancer adjuvant chemotherapy use in older women: CALGB 369901

J. Mandelblatt, V. Sheppard, A. Hurria, G. G. Kimmick, C. Isaacs, K. Taylor, G. Luta, A. Noone, A. B. Kornblith, W. T. Barry *J Clin Oncol* vol 27 (15s) abstr 9544 2009
Abstract Older Adult
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID

1249 Frailty and Long-term Mortality Of Older Breast Cancer Patients: CALGB 369901 (Alliance)

Jeanne S. Mandelblatt, Ling Cai, George Luta, Gretchen Kimmick, Jonathan Clapp, Claudine Isaacs, Brandeyln Pitcher, William Barry, Eric Winer, Stephen Sugarman, Clifford Hudis, Hyman Muss, Harvey J. Cohen, Arti Hurria *Breast Cancer Res Treat* vol 164 (1) 107-117 2017
Manuscript Older Adult <http://www.ncbi.nlm.nih.gov/pubmed/28364214>

1250 Long-term trajectories of self-reported cognitive function in a cohort of older survivors of breast cancer: CALGB 369901 (Alliance)

Jeanne S. Mandelblatt, Jonathan D. Clapp, Gheorghe Luta, Leigh Anne Faul, Michelle D. Tallarico, Trina D. McClendon, Jessica A. Whitley, Ling Cai, Tim A. Ahles, Robert A. Stern, Paul B. Jacobsen, Brent J. Small, Brandelyn N. Pitcher, Estrella Dura-Fernandis, Hyman B. Muss, Arti Hurria, Harvey J. Cohen, Claudine Isaacs *Cancer* 2016
Abstract Older Adult <http://onlinelibrary.wiley.com/doi/10.1002/cncr.30208/pdf>

1251 Longterm trajectories of selfreported cognitive function in a cohort of older survivors of breast cancer: CALGB 369901 (Alliance)

Jeanne S. Mandelblatt, Jonathan D. Clapp, Gheorghe Luta, Leigh Anne Faul, Michelle D. Tallarico, Trina D. McClendon, Jessica A. Whitley, Ling Cai, Tim A. Ahles, Robert A. Stern, Paul B. Jacobsen, Brent J. Small, Brandelyn N. Pitcher, Estrella Dura-Fernandis, Hyman B. Muss, Arti Hurria, Harvey J. Cohen, Claudine Isaacs *Cancer* vol 122 (22) 3555-63 2016
Manuscript Older Adult <http://www.ncbi.nlm.nih.gov/pubmed/27447359>

1252 A planned, prospective comparison of short-term quality of life outcomes among older breast cancer patients treated with standard chemotherapy in a randomized clinical trial vs. an observational study: CALGB 49907 and 369901

Jeanne S. Mandelblatt, Solomon B. Makgoeng, Gheorghe Luta, Arti Hurria, Gretchen Kimmick, Claudine Isaacs, Michelle Tallarico, William T. Barry, Brandy Pitcher, Eric P. Winer, Clifford Hudis, Harvey J. Cohen, Hyman B. Muss *J Geriatr Oncol* vol 4 (4) 353-361 2013
Manuscript Older Adult CALGB-49907 <http://www.ncbi.nlm.nih.gov/pubmed/24472479>

1253 Breast Cancer Adjuvant Chemotherapy Decisions in Older Women: The Role of Patient Preference and Interactions With Physicians

Jeanne S. Mandelblatt, Vanessa B. Sheppard, Arti Hurria, Gretchen Kimmick, Claudine Isaacs, Kathryn L. Taylor, Alice B. Kornblith, Anne-Michelle Noone, Gheorghe Luta, Michelle Tallarico, William T. Barry, Lisa Hunegs, Robin Zon, Michael Naughton, Eric Winer, Clifford Hudis, Stephen B. Edge, Harvey Jay Cohen, Hyman Muss J Clin Oncol vol 28 (19) 3146-3153 2010
Manuscript Older Adult <http://www.ncbi.nlm.nih.gov/pubmed/20516438>

1254 Are actual tumor measurements or categorical tumor response status better at predicting overall survival in cancer clinical trials?

M. D. Mandrekar, S. L. Hillman, M. E. Campbell, B. Hobbs, R. M. Goldberg, A. Adjei, D. J. Sargent J Clin Oncol vol 26 (15s) abstr 6520 2008
Abstract GI
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID

1255 Comparison of progression-free survival (PFS) with best or confirmed response (BR, CR) as an endpoint for overall survival (OS) in advanced non small cell lung cancer (A-NSCLC): A North Central Cancer Treatment Group (NCCTG) investigation

S. J. Mandrekar, S. L. Hillman, K. L. Allen Ziegler, N. F. Reuter, K. M. Rowland Jr, R. S. Marks, S. E. Schild, A. A. Adjei J Clin Oncol vol 26 (15s) abstr 8021 2008
Abstract Respiratory
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID

1256 Systematic evaluation of the impact of disease progression (DP) date determination on progression-free survival (PFS) in advanced lung cancer: a joint North Center Cancer Treatment Group (NCCTG) and Southwest Oncology Group (SWOG) investigation

S. J. Mandrekar, Y. Qi, K. Allen-Ziegler, S. L. Hillman, M. W. Redman, S. E. Schild, D. R. Gandara, A. A. Adjei J Clin Oncol vol 29 (suppl) abstr 7005 2011
Abstract Respiratory
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID

1257 Impact of the Algorithm for Declaring Exact Progression Data on Progression-Free Survival Estimates in Advanced Lung Cancer

S. Mandrekar, S. Hillman, A. Jatoi, J. Jett, S. Schild, A. Adjei, K. Allen-Ziegler J Clin Oncol vol 28 (15s) abstr 7629 2010
Abstract Respiratory http://ascopubs.org/doi/abs/10.1200/jco.2010.28.15_suppl.7629

1258 Impact of disease progression (DP) date determination method on post progression survival (PPS) and DP metrics in advanced lung cancer

Sumithra J. Mandrekar, Nathan R. Foster, Yingwei Qi, Grace K. Dy, Aminah Jatoi, Julian R. Molina, James R. Jett, Philip J. Stella, Steven E. Schild, Alex A. Adjei J Clin Oncol vol 30 (suppl) abstr 7605 2012
Abstract Respiratory
http://meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/7605?sid=3a6df366-f524-429a-860c-c83e9

1259 Analysis of patient (pt) withdrawal of consent using 11,993 pts from 58 alliance for clinical trials in oncology trials.

Sumithra J. Mandrekar, Shauna L. Hillman, Carrie Strand, David Zahrieh, Suzanne George, Aminah Jatoi J Clin Oncol vol 40 (16_suppl) 6513-6513 2022
Abstract SDMC NOS https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.6513

1260 Phase 2 Randomized Trial of Neoadjuvant or Palliative Chemotherapy with or without

Immunotherapy for Peritoneal Mesothelioma (Alliance: A092001)

Aaron Mansfield, Austin Goodrich, Nathan Foster, Vinicius Ernani, Liza Villaruz, Patrick Forde, Kanwal Raghav, Paul Romesser, Krista Garbacz, Liang Cao, Mary Salvatore, Anja Roden, Steven Powell, Ardaman Shergill, Pamela Munster, Gary Schwartz, Travis Grotz J Clin Oncol vol 40 (16_suppl) TPS8598 2022
Abstract Experimental https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.TPS8598

1261 Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era

Simon Mantha, Debra A. Goldman, Sean M. Devlin, Ju-Whei Lee, Diana Zannino, Marnie Collins, Dan Douer, Harry J. Iland, Mark R. Litzow, Eytan M. Stein, Frederick R. Appelbaum, Richard A. Larson, Richard Stone, Bayard L. Powell, Susan Geyer, Kristina Laumann, Jacob M. Rowe, Harry Erba, Steven Coutre, Megan Othus, Jae H. Park, Peter H. Wiernik, Martin S. Tallman Blood vol 129 (13) 1763-1767 2017
Manuscript Leukemia <http://www.ncbi.nlm.nih.gov/pubmed/28082441>

1262 Improving the molecular risk classification for younger (<60 years) de novo cytogenetically normal acute myeloid leukemia (CN AML) patients (pts)

G. Marcucci, K. S. Maharry, S. P. Whitman, P. Paschka, C. D. Baldus, C. Langer, K. A. Mrozek, J. E. Kolitz, R. A. Larson, C. D. Bloomfield J Clin Oncol vol 27 (15s) abstr 7002 2009
Abstract Leuk Corr Sci CALGB-19808, CALGB-20202, CALGB-9621
<http://meetinglibrary.asco.org/content/34742-65>

1263 High ERG expression levels predict adverse outcome and refine molecular risk-based classification of cytogenetically normal (CN) acute myeloid leukemia (AML): A Cancer and Leukemia Group B (CALGB) study

G. Marcucci, K. S. Maharry, S. P. Whitman, T. Vukosavljevic, P. Paschka, C. Langer, K. A. Mrozek, C. Baldus, A. J. Carroll, B. L. Powell, J. E. Kolitz, R. A. Larson, C. D. Bloomfield AACR Annual Meeting vol 45 (580) abstr 2440 2007
Abstract Leuk Corr Sci CALGB-19808, CALGB-20502, CALGB-8461, CALGB-9621, CALGB-9665
<http://www.abstractsonline.com/viewer/viewAbstractPrintFriendly.asp?CKey={602C556E-A3FC-41BE->

1264 IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia (CN-AML): A Cancer and Leukemia Group B (CALGB) Study

G. Marcucci, K. S. Maharry, Y. Wu, M. D. Radmacher, K. A. Mrozek, D. Margeson, K. B. Holland, S. P. Whitman, H. P. Becker, S. Schwind, K. Metzeler, B. L. Powell, T. H. Carter, J. E. Kolitz, M. Wetzler, M. R. Baer, A. J. Carroll, M. A. Caligiuri, R. A. Larson, C. D. Bloomfield Haematologica vol 95 (suppl 2) 456, abstr 1107 2010
Abstract Leuk Corr Sci CALGB-8525, CALGB-10201, CALGB-19808, CALGB-20202, CALGB-20502, CALGB-8461, CALGB-8923, CALGB-9420, CALGB-9621, CALGB-9665, CALGB-9720
<http://online.haematologica.org/EHA15/browserecord.php?-action=browse&-recid=7179>

1265 Gene and microRNA (miRNA) Expression Signatures and Prognostic Significance of CEBPA Mutations in Cytogenetically Normal (CN) Acute Myeloid Leukemia (AML) with High-Risk Molecular Features: A Cancer and Leukemia Group B (CALGB) Study

G. Marcucci, K. Maharry, M. D. Radmacher, K. Mrozek, T. Vukosavljevic, P. Paschka, S. P. Whitman, C. Langer, C. D. Baldus, A. S. Ruppert, B. L. Powell, A. J. Carroll, M. A. Caligiuri, J. E. Kolitz, R. A. Larson, C. D. Bloomfield Blood vol 110 (11) -104 2007
Abstract Leuk Corr Sci CALGB-19808, CALGB-20205, CALGB-20502, CALGB-8461, CALGB-9621, CALGB-9665
<http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;110/11/104>

1266 A phase III randomized trial of intensive induction and consolidation chemotherapy +/- oblimersen, a pro-apoptotic Bcl-2 antisense oligonucleotide in untreated acute myeloid leukemia patients >60 years old

Guido Marcucci, B. K. Moser, W. G. Blum, W. Stock, M. Wetzler, J. E. Kolitz, M. C. Thakuri, T. H. Carter, R. K. Stuart, R. A. Larson *J Clin Oncol* vol 25 (18s) abstr 7012 2007

Abstract *Leukemia*

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID

1267 Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801

Guido Marcucci, Susan Geyer, Kristina Laumann, Weiqiang Zhao, Donna Bucci, Geoffrey L. Uy, William Blum, Ann-Kathrin Eifeld, Timothy S. Pardee, Eunice S. Wang, Wendy Stock, Jonathan E. Kolitz, Jessica Kohlschmidt, Krzysztof Mrózek, Clara D. Bloomfield, Richard M. Stone, Richard A. Larson *Blood Adv* vol 4 (4) 696-705 2020

Manuscript *Leukemia* CALGB-20202 <http://www.ncbi.nlm.nih.gov/pubmed/32092139>

1268 Adding the KIT Inhibitor Dasatinib (DAS) to Chemotherapy Overcomes the Negative Impact of KIT Mutation/over-expression in Core Binding Factor (CBF) Acute Myeloid Leukemia (AML): Results from CALGB study 10801 (Alliance)

Guido Marcucci, Susan Geyer, John Zhao, Andrew J Carroll, Donna Bucci, Geoffrey L Uy, William Blum, Timothy Pardee, Meir Wetzler, Wendy Stock, Jonathan E. Kolitz, Ann-Kathrin Eifeld, Clara D. Bloomfield, Richard M. Stone, Richard A. Larson *Blood* vol 124 (21) abstr 8 2014

Abstract *Leukemia* <http://www.bloodjournal.org/content/124/21/8?rss=1&sso-checked=true>

1269 Adding The KIT Inhibitor Dasatinib (DAS) To Standard Induction and Consolidation Therapy For Newly Diagnosed Patients (pts) With Core Binding Factor (CBF) Acute Myeloid Leukemia (AML): Initial Results Of The CALGB 10801 (Alliance) Study

Guido Marcucci, Susan Geyer, John Zhao, Andrew J Carroll, Donna Bucci, Ravi Vij, William Blum, Timothy Pardee, Meir Wetzler, Wendy Stock, Clara D. Bloomfield, Richard A. Larson, Richard M. Stone *Blood* vol 122 (21) Abstract 357 2013

Abstract *Leuk Corr Sci* <http://www.bloodjournal.org/content/122/21/357.short>

1270 Clinical Role of microRNAs in Cytogenetically Normal Acute Myeloid Leukemia: miR-155 Upregulation Independently Identifies High-Risk Patients

Guido Marcucci, Kati S. Maharry, Klaus H. Metzeler, Stefano Volinia, Yue-Zhong Wu, Krzysztof Mrózek, Deedra Nicolet, Jessica Kohlschmidt, Susan P. Whitman, Jason H. Mender, Sebastian Schwind, Heiko Becker, Ann-Kathrin Eifeld, Andrew J. Carroll, Bayard L. Powell, Jonathan E. Kolitz, Ramiro Garzon, Michael A. Caligiuri, Richard M. Stone, Clara D. Bloomfield *J Clin Oncol* vol 31 (17) 2086-2093 2013

Manuscript *Leuk Corr Sci* CALGB-8461, CALGB-9665, CALGB-20202

<http://www.ncbi.nlm.nih.gov/pubmed/23650424>

1271 Prognostic Significance of, and Gene and MicroRNA Expression Signatures Associated With, CEBPA Mutations in Cytogenetically Normal Acute Myeloid Leukemia With High-Risk Molecular Features: A Cancer and Leukemia Group B Study

Guido Marcucci, Kati Maharry, Michael D. Radmacher, Krzysztof Mrózek, Tamara Vukosavljevic, Peter Paschka, Susan P. Whitman, Christian Langer, Claudia D. Baldus, Chang-Gong Liu, Amy S. Ruppert, Bayard L. Powell, Andrew J. Carroll, Michael A. Caligiuri, Jonathan E. Kolitz, Richard A. Larson, Clara D. Bloomfield *J Clin Oncol* vol 26 (31) 5078-5087 2008

Manuscript *Leuk Corr Sci* CALGB-19808, CALGB-20502, CALGB-8461, CALGB-9621, CALGB-9665 <http://www.ncbi.nlm.nih.gov/pubmed/18809607>

1272 High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study.

Guido Marcucci, Kati Maharry, Susan P Whitman, Tamara Vukosavljevic, Peter Paschka, Christian Langer, Krzysztof Mrózek, Claudia D Baldus, Andrew J Carroll, Bayard L Powell, Jonathan E Koltitz, Richard A Larson, Clara D Bloomfield J Clin Oncol vol 25 (22) 3337-43 2007
Manuscript Leuk Corr Sci CALGB-19808, CALGB-20205, CALGB-20502, CALGB-8461, CALGB-9621, CALGB-9665 <http://www.ncbi.nlm.nih.gov/pubmed/17577018>

1273 IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

Guido Marcucci, Kati Maharry, Yue-Zhong Wu, Michael D. Radmacher, Krzysztof Mrózek, Dean Margeson, Kelsi B. Holland, Susan P. Whitman, Heiko Becker, Sebastian Schwind, Klaus H. Metzeler, Bayard L. Powell, Thomas H. Carter, Jonathan E. Koltitz, Meir Wetzler, Andrew J. Carroll, Maria R. Baer, Michael A. Caligiuri, Richard A. Larson, Clara D. Bloomfield J Clin Oncol vol 28 (14) 2348-2355 2010
Manuscript Leuk Corr Sci CALGB-8421, CALGB-8525, CALGB-10201, CALGB-19808, CALGB-20202, CALGB-20502, CALGB-8923, CALGB-9420, CALGB-9621, CALGB-9665, CALGB-9720 <http://www.ncbi.nlm.nih.gov/pubmed/20368543>

1274 Age-Related Prognostic Impact of Different Types of DNMT3A Mutations in Adults With Primary Cytogenetically Normal Acute Myeloid Leukemia

Guido Marcucci, Klaus H. Metzeler, Sebastian Schwind, Heiko Becker, Kati Maharry, Krzysztof Mrózek, Michael D. Radmacher, Jessica Kohlschmidt, Deedra Nicolet, Susan P. Whitman, Yue-Zhong Wu, Bayard L. Powell, Thomas H. Carter, Jonathan E. Koltitz, Meir Wetzler, Andrew J. Carroll, Maria R. Baer, Joseph O. Moore, Michael A. Caligiuri, Richard A. Larson, Clara D. Bloomfield J Clin Oncol vol 30 (7) 742-750 2012
Manuscript Leuk Corr Sci CALGB-9621, CALGB-19808
<http://www.ncbi.nlm.nih.gov/pubmed/22291079>

1275 MicroRNA expression in cytogenetically normal acute myeloid leukemia.

Guido Marcucci, Michael D Radmacher, Kati Maharry, Krzysztof Mrózek, Amy S Ruppert, Peter Paschka, Tamara Vukosavljevic, Susan P Whitman, Claudia D Baldus, Christian Langer, Chang-Gong Liu, Andrew J Carroll, Bayard L Powell, Ramiro Garzon, Carlo M Croce, Jonathan E Koltitz, Michael A Caligiuri, Richard A Larson, Clara D Bloomfield N Engl J Med vol 358 (18) 1919-28 2008
Manuscript Leuk Corr Sci CALGB-19808, CALGB-20502, CALGB-8461, CALGB-9621, CALGB-9665 <http://www.ncbi.nlm.nih.gov/pubmed/18450603>

1276 Epigenetics Meets Genetics in Acute Myeloid Leukemia: Clinical Impact of a Novel Seven-Gene Score

Guido Marcucci, Pearly Yan, Kati Maharry, David Frankhouser, Deedra Nicolet, Klaus H. Metzeler, Jessica Kohlschmidt, Krzysztof Mrózek, Yue-Zhong Wu, Donna Bucci, John P. Curfman, Susan P. Whitman, Ann-Kathrin Eisfeld, Jason H. Mendler, Sebastian Schwind, Heiko Becker, Constance Bär, Andrew J. Carroll, Maria R. Baer, Meir Wetzler, Thomas H. Carter, Bayard L. Powell, Jonathan E. Koltitz, John C. Byrd, Christoph Plass, Ramiro Garzon, Michael A. Caligiuri, Richard M. Stone, Stefano Volinia, Ralf Bundschuh, Clara D. Bloomfield J Clin Oncol vol 32 (6) 548-556 2014
Manuscript Leuk Corr Sci CALGB-10201, CALGB-9420, CALGB-9720, CALGB-9621, CALGB-19808 <http://www.ncbi.nlm.nih.gov/pubmed/24378410>

1277 Recurring mutations found by sequencing an acute myeloid leukemia genome

E. R. Mardis, L. Ding, D. J. Dooling, D. E. Larson, M. D. McLellan, K. Chen, D. C. Koboldt, R. S. Fulton, K. D. Delehaunty, S. D. Mcgrath, L. A. Fulton, D. P. Locke, V. J. Magrini, R. M. Abbott, T. L. Vickery, J. S. Reed, J. S. Robinson, T. Wylie, S. M. Smith, L. Carmichael, J. M. Eldred, C. C. Harris,

J. Walker, J. B. Peck, F. Du, A. F. Dukes, G. E. Sanderson, A. M. Brummett, E. Clark, J. F. McMichael, R. J. Meyer, J. K. Schindler, C. S. Pohl, J. W. Wallis, X. Shi, L. Lin, H. Schmidt, Y. Tang, C. Haipek, M. E. Wiechert, J. V. Ivy, J. Kalicki, G. Elliott, R. E. Ries, J. E. Payton, P. Westervelt, M. H. Tomasson, M. A. Watson, J. Baty, S. Heath, W. D. Shannon, R. Nagarajan, D. C. Link, M. J. Walter, T. A. Graubert, J. F. Dipersio, R. K. Wilson, T. J. Ley *N Engl J Med* vol 361 (11) 1058-1066 2009

Manuscript *Leuk Corr Sci CALGB-9665, CALGB-8461*
<http://www.ncbi.nlm.nih.gov/pubmed/19657110>

1278 A phase II trial of carboplatin (C) and nab-paclitaxel (ABI-007-nab-P) in patients with unresectable stage IV melanoma: Final data from N057E

S. N. Markovic, V. J. Suman, L. A. Kottschade, T. Amatruda, R. R. McWilliams, S. R. Dakhil, D. A. Nikcevich, R. F. Morton, T. R. Fitch, A. J. Jaslowski *J Clin Oncol* vol 27 (15s) abstr 9055 2009
Abstract Experimental

<http://jco.ascopubs.org/gca?gca=ascomtg%3B27%2F15S%2F9055&allch=&submit=Go>

1279 Aerosolized sargramostim for the treatment of metastatic melanoma to the lungs

S. Markovic, V. Suman, P. Schaefer, K. Rowland Jr, R. Morton *J Clin Oncol* vol 25 (18s (June 20 Supplement)) abstr 2004 2007
Abstract Experimental

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID

1280 Tumor SPARC Microenvironment Signature and Plasma Levels in a Phase II Trial of Unresectable Stage IV Melanoma Treated With nab-Paclitaxel and Carboplatin: A Translational Study of NCCTG Trial N057E

S. Markovic, V. Suman, V. Treiu, X. Liu, W. Yeh, L. Hwang, T. Treece, K. Motamed, P. Pramanik, N. Desai *J Clin Oncol* vol 28 (15s) abstr 8578 2010
Abstract Correl Sci NOS

http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/8578?sid=47f729d6-2db7-45ec-b759-2228

1281 A dose-escalation study of aerosolized sargramostim in the treatment of metastatic melanoma: an NCCTG study1

Svetomir N. Markovic, Vera J. Suman, Wendy K. Nevala, Louis Geeraerts, Edward T. Creagan, Lori A. Erickson, Kendrith M. Rowland, Roscoe F. Morton, William L. Horvath, Mark R. Pittelkow *Am J Clin Oncol* vol 31 (6) 573-579 2008
Manuscript Experimental <http://www.ncbi.nlm.nih.gov/pubmed/19060590>

1282 Impact of high-dose chemotherapy on the ability to deliver subsequent local-regional radiotherapy for breast cancer: analysis of Cancer and Leukemia Group B Protocol 9082

L. B. Marks, C. Cirrincione, T. J. Fitzgerald, F. Laurie, A. S. Glicksman, J. Vredenburgh, L. R. Prosnitz, E. J. Shpall, M. Crump, P. G. Richardson, M. W. Schuster, J. Ma, B. L. Peterson, L. Norton, S. Seagren, I. C. Henderson, D. D. Hurd, W. P. Peters *Int J Radiat Oncol Biol Phys* vol 76 (5) 1305-1313 2010
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/19747781>

1283 Phase III, Double-Blind Study of Depot Octreotide Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy: Results of North Central Cancer Treatment Group N00CA

James A. Martenson, Michele Y. Halyard, Jeff A. Sloan, Gary M. Proulx, Robert C. Miller, Richard L. Deming, Stephen J. Dick, Harold A. Johnson, T.H. Patricia Tai, Angela W. Zhu, Joan Keit, Kathy J. Stien, Pamela J. Atherton *J Clin Oncol* vol 26 (32) 5248-5253 2008
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/18768432>

- 1284 Detection of Occult Micrometastases in Patients With Clinical Stage I Non–Small-Cell Lung Cancer: A Prospective Analysis of Mature Results of CALGB 9761 (Alliance)**
Linda W. Martin, Jonathan D'Cunha, Xiaofei Wang, Debra Herzan, Lin Gu, Naif Abraham, Todd L. Demmy, Frank C. Detterbeck, Shawn S. Groth, David H. Harpole, Mark J. Krasna, Kemp Kernstine, Leslie J. Kohman, G. Alexander Patterson, David J. Sugarbaker, Robin T. Vollmer, Michael A. Maddaus, Robert A. Kratzke *J Clin Oncol* vol 34 (13) 1484-1491 2016
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/26926677>
- 1285 CHIO3: Chemotherapy combined with immune checkpoint inhibitor for operable stage IIIA/B non-small cell lung cancer (AFT-46)**
Linda W. Martin, Xiaofei Wang, Jyoti D. Patel, David Kozono, Carly Crocker, James Urbanic, Everett Vokes, Thomas Stinchcombe *J Thorac Oncol* vol 16 (3S) S648 P79.06 2021
Abstract Respiratory [https://www.jto.org/article/S1556-0864\(21\)01227-2/pdf](https://www.jto.org/article/S1556-0864(21)01227-2/pdf)
- 1286 PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer**
M. Martin, A. Prat, A. Rodriguez-Lescure, R. Caballero, M. T. Ebbert, B. Munarriz, M. Ruiz-Borrego, R. R. Bastien, C. Crespo, C. Davis, C. A. Rodriguez, J. M. Lopez-Vega, V. Furio, A. M. Garcia, M. Casas, M. J. Ellis, D. A. Berry, B. N. Pitcher, L. Harris, A. Ruiz, E. Winer, C. Hudis, I. J. Stijleman, D. P. Tuck, E. Carrasco, C. M. Perou, P. S. Bernard *Breast Cancer Res Treat* vol 138 (2) 457-466 2013
Manuscript Correl Sci NOS CALGB-9342, CALGB-9840
<http://www.ncbi.nlm.nih.gov/pubmed/23423445>
- 1287 Evaluating the addition of bevacizumab (Bev) to endocrine therapy as first-line treatment for hormone-receptor positive (HR+)/HER2-negative advanced breast cancer (ABC): Pooled-analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials.**
Miguel Martin, Sibylle Loibl, Terry Hyslop, Juan de la Haba-Rodriguez, Bahriye Aktas, Constance Cirrincione, Eva Maria Carrasco, Keyur Mehta, William Thomas Barry, Serafin Morales, Lisa A. Carey, Jose Angel Garcia Saenz, Ann Partridge, Noelia Martinez, Olwen Mary Hahn, Eric P. Winer, Angel Guerrero, Cliff Hudis, Maribel Casas, Maura N. Dickler *J Clin Oncol* vol 35 (15 suppl) abstr 1012 2017
Abstract Breast http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.1012
- 1288 How Did a Multi-Institutional Trial Show Feasibility of Electronic Data Capture in Older Patients With Cancer? Results From a Multi-Institutional Qualitative Study (Alliance A171902)**
Nichole A. Martin, Elizabeth S. Harlos, Kathryn D. Cook, Jennifer M. O'Connor, Andrew Dodge, Emily Guerard, Jacqueline M. Lafky, Aminah Jatoui, Jennifer G. Le-Rademacher *JCO Clin Cancer Inform* vol 5 442-9 2021
Manuscript Older Adult Alliance-A171603 <http://www.ncbi.nlm.nih.gov/pubmed/33877885>
- 1289 CALGB 50803 (Alliance): A phase 2 trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma**
P. Martin, S.-H. Jung, J. Johnson, R. Elstrom, N. L. Bartlett, K. Blum, T. Shea, J. Leonard, B. Cheson *Hematol Oncol* vol 31 (suppl 1) abstr 063 2013
Abstract Lymphoma <http://onlinelibrary.wiley.com/doi/10.1002/hon.2057/pdf>
- 1290 A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance)**
P Martin, S -H Jung, B Pitcher, N L Bartlett, K A Blum, T Shea, E D Hsi, J Ruan, S E Smith, J P Leonard, B D Cheson *Ann Oncol* vol 28 (11) 2806-12 2017
Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/28945884>
- 1291 A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma**
Peter Martin, Nancy L. Bartlett, Kristie A. Blum, Steven Park, Kami Maddocks, Jia Ruan, LeAnn

Ridling, Christopher Dittus, Zhengming Chen, Xiangao Huang, Giorgio Inghirami, Maurizio DiLiberto, Selina Chen-Kiang, John P. Leonard Blood vol 133 (11) 1201-4 2019
Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/30692121>

1292 Oral Azacitidine (CC-486) Plus R-CHOP in Patients With High-Risk or Previously Untreated Diffuse Large B-Cell Lymphoma, Grade 3B Follicular Lymphoma, or Transformed Lymphoma (AFT-08)

Peter Martin, Nancy L. Bartlett, Julio C. Chavez, John L. Reagan, Sonali M. Smith, Ann LaCasce, Maria Revuelta, Jeffrey Jones, James Drew, Chengqing Wu, Leandro Cerchietti, John P. Leonard Blood vol 132 (Suppl 1) 2964 2018
Abstract Lymphoma http://www.bloodjournal.org/content/132/Suppl_1/2964

1293 A phase I, open-label, multicenter trial of oral azacitidine (CC-486) plus R-CHOP in patients with high-risk, previously untreated diffuse large B-cell lymphoma, grade 3b follicular lymphoma, or transformed lymphoma (AFT-08)

Peter Martin, Nancy L. Bartlett, Ildefonso Ismael Rodriguez-Rivera, Maria Revuelta, Julio C. Chavez, John Reagan, Sonali M. Smith, Ann LaCasce, Lei Zhang, Merry Zhai, Chengqing Wu, John Leonard, Leandro Cerchietti Blood vol 130 (Suppl 1) 192 2017
Abstract Lymphoma http://www.bloodjournal.org/content/130/Suppl_1/192

1294 Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate-to high-risk DLBCL.

Peter Martin, Nancy L Bartlett, Julio C Chavez, John L Reagan, Sonali M Smith, Ann S LaCasce, Jeffrey Jones, James Drew, Chengqing Wu, Erin Mulvey, Maria V Revuelta, Leandro Cerchietti, John P Leonard Blood vol 139 (8) 1147-59 2022
Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/34428285>

1295 CALGB 50803 (Alliance): A phase II trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma

Peter Martin, Sin-Ho Jung, Jeffrey L. Johnson, Brandy Pitcher, Rebecca L. Elstrom, Nancy Bartlett, Kristie A. Blum, Kristy L. Richards, John Leonard, Bruce D. Cheson J Clin Oncol vol 32 (15 suppl) abstr 8521 2014
Abstract Lymphoma http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/8521

1296 Final results of CALGB 50803 (Alliance): A phase 2 trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma

Peter Martin, Sin-Ho Jung, Brandy Pitcher, Nancy Bartlett, Kristy Blum, Thomas Shea, Jia Ruan, Scott Smith, John Leonard, Bruce Cheson Hematol Oncol vol 35 (suppl S2) 51 2017
Abstract Lymphoma http://onlinelibrary.wiley.com/doi/10.1002/hon.2437_34/epdf

1297 Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials.

M Martín, S Loibl, T Hyslop, J De la Haba-Rodríguez, B Aktas, C T Cirrincione, K Mehta, W T Barry, S Morales, L A Carey, J A Garcia-Saenz, A Partridge, N Martinez-Jañez, O Hahn, E Winer, A Guerrero-Zotano, C Hudis, M Casas, C Rodriguez-Martin, J Furlanetto, E Carrasco, M N Dickler Eur J Cancer vol 117 91-8 2019
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/31276981>

1298 A phase II trial of high dose carboplatin and paclitaxel with G-CSF and peripheral blood stem cell support followed by surgery and/or chest radiation in patients with stage III non-small cell lung cancer: CALGB 9531

Gregory A. Masters, Xiaofei Wang, Lydia Hodgson, Thomas Shea, Everett Vokes, Mark Green Lung

1299 Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data

A. Mauguen, J. P. Pignon, S. Burdett, C. Domerg, D. Fisher, R. Paulus, S. J. Mandrekar, C. P. Belani, F. A. Shepherd, T. Eisen, H. Pang, L. Collette, W. T. Sause, S. E. Dahlberg, J. Crawford, M. O'Brien, S. E. Schild, M. Parmar, J. F. Tierney, C. Le Pechoux, S. Michiels *Lancet Oncol* vol 14 (7) 619-26 2013

Manuscript Respiratory CALGB-8831, CALGB-9310, CALGB-9633, NCCTG-892052, NCCTG-902451, NCCTG-942452 <http://www.ncbi.nlm.nih.gov/pubmed/23680111>

1300 Elevated Pre-Treatment Serum Immunoglobulin Free Light Chains (FLC) Are Associated with Poor Event-Free and Overall Survival in Diffuse Large B-Cell Lymphoma (DLBCL)

M. J. Maurer, I. N. Micallef, J. A. Katzmann, D. Nikcevich, T. E. Witzig *ASH Annual Meeting Abstracts* vol 114 (22) abstr 136 2009

Abstract Lymphoma <http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;114/22/136>

1301 Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy

Matthew J. Maurer, Hervé Ghesquières, Jean-Philippe Jais, Thomas E. Witzig, Corinne Haioun, Carrie A. Thompson, Richard Delarue, Ivana N. Micallef, Frédéric Peyrade, William R. Macon, Thierry Jo Molina, Nicolas Ketterer, Sergei I. Syrбу, Olivier Fitoussi, Paul J. Kurtin, Cristine Allmer, Emmanuelle Nicolas-Virelizier, Susan L. Slager, Thomas M. Habermann, Brian K. Link, Gilles Salles, Hervé Tilly, James R. Cerhan *J Clin Oncol* vol 32 (10) 1066-1073 2014

Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/24550425>

1302 Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials

Matthew J. Maurer, Hervé Ghesquières, Brian K. Link, Jean-Philippe Jais, Thomas M. Habermann, Carrie A. Thompson, Corinne Haioun, Cristine Allmer, Patrick B. Johnston, Richard Delarue, Ivana N. Micallef, Frederic Peyrade, David J. Inwards, Nicolas Ketterer, Umar Farooq, Olivier Fitoussi, William R. Macon, Thierry J. Molina, Sergei Syrбу, Andrew L. Feldman, Susan L. Slager, George J. Weiner, Stephen M. Ansell, James R. Cerhan, Gilles A. Salles, Thomas E. Witzig, Hervé Tilly, Grzegorz S. Nowakowski *J Clin Oncol* vol 36 (16) 1603-10 2018

Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/29672223>

1303 Elevated Serum Free Light Chains Are Associated With Event-Free and Overall Survival in Two Independent Cohorts of Patients With Diffuse Large B-Cell Lymphoma

Matthew J. Maurer, Ivana N.M. Micallef, James R. Cerhan, Jerry A. Katzmann, Brian K. Link, Joseph P. Colgan, Thomas M. Habermann, David J. Inwards, Svetomir N. Markovic, Stephen M. Ansell, Luis F. Porrata, Patrick B. Johnston, Grzegorz S. Nowakowski, Carrie A. Thompson, Mamta Gupta, Sergei I. Syrбу, Paul J. Kurtin, William R. Macon, Daniel A. Nikcevich, Thomas E. Witzig *J Clin Oncol* vol 29 (12) 1620-1626 2011

Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/21383282>

1304 Diagnosis to treatment interval (DTI) is associated with adverse outcome in newly diagnosed patients with mantle cell lymphoma, a MER/LEO and Alliance collaboration

Matthew J. Maurer, Amy S. Ruppert, Brian K. Link, Lawrence D. Kaplan, David Inwards, Andrew Feldman, Eric D. Hsi, Adam Pettinger, Jonathon Cohen, Peter Martin, Brad Kahl, Nancy Bartlett, James R. Cerhan, John P. Leonard, Thomas M. Habermann *Blood* vol 132 (suppl 1) 2878 2018

Abstract Lymphoma http://www.bloodjournal.org/content/132/Suppl_1/2878

1305 Treatment exposure and discontinuation in the PALLAS trial: PALbociclib CoLLaborative Adjuvant Study of palbociclib with adjuvant endocrine therapy for HR+/HER2- early breast cancer (AFT-05)

Erica L. Mayer, Christian Fesl, Amylou Dueck, Michael Gnant, Angela DeMichele 2020
Abstract Breast <https://www.abstractsonline.com/pp8/#!/9223/presentation/783>

1306 PALLAS: A randomized phase III trial of adjuvant palbociclib with endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast cancer

Erica L. Mayer, Michael Gnant, Angela DeMichele, Miguel Martin, Harold J. Burstein, Aleix Prat, Gabor Rubovszky, Kathy Miller, George Pfeiler, Eric P. Winer, Nicholas Zdenkowski, Daniel Anderson, Zbigniew Nowecki, Sibylle Loibl, Hannes Fohler, Otto Metzger, Debora Fumagalli, Kathy Puyana Theall, Christian Fesl, Amylou C. Dueck Annals of Oncology vol 31 (Supplement 4) S1145 2020
Abstract Breast [https://www.annalsofoncology.org/article/S0923-7534\(20\)42322-1/fulltext](https://www.annalsofoncology.org/article/S0923-7534(20)42322-1/fulltext)

1307 Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study.

Erica L Mayer, Amylou C Dueck, Miguel Martin, Gabor Rubovszky, Harold J Burstein, Meritxell Bellet-Ezquerria, Kathy D Miller, Nicholas Zdenkowski, Eric P Winer, Georg Pfeiler, Matthew Goetz, Manuel Ruiz-Borrego, Daniel Anderson, Zbigniew Nowecki, Sibylle Loibl, Stacy Moulder, Alistair Ring, Florian Fitzal, Tiffany Traina, Arlene Chan, Hope S Rugo, Julie Lemieux, Fernando Henao, Alan Lyss, Silvia Antolin Novoa, Antonio C Wolff, Marcus Vetter, Daniel Egle, Patrick G Morris, Eleftherios P Mamounas, Miguel J Gil-Gil, Aleix Prat, Hannes Fohler, Otto Metzger Filho, Magdalena Schwarz, Carter DuFrane, Debora Fumagalli, Kathy Puyana Theall, Dongrui Ray Lu, Cynthia Huang Bartlett, Maria Koehler, Christian Fesl, Angela DeMichele, Michael Gnant Lancet Oncol vol 22 (2) 212-22 2021
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/33460574>

1308 Treatment Exposure and Discontinuation in the PALbociclib CoLLaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03).

Erica L Mayer, Christian Fesl, Dominik Hlauschek, Laura Garcia-Estevez, Harold J Burstein, Nicholas Zdenkowski, Viktor Wette, Kathy D Miller, Marija Balic, Ingrid A Mayer, David Cameron, Eric P Winer, José Juan Ponce Lorenzo, Diana Lake, Gunda Pristauz-Telsnigg, Tufia C Haddad, Lois Shepherd, Hiroji Iwata, Matthew Goetz, Fatima Cardoso, Tiffany A Traina, Dhanusha Sabanathan, Urs Breitenstein, Kerstin Ackerl, Otto Metzger Filho, Karin Zehetner, Kadine Solomon, Sarra El-Abed, Kathy Puyana Theall, Dongrui Ray Lu, Amylou Dueck, Michael Gnant, Angela DeMichele J Clin Oncol vol 40 (5) 449-58 2022
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/34995105>

1309 How Much Missing Data is Too Much? Monte Carlo Simulations to Develop SISAQOL Guidelines for Missing Data Handling.

Gina L. Mazza, Corneel Coens, Madeline Pe, Lien Dorme, Kathy Oliver, Andrew Bottomley, Jeff A. Sloan, Amylou C. Dueck Qual Life Res vol 27 (suppl 1) abst 2018.1 2018
Abstract Health Outcomes
<https://link.springer.com/content/pdf/10.1007%2Fs11136-018-1946-9.pdf>

1310 Missing data strategies for the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Alliance A091105 and COMET-2

Gina L. Mazza, Molly M. Petersen, Brenda Ginos, Blake T. Langlais, Narre Heon, Mrinal M. Gounder, Michelle R. Mahoney, Alexander J. Zoroufy, Gary K. Schwartz, Lauren J. Rogak, Gita Thanarajasingam, Ethan Basch, Amylou C. Dueck Qual Life Res vol 31 (4) 1069-80 2022
Manuscript Health Outcomes Alliance-A091105 <http://www.ncbi.nlm.nih.gov/pubmed/34420143>

- 1311 Incorporating Clinicians' CTCAE Grades as Auxiliary Variables When Imputing Patients' PRO-CTCAE Scores via Multiple Imputation in Alliance A091105**
Gina L. Mazza, Molly M. Petersen, Lauren J. Rogak, Mrinal M. Gounder, Michelle R. Mahoney, Gary K. Schwartz, Gita Thanarajasingam, Ethan Basch, Amylou C. Dueck Quality of Life Research vol 29 (Suppl 1) S83 2020
Abstract Health Outcomes Alliance-A091105
<https://link.springer.com/content/pdf/10.1007/s11136-020-02626-y.pdf>
- 1312 Overall and Progression-Free Survival Adjusted for Treatment Crossover in the CALGB 100104 Study of Lenalidomide Versus Placebo Maintenance After Stem Cell Transplant for Patients With Newly Diagnosed Multiple Myeloma (Alliance)**
Philip L. McCarthy, Sarah A. Holstein, Sin-Ho Jung, Miranda Cooper, Craig J. Gibson, Edward A. Stadtmauer, Benjamin Winograd, Paul Richardson 2017
Abstract Myeloma
[http://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650\(17\)30534-7/abstract](http://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(17)30534-7/abstract)
- 1313 Lenalidomide vs Placebo Maintenance After Stem Cell Transplant for Patients With Multiple Myeloma: Overall Survival and Progression-Free Survival After Adjusting for Treatment Crossover in CALGB**
Philip L. McCarthy, Sarah A. Holstein, Sin-Ho Jung, Miranda Cooper, Craig J. Gibson, Edward A. Stadtmauer, Benjamin Winograd, Paul Richardson Haematologica vol 102 (S2) p 108, abstr p332 2017
Abstract Myeloma <http://www.haematologica.org/content/102/s2/1.full.pdf+html>
- 1314 CALGB/ECOG 100104 (Alliance) Study: Lenalidomide (LEN) vs Placebo (PBO) Maintenance (Maint) After Stem Cell Transplant (SCT) for Patients (Pts) With Multiple Myeloma: Overall Survival (OS) and Progression-Free Survival (PFS) Adjusted for Treatment (Tx) Crossover (XO)**
Philip L. McCarthy, Sarah A. Holstein, Sin-Ho Jung, Miranda Cooper, Craig J. Gibson, Edward A. Stadtmauer, Benjamin Winograd, Paul Richardson J Clin Oncol vol 35 (15 suppl) abstr 8037 2017
Abstract Myeloma http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.8037
- 1315 Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis**
Philip L. McCarthy, Sarah A. Holstein, Maria Teresa Petrucci, Paul G. Richardson, Cyrille Hulin, Patrizia Tosi, Sara Brinthen, Pellegrino Musto, Kenneth C. Anderson, Denis Caillot, Francesca Gay, Philippe Moreau, Gerald Marit, Sin-Ho Jung, Zhinuan Yu, Benjamin Winograd, Robert D. Knight, Antonio Palumbo, Michel Attal J Clin Oncol vol 35 (29) 3279-89 2017
Manuscript Myeloma <http://www.ncbi.nlm.nih.gov/pubmed/28742454>
- 1316 Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma**
Philip L. McCarthy, Kouros Owzar, Craig C. Hofmeister, David D. Hurd, Hani Hassoun, Paul G. Richardson, Sergio Giralt, Edward A. Stadtmauer, Daniel J. Weisdorf, Ravi Vij, Jan S. Moreb, Natalie Scott Callander, Koen Van Besien, Teresa Gentile, Luis Isola, Richard T. Maziarz, Don A. Gabriel, Asad Bashey, Heather Landau, Thomas Martin, Muzaffar H. Qazilbash, Denise Levitan, Brian McClune, Robert Schlossman, Vera Hars, John Postiglione, Chen Jiang, Elizabeth Bennett, Susan Barry, Linda Bressler, Michael Kelly, Michele Seiler, Cara Rosenbaum, Parameswaran Hari, Marcelo C. Pasquini, Mary M. Horowitz, Thomas C. Shea, Steven M. Devine, Kenneth C. Anderson, Charles Linker N Engl J Med vol 366 (19) 1770-1781 2012
Manuscript Myeloma <http://www.ncbi.nlm.nih.gov/pubmed/22571201>
- 1317 Survival analysis from the CALGB trial of lenalidomide (LEN) maintenance therapy in newly diagnosed multiple myeloma (NDMM) post-autologous stem cell transplant (ASCT), adjusting for**

crossover (Alliance)

Philip L. McCarthy, Vera Suman, Miranda Cooper, Owain Saunders, Paul Richardson, Sujith Dhanasiri, Sergio Giral, Ken Anderson, Ed Stadtmauer, Sarah A. Holstein Blood vol 132 (Suppl 1) 4737 2018

Abstract Myeloma http://www.bloodjournal.org/content/132/Suppl_1/4737?sso-checked=true

1318 A phase III trial evaluating the combination of cisplatin, etoposide, and radiation therapy with or without tamoxifen in patients with limited-stage small cell lung cancer: Cancer and Leukemia Group B Study (9235).

Edward F McClay, Jeff Bogart, James E Herndon, Dee Watson, Lisa Evans, Steven L Seagren, Mark R Green Am J Clin Oncol vol 28 (1) 81-90 2005

Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/15685040>

1319 Impact of Age on the Efficacy of Newer Adjuvant Therapies in Patients With Stage II/III Colon Cancer: Findings From the ACCENT Database

Nadine J. McCleary, Jeffrey A. Meyerhardt, Erin Green, Greg Yothers, Aimery de Gramont, Eric Van Cutsem, Michael O'Connell, Christopher J. Twelves, Leonard B. Saltz, Daniel G. Haller, Daniel J. Sargent J Clin Oncol vol 31 (20) 2600-2606 2013

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/23733765>

1320 Age and comorbidity association with survival outcomes in metastatic colorectal cancer: CALGB 80405 analysis

Nadine J. McCleary, Sui Zhang, Chao Ma, Fang-Shu Ou, Tiffany M. Bainter, Alan P. Venook, Donna Niedzwiecki, Heinz-Josef Lenz, Federico Innocenti, Bert H. O'Neil, Blase N. Polite, Howard S.

Hochster, James N. Atkins, Richard M. Goldberg, Kimmie Ng, Robert J. Mayer, Charles D. Blanke,

Eileen M. O'Reilly, Charles S. Fuchs, Jeffrey A. Meyerhardt J Geriatr Oncol vol 13 (4) 469-79 2022

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/35105521>

1321 Challenges of conducting a prospective clinical trial for older patients: Lessons learned from NCCTG N0949 (Alliance)

Nadine J McCleary, Joleen Hubbard, Michelle R Mahoney, Jeffrey A Meyerhardt, Daniel Sargent, Alan Venook, Axel Grothey J Geriatr Oncol vol 9 (1) 24-31 2018

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/28917648>

1322 Impact of smoking on patients with stage III colon cancer: Results from CALGB 89803

Nadine Jackson McCleary, Donna Niedzwiecki, Donna Hollis, Leonard B. Saltz, Paul Schaefer,

Renaud Whittom, Alexander Hantel, Al Benson, Richard Goldberg, Jeffrey A. Meyerhardt Cancer vol 116 (4) 957-966 2010

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/20052723>

1323 Association between molecular subtype membership or hypoxia-associated gene expression signatures and clinical outcomes in the CALGB 90601 (Alliance) Phase 3 clinical trial of Gemcitabine and Cisplatin (GC) plus bevacizumab (B) or placebo (P)

David J McConkey, Woonyoung Choi, Susan Halabi, Bin Luo, Hikmat Al-Ahmadie, Jonathan E. Rosenberg, Jack Mountain, Ashley M. Regazzi, Megan Fong, Gopa Iyer, Eli Van Allen, Kent W.

Mouw, Yujia Wen, Linda McCart, Karla V. Ballman, Misha Beltran, Michael J. Morris J Clin Oncol vol 40 (16_suppl) 4562-4562 2022

Abstract GU https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.4562

1324 Concordance of HER2 Central Assessment by Two International Central Laboratories: a ring study within the framework of the Adjuvant HER2-Positive ALTTO Trial (BIG2-06/N063D/EGF106708).

AE McCullough, P Dell'Orto, MM Reinholz, RD Gelber, AC Dueck, L Russo, RB Jenkins, S

Andrighetto, B Chen, WL Lingle, C Jackisch, EA Perez, MJ Piccart-Gebhart, G. Viale *Cancer Res* vol 70 (24, suppl 2) abstr P3-10-36 2010

Abstract Breast http://cancerres.aacrjournals.org/content/70/24_Supplement/P3-10-36.abstract

1325 Central Pathology Laboratory Review of HER2 and ER in Early Breast Cancer: An ALTO Trial [BIG 2-06 / NCCTG N063D (Alliance)] Ring Study

Ann E. McCullough, Patrizia Dell'Orto, Monica M. Reinholz, Richard D. Gelber, Amylou C. Dueck, Leila Russo, Robert B. Jenkins, Stefania Andrighetto, Beiyun Chen, Christian Jackisch, Michael Untch, Edith A. Perez, Martine J. Piccart-Gebhart *Breast Cancer Res Treat* vol 143 (3) 485-492 2014
Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/24395109>

1326 Baseline Quality of Life is a Strong and Independent Prognostic Factor for Overall Survival in Metastatic Colorectal Cancer

Patrick McGarrah, Joleen Hubbard, Paul J. Novotny, Megan E. Branda, Daniel S. Sargent, Roscoe F. Morton, Charles S. Fuchs, Al B. Benson, Stephen K. Williamson, Brian P. Findlay, Steven R. Alberts, Richard M. Goldberg, Jeff A. Sloan *Cancer Control* vol 30 2023
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/37339926>

1327 A randomized trial of radium-223 (Ra-223) dichloride and cabozantinib in patients (pts) with advanced renal cell carcinoma (RCC) with bone metastases (RADICAL / Alliance A031801)

Rana R. McKay, Pamela Atherton, Heather Jacene, Veronique Marcotte, Archana Ajmera, Shiva Baghaie, Janet Koball, Tyler Zemla, Ronald C. Chen, Atish Choudhury, Joshua M. Lang, Suzanne Cole, Mamta Parikh, Tareq Al Baghdadi, Young Kwok, Alan Tan, Himisha Beltran, Daniel George, Michael J. Morris, Toni K. Choueiri 71 2022
Abstract GU
<https://kcrs.kidneycan.org/wp-content/uploads/2022/10/Abstracts-Book-KCRS22-website-v4.pdf>

1328 A randomized trial of radium-223 dichloride and cabozantinib in patients with advanced renal cell carcinoma (RCC) with bone metastases (RADICAL / Alliance A031801)

Rana R. McKay, Heather Jacene, Pamela Atherton, Gabriela Perez-Burbano, Archana Ajmera, Shiva Baghaie, Janet Koball, Tyler Zemla, Ron Chen, Atish Choudhury, Joshua M. Lang, Suzanne Cole, Tareq Al Baghdadi, Young Kwok, Himisha Beltran, Daniel George, Michael Morris, Toni K. Choueiri
J Clin Oncol vol 39 (no. 15_suppl) TPS4593 2021
Abstract GU https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.TPS4593

1329 Exploring Therapeutic Decisions in Elderly Patients with Non-Small Cell Lung Cancer: Results and Conclusions from North Central Cancer Treatment Group Study N0222

Heidi McKean, Philip J. Stella, Shauna L. Hillman, Kendrith M. Rowland, Michael W. Cannon, Robert J. Behrens, Gerald G. Gross, Mark D. Sborov, Eliot L. Friedman, Aminah Jatoi *Cancer Invest* vol 29 (4) 266-271 2011
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/21345074>

1330 Pharmacogenetic Predictors of Adverse Events and Response to Chemotherapy in Metastatic Colorectal Cancer: Results From North American Gastrointestinal Intergroup Trial N9741

Howard L. McLeod, Daniel J. Sargent, Sharon Marsh, Erin M. Green, Cristi R. King, Charles S. Fuchs, Ramesh K. Ramanathan, Stephen K. Williamson, Brian P. Findlay, Stephen N. Thibodeau, Axel Grothey, Roscoe F. Morton, Richard M. Goldberg *J Clin Oncol* vol 28 (20) 3227-3233 2010
Manuscript PPP <http://www.ncbi.nlm.nih.gov/pubmed/20530282>

1331 Influence of 6q22-23 on overall survival in primary central nervous system lymphoma. Analysis of North Central Cancer Treatment Group trials 86 72 52, 93 73 51 and 96 73 51

Ellen R. McPhail, Mark E. Law, Paul A. Decker, Brian P. O'Neill *Br J Haematol* vol 154 (1) 146-150 2011

- 1332 NCCTG N0879 (Alliance): A randomized phase II trial of carboplatin, paclitaxel, bevacizumab, with or without everolimus for therapy of metastatic malignant melanoma**
Robert R. McWilliams, Jake Allred, Lisa Kottschade, Lori Erickson, Kandelaria Rumilla, Mamta Gupta, Roxana S. Dronca, Rajini Katipamula, Svetomir N. Markovic Eur J Cancer vol 51 (S672) abstr 3324 2015
Abstract Experimental
<http://www.ejancer.com/action/doSearch?searchType=quick&searchText=McWilliams&occurrences=a>
- 1333 NCCTG N0543 (Alliance): A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma**
Robert R. McWilliams, Nathan R. Foster, Michelle R. Mahoney, Thomas C. Smyrk, Joseph A. Murray, Matthew M. Ames, Elise Horvath, Daniel Schneider, Timothy J. Hobday, Aminah Jatoui, Jeffrey P. Meyers, Matthew P. Goetz Cancer vol 123 (18) 3494-501 2017
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/28493308>
- 1334 NCCTG N0879 (Alliance): A randomized phase 2 cooperative group trial of carboplatin, paclitaxel, and bevacizumab±everolimus for metastatic melanoma.**
Robert R McWilliams, Jacob B Allred, Jessica A Slostad, Rajini Katipamula, Roxana S Dronca, Kandelaria M Rumilla, Lori A Erickson, Alan H Bryce, Richard W Joseph, Lisa A Kottschade, David M King, John M Leitch, Svetomir N Markovic Cancer vol 124 (3) 537-45 2018
Manuscript Experimental <http://www.ncbi.nlm.nih.gov/pubmed/29044496>
- 1335 Phase II trial of oxaliplatin/irinotecan/5-fluorouracil/leucovorin for metastatic colorectal cancer.**
Robert R McWilliams, Matthew P Goetz, Bruce W Morlan, Muhammad Salim, Kendrith M Rowland, James E Krook, Matthew M Ames, Charles Erlichman Clin Colorectal Cancer vol 6 (7) 516-21 2007
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/17553200>
- 1336 Microscopically positive margins for primary gastrointestinal stromal tumors: analysis of risk factors and tumor recurrence**
M. D. Mccarter, C. R. Antonescu, K. V. Ballman, R. G. Maki, P. W. Pisters, G. D. Demetri, C. D. Blanke, M. Von Mehren, M. F. Brennan, L. Mccall, D. M. Ota, R. P. Dematteo J Am Coll Surg vol 215 (1) 53-59; discussion 59-60 2012
Manuscript GI ACOSOG-Z9000, ACOSOG-Z9001 <http://www.ncbi.nlm.nih.gov/pubmed/22726733>
- 1337 Phase III intergroup study of lenalidomide (CC-5013) versus placebo maintenance therapy following single autologous stem cell transplant for multiple myeloma (CALGB 100104): Initial report of patient accrual and adverse events**
P. L. Mccarthy, C. Linker, C. C. Hofmeister, K. Owzar, E. Stadtmauer, K. C. Anderson, P. Richardson, D. D. Hurd, D. J. Weisdorf J Clin Oncol vol 28 (15s) Poster Board III-353 2010
Abstract Transplant <https://ash.confex.com/ash/2009/webprogram/Paper22181.html>
- 1338 Phase III Intergroup Study of Lenalidomide Versus Placebo Maintenance Therapy Following Single Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Myeloma: CALGB 100104**
P. L. Mccarthy, K. Owzar, K. C. Anderson, C. C. Hofmeister, D. D. Hurd, H. Hassoun, S. Giralt, E. A. Stadtmauer, P. G. Richardson, D. J. Weisdorf, R. Vij, J. S. Moreb, N. S. Callander, K. Van Besien, T. Gentile, L. Isola, R. T. Maziarz, D. A. Gabriel, A. Bashey, H. Landau, T. Martin, M. H. Qazilbash, D.

Levitan, B. McClune, V. Hars, J. Postiglione, C. Jiang, E. Bennett, S. S. Barry, L. Bressler, M. Kelly, M. Sexton, C. Rosenbaum, H. Parameswaran, M. C. Pasquini, M. M. Horowitz, T. C. Shea, S. M. Devine, C. Linker *Blood* vol 116 (21) -37 2010
Abstract Transplant <http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;116/21/37>

1339 Analysis Of Overall Survival (OS) In The Context Of Cross-Over From Placebo To Lenalidomide And The Incidence Of Second Primary Malignancies (SPM) In The Phase III Study Of Lenalidomide Versus Placebo Maintenance Therapy Following Autologous Stem Cell Transplant (ASCT) For Multiple Myeloma (MM) CALGB (Alliance) ECOG BMT-CTN 100104

P. Mccarthy, K. Owzar, C. Hofmeister, P. Richardson, H. Hassoun, E. Stadtmauer, S. Giralt, D. Hurd, M. Qazilbash, B. McClune, M. Pasquini, V. Hars, C. Jiang, J. Postiglione, M. Kelly, L. Bressler, S. Devine, K. Anderson, C. Linker *Clin Lymphoma Myeloma Leuk* vol 13 (suppl 1) S28 2013
Abstract Myeloma
<http://www.sciencedirect.com/science/article/pii/S2152265013000372/pdf?md5=87528f83cd37541b24>

1340 Impact of older age on the efficacy of newer adjuvant therapies in >12,500 patients (pts) with stage II/III colon cancer: Findings from the ACCENT Database

N. A. J. Mccleary, J. Meyerhardt, E. Green, G. Yothers, A. Degramont, E. Van Cutsem, M. O'Connell, C. Twelves, L. Saltz, D. Sargent, T. a. C. Group *J Clin Oncol* vol 27 (15s, (suppl)) abstr 4010 2009
Abstract GI
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID

1341 100% Concordance between IHC and FISH HER2 Testing Cannot Be Achieved Using N9831 Cohort

A. E. Mccullough, B. Chen, D. W. Hillman, K. S. Tenner, R. B. Jenkins, M. M. Reinholz, W. L. Lingle, A. C. Dueck, E. A. Perez *Lab Invest* vol 90 (Suppl 1) 62A, abstr 267 2010
Abstract Breast <http://www.nature.com/labinvest/journal/v90/n1s/pdf/labinvest201011a.pdf>

1342 Cellular transporter pharmacogenetics in metastatic colorectal cancer: Initial analysis of C80203

H. L. Mcleod, K. Owzar, D. L. Kroetz, F. Innocenti, S. Das, P. N. Friedman, K. Giacomini, R. M. Goldberg, A. P. Venook, M. J. Ratain *J Clin Oncol* vol 26 (May 20 suppl) abstr 3513 2008
Abstract PPP
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID

1343 NCCTG phase I/II trial (N9943) of gemcitabine and pemetrexed in patients with biliary tract or gallbladder carcinoma: phase II results

R. R. Mcwilliams, N. R. Foster, F. J. Quevedo, R. F. Marschke, J. W. Kugler, E. L. Friedman, A. J. Jaslowski, J. R. Sande, S. R. Alberts *J Clin Oncol* vol 25 (18S) abstr 4578 2007
Abstract GI
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID

1344 Pharmacogenetic dosing by UGT1A1 genotype as first-line therapy for advanced small-bowel adenocarcinoma: A North Central Cancer Treatment Group (NCCTG) trial

R. R. Mcwilliams, M. R. Mahoney, B. T. Marchello, A. Jatoi, K. D. Krewer, M. M. Ames, D. J. Schneider, G. R. Seeger, R. B. Mowat, S. R. Alberts, M. P. Goetz *J Clin Oncol* vol 30 (4 suppl) abstr 314 2012
Abstract GI
http://meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/7605?sid=3a6df366-f524-429a-860c-c83e9

1345 A comprehensive analysis of clinical and tumor characteristics with BRAF and KRAS mutations status in adjuvant colon cancer trial N0147.

R. R. Mcwilliams, M. R. Mahoney, D. J. Sargent, G. D. Nelson, F. Sinicrope, P. J. Limburg, S. N.

Thibodeau, A. Grothey, J. M. Hubbard, S. R. Alberts J Clin Oncol vol 30 (Suppl 4) abstr 446 2012
Abstract Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/27983178>

1346 Phase II trial of oxaliplatin, irinotecan, 5-fluorouracil, and leucovorin for metastatic colorectal cancer

R. McWilliams, M. Goetz, B. Morlan, M. Salim, K. Rowland Jr, J. Krook, M. Ames, C. Erlichman
Gastrointestinal Cancers Symposium abstr 383 2007
Abstract GI
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=45&abstractID

1347 Kinetic-Pharmacodynamic Model of Chemotherapy Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel or Ixabepilone: CALGB 40502 (Alliance)

Shailly Mehrotra, Manish R. Sharma, Elizabeth Gray, Kehua Wu, William T. Barry, Clifford Hudis, Eric P. Winer, Alan P. Lyss, Deborah L. Toppmeyer, Alvaro Moreno-Aspitia, Thomas E. Lad, Mario Valasco, Beth Overmoyer, Hope Rugo, Mark J. Ratain, Jogarao V. Gobburu AAPS J vol 19 (5) 1411-23 2017
Manuscript PPP <http://www.ncbi.nlm.nih.gov/pubmed/28620884>

1348 Alliance A059102: A Randomized Phase II US Intergroup Study of CHO(E)P vs CC-486-CHO(E)P vs DUVELISIB-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-Cell Lymphomas

Neha Mehta-Shah, Susan Geyer, Nancy Bartlett, Stefan Barta, Jennifer Amengual, Travis Dockter, Chadwick Wright, Eric Hsi, Shira N. Dinner, Steven Horwitz, Brad Kahl, Jonathan Friedberg, John Leonard 2022
Abstract Lymphoma
https://bioascend.com/wp-content/uploads/2022/05/S11_Mehta-Shah-Neha_-IUCLS-Histology-based-th

1349 Alliance A059102: A Randomized Phase II US Intergroup Study of CHO(E)P vs CC-486-CHO(E)P vs DUVELISIB-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-Cell Lymphomas

Neha Mehta-Shah, Susan Geyer, Nancy Bartlett, Stefan Barta, Jennifer Amengual, Travis Dockter, Chadwick Wright, Eric Hsi, Shira N. Dinner, Steven Horwitz, Brad Kahl, Jonathan Friedberg, John Leonard J Clin Oncol vol 40 (16_suppl) TPS7593-TPS7593 2022
Abstract Lymphoma https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.TPS7593

1350 Molecular Landscape in AML pts from Mexico as an initial study to identify healthcare disparities in Hispanic populations (Alliance).

Nuria Mencia-Trinchant, Jessica Kohlschmidt, Alexandra Gomez-Arteaga, John C. Byrd, Geoffrey Uy, Wendy Stock, Krzysztof Mrózek, Andrew J. Carroll, Richard Stone, Eileen I. Pacheco, Adolfo Martinez Tovar, Irma Olarte Carrillo, Anel Garcia Laguna, Christian Ramos Penafiel, Duane C. Hassane, Ann-Kathrin Einfeld, Monica L. Guzman Blood vol 140 (suppl 1) 11009-10 2022
Abstract Leuk Corr Sci CALGB-20202, CALGB-8461, CALGB-9665
<https://ashpublications.org/blood/article/140/Supplement%201/11009/491493/Molecular-Landscape-in-A>

1351 Poor Outcome of RUNX1-Mutated (RUNX1-mut) Patients (Pts) with Primary, Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) and Associated Gene- and MicroRNA (miR) Expression Signatures

J. H. Mendler, K. Maharry, M. D. Radmacher, K. Mrozek, J. Kohlschmidt, D. Nicolet, H. Becker, K. H. Metzeler, S. Schwind, S. P. Whitman, W. Blum, B. L. Powell, J. E. Kolitz, T. H. Carter, M. Wetzler, J. O. Moore, A. J. Carroll, M. R. Baer, R. A. Larson, M. A. Caligiuri, G. Marcucci, C. D. Bloomfield Blood vol 118 (21) -3454 2011
Abstract Leuk Corr Sci CALGB-8525, CALGB-10201, CALGB-19808, CALGB-8923,

CALGB-9420, CALGB-9621, CALGB-9720

<http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;118/21/3454>

1352 RUNX1 Mutations Are Associated With Poor Outcome in Younger and Older Patients With Cytogenetically Normal Acute Myeloid Leukemia and With Distinct Gene and MicroRNA Expression Signatures

Jason H. Mendler, Kati Maharry, Michael D. Radmacher, Krzysztof Mrózek, Heiko Becker, Klaus H. Metzeler, Sebastian Schwind, Susan P. Whitman, Jihane Khalife, Jessica Kohlschmidt, Deedra Nicolet, Bayard L. Powell, Thomas H. Carter, Meir Wetzler, Joseph O. Moore, Jonathan E. Kolitz, Maria R. Baer, Andrew J. Carroll, Richard A. Larson, Michael A. Caligiuri, Guido Marcucci, Clara D. Bloomfield J Clin Oncol vol 30 (25) 3109-3118 2012
Manuscript Leuk Corr Sci CALGB-8525, CALGB-8461, CALGB-8923, CALGB-9420, CALGB-9621, CALGB-9665, CALGB-9720, CALGB-10201, CALGB-19808, CALGB-20202
<http://www.ncbi.nlm.nih.gov/pubmed/22753902>

1353 Combined-modality therapy of poor prognosis anal canal carcinoma: a phase II study of the Cancer and Leukemia Group B (CALGB)

N. J. Meropol, D. Niedzwiecki, B. Shank, T. Colacchio, J. Ellerton, F. Valone, D. Hollis, S. Budinger, J. M. Dowell, R. J. Mayer Gastrointestinal Cancers Symposium abstr 238 2005
Abstract GI
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=36&abstractID

1354 Induction therapy for poor-prognosis anal canal carcinoma: a phase II study of the Cancer and Leukemia Group B (CALGB 9281).

Neal J Meropol, Donna Niedzwiecki, Brenda Shank, Thomas A Colacchio, John Ellerton, Frank Valone, Susan Budinger, Jeannette M Day, Judy Hopkins, Joel Tepper, Richard M Goldberg, Robert J Mayer J Clin Oncol vol 26 (19) 3229-34 2008
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/18490648>

1355 ASXL1 Mutations Identify a High-Risk Subgroup of Older Patients with Primary Cytogenetically Normal Acute Myeloid Leukemia within the European LeukemiaNet 'Favorable' Genetic Category

K. H. Metzeler, H. Becker, K. Maharry, M. D. Radmacher, J. Kohlschmidt, K. Mrozek, D. Nicolet, S. P. Whitman, Y.-Z. Wu, S. Schwind, B. L. Powell, T. H. Carter, M. Wetzler, J. O. Moore, J. E. Kolitz, M. R. Baer, A. J. Carroll, R. A. Larson, M. A. Caligiuri, G. Marcucci, C. D. Bloomfield Blood vol 118 (21) -417 2011
Abstract Leuk Corr Sci CALGB-20202, CALGB-8461, CALGB-9665
<http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;118/21/417>

1356 An 86-Probe Gene Expression Signature Can Predict Survival in AML with Normal Karyotype Independently of FLT3 ITD and NPM1 Mutation Status - A Collaborative Study from the AMLCG and CALGB Study Groups

K. H. Metzeler, M. Hummel, C. D. Bloomfield, K. Spiekermann, M. C. Sauerland, A. Heinecke, M. Radmacher, G. Marcucci, S. P. Whitman, K. Maharry, P. Paschka, R. A. Larson, W. E. Berdel, T. Buchner, B. Wormann, U. Mansmann, W. Hiddemann, S. K. Bohlander, C. Buske Blood vol 110 (11) -596 2007
Abstract Leuk Corr Sci CALGB-8461, CALGB-9621, CALGB-9665
<http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;110/11/596>

1357 TET2 mutations occur in over 20% of adults with de novo cytogenetically normal AML, and their prevalence increases with age: A Cancer and Leukemia Group B study.

K. H. Metzeler, K. Maharry, D. Margeson, J. Curfman, H. Becker, M. D. Radmacher, K. Mrózek, K. Holland, S. P. Whitman, Y.-Z. Wu, S. Schwind, W. Blum, B. L. Powell, T. H. Carter, M. R. Baer, A. J.

Carroll, J. O. Moore, J. E. Kolitz, R. A. Larson, M. A. Caligiuri, G. Marcucci, C. D. Bloomfield
Haematologica vol 95 (Supplement) 2010
Abstract Leuk Corr Sci CALGB-8525, CALGB-10201, CALGB-19808, CALGB-20202,
CALGB-20502, CALGB-8461, CALGB-8923, CALGB-9420, CALGB-9621, CALGB-9665,
CALGB-9720 http://www.haematologica.org/content/95/supplement_2/1.full.pdf

1358 Mutations In the Tet Oncogene Family Member 2 (TET2) Gene Refine the New European LeukemiaNet Risk Classification of Primary, Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) In Adults: A Cancer and Leukemia Group B (CALGB) Study

K. H. Metzeler, K. Maharry, M. D. Radmacher, K. Mrozek, D. Margeson, H. Becker, J. Curfman, K. B. Holland, S. Schwind, S. P. Whitman, Y.-Z. Wu, W. Blum, B. L. Powell, T. H. Carter, M. Wetzler, J. O. Moore, J. E. Kolitz, M. R. Baer, A. J. Carroll, R. A. Larson, M. A. Caligiuri, G. Marcucci, C. D. Bloomfield Blood vol 116 (21) -98 2010
Abstract Leuk Corr Sci CALGB-8525, CALGB-8641, CALGB-10201, CALGB-19808,
CALGB-20202, CALGB-20502, CALGB-8923, CALGB-9420, CALGB-9621, CALGB-9665,
CALGB-9720 <http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;116/21/98>

1359 A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia

KH Metzeler, K Maharry, J Kohlschmidt, S Volinia, K Mrózek, H Becker, D Nicolet, SP Whitman, JH Mendler, S Schwind, A-K Eisfeld, Y-Z Wu, BL Powell, TH Carter, M Wetzler, JE Kolitz, MR Baer, AJ Carroll, RM Stone, MA Caligiuri, G Marcucci, CD Bloomfield Leukemia vol 27 (10) 2023-2031 2013
Manuscript Leuk Corr Sci CALGB-8461, CALGB-9665, CALGB-20202
<http://www.ncbi.nlm.nih.gov/pubmed/23765227>

1360 ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category

Klaus H. Metzeler, Heiko Becker, Kati Maharry, Michael D. Radmacher, Jessica Kohlschmidt, Krzysztof Mrózek, Deedra Nicolet, Susan P. Whitman, Yue-Zhong Wu, Sebastian Schwind, Bayard L. Powell, Thomas H. Carter, Meir Wetzler, Joseph O. Moore, Jonathan E. Kolitz, Maria R. Baer, Andrew J. Carroll, Richard A. Larson, Michael A. Caligiuri, Guido Marcucci, Clara D. Bloomfield Blood vol 118 (26) 6920-6929 2011
Manuscript Leuk Corr Sci CALGB-20202, CALGB-8461, CALGB-9665
<http://www.ncbi.nlm.nih.gov/pubmed/22031865>

1361 An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia

Klaus H. Metzeler, Manuela Hummel, Clara D. Bloomfield, Karsten Spiekermann, Jan Braess, Maria-Cristina Sauerland, Achim Heinecke, Michael Radmacher, Guido Marcucci, Susan P. Whitman, Kati Maharry, Peter Paschka, Richard A. Larson, Wolfgang E. Berdel, Thomas Büchner, Bernhard Wörmann, Ulrich Mansmann, Wolfgang Hiddemann, Stefan K. Bohlander, Christian Buske Blood vol 112 (10) 4193-201 2008
Manuscript Leuk Corr Sci CALGB-8461, CALGB-9621, CALGB-9665
<http://www.ncbi.nlm.nih.gov/pubmed/18716133>

1362 TET2 Mutations Improve the New European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

Klaus H. Metzeler, Kati Maharry, Michael D. Radmacher, Krzysztof Mrózek, Dean Margeson, Heiko Becker, John Curfman, Kelsi B. Holland, Sebastian Schwind, Susan P. Whitman, Yue-Zhong Wu, William Blum, Bayard L. Powell, Thomas H. Carter, Meir Wetzler, Joseph O. Moore, Jonathan E. Kolitz, Maria R. Baer, Andrew J. Carroll, Richard A. Larson, Michael A. Caligiuri, Guido Marcucci, Clara D. Bloomfield J Clin Oncol vol 29 (10) 1373-1381 2011

Manuscript Leuk Corr Sci CALGB-8525, CALGB-10201, CALGB-19808, CALGB-20202, CALGB-20502, CALGB-8461, CALGB-8923, CALGB-9420, CALGB-9621, CALGB-9665, CALGB-9720 <http://www.ncbi.nlm.nih.gov/pubmed/21343549>

1363 Molecular Subtypes and Response to Neoadjuvant Chemotherapy in TNBC: Results from Brightness Phase III Study AFT-04 (Alliance)

Otto Metzger Filho, Daniel Stover, Sarah Asad, Peter Ansell, Mark Watson, Sibylle Loibl, Charles E Geyer, Joyce O'Shaughnessy, Michael Untch, Hope S Rugo, Jens Huober, Mehra Golshan, William Sikov, David Maag, Gunter von Minckwitz, Priya Rastogi, Kristi McIntyre, Norman Wolmark, Carsten Denkert, Fraser Symmans J Clin Oncol vol 37 (15 suppl) 510 2019
Abstract Breast https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.510

1364 Measurement of endocrine activity (SET2,3) related to prognosis and prediction of benefit from dose-dense chemotherapy in estrogen receptor-positive (ER+) cancer: correlative analysis of C9741 (Alliance).

Otto Metzger, Karla Ballman, Jordan Campbell, Minetta Liu, Jennifer Ligibel, Mark Watson, Eveline Chen, Lili Du, W. Fraser Symmans J Clin Oncol vol 40 (16 suppl;) 505 2022
Abstract PPP https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.505

1365 Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness

Otto Metzger-Filho, Katharine Collier, Sarah Asad, Peter J. Ansell, Mark Watson, Junu Bae, Mathew Cherian, Joyce O'Shaughnessy, Michael Untch, Hope S. Rugo, Jens B. Huober, Mehra Golshan, William M. Sikov, Gunter von Minckwitz, Priya Rastogi, Lang Li, Lijun Cheng, David Maag, Norman Wolmark, Carsten Denkert, W. Fraser Symmans, Charles E. Geyer Jr., Sibylle Loibl, Daniel G. Stover NPJ Breast Cancer vol 7 2021
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/34764307>

1366 Impact of age and comorbidities on treatment effect, tolerance and toxicity in metastatic colorectal cancer (mCRC) patients treated on CALGB 80203

J. A. Meyerhardt, N. A. Jackson, D. Niedzwiecki, D. R. Hollis, A. P. Venook, R. J. Mayer, R. M. Goldberg J Clin Oncol vol 27 (15s) abstr 4038 2009
Abstract GI <http://meetinglibrary.asco.org/content/33181-65>

1367 The impact of dietary patterns on cancer recurrence and survival in patients with stage III colon cancer: Findings from CALGB 89803

J. A. Meyerhardt, D. Niedzwiecki, D. R. Hollis, L. B. Saltz, W. C. Willett, R. J. Mayer, C. S. Fuchs J Clin Oncol vol 25 (18s) abstr 4019 2007
Abstract GI
http://meeting.ascopubs.org/gca?gca=ascomtg%3B25%2F18_suppl%2F4019&allch=&submit=Go

1368 Dietary Glycemic Load and Cancer Recurrence and Survival in Patients with Stage III Colon Cancer: Findings From CALGB 89803

J. A. Meyerhardt, K. Sato, D. Niedzwiecki, C. Ye, L. B. Saltz, R. J. Mayer, R. B. Mowat, R. Whittom, A. Hantel, A. Benson, D. S. Wigler, A. Venook, C. S. Fuchs J Natl Cancer Inst vol 104 (22) 1702-1711 2012
Manuscript Prevention CALGB-89803 <http://www.ncbi.nlm.nih.gov/pubmed/23136358>

1369 Impact of Body Mass Index and Weight Change After Treatment on Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From Cancer and Leukemia Group B 89803

Jeffrey A. Meyerhardt, Donna Niedzwiecki, Donna Hollis, Leonard B. Saltz, Robert J. Mayer, Heidi Nelson, Renaud Whittom, Alexander Hantel, James Thomas, Charles S. Fuchs J Clin Oncol vol 26

(25) 4109-4115 2008

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/18757324>

1370 Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer

Jeffrey A. Meyerhardt, Qian Shi, Charles S. Fuchs, Jeffrey Meyer, Donna Niedzwiecki, Tyler Zemla, Priya Kumthekar, Katherine A. Guthrie, Felix Couture, Philip Kuebler, Johanna C. Bendell, Pankaj Kumar, Dequincy Lewis, Benjamin Tan, Monica Bertagnolli, Axel Grothey, Howard S. Hochster, Richard M. Goldberg, Alan Venook, Charles Blanke, Eileen M. O'Reilly, Anthony F. Shields JAMA vol 325 (13) 1277-85 2021

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/33821899>

1371 Celecoxib in addition to standard adjuvant therapy with 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX) in stage III colon cancer: Results from CALGB/SWOG 80702

Jeffrey A. Meyerhardt, Qian Shi, Charles S. Fuchs, Donna Niedzwiecki, Tyler Zemla, Priya Kumthekar, Katherine A. Guthrie, Felix Couture, Philip Kuebler, Johanna C. Bendell, Pankaj Kumar, Dequincy Lewis, Benjamin Tan, Monica Bertagnolli, Axel Grothey, Howard S. Hochster, Richard M. Goldberg, Alan Venook, Charles Blanke, Anthony F. Shields JCO vol 38 (no. 15_suppl) 4003 2020
Abstract GI https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.4003

1372 Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803.

Jeffrey A Meyerhardt, Denise Heseltine, Donna Niedzwiecki, Donna Hollis, Leonard B Saltz, Robert J Mayer, James Thomas, Heidi Nelson, Renaud Whittom, Alexander Hantel, Richard L Schilsky, Charles S Fuchs J Clin Oncol vol 24 (22) 3535-41 2006

Manuscript Prevention <http://www.ncbi.nlm.nih.gov/pubmed/16822843>

1373 Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer.

Jeffrey A Meyerhardt, Donna Niedzwiecki, Donna Hollis, Leonard B Saltz, Frank B Hu, Robert J Mayer, Heidi Nelson, Renaud Whittom, Alexander Hantel, James Thomas, Charles S Fuchs JAMA vol 298 (7) 754-64 2007

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/17699009>

1374 The utility of positron emission tomography in staging of potentially operable carcinoma of the thoracic esophagus: results of the American College of Surgeons Oncology Group Z0060 trial.

Bryan F Meyers, Robert J Downey, Paul A Decker, Robert J Keenan, Barry A Siegel, Robert J Cerfolio, Rodney J Landreneau, Carolyn E Reed, Dennis M Balfe, Farrokh Dehdashti, Karla V Ballman, Valerie W Rusch, Joe B Putnam J Thorac Cardiovasc Surg vol 133 (3) 738-45 2007

Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/17320575>

1375 Ratio of metastatic to examined lymph nodes is a powerful predictor of overall survival in rectal cancer: An analysis of Intergroup 0114

M. O. Meyers, D. R. Hollis, R. J. Mayer, A. B. Benson 3rd, R. M. Goldberg, B. Cummings, L. Gunderson, J. Martenson, J. S. Macdonald, M. J. O'Connell, J. E. Tepper J Clin Oncol vol 25 (18s) abstr 4006 2007

Abstract GI http://ascopubs.org/doi/abs/10.1200/jco.2007.25.18_suppl.4006

1376 Use of the ratio of metastatic to examined lymph nodes to predict local recurrence in rectal cancer: Analysis of data from intergroup trial 0114.

M. O. Meyers, D. R. Hollis, R. J. Mayer, R. M. Goldberg, A. B. Benson 3rd, B. Cummings, L. L. Gunderson, J. A. Martenson Jr, J. S. Macdonald, M. O'Connell, J. E. Tepper Gastrointestinal Cancers Symposium abstr 384 2009

1377 Ratio of Metastatic to Examined Lymph Nodes is Predictive of Local Recurrence in Rectal Cancer: Analysis of Data From Intergroup Trial 0114

M.O. Meyers, D.R. Hollis, R.J. Mayer, R.M. Goldberg, A.B. Benson III, B. Cummings, L.L. Gunderson, J.A. Martenson, J.S. Macdonald, M. O'Connell, J.E. Tepper *Ann Surg Oncol* vol 16 (1) 90 2009
Abstract GI
<http://download.springer.com/static/pdf/854/art%253A10.1245%252Fs10434-008-0291-6.pdf?originUrl=>

1378 Adjuvant study of amcenestrant (SAR439859) versus tamoxifen for patients with hormone receptor-positive (HR+) early breast cancer (EBC), who have discontinued adjuvant aromatase inhibitor therapy due to treatment-related toxicity (AMEERA-6).

Thomas Meyskens, Otto Metzger, Coralie Poncet, Theodora Goulioti, Eleni Xenophontos, Lei Wang, Giovanna Rossi, Heidi De Swert, Jose Casas, Sandrine Anneheim, Amal Arahmani, Laura Demeulemeester, Christina Herold, Gautier Paux, Amylou Dueck, Etienne Brain, David Cameron *J Clin Oncol* vol 40 (16_suppl) TPS607 2022
Abstract Breast https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.TPS607

1379 Final results of NCCTG N0489: Epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy (ER-CHOP) in patients with previously untreated diffuse large B-cell lymphoma

I. N. Micallef, M. J. Maurer, D. A. Nikcevich, M. W. Cannon, E. W. Schaefer, D. F. Moore Jr, P. Kurtin, T. E. Witzig *J Clin Oncol* vol 27 (15s) abstr 8508 2009
Abstract Lymphoma
<http://www.asco.org/ASCOv2/Meethttp://meeting.ascopubs.org/cgi/content/abstract/27/15S/8508ings/At>

1380 A phase II study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy (ER-CHOP) in patients with previously untreated diffuse large B-cell lymphoma

I. N. Micallef, M. J. Maurer, D. A. Nikcevich, M. Cannon, D. F. Moore Jr, P. Kurtin, T. E. Witzig *J Clin Oncol* vol 86 (15s) abstr 8500 2008
Abstract Lymphoma
http://meeting.ascopubs.org/cgi/content/abstract/26/15_suppl/8500?sid=be945ed9-b3b0-417d-8c78-410b

1381 PET Scan Results of NCCTG N0489: Epratuzumab and Rituximab in Combination with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone Chemotherapy (ER-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

I. N. Micallef, M. J. Maurer, T. E. Witzig, D. Nikcevich, P. Kurtin, M. W. Cannon, P. J. Flynn, G. S. Soori, V. Lowe, G. Wiseman *ASH Annual Meeting Abstracts* vol 114 (22) abstr 137 2009
Abstract Lymphoma <http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;114/22/137>

1382 Promising results of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy (ER-CHOP) in patients with previously untreated diffuse large B-cell lymphoma.

I. N. Micallef, M. Maurer, D. Nikcevich, M. Cannon, D. Moore, P. Kurtin, E. Schaefer, T. Witzig *Ann Oncol* vol 19 (Suppl 4) 161 abstr 257 2008
Abstract Lymphoma http://annonc.oxfordjournals.org/content/19/suppl_4/iv158.full.pdf+html

1383 Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma

Ivana N. M. Micallef, Matthew J. Maurer, Gregory A. Wiseman, Daniel A. Nikcevich, Paul J. Kurtin, Michael W. Cannon, Domingo G. Perez, Gamini S. Soori, Brian K. Link, Thomas M. Habermann,

1384 Phase II trial of paclitaxel-topotecan-etoposide (PTE) followed by consolidation chemoradiotherapy for limited stage small cell lung cancer (LS-SCLC): CALGB 30002

A. A. Miller, J. A. Bogart, D. M. Watson, X. F. Wang, C. M. Rocha Lima, E. E. Vokes, M. R. Green
J Clin Oncol vol 23 (16s) abstract 7170 2005

Abstract Respiratory

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=34&abstractID

1385 Pharmacokinetic (PK) and phase I study of sorafenib (S) for solid tumors and hematologic malignancies in patients with hepatic or renal dysfunction (HD or RD): CALGB 60301

A. A. Miller, D. J. Murry, K. Owzar, D. R. Hollis, G. K. Abou-Alfa, A. Desai, J. J. Hwang, M. A. Villalona-Calero, E. C. Dees, M. J. Ratain J Clin Oncol vol 25 (18s) abstr 2007

Abstract Experimental

http://meeting.ascopubs.org/gca?gca=ascomtg%3B25%2F18_suppl%2F3538&allch=&submit=Go

1386 Phase I and Pharmacokinetic Study of Sorafenib in Patients With Hepatic or Renal Dysfunction: CALGB 60301

Antonius A. Miller, Daryl J. Murry, Kouros Owzar, Donna R. Hollis, Erin B. Kennedy, Ghassan Abou-Alfa, Apurva Desai, Jimmy Hwang, Miguel A. Villalona-Calero, E. Claire Dees, Lionel D. Lewis, Marwan G. Fakih, Martin J. Edelman, Fred Millard, Richard C. Frank, Raymond J. Hohl, Mark J. Ratain J Clin Oncol vol 27 (11) 1800-1805 2009

Manuscript Experimental <http://www.ncbi.nlm.nih.gov/pubmed/19255312>

1387 A Phase II Study of Dasatinib in Patients with Chemo-sensitive Relapsed Small Cell Lung Cancer (CALGB 30602)

Antonius A. Miller, Herbert Pang, Lydia Hodgson, Nithya Ramnath, Gregory A. Otterson, Michael J. Kelley, Robert A. Kratzke, Everett E. Vokes J Thorac Oncol vol 5 (3) 380-384 2010

Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/20087228>

1388 A Phase II Study of Dasatinib in Patients with Chemo-sensitive Relapsed Small Cell Lung Cancer (CALGB 30602)

Antonius A. Miller, Herbert Pang, Lydia Hodgson, Nithya Ramnath, Gregory A. Otterson, Michael J. Kelley, Robert A. Kratzke, Everett E. Vokes J Thorac Oncol vol 4 (9, suppl 1) S816, abstract P2.212 2009

Abstract Respiratory <https://www.jto.org/action/showPdf?pii=S1556-0864%2815%2933608-X>

1389 Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101.

Antonius A Miller, Daryl J Murry, Kouros Owzar, Donna R Hollis, Lionel D Lewis, Hedy L Kindler, John L Marshall, Miguel A Villalona-Calero, Martin J Edelman, Raymond J Hohl, Stuart M Lichtman, Mark J Ratain J Clin Oncol vol 25 (21) 3055-60 2007

Manuscript Experimental <http://www.ncbi.nlm.nih.gov/pubmed/17634483>

1390 Phase II trial of paclitaxel-topotecan-etoposide followed by consolidation chemoradiotherapy for limited-stage small cell lung cancer: CALGB 30002.

Antonius A Miller, Xiaofei F Wang, Jeffrey A Bogart, Lydia D Hodgson, Caio M S Rocha Lima, James E Radford, Everett E Vokes, Mark R Green J Thorac Oncol vol 2 (7) 645-51 2007

Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/17607121>

1391 Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with

advanced non-small cell lung cancer (CALGB 30303).

Antonius A Miller, Xiaofei F Wang, Lin Gu, Philip Hoffman, Jamil Khatri, Frank Dunphy, Martin J Edelman, Michael Bolger, Everett E Vokes, Mark R Green J Thorac Oncol vol 3 (10) 1159-65 2008
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/18827613>

1392 Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers

Christopher A. Miller, Yevgeniy Gindin, Charles Lu, Obi L Griffith, Malachi Griffith, Dong Shen, Jeremy Hoog, Tiandao Li, David E. Larson, Mark Watson, Sherri R Davies, Kelly Hunt, Vera J. Suman, Jacqueline Snider, Thomas Walsh, Graham A. Colditz, Katherine DeSchryver, Richard K. Wilson, Elaine R. Mardis, Matthew J. Ellis Nat Commun vol 7 2016
Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/27502118>

1393 N08C9 (Alliance) - A Phase 3 Randomized Study of Sulfasalazine Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy

R. C. Miller, D. G. Petereit, J. A. Sloan, H. Liu, J. A. Martenson Jr, J. D. Bearden 3rd, R. Sapiante, G. R. Seeger, M. J. Iott, C. L. Loprinzi Int J Radiat Oncol Biol Phys vol 87 (5) 1186 2013
Abstract Symptom Inter <http://www.redjournal.org/article/S0360-3016%2813%2903204-5/fulltext>

1394 Primary and Secondary Endpoint Analysis of N08C9 (Alliance)- A Phase III Randomized Trial of Sulfasalazine versus Placebo in the Prevention of Acute Radiation Enteritis

R. C. Miller, D. G. Petereit, J. A. Sloan, H. Liu, J. A. Martenson Jr, J. D. Bearden 3rd, R. Sapiante, G. R. Seeger, R. B. Mowat, B. Liem, M. J. Iott, C. L. Loprinzi J Clin Oncol vol 33 (3 suppl) 562 2015
Abstract Symptom Inter http://meeting.ascopubs.org/cgi/content/abstract/33/3_suppl/562

1395 Primary and Secondary Endpoint Analysis of N08C9 (Alliance)- A Phase III Randomized Trial of Sulfasalazine versus Placebo in the Prevention of Acute Radiation Enteritis

R. C. Miller, D. G. Petereit, J. A. Sloan, H. Liu, J. A. Martenson Jr, J. D. Bearden 3rd, R. Sapiante, G. R. Seeger, R. B. Mowat, B. Liem, M. J. Iott, C. L. Loprinzi INT J RADIAT BIOL vol 90 (1 supplement) S86 2014
Abstract Symptom Inter <http://www.sciencedirect.com/science/article/pii/S0360301614011274>

1396 N09C6 (Alliance) -A phase III, randomized double-blind study of N09C6 rinse versus placebo in the treatment of acute oral mucositis pain in patients receiving head and neck radiotherapy with or without chemotherapy

R. Miller, J. Leenstra, R. Qun, J. Martenson, J. Dornfeld, J. Bearden, D. Puri, P. Stella, R. Foote, C. Loprinzi Int J Radiat Oncol Biol Phys vol 85 (1) abstr LBA1-21 2013
Abstract Symptom Inter <http://www.redjournal.org/article/S0360-3016%2812%2903772-8/fulltext#sec4>

1397 A Phase III, Randomized Double-Blind Study of Doxepin Rinse versus “Magic Mouthwash” versus Placebo in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Head and Neck Radiotherapy with or without Chemotherapy (Alliance A221304)

Robert C. Miller, Jennifer Le-Rademacher, Terence Sio, James L. Leenstra, Grant Rine, Amy Curtis, Anurag K. Singh, James A. Martenson, Paul J. Novotny, Angelina D. Tan, Paul Reiter, Charles L. Loprinzi Int J Radiat Oncol Biol Phys vol 96 (5) 938 2016
Abstract Symptom Inter <http://pm6mt7vg3j.scholar.serialssolutions.com/?sid=google&auinit=RC&aulast=Miller&atitle=A+Phase>

1398 N09C6 (Alliance) - A Phase III, Randomized Double-Blind Study of Doxepin Rinse versus Placebo in the Treatment of Acute Oral Mucositis Pain: Secondary analysis of the continuation phase

Robert C. Miller, James L. Leenstra, Rui Qin, James A. Martenson, Kenneth J. Dornfeld, James D. Bearden, Dev Puri, Philip J. Stella, Robert L. Foote, C. L. Loprinzi European Journal of Cancer vol

49 S759 2013

Abstract Symptom Inter

<https://www.clinicalkey.com/ui/service/content/url?eid=1-s2.0-S0959804913700650>

1399 N08C9 (Alliance): A Phase 3 Randomized Study of Sulfasalazine vs Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy

Robert C. Miller, Daniel G. Petereit, Jeff A. Sloan, Heshan Liu, James A. Martenson, James D. Bearden, Ronald Sapiante, Grant R. Seeger, Rex B. Mowat, Ben Liem, Matthew J. Iott, Charles L.

Loprinzi *Int J Radiat Oncol Biol Phys* vol 95 (4) 1168-1174 2016

Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/27354129>

1400 Mometasone Furoate Effect on Acute Skin Toxicity in Breast Cancer Patients Receiving Radiotherapy: A Phase 3 Double-Blind, Randomized Trial from the North Central Cancer Treatment Group N06C4

Robert C. Miller, David J. Schwartz, Jeff A. Sloan, Patricia C. Griffin, Richard L. Deming, Jon C. Anders, Thomas J. Stoffel, Robert E. Haselow, Paul L. Schaefer, James D. Bearden, Pamela J.

Atherton, Charles L. Loprinzi, James A. Martenson *Int J Radiat Oncol Biol Phys* vol 79 (5)

1460-1466 2011

Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/20800381>

1401 Development and Validation of a Dominant Clone Precision Medicine Classification for Treatment of Elderly Acute Myeloid Leukemia (Alliance)

Alice S. Mims, Uma Borate, Jessica Kohlschmidt, Brianna Norris, Taylor Bucy, James S. Blachly, Shelley Orwick, Ann-Kathrin Einfeld, Deedra Nicolet, Krzysztof Mrzek, Bhavana Bhatnagar, Eytan Stein, Richard M. Stone, Jonathan E. Kolitz, Eunice S. Wang, Bayard L. Powell, Amy Burd, Ross

Levine, Brian Druker, Clara D. Bloomfield, John C. Byrd *Blood* vol 132 (Suppl 1) 1489 2018

Abstract *Leuk Corr Sci* CALGB-8461, CALGB-20202

http://www.bloodjournal.org/content/132/Suppl_1/1489

1402 A precision medicine classification for treatment of acute myeloid leukemia in older patients

Alice S. Mims, Jessica Kohlschmidt, Uma Borate, James S. Blachly, Shelley Orwick, Ann-Kathrin Einfeld, Dimitrios Papaioannou, Deedra Nicolet, Krzysztof Mrzek, Eytan Stein, Bhavana Bhatnagar, Richard M. Stone, Jonathan E. Kolitz, Eunice S. Wang, Bayard L. Powell, Amy Burd, Ross L. Levine, Brian J. Druker, Clara D. Bloomfield, John C. Byrd *J Hematol Oncol* vol 14 (1) 96 2021

Manuscript *Leuk Corr Sci* CALGB-8321, CALGB-20202, CALGB-8461, CALGB-8721,

CALGB-10502, CALGB-10801, CALGB-11001, CALGB-11002, CALGB-8821, CALGB-8921,

CALGB-8923, CALGB-9420, CALGB-9720 <http://www.ncbi.nlm.nih.gov/pubmed/34162404>

1403 Comparisons between TP53 mutations and TP73 mutations in adult acute myeloid leukemia (AML) (Alliance)

Alice S. Mims, Jessica Kohlschmidt, Ann-Kathrin Einfeld, Krzysztof Mrzek, James S. Blachly, Shelley Orwick, Deedra Nicolet, Deepa Sampath, Richard M. Stone, Bayard L. Powell, Jonathan E. Kolitz,

John C. Byrd, Clara D. Bloomfield *Blood* vol 132 (Suppl 1) 1488 2018

Abstract *Leuk Corr Sci* CALGB-8461, CALGB-20202

http://www.bloodjournal.org/content/132/Suppl_1/1488?sso-checked=true

1404 Comparison of clinical and molecular characteristics of patients with acute myeloid leukemia and either TP73 or TP53 mutations

Alice S. Mims, Jessica Kohlschmidt, Ann-Kathrin Einfeld, Krzysztof Mrzek, James S. Blachly, Shelley Orwick, Dimitrios Papaioannou, Deedra Nicolet, Deepa Sampath, Richard M. Stone, Bayard L.

Powell, Jonathan E. Kolitz, John C. Byrd, Clara D. Bloomfield *Leukemia* vol 35 1188-92 2020

Manuscript *Leuk Corr Sci* CALGB-20202, CALGB-8461, CALGB-9665

<http://www.ncbi.nlm.nih.gov/pubmed/32759975>

1405 Evaluation of the stage IB designation of the 7th edition of the AJCC staging system: Biologic factors are more important

E. Mittendorf, K. Ballman, L. McCall, N. Hansen, A. Lucci, S. Gabram, M. Urist, J. Crow, T. Hurd, K. Hunt, A. Giuliano *Cancer Res* vol 72 (24 suppl) Abstract nr P1-01-06 2012
Abstract Breast http://hwmaint.meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/1130

1406 Evaluation of the Stage IB Designation of the American Joint Committee on Cancer Staging System in Breast Cancer

Elizabeth A. Mittendorf, Karla V. Ballman, Linda M. McCall, Min Yi, Aysegul A. Sahin, Isabelle Bedrosian, Nora Hansen, Sheryl Gabram, Thelma Hurd, Armando E. Giuliano, Kelly K. Hunt *J Clin Oncol* vol 33 (10) 1119-1127 2015
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/25488970>

1407 MiR-139-5p as a novel serum biomarker for recurrence and metastasis in colorectal cancer

Jinsei Miyoshi, Shusuke Toden, Kazuhiro Yoshida, Yuji Toiyama, Steven R. Alberts, Masato Kusunoki, Frank A. Sinicrope, Ajay Goel *Sci Rep* vol 7 2017
Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/28262692>

1408 Electronic patient-reported outcomes monitoring during lung cancer chemotherapy: A nested cohort within the PRO-TECT pragmatic trial (AFT-39).

Gita N Mody, Angela M Stover, Mian Wang, Bellinda L King-Kallimanis, Jennifer Jansen, Sydney Henson, Arlene E Chung, Mattias Jonsson, Antonia Bennett, Angela B Smith, William A Wood, Alison Deal, Brenda Ginos, Amylou C Dueck, Deborah Schrag, Ethan Basch *Lung Cancer* vol 162 1-8 2021
Manuscript Health Outcomes <http://www.ncbi.nlm.nih.gov/pubmed/34634754>

1409 Management of recurrent prostate cancer after radiotherapy: long-term results from CALGB 9687 (Alliance), a prospective multi-institutional salvage prostatectomy series

James L. Mohler, Susan Halabi, Stephen T. Ryan, Ali Al-Daghmin, Mitchell H. Sokoloff, Gary D. Steinberg, Ben L. Sanford, James A. Eastham, Philip J. Walther, Michael J. Morris, Eric J. Small *Prostate Cancer Prostatic Dis* vol 22 (2) 309-16 2019
Manuscript GU <http://www.ncbi.nlm.nih.gov/pubmed/30385835>

1410 A randomized phase II study of pemetrexed (PEM) with or without sorafenib (S) as second line therapy in advanced non-small cell lung cancer (NSCLC) of non-squamous histology: NCCTG N0626 study

J. R. Molina, G. K. Dy, N. R. Foster, Allen Ziegler, A. A. Adjei, K. M. Rowland Jr, M. C. Aurby, P. J. Flynn, S. J. Mandrekar, S. E. Schild *J Clin Oncol* vol 29 (suppl) abstr 7513 2011
Abstract Respiratory http://ascopubs.org/doi/abs/10.1200/jco.2011.29.15_suppl.7513

1411 A randomized double-blinded phase II study of the Seneca Valley Virus (NTX-010) vs placebo for patients with extensive stage SCLC (ES-SCLC) who were stable or responding after at least 4 cycles of platinum-based chemotherapy: NCCTG N0923 (Alliance) Study

J. R. Molina, S. J. Mandrekar, G. Dy, M. C. Aubry, K. A. Ziegler, S. R. Dakhil, B. A. Sachs, J. J. Nieva, S. E. Schild, K. Burroughs, A. Williams, C. M. Rudin, A. A. Adjei *J Clin Oncol* vol 31 (15 suppl) abstr 7509 2013
Abstract Respiratory <http://meetinglibrary.asco.org/content/115112-132>

1412 A phase II study of the VEGFR inhibitor pazopanib (P) in patients with newly diagnosed or relapsed malignant pleural mesothelioma (MPM): an NCCTG study

J. R. Molina, S. J. Mandrekar, K. L. Allen Ziegler, G. S. Soori, K. M. Rowland Jr, S. E. Schild, P. Ivy, A. A. Adjei *J Thorac Oncol* vol 4 (9 suppl 1) PD4.1.2, S456 2009

1413 NCCTG Phase II Trial (N0621) of the SRC inhibitor AZD0530 after 4 cycles of cytoreductive chemotherapy for patients with Extensive Stage Small Cell Lung Cancer (ED-SCLC)

Julian R. Molina, Nathan R. Foster, Garth D. Nelson, Andrew V. Grainger, Preston D. Steen, Daniel A. Nikcevich, Steven E. Schild, John Wright, Alex A. Adjei *J Thorac Oncol* vol 4 (9) abstr PD4.3.4 2009

Abstract Respiratory [http://www.jto.org/article/S1556-0864\(15\)33608-X/fulltext](http://www.jto.org/article/S1556-0864(15)33608-X/fulltext)

1414 A phase II trial of the Src-kinase inhibitor saracatinib after 4 cycles of chemotherapy for patients with extensive stage small cell lung cancer: NCCTG trial N-0621

Julian R. Molina, Nathan R. Foster, Thanyanan Reungwetwattana, Garth D. Nelson, Andrew V. Grainger, Preston D. Steen, Philip J. Stella, Randolph Marks, John Wright, Alex A. Adjei *Lung Cancer* vol 85 (2) 245-250 2014

Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/24957683>

1415 Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: Results of Cancer and Leukemia Group B (CALGB) 9782

J.P. Monk, S. Halabi, J. Picus, A. Hussain, G. Philips, E. Kaplan, T. Ahles, Lin Gu, N. Vogelzang, W.K. Kelly, E.J. Small *Cancer* vol 118 (17) 4139-4147 2012

Manuscript GU <http://www.ncbi.nlm.nih.gov/pubmed/22180287>

1416 Enhancer hijacking drives oncogenic BCL11B expression in lineage ambiguous stem cell leukemia

Lindsey E. Montefiori, Sonja Bendig, Zhaohui Gu, Xiaolong Chen, Petri Pölönen, Xiaotu Ma, Alex Murison, Andy Zeng, Laura Garcia-Prat, Kirsten Dickerson, Ilaria Iacobucci, Sherif Abdelhamed, Ryan Hiltenbrand, Paul E. Mead, Cyrus M. Mehr, Beisi Xu, Zhongshan Cheng, Ti-Cheng Chang, Tamara Westover, Jing Ma, Anna Stengel, Shunsuke Kimura, Chunxu Qu, Marcus B. Valentine, Marissa Rashkovan, Selina Luger, Mark R. Litzow, Jacob M. Rowe, Monique L. den Boer, Victoria Wang, Jun Yin, Steven M. Kornblau, Stephen P. Hunger, Mignon L. Loh, Ching-Hon Pui, Wenjian Yang, Kristine R. Crews, Kathryn G. Roberts, Jun J. Yang, Mary V. Relling, William E. Evans, Wendy Stock, Elisabeth M. Paietta, Adolfo A. Ferrando, Jinghui Zhang, Wolfgang Kern, Torsten Haferlach, Gang Wu, John E. Dick, Jeffery M. Klco, Claudia Haferlach, Charles G. Mullighan *Cancer Discov* vol 11 (11) 2846-67 2021

Manuscript Leuk Corr Sci CALGB-10403, Alliance-A041501
<http://www.ncbi.nlm.nih.gov/pubmed/34103329>

1417 Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222

Joseph O. Moore, Stephen L. George, Richard K. Dodge, Philip C. Amrein, Bayard L. Powell, Jonathan E. Kolitz, Maria R. Baer, Frederick R. Davey, Clara D. Bloomfield, Richard A. Larson, Charles A. Schiffer *Blood* vol 105 (9) 3420-3427 2005

Manuscript Leukemia <http://www.ncbi.nlm.nih.gov/pubmed/15572587>

1418 Dietary Insulin Load and Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803 (Alliance).

Vicente Morales-Oyarvide, Chen Yuan, Ana Babic, Sui Zhang, Donna Niedzwiecki, Jennie C Brand-Miller, Laura Sampson-Kent, Xing Ye, Yanping Li, Leonard B Saltz, Robert J Mayer, Rex B Mowat, Renaud Whittom, Alexander Hantel, Al Benson, Daniel Atienza, Michael Messino, Hedy Kindler, Alan Venook, Shuji Ogino, Kana Wu, Walter C Willett, Edward L Giovannucci, Brian M Wolpin, Jeffrey A Meyerhardt, Charles S Fuchs, Kimmie Ng *J Natl Cancer Inst* vol 111 (2) 170-9 2019

1419 Gabapentin for the management of hot flashes in prostate cancer survivors: A longitudinal continuation study—NCCTG trial N00CB

A. R. Moraska, P. J. Atherton, D. W. Szydlo, D. L. Barton, P. J. Stella, K. M. Rowland Jr, P. L. Schaefer, J. E. Krook, J. Bearden, C. L. Loprinzi *J Clin Oncol* vol 28 (15s) abstr 9139 2010

Abstract Symptom Inter

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID

1420 Gabapentin for the management of hot flashes in prostate cancer survivors: a longitudinal continuation Study-NCCTG Trial N00CB

A. R. Moraska, P. J. Atherton, D. W. Szydlo, D. L. Barton, P. J. Stella, K. M. Rowland Jr, P. L. Schaefer, J. Krook, J. D. Bearden 3rd, C. L. Loprinzi *J Support Oncol* vol 8 (3) 128-132 2010

Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/20552926>

1421 Phase III, randomized, double-blind, placebo-controlled study of long-acting methylphenidate for cancer-related fatigue: North Central Cancer Treatment Group NCCTG-N05C7 trial

A. R. Moraska, A. Sood, S. R. Dakhil, J. A. Sloan, D. Barton, P. J. Atherton, J. J. Suh, P. C. Griffin, D. B. Johnson, A. Ali, P. T. Silberstein, S. F. Duane, C. L. Loprinzi *J Clin Oncol* vol 28 (23) 3673-3679 2010

Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/20625123>

1422 Serum Biomarker Analysis in a Phase II Study of Irinotecan in Refractory Metastatic Breast Cancer

A. Moreno-Aspitia, S. Anderson, M. Reinholz, A. Dueck, J. Lafky, D. Hillman, E. Perez *Cancer Res* vol 69 (2, suppl 1) abstr 6074 2009

Abstract Breast http://cancerres.aacrjournals.org/content/69/2_Supplement/6074

1423 Serum HER2 (sHER2) levels in early-stage HER2 neu (+) breast cancer (HER2 + BC): Results from the NCCTG adjuvant intergroup trial N9831

A. Moreno-Aspitia, A. Dueck, W. Lingle, L. Kutteh, K. Tenner, N. Davidson, S. Martino, P. Kaufman, W. Carney, E. Perez *J Clin Oncol* vol 26 (15s) abstr 529 2008

Abstract Breast http://meeting.ascopubs.org/cgi/content/abstract/26/15_suppl/529

1424 Paclitaxel-Related Peripheral Neuropathy Associated with Improved Outcome of Patients with Early Stage HER2+ Breast Cancer Who Did Not Receive Trastuzumab in the N9831 Clinical Trial

A. Moreno-Aspitia, A. Dueck, T. Patel, D. Hillman, K. Tenner, S. Dakhil, K. Rowland Jr, S. McLaughlin, E. Perez, Tbc Breast Cancer Intergroup of North America *Cancer Res* vol 69 (24 Supplement) abstr 2100 2009

Abstract Breast http://cancerres.aacrjournals.org/cgi/content/abstract/69/24_MeetingAbstracts/2100

1425 Baseline and recurrence levels of soluble HER2 (sHER2) in early-stage HER2-neu positive breast cancer (HER2+BC) from the NCCTG adjuvant Intergroup trial N9831

A. Moreno-Aspitia, D. W. Hillman, A. C. Dueck, W. P. Carney, W. L. Lingle, K. S. Tenner, J. M. Lafky, M. M. Reinholz, L. A. Kutteh, E. A. Perez *J Clin Oncol* vol 27 (15s) abstr 539 2009

Abstract Breast <http://meetinglibrary.asco.org/content/33967-65>

1426 Soluble HER2 (sHER2) levels in HER2-positive breast cancer patients receiving chemotherapy with or without trastuzumab: Results from the NCCTG adjuvant trial N9831

A. Moreno-Aspitia, D. W. Hillman, S. H. Dyar, K. S. Tenner, J. Gralow, P. A. Kaufman, N. E.

Davidson, J. M. Lafky, M. M. Reinholz, W. L. Lingle, L. A. Kutteh, W. P. Carney, A. C. Dueck, E. A. Perez *Cancer* vol 119 (15) 2675-2682 2013

Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/23744760>

1427 N0937 (Alliance): Final clinical results and correlative data from the phase II trial of cisplatin (C) and the novel agent brostallicin (B) in patients with metastatic triple-negative breast cancer (mTNBC)

A. Moreno-Aspitia, H. Liu, D. Hillman, K. M. Rowland Jr, X. Geiger, P. J. Stella, P. Kourlas, H. M. Gross, N. Karlin, M. J. Bury, G. S. Soori, A. Nassar, E. A. Perez J Clin Oncol vol 31 (15 suppl) abstr 1059 2013

Abstract Breast <http://meetinglibrary.asco.org/content/115710-132>

1428 N0937 (Alliance): Preliminary results of a phase II clinical trial of cisplatin and the novel agent brostallicin in patients with metastatic triple negative breast cancer (mTNBC)

A. Moreno-Aspitia, K. M. Rowland Jr, J. B. Allred, H. Liu, P. J. Stella, H. M. Gross, G. S. Soori, N. Karlin, E. A. Perez Cancer Res vol 72 (24 Suppl) P1-12-06 2012

Abstract Breast http://cancerres.aacrjournals.org/content/72/24_Supplement/P1-12-06.short

1429 Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D)

Alvaro Moreno-Aspitia, Eileen M. Holmes, Christian Jackisch, Evandro de Azambuja, Frances Boyle, David W. Hillman, Larissa Korde, Debora Fumagalli, Miguel A. Izquierdo, Ann E. McCullough, Antonio C. Wolff, Kathleen I. Pritchard, Michael Untch, Sébastien Guillaume, Michael S. Ewer, Zhimin Shao, Sung Hoon Sim, Zeba Aziz, Georgia Demetriou, Ajay O. Mehta, Michael Andersson, Masakazu Toi, Istvan Lang, Binghe Xu, Ian E. Smith, Carlos H. Barrios, Jose Baselga, Richard D. Gelber, Martine Piccart-Gebhart Eur J Cancer vol 148 287-96 2021

Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/33765513>

1430 Updated results from the phase III ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (TL) or their combination (L+T) in the adjuvant treatment of HER2-positive early breast cancer

Alvaro Moreno-Aspitia, Eileen Holmes, Christian Jackisch, Evandro de Azambuja, Frances Boyle, David W. Hillman, Larissa Korde, Debora Fumagalli, Miguel Izquierdo, Ann McCullough, Antonio C. Wolff, Kathleen Pritchard, Michael Untch, Istvan Lang, Binghe Xu, Ian Smith, Carlos H. Barrios, Rich Gelber, Jose Baselga, Martine Piccart-Gebhart J Clin Oncol vol 35 (15 suppl) abstr 502 2017

Abstract Breast http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.502

1431 Phase II Trial of Sorafenib in Patients With Metastatic Breast Cancer Previously Exposed to Anthracyclines or Taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336

Alvaro Moreno-Aspitia, Roscoe F. Morton, David W. Hillman, Wilma L. Lingle, Kendrith M. Rowland, Martin Wiesenfeld, Patrick J. Flynn, Tom R. Fitch, Edith A. Perez J Clin Oncol vol 27 (1) 11-15 2009

Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/19047293>

1432 Alliance A031201: A phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC)

Michael J. Morris, Glenn Heller, Alan Bryce, Andrew Armstrong, Himisha Beltran, Olwen Hahn, Eric C. McGary, Paul Mehan, Bruce Roth, Han Xiao, Colleen Watt, David Hillman, Mary Ellen Taplin, Charles J. Ryan, Susan Halabi, Eric Small J Clin Oncol vol 37 (suppl) abstr 5008 2019

Abstract GU <https://meetinglibrary.asco.org/record/172903/abstract>

1433 Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial)

Michael J. Morris, Glenn Heller, David W. Hillman, Olivia Bobek, Charles Ryan, Emmanuel S. Antonarakis, Alan H. Bryce, Olwen Hahn, Himisha Beltran, Andrew J. Armstrong, Lawrence Schwartz, Lionel D. Lewis, Jan H. Beumer, Brooke Langevin, Eric C. McGary, Paul T. Mehan, Amir

1434 A phase II trial of bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma (MCL) (CALGB 50501): Results of a planned interim analysis.

V. A. Morrison, J. L. Johnson, S. Jung, J. P. Leonard, B. D. Cheson J Clin Oncol vol 28 (15s) abstr 8106 2010

Abstract Lymphoma <http://meetinglibrary.asco.org/content/47551-74>

1435 Salvage Therapy with Bortezomib Plus Lenalidomide for Relapsed/Refractory Mantle Cell Lymphoma: Initial Results of a Phase II Trial (Alliance/CALGB 50501)

V. A. Morrison, S.-H. Jung, J. Johnson, A. Lacasce, K. A. Blum, N. L. Bartlett, B. D. Cheson ASH Annual Meeting Abstracts vol 120 (21) -3696 2012

Abstract Lymphoma <https://ash.confex.com/ash/2012/webprogram/Paper51222.html>

1436 Therapy with bortezomib plus lenalidomide is tolerable in patients (pts) with relapsed/refractory mantle cell lymphoma (MCL): Interim results of CALGB 50501

V. A. Morrison, S. Jung, J. Johnson, J. Leonard, B. Cheson Ann Oncol vol 22 (221-222) abstr 436 2011

Abstract Lymphoma

http://annonc.oxfordjournals.org/content/22/suppl_4/iv220.full.pdf+html?sid=3b797230-91b6-427e-a6e4

1437 A phase II trial of bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma (MCL) (CALGB 50501)

V. A. Morrison, S. Jung, J. Leonard, B. D. Cheson J Clin Oncol vol 29 (suppl) abstr TPS223 2011

Abstract Lymphoma <http://meetinglibrary.asco.org/content/47551-74>

1438 Alemtuzumab Increases Serious Infections in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) Receiving Fludarabine-Based Therapy: A Comparative Analysis of 3 Cancer and Leukemia Group B Studies (CALGB 9011, 9712, 19901)

V. A. Morrison, B. L. Peterson, K. R. Rai, J. C. Byrd, R. A. Larson Blood vol 110 (11) 756 2007

Abstract Leukemia CALGB-9011, CALGB-19901, CALGB-9712

<http://www.bloodjournal.org/content/110/11/756.full>

1439 Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: Final results of a phase II trial (CALGB 50501)

Vicki A. Morrison, Sin-Ho Jung, Jeffrey Johnson, Ann LaCasce, Kristie A. Blum, Nancy L. Bartlett, Brandelyn N. Pitcher, Bruce D. Cheson Leuk Lymphoma vol 56 (4) 958-964 2015

Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/24996441>

1440 The Impact of Actual Body Weight-Based Chemotherapy Dosing and Body Size on Adverse Events and Outcome in Older Patients with Breast Cancer: Results from Cancer and Leukemia Group B (CALGB) Trial 49907 (Alliance A151436)

Vicki A. Morrison, Linda McCall, Hyman B. Muss, Aminah Jatoui, Harvey J. Cohen, Constance T. Cirrincione, Jennifer A. Ligibel, Jacqueline M. Lafky, Arti Hurria J Geriatr Oncol vol 9 (3) 228-34 2018

Manuscript Older Adult CALGB-49907 <http://www.ncbi.nlm.nih.gov/pubmed/29233548>

1441 Randomized phase II study of loratadine for the prevention of bone pain caused by pegfilgrastim

J. Moukharskaya, D.M. Abrams, T. Ashikaga, F. Khan, J. Schwartz, K. Wilson, C. Verschraegen, T. Openshaw, J. Valentine, J. Eneman, P. Unger, S. Ades Support Care Cancer vol 24 (7) 3085-3093

2016

Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/26894485>

1442 Randomized phase II pilot study of loratadine for the prevention of bone pain caused by pegfilgrastim.

Julia Moukharskaya, Deborah Michelle Abrams, Farrah B. Khan, Joanna Schwartz, Steven Ades, Takamaru Ashikaga, Thomas H. Openshaw, Claire F. Verschraegen, Steven M. Grunberg *J Clin Oncol* vol 32 (5s) abstr 9628 2014

Abstract Symptom Inter http://abstracts.asco.org/144/AbstView_144_130880.html

1443 SULT1A1, CYP2C19 and disease-free survival in early breast cancer patients receiving tamoxifen

Ann M Moyer, Vera J Suman, Richard M Weinshilboum, Rajeswari Avula, John L Black, Stephanie L Safgren, Mary J Kuffel, Matthew M Ames, James N Ingle, Matthew P Goetz *Pharmacogenomics* vol 12 (11) 1535-1543 2011

Manuscript PPP <http://www.ncbi.nlm.nih.gov/pubmed/21961651>

1444 Prognostic Significance of Unbalanced Chromosome Abnormalities Used by 2008 World Health Organization (WHO) Classification to Define Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes in Adults: a Cancer and Leukemia Group B (CALGB) Study

K. Mrozek, K. B. Holland, M. J. Pettenati, K. Maharry, G. Marcucci, M. R. Baer, J. E. Kolitz, D. Margeson, C. G. Edwards, A. J. Carroll, R. A. Larson, C. D. Bloomfield *Blood* vol 114 (22) abstr 2602 2009

Abstract *Leuk Corr Sci* <http://www.bloodjournal.org/content/114/22/2602>

1445 Prognostic Utility of the European LeukemiaNet (ELN) Genetic-Risk Classification in Adults with De Novo Acute Myeloid Leukemia (AML): A Study of 1,550 Patients (Pts)

K. Mrozek, G. Marcucci, K. Maharry, D. Nicolet, H. Becker, S. P. Whitman, K. H. Metzeler, S. Schwind, Y.-Z. Wu, J. Kohlschmidt, M. J. Pettenati, P. R. K. Koduru, N. A. Heerema, A. W. Block, S. R. Patil, M. R. Baer, J. E. Kolitz, J. O. Moore, A. J. Carroll, R. A. Larson, C. D. Bloomfield *Blood* vol 118 (21) -414 2011

Abstract *Leuk Corr Sci* CALGB-8525, CALGB-10201, CALGB-19808, CALGB-20202, CALGB-8461, CALGB-8923, CALGB-9420, CALGB-9621, CALGB-9665, CALGB-9720
<http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;118/21/414>

1446 Central review of cytogenetics is necessary for cooperative group correlative and clinical studies of adult acute leukemia: The Cancer and Leukemia Group B experience

Krzysztof Mrózek, Andrew J. Carroll, Kati Maharry, Kathleen W. Rao, Shivanand R. Patil, Mark J. Pettenati, Michael S. Watson, Diane C. Arthur, Ramana Tantravahi, Nyla A. Heerema, Prasad R. K. Koduru, AnneMarie W. Block, Mazin B. Qumsiyeh, Colin G. Edwards, Lisa J. Sterling, Kelsi B. Holland, Clara D. Bloomfield *Int J Oncol* vol 33 (2) 239-244 2008

Manuscript *Leuk Corr Sci* <http://www.ncbi.nlm.nih.gov/pubmed/18636143>

1447 Molecular landscape and clinical features of acute myeloid leukemia (AML) with complex karyotype (CK) CALGB 20202 and 8461 (Alliance)

Krzysztof Mrózek, Ann-Kathrin Eisfeld, Jessica Kohlschmidt, Andrew J. Carroll, Deedra Nicolet, James S. Blachly, Christopher J. Walker, Eunice S. Wang, Geoffrey L. Uy, Jonathan E. Kolitz, Bayard L. Powell, William Blum, Richard M. Stone, John C. Byrd, Clara D. Bloomfield *Blood* vol 130 (Suppl 1) 1404 2017

Abstract *Leuk Corr Sci* CALGB-20202, CALGB-8461
http://www.bloodjournal.org/content/130/Suppl_1/1404

1448 Complex karyotype in de novo acute myeloid leukemia: typical and atypical subtypes differ

molecularly and clinically

Krzysztof Mrózek, Ann-Kathrin Einfeld, Jessica Kohlschmidt, Andrew J. Carroll, Christopher J. Walker, Deedra Nicolet, James S. Blachly, Marius Bill, Dimitrios Papaioannou, Eunice S. Wang, Geoffrey L. Uy, Jonathan E. Kolitz, Bayard L. Powell, William Blum, Richard M. Stone, John C. Byrd, Clara D. Bloomfield *Leukemia* vol 33 (7) 1620-34 2019
Manuscript *Leuk Corr Sci* CALGB-8461, CALGB-9665, CALGB-20202
<http://www.ncbi.nlm.nih.gov/pubmed/30737482>

1449 Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study

Krzysztof Mrózek, Jessica Kohlschmidt, James S. Blachly, Deedra Nicolet, Andrew J. Carroll, Kellie J. Archer, Alice S. Mims, Karilyn T. Larkin, Shelley Orwick, Christopher C. Oakes, Jonathan E. Kolitz, Bayard L. Powell, William G. Blum, Guido Marcucci, Maria R. Baer, Geoffrey L. Uy, Wendy Stock, John C. Byrd, Ann-Kathrin Einfeld *Leukemia* vol 37 (4) 788-98 2023
Manuscript *Leuk Corr Sci* CALGB-20202, CALGB-8461, CALGB-9665
<http://www.ncbi.nlm.nih.gov/pubmed/36823396>

1450 Outcome prediction of the new 2022 European LeukemiaNet (ELN) risk classification by genetics for adult acute myeloid leukemia (AML) patients (pts): An Alliance study

Krzysztof Mrózek, Jessica Kohlschmidt, James S. Blachly, Deedra Nicolet, Andrew J. Carroll, Kellie J. Archer, Alice S. Mims, Karilyn T. Larkin, Shelley Orwick, Christopher C. Oakes, Jonathan E. Kolitz, Bayard L. Powell, William G. Blum, Guido Marcucci, Maria R. Baer, Geoffrey Uy, Wendy Stock, John C. Byrd, Ann-Kathrin Einfeld *Blood* vol 140 (suppl 1) 6318–20 2022
Abstract *Leuk Corr Sci* CALGB-20202, CALGB-8461, CALGB-9665
<https://ashpublications.org/blood/article/140/Supplement%201/6318/490770/Outcome-Prediction-By-the>

1451 Prognostic Significance of the European LeukemiaNet Standardized System for Reporting Cytogenetic and Molecular Alterations in Adults With Acute Myeloid Leukemia

Krzysztof Mrózek, Guido Marcucci, Deedra Nicolet, Kati S. Maharry, Heiko Becker, Susan P. Whitman, Klaus H. Metzeler, Sebastian Schwind, Yue-Zhong Wu, Jessica Kohlschmidt, Mark J. Pettenati, Nyla A. Heerema, AnneMarie W. Block, Shivanand R. Patil, Maria R. Baer, Jonathan E. Kolitz, Joseph O. Moore, Andrew J. Carroll, Richard M. Stone, Richard A. Larson, Clara D. Bloomfield *J Clin Oncol* vol 30 (36) 4515-4523 2012
Manuscript *Leuk Corr Sci* CALGB-10201, CALGB-19808, CALGB-8461, CALGB-8525, CALGB-8923, CALGB-9420, CALGB-9621, CALGB-9720
<http://www.ncbi.nlm.nih.gov/pubmed/22987078>

1452 Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?

Krzysztof Mrózek, Guido Marcucci, Peter Paschka, Susan P. Whitman, Clara D. Bloomfield *Blood* vol 109 (2) 431-448 2007
Manuscript *Leuk Corr Sci* <http://www.ncbi.nlm.nih.gov/pubmed/16960150>

1453 Who Participates in an Adult Cooperative Group Trial for Adolescent and Young Adults (AYAs)? Baseline Demographic and Psychosocial Characteristics of AYAs Enrolled On Intergroup Trial C10403 for Acute Lymphoblastic Leukemia (ALL)

L. S. Muffly, W. Stock, K. Breitenbach, F. Mulkey, S. Luger, A. Advani, E. Parker, M. C. Foster, M. Liedtke, R. Garcia, K. Coffan, J. Sipin-Sayno, J. Mcneer, M. S. Tallman, F. R. Appelbaum, R. M. Stone, R. A. Larson *Blood* vol 120 (21) 3535 2012
Abstract *Disparities* CALGB-10403 <http://www.bloodjournal.org/content/120/21/3535>

1454 Enrollment Characteristics and Outcomes of Hispanic and Black AYA ALL Patients Enrolled on a U.S. Intergroup Clinical Trial: A Comparison of the CALGB 10403 Cohort with U.S.

Population-Level Data (Alliance)

Lori Muffly, Jun Yin, Sawyer Jacobson, Anjali S. Advani, Selina M. Luger, Martin S. Tallman, Mark Litzow, Matthew Foster, Richard A. Larson, Teresa H. Keegan, Wendy Stock *Blood* vol 138 (Supplement 1) 337 2021

Abstract *Leukemia* <https://www.sciencedirect.com/science/article/pii/S000649712102334X>

1455 Disparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemia

Lori Muffly, Jun Yin, Sawyer Jacobson, Anna Wall, Elisa Quiroz, Anjali S. Advani, Selina M. Luger, Martin S. Tallman, Mark R. Litzow, Matthew C. Foster, Harry P. Erba, Frederick R. Appelbaum, Richard A. Larson, Theresa H.M. Keegan, Wendy Stock *Blood Adv* vol 6 (14) 4085-92 2022

Manuscript *Leukemia* <http://www.ncbi.nlm.nih.gov/pubmed/35838753>

1456 MRI phenotype and tumor subtype affect breast conservation eligibility and MRI accuracy in the I-SPY 1 trial

R. A. Mukhtar, N. M. Hylton, M. Rosen *Cancer Res* vol 71 (24, suppl 3) abstr SABCS11-PD02-05 2011

Abstract *Breast* http://cancerres.aacrjournals.org/content/71/24_Supplement/PD02-05

1457 Lobular breast cancer and NAC: Combined results from the NKI and I-SPY 1 trial

R. A. Mukhtar, E. Lips, J. Wesseling, C. Livasy, C. Yau, D. A. Berry, L. Van't Veer, L. A. Carey, L. J. Esserman, S. Rodenhuis, E. S. Hwang *Cancer Res* vol 71 (24, suppl 3) abstr 11-P11-06-10 2011

Abstract *Correl Sci NOS ACRIN-6657, CALGB-150007*

http://cancerres.aacrjournals.org/content/71/24_Supplement/P1-06-10

1458 PCNA+ tumor associated macrophages are associated with M1 and M2 gene expression, and confer poor prognosis in the absence of anti-tumor immune environment

R. A. Mukhtar, D. Wolf, V. Tandon, J. Zhu, M. Lenburg, L. Van't Veer, M. Campbell, L. J. Esserman *Cancer Res* vol 71 (24, suppl 3) abstr SABCS11-P14-09-19 2011

Abstract *Correl Sci NOS ACRIN-6657, CALGB-150007*

http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/71/24_MeetingAbstracts/P4-09-19

1459 Clinically Meaningful Tumor Reduction Rates Vary by Prechemotherapy MRI Phenotype and Tumor Subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)

Rita A. Mukhtar, Christina Yau, Mark Rosen, Vickram J. Tandon, Nola Hylton, Laura J. Esserman *Ann Surg Oncol* vol 20 (12) 3823-3830 2013

Manuscript *Breast* <http://www.ncbi.nlm.nih.gov/pubmed/23780381>

1460 Standard chemotherapy (CMF or AC) versus capecitabine in early-stage breast cancer (BC) patients aged 65 and older: Results of CALGB/CTSU 49907

H. B. Muss, D. A. Berry, C. T. Cirincione, M. Theodoulou, A. M. Mauer, H. J. Cohen, A. H.

Partridge, L. Norton, C. A. Hudis, E. P. Winer *J Clin Oncol* vol 26 (May 20 suppl) abstr 507 2008

Abstract *Older Adult*

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID

1461 Standard chemotherapy vs capecitabine for older women with early-stage breast cancer: Long-term results of CALGB 49907 (Alliance)

Hyman B. Muss, Donald A. Berry, Constance T. Cirincione, Maria Theodoulou, Arti Hurria, Harvey J. Cohen, Ann H. Partridge, Larry Norton, Clifford A. Hudis, Eric P. Winer *J Clin Oncol* vol 33 (suppl) abstr 1022 2015

Abstract *Breast* <http://meetinglibrary.asco.org/content/143212-156>

1462 Adjuvant Chemotherapy in Older Women with Early-Stage Breast Cancer

Hyman B. Muss, Donald A. Berry, Constance T. Cirrincione, Maria Theodoulou, Ann M. Mauer, Alice B. Kornblith, Ann H. Partridge, Lynn G. Dressler, Harvey J. Cohen, Heather P. Becker, Patricia A. Kartcheske, Judith D. Wheeler, Edith A. Perez, Antonio C. Wolff, Julie R. Gralow, Harold J. Burstein, Ahmad A. Mahmood, Gustav Magrinat, Barbara A. Parker, Ronald D. Hart, Debjani Grenier, Larry Norton, Clifford A. Hudis, Eric P. Winer *N Engl J Med* vol 360 (20) 2055-2065 2009
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/19439741>

1463 Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial

Hyman B. Muss, Mei-Yin C. Polley, Donald A. Berry, Heshan Liu, Constance T. Cirrincione, Maria Theodoulou, Ann M. Mauer, Alice B. Kornblith, Ann H. Partridge, Lynn G. Dressler, Harvey J. Cohen, Patricia A. Kartcheske, Edith A. Perez, Antonio C. Wolff, Julie R. Gralow, Harold J. Burstein, Ahmad A. Mahmood, Linda M. Sutton, Gustav Magrinat, Barbara A. Parker, Ronald D. Hart, Debjani Grenier, Arti Hurria, Aminah Jatoui, Larry Norton, Clifford A. Hudis, Eric P. Winer, Lisa Carey *J Clin Oncol* vol 37 (26) 2338-48 2019
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/31339827>

1464 Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience.

Hyman B. Muss, Donald A. Berry, Constance Cirrincione, Daniel R. Budman, I. Craig Henderson, Marc L. Citron, Larry Norton, Eric P. Winer, Clifford A. Hudis *J Clin Oncol* vol 25 (24) 3699-704 2007
Manuscript Breast CALGB-8541, CALGB-9741 <http://www.ncbi.nlm.nih.gov/pubmed/17704418>

1465 Alliance A032002 (ART): Phase II randomized trial of atezolizumab versus atezolizumab and radiation therapy for platinum ineligible/refractory metastatic urothelial cancer

Himanshu Nagar, Karla Ballman, Scott T. Tagawa, Alan Tan, Bishoy M. Faltas, Arshin Sheybani, Shiva Baghaie, Lawrence H. Schwartz, David Kozono, Jeffrey Bogart, Olivia Conway, Gina Mazza, Ronald Chen, Andrew Lacetti, Jonathan Rosenberg, Michael J. Morris *J Clin Oncol* vol 41 (6) TPS589 *Journal of Clinical Oncology* 2023
Abstract GU https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.6_suppl.TPS589

1466 Quality of life (QOL) and toxicity among patients in CALGB 80405

M. J. Naughton, D. Schrag, A. P. Venook, D. Niedzwiecki, R. T. Anderson, H.-J. Lenz, S. S. Grubbs *J Clin Oncol* vol 31 (15 suppl) abstr 3611 2013
Abstract Health Outcomes
http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/3611?sid=c1634dd9-82ab-4bf4-bb6f-25af4

1467 Health-related quality of life outcomes for the LEAP Study - Alliance 70305: a lymphedema prevention intervention trial for newly-diagnosed breast cancer patients

MJ Naughton, DK Seisler, JA Sloan, H Liu, J Le-Rademacher, J Oliveri, JM Armer, G Unzeitig, M Schwartz, M Melnik, JR Taylor, ED Paskett *Qual Life Res* vol 27 (suppl 1) abstr 2019 2018
Abstract Health Outcomes <https://link.springer.com/journal/11136/27/1/suppl>

1468 Health-Related Quality of Life Outcomes for the LEAP Study - CALGB 70305 (Alliance): A Lymphedema Prevention Intervention Trial for Newly Diagnosed Breast Cancer Patients

Michelle J. Naughton, Heshan Liu, Drew Seisler, Jennifer Le-Rademacher, Jane M. Armer, Jill M. Oliveri, Jeffrey A. Sloan, Karen Hock, Michael Schwartz, Gary Unzeitig, Marianne Melnik, Lisa D. Yee, Gini F. Fleming, John R. Taylor, Charles Loprinzi, Electra D. Paskett *Cancer* vol 127 (2) 300-9 2021
Manuscript Health Outcomes <http://www.ncbi.nlm.nih.gov/pubmed/33079393>

1469 Quality of Life and Symptom Severity in the PALLAS Randomized Trial of Palbociclib with Adjuvant Endocrine Therapy in Early Breast Cancer (AFT-05)

Michelle Naughton, David Zahrieh, Michael Gnant, Nick Zdenkowski, Julie Lemieux, Jun Mao, Vesna Bjelic-Radistic, Eileen Shinn, Marija Balic, Christoph Thomssen, Jane Meisel, Manuel Ruiz-Echarri, Sibylle Loibl, Claudine Isaacs, David Cameron, Fernando Manuel Henao Carrasco, Matthew Goetz, Viktor Wette, Gustavo Werutsky, Hope Rugo, Marcus Vetter, Ling-Ming Tseng, Kathy Miller, Florian Fitzal, Juan Miguel Gil Gil, Haeseong Park, Barbro Linderholm, Emilio Bajetta, Zoneddy Dayao, Aleix Prat, Karin Ehrhardt, Otto Metzger, Amal Arahmani, Ernest Law, Ann Partridge, Lisa Carey, Alex Zoroufy, Amylou Dueck, Dominik Hlauschek, Angela DeMichele, Erica Mayer Cancer Res vol 82 (4_Supplement) P4-10-01 2022

Abstract Health Outcomes

https://aacrjournals.org/cancerres/article/82/4_Supplement/P4-10-01/681169

1470 A Placebo Controlled, Randomized, Double Blinded Trial of Olanzapine for the Treatment of Chronic Nausea and/or Vomiting, Unrelated to Chemotherapy/Radiation

RM Navari, C Pywell, JG Le-Rademacher, AB Dodge PH White, CL Loprinzi J Clin Oncol vol 37 (suppl 31) abstr 118 2019

Abstract Symptom Inter <https://meetinglibrary.asco.org/record/179620/abstract>

1471 Olanzapine for the Treatment of Advanced Cancer-Related Chronic Nausea and/or Vomiting

Rudolph M. Navari, Cameron M. Pywell, Jennifer G. Le-Rademacher, Patrick White, Andrew B. Dodge, Costantine Albany, Charles L. Loprinzi JAMA Oncol vol 6 (6) 1-5 2020

Manuscript Symptom Inter NCT03137121 <http://www.ncbi.nlm.nih.gov/pubmed/32379269>

1472 Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting

Rudolph M. Navari, Rui Qin, Kathryn J. Ruddy, Heshan Liu, Steven F. Powell, Madhuri Bajaj, Leah Dietrich, David Biggs, Jacqueline M. Lafky, Charles L. Loprinzi N Engl J Med vol 375 (2) 134-142 2016

Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/27410922>

1473 Olanzapine For The Prevention Of Chemotherapy Induced Nausea And Vomiting (CINV) In Patients Receiving Highly Emetogenic Chemotherapy (HEC): Alliance A221301 A Randomized, Double-Blind, Placebo-Controlled Trial

Rudolph M. Navari, Rui Qin, Kathryn J. Ruddy, Heshan Liu, Steven Powell, Charles L. Loprinzi J Clin Oncol vol 33 (suppl 29S) abstr 176 2015

Abstract Symptom Inter <http://meetinglibrary.asco.org/content/155048-165>

1474 Olanzapine With or Without Fosaprepitant for Preventing Chemotherapy Induced Nausea and Vomiting In Patients Receiving Highly Emetogenic Chemotherapy: A Phase III Randomized, Double-Blind, Placebo-Controlled Trial (Alliance A221602)

Rudolph M Navari, Jennifer Le-Rademacher, Fabrice Smielliauskas, Kathryn J. Ruddy, Thomas J. Saphner, Heshan Liu, Beth Harlos, Adedayo Onitilo, Karthik Giridhar, Preet Paul Singh, Pavan Reddy, Flavio Kruter, George Raptis, Charles L. Loprinzi J Clin Oncol vol 40 (suppl 16) abstr 12107 2022

Abstract Symptom Inter https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.12107

1475 Olanzapine With or Without Fosaprepitant for Preventing Chemotherapy Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy: A Phase III Randomized, Double-Blind, Placebo-Controlled Trial (ALLIANCE A221602)

Rudolph M Navari, Jennifer Le-Rademacher, Fabrice Smielliauskas, Kathryn J Ruddy, Thomas James Saphner, Heshan Liu, Elizabeth Harlos, Adedayo A Onitilo, Karthik Giridhar, Preet Paul Singh, Pavan S Reddy, Selina Chow, Flavio Kruter, George Raptis, Charles L Loprinzi Oncologist vol 28 (8) 722-9 2023

Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/37284847>

1476 Comparison of provider-assessed and patient-reported outcome measures of acute skin toxicity

during a phase III trial of mometasone cream versus placebo during breast radiotherapy: the North Central Cancer Treatment Group (N06C4)

Michelle A. Neben-Wittich, Pamela J. Atherton, David J. Schwartz, Jeff A. Sloan, Patricia C. Griffin, Richard L. Deming, Jon C. Anders, Charles L. Loprinzi, Kelli N. Burger, James A. Martenson, Robert C. Miller Int J Radiat Oncol Biol Phys vol 81 (2) 397-402 2011
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/20888137>

1477 Cancer and Aging: Reflections for Elders (CARE): A pilot randomized controlled trial of a psychotherapy intervention for older adults with cancer

Christian J. Nelson, Rebecca M. Saracino, Andrew J. Roth, Elizabeth Harvey, Anne Martin, Mark Moore, Dana Marcone, Shannon R. Poppito, Jimmie Holland Psycho-Oncol vol 28 (1) 39-47 2019
Manuscript Older Adult <http://www.ncbi.nlm.nih.gov/pubmed/30296337>

1478 A comparison of laparoscopically assisted and open colectomy for colon cancer.

Heidi Nelson, Daniel J Sargent, H Sam Wieand, James Fleshman, Mehran Anvari, Steven J Stryker, Robert W Beart, Michael Hellinger, Richard Flanagan, Walter Peters, David Ota N Engl J Med vol 350 (20) 2050-9 2004
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/15141043>

1479 Patients With Acute Myeloid Leukemia and RAS Mutations Benefit Most From Postremission High-Dose Cytarabine: A Cancer and Leukemia Group B Study

Andreas Neubauer, Kati Maharry, Krzysztof Mrózek, Christian Thiede, Guido Marcucci, Peter Paschka, Robert J. Mayer, Richard A. Larson, Edison T. Liu, Clara D. Bloomfield J Clin Oncol vol 26 (28) 4603-4609 2008
Manuscript Leuk Corr Sci CALGB-8525, CALGB-8765, CALGB-8461, CALGB-9665
<http://www.ncbi.nlm.nih.gov/pubmed/18559876>

1480 The influence of anatomic stage and receptor status on first recurrence for breast cancer within 5 years (AFT-01)

Heather B. Neuman, Jessica R. Schumacher, Stephen B. Edge, Kathryn J. Ruddy, Ann H. Partridge, Menggang Yu, David J. Vanness, Bret M. Hanlon, Jennifer G. Le-Rademacher, Dou-Yan Yang, Jeffrey Havlena, Carrie A. Strand, Caprice C. Greenberg Cancer vol 129 (9) 1351-60 2023
Manuscript CCDR <http://www.ncbi.nlm.nih.gov/pubmed/36872873>

1481 FTY720, a new and alternative strategy for treating blast crisis CML and Ph1 ALL patients

P. Neviani, R. Santhanam, J. Oaks, A. Eiring, M. Notari, B. W. Blaser, S. Liu, R. Trotta, N. Muthusamy, C. Gambacorti, B. J. Druker, J. Cortes, G. Marcucci, C. Chen, D. C. Roy, M. A. Caligiuri, C. D. Bloomfield, J. C. Byrd, D. Perrotti AACR Annual Meeting abstr 1638 2007
Abstract Leuk Corr Sci CALGB-8461, CALGB-9665
<http://www.abstractsonline.com/viewer/viewAbstractPrintFriendly.asp?CKey={6D254926-C351-44CF-8>

1482 FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia

Paolo Neviani, Ramasamy Santhanam, Joshua J. Oaks, Anna M. Eiring, Mario Notari, Bradley W. Blaser, Shujun Liu, Rossana Trotta, Natarajan Muthusamy, Carlo Gambacorti-Passerini, Brian J. Druker, Jorge Cortes, Guido Marcucci, Ching-Shih Chen, Nicole M. Verrills, Denis C. Roy, Michael A. Caligiuri, Clara D. Bloomfield, John C. Byrd, Danilo Perrotti J Clin Invest vol 117 (9) 2408-2421 2007
Manuscript Leuk Corr Sci CALGB-8461, CALGB-9665
<http://www.ncbi.nlm.nih.gov/pubmed/17717597>

1483 Genetic correlates of therapeutic toxicities of stage III colon cancer (CC) patients treated with adjuvant FOLFOX+/-cetuximab (Alliance NCCTG N0147)

Polly A. Newcomb, Wei Sun, Xinwei Hua, Barbara Banbury, Amanda I. Phipps, Jonathan M. Kocarnik, Tabitha A. Harrison, Qian Shi, Frank Sinicrope, Steve Thibodeau, Emily Chan, Sharlene Gill, Richard M. Goldberg, Morton Kahlenberg, Suresh Nair, Anthony Shields, Ulrike Peters, Steve R. Alberts, Andrew T. Chan J Clin Oncol vol 35 (15 suppl) abstr 3604 2017
Abstract PPP http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.3604

1484 Aspirin and COX-2 Inhibitor Use in Patients With Stage III Colon Cancer

Kimmie Ng, Jeffrey A. Meyerhardt, Andrew T. Chan, Kaori Sato, Jennifer A. Chan, Donna Niedzwiecki, Leonard B. Saltz, Robert J. Mayer, Al B. Benson, Paul L. Schaefer, Renaud Whittom, Alexander Hantel, Richard M. Goldberg, Alan P. Venook, Shuji Ogino, Edward L. Giovannucci, Charles S. Fuchs J Natl Cancer Inst vol 107 (1) 2014
Manuscript Prevention <http://www.ncbi.nlm.nih.gov/pubmed/25432409>

1485 Multivitamin Use Is Not Associated With Cancer Recurrence or Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803

Kimmie Ng, Jeffrey A. Meyerhardt, Jennifer A. Chan, Donna Niedzwiecki, Donna R. Hollis, Leonard B. Saltz, Robert J. Mayer, Al B. Benson, Paul L. Schaefer, Renaud Whittom, Alexander Hantel, Richard M. Goldberg, Charles S. Fuchs J Clin Oncol vol 28 (28) 4354-4363 2010
Manuscript GI CALGB-8461, CALGB-9665 <http://www.ncbi.nlm.nih.gov/pubmed/20805450>

1486 Relationship Between Statin Use and Colon Cancer Recurrence and Survival: Results From CALGB 89803

Kimmie Ng, Shuji Ogino, Jeffrey A. Meyerhardt, Jennifer A. Chan, Andrew T. Chan, Donna Niedzwiecki, Donna Hollis, Leonard B. Saltz, Robert J. Mayer, Al B. Benson, Paul L. Schaefer, Renaud Whittom, Alexander Hantel, Richard M. Goldberg, Monica M. Bertagnolli, Alan P. Venook, Charles S. Fuchs J Natl Cancer Inst vol 103 (20) 1540-1551 2011
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/21849660>

1487 Vitamin D Status in Patients With Stage IV Colorectal Cancer: Findings From Intergroup Trial N9741

Kimmie Ng, Daniel J. Sargent, Richard M. Goldberg, Jeffrey A. Meyerhardt, Erin M. Green, Henry C. Pitot, Bruce W. Hollis, Michael N. Pollak, Charles S. Fuchs J Clin Oncol vol 29 (12) 1599-1606 2011
Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/21422438>

1488 Vitamin D status and survival of metastatic colorectal cancer patients: Results from CALGB 80405 (Alliance)

Kimmie Ng, Alan P. Venook, Kaori Sato, Bruce W. Hollis, Donna Niedzwiecki, Cynthia Ye, I-Wen Chang, Bert H. O'Neil, Federico Innocenti, Heinz-Josef Lenz, Charles David Blanke, Robert J. Mayer, Charles S. Fuchs, Jeffrey A. Meyerhardt J Clin Oncol vol 33 (suppl 3) abstr 507 2015
Abstract GI <http://meetinglibrary.asco.org/content/139861-158>

1489 Vitamin D status and survival of metastatic colorectal cancer patients: Results from CALGB/SWOG 80405 (Alliance)

Kimmie Ng, Alan P. Venook, Kaori Sato, Chen Yuan, Bruce W. Hollis, Donna Niedzwiecki, Cynthia Ye, I-Wen Chang, Bert H. O'Neil, Federico Innocenti, Heinz-Josef Lenz, Charles David Blanke, Robert J. Mayer, Charles S. Fuchs, Jeffrey A. Meyerhardt J Clin Oncol vol 33 (suppl) abstr 3503 2015
Abstract GI <http://meetinglibrary.asco.org/content/149805-156>

1490 High expression of DNMT3B negatively impacts on clinical outcome of older patients (pts) with primary cytogenetically normal (CN) acute myeloid leukemia (AML) [CALGB 20202 (Alliance)].

C. Niederwieser, J. Kohlschmidt, K. Maharry, K. Mrózek, K. H. Metzeler, S. Volinia, P. Yan, D.

Frankhouser, S. P. Whitman, H. Becker, Ann-Kathrin Eisfeld, S. Schwind, J. Curfman, Y.-Z. Wu, M. R. Baer, B. L. Powell, J. E. Kolitz, J. O. Moore, T. H. Carter, G. Marcucci, C. D. Bloomfield
European Hematology Association Congress abstr S1168 2013
Abstract Leuk Corr Sci <https://b-com.mci-group.com/EventProgramme/EHA18.aspx>

1491 Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia

Christian Niederwieser, Jessica Kohlschmidt, Stefano Volinia, Susan P. Whitman, Klaus H. Metzeler, Ann-Kathrin Eisfeld, Kati Maharry, Pearly Yan, David Frankhouser, Heiko Becker, Sebastian Schwind, Andrew J. Carroll, Deedra Nicolet, Jason H. Mendler, John P. Curfman, Yue-Zhong Wu, Maria R. Baer, Bayard L. Powell, Jonathan E. Kolitz, Joseph O. Moore, Thomas H. Carter, Ralf Bundschuh, Richard A. Larson, Richard M. Stone, Krzysztof Mrózek, Guido Marcucci, Clara D. Bloomfield *Leukemia* vol 29 (3) 567-575 2015
Manuscript *Leuk Corr Sci* CALGB-8461, CALGB-9665, CALGB-10201, CALGB-20202, CALGB-8525, CALGB-8923, CALGB-9420, CALGB-9720
<http://www.ncbi.nlm.nih.gov/pubmed/25204569>

1492 Chromosome abnormalities at onset of complete remission are associated with worse outcome in patients with acute myeloid leukemia and an abnormal karyotype at diagnosis: CALGB 8461 (Alliance)

Christian Niederwieser, Deedra Nicolet, Andrew J. Carroll, Jonathan E. Kolitz, Bayard L. Powell, Jessica Kohlschmidt, Richard M. Stone, John C. Byrd, Krzysztof Mrózek, Clara D. Bloomfield *Haematologica* vol 101 (12) 1516-23 2016
Manuscript *Leuk Corr Sci* CALGB-10201, CALGB-10502, CALGB-10503, CALGB-10603, CALGB-10801, CALGB-11002, CALGB-19808, CALGB-8461, CALGB-8525, CALGB-8923, CALGB-9022, CALGB-9621, CALGB-9720 <http://www.ncbi.nlm.nih.gov/pubmed/27470602>

1493 Documenting the Natural History of Patients With Resected Stage II Adenocarcinoma of the Colon After Random Assignment to Adjuvant Treatment With Edrecolomab or Observation: Results From CALGB 9581

Donna Niedzwiecki, Monica M. Bertagnolli, Robert S. Warren, Carolyn C. Compton, Nancy E. Kemeny, Al Bowen Benson, S. Gail Eckhardt, Steven Alberts, Gity N. Porjosh, David J. Kerr, Anthony Fields, Philippe Rougier, J. Marc Pipas, Joel H. Schwartz, James Atkins, Mark O'Rourke, Michael C. Perry, Richard M. Goldberg, Robert J. Mayer, Thomas A. Colacchio *J Clin Oncol* vol 29 (23) 3146-3152 2011
Manuscript *GI* <http://www.ncbi.nlm.nih.gov/pubmed/21747085>

1494 Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance)

Donna Niedzwiecki, Wendy L. Frankel, Alan P. Venook, Xing Ye, Paula N. Friedman, Richard M. Goldberg, Robert J. Mayer, Thomas Anthony Colacchio, Jude Marie Mulligan, Timothy S. Davison, Eamonn O'Brien, Peter Kerr, Patrick G. Johnston, Richard D. Kennedy, D. Paul Harkin, Richard L. Schilsky, Monica M. Bertagnolli, Robert S. Warren, Federico Innocenti *J Clin Oncol* vol 34 (25) 3047-3053 2016
Manuscript *Correl Sci NOS* CALGB-9581 <http://www.ncbi.nlm.nih.gov/pubmed/27432924>

1495 A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803

Donna Niedzwiecki, Rian M. Hasson, HeinzJosef Lenz, Cynthia Ye, Mark Redston, Shuji Ogino, Charles S. Fuchs, Carolyn C. Compton, Robert J. Mayer, Richard M. Goldberg, Thomas A. Colacchio, Leonard B. Saltz, Robert S. Warren, Monica M. Bertagnolli *Oncologist* vol 22 (1) 107-114 2017
Manuscript *GI* CALGB-89803, CALGB-9581 <http://www.ncbi.nlm.nih.gov/pubmed/27821793>

1496 Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732.

Harvey B Niell, James E Herndon, Antonius A Miller, Dorothy M Watson, Alan B Sandler, Karen Kelly, Randolph S Marks, Micheal C Perry, Rafat H Ansari, Grefory Otterson, John Ellerton, Everett E Vokes, Mark R Green J Clin Oncol vol 23 (16) 3752-9 2005
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/15923572>

1497 Intrinsic subtype and response to paclitaxel in CALGB 9344 tissue microarrays

T. O. Nielsen, S. D. Jewell, A. D. Thor, D. Gao, C. M. Perou, G. Broadwater, L. N. Harris, D. F. Hayes, D. A. Berry, M. J. Ellis Breast Cancer Symposium abstr 23 2009
Abstract Correl Sci NOS CALGB-9344 <http://meetinglibrary.asco.org/content/40158-70>

1498 A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor positive breast cancer

Torsten O. Nielsen, Joel S Parker, Samuel Leung, David Voduc, Mark Ebbert, Tammi Vickery, Sherri R. Davies, Jacqueline Snider, Inge J. Stijleman, Jerry Reed, Maggie C.U. Cheang, Elaine R. Mardis, Charles M. Perou, Philip S. Bernard, Matthew J. Ellis Clin Cancer Res vol 16 (21) 5222-5232 2010
Manuscript Correl Sci NOS CALGB-159905, CALGB-9344
<http://www.ncbi.nlm.nih.gov/pubmed/20837693>

1499 Pilot randomized trial of an electronic symptom monitoring intervention for hospitalized patients with cancer

R D Nipp, A El-Jawahri, M Ruddy, C Fuh, B Temel, S M D'Arpino, B J Cashavelly, V A Jackson, D P Ryan, E P Hochberg, J A Greer, J S Temel Ann Oncol vol 30 (2) 274-80 2019
Manuscript Health Outcomes <http://www.ncbi.nlm.nih.gov/pubmed/30395144>

1500 Effect of a Symptom Monitoring Intervention for Patients Hospitalized With Advanced Cancer

Ryan D. Nipp, Nora K. Horick, Carolyn L. Qian, Helen P. Knight, Emilia R. Kaslow-Zieve, Chinenye C. Azoba, Madeleine Elyze, Sophia L. Landay, Paul S. Kay, David P. Ryan, Vicki A. Jackson, Joseph A. Greer, Areej El-Jawahri, Jennifer S. Temel JAMA Oncol vol 8 (4) 571-8 2022
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/35142814>

1501 Randomized Trial of a Symptom Monitoring Intervention for Hospitalized Patients with Advanced Cancer. (NCT03396510)

Ryan D. Nipp, Nora Horick, Emilia R. Kaslow-Zieve, Chinenye Azoba, Carolyn Qian, Madeleine Elyze, Helen Knight, Vicki A. Jackson, David P. Ryan, Joseph A. Greer, Areej El-Jawahri, Jennifer S. Temel J Clin Oncol vol 38 (15_suppl) 12014 2020
Abstract Health Outcomes https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.12014

1502 Electronic Patient-Reported Outcomes and Toxicities During Radiotherapy for Head and Neck Cancer

Joshua R. Niska, Michele Y. Halyard, Angelina D. Tan, Pamela J. Atherton, Samir H. Patel, Jeff A. Sloan Qual Life Res vol 26 (7) 1721-31 2017
Manuscript Health Outcomes <http://www.ncbi.nlm.nih.gov/pubmed/28247313>

1503 Identification of predictive biomarkers of overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (I) with or without bevacizumab (B): Results from CALGB 90206 (Alliance)

A. B. Nixon, S. Halabi, I. Shterev, M. D. Starr, J. C. Brady, J. P. Dutcher, J. O. Hopkins, H. I. Hurwitz, E. Small, B. Rini, P. G. Febbo, D. George J Clin Oncol vol 31 (15 suppl) abstr 4520 2013
Abstract GU <http://meetinglibrary.asco.org/content/112878-132>

- 1504 Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: Results from CALGB 80303**
A. B. Nixon, H. Pang, M. D. Starr, D. R. Hollis, M. M. Bertagnolli, H. L. Kindler, R. M. Goldberg, A. P. Venook, H. I. Hurwitz J Clin Oncol vol 29 (suppl) abstr 10508 2011
Abstract GI
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID
- 1505 Predictive biomarkers of overall survival in patients with advanced renal cell carcinoma treated with interferon alpha +/- bevacizumab: Results from CALGB 90206 (Alliance)**
Andrew B. Nixon, Susan Halabi, Yingmiao Liu, Mark D. Starr, John C. Brady, Ivo Shterev, Bin Luo, Herbert I. Hurwitz, Phillip G. Febbo, Brian I. Rini, Himisha Beltran, Eric J. Small, Michael J. Morris, Daniel J. George Clin Cancer Res vol 28 (13) 2771-8 2022
Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/34965953>
- 1506 Prognostic and Predictive Blood-Based Biomarkers in Patients with Advanced Pancreatic Cancer: Results from CALGB80303 (Alliance)**
Andrew B. Nixon, Herbert Pang, Mark D. Starr, Paula N. Friedman, Monica M. Bertagnolli, Hedy L. Kindler, Richard M. Goldberg, Alan P. Venook, Herbert I. Hurwitz Clin Cancer Res vol 19 (24) 6957-6966 2013
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/24097873>
- 1507 Blood-based biomarkers (BMs) in patients (pts) with metastatic colorectal cancer (mCRC) treated with FOLFOX or FOLFIRI + bevacizumab (Bev), cetuximab (Cetux) or Bev + Cetux: Results from CALGB 80405**
Andrew B. Nixon, Alexander B. Sibley, Ace J. Hatch, Yingmiao Liu, Chen Jiang, Flora Mulkey, Mark D. Starr, John C. Brady, Donna Niedzwiecki, Federico Innocenti, Alan P. Venook, Howard Hochster, Heinz-Josef Lenz, Kouros Owzar, Herbert I. Hurwitz J Clin Oncol vol 34 (suppl) abstr 3597 2016
Abstract Correl Sci NOS <http://meetinglibrary.asco.org/content/169258-176>
- 1508 Plasma protein biomarkers in advanced or metastatic colorectal cancer patients receiving chemotherapy with bevacizumab or cetuximab: Results from CALGB 80405 (Alliance)**
Andrew B. Nixon, Alexander B. Sibley, Yingmiao Liu, Ace J. Hatch, Chen Jiang, Flora Mulkey, Mark D. Starr, John C. Brady, Donna Niedzwiecki, Alan P. Venook, Luis Baez-Diaz, Heinz-Josef Lenz, Bert H. O'Neil, Federico Innocenti, Jeffrey A. Meyerhardt, Eileen M O'Reilly, Kouros Owzar, Herbert I. Hurwitz Clin Cancer Res vol 28 (13) 2779-88 2022
Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/34965954>
- 1509 An End-of-study Subgroup Analysis of Black Patients From the Phase 2 GRIFFIN (AFT-29) Study of Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients With Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM)**
Ajay K. Nooka, Jonathan L. Kaufman, Cesar Rodriguez, Andrzej Jakubowiak, Yvonne Efebera, Brandi Reeves, Tanya M. Wildes, Sarah A. Holstein, Larry D. Anderson Jr., Ashraf Badros, Leyla Shune, Ajai Chari, Huiling Pei, Annelore Cortoos, Sharmila Patel, Thomas S. Lin, Shira Dinner, Paul G. Richardson, Saad Z Usmani, Peter Voorhees Blood vol 140 (suppl 1) 10154-6 2022
Abstract Myeloma
<https://ashpublications.org/blood/article/140/Supplement%201/10154/489632/An-End-of-Study-Subgrou>
- 1510 Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN**
Ajay K. Nooka, Jonathan L. Kaufman, Cesar Rodriguez, Andrzej Jakubowiak, Yvonne Efebera, Brandi Reeves, Tanya Wildes, Sarah A. Holstein, Larry D. Anderson Jr, Ashraf Badros, Leyla Shune, Ajai Chari, Huiling Pei, Annelore Cortoos, Sharmila Patel, J. Blake Bartlett, Jessica Vermeulen, Thomas S. Lin, Paul G. Richardson, Peter Voorhees Blood Cancer J vol 12 (4) 2022

1511 Daratumumab (DARA) + Lenalidomide/Bortezomib/Dexamethasone (RVd) in African American/Black Patients (Pts) With Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of GRIFFIN

Ajay K. Nooka, Jonathan L. Kaufman, Cesar Rodriguez, Andrzej Jakubowiak, Leyla Shune, Ashraf Badros, Ajai Chari, Paul G. Richardson, Huiling Pei, Jon Ukropec, Jessica Vermeulen, Daniela Hoehn, Thomas S. Lin, Peter M. Voorhees 2020

Abstract Myeloma <https://clml-soho2020.elsevierdigitaledge.com/II/index.html>

1512 Feasibility of a text-based smoking cessation intervention in rural older adults

D Noonan, S Silva, J Njuru, T Bishop, L J Fish, L A Simmons, S H Choi, K I Pollak Health Educ Res vol 33 (1) 81-88 2018

Manuscript Prevention <http://www.ncbi.nlm.nih.gov/pubmed/29309599>

1513 Impact of Depression and Nicotine Dependence on Executive Functioning in Rural Older Adult Smokers: A Brief Report (NCT02510716)

Devon Noonan, Nikolas J. Silva, Shawn M. McClintock, Susan G. Silva J Addict Nurs vol 32 (4) 249-54 2021

Manuscript Prevention <http://www.ncbi.nlm.nih.gov/pubmed/34855323>

1514 Addressing Tobacco Use Disparities in Rural Older Adults through a Mobile Phone Intervention: Project Wise

Devon Noonan, Susan Silva, Laura Fish, Leigh Ann Simmons, Kathryn Pollak 2017

Abstract Prevention http://www.memphis.edu/sph/rural_cancer_pdfs/rcc_posterabstracts.pdf

1515 Addressing Tobacco Use Disparities in Rural Older Adults through a Mobile Phone Intervention: Project Wise

Devon Noonan, Susan Silva, J. Njuru, T. Bishop, Laura J. Fish, Leigh Ann Simmons, Seung Hee Choi, Kathryn I. Pollak 2017

Abstract Prevention

1516 Phase II trial combining nab-paclitaxel (NP), gemcitabine (G) and bevacizumab (B) in patients (pts) with metastatic breast cancer (MBC): NCCTG N0735

D. W. Northfelt, A. C. Dueck, T. P. Flynn, P. J. Stella, P. J. Zander, M. K. Melnik, E. S. Pavey, E. A. Perez J Clin Oncol vol 29 (suppl) abstr 1126 2011

Abstract Breast

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID

1517 Phase II trial of polyglutamated paclitaxel (PPX) with capecitabine for metastatic breast cancer

D. Northfelt, J. Allred, H. Liu, T. Hobday, M. Rodacker, A. Lyss, T. Fitch, E. Perez J Clin Oncol vol 26 (May 20 suppl) abstr 1063 2008

Abstract Breast

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID

1518 Phase 2 Trial of Paclitaxel Polyglumex with Capecitabine for Metastatic Breast Cancer

DW Northfelt, JB Allred, H Liu, TJ Hobday, MW Rodacker, AP Lyss, TR Fitch, EA Perez Am J Clin Oncol vol 37 (2) 167-171 2014

Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/23211220>

1519 Association Studies of Fc Receptor Polymorphisms with Outcome in HER2+ Breast Cancer Patients Treated with Trastuzumab in NCCTG (Alliance) Trial N9831

Nadine Norton, Rebecca M. Olson, Mark Pegram, Kathleen Tenner, Karla V. Ballman, Raphael

1520 Bendamustine and rituximab and lenalidomide (BRR) in the treatment of relapsed and refractory low grade non-Hodgkin lymphoma (NHL): Final results of phase 1 study NCCTG N1088/Alliance

Grzegorz S. Nowakowski, Betsy LaPlant, William R. Macon, Morie A. Gertz, Thomas M. Habermann, David J. Inwards, Ivana N. Micallef, Donald B. Wender, John P. Leonard, Thomas E. Witzig J Clin Oncol vol 33 (suppl) abstr 8540 2015
Abstract Lymphoma <http://meetinglibrary.asco.org/content/152133-156>

1521 VATS Lobectomy Has Better Peri-operative Outcomes than Open Lobectomy: Ancillary Analysis of CALGB 140202 (Alliance)

C. E. Nwogu, J. D'cunha, H. Pang, L. Gu, X. Wang, W. G. Richards, L. J. Veit, T. L. Demmy, D. J. Sugarbaker, L. J. Kohman, S. J. Swanson 2014
Abstract Respiratory
<http://www.sts.org/search/google?cx=014846217445771685953%3Aindljwu5dcc&cof=FORID%3A11&>

1522 VATS Lobectomy Has Better Peri-operative Outcomes than open Lobectomy: CALGB 31001, an Ancillary Analysis of CALGB 140202 (Alliance)

Chukwumere E. Nwogu, Jonathan D'Cunha, Herbert Pang, Lin Gu, Xiaofei Wang, William G. Richards, Linda J. Veit, Todd L. Demmy, David J. Sugarbaker, Leslie J. Kohman, Scott J. Swanson Ann Thorac Surg vol 99 (2) 399-405 2015
Manuscript Respiratory CALGB-140202 <http://www.ncbi.nlm.nih.gov/pubmed/25499481>

1523 Trial In Progress: A Phase II Study of Lenalidomide, Ixazomib, Dexamethasone, and Daratumumab in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (AFT-41).

Elizabeth O'Donnell, Vera Suman, Susan Geyer, Omar Nadeem, Shira Dinner, Andrew J. Yee, Jacob Laubach, Clifton Mo, Sascha Tuchman, Kristen Donadio, Sarah Sinclair, Noopur Raje, Paul Richardson Blood vol 138 (Supplement 1) 4776 2021
Abstract Myeloma
<https://ashpublications.org/blood/article/138/Supplement%201/4776/481794/A-Phase-II-Study-of-Lenali>

1524 A phase II trial of sunitinib (S) in previously-treated pancreas adenocarcinoma (PAC), CALGB 80603

E. M. O'Reilly, L. F. Gilman-Rosen, D. Niedzwiecki, D. R. Hollis, S. L. Sutherland, F. M. Overcash, R. M. Goldberg J Clin Oncol vol 26 (May 20 suppl) abstr 4515 2008
Abstract GI
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID

1525 A Cancer and Leukemia Group B Phase II Study of Sunitinib Malate in Patients with Previously Treated Metastatic Pancreatic Adenocarcinoma (CALGB 80603)

Eileen M. O'Reilly, Donna Niedzwiecki, Margaret Hall, Donna Hollis, Tanios Bekaii-Saab, Timothy Pluard, Kathe Douglas, Ghassan K. Abou-Alfa, Hedy L. Kindler, Richard L. Schilsky, Richard M. Goldberg Oncologist vol 15 (12) 1310-1319 2010
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/21148613>

1526 Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer (NCT04457596)

Ciara C. O'Sullivan, Karla V. Ballman, Linda McCall, Tyler Zemla, Anna Weiss, Melissa Mitchell, Victoria Blinder, Nadine M. Tung, William J. Irvin, Myounghee Lee, Matthew P. Goetz, W. Fraser Symmans, Virginia F. Borges, Ian Krop, Ann H. Partridge, Lisa A. Carey J Clin Oncol vol 39 (suppl 15) TPS595 2021

1527 Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer

Ciara C O'Sullivan, Karla V Ballman, Linda McCall, Anuhya Kommalapati, Tyler Zemla, Anna Weiss, Melissa Mitchell, Victoria Blinder, Nadine M Tung, William J Irvin, Myounghee Lee, Matthew P Goetz, William Fraser Symmans, Virginia F Borges, Ian Krop, Lisa A Carey, Ann H Partridge *Future Oncol* vol 17 (34) 4665-76 2021

Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/34636255>

1528 LE-SN38 for metastatic colorectal cancer after progression on oxaliplatin CALGB 80402

A. J. Ocean, D. Niedzwiecki, J. N. Atkins, B. A. Parker, B. O'Neil, J. W. Lee, S. Wadler, R. M. Goldberg *J Clin Oncol* vol 26 (May 20 suppl) abstr 4109 2008

Abstract GI http://meeting.ascopubs.org/cgi/content/short/26/15_suppl/4109

1529 KRAS mutation is not associated with recurrence or survival in 508 stage III colon cancers: Findings from multicenter adjuvant trial CALGB 89803

S. Ogino, J. A. Meyerhardt, N. Irahara, D. Niedzwiecki, D. R. Hollis, L. B. Saltz, R. J. Mayer, P. Schaefer, R. Whittom, A. Hantel, A. B. Benson 3rd, R. M. Goldberg, M. M. Bertagnolli, C. S. Fuchs *Annual Meeting Association of Molecular Pathology STO2* 2009

Abstract GI http://www.amp.org/meetings/past_meetings.cfm

1530 Predictive and Prognostic Analysis of PIK3CA Mutation in Stage III Colon Cancer Intergroup Trial

Shuji Ogino, Xiaoyun Liao, Yu Imamura, Mai Yamauchi, Nadine J. McCleary, Kimmie Ng, Donna Niedzwiecki, Leonard B. Saltz, Robert J. Mayer, Renaud Whittom, Alexander Hantel, Al B. Benson, Rex B. Mowat, Donna Spiegelman, Richard M. Goldberg, Monica M. Bertagnolli, Jeffrey A. Meyerhardt, Charles S. Fuchs *J Natl Cancer Inst* vol 105 (23) 1789-1798 2013

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/24231454>

1531 KRAS Mutation in Stage III Colon Cancer and Clinical Outcome Following Intergroup Trial CALGB 89803

Shuji Ogino, Jeffrey A. Meyerhardt, Natsumi Irahara, Donna Niedzwiecki, Donna Hollis, Leonard B. Saltz, Robert J. Mayer, Paul Schaefer, Renaud Whittom, Alexander Hantel, Al B. Benson, Richard M. Goldberg, Monica M. Bertagnolli, Charles S. Fuchs *Clin Cancer Res* vol 15 (23) 7322-7329 2009

Manuscript GI CALGB-89803 <http://www.ncbi.nlm.nih.gov/pubmed/19934290>

1532 Predictive and Prognostic Roles of BRAF Mutation in Stage III Colon Cancer: Results from Intergroup Trial CALGB 89803

Shuji Ogino, Kaori Shima, Jeffrey A. Meyerhardt, Nadine J. McCleary, Kimmie Ng, Donna Hollis, Leonard B. Saltz, Robert J. Mayer, Paul Schaefer, Renaud Whittom, Alexander Hantel, Al B. Benson, Donna Spiegelman, Richard M. Goldberg, Monica M. Bertagnolli, Charles S. Fuchs *Clin Cancer Res* vol 18 (3) 890-900 2012

Manuscript GI CALGB-89803 <http://www.ncbi.nlm.nih.gov/pubmed/22147942>

1533 A phase 2 study of gemcitabine and epirubicin for the treatment of pleural mesothelioma: a North Central Cancer Treatment Study, N0021.

Scott H Okuno, Robert Delaune, Jeff A Sloan, Nathan R Foster, Matthew J Maurer, Marie-Christine Aubry, Kendrith M Rowland, Gamini S Soori, Daniel A Nikcevich, Carl G Kardinal, Donald W Northfelt, Alex A Adjei *Cancer* vol 112 (8) 1772-9 2008

Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/18224661>

1534 Arm swelling and psychological well-being among long-term breast cancer survivors

J. M. Oliveri, J. Day, C. M. Alfano, J. E. Herndon 2nd, M. L. Katz, M. L. Bittoni, E. D. Paskett
American Public Health Association Annual Meeting vol 135 abstr 163789 2007
Abstract Health Outcomes http://apha.confex.com/apha/135am/techprogram/paper_163789.htm

1535 Arm/Hand Swelling and Perceived Functioning among Breast Cancer Survivors 12 Years Post-diagnosis: CALGB 79804

Jill M. Oliveri, Jeannette M. Day, Catherine M. Alfano, James E. Herndon, Mira L. Katz, Marisa A. Bittoni, Kathleen Donohue, Electra D. Paskett J Cancer Surviv vol 2 (4) 233-242 2008
Manuscript Health Outcomes <http://www.ncbi.nlm.nih.gov/pubmed/18792786>

1536 Impact of neoadjuvant chemotherapy plus HER2-targeting on breast conservation rates: Surgical results from CALGB 40601 (Alliance)

D. Ollila, D. Berry, C. Cirrincione, L. Carey, K. Amos, N. L. Henry, E. Winer, C. Hudis, M. Golshan J Clin Oncol vol 31 (15 suppl) abstr 501 2013
Abstract Breast
http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/501?sid=211d90d6-54e6-40ec-951b-49deb

1537 Axillary Management of Stage II/III Breast Cancer Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-positive) and CALGB 40603 (Triple-negative)

David W Ollila, Constance T Cirrincione, Donald A Berry, Lisa A Carey, William M Sikov, Clifford A Hudis, Eric P Winer, Mehra Golshan J Am Coll Surg vol 224 (4) 688-94 2017
Manuscript Breast CALGB-40601, CALGB-40603 <http://www.ncbi.nlm.nih.gov/pubmed/28089784>

1538 Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL

Adam Olshen, Denise Wolf, Ella F. Jones, David Newitt, Laura J. van 't Veer, Christina Yau, Laura Esserman, Julia D. Wulfkuhle, Rosa I. Gallagher, Lisa Singer, Emanuel F. Petricoin, Nola Hylton, Catherine C. Park J Med Imaging (Bellingham) vol 5 (1) 011014 2018
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/29296631>

1539 Correlates of overall survival (OS) in metastatic vs. primary uveal melanoma (UM) and results of a randomized trial of cabozantinib (cabo) vs. chemotherapy (chemo) Alliance A091201

Daniel J. Olson, Riyue Bao, Jacob B. Allred, Carrie A. Strand, Yuanyuan Zha, Timothy Carll, Brian W. Labadie, Bruno R. Bastos, Marcus Butler, Pamela Munster, Gary K. Schwartz, Jason J. Luke J Clin Oncol vol 37 (suppl) abstr 9506 2019
Abstract Experimental <https://meetinglibrary.asco.org/record/173443/abstract>

1540 ACOSOG Z1031: A randomized phase II trial comparing exemestane, letrozole and anastrozole in postmenopausal women with clinical stage II/III estrogen receptor positive breast cancer

J. A. Olson Jr, G. V. Babiera, G. Unzeitig, P. K. Marcom, J. M. Guenther, K. Deschryver, C. Allred, V. Suman, K. Hunt, M. J. Ellis Breast Cancer Symposium abstr 91 2010
Abstract Breast http://ascopubs.org/doi/abs/10.1200/jco.2010.28.18_suppl.lba513

1541 Impact of immediate versus delayed axillary node dissection on surgical outcomes in breast cancer patients with positive sentinel nodes: results from American College of Surgeons Oncology Group Trials Z0010 and Z0011.

John A Olson, Linda M McCall, Peter Beitsch, Pat W Whitworth, Douglas S Reintgen, Peter W Blumencranz, A Marilyn Leitch, Sukamal Saha, Kelly K Hunt, Armando E Giuliano J Clin Oncol vol 26 (21) 3530-5 2008
Manuscript Breast ACOSOG-Z0010, ACOSOG-Z0011
<http://www.ncbi.nlm.nih.gov/pubmed/18640934>

- 1542 Relationship of dietary and red blood cell (RBC) polyunsaturated fatty acids (PUFAs) to inflammatory markers in breast cancer survivors taking Aromatase Inhibitors (AI)**
TS Orchard, X Pan, Lester. J, A Logan, CL Shapiro, RD Jackson, MA Belury, L Yee, MB Lustberg
Cancer Res vol 75 (9 suppl) abstr P1-09-30 2015
Abstract Symptom Inter http://cancerres.aacrjournals.org/content/75/9_Supplement/P1-09-30
- 1543 Testing a Mixture of Fats and Oils for Use as a Placebo in Clinical Trials.**
Tonya S. Orchard, Martha A. Belury, Rachel Cole, Rebecca Andridge, Xueliang Pan, Joanne Lester, Amanda Logan, Lisa Yee, Maryam B. Lustberg 2015
Abstract Symptom Inter
<http://www.aocs.org/attend-meetings/archives/106th-aocs-annual-meeting-and-short-courses>
- 1544 Diet Quality, Inflammation and Quality of Life in Breast Cancer Survivors; a Cross-Sectional Analysis of Pilot Study Data**
Tonya Orchard, Rebecca R. Andridge, Lisa D. Yee, Maryam B. Lustberg J Acad Nutr Diet vol 118 (4) 578-88 2018
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/29233615>
- 1545 Bortezomib and Pegylated Liposomal Doxorubicin as Induction Therapy for Adult Patients with Symptomatic Multiple Myeloma: Cancer and Leukemia Group B Study 10301**
R. Z. Orlowski, B. L. Peterson, B. Sanford, A. A. Chanan-Khan, L. M. Zehngebot, P. R. Watson, M. A. Caligiuri, R. A. Larson, The Cancer Leukemia Group B ASH Annual Meeting Abstracts vol 108 (11) 797 2006
Abstract Leukemia <http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;108/11/797>
- 1546 Survival implications of variation in the thoroughness of pathologic lymph node examination in American College of Surgeons Oncology Group Z0030 (Alliance)**
Raymond U. Osarogiagbon, Paul A. Decker, Karla Ballman, Dennis Wigle, Mark S. Allen, Gail E. Darling Ann Thorac Surg vol 102 (2) 363-369 2016
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/27262908>
- 1547 Survival implications of variation in the lymph node (LN) count in ACOSOG Z0030 (Alliance)**
Raymond U. Osarogiagbon, Paul Decker, Karla Ballman, Dennis Wigle, Mark Allen, Gail Darling J Thorac Oncol vol 10 (9) suppl 2, abstr 34-05 2015
Abstract Respiratory [http://www.jto.org/article/S1556-0864\(16\)30010-7/fulltext](http://www.jto.org/article/S1556-0864(16)30010-7/fulltext)
- 1548 Phase II Study of the HDAC Inhibitor Romidepsin in Relapsed Small Cell Lung Cancer (CALGB 30304)**
G.A. Otterson, L. Hodgson, H. Pang, E.E. Vokes J Thorac Oncol vol 5 (10) 1644-1648 2010
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/20871263>
- 1549 Milestone prediction for time-to-event endpoint monitoring in clinical trials**
Fang-Shu Ou, Martin Heller, Qian Shi Pharm Stat vol 18 (4) 433-46 2019
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/30806485>
- 1550 Concomitant use of midostaurin with Strong CYP3A4 inhibitors: An analysis from the CALGB 10603/RATIFY Trial (Alliance)**
Taoufik Ouatas, Vincent Duval, Karen Sinclair, Noah Berkowitz Blood vol 130 (Suppl 1) 3814 2017
Abstract Leukemia http://www.bloodjournal.org/content/130/Suppl_1/3814
- 1551 Adjuvant targeted therapy following standard adjuvant therapy for resected NSCLC: An initial report from ALCHEMIST (Alliance A151216)**
Geoffrey R. Oxnard, Sumithra Mandrekar, Shauna Hillman, Angelina Tan, Ramaswamy Govindan,

Dennis Wigle, Shakun Malik, Colleen Watt, David Gerber, Jamie Chaft, Suzanne Dahlberg, Karen Kelly, David R. Gandara, Meredith Faggen, TBD, Philip Stella, Karim Tazi, Suresh Ramalingam, Thomas E. Stinchcombe J Thorac Oncol vol 13 (10) S646-47, abstr P1.16-47 2018
Abstract Respiratory [https://www.jto.org/article/S1556-0864\(18\)31974-9/fulltext](https://www.jto.org/article/S1556-0864(18)31974-9/fulltext)

1552 Effectiveness of an online decision support tool in communicating information about treatment options and related risks for ductal carcinoma in situ (DCIS) (AFT-25)

Elissa Ozanne, Ann Partridge, Shelley Hwang, Alastair Thompson, Elizabeth Frank, Donna Pinto, Deborah Collyar, Desiree Basila, Thomas Lynch, Terry Hyslop, Marc D. Ryser, Rinaa Punglia 2021
Abstract Breast

1553 White Blood Cell Count (WBC) Levels Are Associated With Prognosis and Molecular Profiles of Younger (<60 Years) Patients (Pts) Diagnosed with Acute Myeloid Leukemia (AML) (Alliance)

Michael Ozga, Deedra Nicolet, Krzysztof Mrózek, Christopher J. Walker, James S. Blachly, Jessica Kohlschmidt, Shelley Orwick, Andrew J. Carroll, Jonathan E. Kolitz, Bayard L. Powell, Richard M. Stone, John C. Byrd, Alice S. Mims, Ann-Kathrin Einfeld Blood vol 138 (Supplement 1) 3369 2021
Abstract Leuk Corr Sci CALGB-20202, CALGB-8461, CALGB-9665
<https://ashpublications.org/blood/article/138/Supplement%201/3369/479241/White-Blood-Cell-Count-W>

1554 Sex-associated differences in frequencies and outcome prognostication of recurrent molecular features in adults with acute myeloid leukemia (AML) (Alliance)

Michael Ozga, Deedra Nicolet, Krzysztof Mrózek, Selen A. Yilmaz, Jessica Kohlschmidt, Karilyn T. Larkin, James S. Blachly, Christopher C. Oakes, Jill Buss, Christopher J. Walker, Shelley Orwick, Vindi Jurinovic, Maja Rothenberg-Thurley, Annika Dufour, Stephanie Schneider, Maria Cristina Sauerland, Dennis Görlich, Utz Krug, Wolfgang E. Berdel, Bernhard J. Woermann, Wolfgang Hiddemann, Jan Braess, Marion Subklewe, Karsten Spiekermann, Andrew J. Carroll, William G. Blum, Bayard L. Powell, Jonathan E. Kolitz, Joseph O. Moore, Robert J. Mayer, Richard A. Larson, Geoffrey Uy, Wendy Stock, Klaus H. Metzeler, Harry L. Grimes, John C. Byrd, Nathan Salomonis, Tobias Herold, Alice S. Mims, Ann-Kathrin Einfeld Blood (vol 140 (suppl 1) 936–9 2022
Abstract Leuk Corr Sci CALGB-20202, CALGB-8461, CALGB-9665
<https://ashpublications.org/blood/article/140/Supplement%201/936/487328/Sex-Associated-Differences->

1555 Randomized Clinical Trial of Imiquimod: An Adjunct to Treating Cervical Dysplasia

Deirdre R. Pachman, Debra L. Barton, Amy H. Clayton, Renee M. McGovern, John A. Jefferies, Paul J. Novotny, Jeff A. Sloan, Charles L. Loprinzi, Bobbie S. Gostout Am J Obstet Gynecol vol 206 (1) 42.e1-42.e7 2012
Manuscript Prevention <http://www.ncbi.nlm.nih.gov/pubmed/21907959>

1556 Clinical course of patients with oxaliplatin-associated neuropathy: N08CB (Alliance)

Deirdre R. Pachman, Rui Qin, Drew K. Seisler, Ellen M. Lavoie Smith, Andreas S. Beutler, Lauren E. Ta, Jacqueline M. Lafky, Nina Wagner-Johnston, Kathryn Jean Ruddy, Shaker R. Dakhil, Axel Grothey, Charles L. Loprinzi J Clin Oncol vol 32 (15_suppl) 3595 2014
Abstract Symptom Inter http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/3595

1557 Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance)

Deirdre R. Pachman, Rui Qin, Drew K. Seisler, Ellen M.L. Smith, Andreas S. Beutler, Lauren E. Ta, Jacqueline M. Lafky, Nina D. Wagner-Johnston, Kathryn J. Ruddy, Shaker Dakhil, Nathan P. Staff, Axel Grothey, Charles L. Loprinzi J Clin Oncol vol 33 (30) 3416-3422 2015
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/26282635>

1558 Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505)

Deirdre R. Pachman, Rui Qin, Drew Seisler, Ellen M. Lavoie Smith, Suneetha Kaggal, Paul Novotny,

Kathryn J. Ruddy, Jacqueline M. Lafky, Lauren E. Ta, Andreas S. Beutler, Nina D. Wagner-Johnston, Nathan P. Staff, Axel Grothey, Patrick M. Dougherty, Guido Cavaletti, Charles L. Loprinzi Support Care Cancer vol 24 (12) 5059-5068 2016
Manuscript Symptom Inter NCCTG-N08C1, NCCTG-N08CB
<http://www.ncbi.nlm.nih.gov/pubmed/27534963>

1559 The comparative effectiveness of decision aids in diverse populations with early stage prostate cancer: a study protocol for a cluster-randomized controlled trial in the NCI Community Oncology Research Program (NCORP), Alliance A191402CD

Joel E. Pacyna, Simon Kim, Kathleen Yost, Hillary Sedlacek, Daniel Petereit, Judith Kaur, Bruce Rapkin, Robert Grubb, Electra Paskett, George J. Chang, Jeff Sloan, Ethan Basch, Brittany Major, Paul Novotny, John Taylor, Jan Buckner, J. Kellogg Parsons, Michael Morris, Jon C. Tilburt BMC Cancer vol 18 (1) 788 2018
Manuscript CCDR <http://www.ncbi.nlm.nih.gov/pubmed/30081846>

1560 Lessons learned from implementing the first Alliance NCORP Research Base Cancer Care Delivery Research (CCDR) trial A191402CD

Joel E. Pacyna, Jeff Sloan, Simon Kim, Hillary Sedlacek, Jon Tilburt J Clin Oncol vol 36 (30_suppl) abstr 175 2018
Abstract Disparities http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.30_suppl.175?af=R

1561 Lessons learned from conducting the first cancer care delivery trial in the Alliance for Clinical Trials in Oncology (Alliance A191402CD).

Joel E Pacyna, Amylou C Dueck, George J Chang, Selina Chow, Electra D Paskett, Simon Kim, Jon C Tilburt Clin Trials vol 20 (5) 559-63 2023
Manuscript CCDR <http://www.ncbi.nlm.nih.gov/pubmed/37050880>

1562 Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor positive (HR+) early breast cancer (BC): Update of the combined TEXT and SOFT trials

Olivia Pagani, Meredith M. Regan, Gini F. Fleming, Barbara A. Walley, Marco Colleoni, István Láng, Henry L. Gomez, Carlo Tondini, Harold J. Brustein, Matthew P. Goetz, Eva M. Ciruelos, Vered Stearns, Hervé R. Bonefoi, Silvana Martino, Charles E. Geyer Jr., Graziella Pinotti, Alan S. Coates, Aron Goldhirsch, Richard D. Gelber, Prudence A. Francis Cancer Res vol 78 (4 Supplement) GS4-02 2018
Abstract Breast IBCSG-24-02 (SOFT-TEXT), IBCSG-25-02 (TEXT)
http://cancerres.aacrjournals.org/content/78/4_Supplement/GS4-02

1563 Prognostic value of clinical treatment score post-5 years (CTS5) and late relapse risk in hormone receptor-positive HER2-positive breast cancer in the North Central Cancer treatment group (NCCTG) N9831 (Alliance) and NSABP-B31 (NRG) trials

Tanmayi Pai, Angelica Gil, Yaohua Ma, Zhuo Li, Pooja Advani, Alvaro Moreno-Aspitia, Gerardo Colon-Otero, Edith A. Perez, Yan Asmann, Katherine Pogue-Geile, E.A. Thompson, Saranya Chumsri Cancer Res vol 81 (4 Supplement) PS6-03 2020
Abstract Breast NCCTG-N9831, NSABP B-31
https://cancerres.aacrjournals.org/content/81/4_Supplement/PS6-03

1564 Value of CTS5 for Late Relapse Risk Assessment in Patients with Early Stage HER2+ Breast Cancer in the NCCTG N9831 (Alliance) Trial

Tanmayi Pai, Angelica Gil, Yaohua Ma, Zhuo Li, Pooja Advani, Alvaro Moreno-Aspitia, Gerardo Colon-Otero, Edith A. Perez, E.A. Thompson, Saranya Chumsri J Clin Oncol vol 38 (15_suppl) 529 2020
Abstract Breast https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.529

1565 Association of Long-term Outcomes With Stereotactic Radiosurgery vs Whole-Brain Radiotherapy for Resected Brain Metastasis

Joshua D. Palmer, Brett G. Klamer, Karla V. Ballman, Paul D. Brown, Jane H. Cerhan, S. Keith Anderson, Xiomara W. Carrero, Anthony C. Whitton, Jeffrey Greenspoon, Ian F. Parney, Nadia N.I. Laack, Jonathan B. Ashman, Jean-Paul Bahary, Costas G. Hadjipanayis, James J. Urbanic, Fred G. Barker II, Elana Farace, Deepak Khuntia, Caterina Giannini, Jan C. Buckner, Evanthia Galanis, David Roberge JAMA Oncol vol 8 (12) 1809-15 2022

Manuscript Neuro-Onc <http://www.ncbi.nlm.nih.gov/pubmed/36264568>

1566 Effect of stereotactic radiosurgery compared to whole-brain radiotherapy for limited brain metastasis on long term cognition and quality of life: A pooled analysis of N107C/CEC.3 and N0574 randomized clinical trials (Alliance)

Joshua D. Palmer, Brett G. Klamer, Karla V. Ballman, Paul D. Brown, Jane H. Cerhan, S. Keith Anderson, Anthony C. Whitton, Jeffrey Greenspoon, Caroline Chung, Stuart H. Burri, Ian F. Parney, Volker W. Stieber, Bruce E. Pollock, Nadia N.I. Laack, Jonathan B. Ashman, Jean-Paul Bahary, Fred G. Barker II, Evanthia Galanis, Anthony L. Asher, David Roberge Int J Radiation Biol Physics vol 108 (3, Supplement) S175-S176 2020

Abstract Health Outcomes NCCTG-N0574, NCCTG-N107C

[https://www.redjournal.org/article/S0360-3016\(20\)32374-9/abstract](https://www.redjournal.org/article/S0360-3016(20)32374-9/abstract)

1567 Validation of survival prognostic models for non-small-cell lung cancer instage- and age-specific groups

H. Pang, L. Gu, W. Richards, J. Crawford, M. Green, E. Vokes, X. Wang Cancer Res vol 73 (8 (suppl)) abstr 4707 2013

Abstract Respiratory CALGB-8834, CALGB-8836, CALGB-8931, CALGB-8932, CALGB-9132, CALGB-9532, CALGB-140202, CALGB-140203, CALGB-30203, CALGB-30303, CALGB-30402, CALGB-30406, CALGB-30506, CALGB-30704, CALGB-39802, CALGB-39809, CALGB-39904, CALGB-9238, CALGB-9335, CALGB-9633, CALGB-9730, CALGB-9731, CALGB-9761

http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/73/8_MeetingAbstracts/4707

1568 Validation of the CALGB and EORTC Prognostic Models for Mesothelioma Based on Multiple CALGB Trials (Alliance)

Herbert Pang, Lydia Hodgson, Robert Kratzke, Jeffrey Crawford, Hedy Kindler, Everett Vokes, Xiaofei Wang J Thorac Oncol vol 8 (2) 933, abstract P2.14-002 2013

Abstract Respiratory CALGB-8435, CALGB-8638, CALGB-8833, CALGB-8933, CALGB-9031, CALGB-9131, CALGB-9234, CALGB-9530, CALGB-9631, CALGB-9733, CALGB-30101, CALGB-30107, CALGB-30307, CALGB-30601, CALGB-39807

http://library.iaslc.org/search-speaker?search_speaker=20847

1569 Prognostic Model for Mesothelioma Based on Cancer and Leukemia Group B (CALGB) Trials (Alliance)

Herbert Pang, Kang Yan, Robert Kratzke, Thomas Stinchcombe, Jeffrey Crawford, Hedy Kindler, Everett Vokes, Xiaofei Wang J Thorac Oncol vol 12 (1) Suppl, pg S1367 2017

Abstract Respiratory CALGB-30101, CALGB-30107, CALGB-30307, CALGB-30601, CALGB-39807, CALGB-8435, CALGB-8638, CALGB-8833, CALGB-8933, CALGB-9031, CALGB-9131, CALGB-9234, CALGB-9530, CALGB-9631, CALGB-9733

[http://www.jto.org/article/S1556-0864\(16\)33176-8/abstract](http://www.jto.org/article/S1556-0864(16)33176-8/abstract)

1570 Differential Clinical Impact Of Gene Mutations and Their Combinations In Primary Cytogenetically Normal Acute Myeloid Leukemia (CN-AML)

Dimitrios Papaioannou, Kati Maharry, Krzysztof Mrózek, Heiko Becker, Klaus H. Metzeler, Jason H. Mender, Susan P. Whitman, Ann-Kathrin Eisfeld, Sebastian Schwind, Yue-Zhong Wu, Deedra

Nicolet, Jonathan E. Kolitz, Maria R. Baer, Bayard L. Powell, Donna Bucci, Michael A. Caligiuri, Andrew J. Carroll, Stefano Volinia, Richard M. Stone, Guido Marcucci, Clara D. Bloomfield *Blood* vol 122 (21) Abstract 2540 2013
Abstract *Leuk Corr Sci* CALGB-20202, CALGB-9665, CALGB-8461
<http://www.bloodjournal.org/content/122/21/2540.abstract?sso-checked=true>

1571 Next-Generation RNA Sequencing-Based Analysis Identifies a Novel Set of Prognostic MicroRNAs (miRs) in Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) (Alliance)

Dimitrios Papaioannou, Deedra Nicolet, Kellie J. Archer, Allison Walker, Krzysztof Mrózek, Andrew J. Carroll, Jessica Kohlschmidt, Ann-Kathrin Einfeld, Bayard L. Powell, Geoffrey L. Uy, Jonathan E. Kolitz, Richard M. Stone, John C. Byrd, Ramiro Garzon, Clara D. Bloomfield *Blood* vol 134 (Supplement_1) 2694 2019
Abstract *Leuk Corr Sci* CALGB-20202, CALGB-8461, CALGB-9665
https://ashpublications.org/blood/article/134/Supplement_1/2694/423120/Next-Generation-RNA-Sequen

1572 Prognostic and Biologic Relevance of Clinically Applicable Long Non-Coding RNA Profiling in Older Patients with Cytogenetically Normal Acute Myeloid Leukemia

Dimitrios Papaioannou, Deedra Nicolet, Hatice G. Ozer, Krzysztof Mrózek, Stefano Volinia, Paolo Fadda, Andrew J. Carroll, Jessica Kohlschmidt, Jonathan E. Kolitz, Eunice S. Wang, Richard M. Stone, John C. Byrd, Ramiro Garzon, Clara D. Bloomfield *Mol Cancer Ther* vol 18 (8) 1451-9 2019
Manuscript *Leuk Corr Sci* CALGB-8525, CALGB-8621, CALGB-9720, CALGB-10201, CALGB-10502, CALGB-10801, CALGB-11001, CALGB-8923
<http://www.ncbi.nlm.nih.gov/pubmed/31164409>

1573 Prognostic and biologic significance of long non-coding RNA (lncRNA) profiling in cytogenetically abnormal acute myeloid leukemia (CA-AML)

Dimitrios Papaioannou, Deedra Nicolet, Xiaoqing Rong-Mullins, Krzysztof Mrózek, Jessica Kohlschmidt, Andrew J. Carroll, John C. Byrd, Kellie J. Archer, Jonathan E. Kolitz, Bayard L. Powell, Richard M. Stone, Geoffrey L. Uy, Eunice S. Wang, Wendy Stock, Ramiro Garzon, Clara D. Bloomfield *Blood* vol 132 abstr 2767 2018
Abstract *Leuk Corr Sci* CALGB-8461, CALGB-9665, CALGB-20202
http://www.bloodjournal.org/content/132/Suppl_1/2767

1574 Prognostic and biologic significance of long non-coding RNA profiling in younger adults with cytogenetically normal acute myeloid leukemia

Dimitrios Papaioannou, Deedra Nicolet, Stefano Volinia, Krzysztof Mrózek, Pearly Yan, Ralf Bundschuh, Andrew J. Carroll, Jessica Kohlschmidt, William Blum, Bayard L. Powell, Geoffrey L. Uy, Jonathan E. Kolitz, Eunice S. Wang, Ann-Kathrin Einfeld, Shelley J. Orwick, David M. Lucas, Michael A. Caligiuri, Richard M. Stone, John C. Byrd, Ramiro Garzon, Clara D. Bloomfield *Haematologica* vol 102 (8) 1391-1400 2017
Manuscript *Leuk Corr Sci* CALGB-10503, CALGB-10603, CALGB-19808, CALGB-20202, CALGB-8461, CALGB-8525, CALGB-9022, CALGB-9222, CALGB-9621, CALGB-9665
<http://www.ncbi.nlm.nih.gov/pubmed/28473620>

1575 Long non-coding RNA profiling provides important prognostic information and biologic insights in younger patients (pts) with cytogenetically normal acute myeloid leukemia (CN-AML) (Alliance) CALGB 8461, 9665, and 20202.

Dimitrios Papaioannou, Deedra Nicoleta, Stefano Volinia, Krzysztof Mrózek, Pearly Yan, Andrew J. Carroll, Jessica Kohlschmidt, William Bluma, Bayard L. Powell, Geoffrey L. Uy, Jonathan E. Kolitz, Eunice S. Wang, Ann-Kathrin Einfeld, David M. Lucas, Michael A. Caligiuri, Richard M. Stone, John C. Byrd, Ramiro Garzon, Clara D. Bloomfield 2016
Abstract *Leuk Corr Sci* CALGB-20202, CALGB-8461, CALGB-9665
<http://learningcenter.ehaweb.org/eha/2016/21st/135304/dimitrios.papaioannou.long.non-coding.rna.profi>

1576 Recurrent Genetic Variants of Long Non-Coding RNAs Independently Associate with Clinical Outcome of Younger Adults with Cytogenetically Normal Acute Myeloid Leukemia (ALLIANCE/CALGB 8461, 9665, 20202)

Dimitrios Papaioannou, Gulcin H. Ozer, Deedra Nicolet, Krzysztof Mrózek, Stefano Volinia, Andrew J. Carroll, Jessica Kohlschmidt, William Blum, Bayard L. Powell, Geoffrey L. Uy, Eunice S. Wang, Jonathan E. Kolitz, Ann-Kathrin Einfeld, Richard M. Stone, John C. Byrd, Ramiro Garzon, Clara D. Bloomfield *Blood* vol 130 (Suppl 1) 1401 2017

Abstract *Leuk Corr Sci* CALGB-20202, CALGB-8461, CALGB-9665
http://www.bloodjournal.org/content/130/Suppl_1/1401

1577 Clinical and molecular relevance of genetic variants in the non-coding transcriptome of patients with cytogenetically normal acute myeloid leukemia

Dimitrios Papaioannou, Hatice G. Ozer, Deedra Nicolet, Amog P. Urs, Tobias Herold, Krzysztof Mrózek, Aarif M.N. Batcha, Klaus H. Metzeler, Ayse S. Yilmaz, Stefano Volinia, Marius Bill, Jessica Kohlschmidt, Maciej Pietrzak, Christopher J. Walker, Andrew J. Carroll, Jan Braess, Bayard L. Powell, Ann-Kathrin Einfeld, Geoffrey L. Uy, Eunice S. Wang, Jonathan E. Kolitz, Richard M. Stone, Wolfgang Hiddemann, John C. Byrd, Clara D. Bloomfield, Ramiro Garzon *Haematologica* vol 107 (5) 1034-44 2021

Manuscript *Leuk Corr Sci* CALGB-20202 <http://www.ncbi.nlm.nih.gov/pubmed/34261293>

1578 Prognostic and biological significance of the proangiogenic factor EGFL7 in acute myeloid leukemia

Dimitrios Papaioannou, Changxian Shen, Deedra Nicolet, Betina McNeil, Marius Bill, Malith Karunasiri, Matthew H. Burke, Hatice Gulcin Ozer, Selen A. Yilmaz, Nina Zitzer, Gregory K. Behbehani, Christopher C. Oakes, Damian J. Steiner, Guido Marcucci, Bayard L. Powell, Jonathan E. Kolitz, Thomas H. Carter, Eunice S. Wang, Krzysztof Mrózek, Carlo M. Croce, Michael A. Caligiuri, Clara D. Bloomfield, Ramiro Garzon, Adrienne M. Dorrance *Proc Natl Acad Sci USA* vol 114 (23) E4641-E4647 2017

Manuscript *Leuk Corr Sci* CALGB-10201, CALGB-10503, CALGB-10603, CALGB-19808, CALGB-20202, CALGB-8461, CALGB-8525, CALGB-8923, CALGB-9022, CALGB-9120, CALGB-9222, CALGB-9420, CALGB-9665, CALGB-9720
<http://www.ncbi.nlm.nih.gov/pubmed/28533390>

1579 Prognostic and biologic significance of circular RNA profiling in younger adult patients with cytogenetically normal acute myeloid leukemia (CN-AML) (CALGB/Alliance 8461, 9665, 20202)

Dimitrios Papaioannou, Stefano Volinia, Deedra Nicolet, Michal Swierniak, Andreas Petrie, Krzysztof Mrózek, Andrew J. Carroll, Jessica Kohlschmidt, Bayard L. Powell, Geoffrey L. Uy, Jonathan E. Kolitz, Eunice S. Wang, Sakari Kauppinen, Richard M. Stone, Ramiro Garzon, Clara D. Bloomfield 2018

Abstract *Leuk Corr Sci* CALGB-20202, CALGB-8461, CALGB-9665
<https://learningcenter.ehaweb.org/eha/2018/stockholm/214594/dimitrios.papaioannou.prognostic.and.bio>

1580 Clinical and functional significance of circular RNAs in cytogenetically normal AML

Dimitrios Papaioannou, Stefano Volinia, Deedra Nicolet, Micha wierniak, Andreas Petri, Krzysztof Mrózek, Marius Bill, Felice Pepe, Christopher J. Walker, Allison E. Walker, Andrew J. Carroll, Jessica Kohlschmidt, Ann-Kathrin Einfeld, Bayard L. Powell, Geoffrey L. Uy, Jonathan E. Kolitz, Eunice S. Wang, Sakari Kauppinen, Adrienne Dorrance, Richard M. Stone, John C. Byrd, Clara D. Bloomfield, Ramiro Garzon *Blood Adv* vol 4 (2) 239-51 2020

Manuscript *Leuk Corr Sci* CALGB-8721, CALGB-8821, CALGB-10503, CALGB-10603, CALGB-19808, CALGB-8525, CALGB-9022, CALGB-9120, CALGB-9222
<http://www.ncbi.nlm.nih.gov/pubmed/31945158>

- 1581 Validity of Adjuvant! Online in Older Patients with Stage III Colon Cancer Based on 2,967 Patients from the ACCENT Database**
Demetris Papamichael, Lindsay A. Renfro, Christiana Matthaïou, Greg Yothers, Leonard Saltz, Katherine Guthrie, Eric Van Cutsem, Hans-Joachim Schmoll, Roberto Labianca, Thierry André, Michael O'Connell, Steven R. Alberts, Daniel G. Haller, Panteleimon Kountourakis, Daniel J. Sargent
J Geriatr Oncol vol 7 (6) 422-9 2016
Manuscript GI ACCENT <http://www.ncbi.nlm.nih.gov/pubmed/27468630>
- 1582 A Phase II Study of Pazopanib in Patients with Malignant Pleural Mesothelioma: NCCTG N0623 (Alliance)**
Kaushal Parikh, Sumithra J. Mandrekar, Katie AllenZiegler, Brandt Esplin, Angelina D. Tan, Benjamin Marchello, Alex A. Adjei, Julian R. Molina Oncologist vol 25 (6) 523-531 2020
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/31872928>
- 1583 Predictive polygenic score for outcome after first-line oxaliplatin-based chemotherapy in colorectal cancer patients using supervised principal component analysis**
A. Park, Dominic Edelmann, Federico Canzian, Tabitha A. Harrison, Xinwei Hua, Qian Shi, Allison Silverman, Martin Schneider, Richard M. Goldberg, Steven R. Alberts, Michael Hoffmeister, Hermann Brenner, Andrew T. Chan, Ulrike Peters, Polly A. Newcomb, Jenny Chang-Claude Cancer Epidemiol Biomarkers Prev vol 31 (11) 2087-2091 2022
Abstract PPP NCCTG-9741, NCCTG-N0147 <http://www.ncbi.nlm.nih.gov/pubmed/35984985>
- 1584 NCCTG N10C2 (Alliance) – A Double-Blind, Placebo-Controlled Study of Magnesium Supplements to Reduce Menopausal Hot Flashes**
Haeseong Park, Rui Qin, Thomas J. Smith, Pamela J. Atherton, Debra L. Barton, Keren Sturtz, Shaker R. Dakhil, Daniel M. Anderson, Kathleen Flynn, Suneetha Puttabasavaiah, Nguyet Anh Le-Lindqwister, Gilbert D.A. Padula, Charles L. Loprinzi Menopause vol 22 (6) 627-632 2015
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/25423327>
- 1585 NCCTG N10C2 (Alliance): A double-blind, placebo-controlled study of magnesium supplements to reduce menopausal hot flashes**
Haeseong Park, Rui Qin, Thomas J. Smith, Pamela J. Atherton, Debra L. Barton, Keren Sturtz, Shaker R. Dakhil, Daniel M. Anderson, Philip J. Stella, Suneetha Puttabasavaiah, Nguyet A Le-Lindqwister, Gilbert D. A. Padula, Charles L. Loprinzi J Clin Oncol vol 32 (15 suppl) 9508 2014
Abstract Symptom Inter
http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/9508?sid=22c46b74-3a55-4f00-a2d2-5a10
- 1586 Genome-wide study of genetic polymorphisms predictive for outcome from first-line oxaliplatin-based chemotherapy in colorectal cancer patients.**
Hanla A Park, Dominic Edelmann, Federico Canzian, Petra Seibold, Tabitha A Harrison, Xinwei Hua, Qian Shi, Allison Silverman, Axel Benner, Angelica Macaуда, Martin Schneider, Richard M Goldberg, Steven R Alberts, Michael Hoffmeister, Hermann Brenner, Andrew T Chan, Ulrike Peters, Polly A Newcomb, Jenny Chang-Claude Int J Cancer vol 153 (9) 1623-34 2023
Manuscript PPP NCCTG-N0147, NCCTG-N9741 <http://www.ncbi.nlm.nih.gov/pubmed/37539667>
- 1587 Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140.**
H L Parnes, C Cirrincione, J Aisner, D A Berry, S L Allen, J Abrams, E Chuang, M R Cooper, M C Perry, D B Duggan, T P Szatrowski, I C Henderson, L Norton J Clin Oncol vol 21 (9) 1819-24 2003
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/12721259>
- 1588 Dietary modification in patients with prostate cancer on active surveillance: a randomized, multicentre feasibility study.**

J Kellogg Parsons, Vicky A Newman, James L Mohler, John P Pierce, Shirley Flatt, James Marshall
BJU Int vol 101 (10) 1227-31 2008
Manuscript Prevention <http://www.ncbi.nlm.nih.gov/pubmed/18218061>

1589 The Men's Eating and Living (MEAL) study: a Cancer and Leukemia Group B pilot trial of dietary intervention for the treatment of prostate cancer.

J Kellogg Parsons, Vicky Newman, James L Mohler, John P Pierce, Electra Paskett, James Marshall
Urology vol 72 (3) 633-7 2008
Manuscript Prevention <http://www.ncbi.nlm.nih.gov/pubmed/18280560>

1590 A Randomized Trial of Diet in Men with Early Stage Prostate Cancer on Active Surveillance: Rationale and Design of the Men's Eating and Living (MEAL) Study (CALGB 70807 [Alliance])

J. Kellogg Parsons, John P. Pierce, James Mohler, Electra Paskett, Sin-Ho Jung, Peter Humphrey, John R. Taylor, Vicky A. Newman, Leslie Barbier, Cheryl L. Rock, James Marshall Contemp Clin Trials vol 38 (2) 198-203 2014
Manuscript Prevention <http://www.ncbi.nlm.nih.gov/pubmed/24837543>

1591 The Men's Eating and Living (MEAL) Study (CALGB 70807 [Alliance]): Recruitment Feasibility and Baseline Demographics of a Randomized Trial of Diet in Men on Active Surveillance for Prostate Cancer

J. Kellogg Parsons, John P. Pierce, James Mohler, Electra Paskett, Sin-Ho Jung, Michael J. Morris, Eric Small, Olwen Hahn, Peter Humphrey, John Taylor, James Marshall BJU Int vol 121 (4) 534-9 2018
Manuscript Prevention <http://www.ncbi.nlm.nih.gov/pubmed/28437029>

1592 A Randomized Pilot Trial of Dietary Modification for the Chemoprevention of Non-invasive Bladder Cancer: The Dietary Intervention in Bladder Cancer Study (DIBS)

J. Kellogg Parsons, John P. Pierce, Loki Natarajan, Vicky A. Newman, Leslie Barbier, James Mohler, Cheryl L. Rock, Dennis D. Heath, Khurshid Guru, Michael B. Jameson, Hongying Li, Hossein Mirheydar, Michael A. Holmes, James Marshall Cancer Prev Res (Phila) vol 6 (9) 2013
Manuscript Prevention <http://www.ncbi.nlm.nih.gov/pubmed/23867158>

1593 Effect of a Behavioral Intervention to Increase Vegetable Consumption on Cancer Progression Among Men With Early-Stage Prostate Cancer

J. Kellogg Parsons, David Zahrieh, James L. Mohler, Electra Paskett, Donna E. Hansel, Adam S. Kibel, Heshan Liu, Drew K. Seisler, Loki Natarajan, Martha White, Olwen Hahn, John Taylor, Sheri J. Hartman, Sean P. Stroup, Peter Van Veldhuizen, Lannis Hall, Eric J. Small, Michael J. Morris, John P. Pierce, James Marshall JAMA vol 323 (2) 140-8 2020
Manuscript Prevention <http://www.ncbi.nlm.nih.gov/pubmed/31935026>

1594 Diet and Health-related Quality of Life Among Men on Active Surveillance for Early-stage Prostate Cancer: The Men's Eating and Living Study (Cancer and Leukemia Group 70807 [Alliance])

J. Kellogg Parsons, David Zahrieh, Devin Patel, James L. Mohler, Ronald C. Chen, Electra D. Paskett, Heshan Liu, Elizabeth S. Peil, Cheryl L. Rock, Olwen Hahn, John Taylor, Peter J. Van Veldhuizen, Eric J. Small, Michael J. Morris, Michelle J. Naughton, John P. Pierce, James Marshall Eur Urol Focus vol 8 (6) 1607-16 2022
Manuscript Prevention <http://www.ncbi.nlm.nih.gov/pubmed/35504836>

1595 The Men's Eating and Living (MEAL) Study (CALGB 70807 [Alliance]): A Randomized Clinical Trial of a Diet Intervention in Men on Active Surveillance for Prostate Cancer

J. Kellogg Parsons, David Zariéh, John P. Pierce, James Mohler, Electra Paskett, Donna Hansel, Adam Kibel, Olwen Hahn, John Taylor, Robert Grubb, Sean Stroup, Eric Small, Peter Van Veldhuizen, Michael J. Morris, James Marshall J Urol vol 199 (4S) p. e1077 2018

1596 CALGB 60104: Adherence with adjuvant capecitabine among women age 65 and older with early stage breast cancer treated on CALGB 49907

A. H. Partridge, L. E. Archer, A. B. Kornblith, J. Gralow, D. Grenier, H. B. Muss, E. Perez, A. C. Wolff, C. A. Hudis, E. P. Winer *J Clin Oncol* vol 26 (May 20 suppl) abstr 6542 2008

Abstract Experimental

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID

1597 Adherence and Persistence With Oral Adjuvant Chemotherapy in Older Women With Early-Stage Breast Cancer in CALGB 49907: Adherence Companion Study 60104

Ann H. Partridge, Laura Archer, Alice B. Kornblith, Julie Gralow, Debjani Grenier, Edith Perez, Antonio C. Wolff, Xiaofei Wang, Helen Kastrissios, Donald Berry, Clifford Hudis, Eric Winer, Hyman Muss *J Clin Oncol* vol 28 (14) 2418-2422 2010

Manuscript Experimental CALGB-49907 <http://www.ncbi.nlm.nih.gov/pubmed/20368559>

1598 Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer

Ann H. Partridge, Samuel M. Niman, Monica Ruggeri Fedro A. Peccatori, Hatem A. Azim Jr, Marco Colleoni, Cristina Saura, Chikako Shimizu, Anna B. Sætersdal, Judith R. Kroep, Audrey Mailliez, Ellen Warner, Virginia F. Borges, Frédéric Amant, Andrea Gombos, Akemi Kataoka, Christine Rousset-Jablonski, Simona Borstnar, Junko Takei, Jeong E. Lee, Janice M. Walshe, Manuel Ruíz-Borrego, Halle C.F. Moore, Christobel Saunders, Vesna Bjelic-Radisic, Snezana Susnjar, Fatima Cardoso, Karen L. Smith, Teresa Ferreiro, Karin Ribí, Kathryn Ruddy, Roswitha Kammler, Sarra El-Abed, Giuseppe Viale, Martine Piccart, Larissa A. Korde, Aron Goldhirsch, Richard D. Gelber, Olivia Pagani *N Engl J Med* vol 388 (18) 1645-56 2023

Manuscript Symptom Inter IBSCG 48-14, BIG 8-13

<http://www.ncbi.nlm.nih.gov/pubmed/37133584>

1599 Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy

Ann H. Partridge, Samuel M. Niman, Monica Ruggeri, Fedro A. Peccatori, Hatem A. Azim Jr, Marco Colleoni, Cristina Saura, Chikako Shimizu, Anna Barbro Sætersdal, Judith R. Kroep, Audrey Mailliez, Ellen Warner, Virginia F. Borges, Frédéric Amant, Andrea Gombos, Akemi Kataoka, Christine Rousset-Jablonski, Simona Borstnar, Junko Takei, Jeong Eon Lee, Janice M. Walshe, Manuel Ruíz Borrego, Halle CF. Moore, Christobel Saunders, Fatima Cardoso, Snezana Susnjar, Vesna Bjelic-Radisic, Karen L. Smith, Martine Piccart, Larissa A. Korde, Aron Goldhirsch, Richard D. Gelber, Olivia Pagani *Breast* vol 59 327-38 2021

Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/34390999>

1600 Baseline Characteristics of Women Enrolled in the POSITIVE Trial (Pregnancy Outcome and Safety of Interrupting Therapy for women with endocrine responsive breast cancer)

Ann H Partridge, Samuel M Niman, Monica Ruggeri, Fedro A Peccatori, Hatem A Azim Jr, Marco Colleoni, Cristina Saura, Chikako Shimizu, Anna Barbro Sætersdal, Judith Kroep, Ellen Warner, Virginia Borges, Andrea Gombos, Akemi Kataoka, Christine Rousset-Jablonski, Simona Borstnar, Hideko Yamauchi, Jeong Eon Lee, Janice Walshe, Manuel Ruíz Borrego, Halle Moore, Christobel Saunders, Fatima Cardoso, Snežana Šušnjar, Vesna Bjelic-Radisic, Karen Smith, Martine Piccart, Larissa A Korde, Aron Goldhirsch, Richard D Gelber, Olivia Pagani *Cancer Res* vol 81 (4 Suppl) PS12-17 2021

Abstract Symptom Inter Alliance-A221405, IBSCG 48-14

https://www.researchgate.net/publication/349322445_Abstract_PS12-17_Baseline_characteristics_of_wc

1601 Prognostic impact of NPM1 mutations in cytogenetically normal (CN) acute myeloid leukemia (AML) is adversely affected by high expression of the ERG gene: A Cancer and Leukemia Group B

(CALGB) study

P. Paschka, G. Marcucci, K. S. Maharry, S. P. Whitman, A. S. Ruppert, T. Vukosavljevic, K. A. Mrozek, B. L. Powell, J. E. Kolitz, R. A. Larson, C. D. Bloomfield *Haematol-Hematol J* vol 92 (suppl 1) 145, abstr 396 2007
Abstract *Leuk Corr Sci* CALGB-19808, CALGB-20502, CALGB-8461, CALGB-9621, CALGB-9665 http://www.haematologica.org/content/92/supplement_1/1.full.pdf

1602 Wilms Tumor 1 (WT1) Gene Mutations Predict Poor Outcome in Adults with Cytogenetically Normal (CN) Acute Myeloid Leukemia (AML): A Cancer and Leukemia Group B (CALGB) Study

P. Paschka, G. Marcucci, A. S. Ruppert, K. Mrozek, S. P. Whitman, K. Maharry, C. Langer, C. D. Baldus, B. L. Powell, M. R. Baer, A. J. Carroll, M. A. Caligiuri, J. E. Kolitz, R. A. Larson, C. D. Bloomfield *Blood* vol 110 (11) -362 2007
Abstract *Leuk Corr Sci* CALGB-19808, CALGB-20502, CALGB-8461, CALGB-9621, CALGB-9665 <http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;110/11/362>

1603 Outcome prediction in adult core binding factor (CBF) acute myeloid leukemia (AML) with gene expression profiling: A Cancer and Leukemia Group B (CALGB) study

P. Paschka, M. D. Radmacher, G. Marcucci, A. S. Ruppert, T. Vukosavljevic, S. P. Whitman, K. A. Mrozek, C. Liu, R. A. Larson, C. D. Bloomfield *J Clin Oncol* vol 25 (18S) abstr 7011 2007
Abstract *Leuk Corr Sci* CALGB-8525, CALGB-9022, CALGB-19808, CALGB-8461, CALGB-9222, CALGB-9621, CALGB-9665
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID

1604 Wilms' Tumor 1 Gene Mutations Independently Predict Poor Outcome in Adults With Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

Peter Paschka, Guido Marcucci, Amy S. Ruppert, Susan P. Whitman, Krzysztof Mrózek, Kati Maharry, Christian Langer, Claudia D. Baldus, Weiqiang Zhao, Bayard L. Powell, Maria R. Baer, Andrew J. Carroll, Michael A. Caligiuri, Jonathan E. Kolitz, Richard A. Larson, Clara D. Bloomfield *J Clin Oncol* vol 26 (28) 4595-4602 2008
Manuscript *Leuk Corr Sci* CALGB-19808, CALGB-20502, CALGB-8461, CALGB-9621, CALGB-9665 <http://www.ncbi.nlm.nih.gov/pubmed/18559874>

1605 Independent validation of the PAM50-based chemo-endocrine score (CES) in hormonal receptor positive (HR+)/HER2+ breast cancer (BC) treated with neoadjuvant anti-HER2-targeted therapy

Tomás Pascual, Aranzazu Fernandez-Martinez, Maki Tanioka, M. Vittoria Dieci, Sonia Pernas, Joaquin Gavila, Valentina Guarnieri, Javier Cortes, Patricia Villagrana, Núria Chic, Maria Vidal, Barbara Adamo, Montserrat Muñoz, Gaia Griguolo, Antonio Llombart, Pierfranco Conte, Mafalda Oliveira, Benedetta Conte, Laia Paré, Patricia Galvan, Lisa Carey, Charles M. Perou, Aleix Prat *Ann Oncol* vol 31 (Supplement 2) S17 2020
Abstract *Breast* <https://www.sciencedirect.com/science/article/pii/S0923753420362190>

1606 Independent validation of the PAM50-based Chemo-Endocrine Score (CES) in hormonal receptor positive HER2-positive breast cancer treated with neoadjuvant anti-HER2-based therapy

Tomás Pascual, Aranzazu Fernandez-Martinez, Maki Tanioka, M. Vittoria Dieci, Sonia Pernas, Joaquin Gavila, Valentina Guarnieri, Javier Cortes, Patricia Villagrana, Núria Chic, Maria Vidal, Barbara Adamo, Montserrat Muñoz, Gaia Griguolo, Antonio Llombart, Pierfranco Conte, Mafalda Oliveira, Benedetta Conte, Laia Paré, Patricia Galvan, Lisa A. Carey, Charles M. Perou, Aleix Prat *Clin Cancer Res* vol 27 (11) 3116-25 2021
Manuscript *Breast* CALGB-40601 <http://www.ncbi.nlm.nih.gov/pubmed/33632929>

1607 Independent validation of the PAM50-based Chemo-Endocrine Score (CES) in hormonal receptor positive (HR+)/HER2+ breast cancer (BC) treated with neoadjuvant anti-HER2-based

therapy.

Tomás Pascual, Maki Tanioka, M. Vittoria Dieci, Sonia Pernas, Joaquin Gavila, Valentina Guarneri, Javier Cortes, Antonio Llombart, Mafalda Oliveira, Laia Paré, Donald Berry, Patricia Galvan, Steven Isakoff, Charles M. Perou, Aleix Prat, Lisa Carey *Cancer Res* vol 78 (4 Supplement) P2-09-05 2018
Abstract *Breast* http://cancerres.aacrjournals.org/content/78/4_Supplement/P2-09-05

1608 Applying a Conceptual Model for Examining Health-Related Quality of Life in Long-Term Breast Cancer Survivors: CALGB Study 79804

Electra D. Paskett, James E. Herndon, Jeannette M. Day, Nancy N. Stark, Eric P. Winer, Stephen S. Grubbs, Michael D. Pavy, Charles L. Shapiro, Marcy A. List, Martee L. Hensley, Michelle A. Naughton, Alice B. Kornblith, Karleen R. Habin, Gini F. Fleming, Marisa A. Bittoni *Psycho-Oncol* vol 17 (11) 1108-1120 2008
Manuscript *Health Outcomes* <http://www.ncbi.nlm.nih.gov/pubmed/18314912>

1609 A randomized study to prevent lymphedema in women treated for breast cancer: CALGB 70305 (Alliance)

Electra D. Paskett, Jennifer Le-Rademacher, Jill M. Oliveri, Heshan Liu, Drew K. Seisler, Jeff A. Sloan, Jane M. Armer, Michelle J. Naughton, Karen Hock, Michael Schwartz, Gary Unzeitig, Marianne Melnik, Lisa D. Yee, Gini F. Fleming, John R. Taylor, Charles Loprinzi *Cancer* vol 127 (2) 291-9 2021
Manuscript *Symptom Inter* <http://www.ncbi.nlm.nih.gov/pubmed/33079411>

1610 The LEAP Study: Effects of a lymphedema prevention intervention on swelling, range of motion and quality of life (Alliance)

Electra D. Paskett, Jennifer Le-Rademacher, Jill Oliveri, Michelle Naughton, Jane M. Armer, Heshan Liu, Drew Seisler, John Taylor, Jeffrey Sloan *Psycho-Oncol* vol 27 (1) abstract 198 2018
Abstract *Symptom Inter* <https://onlinelibrary.wiley.com/doi/full/10.1002/pon.4878>

1611 Effects of a lymphedema prevention intervention on range of motion among women receiving lymph node dissection for breast cancer treatment (Alliance) CALGB 70305.

Electra D. Paskett, Heshan Liu, Jill Oliveri, Drew K. Seisler, Michael A Schwartz, Jennifer Le-Rademacher, Jeff A. Sloan, Jane M. Armer *JCO* vol 36 (no. 7_suppl) 123-123 2018
Abstract *Symptom Inter* https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.7_suppl.123

1612 Health-Related Quality of Life in Long-Term Breast Cancer Survivors: Differences by Adjuvant Chemotherapy Dose in CALGB Study 8541

Electra Paskett, James Herndon, Kathleen Donohue, Michelle Naughton, Stephen Grubbs, Michael Pavy, Martee Hensley, Nancy Stark, Alice Kornblith, Marisa Bittoni *Cancer* vol 115 (5) 1109-1120 2009
Manuscript *Health Outcomes* CALGB-8541, CALGB-79804
<http://www.ncbi.nlm.nih.gov/pubmed/19170232>

1613 Prevention of Lymphedema in Women with Breast Cancer: Results of CALGB 70305 (Alliance)

Electra Paskett, Jill Oliveri, Jennifer Le-Rademacher, Heshan Liu, Drew Seisler, Jeffrey Sloan, Jane Armer, Michelle Naughton, Karen Hock, Michael Schwartz, Gary Unzeitig, Gilbert Padula, Stephen Grubbs, Lisa Yee, Lisa Bailey, Shawna Willey, Thomas Sunnenberg, Lisa Baddi, Gini Fleming *J Clin Oncol* vol 35 (5 suppl) 104 2017
Abstract *Symptom Inter* http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.5_suppl.104

1614 Bevacizumab and risk of arterial and venous thromboembolism in metastatic castration-resistant prostate cancer patients treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance)

Jai N. Patel, Chen Jiang, Daniel L. Hertz, Flora A. Mulkey, Kouros Owzar, Susan Halabi, Mark J. Ratain, Paula N. Friedman, Eric J. Small, Michael A. Carducci, John F. Mahoney, Michael J. Kelley, Michael J. Morris, William K. Kelly, Howard L. McLeod *Cancer* vol 121 (7) 1025-1031 2015
Manuscript GU <http://www.ncbi.nlm.nih.gov/pubmed/25417775>

1615 A discovery study to identify clinical and genetic risk factors for bevacizumab (BEV)-related gastrointestinal (GI) hemorrhage (HEM) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated on CALGB 90401 (Alliance)

Jai N. Patel, Chen Jiang, Kouros Owzar, Daniel L. Hertz, Flora A. Mulkey, William K. Kelly, Susan Halabi, Yoichi Furukawa, Cameron Lassiter, Susan G. Dorsey, Paula N. Friedman, Eric J. Small, Phillip G. Febbo, Deanna L. Kroetz, Michael A. Carducci, John F. Mahoney, Michael J. Kelley, Yusuke Nakamura, Michiaki Kubo, Mark J. Ratain, Michael J. Morris, Howard L. McLeod *Cancer Res* vol 76 (14 suppl) abstr 2037 2016
Abstract PPP http://cancerres.aacrjournals.org/content/76/14_Supplement/2037

1616 Pharmacogenetic Study in Gastric Cancer Patients Treated with Adjuvant Fluorouracil/Leucovorin or Epirubicin/Cisplatin/Fluorouracil Before and After Chemoradiation on CALGB 80101 (Alliance)

Jai N. Patel, Chen Jiang, Kouros Owzar, Flora Mulkey, Jasmine A. Luzum, Harvey J. Mamon, Daniel G. Haller, Tomislav Dragovich, Steven R. Alberts, Georg Bjarnason, Christopher G. Willet, Donna Niedzwiecki, Peter Enzinger, Mark J. Ratain, Charles Fuchs, Howard L. McLeod *Pharmacogenet Genomics* vol 31 (9) 215-20 2021
Manuscript PPP <http://www.ncbi.nlm.nih.gov/pubmed/34149004>

1617 Bevacizumab (BEV) and risk of hemorrhage (HEM) in metastatic castration-resistant prostate cancer (mCRPC) patients treated on CALGB 90401 (Alliance).

Jai Narendra Patel, Chen Jiang, Daniel Louis Hertz, Flora Mulkey, Paula N. Friedman, Susan Halabi, Mark J. Ratain, Michael J. Morris, Eric Jay Small, Kouros Owzar, William Kevin Kelly, Howard L. McLeod *J Clin Oncol* vol 32 (15_suppl) e16061 2014
Abstract GU http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/e16061

1618 Oral Cancer Chemotherapy Adherence and Adherence Assessment Tools: A Report from North Central Cancer Group Trial N0747 and a Systematic Review of the Literature

Krishna Patel, Nathan R. Foster, Ann Farrell, Nguyet Anh Le-Lindqwister, Josy Mathew, Brian Costello, John Reynolds, Jeffrey P. Meyers, Aminah Jatoi *J Cancer Educ* vol 28 (4) 2013
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/23872949>

1619 MRE11-Deficiency Associated with Improved Long-Term Disease Free Survival and Overall Survival in a Subset of Stage III Colon Cancer Patients in Randomized CALGB 89803 Trial

Thomas Pavelitz, Lindsay Renfro, Nathan R. Foster, Amber Caracol, Piri Welsch, Victoria Valinluck Lao, William B. Grady, Donna Niedzwiecki, Leonard B. Saltz, Monica M. Bertagnolli, Richard M. Goldberg, Peter S. Rabinovitch, Mary Emond, Raymond J. Monnat, Nancy Maizels *PLoS ONE* vol 9 (10) 2014
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/25310185>

1620 Multiplexed Digital Quantification of mRNA Abundance: a Highly Reproducible, PCR-independent Assessment of BAALC, ERG, and MN1 mRNA Levels in Acute Myeloid Leukemia (AML) Bone Marrow (BM) and Peripheral Blood (PB) Samples

J. E. Payton, G. Marcucci, M. D. Radmacher, K. Maharry, C. Langer, C. D. Baldus, C. D. Bloomfield, T. J. Ley *ASH Annual Meeting Abstracts* vol 114 (22) abstr 1599 2009
Abstract *Leuk Corr Sci* CALGB-9665, CALGB-8461
<http://www.bloodjournal.org/content/114/22/1599?sso-checked=true>

1621 High throughput digital quantification of mRNA abundance in primary human acute myeloid leukemia samples

Jacqueline E. Payton, Nicole R. Grieselhuber, Li-Wei Chang, Mark Murakami, Gary K. Geiss, Daniel C. Link, Rakesh Nagarajan, Mark A. Watson, Timothy J. Ley J Clin Invest vol 119 (6) 1714-1726 2009

Manuscript Leuk Corr Sci CALGB-8461, CALGB-9665
<http://www.ncbi.nlm.nih.gov/pubmed/19451695>

1622 Improving standards of patient reported outcomes analysis: developing a consensus taxonomy of key research objectives – a SISAQOL initiative

Madeline Pe, Lien Dorme, Corneel Coens, Ethan Basch, Melanie Calvert, Alicyn Campbell, Charles Kim Cocks, Laurence Collette, Nancy Devlin, Amylou Dueck, Hans-Henning Flechtner, Carolyn Gotay Qual Life Res vol 27 (suppl 1) abst 203.4 2018

Abstract Health Outcomes

<https://link.springer.com/content/pdf/10.1007%2Fs11136-018-1946-9.pdf>

1623 Analysis of the associations of FC gamma receptor polymorphisms (FCGR3A, FCGR2A, and FCGR2B) with outcome in HER2+ breast cancer patients treated with trastuzumab in NCCTG (Alliance) trial N9831

Mark Pegram, Nadine Norton, Kathleen Tenner, Karla L. Ballman, Raphael Clynes, Keith L. Knutson, Edith A. Perez Mol Cancer Res vol 11 (10 Suppl) B123 2013

Abstract Breast http://mcr.aacrjournals.org/content/11/10_Supplement/B123.abstract

1624 Genetic Variant Associated with Survival of Patients with Stage II-III Colon Cancer

Kathryn L. Penney, Barbara L. Banbury, Stephanie Bien, Tabitha A. Harrison, Xinwei Hua, Amanda I. Phipps, Wei Sun, Mingyang Song, Amit D. Joshi, Steven R. Alberts, Carmen J. Allegra, James Atkins, Linda H. Colangelo, Thomas J. George, Richard M. Goldberg, Peter C. Lucas, Suresh G. Nair, Qian Shi, Frank A. Sinicrope, Norman Wolmark, Greg Yothers, Ulrike Peters, Polly A. Newcomb, Andrew T. Chan Clin Gastroenterol Hepatol vol 18 (12) 2717-23.e3 2020

Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/31811950>

1625 Genome-wide association with survival in stage II-III colon cancer (CC) clinical trials (NCCTG N0147, Alliance for Clinical Trials in Oncology; NSABP C-08, NRG Oncology)

Kathryn Penney, Barbara L. Banbury, Qian Shi, Carmen J. Allegra, Steven R. Alberts, Ulrike Peters, Greg Yothers, Frank A. Sinicrope, Wei Sun, Norman Wolmark, Suresh G. Nair, Tabitha Harrison, Richard M. Goldberg, Peter Lucas, Thomas J. George, Linda H Colangelo, James Atkins, Polly A. Newcomb, Andrew T. Chan J Clin Oncol vol 36 (suppl) 3582 2018

Abstract PPP <https://meetinglibrary.asco.org/record/158813/abstract>

1626 Ethics of Mandatory Research Biopsy for Correlative End Points Within Clinical Trials in Oncology

Jeffrey Peppercorn, Iuliana Shapira, Deborah Collyar, Teresa Deshields, Nancy Lin, Ian Krop, Hans Grunwald, Paula Friedman, Ann H. Partridge, Richard L. Schilsky, Monica M. Bertagnolli J Clin Oncol vol 28 (15) 2635-2640 2010

Manuscript Ethics <http://www.ncbi.nlm.nih.gov/pubmed/20406927>

1627 Phase II trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma

D. Perez, V. Suman, T. Amatruda, M. Gornet, R. Morton, S. Jilani, C. Constantinou, J. Egner, S. Markovic J Clin Oncol vol 25 (18s) abstr 8560 2007

Abstract Experimental http://meeting.ascopubs.org/cgi/content/abstract/25/18_suppl/8560

1628 Phase II Trial of Carboplatin, Weekly Paclitaxel and Biweekly Bevacizumab in Patients with

Unresectable Stage IV Melanoma – A North Central Cancer Treatment Group (NCCTG) Study, N047A1

Domingo G. Perez, Vera J. Suman, Tom R. Fitch, Thomas Amatruda, Roscoe F. Morton, Shamim Z. Jilani, Costas L. Constantinou, James R. Egner, Lisa A. Kottschade, Svetomir N. Markovic *Cancer* vol 115 (1) 119-127 2009
Manuscript *Experimental* <http://www.ncbi.nlm.nih.gov/pubmed/19090009>

1629 Round-Robin Review of HER2 Testing in the Context of Adjuvant Therapy for Breast Cancer.

E. A. Perez, A. C. Dueck, M. F. Press, B. Chen, R. B. Jenkins, S. Paik, C. Kim, A. E. Wiktor, R. G. Meyer, R. P. Ketterling, I. Villalobos, M. Finnigan, M. Buyse, J. Zujewski, M. Shing, H. Stern, W. L. Lingle, M. M. Reinholz, D. J. Slamon *Cancer Res* vol 70 (24 supplement) PD10-02 2010
Abstract *Breast* http://cancerres.aacrjournals.org/cgi/content/abstract/69/24_MeetingAbstracts/2100

1630 North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer

E. A. Perez, D. W. Hillman, T. Dentchev, N. A. Le-Lindqwister, L. H. Geeraerts, T. R. Fitch, H. Liu, D. L. Graham, S. P. Kahanic, H. M. Gross, T. A. Patel, F. M. Palmieri, A. C. Dueck *Ann Oncol* vol 21 (2) 269-274 2010
Manuscript *Breast* <http://www.ncbi.nlm.nih.gov/pubmed/19901014>

1631 Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005)

E. A. Perez, M. F. Press, A. C. Dueck, R. B. Jenkins, C. Kim, B. Chen, I. Villalobos, S. Paik, M. Buyse, A. E. Wiktor, R. Meyer, M. Finnigan, J. Zujewski, M. Shing, H. M. Stern, W. L. Lingle, M. M. Reinholz, D. J. Slamon *Breast Cancer Res Treat* vol 138 (1) 99-108 2013
Manuscript *Breast* <http://www.ncbi.nlm.nih.gov/pubmed/23420271>

1632 Do the ASCO/CAP 2007 HER2 testing guidelines improve prediction of benefit to adjuvant trastuzumab?: Data from North Central Cancer Treatment Group N9831 Adjuvant trial.

E. A. Perez, M. M. Reinholz, A. C. Dueck, K. S. Tenner, N. E. Davidson, J. R. Gralow, L. N. Harris, L. A. Kutteh, R. B. Jenkins, B. Chen *Cancer Res* vol 69 (24 Suppl 3) abstr 701 2009
Abstract *Breast* http://cancerres.aacrjournals.org/cgi/content/abstract/69/24_MeetingAbstracts/701

1633 Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with or without trastuzumab (H) in patients (pts) with HER2-positive breast cancer

E. A. Perez, E. H. Romond, V. J. Suman, J. Jeong, N. E. Davidson, C. E. Geyer Jr, S. Martino, E. P. Mamounas, P. A. Kaufman, N. Wolmark, Ncctg/Nsabp *J Clin Oncol* vol 25 (18S) abstr 512 2007
Abstract *Breast*
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID

1634 The relationship between quantitative HER2 gene expression by the 21-gene RT-PCR assay and adjuvant trastuzumab (H) benefit in NCCTG (Alliance) N9831

E. Perez, S. Butler, A. Dueck, F. Baehner, F. Jamshidian, D. Cherbavaz, E. Thompson, S. Shak, P. Kaufman, N. Davidson, J. Gralow, Y. Asmann, K. Ballman *J Clin Oncol* vol 31 (15 suppl) abstr 520 2013
Abstract *Breast*
http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/520?sid=02ec31c3-4740-487b-98f2-9de29

1635 Effect of PTEN protein expression on benefit to adjuvant trastuzumab in early-stage HER2+ breast cancer in NCCTG adjuvant trial N9831

E. Perez, A. L. Dueck, M. M. Reinholz, B. Chen, X. Geiger, R. B. Jenkins, W. Lingle, C. Andorfer, N. E. Davidson, S. Martino, P. Kaufman, L. A. Kutteh, G. W. Sledge, L. N. Harris, J. R. Gralow, A. E. Mccullough *J Clin Oncol* vol 29 (suppl) abstr 10504 2011

1636 Predictive genomic markers to chemotherapy and adjuvant trastuzumab via whole genome expression DASL profiling in the N9831 adjuvant study

E. Perez, J. Eckel-Passow, K. Ballman, S. Anderson, E. Thompson, Y. Asmann, J. Jen, A. Dueck, W. Lingle, G. Sledge, E. Winer, J. Gralow, R. Jenkins, M. Reinholz *Cancer Res* vol 72 (24 supplement) PD10-04 2012

Abstract Breast http://cancerres.aacrjournals.org/content/72/24_Supplement/PD10-04.abstract

1637 c-MYC (MYC) Amplification and Correlation With Patient Outcome in Early Stage HER2 + Breast Cancer (BC) From the NCCTG Adjuvant Intergroup Trial N9831

E. Perez, M. Reinholz, A. Dueck, A. Wiktor, W. Lingle, N. Davidson, S. Martino, P. Kaufman, L. Kutteh, R. Jenkins *Cancer Res* vol 69 (2, suppl 1) abstr SABCS-56 2009

Abstract Breast http://cancerres.aacrjournals.org/content/69/2_Supplement/56.short

1638 The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831

Edith A. Perez, Frederick L. Baehner, Steven M. Butler, E. Aubrey Thompson, Amylou C. Dueck, Farid Jamshidian, Diana Cherbavaz, Carl Yoshizawa, Steven Shak, Peter A. Kaufman, Nancy E. Davidson, Julie Gralow, Yan W. Asmann, Karla V. Ballman *Breast Cancer Res* vol 17 2015

Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/26429296>

1639 Stromal tumor infiltrating lymphocytes: In the Alliance N9831 trial STILS are prognostic of chemotherapy benefit but not predictive of trastuzumab benefit

Edith A. Perez, Karla V. Ballman, S. Keith Anderson, E. Aubrey Thompson, S.S. Badve, H. Bailey, F.L. Baehner *Cancer Res* vol 75 (9 Supplement) abstr S1-06 2015

Abstract Breast

http://cancerres.aacrjournals.org/content/75/9_Supplement/S1-06.abstract?sid=b0d523ff-b595-47a8-8352

1640 Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breast Tumors from the NCCTG (Alliance) N9831 Trial

Edith A. Perez, Karla V. Ballman, Afshin Mashadi-Hosseini, Kathleen S. Tenner, Jennifer M. Kachergus, Nadine Norton, Brian M. Necela, Jennifer M. Carr, Sean Ferree, Charles M. Perou, Frederick Baehner, Maggie Chon U. Cheang, E. Aubrey Thompson *J Natl Cancer Inst* vol 109 (2) 2016

Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/27794124>

1641 Intrinsic subtype and therapeutic response among early stage HER2-positive breast tumors from the North Central Cancer Treatment Group (Alliance) N9831 trial

Edith A. Perez, Karla V. Ballman, Afshin Mashadi-Hosseini, Kathleen S. Tenner, Jennifer M. Kachergus, Nadine Norton, Brian M. Necela, Jennifer M. Carr, Sean Ferree, Charles M. Perou, Maggie Chon U. Cheang, E. Aubrey Thompson *Cancer Res* vol 76 (4 Suppl) P3-07-04 2016

Abstract Breast http://cancerres.aacrjournals.org/content/76/4_Supplement/P3-07-04

1642 Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer

Edith A. Perez, Karla V. Ballman, Kathy S. Tenner, E. Aubrey Thompson, Sunil S. Badve, Helen Bailey, Frederick L. Baehner *JAMA Oncol* vol 2 (1) 56-64 2016

Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/26469139>

1643 Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer

Treatment Group N9831 trial

Edith A. Perez, Amylou C. Dueck, Ann E. McCullough, Beiyun Chen, Xochiquetzal J. Geiger, Robert B. Jenkins, Wilma L. Lingle, Nancy E. Davidson, Silvana Martino, Peter A. Kaufman, Leila A. Kutteh, George W. Sledge, Lyndsay N. Harris, Julie R. Gralow, Monica M. Reinholz *J Clin Oncol* vol 31 (17) 2115-2122 2013
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/23650412>

1644 Predictability of Adjuvant Trastuzumab Benefit in N9831 Patients Using the ASCO/CAP HER2-Positivity Criteria

Edith A. Perez, Amylou C. Dueck, Ann E. McCullough, Monica M. Reinholz, Kathleen S. Tenner, Nancy E. Davidson, Julie Gralow, Lyndsay N. Harris, Leila A. Kutteh, David W. Hillman, Robert B. Jenkins, Beiyun Chen *J Natl Cancer Inst* vol 104 (2) 159-162 2012
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/22138096>

1645 Disease-free survival (DFS) and treatment effect estimates of the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance]; N063D) in the adjuvant treatment of HER2-positive early breast cancer (EBC) patients according to hormone receptor status

Edith A. Perez, Eileen Holmes, José Baselga, Evandro de Azambuja, Amylou C. Dueck, Giuseppe Viale, Jo Anne Zujewski, Aron Goldhirsch, Rocco Crescenzo, Kathleen I. Pritchard, Antonio C. Wolff, Christian Jackisch, Istvan Lang, Michael Untch, Ian Smith, Frances Boyle, Binghe Xu, Henry Gomez, Richard D. Gelber, Martine Piccart-Gebhart *Ann Oncol* vol 25 (suppl 4) 2014
Abstract Breast http://annonc.oxfordjournals.org/content/25/suppl_4/mdu438.2

1646 C-MYC Alterations and Association With Patient Outcome in Early-Stage HER2-Positive Breast Cancer From the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial

Edith A. Perez, Robert B. Jenkins, Amylou C. Dueck, Anne E. Wiktor, Patrick P. Bedroske, S. Keith Anderson, Rhett P. Ketterling, William R. Sukov, Kazunori Kanehira, Beiyun Chen, Xochiquetzal J. Geiger, Cathy A. Andorfer, Ann E. McCullough, Nancy E. Davidson, Silvana Martino, George W. Sledge, Peter A. Kaufman, Leila A. Kutteh, Julie R. Gralow, Lyndsay N. Harris, James N. Ingle, Wilma L. Lingle, Monica M. Reinholz *J Clin Oncol* vol 29 (6) 651-659 2011
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/21245420>

1647 HER2 and Chromosome 17 Effect on Patient Outcome in the N9831 Adjuvant Trastuzumab Trial

Edith A. Perez, Monica M. Reinholz, David W. Hillman, Kathleen S. Tenner, Matthew J. Schroeder, Nancy E. Davidson, Silvana Martino, George W. Sledge, Lyndsay N. Harris, Julie R. Gralow, Amylou C. Dueck, Rhett P. Ketterling, James N. Ingle, Wilma L. Lingle, Peter A. Kaufman, Daniel W. Visscher, Robert B. Jenkins *J Clin Oncol* vol 28 (28) 4307-4315 2010
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/20697084>

1648 Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31

Edith A. Perez, Edward H. Romond, Vera J. Suman, Jong-Hyeon Jeong, Nancy E. Davidson, Charles E. Geyer, Silvana Martino, Eleftherios P. Mamounas, Peter A. Kaufman, Norman Wolmark *J Clin Oncol* vol 29 (25) 3366-3373 2011
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/21768458>

1649 Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831

Edith A. Perez, Edward H. Romond, Vera J. Suman, Jong-Hyeon Jeong, George Sledge, Charles E. Geyer, Silvana Martino, Priya Rastogi, Julie Gralow, Sandra M. Swain, Eric P. Winer, Gerardo

Colon-Otero, Nancy E. Davidson, Eleftherios Mamounas, Jo Anne Zujewski, Norman Wolmark J Clin Oncol vol 32 (33) 3744-3752 2014
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/25332249>

1650 Sequential Versus Concurrent Trastuzumab in Adjuvant Chemotherapy for Breast Cancer
Edith A. Perez, Vera J. Suman, Nancy E. Davidson, Julie R. Gralow, Peter A. Kaufman, Daniel W. Visscher, Beiyun Chen, James N. Ingle, Shaker R. Dakhil, JoAnne Zujewski, Alvaro Moreno-Aspitia, Thomas M. Pisansky, Robert B. Jenkins J Clin Oncol vol 29 (34) 4491-4497 2011
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/22042958>

1651 Association of genomic analysis of immune function genes and clinical outcome in the NCCTG (Alliance) N9831 adjuvant trastuzumab trial.
Edith A. Perez, E. Aubrey Thompson, S. Keith Anderson, Yan W. Asmann, Krishna R. Kalari, Jeanette Eckel-Passow, Amylou C. Dueck, Kathleen S. Tenner, Jin Jen, Jian-Bing Fan, Xochiquetzal Geiger, Ann E. McCullough, Beiyun Chen, Michael Zschunke, Robert B. Jenkins, George W. Sledge, Eric P. Winer, Julie Gralow, Monica Madden Reinholz, Karla V. Ballman J Clin Oncol vol 32 (15_suppl) 509 2014
Abstract Breast meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/509

1652 Genomic Analysis Reveals That Immune Function Genes Are Strongly Linked to Clinical Outcome in the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial
Edith A. Perez, E. Aubrey Thompson, Karla V. Ballman, S. Keith Anderson, Yan W. Asmann, Krishna R. Kalari, Jeanette E. Eckel-Passow, Amylou C. Dueck, Kathleen S. Tenner, Jin Jen, Jian-Bing Fan, Xochiquetzal J. Geiger, Ann E. McCullough, Beiyun Chen, Robert B. Jenkins, George W. Sledge, Eric P. Winer, Julie R. Gralow, Monica M. Reinholz J Clin Oncol vol 33 (7) 701-708 2015
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/25605861>

1653 Updated analysis of a Phase III study of surgical resection and chemotherapy (paclitaxel/carboplatin) (CT) with or without adjuvant radiation therapy (RT) for resected stage III non-small cell lung cancer (NSCLC) CALGB 9734
M. C. Perry, L. Kohman, J. Bonner, L. Gu, X. Wang, E. Vokes, M. R. Green J Clin Oncol vol 23 (16s) abstr 7145 2005
Abstract Respiratory
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=34&abstractID

1654 A phase III study of surgical resection and paclitaxel/carboplatin chemotherapy with or without adjuvant radiation therapy for resected stage III non-small-cell lung cancer: Cancer and Leukemia Group B 9734.
Michael C Perry, Leslie J Kohman, James A Bonner, Lin Gu, Xiaofei Wang, Everett E Vokes, Mark R Green Clin Lung Cancer vol 8 (4) 268-72 2007
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/17311692>

1655 Tobacco Assessment in Completed Lung Cancer Treatment Trials
Erica N. Peters, Graham W. Warren, Jeff A. Sloan, James R. Marshall Cancer vol 122 (21) 3260-3262 2016
Manuscript Prevention <http://www.ncbi.nlm.nih.gov/pubmed/27459400>

1656 Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13.
William P Peters, Gary L Rosner, James J Vredenburgh, Elizabeth J Shpall, Michael Crump, Paul G Richardson, Michael W Schuster, Lawrence B Marks, Constance Cirrincione, Larry Norton, I C Henderson, Richard L Schilsky, David D Hurd J Clin Oncol vol 23 (10) 2191-200 2005

1657 High dose CHOP: a phase II study of initial treatment in aggressive non-Hodgkin lymphoma. Cancer and Leukemia Group B 9351.

Bruce A Peterson, Jeffrey Johnson, Margaret A Shipp, Maurice Barcos, Jon P Gockerman, George P Canellos Leuk Lymphoma vol 48 (5) 870-80 2007

Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/17487729>

1658 Safety of adjuvant CDK4/6 inhibitors during the COVID-19 pandemic

Georg Pfeiler, Angela DeMichele, Amylou C Dueck, Christian Fesl, Michael Gnant, Erica L Mayer Lancet Oncol vol 23 (2) 195-7 2022

Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/35114114>

1659 Impact of body mass index on treatment and outcomes in patients with early hormone receptor-positive breast cancer receiving endocrine therapy with or without palbociclib in the PALLAS trial.

Georg Pfeiler, Dominik Hlauschek, Erica L Mayer, Christine Deutschmann, Stephanie Kacerovski-Strobl, Miguel Martin, Jane Meisel, Nicholas Zdenkowski, Sybille Loibl, Marija Balic, Heaseong Park, Aleix Prat, Claudine Isaacs, Jana Machacek-Link, Céline Schurmans, Christian Fesl, Amylou Dueck, Angela DeMichele, Michael Gnant J Clin Oncol vol 40 (16_suppl) 518-518 2022
Abstract Breast https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.518

1660 A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102

G. K. Philips, S. Halabi, B. L. Sanford, D. Bajorin, E. J. Small Ann Oncol vol 20 (6) 1074-1079 2009

Manuscript GU <http://www.ncbi.nlm.nih.gov/pubmed/19168670>

1661 Adjuvant ovarian function suppression and cognitive function in women with breast cancer

Kelly-Anne Phillips, Meredith M Regan, Karin Ribic, Prudence A Francis, Fabio Puglisi, Meritxell Bellet, Simon Spazzapan, Per Karlsson, Daniel R Budman, Khalil Zaman, Ehtesham A Abdi, Susan M Domchek, Yang Feng, Karen N Price, Alan S Coates, Richard D Gelber, Paul Maruff, Frances Boyle, John F Forbes, Tim Ahles, Gini F Fleming, Jürg Bernhard Br J Cancer vol 114 (9) 956-964 2016

Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/27092785>

1662 Smoking status and prognosis in patients with stage III colon cancer: A correlative analysis of NCCTG phase III trial N0147

A. I. Phipps, Q. Shi, P. L. J. Limburg, G. D. Nelson, D. J. Sargent, P. A. Newcomb, S. R. Alberts J Clin Oncol vol 30 (15 suppl) abstr 3526 2012

Abstract GI

http://meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/3526?sid=0392af30-b7db-4da1-8d41-cf8cc

1663 Associations Between Cigarette Smoking Status and Colon Cancer Prognosis Among Participants in North Central Cancer Treatment Group Phase III Trial N0147

A. I. Phipps, Q. Shi, P. A. Newcomb, G. D. Nelson, D. J. Sargent, S. R. Alberts, P. J. Limburg J Clin Oncol vol 31 (16) 2016-2023 2013

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/23547084>

1664 Pre-diagnostic physical activity and outcomes in patients with stage III colon cancer: A correlative analysis of phase III trial NCCTG N0147 (Alliance)

Amanda I. Phipps, Qian Shi, Emily Chan, Sharlene Gill, Richard M. Goldberg, Sheetal Hardikar, Paul J. Limburg, Polly A. Newcomb, Frank A. Sinicrope, Tyler J. Zemla, Balkrishna Jahagirdar, Crystal S. Denlinger, Daniel J. Sargent, Steven R. Alberts 2017

1665 Alcohol consumption and colon cancer prognosis among participants in North Central Cancer Treatment Group phase III trial N0147

Amanda I. Phipps, Qian Shi, Paul J. Limburg, Garth D. Nelson, Daniel J. Sargent, Frank A. Sinicrope, Emily Chan, Sharlene Gill, Richard M. Goldberg, Morton Kahlenberg, Suresh Nair, Anthony F. Shields, Polly A. Newcomb, Steven R. Alberts Int J Cancer vol 139 (5) 986-995 2016
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/27060850>

1666 Alcohol consumption and prognosis in patients with stage III colon cancer: a correlative analysis of NCCTG phase III trial N0147

Amanda I. Phipps, Qian Shi, Paul J. Limburg, Garth D. Nelson, Daniel J. Sargent, Frank A. Sinicrope, Emily Chan, Sharlene Gill, Richard M. Goldberg, Morton Kahlenberg, Suresh Nair, Anthony F. Shields, Polly A. Newcomb, Steven R. Alberts J Clin Oncol vol 33 (suppl) abstr 1508 2015
Abstract GI http://meeting.ascpubs.org/cgi/content/abstract/33/15_suppl/1508

1667 Physical activity and outcomes in patients with stage III colon cancer: A correlative analysis of phase III trial NCCTG N0147 (Alliance)

Amanda I. Phipps, Qian Shi, Tyler J. Zemla, Efrat Dotan, Sharlene Gill, Richard M. Goldberg, Sheetal Hardikar, Balkrishna Jahagirdar, Paul J. Limburg, Polly A. Newcomb, Anthony Shields, Frank A. Sinicrope, Daniel J. Sargent, Steven R. Alberts Cancer Epidemiol Biomarkers Prev vol 27 (6) 696-703 2018
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/29563133>

1668 Highly efficient clinical trial designs for reliable screening of under-performing treatments: Application to the COVID-19 Pandemic.

Piantadosi, Steven Clin Trials 1740774520940227 2020
Manuscript SDMC NOS <http://www.ncbi.nlm.nih.gov/pubmed/32666816>

1669 First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (TL), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC).

Martine J. Piccart-Gebhart, Andrew Peter Holmes, Jose Baselga, Evandro de Azambuja, Amylou C. Dueck, Giuseppe Viale, Jo Anne Zujewski, Aron Goldhirsch, Sergio Santillana, Kathleen I. Pritchard, Antonio C. Wolff, Christian Jackisch, Istvan Lang, Michael Untch, Ian E. Smith, Frances Boyle, Binghe Xu, Henry Leonidas Gomez, Richard D. Gelber, Edith A. Perez J Clin Oncol vol 32 (15_suppl) LBA4 2014
Abstract Breast http://meeting.ascpubs.org/cgi/content/abstract/32/15_suppl/LBA4

1670 Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial

Martine Piccart-Gebhart, Eileen Holmes, José Baselga, Evandro de Azambuja, Amylou C. Dueck, Giuseppe Viale, Jo Anne Zujewski, Aron Goldhirsch, Alison Armour, Kathleen I. Pritchard, Ann E. McCullough, Stella Dolci, Eleanor McFadden, Andrew P. Holmes, Liu Tonghua, Holger Eidtmann, Phuong Dinh, Serena Di Cosimo, Nadia Harbeck, Sergei Tjulandin, Im Young-Hyuck, Chiun-Sheng Huang, Véronique Diéras, David W. Hillman, Antonio C. Wolff, Christian Jackisch, Istvan Lang, Michael Untch, Ian Smith, Frances Boyle, Binghe Xu, Henry Gomez, Thomas Suter, Richard D. Gelber, Edith A. Perez J Clin Oncol vol 34 (10) 1034-1042 2016
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/26598744>

1671 Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACOSOG Trial Z05031

V. J. Picozzi, R. A. Abrams, P. A. Decker, W. Traverso, E. M. O'Reilly, E. Greeno, R. C. Martin, L. S. Wilfong, M. L. Rothenberg, M. C. Posner, P. W. T. Pisters *Ann Oncol* vol 22 (2) 348-354 2011
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/20670978>

1672 Report on a multicenter, phase II trial for adjuvant therapy of resected pancreatic cancer using cisplatin, 5-FU, and alpha-interferon

V. J. Picozzi, R. A. Abrams, L. W. Traverso, E. M. O'Reilly, E. Greeno, R. C. Martin, L. S. Wilfong, P. A. Decker, P. W. Pisters, M. C. Posner *J Clin Oncol* vol 26 (May 20 suppl) abstr 4505 2008
Abstract GI
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID

1673 Long term efficacy of peripheral androgen blockade on prostate cancer: CALGB 9782.

J. Picus, S. Halabi, E. Small, A. Hussain, G. Philips, E. Kaplan, N. Vogelzang *J Clin Oncol* vol 24 (18s) abstr 4573 2006
Abstract GU
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=40&abstractID

1674 A Phase II Study Of Estramustine, Docetaxel, And Bevacizumab In Men With Castrate Resistant Prostate Cancer: Results Of Cancer And Leukemia Group B (CALGB) 90006

Joel Picus, Susan Halabi, W. Kevin Kelly, Nicholas J. Vogelzang, Young E. Whang, Ellen B. Kaplan, Walter M. Stadler, Eric J. Small *Cancer* vol 117 (3) 526-533 2011
Manuscript GU <http://www.ncbi.nlm.nih.gov/pubmed/20862750>

1675 LACE-Bio: Cross-validation and Pooled Analyses of the Putative Prognostic/Predictive Biomarkers p27, p16 and cyclin E in IALT, ANITA, JBR10 and CALGB 9633

R. Pirker, V. Rousseau, E. Paris, M. S. Tsao, S. Aviel-Ronen, M. Taron, R. Kratzke, E. Brambilla, L. Seymour, M. Filipits *J Thorac Oncol* vol 5 (12) S503 2010
Abstract Respiratory <http://journals.lww.com/jto/Citation/2010/12003/Abstracts.5.aspx>

1676 Impact of poor prognostic features on the surgical treatment of breast cancer in an intergroup adjuvant chemotherapeutic trial

B. A. Pockaj, A. Dueck, K. Tenner, E. Perez *J Clin Oncol* vol 25 (18s) abstr 612 2007
Abstract Breast http://ascopubs.org/doi/abs/10.1200/jco.2007.25.18_suppl.612

1677 Effect of Docetaxel and Carboplatin on VEGF, PGE2, and Immune cells in Patients With Stage II or III Breast Cancer

B. Pockaj, T. Tinder, C. Klosterman, J. Allred, V. Roy, E. Perez, P. Mukherjee *Cancer Res* vol 69 (2, suppl 1) abstr 5110 2009
Abstract Breast http://cancerres.aacrjournals.org/content/69/2_Supplement/5110

1678 Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype

Xavier Poiré, Barry K. Moser, Robert E. Gallagher, Kristina Laumann, Clara D. Bloomfield, Bayard L. Powell, Gregory Koval, Kabir Gulati, Nicholas Holowka, Richard A. Larson, Martin S. Tallman, Frederick R. Appelbaum, Dorie Sher, Cheryl Willman, Elisabeth Paietta, Wendy Stock *Leuk Lymphoma* vol 55 (7) 1523-1532 2014
Manuscript Leukemia <http://www.ncbi.nlm.nih.gov/pubmed/24160850>

1679 Differences in psychosocial factors among diverse women enrolled in a phase III cooperative group metastatic breast cancer trial (CALGB 40502/Alliance)

B. N. Polite, J. B. Allred, H. S. Rugo, T. Cipriano, C. Cirrincione, S. J. Gehlert, E. D. Paskett, C. Hudis, E. P. Winer *J Clin Oncol* vol 31 (15 suppl) abstr 9581 2013
Abstract Disparities

1680 Racial Differences in Clinical Outcomes From Metastatic Breast Cancer: A Pooled Analysis of CALGB 9342 and 9840—Cancer and Leukemia Group B

Blase N. Polite, Constance Cirrincione, Gini F. Fleming, Donald A. Berry, Andrew Seidman, Hyman Muss, Larry Norton, Charles Shapiro, Kamal Bakri, Kelly Marcom, Diana Lake, Joel H. Schwartz, Clifford Hudis, Eric P. Winer *J Clin Oncol* vol 26 (16) 2659-65 2008

Manuscript Breast CALGB-40501, CALGB-9342, CALGB-9840

<http://www.ncbi.nlm.nih.gov/pubmed/18509177>

1681 Tolerability and Toxicity of Trastuzumab or Trastuzumab + Lapatinib in Older Patients

Noam Falbel Ponde, Dominique Agbor-Tarh, Lissandra Dal Lago, Larissa A. Korde, Florentine Hilbers, Christian Jackisch, Olena Werner, Richard D. Gelber, Aminah Jatoui, Amylou C. Dueck, Alvaro Moreno-Aspitia, Christos Sotiriou, Evandro de Azambuja, Martine Piccart *JCO* vol 37 (no. 15_suppl) 11553-11553 2019

Abstract Breast https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.11553

1682 Tolerability and toxicity of trastuzumab or trastuzumab-lapatinib in older patients: a sub-analysis of the ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D).

Noam Pondé, Dominique Agbor-Tarh, Lissandra Dal Lago, Larissa A Korde, Florentine Hilbers, Christian Jackisch, Olena Werner, Richard D Gelber, Aminah Jatoui, Amylou C Dueck, Alvaro Moreno-Aspitia, Christos Sotiriou, Evandro de Azambuja, Martine Piccart *Breast Cancer Res Treat* vol 185 (1) 107-16 2021

Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/32951084>

1683 A Phase III randomized, double-blind placebo controlled study of armodafinil (nuvigil®) to reduce cancer-related fatigue in patients with high grade glioma (Alliance A221101)

Alyx B. Porter, Sadhna Kohli, Jane Cerhan, Jeff Sloan, Heshan Liu, Ryan McMurray, Jennifer Le-Rademacher, Charles Loprinzi, John L. Villano, Sani Kizilbash, Minesh P. Mehta, Kurt Jaeckle, Paul D. Brown *J Clin Oncol* vol 38 (15_suppl) 12007 2020

Abstract Symptom Inter https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.12007

1684 Efficacy of Treatment With Armodafinil for Cancer-Related Fatigue in Patients With High-grade Glioma

Alyx B. Porter, Heshan Liu, Sadhna Kohli, Jane L. Cerhan, Jeff Sloan, Ryan P. McMurray, Jennifer Le-Rademacher, Charles L. Loprinzi, John L. Villano, Sani H. Kizilbash, Minesh P. Mehta, Kurt A. Jaeckle, Paul D. Brown *JAMA Oncol* vol 8 (2) 1-9 2022

Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/34882169>

1685 A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group B study 89903.

Mitchell C Posner, Donna Niedzwiecki, Alan P Venook, Donna R Hollis, Hedy L Kindler, Edward W Martin, Richard L Schilsky, Richard M Goldberg, Robert J Mayer *Ann Surg Oncol* vol 15 (1) 158-64 2008

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/18008108>

1686 Adding Mercaptopurine and Methotrexate to Alternate Week ATRA Maintenance Therapy Does Not Improve the Outcome for Adults with Acute Promyelocytic Leukemia (APL) in First Remission: Results From North American Leukemia Intergroup Trial C9710

B. L. Powell, B. K. Moser, W. Stock, R. E. Gallagher, C. L. Willman, R. M. Stone, J. M. Rowe, S. E. Coutre, J. H. Feusner, J. Gregory, S. Couban, F. R. Appelbaum, M. S. Tallman, R. A. Larson *Blood* vol 118 (21) -258 2011

1687 Effect of consolidation with arsenic trioxide (As₂O₃) on event-free survival (EFS) and overall survival (OS) among patients with newly diagnosed acute promyelocytic leukemia (APL): North American Intergroup Protocol C9710.

B. L. Powell, B. Moser, W. Stock, R. E. Gallagher, C. Willman, S. Coutre, J. H. Feusner, F. R. Appelbaum, M. S. Tallman, R. A. Larson *J Clin Oncol* vol 25 (18S, June 20 Supplement) 2 2007
Abstract Leukemia
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID

1688 Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710

Bayard L. Powell, Barry Moser, Wendy Stock, Robert E. Gallagher, Cheryl L. Willman, Richard M. Stone, Jacob M. Rowe, Steven Coutre, James H. Feusner, John Gregory, Stephen Couban, Frederick R. Appelbaum, Martin S. Tallman, Richard A. Larson *Blood* vol 116 (19) 3751-3757 2010
Manuscript Leukemia <http://www.ncbi.nlm.nih.gov/pubmed/20705755>

1689 Predicting response and survival in chemotherapy-treated triple-negative breast cancer

A Prat, A Lluch, J Albanell, W T Barry, C Fan, J I Chacón, J S Parker, L Calvo, A Plazaola, A Arcusa, M A Seguí-Palmer, O Burgues, N Ribelles, A Rodriguez-Lescure, A Guerrero, M Ruiz-Borrego, B Munarriz, J A López, B Adamo, M C U Cheang, Y Li, Z Hu, M L Gulley, M J Vidal, B N Pitcher, M C Liu, M L Citron, M J Ellis, E Mardis, T Vickery, C A Hudis, E P Winer, L A Carey, R Caballero, E Carrasco, M Martín, C M Perou, E Alba *Br J Cancer* vol 111 (8) 1532-1541 2014
Manuscript Breast CALGB-9741 <http://www.ncbi.nlm.nih.gov/pubmed/25101563>

1690 The evaluation of flaxseed for hot flashes: Results of a randomized, controlled trial, NCCTG study N08C7

S. Pruthi, R. Qin, S. A. Terstriep, H. Liu, C. L. Loprinzi, T. R. C. Shah, K. F. Tucker, S. R. Dakhil, M. J. Bury, R. L. Carolla, P. D. Steen, J. Vuky, D. L. Barton *J Clin Oncol* vol 29 (supplement) abstr CRA9015 2011
Abstract Symptom Inter
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID

1691 A Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of Flaxseed for the Treatment of Hot Flashes: NCCTG N08C7

Sandhya Pruthi, Rui Qin, Shelby A. Terstreip, Heshan Liu, Charles L. Loprinzi, Tushar R. C. Shah, Kenneth F. Tucker, Shaker R. Dakhil, Martin J. Bury, Robert L. Carolla, Preston D. Steen, Jacqueline Vuky, Debra L. Barton *Menopause* vol 19 (1) 48-53 2012
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/21900849>

1692 Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer

Nindo B. Punturi, Sinem Seker, Vaishnavi Devarakonda, Aloran Mazumder, Rashi Kalra, Ching Hui Chen, Shunqiang Li, Tina Primeau, Matthew J. Ellis, Shyam M. Kavuri, Svasti Haricharan *Nat Commun* vol 12 2021
Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/34011995>

1693 Incidence of bleeding and thrombosis among elderly patients undergoing systemic chemotherapy in advanced non-small cell lung cancer: An analysis of North Central Cancer Treatment Group trials

Y. Qi, G. K. Dy, G. D. Nelson, S. E. Schild, S. J. Mandrekar, A. A. Adjei *J Clin Oncol* vol 28 (15s) abstr e18093 2010
Abstract Respiratory <http://meetinglibrary.asco.org/content/53472-74>

- 1694 Impact of disease progression date determination on progression-free survival estimates in advanced lung cancer**
Y. Qi, K. L. Allen Ziegler, S. L. Hillman, M. W. Redman, S. E. Schild, D. R. Gandara, A. A. Adjei, S. J. Mandrekar *Cancer* vol 118 (21) 5358-5365 2012
Manuscript Respiratory NCCTG-N0022, NCCTG-N0026, NCCTG-N0222, NCCTG-N0323, NCCTG-N0326, NCCTG-N0426, NCCTG-N0528, NCCTG-N0626, NCCTG-N0821, NCCTG-N9921
<http://www.ncbi.nlm.nih.gov/pubmed/22434489>
- 1695 Pretreatment Quality of Life Is an Independent Prognostic Factor for Overall Survival in Patients with Advanced Stage Non-small Cell Lung Cancer**
Yingwei Qi, Steven E. Schild, Sumithra J. Mandrekar, Angelina D. Tan, James E. Krook, Kendrith M. Rowland, Yolanda I. Garces, Gamini S. Soori, Alex A. Adjei, Jeff A. Sloan *J Thorac Oncol* vol 4 (9) 1075-1082 2009
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/19546817>
- 1696 Quality of Life Analysis of N0877 (Alliance): Phase II Trial of Either Dasatinib or Placebo Combined with Standard Chemo-Radiotherapy for Newly Diagnosed Glioblastoma Multiforme (GBM)**
Rui Qin, Angelina D. Tan, Jeff A. Sloan, Derek Richard Johnson, Glenn Jay Lesser, S. Keith Anderson, Nadia N. Laack *J Clin Oncol* vol 33 (suppl) abstr e17715 2015
Abstract Health Outcomes <http://meetinglibrary.asco.org/content/146850-156>
- 1697 Pilot Study of Fractional CO2 Laser Therapy for Genitourinary Syndrome of Menopause in Gynecologic Cancer Survivors**
Allison Quick, Travis Dockter, Jennifer Le-Rademacher, Ritu Salani, Catherine Hudson, Andrew Hundley, Shelby Terstriep, Lauren Streicher, Stephanie Faubion, Charles Loprinzi, Jenell S. Coleman, Karen Wang, Maryam Lustberg *Maturitas* vol 144 37-44 2021
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/33358206>
- 1698 Polygenic risk scores for blood pressure to assess the risk of severe bevacizumab-induced hypertension in cancer patients (Alliance)**
Julia C. F. Quintanilha, Amy S. Etheridge, Brady J. Graynor, Nicholas B. Larson, Daniel J. Crona, Braxton D. Mitchell, Federico Innocenti *Clin Pharmacol Ther* vol 112 (2) 364-71 2022
Manuscript Correl Sci NOS CALGB-40502, CALGB-40503, CALGB-80303, CALGB-90401
<http://www.ncbi.nlm.nih.gov/pubmed/35527502>
- 1699 KDR genetic predictor of toxicities induced by sorafenib and regorafenib**
Julia C. F. Quintanilha, Susan Geyer, Amy S. Etheridge, Alessandro Racioppi, Kelli Hammond, Daniel J. Crona, Carol E. Peña, Sawyer Jacobson, Federica Marmorino, Daniele Rossini, Chiara Cremolini, Hanna K. Sanoff, Ghassan K. Abou-Alfa, Federico Innocenti *Pharmacogenomics J* vol 22 (5-6) 251-7 2022
Manuscript PPP <http://www.ncbi.nlm.nih.gov/pubmed/35484400>
- 1700 Genetic predictor of sorafenib-induced diarrhea and hand-foot syndrome (Alliance)**
Julia C. F. Quintanilha, Susan Geyer, Jin Wang, Amy S. Etheridge, Stefanie Denning, Alessandro Racioppi, Kelli Hammond, Daniel J. Crona, Carol E. Peña, Sawyer Jacobson, Ghassan K. Abou-Alfa, Federico Innocenti *J Clin Oncol* vol 39 (no. 15_suppl) 3030 2021
Abstract PPP https://ascopubs.org/doi/10.1200/JCO.2021.39.15_suppl.3030
- 1701 Plasma levels of angiopoietin-2, VEGF-A, and VCAM-1 as markers of bevacizumab-induced hypertension: CALGB 80303 and 90401 (Alliance)**
Julia C. F. Quintanilha, Yingmiao Liu, Amy S. Etheridge, Akram Yazdani, Hedy L. Kindler, William Kevin Kelly, Andrew B. Nixon, Federico Innocenti *Angiogenesis* vol 25 (1) 47-55 2022

Manuscript Correl Sci NOS CALGB-80303, CALGB-90401
<http://www.ncbi.nlm.nih.gov/pubmed/34028627>

1702 PIK3R5 genetic predictors of hypertension induced by VEGF-pathway inhibitors

Julia C. F. Quintanilha, Alessandro Racioppi, Jin Wang, Amy S. Etheridge, Stefanie Denning, Carol E. Peña, Andrew D. Skol, Daniel J. Crona, Danyu Lin, Federico Innocenti *Pharmacogenomics J* vol 22 (1) 82-8 2022

Manuscript PPP CALGB-40502, CALGB-40503, CALGB-80303, CALGB-90401
<http://www.ncbi.nlm.nih.gov/pubmed/34775477>

1703 Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients

Julia C. F. Quintanilha, Jin Wang, Alexander B. Sibley, Chen Jiang, Amy S. Etheridge, Fei Shen, Guanglong Jiang, Flora Mulkey, Jai N. Patel, Daniel L. Hertz, Elizabeth Claire Dees, Howard L. McLeod, Monica Bertagnolli, Hope Rugo, Hedy L. Kindler, William Kevin Kelly, Mark J. Ratain, Deanna L. Kroetz, Kouros Owzar, Bryan P. Schneider, Danyu Lin, Federico Innocenti *Br J Cancer* vol 126 (2) 265-274 2022

Manuscript PPP CALGB-40502, CALGB-40503, CALGB-80303, CALGB-90401
<http://www.ncbi.nlm.nih.gov/pubmed/34616010>

1704 Genome-wide association studies of survival in 1,520 cancer patients treated with bevacizumab-containing regimens

Julia C.F. Quintanilha, Jin Wang, Alexander B. Sibley, Wei Xu, Osvaldo Espin-Garcia, Chen Jiang, Amy S. Etheridge, Mark J. Ratain, Heinz-Josef Lenz, Monica Bertagnolli, Hedy L. Kindler, Maura N. Dickler, Alan Venook, Geoffrey Liu, Kouros Owzar, Danyu Lin, Federico Innocenti *Int J Cancer* vol 150 (2) 279-89 2022

Manuscript PPP CALGB-40503, CALGB-80303, CALGB-80405, ICON7
<http://www.ncbi.nlm.nih.gov/pubmed/34528705>

1705 MicroRNA (miR) expression signatures in molecular subsets of cytogenetically normal (CN) acute myeloid leukemia (AML): A Cancer and Leukemia Group B (CALGB) study

M. D. Radmacher, G. Marcucci, P. Paschka, T. Vukosavljevic, S. P. Whitman, A. S. Ruppert, K. A. Mrozek, J. E. Kolitz, R. A. Larson, C. D. Bloomfield *J Clin Oncol* vol 25 (18s) abstr 7010 2007
Abstract *Leuk Corr Sci* CALGB-19808, CALGB-20502, CALGB-8461, CALGB-9621, CALGB-9665

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID

1706 Acquired Genomic Alterations on First-Line Chemotherapy With Cetuximab in Advanced Colorectal Cancer: Circulating Tumor DNA Analysis of the CALGB/SWOG-80405 Trial (Alliance)

Kanwal Raghav, Fang-Shu Ou, Alan P. Venook, Federico Innocenti, Ryan Sun, Heinz-Josef Lenz, Scott Kopetz *J Clin Oncol* vol 41 (3) 472-8 2023

Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/36067452>

1707 Circulating tumor DNA dynamics on front line chemotherapy with bevacizumab or cetuximab in metastatic colorectal cancer: a biomarker analysis for acquired genomic alterations in CALGB/SWOG 80405 (Alliance) randomized trial

Kanwal Raghav, Fang-Shu Ou, Alan P Venook, Federico Innocenti, Ryan Sun, Heinz-Josef Lenz, Scott Kopetz *J Clin Oncol* vol 40 (4_suppl) abstr 193 2022

Abstract *Correl Sci NOS* https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.4_suppl.193?af=R

1708 Long-Term Survival Analysis of the North American Intergroup Study C9011 Comparing Fludarabine (F) and Chlorambucil (C) in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL)

K. R. Rai, B. L. Peterson, F. R. Appelbaum, M. S. Tallman, A. Belch, V. A. Morrison, R. A. Larson
Blood vol 114 (22) abstr 536 2009
Abstract Leukemia <http://www.bloodjournal.org/content/114/22/536>

1709 Alliance A031902 (CASPAR): A randomized, phase III trial of enzalutamide (ENZ) with rucaparib (RUCA)/placebo (PBO) as novel therapy in first-line metastatic castration-resistant prostate cancer (mCRPC).

Arpit Rao, Glenn Heller, Charles J. Ryan, David James VanderWeele, Lionel D Lewis, Alan Tan, Colleen Watt, Ronald C. Chen, Manish Kohli, Pedro Barata, Benjamin Gartrell, Robert Grubb, Amylou Dueck, Yujia Wen, Michael J. Morris J Clin Oncol vol 40 (suppl 6) TPS194 2022
Abstract GU <https://meetings.asco.org/abstracts-presentations/205864>

1710 Alliance A031902 (CASPAR): A randomized, phase 3 trial of enzalutamide (ENZ) with rucaparib (RUCA)/placebo (PBO) in first-line metastatic castration-resistant prostate cancer (mCRPC)

Arpit Rao, Glenn Heller, Charles J. Ryan, David James VanderWeele, Lionel D Lewis, Alan Tan, Colleen Watt, Ronald C. Chen, Manish Kohli, Pedro Barata, Benjamin Gartrell, Robert Grubb, Amylou Dueck, Yujia Wen, Michael J. Morris J Clin Oncol vol 41 (6) 208 2023
Abstract GU https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.6_suppl.208?af=R

1711 CASPAR (Alliance A031902) - A Randomized, Phase III Trial of Enzalutamide with/without Rucaparib as a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Arpit Rao, Charles J Ryan, David Vanderweele, Glenn Heller, Lionel D. Lewis, Colleen Watt, Ronald C Chen, Robert Grubb, Olwen Hahn, Himisha Beltran, Michael J Morris J Clin Oncol vol 40 (16_suppl) TPS5107 2022
Abstract GU <https://meetings.asco.org/abstracts-presentations/213437>

1712 CASPAR (Alliance A031902) - A Randomized, Phase III Trial of Enzalutamide with/without Rucaparib as a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Arpit Rao, Charles J Ryan, David Vanderweele, Glenn Heller, Lionel D. Lewis, Colleen Watt, Ronald C Chen, Robert Grubb, Olwen Hahn, Himisha Beltran, Michael J Morris J Clin Oncol vol 39 (6_suppl) TPS181 2021
Abstract GU https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.6_suppl.TPS181

1713 Results of NCCTG phase II trial of the mTOR inhibitor RAD-001 in metastatic melanoma

R. D. Rao, J. B. Allred, H. E. Windschitl, W. J. Maples, R. R. McWilliams, E. T. Creagan, J. S. Kaur, M. K. Gornet, B. A. Pockaj, S. N. Markovic J Clin Oncol vol 25 (18s) abstr 8530 2007
Abstract Experimental
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID

1714 A Pharmacogenetic Prediction Model of Progression-Free Survival in Breast Cancer using Genome-Wide Genotyping Data from CALGB 40502 (Alliance)

Sara R. Rashkin, Katherina C. Chua, Carol Ho, Flora Mulkey, Chen Jiang, Tasei Mushiroda, Michiaki Kubo, Paula N. Friedman, Hope S. Rugo, Howard L. McLeod, Mark J. Ratain, Francisco Castillos, Michael Naughton, Beth Overmoyer, Deborah Toppmeyer, John S. Witte, Kouros Owzar, Deanna L. Kroetz Clin Pharmacol Ther vol 105 (3) 738-45 2019
Manuscript PPP <http://www.ncbi.nlm.nih.gov/pubmed/30260474>

1715 A phase II study of cisplatin(C), irinotecan (I) and bevacizumab (B) for untreated extensive stage small cell lung cancer (ES-SCLC)

N. E. Ready, A. Z. Dudek, X Wang, S. L. Graziano, M. R. Green, E. E. Vokes J Clin Oncol vol 25

(18s) abstr 7563 2007

Abstract Respiratory

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID

1716 Combination chemotherapy with sunitinib (IND 74019; NSC 736511) for untreated extensive stage small cell lung cancer (SCLC): CALGB 30504 phase IB safety results

N. E. Ready, F. R. Dunphy, H. Pang, R. V. Heinze, J. Crawford, E. E. Vokes J Clin Oncol vol 28

(15s) abstr 7056 2010

Abstract Respiratory

http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/7056?sid=27c902e6-3697-427f-b482-c2cac

1717 Chemotherapy with or without maintenance sunitinib for untreated extensive-stage small cell lung cancer: A randomized, placebo controlled phase II study CALGB 30504 (ALLIANCE)

N. E. Ready, H. H. Pang, L. Gu, G. A. Otterson, S. P. Thomas, A. A. Miller, M. Q. Baggstrom, G. A. Masters, S. L. Graziano, J. Crawford, J. Bogart, E. E. Vokes J Clin Oncol vol 31 (15 suppl) abstr 7506 2013

Abstract Respiratory

http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/7506?sid=3204ebb7-e5d3-4684-ab2e-9ed3

1718 Cisplatin, Irinotecan, and Bevacizumab for Untreated Extensive-Stage Small-Cell Lung Cancer: CALGB 30306, a Phase II Study

Neal E. Ready, Arkadiusz Z. Dudek, Herbert H. Pang, Lydia D. Hodgson, Stephen L. Graziano, Mark R. Green, Everett E. Vokes J Clin Oncol vol 29 (33) 4436-4441 2011

Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/21969504>

1719 Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study—CALGB 30504 (Alliance)

Neal E. Ready, Herbert H. Pang, Lin Gu, Gregory A. Otterson, Sachdev P. Thomas, Antonius A. Miller, Maria Baggstrom, Gregory A. Masters, Stephen L. Graziano, Jeffrey Crawford, Jeffrey Bogart, Everett E. Vokes J Clin Oncol vol 33 (15) 1660-1665 2015

Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/25732163>

1720 Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: Cancer and Leukemia group B (CALGB) 30106, a CALGB-stratified phase II trial.

Neal Ready, Pasi A Jänne, Jeffrey Bogart, Thomas Dipetrillo, Jennifer Garst, Stephen Graziano, Lin Gu, Xiaofei Wang, Mark R Green, Everett E Vokes J Thorac Oncol vol 5 (9) 1382-90 2010

Manuscript Respiratory CALGB-150508 <http://www.ncbi.nlm.nih.gov/pubmed/20686428>

1721 Association of social deprivation with survival in younger adult patients with AML: an Alliance study

Melanie Rebechi, Jessica Kohlschmidt, Krzysztof Mrózek, Deedra Nicolet, Alice S. Mims, James S. Blachly, Shelley Orwick, Karilyn T. Larkin, Christopher C. Oakes, Andrew Hantel, Andrew J. Carroll, William G. Blum, Bayard L. Powell, Geoffrey L. Uy, Richard M. Stone, Richard A. Larson, John C. Byrd, Electra D. Paskett, Jesse J. Plascak, Ann-Kathrin Eisfeld Blood Adv vol 7 (15) 4019-23 2023

Manuscript Leuk Corr Sci CALGB-20202, CALGB-8461, CALGB-9665

<http://www.ncbi.nlm.nih.gov/pubmed/37196637>

1722 Social Deprivation Associated with Survival in Younger Patients with Acute Myeloid Leukemia (Alliance)

Melanie Rebechi, Jessica Kohlschmidt, Deedra Nicolet, Krzysztof Mrózek, James S. Blachly, Alice S. Mims, Shelley Orwick, Andrew J. Carroll, William E. Blum, Bayard L. Powell, Geoffrey L. Uy,

Richard M. Stone, Electra D. Paskett, John C. Byrd, Jesse Plascak, Ann-Kathrin Eisfeld Blood vol 138 (Supplement 1) 1983–2021
Abstract Leuk Corr Sci CALGB-20202, CALGB-8461, CALGB-9665
<https://www.sciencedirect.com/science/article/pii/S0006497121039446>

1723 A phase II study of neoadjuvant therapy with cisplatin, docetaxel, panitumumab plus radiation therapy followed by surgery in patients with locally advanced adenocarcinoma of the distal esophagus (ACOSOG Z4051)

C. Reed, P. Decker, T. Schefter, B. Meyers, M. Ferguson, A. Oeltjen, J. Putnam, S. Cassivi, A. Lockhart J Clin Oncol vol 30 (suppl) abstr 4062 2012
Abstract GI <https://meetinglibrary.asco.org/content/92693-114>

1724 Natural history of paclitaxel-associated acute pain syndrome (P-APS): NCCTG trial N08C1

B. Reeves, S. R. Dakhil, J. A. Sloan, A. Kamal, S. L. Wolf, K. N. Burger, N. Lelindqwister, G. S. Soori, A. J. Jaslowski, C. L. Loprinzi J Clin Oncol vol 28 (15s) abstr 9135 2010
Abstract Health Outcomes
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID

1725 Further data supporting that paclitaxel-associated acute pain syndrome is associated with development of peripheral neuropathy: North Central Cancer Treatment Group trial N08C1.

Brandi N Reeves, Shaker R Dakhil, Jeff A Sloan, Sherry L Wolf, Kelli N Burger, Arif Kamal, Nguyet A Le-Lindqwister, Gamini S Soori, Anthony J Jaslowski, Joseph Kelaghan, Paul J Novotny, Daniel H Lachance, Charles L Loprinzi Cancer vol 118 (20) 5171-8 2012
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/22415454>

1726 Efficacy of carboplatin–taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials

M. M. Regan, E. K. O'Donnell, W. K. Kelly, S. Halabi, W. Berry, S. Urakami, N. Kikuno, W. K. Oh Ann Oncol vol 21 (2) 312-318 2010
Manuscript GU <http://www.ncbi.nlm.nih.gov/pubmed/19633053>

1727 Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT

M. M. Regan, B. A. Walley, P. A. Francis, G. F. Fleming, I. Láng, H. L. Gómez, M. Colleoni, C. Tondini, G. Pinotti, M. Salim, S. Spazzapan, V. Parmar, T. Ruhstaller, E. A. Abdi, R. D. Gelber, A. S. Coates, A. Goldhirsch, O. Pagani Ann Oncol vol 28 (9) 2225-32 2017
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/28911092>

1728 Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer: TEXT and SOFT Trials

Meredith M. Regan, Prudence A. Francis, Olivia Pagani, Gini F. Fleming, Barbara A. Walley, Giuseppe Viale, Marco Colleoni, István Láng, Henry L. Gómez, Carlo Tondini, Graziella Pinotti, Karen N. Price, Alan S. Coates, Aron Goldhirsch, Richard D. Gelber J Clin Oncol vol 34 (19) 2221-2231 2016
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/27044936>

1729 Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: Design of the TEXT and SOFT trials

Meredith M. Regan, Olivia Pagani, Gini F. Fleming, Barbara A. Walley, Karen N. Price, Manuela Rabaglio, Rudolf Maibach, Barbara Ruepp, Alan S. Coates, Aron Goldhirsch, Marco Colleoni, Richard D. Gelber, Prudence A. Francis Breast vol 22 (6) 1094-100 2013

1730 Predictive value and clinical utility of centrally-assessed ER, PgR and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials

Meredith M. Regan, Olivia Pagani, Prudence A. Francis, Gini F. Fleming, Barbara A. Walley, Roswitha Kammler, Patrizia Dell'Orto, Leila Russo, János Szke, Franco Doimi, Laura Villani, Stefano Pizzolitto, Christian Öhlschlegel, Fausto Sessa, Vicente Peg Cámara, José Luis Rodríguez Peralto, Gaëtan MacGrogan, Marco Colleoni, Aron Goldhirsch, Karen N. Price, Alan S. Coates, Richard D. Gelber, Giuseppe Viale Breast Cancer Res Treat vol 154 (2) 275-286 2015
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/26493064>

1731 Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status

R L Rego, N R Foster, T C Smyrk, M Le, M J O'Connell, D J Sargent, H Windschitl, F A Sinicrope Br J Cancer vol 102 (1) 165-172 2010
Manuscript Correl Sci NOS NCCTG-894651, NCCTG-91-46-53
<http://www.ncbi.nlm.nih.gov/pubmed/19997103>

1732 EGFR expression is associated with increased cell turnover and poor histologic grade in human colon carcinomas.

R. L. Rego, T. C. Smyrk, N. R. Foster, D. J. Sargent, B. F. Kabat, A. J. French, S. N. Thibodeau, H. Windschitl, M. J. O'Connell, F. A. Sinicrope J Clin Oncol vol 25 (18s) abstr 21046 2007
Abstract GI
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID

1733 Activated EGFR as a prognostic marker in human colon cancer

R. L. Rego, T. C. Smyrk, N. R. Foster, D. J. Sargent, S. N. Thibodeau, S. R. Alberts, H. E. Windschitl, F. A. Sinicrope J Clin Oncol vol 26 (15s) abstr 22119 2008
Abstract GI
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID

1734 Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials

T. Reiman, R. Lai, A. S. Veillard, E. Paris, J. C. Soria, R. Rosell, M. Taron, S. Graziano, R. Kratzke, L. Seymour, F. A. Shepherd, J. P. Pignon, P. Seve Ann Oncol vol 23 (1) 86-93 2012
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/21471564>

1735 Prognostic value of Class III B-Tubulin (TUBB3) in operable non-small cell lung cancer (NSCLC) and predictive value for adjuvant cisplatin based chemotherapy (CT): A validation study on 3 randomized trials

T. Reiman, P. Seve, A. Vataire, A. Dunant, R. Rosell, S. L. Graziano, L. Seymour, R. Pirker, R. Lai J Clin Oncol vol 26 (May 20 suppl) abstr 7506 2008
Abstract Respiratory
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID

1736 Validation of the prognostic and predictive value of class III beta tubulin (TUBB3) for adjuvant chemotherapy (ACT) in completely resected non-small cell lung cancer (R-NSCLC): Results from four randomized trials

Tony Reiman, Pascal Seve, Anne-Sophie Veillard, Jean-Charles Soria, Rafael Rosell, Miquel Taron, Stephen Graziano, Robert Kratzke, Lesley Seymour, Frances Shepherd, Jean-Pierre Pignon, Raymond Lai J Thorac Oncol vol 4 (9 suppl 1) abstr A4.2 2009
Abstract Respiratory [http://www.jto.org/article/S1556-0864\(15\)33608-X/fulltext](http://www.jto.org/article/S1556-0864(15)33608-X/fulltext)

- 1737 Effect of IGF1R protein expression on benefit to adjuvant trastuzumab in early-stage HER2+ breast cancer in NCCTG N9831 trial**
M. M. Reinholz, A. L. Dueck, B. Chen, X. Geiger, A. McCullough, R. Jenkins, W. Lingle, C. Andorfer, N. Davidson, S. Martino, P. Kaufman, L. Kutteh, G. Sledge, L. Harris, J. Gralow, E. Perez J Clin Oncol vol 29 (suppl) abstr 10503 2011
Abstract Breast <http://meetinglibrary.asco.org/content/81832-102>
- 1738 MYC protein expression and copy number anomalies in early-stage HER2+ breast cancer in context of the NCCTG adjuvant trial, N9831.**
M. M. Reinholz, X. Geiger, A. C. Dueck, A. E. Wiktor, W. L. Lingle, C. Andorfer, W. R. Sukov, R. P. Ketterling, R. B. Jenkins, E. A. Perez, N. E. Davidson, S. Martino, P. A. Kaufman, L. A. Kutteh, G. W. Sledge, L. N. Harris, J. R. Gralow Molecular Markers in Cancer abstr 66 2010
Abstract Breast <http://meetinglibrary.asco.org/content/60958-101>
- 1739 The concordance between NCCTGs and NSABPs C-myc FISH assays**
M. Reinholz, A. Dueck, W. Lingle, A. Ziegler, A. Wiktor, S. Paik, R. Jenkins, E. Perez J Clin Oncol vol 26 (May 20 suppl) abstr 22110 2008
Abstract Correl Sci NOS http://meeting.ascopubs.org/cgi/content/short/26/15_suppl/22110
- 1740 Cytokeratin-19 (CK19) and mammaglobin (MGB1) gene expression in circulating tumor cells (CTCs) from metastatic breast cancer patients enrolled in the NCCTG trials, N0436 and N0437**
M. Reinholz, K. Kitzmann, T. Hobday, D. Northfelt, B. Laplant, J. Allred, A. Dueck, P. Stella, W. Lingle, E. Perez J Clin Oncol vol 27 (15s) abstr 11095 2009
Abstract Breast NCCTG-N0436, NCCTG-N0437 <http://meetinglibrary.asco.org/content/33733-65>
- 1741 Circulating tumor cells in North Central Cancer Treatment Group breast clinical trials**
M. Reinholz, K. Kitzmann, K. Tenner, D. Hillman, T. Hobday, V. Roy, A. Moreno-Aspitia, D. Northfelt, J. Allred, B. Laplant, A. Dueck, E. Perez, W. Lingle 7th International Symposium on Minimal Residual Cancer abstr O24 2009
Abstract Breast NCCTG-N0234, NCCTG-N0336, NCCTG-N0338, NCCTG-N0436, NCCTG-N0437
<http://www.erasmus.gr/en/congresses/athens/2009/7th-international-symposium-on-minimal-residual-car>
- 1742 c-MYC (MYC) Protein Expression and Associations with Trastuzumab Benefit in Early-Stage, HER2+ Breast Cancer in Context of the NCCTG Adjuvant Trial, N9831**
MM Reinholz, AC Dueck, AE Wiktor, WL Lingle, RB Jenkins, NE Davidson, S Martino, PA Kaufman, LA Kutteh, GW Sledge, LN Harris, JR Gralow, X Geiger, EA. Perez Cancer Res vol 70 (24, suppl 2) abstr P2-09-08 2010
Abstract Breast http://cancerres.aacrjournals.org/content/70/24_Supplement/P2-09-08.short
- 1743 IGF1R Protein Expression is Not Associated with Differential Benefit to Concurrent Trastuzumab in Early-Stage HER2-positive Breast Cancer from the North Central Cancer Treatment Group (Alliance) Adjuvant Trastuzumab Trial N9831**
Monica M. Reinholz, Beiyun Chen, Amylou C. Dueck, Kathleen Tenner, Karla Ballman, Darren Riehle, Robert B. Jenkins, Xochiquetzal J. Geiger, Ann E McCullough, Edith A. Perez Clin Cancer Res vol 23 (15) 4203-11 2017
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/28533226>
- 1744 Cytokeratin-19 and mammaglobin gene expression in circulating tumor cells from metastatic breast cancer patients enrolled in North Central Cancer Treatment Group (NCCTG) trials, N0234/336/436/437**
Monica M. Reinholz, Kathleen A. Kitzmann, Kathleen Tenner, David Hillman, Amylou C. Dueck,

Timothy J. Hobday, Donald W. Northfelt, Alvaro Moreno-Aspitia, Vivek Roy, Betsy LaPlant, Jake B. Allred, Philip J. Stella, Wilma L. Lingle, Edith A. Perez *Clin Cancer Res* vol 17 (22) 7183-7193 2011

Manuscript Breast NCCTG-N0234, NCCTG-N0336, NCCTG-N0338, NCCTG-N0436, NCCTG-N0437 <http://www.ncbi.nlm.nih.gov/pubmed/21976532>

1745 Findings from the Adjuvant Colon Cancer End Points (ACCENT) Collaborative Group: the power of pooled individual patient data from multiple clinical trials.

Lindsay A Renfro, Daniel J Sargent *Chin Clin Oncol* vol 5 (6) 80 2016
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/28061544>

1746 Brief report: a phase II "window-of-opportunity" frontline study of the MTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG study.

Thanyanan Reungwetwattana, Julian R Molina, Sumithra J Mandrekar, Katie Allen-Ziegler, Kendrith M Rowland, Nicholas F Reuter, Ronnie F Luyun, Grace K Dy, Randolph S Marks, Steven E Schild, James R Jett, Alex A Adjei *J Thorac Oncol* vol 7 (5) 919-22 2012
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/22722792>

1747 Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial

Karin Ribí, Weixiu Luo, Jürg Bernhard, Prudence A. Francis, Harold J. Burstein, Eva Ciruelos, Meritxell Bellet, Lorenzo Pavesi, Ana Lluch, Marilena Visini, Vani Parmar, Carlo Tondini, Pierre Kerbrat, Antonia Perelló, Patrick Neven, Roberto Torres, Davide Lombardi, Fabio Puglisi, Per Karlsson, Thomas Ruhstaller, Marco Colleoni, Alan S. Coates, Aron Goldhirsch, Karen N. Price, Richard D. Gelber, Meredith M. Regan, Gini F. Fleming *J Clin Oncol* vol 34 (14) 1601-1610 2016
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/27022111>

1748 The effects of treatment-induced symptoms, depression and age on sexuality in premenopausal women with early breast cancer receiving adjuvant endocrine therapy

Karin Ribí, Weixiu Luo, Harold J. Burstein, Michael J. Naughton, Jacquie Chirgwin, Rafat H. Ansari, Barbara A. Walley, Muhammed Salim, Andre van der Westhuizen, Ehtesham Abdi, Prudence A. Francis, Daniel R. Budman, Hagen Kennecke, Vernon J. Harvey, Anita Giobbie-Hurder, Gini F. Fleming, Olivia Pagani, Meredith M. Regan, Jürg Bernhard *Cancer Research* vol 77 (7) Suppl-4 2017
Abstract Breast http://cancerres.aacrjournals.org/content/77/4_Supplement/P2-09-09

1749 Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy.

Karin Ribí, Weixiu Luo, Barbara A Walley, Harold J Burstein, Jacquie Chirgwin, Rafat H Ansari, Muhammed Salim, Andre van der Westhuizen, Ehtesham Abdi, Prudence A Francis, Stephen Chia, Vernon J Harvey, Anita Giobbie-Hurder, Gini F Fleming, Olivia Pagani, Angelo Di Leo, Marco Colleoni, Richard D Gelber, Aron Goldhirsch, Alan S Coates, Meredith M Regan, Jürg Bernhard *Breast Cancer Res Treat* vol 181 (2) 347-59 2020
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/32274665>

1750 EGFR expression measured by quantitative immunofluorescence is associated with decreased benefit from trastuzumab in the adjuvant setting in the NCCTG (Alliance) N9831 trial.

D. L. Rimm, K. Ballman, H. Cheng, M. Vassilakopoulou, B. Chen, J. Gralow, C. Hudis, N. E. Davidson, G. Fountzilias, A. Psyrris, E. A. Perez *Cancer Res* vol 72 (24) abstr S5-4 2012
Abstract Correl Sci NOS http://cancerres.aacrjournals.org/content/72/24_Supplement/S5-4.short

1751 Uniformly positive (>80%) HER2 expression maximizes sensitivity and specificity for

prediction of response to trastuzumab in CALGB 9840

D. L. Rimm, G. Broadwater, P. N. Friedman, D. A. Berry, A. D. Seidman, C. A. Hudis, E. P. Winer, L. N. Harris, A. D. Thor *Cancer Res* vol 69 (2 Suppl 1) abstr 6046 2009
Abstract Breast http://cancerres.aacrjournals.org/content/69/2_Supplement/6046

1752 Cancer and Leukemia Group B Pathology Committee Guidelines for Tissue Microarray Construction Representing Multicenter Prospective Clinical Trial Tissues

David L. Rimm, Torsten O. Nielsen, Scott D. Jewell, Daniel C. Rohrer, Gloria Broadwater, Frederic Waldman, Kisha A. Mitchell, Baljit Singh, Gregory J. Tsongalis, Wendy L. Frankel, Anthony M. Magliocco, Jonathan F. Lara, Eric D. Hsi, Ira J. Bleiweiss, Sunil S. Badve, Beiyun Chen, Peter M. Ravdin, Richard L. Schilsky, Ann Thor, Donald A. Berry *J Clin Oncol* vol 29 (16) 2282-2290 2011
Manuscript Pathology CALGB-9741, CALGB-9840
<http://www.ncbi.nlm.nih.gov/pubmed/21519016>

1753 CALGB 90206: A phase III trial of bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in metastatic renal cell carcinoma

B. I. Rini, S. Halabi, J. E. Rosenberg, W. M. Stadler, J. Picus, J. N. Atkins, S. Ou, J. Tanguay, J. Dutcher, E. J. Small *Genitourinary Cancers Symposium* abstr 350 2008
Abstract GU
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=54&abstractID

1754 Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: Results of overall survival for CALGB 90206

B. I. Rini, S. Halabi, J. E. Rosenberg, W. M. Stadler, D. A. Vaena, J. N. Atkins, J. Picus, P. Czaykowski, J. Dutcher, E. J. Small *J Clin Oncol* vol 27 (15s) abstr LBA5019 2009
Abstract GU
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID

1755 Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206

Brian I. Rini, Susan Halabi, Jonathan E. Rosenberg, Walter M. Stadler, Daniel A. Vaena, Laura Archer, James N. Atkins, Joel Picus, Piotr Czaykowski, Janice Dutcher, Eric J. Small *J Clin Oncol* vol 28 (13) 2137-43 2010
Manuscript GU <http://www.ncbi.nlm.nih.gov/pubmed/20368558>

1756 Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206

Brian I. Rini, Susan Halabi, Jonathan E. Rosenberg, Walter M. Stadler, Daniel A. Vaena, San-San Ou, Laura Archer, James N. Atkins, Joel Picus, Piotr Czaykowski, Janice Dutcher, Eric J. Small *J Clin Oncol* vol 26 (33) 5422-28 2008
Manuscript GU <http://www.ncbi.nlm.nih.gov/pubmed/18936475>

1757 Geriatric assessment for older adults receiving less-intensive therapy for acute myeloid leukemia: report of CALGB 361101

Ellen K. Ritchie, Heidi D. Klepin, Elizabeth Storricks, Brittny Major, Jennifer Le-Rademacher, Martha Wadleigh, Alison Walker, Richard A. Larson, Gail J. Roboz *Blood Adv* vol 6 (12) 3812-20 2022
Manuscript Older Adult CALGB-11002 <http://www.ncbi.nlm.nih.gov/pubmed/35420672>

1758 Efficacy and Toxicity of Rituximab and Brief Duration, High Intensity Chemotherapy with Filgrastim Support for Burkitt or Burkitt - Like Leukemia/Lymphoma: Cancer and Leukemia Group B (Calgb) Study 10002

D. A. Rizzieri, J. L. Johnson, J. C. Byrd, G. Lozanski, B. L. Powell, T. C. Shea, S. Nattom, E. Hoke, B. D. Cheson, R. Larson *Blood* vol 116 (21) -858 2010

1759 Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: Cancer and Leukemia Group B study 10002

David A. Rizzieri, Jeffrey L. Johnson, John C. Byrd, Gerard Lozanski, Kristie A. Blum, Bayard L. Powell, Thomas C. Shea, Sreenivasa Nattam, Eva Hoke, Bruce D. Cheson, Richard A. Larson *Br J Haematol* vol 165 (1) 102-111 2014

Manuscript Leukemia <http://www.ncbi.nlm.nih.gov/pubmed/24428673>

1760 Role and regulation of MicroRNAs targeting BTK in acute myelogenous leukemia

Lara Rizzotto, Tzung-Huei Lai, Arianna Bottoni, Jennifer A Woyach, Rosa Lapalombella, Clara D Bloomfield, John C Byrd, Deepa Sampath *Leuk Lymphoma* vol 59 (6) 1461-1465 2018

Manuscript Leuk Corr Sci CALGB-8461 <http://www.ncbi.nlm.nih.gov/pubmed/28918688>

1761 N107C/CEC.3 (Alliance for Clinical Trials in Oncology/Canadian Cancer Trials Group): Phase III Trial of Post-Operative Stereotactic Radiosurgery (SRS) Compared with Whole Brain Radiotherapy (WBRT) for Resected Metastatic Brain Disease: Cognitive function of long-term survivors

David Roberge, Karla V. Ballman, Jane H. Cerhan, S. Keith Anderson, Xiomara W. Carrero, Anthony C. Whitton, Jeffrey Greenspoon, Ian F., Nadia N.I. Laack, Jonathan B. Ashman, Jean-Paul Bahary, Costas G. Hadjipanayis, James J. Urbanic, Fred G. Barker II, Elana Farace, Deepak Khuntia, Yolanda Garces, Caterina Giannini, Jan C. Buckner, Evanthia Galanis, Paul D. Brown *Neuro-oncology* vol 19 (suppl 6) abstr NCOG-06. 2017

Abstract Neuro-Onc

https://watermark.silverchair.com/nox168.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9

1762 Identification of Potential Prognostic Biomarkers in Patients with Untreated, Advanced Pancreatic Cancer from a Phase III Trial (CALGB 80303)

Andrew S. Roberts, Michael J. Campa, Elizabeth B. Gottlin, Chen Jiang, Kouros Owzar, Hedy L. Kindler, Alan P. Venook, Richard M. Goldberg, Eileen M. O'Reilly, Edward F. Patz *Cancer* vol 118 (2) 571-578 2012

Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/21713765>

1763 Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance)

Gail J. Roboz, Sumithra J. Mandrekar, Pinkal Desai, Kristina Laumann, Alison R. Walker, Eunice S. Wang, Jonathan E. Kolitz, Bayard L. Powell, Eyal C. Attar, Wendy Stock, Clara D. Bloomfield, Jessica Kohlschmidt, Krzysztof Mrózek, Duane C. Hassane, Levi Garraway, Judit Jané-Valbuena, Michele Baltay, Adam Tracy, Guido Marcucci, Richard M. Stone, Richard A. Larson *Blood Adv* vol 2 (24) 3608-17 2018

Manuscript Leukemia <http://www.ncbi.nlm.nih.gov/pubmed/30567725>

1764 Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and Leukemia Group B Study 39902.

C M Rocha-Lima, J E Herndon, M E Lee, J N Atkins, A Mauer, E Vokes, M R Green *Ann Oncol* vol 18 (2) 331-7 2007

Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/17065590>

1765 Daratumumab (DARA) + lenalidomide, bortezomib, and dexamethasone (RVd) in transplant-eligible newly diagnosed multiple myeloma (NDMM): a post hoc analysis of sustained minimal residual disease (MRD) negativity from GRIFFIN (AFT-29)

Cesar Rodriguez, Jonathan L. Kaufman, Jacob Laubach, Douglas W. Sborov, Brandi Reeves, Ajai Chari, Rebecca Silbermann, Luciano J. Costa, Larry D. Anderson Jr, Nitya Nathwani, Nina Shah,

Naresh Bumma, Andrzej Jakubowiak, Robert Z. Orlowski, Huiling Pei, Annelore Cortoos, Sharmila Patel, Thomas S. Lin, Paul G. Richardson, Peter M. Voorhees J Clin Oncol vol 40 (16_suppl) 8011 2022

Abstract Myeloma https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.8011

1766 Comparison of performance status with peak oxygen consumption in operable patients with non-small-cell lung cancer

Michael A. Roman, Graeme J. Koelwyn, Neil D. Eves, Whitney E. Hornsby, Dorothy Watson, James E. Herndon, Leslie Kohman, Gregory Loewen, Lee W. Jones Respirology vol 19 (1) 105-8 2014
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/23890224>

1767 Does health-related quality of life (HRQL) improve for patients who respond to chemotherapy? Analysis of patients with advanced pancreas cancer (APC) receiving gemcitabine on Cancer and Leukemia Group B (CALGB) study 80303

D. Romanus, L. E. Archer, X. Wang, R. M. Goldberg, M. Mulcahy, H. L. Kindler, D. Schrag J Clin Oncol vol 25 (18s) abstr 9008 2007
Abstract GI
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID

1768 Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? Analysis of a randomized phase III trial of the cancer and leukemia group B (CALGB 80303).

Dorothy Romanus, Hedy L Kindler, Laura Archer, Ethan Basch, Donna Niedzwiecki, Jane Weeks, Deborah Schrag J Pain Symptom Manage vol 43 (2) 205-17 2012
Manuscript Health Outcomes <http://www.ncbi.nlm.nih.gov/pubmed/22104618>

1769 Trastuzumab plus adjuvant chemotherapy for HER2-positive breast cancer: Final planned joint analysis of overall survival (OS) from NSABP B-31 and NCCTG N9831

E. H. Romond, V. J. Suman, J.-H. Jeong, G. Sledge, C. E. Geyer Jr, S. Martino, P. Rastogi, J. Gralow, S. M. Swain, E. Winer, G. Colon-Otero, C. Hudis, S. Paik, N. E. Davidson, E. Mamounas, J. Zujewski, N. Wolmark, E. A. Perez Cancer Res vol 72 (24 supplement) S5 2012
Abstract Breast
http://cancerres.aacrjournals.org/cgi/content/short/72/24_MeetingAbstracts/S5-5?rss=1

1770 Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

Edward H Romond, Edith A Perez, John Bryant, Vera J Suman, Charles E Geyer, Nancy E Davidson, Elizabeth Tan-Chiu, Silvana Martino, Soonmyung Paik, Peter A Kaufman, Sandra M Swain, Thomas M Pisansky, Louis Fehrenbacher, Leila A Kutteh, Victor G Vogel, Daniel W Visscher, Greg Yothers, Robert B Jenkins, Ann M Brown, Shaker R Dakhil, Eleftherios P Mamounas, Wilma L Lingle, Pamela M Klein, James N Ingle, Norman Wolmark N Engl J Med vol 353 (16) 1673-84 2005
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/16236738>

1771 Disease-free survival as a surrogate for overall survival in neoadjuvant trials of gastroesophageal adenocarcinoma: Pooled analysis of individual patient data from randomised controlled trials

Ulrich Ronellenfitsch, Katrin Jensen, Svenja Seide, Meinhard Kieser, Matthias Schwarzbach, Tracy E. Slinger, Bryan Burmeister, David Kelsen, Donna Niedzwiecki, Guillaume Piessen, Christoph Schuhmacher, Susan Urba, Cornelis van de Velde, Marc Ychou, Ralf Hofheinz, Sylvie Lorenzen Eur J Cancer vol 123 101-111 2019
Manuscript GI CALGB-9781 <http://www.ncbi.nlm.nih.gov/pubmed/31678767>

1772 Phase II Trial of Ofatumumab (OFA) in Previously Untreated Follicular Non-Hodgkin Lymphoma (NHL): CALGB 50901 (Alliance)

Cara A. Rosenbaum, Brandelyn Pitcher, Nancy L Bartlett, Sonali Smith, Kristie Blum, Eric Hsi, Sin-Ho Jung, John P. Leonard, Bruce D. Cheson *Blood* vol 126 (23) abstr 2741 2015
Abstract Lymphoma <http://www.bloodjournal.org/content/126/23/2741>

1773 Phase 2 multicentre study of single-agent ofatumumab in previously untreated follicular lymphoma: CALGB 50901 (Alliance).

Cara A Rosenbaum, Sin-Ho Jung, Brandelyn Pitcher, Nancy L Bartlett, Sonali M Smith, Eric Hsi, Nina Wagner-Johnston, Sachdev P Thomas, John P Leonard, Bruce D Cheson *Br J Haematol* vol 185 (1) 53-64 2019
Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/30723894>

1774 Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207

J. E. Rosenberg, S. Halabi, B. L. Sanford, A. L. Himmelstein, J. N. Atkins, R. J. Hohl, F. Millard, D. F. Bajorin, E. J. Small *Ann Oncol* vol 19 (5) 946-950 2008
Manuscript GU <http://www.ncbi.nlm.nih.gov/pubmed/18272914>

1775 Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance)

Jonathan E. Rosenberg, Karla A. Ballman, Susan Halabi, Pamela J. Atherton, Amir Mortazavi, Christopher Sweeney, Walter M. Stadler, Benjamin A. Teply, Joel Picus, Scott T. Tagawa, Sreedhar Katragadda, Daniel Vaena, Jamal Misleh, Christopher Hoimes, Elizabeth R. Plimack, Thomas W. Flaig, Robert Dreicer, Dean Bajorin, Olwen Hahn, Eric J. Small, Michael J. Morris *J Clin Oncol* vol 39 (22) 2486-96 2021
Manuscript GU <http://www.ncbi.nlm.nih.gov/pubmed/33989025>

1776 CALGB 90601 (Alliance): Randomized, double blind, placebo-controlled phase III trial comparing gemcitabine and cisplatin with bevacizumab or placebo in patients with metastatic urothelial carcinoma

Jonathan Rosenberg, Karla Ballman, Susan Halabi, Colleen Watt, Olwen Mary Hahn, Preston D. Steen, Hahn Olwen Dreicer, Robert, Thomas Flaig, Walter Stadler, Christopher Sweeney, Amir Mortazavi, Michael Morris *J Clin Oncol* vol 37 (15 suppl) abstr 4503 2019
Abstract GU https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.4503

1777 Cosmetic outcome following breast conservation surgery and radiation for multiple ipsilateral breast cancer: Data from the Alliance Z11102 Study

Kari M. Rosenkranz, Karla V. Ballman, Linda McCall, Colleen McCarthy, Judy C. Boughey *Ann Surg Oncol* 2020
Abstract Breast <https://link.springer.com/article/10.1245/s10434-020-08893-w>

1778 The feasibility of breast-conserving surgery for multiple ipsilateral breast cancer: An initial report from ACOSOG Z11102 (Alliance) trial

Kari M. Rosenkranz, Karla Ballman, Linda McCall, Charlotte Kubicky, Laurie Cuttino, Huong Le-Petross, Kelly K. Hunt, Armando Giuliano, Kimberly J. Van Zee, Bruce Haffty, Judy C. Boughey *Ann Surg Oncol* vol 25 (10) 2858-66 2018
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/29987605>

1779 Cosmetic outcomes following breast conservation surgery and radiation for multiple ipsilateral breast cancer: Data from the Alliance Z11102 Study

Kari M. Rosenkranz, Karla Ballman, Linda McCall, Colleen McCarthy, Charlotte D. Kubicky, Laurie Cuttino, Kelly K. Hunt, Armando Giuliano, Kimberly J. Van Zee, Bruce Haffty, Judy C. Boughey *Ann Surg Oncol* vol 27 (12) 4650-61 2020
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/32699926>

- 1780 ASO Author Reflections: Multiple Ipsilateral Breast Cancer: Where Have We Been, Where are We Going.**
Kari M Rosenkranz, Judy C Boughey Ann Surg Oncol vol 27 (Suppl 3) 686-7 2020
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/32808160>
- 1781 The feasibility of breast conserving surgery for multiple ipsilateral breast cancer: an initial report from ACOSOG Z11102 (Alliance) trial**
Kari Rosenkranz, Linda McCall, Karla Ballman, Charlotte Kubicky, Laurie Cuttino, Huong T. Le-Petross, Kelly Hunt, Judy C. Boughey Ann Surg Oncol vol 25 (Suppl 2) 257 2018
Abstract Breast <https://link.springer.com/content/pdf/10.1245%2Fs10434-018-6534-2.pdf>
- 1782 Feasibility of Implementing an Exercise Intervention in Older Adults with Hematologic Malignancy**
Ashley E. Rosko, Ying Huang, Desiree Jones, Carolyn J. Presley, Jordon Jagers, ReNea Owens, Michelle Naughton, Jessica L. Krok-Schoen J Geriatr Oncol vol 13 (2) 234-40 2022
Manuscript Older Adult <http://www.ncbi.nlm.nih.gov/pubmed/34446377>
- 1783 Exercise Is Medicine: Restoring Function in Older Adults with Hematologic Malignancy**
Ashley E. Rosko, Sarah A Wall, Carolyn Presley, ReNea Owens, Desiree Jones, Ying Huang, Michelle Naughton Blood vol 132 (1) 4870 2018
Abstract Older Adult
<https://ashpublications.org/blood/article/132/Supplement%201/4870/262210/Exercise-Is-Medicine-Restc>
- 1784 Aging Phenotypes and Restoring Functional Deficits in Older Adults With Hematologic Malignancy.**
Ashley E Rosko, Sarah Wall, Robert Baiocchi, Don M Benson, Jonathan E Brammer, John C Byrd, Yvonne A Efebera, Kami Maddocks, Kerry A Rogers, Desiree Jones, Lara Sucheston-Campbell, Hancong Tang, Hatice Gulcin Ozer, Ying Huang, Christin E Burd, Michelle J Naughton J Natl Compr Canc Netw vol 19 (9) 1027-36 2021
Manuscript Older Adult <http://www.ncbi.nlm.nih.gov/pubmed/33770752>
- 1785 Phase II Trial of Atezolizumab Before and After Definitive Chemoradiation for Patients with Unresectable Stage III NSCLC**
Helen J. Ross, David Kozono, James Urbanic, Terence Williams, Carter DuFrane, Ilze Bara, Mayank Gandhi, Katja Schulze, J. Michelle Brockman, Xiaofei Wang, Everett E. Vokes, Thomas E. Stinchcombe J Thorac Oncol vol 12 (11, suppl 2) S2285-86 2017
Abstract Respiratory [http://www.jto.org/article/S1556-0864\(17\)32396-1/fulltext](http://www.jto.org/article/S1556-0864(17)32396-1/fulltext)
- 1786 AFT-16: Phase II Trial of Atezolizumab Before and After Definitive Chemoradiation for Unresectable Stage III NSCLC**
Helen J. Ross, David Kozono, James Urbanic, Terence Williams, Carter Dufrane, Ilze Bara, Mayank Gandhi, Katja Schulze, J. Michelle Brockman, Xiaofei Wang, Junheng Gao, Everett E. Vokes, Thomas E. Stinchcombe J Clin Oncol vol 38 (15_suppl) 9045 2020
Abstract Respiratory https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.9045
- 1787 AFT-16: Phase II Trial of Neoadjuvant and adjuvant Atezolizumab (A) and Chemoradiation (CRT) for Stage III Non-small Cell Lung Cancer (NSCLC)**
Helen J. Ross, David Kozono, James Urbanic, Terence Williams, Carter Dufrane, Ilze Bara, Katja Schulze, J. Michelle Brockman, Xiaofei Wang, Junheng Gao, Everett E. Vokes, Thomas E. Stinchcombe J Clin Oncol vol 39 (no. 15_suppl) 8513 2021
Abstract Respiratory https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.8513

- 1788 Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane®) in combination with gemcitabine in patients with metastatic breast cancer (N0531)**
V. Roy, B. R. LaPlant, G. G. Gross, C. L. Bane, F. M. Palmieri Ann Oncol vol 20 (3) 449-453 2009
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/19087987>
- 1789 NCCTG phase II trial N0531 of weekly nab-paclitaxel (nab-p) in combination with gemcitabine (gem) in patients with metastatic breast cancer (MBC)**
V. Roy, B. Laplant, G. Gross, F. Palmieri, E. Perez J Clin Oncol vol 25 (18S) abstr 1048 2007
Abstract Breast
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID
- 1790 N0338 phase II trial of docetaxel and carboplatin administered every two weeks as induction therapy for stage II or III breast cancer**
V. Roy, B. Pockaj, D. Northfelt, J. Allred, H. Liu, D. Nikceovich, B. Mattar, E. Perez J Clin Oncol vol 26 (May 20 suppl) abstr 563 2008
Abstract Breast
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID
- 1791 A Phase II trial of docetaxel and carboplatin administered every two weeks as preoperative therapy for stage II or III breast cancer: NCCTG Study N0338**
Vivek Roy, Barbara A. Pockaj, Jacob B. Allred, Heidi Apsey, Donald W. Northfelt, Daniel Nikceovich, Bassam Mattar, Edith A. Perez Am J Clin Oncol vol 36 (6) 2013
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/22868240>
- 1792 BCL6 Expression and Treatment Delay Correlate with Adverse Outcome in Newly Diagnosed Primary CNS Lymphoma: Final Report of CALGB 50202 (Alliance)**
J. L. Rubenstein, E. D. Hsi, J. L. Johnson, S.-H. Jung, B. Grant, B. D. Cheson, L. D. Kaplan ASH Annual Meeting Abstracts vol 120 (21) -301 2012
Abstract Lymphoma <http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;120/21/301>
- 1793 Intensive Chemotherapy and Immunotherapy in Patients With Newly Diagnosed Primary CNS Lymphoma: CALGB 50202 (Alliance 50202)**
J. L. Rubenstein, E. D. Hsi, J. L. Johnson, S.-H. Jung, M. O. Nakashima, B. Grant, B. D. Cheson, L. D. Kaplan J Clin Oncol vol 31 (25) 3061-8 2013
Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/23569323>
- 1794 Intensive Chemotherapy and Immunotherapy, without Brain Irradiation, In Newly Diagnosed Patients with Primary CNS Lymphoma: Results of CALGB 50202**
J. L. Rubenstein, J. L. Johnson, S.-H. Jung, B. D. Cheson, L. D. Kaplan Blood vol 116 (21) -763 2010
Abstract Lymphoma <http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;116/21/763>
- 1795 Persistence, adherence, and toxicity with oral CMF in older women with early-stage breast cancer (Adherence Companion Study 60104 for CALGB 49907)**
K. J. Ruddy, B. N. Pitcher, L. E. Archer, H. J. Cohen, E. P. Winer, C. A. Hudis, H. B. Muss, A. H. Partridge Ann Oncol vol 23 (12) 3075-3081 2012
Manuscript Experimental CALGB-49907, CALGB-60104
<http://www.ncbi.nlm.nih.gov/pubmed/22767584>
- 1796 Adherence, persistence and toxicity with oral CMF in older women with early stage breast cancer in CALGB 49907 (adherence companion study 60104)**
K. Ruddy, L. E. Archer, H. J. Cohen, E. P. Winer, C. A. Hudis, H. B. Muss, A. H. Partridge Cancer Res vol 70 (24, suppl 2) abstr P5-10-12 2010

- 1797 Dexamethasone to prevent everolimus-induced stomatitis (Alliance MIST Trial: A221701)**
Kathryn J. Ruddy, David Zahrieh, Jun He, Blake Waechter, Julianne L. Holleran, Lionel D. Lewis, Selina Chow, Jan Beumer, Matthias Weiss, Nikolaos Trikalinos, Bryan Faller, Maryam Lustberg, Hope S. Rugo, Charles Loprinzi *Semin Oncol* vol 50 (1-2) 7-10 2023
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/36693773>
- 1798 A Comparison of the Natural History of Oxaliplatin- and Paclitaxel-Induced Neuropathy (NCCTG N08C1, N08CB/Alliance)**
Kathryn Jean Ruddy, Dierdre Pachman, Rui Qin, Drew K. Seisler, Ellen M. Lavoie Smith, Suneetha Puttabasavaiah, Paul J. Novotny, Lauren E. Ta, Andreas S. Beutler, Nina D. Wagner-Johnston, Nathan Staff, Axel Grothey, Shaker R. Dakhil, Charles L. Loprinzi *J Clin Oncol* vol 33 (suppl) abstr 9564 2015
Abstract Symptom Inter NCCTG-N08C1, NCCTG-N08CB
<http://meetinglibrary.asco.org/content/145135-156>
- 1799 CALGB 30103: A randomized phase II study of carboplatin and etoposide (CE) with or without G3139 in patients with extensive stage small cell lung cancer (ES-SCLC).**
C. M. Rudin, R. Salgia, X. F. Wang, M. R. Green, E. E. Vokes *J Clin Oncol* vol 23 (16s) abstract 7168 2005
Abstract Respiratory
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=34&abstractID
- 1800 Randomized Phase II Study of Carboplatin and Etoposide With or Without the bcl-2 Antisense Oligonucleotide Oblimersen for Extensive-Stage Small-Cell Lung Cancer: CALGB 30103**
Charles M. Rudin, Ravi Salgia, Xiaofei Wang, Lydia D. Hodgson, Gregory A. Masters, Mark Green, Everett E. Vokes *J Clin Oncol* vol 26 (6) 870-876 2008
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/18281659>
- 1801 CALGB 40502/NCCTG N063H: Randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC)**
H. S. Rugo, W. T. Barry, A. Moreno-Aspitia, A. P. Lyss, C. Cirrincione, E. L. Mayer, M. Naughton, R. M. Layman, L. A. Carey, R. A. Somer, E. A. Perez, C. Hudis, E. P. Winer *J Clin Oncol* vol 30 (18 suppl) abstr CRA1002 2012
Abstract Breast NCCTG-N063H
http://meeting.ascopubs.org/cgi/content/abstract/30/18_suppl/CRA1002?sid=9319c70d-f68e-40ab-8ad4-l
- 1802 Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance)**
Hope S. Rugo, William T. Barry, Alvaro Moreno-Aspitia, Alan P. Lyss, Constance Cirrincione, Eleanor Leung, Erica L. Mayer, Michael Naughton, Deborah Toppmeyer, Lisa A. Carey, Edith A. Perez, Clifford Hudis, Eric P. Winer *J Clin Oncol* vol 33 (21) 2361-2369 2015
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/26056183>
- 1803 Long-term follow-up (fu) of (Alliance) CALGB 40502/NCCTG N063H: a randomized phase iii trial of weekly paclitaxel (p) compared to weekly nanoparticle albumin bound nab-paclitaxel (np) or ixabepilone (ix) +/- bevacizumab (b) as first-line therapy for locally recurrent or metastatic breast cancer (MBC)**

Hope S. Rugo, William T. Barry, Alvaro Moreno-Aspitia, Alan Lyss, Lucas Huebner, Erica L. Mayer, Michael Naughton, RM Layman, Lisa A. Carey, RA Somer, D Toppmeyer, M Velasco, Edith A. Perez, Clifford Hudis, Eric Winer *Cancer Res* vol 78 (4 Supplement) GS3-06. 2018
Abstract Breast
https://aacrjournals.org/cancerres/article/78/4_Supplement/GS3-06/631967/Abstract-GS3-06-Long-term

1804 Prophylactic Cranial Irradiation in Elderly Patients with Small Cell Lung Cancer: Findings from a North Central Cancer Treatment Group Pooled Analysis

W. G. Rule, N. R. Foster, J. P. Meyers, J. B. Ashman, S. A. Vora, T. F. Kozelsky, Y. I. Garces, J. J. Urbanic, J. K. Salama, S. E. Schild *J Geriatr Oncol* vol 6 (2) 119-126 2015
Manuscript Respiratory NCCTG-86-20-51, NCCTG-89-20-51, NCCTG-89-20-52, NCCTG-95-20-53 <http://www.ncbi.nlm.nih.gov/pubmed/25482023>

1805 Results of NCCTG N0275 (Alliance) – a phase II trial evaluating resection followed by adjuvant radiation therapy for patients with desmoplastic melanoma

William G. Rule, Jacob B. Allred, Barbara A. Pockaj, Svetomir N. Markovic, David J. DiCaudo, Lori A. Erickson, Richard L. Deming, Steven E. Schild *Cancer Med* vol 5 (8) 1890-1896 2016
Manuscript Experimental <http://www.ncbi.nlm.nih.gov/pubmed/27368067>

1806 Application of a sequential multiple assignment randomized trial (SMART) design in older patients with chronic lymphocytic leukemia

A S Ruppert, J Yin, M Davidian, A A Tsiatis, J C Byrd, J A Woyach, S J Mandrekar *Ann Oncol* vol 30 (4) 542-50 2019
Manuscript Leukemia <http://www.ncbi.nlm.nih.gov/pubmed/30799502>

1807 Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202

Amy S. Ruppert, Allison M. Booth, Wei Ding, Nancy L. Bartlett, Danielle M. Brander, Steven Coutre, Jennifer R. Brown, Sreenivasa Nattam, Richard A. Larson, Harry Erba, Mark Litzow, Carolyn Owen, Charles S. Kuzma, Jeremy S. Abramson, Richard F. Little, Scott E. Smith, Richard M. Stone, John C. Byrd, Sumithra J. Mandrekar, Jennifer A. Woyach *Leukemia* vol 35 (10) 2854-61 2021
Manuscript Leukemia <http://www.ncbi.nlm.nih.gov/pubmed/34274940>

1808 A Genetic Risk-Stratified, Phase II Study of Fludarabine/Antibody Combinations in Symptomatic, Untreated Chronic Lymphocytic Leukemia (CLL): Final Results of Cancer and Leukemia Group B (CALGB) 10404 (Alliance)

Amy S. Ruppert, John C. Byrd, Nyla A. Heerema, Mitchell Smith, John Godwin, Stephen Couban, Todd A. Fehniger, Michael Thirman, Alese E. Halvorson, Bercedis L. Peterson, Martin S. Tallman, Frederick R. Appelbaum, Richard M. Stone, Sue Robinson, Julie E. Chang, Sumithra J. Mandrekar, Richard A. Larson *J Clin Oncol* vol 35 (15 suppl) abstr 7503 2017
Abstract Leukemia http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.7503

1809 Toxicity burden in older patients with chronic lymphocytic leukemia (CLL) receiving bendamustine with rituximab (BR) or ibrutinib (IB) regimens: Alliance A041202

Amy S. Ruppert, Sumithra J. Mandrekar, Allison M Booth, Wei Ding, Nancy L. Bartlett, Danielle M. Brander, Steven Coutre, Jennifer R. Brown, Sreenivasa Nattam, Richard A. Larson, Harry Erba, Mark Litzow, Carolyn Owen, Charles Kuzma, Jeremy S. Abramson, Richard F. Little, Scott Smith, Richard M. Stone, John C. Byrd, Jennifer A. Woyach *JCO* vol 38 (no. 15_suppl) e20004 2020
Abstract Leukemia https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.e20004

1810 Local Review versus (vs) Central Review of Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) in Diffuse Large B-Cell Lymphoma (DLBCL): Results from the CALGB 50303 Trial (Alliance)

Amy S. Ruppert, Levi D. Pederson, Michael V. Knopp, David Poon, Jun Zhang, Brad S. Kahl, Jonathan W. Friedberg, Lawrence H. Schwartz, Windham H. Wilson, John P. Leonard, Nancy L. Bartlett, Heiko Schoder *Blood* vol 136 (Supplement 1) 50 2020
Abstract Lymphoma

<https://ashpublications.org/blood/article/136/Supplement%201/50/470860/Local-Review-Versus-vs-Cent>

1811 Occult Metastases in Lymph Nodes Predict Survival in Resectable Non–Small-Cell Lung Cancer: Report of the ACOSOG Z0040 Trial

V. W. Rusch, D. Hawes, P. A. Decker, S. E. Martin, A. Abati, R. J. Landreneau, G. A. Patterson, R. I. Incelet, D. R. Jones, R. A. Malthaner, R. G. Cohen, K. Ballman, J. B. Putnam Jr, R. J. Cote *J Clin Oncol* vol 29 (32) 4313-4319 2011

Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/21990404>

1812 Mutations Associated with Progression in Follicular Lymphoma Predict Inferior Outcomes in Newly Diagnosed Patients (Alliance)

David A. Russler-Germain, Kilannin Krysiak, Cody Ramirez, Matthew Mosior, Marcus Watkins, Felicia Gomez, Zachary Skidmore, Lee Trani, Jason Kunasaki, Feng Gao, Susan Geyer, Amanda F. Cashen, Neha Mehta-Shah, Brad S. Kahl, Nancy L. Bartlett, Izidore S. Lossos, Eric D. Hsi, John P. Leonard, Malachi Griffith, Obi L. Griffith, Todd A. Fehniger *Blood* vol 140 (suppl 1) 3543–5 2022
Abstract Lymphoma CALGB-50402, CALGB-50701, CALGB-50803

<https://ashpublications.org/blood/article/140/Supplement%201/3543/488385/Mutations-Associated-with->

1813 Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303.

David A Russler-Germain, Kilannin Krysiak, Cody Ramirez, Matthew Mosior, Marcus P Watkins, Felicia Gomez, Zachary L Skidmore, Lee Trani, Feng Gao, Susan Geyer, Amanda F Cashen, Neha Mehta-Shah, Brad S Kahl, Nancy L Bartlett, Juan P Alderuccio, Izidore S Lossos, Sarah L Ondrejka, Eric D Hsi, Peter Martin, John P Leonard, Malachi Griffith, Obi L Griffith, Todd A Fehniger *Blood Adv* vol 7 (18) 5524-39 2023

Manuscript Lymphoma CALGB-50402, CALGB-50701, CALGB-50803

<http://www.ncbi.nlm.nih.gov/pubmed/37493986>

1814 Impact of Imaging Study Frequency on Progression Free Survival in Alliance Clinical Trials Enrolling Patients with Untreated Follicular Lymphoma

Sarah C. Rutherford, Jun Yin, Levi Pederson, Kristie A. Blum, Peter Martin, Sing-Ho Jung, Barbara Grant, Cara Rosenbaum, Bruce D. Cheson, Nancy L. Bartlett, Sumithra Mandrekar, John P. Leonard *J Clin Oncol* vol 41 (16S) 7520 2023

Abstract Lymphoma Alliance-A051103, CALGB-50701, CALGB-50803, CALGB-50901, CALGB-50904 https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.7520

1815 Bone marrow biopsies are not relevant for response assessment in cooperative group follicular lymphoma clinical trials

Sarah C. Rutherford, Jun Yin, Levi Pederson, Betsy LaPlant, Mazyar Shadman, Hongli Li, Michael L LeBlanc, Kristie Blum, Travis Dockter, Peter Martin, Sing-Ho Jung, Barbara Grant, Cara Rosenbaum, Chaitra Ujjani, Paul M. Barr, Joseph Unger, Nancy L. Bartlett, Jonathan Friedberg, John P. Leonard *J Clin Oncol* vol 38 (15_suppl) 8038 2020

Abstract Lymphoma Alliance-A051103, CALGB-50701, CALGB-50801, CALGB-50901, SWOG-S0016, SWOG-S0816 https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.8038

1816 Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials

Sarah C. Rutherford, Jun Yin, Levi Pederson, Gabriela Perez Burbano, Betsy LaPlant, Mazyar Shadman, Hongli Li, Michael L. LeBlanc, Vaishalee P. Kenkre, Fangxin Hong, Kristie A. Blum,

Travis Dockter, Peter Martin, Sin-Ho Jung, Barbara Grant, Cara Rosenbaum, Chaitra Ujjani, Paul M. Barr, Joseph M. Unger, Bruce D. Cheson, Nancy L. Bartlett, Brad Kahl, Jonathan W. Friedberg, Sumithra J. Mandrekar, John P. Leonard *J Clin Oncol* vol 41 (2) 336-342 2023
Manuscript Lymphoma Alliance-A051103, CALGB-50701, CALGB-50801, CALGB-50901, SWOG-S0016, SWOG-S0816 <http://www.ncbi.nlm.nih.gov/pubmed/35787017>

1817 Androgens and Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Docetaxel

Charles J Ryan, Sandipan Dutta, William K Kelly, Rob Middleberg, Carly Russell, Michael J. Morris, Mary-Ellen Taplin, Susan Halabi *Clin Genitourin Cancer* vol 18 (3) 222-9.e2 2020
Manuscript GU <http://www.ncbi.nlm.nih.gov/pubmed/32273234>

1818 Serum Androgens and Survival in metastatic Castration Resistant Prostate Cancer (mCRPC) Patients Treated with Docetaxel and Prednisone: Results from CALGB 90401 (Alliance)

Charles J Ryan, Sandipan Dutta, William K Kelly, Rob Middleberg, Carly Russell, Eric J. Small, Michael J. Morris, Mary-Ellen Taplin, Susan Halabi *J Clin Oncol* vol 35 (15 suppl) abstr 5067 2017
Abstract GU http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.5067

1819 Androgen Decline and Survival During Docetaxel Therapy in metastatic Castration Resistant Prostate Cancer (mCRPC)

Charles J Ryan, Sandipan Dutta, William K Kelly, Carly Russell, Eric J. Small, Michael J. Morris, Mary-Ellen Taplin, Susan Halabi *Prostate Cancer Prostatic Dis* vol 23 (1) 66-73 2020
Manuscript GU <http://www.ncbi.nlm.nih.gov/pubmed/31053766>

1820 Decline in serumandrogens and survival in metastatic castration resistant prostate cancer (mCRPC) patients treated with docetaxel and prednisone: results from CALGB 90401 (Alliance)

Charles J Ryan, Sandipan Dutta, William K Kelly, Carly Russell, Eric J. Small, Michael J. Morris, Mary-Ellen Taplin, Susan Halabi *Eur Urol* vol 17 (2) e1073 2018
Abstract GU
[https://www.eusupplements.europeanurology.com/article/S1569-9056\(18\)31580-X/pdf](https://www.eusupplements.europeanurology.com/article/S1569-9056(18)31580-X/pdf)

1821 Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study.

Charles J Ryan, Susan Halabi, San-San Ou, Nicholas J Vogelzang, Philip Kantoff, Eric J Small *Clin Cancer Res* vol 13 (7) 2030-7 2007
Manuscript GU <http://www.ncbi.nlm.nih.gov/pubmed/17404083>

1822 Prognostic impact of insertion site in acute myeloid leukemia with FLT3 internal tandem duplication: results from the RATIFY study (Alliance)

Frank G. Rücker, Ling Du, Tamara J. Blätte, Axel Benner, Julia Krzykalla, Insa Gathmann, Richard A. Larson, Francesco Lo-Coco, Sergio Amadori, Thomas W. Prior, Joseph M. Brandwein, Frederick R. Appelbaum, Bruno C. Medeiros, Michelle Geddes, Jorge Sierra, Eva Tiecke, Celine Pallaud, Miguel Sanz, Theo de Witte, Dietger Niederwieser, Gerhard Ehninger, Michael Heuser, Arnold Ganser, Lars Bullinger, Clara D. Bloomfield, Richard M. Stone, Hartmut Döhner, Christian Thiede, Konstanze Döhner *Blood* vol 132 (Suppl 1) 435 2018
Abstract Leukemia http://www.bloodjournal.org/content/132/Suppl_1/435.abstract

1823 Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results

Frank G. Rücker, Ling Du, Tamara J. Luck, Axel Benner, Julia Krzykalla, Insa Gathmann, Maria Teresa Voso, Sergio Amadori, Thomas W. Prior, Joseph M. Brandwein, Frederick R. Appelbaum, Bruno C. Medeiros, Martin S. Tallman, Lynn Savoie, Jorge Sierra, Celine Pallaud, Miguel A. Sanz, Joop H. Jansen, Dietger Niederwieser, Thomas Fischer, Gerhard Ehninger, Michael Heuser, Arnold

Ganser, Lars Bullinger, Richard A. Larson, Clara D. Bloomfield, Richard M. Stone, Hartmut Döhner, Christian Thiede, Konstanze Döhner *Leukemia* vol 36 (1) 90-9 2022
Manuscript *Leukemia* CALGB-10603 <http://www.ncbi.nlm.nih.gov/pubmed/34316017>

1824 Predictors of duloxetine response in patients with oxaliplatin-induced painful chemotherapy-induced peripheral neuropathy (CIPN): a secondary analysis of randomised controlled trial – CALGB/alliance 170601

E.M.L. SMITH, H. PANG, C. YE, C. CIRRINCIONE, S. FLEISHMAN, E.D. PASKETT, T. AHLES, L.R. BRESSLER, N. LE-LINDQWISTER, C.E. FADUL, C. LOPRINZI, C.L. SHAPIRO *Eur J Cancer Care (Engl)* vol 26 (2) 2017
Manuscript *Health Outcomes* <http://www.ncbi.nlm.nih.gov/pubmed/26603828>

1825 Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1year: a systematic review and meta-analysis

Everardo D Saad, Pierre Squifflet, Tomasz Burzykowski, Emmanuel Quinaux, Suzette Delalogue, Dimitris Mavroudis, Edith Perez, Martine Piccart-Gebhart, Bryan P Schneider, Dennis Slamon, Norman Wolmark, Marc Buyse *Lancet Oncol* vol 20 (3) 361-370 2019
Manuscript *Breast* NCCTG-N9831, NSABP B-31 <http://www.ncbi.nlm.nih.gov/pubmed/30709633>

1826 Association of Tumor-infiltrating Lymphocytes (TILs) with Survival Depends on Primary Tumor Sidedness in Stage III Colon Cancers (NCCTG N0147) [Alliance]

B. Saberzadeh-Ardestani, N. R. Foster, H. E. Lee, Q. Shi, S. R. Alberts, T. C. Smyrk, F. A. Sinicrope *Ann Oncol* vol 33 (11) 1159-67 2022
Manuscript *Correl Sci NOS* <http://www.ncbi.nlm.nih.gov/pubmed/35963480>

1827 Effect of Primary Tumor Sidedness on the Association of Tumor-infiltrating Lymphocytes with Survival of Patients with Stage III Colon Cancer (NCCTG N0147) (Alliance)

Bahar Saberzadeh-Ardestani, Hee Eun Lee, Nathan R. Foster, Qian Shi, Steven R. Alberts, Thomas C. Smyrk, F.A. Sinicrope *J Clin Oncol* vol 40 (16_suppl) 3525-3525 2022
Abstract *Correl Sci NOS* https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.3525

1828 Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials

Poornima Saha, Meredith M. Regan, Olivia Pagani, Prudence A. Francis, Barbara A. Walley, Karin Ribí, Jürg Bernhard, Weixiu Luo, Henry L. Gómez, Harold J. Burstein, Vani Parmar, Roberto Torres, Josephine Stewart, Meritxell Bellet, Antonia Perelló, Faysal Dane, Antonio Moreira, Daniel Vorobiof, Michelle Nottage, Karen N. Price, Alan S. Coates, Aron Goldhirsch, Richard D. Gelber, Marco Colleoni, Gini F. Fleming *J Clin Oncol* vol 35 (27) 3113-22 2017
Manuscript *Breast* <http://www.ncbi.nlm.nih.gov/pubmed/28654365>

1829 Interim analysis of CALGB 150607: A pilot project to study the expression of MET and p53 in resected lung adenocarcinoma specimens

A. K. Salama, R. A. Kratzke, W. Richards, H. Pang, E. E. Vokes, R. Salgia *J Clin Oncol* vol 28 (15s) abstr 10633 2010
Abstract *Correl Sci NOS*
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID

1830 Predictors of pulmonary toxicity in limited stage (LS) small cell lung cancer (SCLC) patients treated with concurrent chemotherapy (CTX) and high dose (70 Gy) daily radiotherapy (RT), a pooled analysis of three CALGB studies

J. K. Salama, L. D. Hodgson, H. Pang, M. R. Green, J. J. Urbanic, A. W. Blackstock, J. Crawford, J. A. Bogart, E. E. Vokes *J Clin Oncol* vol 29 (suppl) abstr 7078 2011
Abstract *Respiratory* CALGB-30002, CALGB-30206, CALGB-30904, CALGB-39808

1831 A Pooled Analysis of Limited-Stage Small-Cell Lung Cancer Patients Treated with Induction Chemotherapy Followed by Concurrent Platinum-Based Chemotherapy and 70 Gy Daily Radiotherapy: CALGB 30904

J. K. Salama, L. Hodgson, H. Pang, J. J. Urbanic, A. W. Blackstock, S. E. Schild, J. Crawford, J. A. Bogart, E. E. Vokes J Thorac Oncol vol 8 (8) 1043-9 2013
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/23715301>

1832 Positive Interaction Between Prophylactic Cranial Irradiation And Maintenance Sunitinib For Untreated Extensive Stage Small Cell Lung Cancer Patients After Standard Chemotherapy: A Secondary Analysis Of CALGB 30504 (Alliance)

Joseph K. Salama, Lin Gu, Xiaofei Wang, Herbert H. Pang, Jeffrey A. Bogart, Jeffrey Crawford, Steven E. Schild, Everett E. Vokes, Neal E. Ready J Thorac Oncol vol 11 (3) 361-369 2016
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/26723241>

1833 Predictors of pulmonary toxicity in limited stage small cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy: CALGB 30904

Joseph K. Salama, Herbert Pang, Jeffery A. Bogart, A. William Blackstock, James J. Urbanic, Lydia Hodgson, Jeffery Crawford, Everett E. Vokes Lung Cancer vol 82 (3) 436-440 2013
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/24396884>

1834 Pulmonary toxicity in stage III non-small cell lung cancer patients treated with high dose (74 Gy) 3-dimensional conformal thoracic radiotherapy and concurrent chemotherapy following induction chemotherapy: A secondary analysis of Cancer and Leukemia Group B (CALGB) trial 30105

Joseph K. Salama, Thomas E. Stinchcombe, Lin Gu, Xiaofei Wang, Karen Morano, Jeffrey A. Bogart, Jeffrey C. Crawford, Mark A. Socinski, A. William Blackstock, Everett E. Vokes Int J Radiat Oncol Biol Phys vol 81 (4) e269-e274 2011
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/21477940>

1835 PCI Survival Improvement for Extensive Stage SCLC Limited to Patients on Maintenance Systemic Therapy: A Secondary Analysis of CALGB 30504 (Alliance)

Joseph K. Salama, Lin Gu, Xiaofei Wang, Jeffrey Bogart, Jeffrey Crawford, Steven Schild, Neil Ready, Everett E Vokes J Thorac Oncol vol 10 (9) suppl 2, abstr MINI37.07 2015
Abstract Respiratory [http://www.jto.org/article/S1556-0864\(16\)30011-9/fulltext](http://www.jto.org/article/S1556-0864(16)30011-9/fulltext)

1836 Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database.

M E Salem, J Yin, R M Goldberg, L D Pederson, N Wolmark, S R Alberts, J Taieb, J L Marshall, S Lonardi, T Yoshino, R S Kerr, G Yothers, A Grothey, T Andre, A De Gramont, Q Shi Ann Oncol vol 31 (4) 480-6 2020
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/32085892>

1837 An Interim Analysis Of CALGB 150607: Expression And Mutational Status Of c-MET, HGF, EGFR, KRAS, p53, c-CBL, And E-cadherin In Resected Lung Adenocarcinoma Specimens

R. Salgia, V. Nallasura, H. Pang, C. Rolle, W. Richards, L. Hodgson, Q. Arif, A. Husain, R. Kratzke, E. Vokes Clin Cancer Res vol 18 abstr A37 2012
Abstract Correl Sci NOS
http://clincancerres.aacrjournals.org/content/18/3_Supplement/A37.abstract

1838 Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as

adjuvant treatment for stage III colon cancer: results of CALGB 89803.

Leonard B Saltz, Donna Niedzwiecki, Donna Hollis, Richard M Goldberg, Alexander Hantel, James P Thomas, Anthony L A Fields, Robert J Mayer J Clin Oncol vol 25 (23) 3456-61 2007
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/17687149>

1839 Separate and unequal: examining the role of race and site of care on health-related quality of life among metastatic cancer patients (AFT-39)

Cleo A. Samuel, Olive Mbah, Wendi Elkins, Marjory Charlot, Amylou Dueck, Brenda F. Ginos, Jennifer Jansen, Deborah Schrag, Patty Spears, Angela Stover, Ethan Basch Cancer Epidemio, Biomarkers Prevention vol 29 (12, supplement) Abstract PO-119 2020
Abstract CCDD https://cebp.aacrjournals.org/content/29/12_Supplement/PO-119

1840 Validation of the Preoperative Endocrine Prognostic Index in the ACOSOG (Alliance) Z1031 Neoadjuvant Aromatase Inhibitor Trial

Souzan Sanati, Vera J. Suman, R. Goncalves, K. DeSchryver, C.X. Ma, J. Hoog, E. Crouch, M. Barnes, G. Unzeitig, A.M. Leitch, Kelly K. Hunt, Matthew J. Ellis Cancer Res vol 75 (suppl 9) abstr P4-11-13 2015
Abstract Breast http://cancerres.aacrjournals.org/content/75/9_Supplement/P4-11-13.short?rss=1

1841 A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer.

Robert S Sandler, Susan Halabi, John A Baron, Susan Budinger, Electra Paskett, Roger Keresztes, Nicholas Petrelli, J Marc Pipas, Daniel D Karp, Charles L Loprinzi, Gideon Steinbach, Richard Schilsky N Engl J Med vol 348 (10) 883-90 2003
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/12621132>

1842 Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO)

Jacob M Sands, Sumithra J Mandrekar, David Kozono, Geoffrey R Oxnard, Shauna L Hillman, Dennis A Wigle, Ramaswamy Govindan, Jennifer Carlisle, Jhanelle Gray, Joseph K Salama, Luis Raez, Apar Ganti, Nathan Foster, Shakun Malik, Jeffrey Bradley, Karen Kelly, Suresh S Ramalingam, Thomas E Stinchcombe Immunotherapy vol 13 (9) 727-34 2021
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/33878954>

1843 ALCHEMIST: Adjuvant targeted therapy or immunotherapy for high risk resected NSCLC (Alliance)

Jacob Sands, Geoffrey R. Oxnard, David Kozono, Sumithra J. Mandrekar, Shauna L. Hillman, Suzanne E. Dahlberg, Jamie E. Chaft, Ramaswamy Govindan, David E. Gerber, Jhanelle Gray, Shakun Malik, Margaret Mooney, Pasi A. Jänne, Everett E. Vokes, Dennis A. Wigle, David R. Gandara, Suresh S. Ramalingam, Thomas E. Stinchcombe J Clin Oncol vol 38 (15_suppl) TPS9077 2020
Abstract Respiratory Alliance-A081105, Alliance-A151216, Alliance-A081801
https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.TPS9077

1844 Risk stratified analysis improves prediction of treatment (Rx) benefit over subgroup analysis: Findings from Intergroup N9741

H. K. Sanoff, M. E. Campbell, H. C. Pitot, R. M. Goldberg, D. J. Sargent J Clin Oncol vol 26 (suppl) abstr 4018 2008
Abstract GI
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID

1845 N9741: Survival update and prognostic factor analysis of oxaliplatin (Ox) and irinotecan (Iri) combinations for metastatic colorectal cancer (MCRC)

H. K. Sanoff, D. J. Sargent, M. E. Campbell, R. Morton, C. S. Fuchs, R. Ramanathan, S. Williamson,

B. Findlay, H. Pitot, R. M. Goldberg J Clin Oncol vol 25 (18s) abstr 4067 2007

Abstract GI

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID

1846 Five-Year Data and Prognostic Factor Analysis of Oxaliplatin and Irinotecan Combinations for Advanced Colorectal Cancer: N9741

Hanna K. Sanoff, Daniel J. Sargent, Megan E. Campbell, Roscoe F. Morton, Charles S. Fuchs, Ramesh K. Ramanathan, Stephen K. Williamson, Brian P. Findlay, Henry C. Pitot, Richard M. Goldberg J

Clin Oncol vol 26 (35) 5721-5727 2008

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/19001325>

1847 Racial Differences in Advanced Colorectal Cancer Outcomes and Pharmacogenetics: A Subgroup Analysis of a Large Randomized Clinical Trial

Hanna K. Sanoff, Daniel J. Sargent, Erin M. Green, Howard L. McLeod, Richard M. Goldberg J Clin Oncol vol 27 (25) 4109-4115 2009

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/19636001>

1848 Phase II trial of two different irinotecan schedules with pharmacokinetic analysis in patients with recurrent glioma: North Central Cancer Treatment Group results

Marta Santisteban, Jan C. Buckner, Joel M. Reid, Wenting Wu, Bernd W. Scheithauer, Matthew M. Ames, Sara J. Felten, Daniel A. Nikcevich, Martin Wiesenfeld, Kurt A. Jaeckle, Evanthia Galanis J

Neurooncol vol 92 (2) 165-175 2009

Manuscript Neuro-Onc <http://www.ncbi.nlm.nih.gov/pubmed/19066728>

1849 Overall and 12 week tumor response versus actual tumor measurements as predictors of overall survival (OS) in advanced colorectal cancer (ACRC): Findings from NCCTG N9741.

D. J. Sargent, M. E. Campbell, A. Grothey, R. M. Goldberg Gastrointestinal Cancers Symposium abstr 446 2008

Abstract GI

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=53&abstractID

1850 Use of two-year disease-free survival (DFS) as a primary endpoint in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: New data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, NSAPB C-06 and C-07, and C89803.

D. J. Sargent, G. Yothers, E. Van Cutsem, J. Cassidy, L. Saltz, N. Wolmark, Q. Shi, M. Buyse, A. De Gramont, A. Grp J Clin Oncol vol 27 (15) abstr 4011 2009

Abstract GI

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID

1851 Benefits and adverse events in younger (age<50) vs. older patients receiving adjuvant chemotherapy for colon cancer: Findings From the 33,574 pt ACCENT dataset.

D. Sargent, G. Yothers, E. Green, C. Blanke, M. O'Connell, R. Labianca, A. Bleyer, A. Degramont, D. Thomas J Clin Oncol vol 28 (15s) abstr 3523 2010

Abstract GI

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID

1852 Two or Three Year Disease Free Survival (DFS) as a Primary Endpoint in Stage III Adjuvant Colon Cancer Trials with fluoropyrimidines with or without Oxaliplatin or Irinotecan: Data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07, and C89803

D Sargent, Q Shi, G Yothers, E Van Cutsem, J Cassidy, L Saltz, N Wolmark, B Bot, A Grothey, M Buyse, A de Gramont Eur J Cancer vol 47 (7) 990-996 2011

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/21257306>

1853 Pooled Safety and Efficacy Analysis Examining the Effect of Performance Status on Outcomes in Nine First-Line Treatment Trials Using Individual Data From Patients With Metastatic Colorectal Cancer

Daniel J. Sargent, Claus Henning Köhne, Hanna Kelly Sanoff, Brian M. Bot, Matthew T. Seymour, Aimery de Gramont, Ranier Porschen, Leonard B. Saltz, Philippe Rougier, Christopher Tournigand, Jean-Yves Douillard, Richard J. Stephens, Axel Grothey, Richard M. Goldberg J Clin Oncol vol 27 (12) 1948-1955 2009

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/19255311>

1854 Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer

Daniel J. Sargent, Silvia Marsoni, Genevieve Monges, Stephen N. Thibodeau, Roberto Labianca, Stanley R. Hamilton, Amy J. French, Brian Kabat, Nathan R. Foster, Valter Torri, Christine Ribic, Axel Grothey, Malcolm Moore, Alberto Zaniboni, Jean-Francois Seitz, Frank Sinicrope, Steven Gallinger J Clin Oncol vol 28 (20) 3219-3226 2010

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/20498393>

1855 End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group.

Daniel J Sargent, Smitha Patiyil, Greg Yothers, Daniel G Haller, Richard Gray, Jacqueline Benedetti, Marc Buyse, Roberto Labianca, Jean Francois Seitz, Christopher J O'Callaghan, Guido Francini, Axel Grothey, Michael O'Connell, Paul J Catalano, David Kerr, Erin Green, Harry S Wieand, Richard M Goldberg, Aimery de Gramont J Clin Oncol vol 25 (29) 4569-74 2007

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/17876008>

1856 Time-dependent patterns of failure and treatment benefit from adjuvant therapy for resectable colon cancer: Lessons from the 20,800 patient ACCENT dataset

Sargent, D. J. J Clin Oncol vol 25 (18s) abstr 4008 2007

Abstract GI

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=45&abstractID

1857 Socioeconomic disparities in gastric cancer and identification of a single SES variable for predicting risk

Srawani Sarkar, Marc J. Dauer, Haejin In J Gastrointest Cancer vol 53 (1) 170-8 2022

Manuscript Disparities <http://www.ncbi.nlm.nih.gov/pubmed/33404986>

1858 NCCTG phase I trial of Everolimus (RAD001) and Temozolomide (TMZ) in combination with radiation therapy (RT) in newly diagnosed glioblastoma multiforme (GBM) patients (N057K).

J. N. Sarkaria, E. Galanis, P. J. Peller, P. D. Brown, W. Wu, S. J. Felten, J. H. Uhm, C. Giannini, K. A. Jaeckle, J. C. Buckner Mol Cancer Ther vol 8 (12s) abstr C56 2009

Abstract Neuro-Onc

http://mct.aacrjournals.org/cgi/content/meeting_abstract/8/12_MeetingAbstracts/C56?sid=1123373f-30d

1859 NCCTG phase I trial of temsirolimus (CCI-779) and temozolomide (TMZ) in combination with radiation therapy (RT) in newly diagnosed glioblastoma multiforme (GBM) patients

J. N. Sarkaria, E. Galanis, W. Wu, C. Giannini, K. A. Jaeckle, L. Doyle, J. Uhm, P. Brown, A. B. Dietz, J. Buckner J Clin Oncol vol 27 (15) abstr 2019 2009

Abstract Neuro-Onc

<http://meeting.ascopubs.org/gca?gca=ascomtg%3B27%2F15S%2F2019&allch=&submit=Go>

1860 Effect of combined therapy with temsirolimus (CCI-779), temozolomide (TMZ), and radiation (RT) in newly diagnosed glioblastoma multiforme (GBM) patients on immune suppression: results

from NCCTG N027D

J. Sarkaria, E. Galanis, M. Gustafson, A. Dietz, W. Wu, P. Brown, J. H. Uhm, C. Giannini, K. Jaeckle, J. Buckner J Clin Oncol vol 28 (15s) 183s abstr 2016 2010
Abstract Neuro-Onc
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID

1861 FLT-PET analysis of early response to everolimus in newly diagnosed glioblastoma patients enrolled on NCCTG N057K

J. Sarkaria, P. Peller, E. Galanis, M. Jacobson, W. Wu, K. Jaeckle, J. Buckner J Clin Oncol vol 29 (15s) abstr e12501 2011
Abstract Neuro-Onc
http://meeting.ascopubs.org/gca?allch=&submit=Go&gca=ascomtg%3B29%2F15_suppl%2Fe12501

1862 Randomized Phase II/III trial of veliparib or placebo in combination with adjuvant temozolomide in newly diagnosed glioblastoma (GBM) with MGMT promoter hypermethylation

Jann N. Sarkaria, Karla V. Ballman, Sani H. Kizilbash, Erik P. Sulman, Caterina Giannini, Bret Friday, Jesse G. Dixon, Brian F. Kabat, Nadia Laack, Leland Hu, Ben Ellingson, S. Keith Anderson, Evanthia Galanis J Clin Oncol vol 40 (16_suppl) 2001-2001 2022
Abstract Neuro-Onc https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.2001

1863 Combination of temsirolimus (CCI-779) with chemo-radiation in newly diagnosed GBM (NCCTG trial N027D) is associated with increased infectious risks¹

Jann N. Sarkaria, Eva Galanis, Wenting Wu, Allan B. Dietz, Timothy J. Kaufmann, Michael P. Gustafson, Paul D. Brown, Joon H. Uhm, Ravi D. Rao, Laurence Doyle, Caterina Giannini, Kurt A. Jaeckle, Jan C. Buckner Clin Cancer Res vol 16 (22) 5573-5580 2010
Manuscript Neuro-Onc <http://www.ncbi.nlm.nih.gov/pubmed/20921209>

1864 NCCTG Phase I Trial N057K of Everolimus (RAD001) and Temozolomide in Combination with Radiation Therapy in Newly Diagnosed Glioblastoma Multiforme Patients¹

Jann N. Sarkaria, Evanthia Galanis, Wenting Wu, Patrick J. Peller, Caterina Giannini, Paul D. Brown, Joon H. Uhm, Steven McGraw, Kurt A. Jaeckle, Jan C. Buckner Int J Radiat Oncol Biol Phys vol 81 (2) 468-475 2011
Manuscript Neuro-Onc <http://www.ncbi.nlm.nih.gov/pubmed/20864273>

1865 Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of Vascular Thrombotic Events (VTEs) in the GRIFFIN Study (AFT-29)

Douglas W. Sborov, Muhamed Baljevic, Brandi Reeves, Jacob Laubach, Yvonne A. Efebera, Cesar Rodriguez, Luciano J. Costa, Ajai Chari, Rebecca Silbermann, Sarah A. Holstein, Larry D. Jr. Anderson, Jonathan L. Kaufman, Nina Shah, Huiling Pei, Sharmila Patel, Annelore Cortoos, Blake Bartlett, Jessica Vermeulen, Thomas S. Lin, Peter M. Voorhees, Paul G. Richardson Clin Lymphoma Myeloma Leuk vol 21 (suppl 2) abstr P-180 2021
Abstract Myeloma
[https://www.clinical-lymphoma-myeloma-leukemia.com/issue/S2152-2650\(21\)X0012-2](https://www.clinical-lymphoma-myeloma-leukemia.com/issue/S2152-2650(21)X0012-2)

1866 Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study

Douglas W. Sborov, Muhamed Baljevic, Brandi Reeves, Jacob Laubach, Yvonne A. Efebera, Cesar Rodriguez, Luciano J. Costa, Ajai Chari, Rebecca Silbermann, Sarah A. Holstein, Larry D. Anderson Jr, Jonathan L. Kaufman, Nina Shah, Huiling Pei, Sharmila Patel, Annelore Cortoos, J. Blake Bartlett, Jessica Vermeulen, Thomas S. Lin, Peter M. Voorhees, Paul G. Richardson Br J Haematol vol 199 (3) 355-65 2022
Manuscript Myeloma <http://www.ncbi.nlm.nih.gov/pubmed/36111391>

1867 Daratumumab (DARA) + Lenalidomide, Bortezomib, and Dexamethasone (RvD) in Patients (Pts) With Transplant-eligible Newly Diagnosed Multiple Myeloma, daratumumab, autologous stem cell transplanteloma (NDMM): Final Analysis of GRIFFIN

Douglas W. Sborov, Jacob Laubach, Jonathan L. Kaufman, Brandi Reeves, Cesar Rodriguez, Ajai Chari, Rebecca Silbermann, Luciano J. Costa, Larry D. Anderson Jr., Nitya Nathwani, Nina Shah, Naresh Bumma, Sarah A. Holstein, Caitlin Costello, Andrzej Jakubowiak, Robert Z. Orlowski, Kenneth H. Shain, Andrew J. Cowan, Huiling Pei, Annelore Cortoos, Sharmila Patel, Thomas S. Lin, Paul Richardson, Saad Z. Usmani, Peter M. Voorhees OAB-057 2022
Abstract Myeloma <https://events.jspargo.com/IMW22/CUSTOM/pdf/IMS2022Abstracts.pdf>

1868 A Phase II Study of Neoadjuvant Therapy with Cisplatin, Docetaxel, Panitumumab Plus Radiation Therapy Followed by Surgery in Patients with Locally Advanced Adenocarcinoma of the Distal Esophagus. (Results of ACOSOG Z4051 (Alliance))

T. Schefter, P. Decker, B. Meyers, M. Ferguson, A. Oeltjen, J. B. Putnam Jr, S. Cassivi, C. E. Reed, C. A. Lockhart Int J Radiat Oncol Biol Phys vol 87 (2 Supplement) S85-S86 2013
Abstract GI <http://www.sciencedirect.com/science/article/pii/S0360301613008924>

1869 A Randomized Double-Blind Phase II Study of the Seneca Valley Virus (NTX-010) versus Placebo for Patients with Extensive-Stage SCLC (ES SCLC) Who Were Stable or Responding after at Least Four Cycles of Platinum-Based Chemotherapy: North Central Cancer Treatment Group (Alliance) N0923 Study.

Erin L Schenk, Sumithra J Mandrekar, Grace K Dy, Marie Christine Aubry, Angelina D Tan, Shaker R Dakhil, Bradley A Sachs, Jorge J Nieva, Erin Bertino, Christine Lee Hann, Steven E Schild, Troy W Wadsworth, Alex A Adjei, Julian R Molina J Thorac Oncol vol 15 (1) 110-9 2020
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/31605793>

1870 Phase I study of temsirolimus (CCI-779) and sorafenib in recurrent glioblastoma: North central cancer treatment group (NCCTG) N0572

D. Schiff, J. Sarkaria, P. Decker, J. Buckner, E. Galanis, J. Dancey, C. Giannini, P. Brown, M. Wiesenfeld, K. Jaeckle Neuro-oncology vol 9 (4) 518-518 2007
Abstract Neuro-Onc <http://neuro-oncology.oxfordjournals.org/content/9/4/467.full.pdf+html>

1871 Feasibility/tolerability results from a phase I/II study of temsirolimus (CCI-779) and sorafenib in recurrent glioblastoma: North Central Cancer Treatment Group (NCCTG) N0572

D. Schiff, J. Sarkaria, P. Decker, J. Buckner, E. Galanis, J. Dancey, C. Giannini, P. Brown, M. Wiesenfeld, K. Jaeckle Neuro-oncology vol 11 (2) 232-232 2009
Abstract Neuro-Onc <http://neuro-oncology.oxfordjournals.org/content/11/2/217.full.pdf+html>

1872 Phase I/II Trial of Temsirolimus and Sorafenib in Treatment of Patients with Recurrent Glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572

David Schiff, Kurt A Jaeckle, S. Keith Anderson, Evanthia Galanis, Caterina Giannini, Jan C. Buckner, Phillip Stella, Patrick J Flynn, Bradley J Erickson, John F Schwerkoske, Vesna Kaluza, Erin Twohy, Janet Dancey, John Wright, Jann N. Sarkaria Cancer vol 124 (7) 1455-1463 2018
Manuscript Neuro-Onc <http://www.ncbi.nlm.nih.gov/pubmed/29313954>

1873 Prophylactic cranial irradiation in small-cell lung cancer: findings from a North Central Cancer Treatment Group Pooled Analysis

S. E. Schild, N. R. Foster, J. P. Meyers, H. J. Ross, P. J. Stella, Y. I. Garces, K. R. Olivier, J. R. Molina, L. R. Past, A. A. Adjei Ann Oncol vol 23 (11) 2919-2924 2012
Manuscript Respiratory NCCTG-86-20-51, NCCTG-89-20-51, NCCTG-89-20-52, NCCTG-95-20-53 <http://www.ncbi.nlm.nih.gov/pubmed/22782333>

- 1874 N0321: A phase II study of bortezomib, paclitaxel, carboplatin, and radiotherapy for locally advanced non-small cell lung cancer**
S. E. Schild, J. R. Molina, G. K. Dy, K. M. Rowland Jr, J. N. Sarkaria, S. P. Thomas, D. W. Northfelt, J. W. Kugler, N. R. Foster, A. A. Adjei J Clin Oncol vol 30 (15 suppl) abstr 7073 2012
Abstract Respiratory
http://meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/7073?sid=1d518509-b067-40df-8465-669d
- 1875 Baseline quality of life (QOL) as a prognostic factor for overall survival (OS) in patients (Pts) with advanced stage non-small cell lung cancer (A-NSCLC): An analysis of NCCTG studies.**
S. E. Schild, Y. Qi, A. D. Tan, S. J. Mandrekar, A. A. Adjei, J. E. Krook, K. M. Rowland Jr, Y. I. Garces, G. S. Soori, J. A. Sloan J Clin Oncol vol 26 (15s) abstr 8076 2008
Abstract Respiratory
http://meeting.ascopubs.org/cgi/content/abstract/26/15_suppl/8076?sid=d8821ba2-45c3-45ae-af7d-b8231
- 1876 Prophylactic cranial irradiation (PCI) in small cell lung cancer (SCLC): Findings from a North Central Cancer Treatment Group (NCCTG) pooled analysis.**
S. Schild, N. Foster, J. Meyers, K. Olivier, H. Ross, J. Molina, P. Stella, L. Past, Y. Garces, A. Adjei J Clin Oncol vol 29 (15s) abstr 7074 2011
Abstract Respiratory NCCTG-89-20-51, NCCTG-89-20-52, NCCTG-892052, NCCTG-95-20-53
http://meeting.ascopubs.org/cgi/content/abstract/29/15_suppl/7074
- 1877 Survival of patients (pts) treated with high-dose radiotherapy (RT) and concurrent chemotherapy for unresectable non-small cell lung cancer (NSCLC).**
S. Schild, D. Graham, S. Hillman, S. Vora, G. Yolanda, J. Molina, H. Shahidi, J. Kugler, A. Adjei J Clin Oncol vol 27 (15S) 7544 2009
Abstract Respiratory
<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/7544?sid=85d951d9-44ea-49c0-b15d-2bc919a61>
- 1878 Long-term Survival of Patients (pts) Treated with High-dose Radiotherapy(rt) and Concurrent Chemotherapy for Unresectable Non-small Cell Lung Cancer (nslc)**
S. Schild, S. Hillman, D. Graham, S. Vora, Y. Garces, K. Olivier, J. Kugler, H. Ross, J. Molina, A. Adjei J Thorac Oncol vol 7 (15 (suppl 4)) 234, Abstract 158 2012
Abstract Respiratory <http://www.jto.org/article/S1556-0864%2815%2933009-4/fulltext>
- 1879 The value of combined modality therapy in elderly patients with stage III non-small cell lung cancer (NSCLC)**
S. Schild, S. Mandrekar, A. Jatoi, W. McGinnis, P. Stella, R. Deming, J. Jett, Y. Garces, K. Allen, A. Adjei J Clin Oncol vol 28 (18s) 19503 2007
Abstract Respiratory NCCTG-94-24-52, NCCTG-90-24-51
http://meeting.ascopubs.org/cgi/content/abstract/25/18_suppl/19503?sid=144cd6d1-2a9a-428d-8e31-041
- 1880 N0321: A Phase I Study of bortezomib, Paclitaxel, Carboplatin (CBDCA) & Radiotherapy (RT) for Locally-Advanced Non-Small Cell Lung Cancer (NSCLC)**
S. Schild, J. Molina, G. Dy, K. Rowland Jr, J. Sarkaria, S. Thomas, D. Northfelt, J. Kugler, N. Foster, A. Adjei J Clin Oncol vol 28 (15s) abstr 7085 2010
Abstract Respiratory
http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/7085?sid=1d518509-b067-40df-8465-669d
- 1881 Brain Metastases From Melanoma**
Steven E. Schild, Deepti Behl, Svetomir N. Markovic, Paul D. Brown, Jonathan R. Sande, Richard L. Deming, Kendrith M. Rowland, James D. Bearden Am J Clin Oncol vol 33 (6) 633-636 2010
Manuscript Neuro-Onc <http://www.ncbi.nlm.nih.gov/pubmed/20042969>

- 1882 Long-terms results of a trial of concurrent chemotherapy and escalating doses of radiation for unresectable non–small cell lung cancer: NCCTG N0028 (Alliance)**
Steven E. Schild, Shauna L. Hillman, Angelina D. Tan, Helen J. Ross, William L. McGinnis, Yolanda A. Garces, David L. Graham, Alex A. Adjei, James R. Jett J Thorac Oncol vol 12 (4) 697-703 2017
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/28089762>
- 1883 Alliance A082002 SBRT for PD-11-negative, advanced non-small cell lung cancer**
Steven E. Schild, Xiaofei Wang, Christine M. Bestvina, Terence Williams, Greg Masters, Anurag Singh, Thomas E. Stinchcombe, Joseph K. Salama, Steven Wolf, Tyler Zemla, Narjust Duma, Stephen G. Chun, Arya Amini, David Kozono, Colleen Watt Clin Lung Cancer vol 23 (5) e317-e320 2022
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/35613998>
- 1884 Results of a phase II study of high-dose thoracic radiation therapy with concurrent cisplatin and etoposide in limited-stage small-cell lung cancer (NCCTG 95-20-53).**
Steven E Schild, James A Bonner, Shauna Hillman, Timothy F Kozelsky, Antonio P G Vigliotti, Randolph S Marks, David L Graham, Gamini S Soori, John W Kugler, Richard C Tenglin, Donald B Wender, Alex Adjei J Clin Oncol vol 25 (21) 3124-9 2007
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/17634491>
- 1885 The value of combined-modality therapy in elderly patients with stage III nonsmall cell lung cancer.**
Steven E Schild, Sumithra J Mandrekar, Aminah Jatoi, William L McGinnis, Phillip J Stella, Richard L Deming, James R Jett, Yolanda I Garces, Katie L Allen, Alex A Adjei Cancer vol 110 (2) 363-8 2007
Manuscript Respiratory NCCTG-90-24-51, NCCTG-94-24-52
<http://www.ncbi.nlm.nih.gov/pubmed/17542000>
- 1886 Results of a Phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small-cell lung cancer.**
Steven E Schild, William L McGinnis, David Graham, Shauna Hillman, Tom R Fitch, Donald Northfelt, Yolanda I Garces, Homayoon Shahidi, Loren K Tschetter, Paul L Schaefer, Alex Adjei, James Jett Int J Radiat Oncol Biol Phys vol 65 (4) 1106-11 2006
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/16730134>
- 1887 A patterns-of-care study of post-progression treatment (Rx) among patients (pts) with advanced pancreas cancer (APC) after gemcitabine therapy on Cancer and Leukemia Group B (CALGB) study 80303**
D. Schrag, L. E. Archer, X. Wang, D. Romanus, M. Mulcahy, R. M. Goldberg, H. L. Kindler J Clin Oncol vol 25 (18S) abstr 4524 2007
Abstract Health Outcomes
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID
- 1888 Clinical trial participants' strategies for coping with prescription drug costs: A companion study to CALGB 80405**
D. Schrag, M. J. Naughton, A. Kesselheim, L. E. Archer, D. Niedzwiecki, D. Romanus, R. M. Goldberg, A. P. Venook J Clin Oncol vol 27 (15s) abstr 9503 2009
Abstract Health Outcomes <http://meetinglibrary.asco.org/content/34985-65>
- 1889 Cost of chemotherapy for metastatic colorectal cancer with either bevacizumab or cetuximab: Economic analysis of CALGB/SWOG 80405.**
Deborah Schrag, Amylou C. Dueck, Michelle Joy Naughton, Donna Niedzwiecki, Craig Earle, James Edward Shaw, Axel Grothey, Howard S. Hochster, Charles David Blanke, Alan P. Venook J Clin Oncol vol 33 (suppl) abstr 6504 2015

1890 Preoperative Treatment of Locally Advanced Rectal Cancer.

Deborah Schrag, Qian Shi, Martin R Weiser, Marc J Gollub, Leonard B Saltz, Benjamin L Musher, Joel Goldberg, Tareq Al Baghdadi, Karyn A Goodman, Robert R McWilliams, Jeffrey M Farma, Thomas J George, Hagen F Kennecke, Ardaman Shergill, Michael Montemurro, Garth D Nelson, Brian Colgrove, Vallerie Gordon, Alan P Venook, Eileen M O'Reilly, Jeffrey A Meyerhardt, Amylou C Dueck, Ethan Basch, George J Chang, Harvey J Mamon *N Engl J Med* vol 389 (4) 322-34 2023
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/37272534>

1891 PROSPECT: A randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by Total Mesorectal Excision (TME) for treatment of locally advanced rectal cancer (LARC). (Alliance N1048)

Deborah Schrag, Qian Shi, Martin Weiser, Marc Gollub, Leonard Saltz, George Chang, Rebecca Auer, Jeffrey Farma, Thom George, Hagen Kennecke, Benjamin Musher, Joel Goldberg, Tareq Al baghdadi, AmyLou Dueck, Ethan Basch, Alan Venook, Karyn Goodman, Eileen O'Reilly, Jeffrey Meyerhardt, Harvey Mamon *JCO* vol 41 (suppl 17) LBA2 2023
Abstract GI 10.1200/JCO.2023.41.17_suppl.LBA2

1892 The Comparative Effectiveness of Direct Oral Anti-Coagulants and Low Molecular Weight Heparins for Prevention of Recurrent Venous Thromboembolism in Cancer: The CANVAS Pragmatic Randomized Trial (AFT-28)

Deborah Schrag, Hajime Uno, Rachel Rosovsky, Cynthia Rutherford, Kristen Sanfilippo, John L Villano, Monic Drescher, Nagesh Jayaram, Chris Holmes, Lawrence Feldman, Ottavia Zattra, Christine Cronin, Ethan Basch, Anna Weiss, Jean Connors *J Clin Oncol* vol 39 (no. 15_suppl) 12020 2021
Abstract Prevention https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.12020

1893 Challenges and Solutions in the Design and Execution of the PROSPECT Phase II/III Neoadjuvant Rectal Cancer Trial (NCCTG N1048/Alliance)

Deborah Schrag, Martin Weiser, Leonard Saltz, Harvey Mamon, Marc Gollub, Ethan Basch, Alan Venook, Qian Shi *Clin Trials* vol 16 (2) 165-75 2019
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/30688523>

1894 Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen

Werner Schroth, Matthew P. Goetz, Ute Hamann, Peter A. Fasching, Marcus Schmidt, Stefan Winter, Peter Fritz, Wolfgang Simon, Vera J. Suman, Matthew M. Ames, Stephanie L. Safgren, Mary J. Kuffel, Hans Ulrich Ulmer, Julia Boländer, Reiner Strick, Matthias W. Beckmann, Heinz Koelbl, Richard M. Weinshilboum, James N. Ingle, Michel Eichelbaum, Matthias Schwab, Hiltrud Brauch *JAMA* vol 302 (13) 1429-1436 2009
Manuscript PPP <http://www.ncbi.nlm.nih.gov/pubmed/19809024>

1895 A National Study of the Use of Asymptomatic Systemic Imaging for Surveillance Following Breast Cancer Treatment

Jessica R. Schumacher, Heather B. Neuman, George J. Chang, Benjamin D. Kozower, Stephen Edge, Menggang Yu, David J Vanness, Yajuan Si, Elizabeth A. Jacobs, Amanda B. Francescatti, Patricia Spears, Jeffrey Havlena, Taiwo Adesoye, Daniel McKellar, David Winchester, Elizabeth Burnside, Caprice C. Greenberg *Ann Surg Oncol* vol 25 (9) 2587-95 2018
Manuscript CCDR <http://www.ncbi.nlm.nih.gov/pubmed/29777402>

1896 Local/regional recurrence rates after breast conserving therapy in patients enrolled in legacy trials of the Alliance for Clinical Trials in Oncology (AFT-01)

Jessica R. Schumacher, Alyssa A. Wiener, Caprice C. Greenberg, Bret Hanlon, Stephen B. Edge, Kathryn J. Ruddy, Ann H. Partridge, Jennifer G. Le-Rademacher, Menggang Yu, David J Vanness, Dou-Yan Yang, Jeffrey Havlena, Carrie Strand, Heather B. Neuman *Ann Surg* 2022
Manuscript CCIDR <http://www.ncbi.nlm.nih.gov/pubmed/36521077>

1897 Surveillance Imaging vs Symptomatic Recurrence Detection and Survival in Stage II-III Breast Cancer (AFT-01)

Jessica R Schumacher, Heather B Neuman, Menggang Yu, David J Vanness, Yajuan Si, Elizabeth S Burnside, Kathryn J Ruddy, Ann H Partridge, Deborah Schrag, Stephen B Edge, Ying Zhang, Elizabeth A Jacobs, Jeffrey Havlena, Amanda B Francescatti, David P Winchester, Daniel P McKellar, Patricia A Spears, Benjamin D Kozower, George J Chang, Caprice C Greenberg, Karla Ballman, Patrick Gavin, Bettye Green, Jane Perlmutter, Elizabeth Berger, Rinaa Punglia, Ronald Chen, Nicole Brys, Taiwo Adesoye *J Natl Cancer Inst* vol 114 (10) 1371-9 2022
Manuscript CCIDR <http://www.ncbi.nlm.nih.gov/pubmed/35913454>

1898 Increasing socioeconomically disadvantaged patients' engagement in breast cancer surgery decision-making through a shared decision-making intervention (A231701CD): protocol for a cluster randomised clinical trial

Jessica R Schumacher, David Zahrieh, Selina Chow, John Taylor, Rachel Wills, Bret M Hanlon, Paul J Rathouz, Jennifer L Tucholka, Heather B Neuman *BMJ Open* vol 12 (11) e063895 2022
Manuscript CCIDR <http://www.ncbi.nlm.nih.gov/pubmed/36396308>

1899 Higher MN1 expression is an unfavorable prognosticator in older patients (Pts) with cytogenetically normal acute myeloid leukemia (CN-AML): A CALGB study

S. Schwind, G. Marcucci, K. B. Holland, K. Mrózek, M. D. Radmacher, K. Maharry, H. Becker, S. P. Whitman, Y.-Z. Wu, T. H. Carter, B. L. Powell, M. A. Caligiuri, M. R. Baer, R. A. Larson, C. D. Bloomfield *AACR Annual Meeting abstr* 2717 2010
Abstract *Leuk Corr Sci* CALGB-20502, CALGB-9665, CALGB-8461, CALGB-9621, CALGB-19808
<http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=3a98c08e-5100-427d-b077-f6c5984fe48>

1900 MicroRNA 181a (miR-181a) expression as a prognosticator in cytogenetically normal acute myeloid leukemia (CN AML)

S. Schwind, G. Marcucci, K. S. Maharry, M. D. Radmacher, S. P. Whitman, P. Paschka, K. A. Mrozek, J. E. Kolitz, R. A. Larson, C. D. Bloomfield *J Clin Oncol* vol 27 (15s) abstr 7001 2009
Abstract *Leuk Corr Sci* CALGB-9621, CALGB-19808
<http://meeting.ascopubs.org/gca?allch=&submit=Go&gca=ascomtg%3B27%2F15S%2F7001>

1901 Aberrant Gene Expression of BAALC and ERG in Older \geq 60 Years (y) De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML): A Cancer and Leukemia Group B (CALGB) Study

S. Schwind, G. Marcucci, K. Maharry, K. Mrozek, M. D. Radmacher, K. B. Holland, H. Becker, S. P. Whitman, Y. Z. Wu, M. R. Baer, B. L. Powell, A. J. Carroll, M. A. Caligiuri, R. A. Larson, C. D. Bloomfield *Blood* vol 114 (22) 93-94 2009
Abstract *Leuk Corr Sci* CALGB-10201, CALGB-20202, CALGB-8461, CALGB-9720
<https://ash.confex.com/ash/2009/webprogram/Paper22613.html>

1902 *inv*(16)/*t*(16;16) acute myeloid leukemia with non-type A CBF β -MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations

Sebastian Schwind, Colin G. Edwards, Deedra Nicolet, Krzysztof Mrózek, Kati Maharry, Yue-Zhong Wu, Peter Paschka, Ann-Kathrin Einfeld, Pia Hoellerbauer, Heiko Becker, Klaus H. Metzeler, John

Curfman, Jessica Kohlschmidt, Thomas W. Prior, Jonathan E. Kolitz, William Blum, Mark J. Pettenati, Paola Dal Cin, Andrew J. Carroll, Michael A. Caligiuri, Richard A. Larson, Stefano Volinia, Guido Marcucci, Clara D. Bloomfield *Blood* vol 121 (2) 385-391 2013
Manuscript *Leuk Corr Sci* CALGB-8461, CALGB-8525, CALGB-8821, CALGB-8923, CALGB-9022, CALGB-9120, CALGB-9222, CALGB-9621, CALGB-9720, CALGB-19808, CALGB-10201, CALGB-10502, CALGB-10503, CALGB-10603
<http://www.ncbi.nlm.nih.gov/pubmed/23160462>

1903 Prognostic Significance of Expression of a Single MicroRNA, miR-181a, in Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

Sebastian Schwind, Kati Maharry, Michael D. Radmacher, Krzysztof Mrózek, Kelsi B. Holland, Dean Margeson, Susan P. Whitman, Christopher Hickey, Heiko Becker, Klaus H. Metzeler, Peter Paschka, Claudia D. Baldus, Shujun Liu, Ramiro Garzon, Bayard L. Powell, Jonathan E. Kolitz, Andrew J. Carroll, Michael A. Caligiuri, Richard A. Larson, Guido Marcucci, Clara D. Bloomfield *J Clin Oncol* vol 28 (36) 5257-5264 2010
Manuscript *Leuk Corr Sci* CALGB-19808, CALGB-20202, CALGB-20502, CALGB-8461, CALGB-9621, CALGB-9665 <http://www.ncbi.nlm.nih.gov/pubmed/21079133>

1904 Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia

Sebastian Schwind, Guido Marcucci, Jessica Kohlschmidt, Michael D. Radmacher, Krzysztof Mrózek, Kati Maharry, Heiko Becker, Klaus H. Metzeler, Susan P. Whitman, Yue-Zhong Wu, Bayard L. Powell, Maria R. Baer, Jonathan E. Kolitz, Andrew J. Carroll, Richard A. Larson, Michael A. Caligiuri, Clara D. Bloomfield *Blood* vol 118 (15) 4188-4198 2011
Manuscript *Leuk Corr Sci* CALGB-8525, CALGB-10201, CALGB-20202, CALGB-8461, CALGB-8923, CALGB-9420, CALGB-9665, CALGB-9720
<http://www.ncbi.nlm.nih.gov/pubmed/21828125>

1905 BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

Sebastian Schwind, Guido Marcucci, Kati Maharry, Michael D. Radmacher, Krzysztof Mrózek, Kelsi B. Holland, Dean Margeson, Heiko Becker, Susan P. Whitman, Yue-Zhong Wu, Klaus H. Metzeler, Bayard L. Powell, Jonathan E. Kolitz, Thomas H. Carter, Joseph O. Moore, Maria R. Baer, Andrew J. Carroll, Michael A. Caligiuri, Richard A. Larson, Clara D. Bloomfield *Blood* vol 116 (25) 5660-5669 2010
Manuscript *Leuk Corr Sci* CALGB-8525, CALGB-10201, CALGB-20202, CALGB-8923, CALGB-9420, CALGB-9720 <http://www.ncbi.nlm.nih.gov/pubmed/20841507>

1906 Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 clinical trial

Heiko Schöder, Mei-Yin C. Polley, Michael V. Knopp, Nathan Hall, Lale Kostakoglu, Jun Zhang, Howard R. Higley, Gary Kelloff, Heshan Liu, Andrew D. Zelenetz, Bruce D. Cheson, Nina Wagner-Johnston, Brad S. Kahl, Jonathan W. Friedberg, Eric D. Hsi, John P. Leonard, Lawrence H. Schwartz, Wyndham H. Wilson, Nancy L. Bartlett *Blood* vol 135 (25) 2224-34 2020
Manuscript *Lymphoma* <http://www.ncbi.nlm.nih.gov/pubmed/32232481>

1907 High proliferation by the MCL35 assay is associated with inferior outcomes in patients treated with intensive regimens – a correlative study from the Alliance 50403 trial.

David W. Scott, Brandelyn Pitcher, Yi Tian Liu, Merrill Boyle, Anja Mottok, Jonathan Said, Amy Chadburn, Raymond Lai, Sin-Ho Jung, John P. Leonard, Lawrence D. Kaplan, Eric D. Hsi *Hematol Oncol* vol 35 (suppl S2) 152-2 2017
Abstract *Correl Sci NOS* http://onlinelibrary.wiley.com/doi/10.1002/hon.2438_5/abstract

- 1908 Perioperative Outcomes of Video-Assisted (VATS) Lobectomy for Lung Cancer Compared to Open Thoracotomy and Lobectomy, An Analysis of Data from the American College of Surgeons Oncology Group (ACOSOG) Z0030 Clinical Trials**
W. J. Scott, M. Allen, G. Darling, B. F. Meyers, P. A. Decker, J. B. Putnam Jr, R. W. Mckenna, R. J. Landreneau, J. R. David, R. I. Inculet, R. A. Malthaner 2009
Abstract Respiratory
<http://westernthoracic.org/search.cgi?cx=009762188130679964917%3Aq202knjprxc&cof=FORID%3A>
- 1909 Video-assisted thoracic surgery versus open lobectomy for lung cancer: a secondary analysis of data from the American College of Surgeons Oncology Group Z0030 randomized clinical trial.**
Walter J Scott, Mark S Allen, Gail Darling, Bryan Meyers, Paul A Decker, Joe B Putnam, Robert W McKenna, Rodney J Landreneau, David R Jones, Richard I Inculet, Richard A Malthaner J Thorac Cardiovasc Surg vol 139 (4) 976-81; discussion 981-3 2010
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/20172539>
- 1910 The Complicated ‘Yes’: Decision -Making Processes and Receptivity to Lung Cancer Screening Among Head and Neck Cancer Survivors**
Aaron T. Seaman, Kimberly Dukes, Richard M. Hoffman, Alan J. Christensen, Nicholas Kendell, Andrew L. Sussman, Miriam Veléz-Bermúdez, Robert J. Volk, Nitin A. Pagedar Patient Educ Couns vol 101 (10) 1741-7 2018
Manuscript Prevention <http://www.ncbi.nlm.nih.gov/pubmed/29709410>
- 1911 High-dimensional genomic feature selection with the ordered stereotype logit model**
Anna Eames Seffernick, Krzysztof Mrózek, Deedra Nicolet, Richard M Stone, Ann-Kathrin Eisfeld, John C Byrd, Kellie J Archer Brief Bioinform vol 23 (6) 2022
Manuscript Leuk Corr Sci CALGB-8721, CALGB-10201, CALGB-10502, CALGB-10503, CALGB-10603, CALGB-11001, CALGB-11002, CALGB-19808, CALGB-8525, CALGB-8821, CALGB-8923, CALGB-9022, CALGB-9222, CALGB-9420, CALGB-9621, CALGB-9720
<http://www.ncbi.nlm.nih.gov/pubmed/36184192>
- 1912 Association of RAS mutations with race in metastatic colorectal cancer CALGB 80405 (Alliance)**
Amikar Sehdev, Donna Niedzwiecki, Alan P. Venook, Heinz-Josef Lenz, Federico Innocenti, Michelle R. Mahoney, James Edward Shaw, Blase N. Polite, Howard S. Hochster, James Norman Atkins, Richard M. Goldberg, Robert J. Mayer, Richard L. Schilsky, Monica M. Bertagnolli, Charles David Blanke, Bert O'Neil J Clin Oncol vol 36 (supple 4S) abstr 638 2018
Abstract Correl Sci NOS <https://meetinglibrary.asco.org/record/155707/abstract>
- 1913 Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840.**
Andrew D Seidman, Donald Berry, Constance Cirincione, Lyndsay Harris, Hyman Muss, P Kelly Marcom, Grandella Gipson, Harold Burstein, Diana Lake, Charles L Shapiro, Peter Ungaro, Larry Norton, Eric Winer, Clifford Hudis J Clin Oncol vol 26 (10) 1642-9 2008
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/18375893>
- 1914 Genome-wide association study of cardiotoxicity in NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial**
DJ Serie, JE Crook, BM Necela, TJ Dockter, X Wang, YW Asmann, D Fairweather, KA Bruno, G Colon-Otero, EA Perez, EA Thompson, N Norton Pharmacogenet Genomics vol 27 (10) 378-85 2017
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/28763429>

- 1915 Prognostic and Predictive Biomarkers for ACT (Adjuvant Chemotherapy) in Resected Non-Small Cell Lung Cancer (R-NSCLC): LACE-Bio**
L. K. Seymour, G. Le Teuff, M. Tsao, E. Brambilla, F. Shepherd, J-C. Soria, R. Kratzke, S. Graziano, J. Y. Douillard, R. Rosell, A. Reiman, B. Lacas, A. Bourredjem, T. LeChavalier, R. Pirker, M. Filipits, P. Hainaut, P. A. Janne, J. P. Pignon *Ann Oncol* vol 25 (suppl. 4) iv58-iv84 2014
Abstract Respiratory CALGB-9633
<http://oncologypro.esmo.org/Meeting-Resources/ESMO-2014/Biomarkers/Prognostic-and-predictive-bio>
- 1916 Tumor infiltrating lymphocytes and tumor budding refine prognostication in patients with low and high risk stage III colon cancers (NCCTG N0147)[Alliance]**
D. Sha, H. Lee, N.R. Foster, Q. Shi, S.R. Alberts, T.C. Smyrk, F.A. Sinicrope *J Clin Oncol* vol 38 (15_suppl) 2020
Abstract GI https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.4065
- 1917 Association study of the let-7 microRNA-binding site polymorphism in 3-untranslated region (UTR) of the KRAS gene in stage III colon cancers from adjuvant trial NCCTG N0147**
Dan Sha, Adam Lee, Qian Shi, Steven R. Alberts, Daniel J. Sargent, Frank A. Sinicrope, Robert B. Diasio *J Clin Oncol* vol 30 (15 suppl) abstr 3564 2012
Abstract Correl Sci NOS https://ascopubs.org/doi/abs/10.1200/jco.2012.30.15_suppl.3564
- 1918 Association study of the let-7 miRNA-complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 clinical trial)**
Dan Sha, Adam Lee, Qian Shi, Steven R. Alberts, Daniel J. Sargent, Frank A. Sinicrope, Robert B. Diasio *Clin Cancer Res* vol 20 (12) 3319-3327 2014
Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/24727325>
- 1919 Changing pattern for HER2 positivity due to updated ASCO/CAP guidelines for HER2 testing and its impact.**
Mithun Vinod Shah, Anne E. Wiktor, Reid G. Meyer, Kathleen S. Tenner, Karla V. Ballman, Rhett P. Ketterling, Edith A. Perez, Robert B. Jenkins *J Clin Oncol* vol 32 (5s) (suppl; abstr 523) 2014
Abstract Breast http://abstracts.asco.org/144/AbstView_144_126631.html
- 1920 Phase II Trials of Single Agent Anti-VEGF Therapy for Patients with Chronic Lymphocytic Leukemia (CLL)**
Tait Shanafelt, Clive Zent, John Byrd, Charles Erlichman, Betsy LaPlant, Asish Ghosh, Timothy Call, Miguel Villalona-Calero, Diane Jelinek, Deborah Bowen, Kristina Laumann, Wenting Wu, Curtis Hanson, Neil Kay *Leuk Lymphoma* vol 51 (12) 2222-2229 2010
Manuscript Leukemia NCCTG-N048F, NCCTG-N0683
<http://www.ncbi.nlm.nih.gov/pubmed/21054149>
- 1921 Effect of zoledronic acid (ZA) on bone mineral density (BMD) in premenopausal women who develop ovarian failure (OF) due to adjuvant chemotherapy (AdC): First results from CALGB trial 79809**
C. L. Shapiro, S. Halabi, G. Gibson, R. J. Friedlander, J. Kirshner, W. Sikov, E. P. Winer, C. A. Hudis, C. Issac *J Clin Oncol* vol 26 (suppl) abstr 512 2008
Abstract Symptom Inter http://www.abstract.asco.org/AbstView_55_31982.html
- 1922 Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: Final results from CALGB trial 79809**
C. L. Shapiro, S. Halabi, V. Hars, L. Archer, D. Weckstein, J. Kirshner, W. Sikov, E. Winer, H.J. Burstein, C. Hudis, C. Isaacs, R. Schilsky, E. Paskett *Eur J Cancer* vol 47 (5) 683-689 2011
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/21324674>

1923 Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance)

Charles L. Shapiro, James P. Moriarty, Stacie Dusetzina, Andrew L. Himmelstein, Jared C. Foster, Stephen S. Grubbs, Paul J. Novotny, Bijan J. Borah J Clin Oncol vol 35 (35) 3949-55 2017
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/29023215>

1924 Resampling the N9741 Trial to Compare Tumor Dynamic Versus Conventional End Points in Randomized Phase II Trials

Manish R. Sharma, Elizabeth Gray, Richard M. Goldberg, Daniel J. Sargent, Theodore G. Karrison J Clin Oncol vol 33 (1) 36-41 2015
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/25349295>

1925 Personalized Management of Chemotherapy-Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance)

Manish R. Sharma, Shailly Mehrotra, Elizabeth Gray, Kehua Wu, William T. Barry, Clifford Hudis, Eric P. Winer, Alan P. Lyss, Deborah L. Toppmeyer, Alvaro Moreno-Aspitia, Thomas E. Lad, Mario Velasco, Beth Overmoyer, Hope S. Rugo, Mark J. Ratain, Jogarao V. Gobburu J Clin Pharmacol vol 60 (4) 444-52 2020
Manuscript PPP <http://www.ncbi.nlm.nih.gov/pubmed/31802506>

1926 A model-based approach to dose optimization of neurotoxic chemotherapy drugs for metastatic breast cancer (MBC)

Manish Sharma, Elizabeth Gray, Shailly Mehrotra, Kehua Wu, William Thomas Barry, Clifford A. Hudis, Eric P. Winer, Alan P. Lyss, Deborah Toppmeyer, Alvaro Moreno-Aspitia, Hope S. Rugo, Mark J. Ratain, Jogarao Gobburu J Clin Oncol vol 33 (suppl) abstr 1041 2015
Abstract Breast <http://meetinglibrary.asco.org/content/151093-156>

1927 Reduced intensity allogeneic transplantation provides high disease-free and overall survival in patients (Pts) with advanced indolent NHL and CLL: CALGB 109901

T. C. Shea, J. Johnston, W. Walsh, S. Farag, J. Mccarty, A. Bashey, L. Isola, M. Stewart, M. Kelly, K. Owzar, C. Linker Blood vol 110 (11) 150A-150A 2007
Abstract Transplant http://www.abstracts2view.com/hem07/view.php?nu=HEM07L1_1208

1928 Reduced Intensity Allogeneic Transplantation Provides High Event-Free And Overall Survival In Patients With Advanced Indolent B Cell Malignancies: CALGB 109901

Thomas Shea, Jeffrey Johnson, Peter Westervelt, Sherif Farag, John McCarty, Asad Bashey, Luis Isola, Lee-Anne Baxter-Lowe, Michael Kelly, Kouros Owzar, Charles Linker Biol Blood Marrow Transplant vol 17 (9) 1395-1403 2011
Manuscript Transplant <http://www.ncbi.nlm.nih.gov/pubmed/21296675>

1929 Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study

K. Shedden, J. M. Taylor, S. A. Enkemann, M. S. Tsao, T. J. Yeatman, W. L. Gerald, S. Eschrich, I. Jurisica, T. J. Giordano, D. E. Misek, A. C. Chang, C. Q. Zhu, D. Strumpf, S. Hanash, F. A. Shepherd, K. Ding, L. Seymour, K. Naoki, N. Pennell, B. Weir, R. Verhaak, C. Ladd-Acosta, T. Golub, M. Gruidl, A. Sharma, J. Szoke, M. Zakowski, V. Rusch, M. Kris, A. Viale, N. Motoi, W. Travis, B. Conley, V. E. Seshan, M. Meyerson, R. Kuick, K. K. Dobbin, T. Lively, J. W. Jacobson, D. G. Beer Nat Med vol 14 (8) 822-7 2008
Manuscript Respiratory CALGB-150302 <http://www.ncbi.nlm.nih.gov/pubmed/18641660>

1930 Convolutional neural networks for the automated segmentation of malignant pleural

mesothelioma: analysis of performance based on probability map threshold (Alliance)

Mena Shenouda, Eyjólfur Guðmundsson, Feng Li, Christopher Straus, Hedy L. Kindler, Arkadiusz Z. Dudek, Thomas E. Stinchcombe, Xiaofei Wang, Adam Starkey, Samuel G. Armato III Med Phys vol 49 (6) pp e680-e681 2022

Abstract Respiratory

<https://aapm.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/mp.15769?download=true&campaigns=%5E>

1931 Prognostic and predictive effects of KRAS mutation subtype in completely resected non-small cell lung cancer (NSCLC): A LACE-bio study.

F. A. Shepherd, A. Bourredjem, E. Brambilla, C. Domerg, J.-Y. Douillard, M. Filipits, S. L. Graziano, P. Hainaut, P. A. Janne, T. Le Chevalier, G. Le Teuff, J.-P. Pignon, R. Pirker, L. Seymour, J.-C. Soria, M. Taron, M. S. Tsao, L.-B. C. R. Group J Clin Oncol vol 30 (Supplement) abstr 7007 2012

Abstract Respiratory

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID

1932 Pooled Analysis of the Prognostic and Predictive Effects of KRAS Mutation Status and KRAS Mutation Subtype in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy

Frances A. Shepherd, Caroline Domerg, Pierre Hainaut, Pasi A. Jänne, Jean-Pierre Pignon, Stephen Graziano, Jean-Yves Douillard, Elizabeth Brambilla, Thierry Le Chevalier, Lesley Seymour, Abderrahmane Bourredjem, Gwénaél Le Teuff, Robert Pirker, Martin Filipits, Rafael Rosell, Robert Kratzke, Bizhan Bandarchi, Xiaoli Ma, Marzia Capelletti, Jean-Charles Soria, Ming-Sound Tsao J Clin Oncol vol 31 (17) 2173-2181 2013

Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/23630215>

1933 CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer

Jonathan H. Shepherd, Karla Ballman, Mei-Yin C. Polley, Jordan D. Campbell, Cheng Fan, Sara Selitsky, Aranzazu Fernandez-Martinez, Joel S. Parker, Katherine A. Hoadley, Zhiyuan Hu, Yan Li, Matthew G. Soloway, Patricia A. Spears, Baljit Singh, Sara M. Tolaney, George Somlo, Elisa R. Port, Cynthia Ma, Charles Kuzma, Eleftherios Mamounas, Mehra Golshan, Jennifer R. Bellon, Deborah Collyar, Olwen M. Hahn, Clifford A. Hudis, Eric P. Winer, Ann Partridge, Terry Hyslop, Lisa A. Carey, Charles M. Perou, William M. Sikov J Clin Oncol vol 40 (12) 1323-34 2022

Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/35044810>

1934 Genomic analysis of the CALGB 40603 (Alliance) neoadjuvant trial in TNBC identifies immune features associated with pathological complete response and event-free survival

Jonathan H. Shepherd, Cheng Fan, Aranzazu Fernandez-Martinez, Joel S. Parker, Katherine A. Hoadley, Zhiyuan Hu, Yan Li, Matthew G. Soloway, Patricia A. Spears, Ann Partridge, Terry Hyslop, William M. Sikov, Lisa A. Carey, Charles M. Perou Cancer Res vol 81 (4 Supplement) PD9-03 2020

Abstract Breast https://cancerres.aacrjournals.org/content/81/4_Supplement/PD9-03.short

1935 Frailty and Adherence to Adjuvant Hormonal Therapy in Older Women With Breast Cancer: CALGB Protocol 369901

Vanessa B. Sheppard, Leigh Anne Faul, George Luta, Jonathan D. Clapp, Rachel L. Yung, Judy Huei-yu Wang, Gretchen Kimmick, Claudine Isaacs, Michelle Tallarico, William T. Barry, Brandelyn N. Pitcher, Clifford Hudis, Eric P. Winer, Harvey J. Cohen, Hyman B. Muss, Arti Hurria, Jeanne S. Mandelblatt J Clin Oncol vol 32 (22) 2318-2327 2014

Manuscript Older Adult <http://www.ncbi.nlm.nih.gov/pubmed/24934786>

1936 Randomized phase II study of sorafenib with or without everolimus in patients with radioactive

iodine refractory Hürthle cell thyroid cancer (HCC) (Alliance A091302)

Eric Sherman, Nathan R. Foster, Yungpo Bernard Su, Ardaman Shergill, Alan Ho, Bhavana Konda, Ronald A. Ghossein, Ian Ganly, Gary K. Schwartz J Clin Oncol vol 39 (no. 15_suppl) 6076 2021
Abstract Experimental https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.6076

1937 Patient reported outcomes with vitamin E and pentoxifylline after PMRT and reconstruction, initial results from a prospective pilot trial.

Arshin Sheybani, Hope Guzzo, Scott Hamling, Jonathan R Hurdelbrink, Robert Isaak, Daniel Kollmorgen, Ashlea Semmens, Lester Yen, Robert Behrens Int J Rad Oncol Biol Phys vol 111 (3 Supplement) E164 2021
Abstract Breast [https://www.redjournal.org/article/S0360-3016\(21\)01509-1/fulltext](https://www.redjournal.org/article/S0360-3016(21)01509-1/fulltext)

1938 Lymph node (LN) ratio (LNR) risk classification (RC) in stage III colon cancer (CC): A pooled analysis of 16,425 patients from the ACCENT database.

Q. Shi, J. M. Hubbard, G. A. Yothers, T. Andre, L. Saltz, G. Francini, B. M. Bot, C. Twelves, M. E. Buyse, A. Grothey, D. J. Sargent J Clin Oncol vol 29 (suppl) abstr 3556 2011
Abstract GI
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID

1939 Comparison of Outcomes After Fluorouracil-Based Adjuvant Therapy for Stages II and III Colon Cancer Between 1978 to 1995 and 1996 to 2007: Evidence of Stage Migration From the ACCENT Database

Qian Shi, Thierry Andre, Axel Grothey, Greg Yothers, Stanley R. Hamilton, Brian M. Bot, Daniel G. Haller, Eric Van Cutsem, Chris Twelves, Jacqueline K. Benedetti, Michael J. O'Connell, Daniel J. Sargent J Clin Oncol vol 31 (29) 3656-3663 2013
Manuscript GI CALGB-89803, NCCTG-784852, NCCTG-874651, NCCTG-894651, NCCTG-914653 <http://www.ncbi.nlm.nih.gov/pubmed/23980089>

1940 Prospective pooled analysis of six phase III trials investigating duration of adjuvant oxaliplatin-based therapy (3 versus 6 months) for patients with stage III colon cancer: The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration (Alliance)

Qian Shi, Alberto Sobrero, Anthony Shields, Takayuki Yoshino, TBN, Julien Taieb, Ioannis Souglakos, Roberto Labianca, Jeffrey Meyerhardt, Franck Bonnetain, Toshiaki Watanabe, Ioannis Mpoukovanas, Lindsay Renfro, Axel Grothey, Donna Niedzwiecki, Valter Torri, Thierry Andre, Dan Sargent J Clin Oncol vol 35 (18 suppl) abstr LBA1 2017
Abstract GI CALGB-80702 http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.18_suppl.LBA1

1941 Cancer registries: a novel alternative to long-term clinical trial follow-up based on results of a comparative study

Qian Shi, Y Nancy You, Heidi Nelson, Mark S Allen, David Winchester, Andrew Stewart, Tonia Young-Fadok, Paul A Decker, Erin M Green, Sara J Holton, Karla V Ballman Clin Trials vol 7 (6) 686-695 2010
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/20729254>

1942 Effect of age, gender, and performance status (PS) on the duration results of adjuvant chemotherapy for stage III colon cancer: the IDEA collaboration

Anthony F. Shields, Fang-Shu Ou, James Paul, Alberto F. Sobrero, Takayuki Yoshino, Julien Taieb, John Souglakos, Qian Shi, Rachel Kerr, Roberto Labianca, Takeharu Yamanaka, J Dewi Vernerey, Ioannis Boukovinas, Takeshi Kato, Valter Torri, Stylianos Kakolyris, Thierry Andre, Axel Grothey, Jeffrey A. Meyerhardt, Timothy Iveson J Clin Oncol vol 36 (Suppl) abstr 3599 2018
Abstract GI CALGB-80702 <https://meetinglibrary.asco.org/record/158923/abstract>

1943 Radiation treatment volumes before and after BRAF/MEK therapy in newly diagnosed

papillary craniopharyngiomas: A correlative analysis of the Alliance A071601 phase II trial

Helen A. Shih, Shervin Tabrizi, Brian F. Kabat, Erin Twohy, Susan Geyer, Shivangi Vora, Elizabeth R. Gerstner, Timothy J. Kaufmann, Michael Ruff, David Reardon, Adam Cohen, Daniela Bota, Pankaj K Agarwalla, Macarena De La Fuente, Glenn Lesser, Jian Campian, Priya Kumthekar, Michael V. Knopp, Daniel P. Cahill, Sandro Santagata, Frederick G. Barker II, Evanthia Galanis, Priscilla Brastianos, Paul D. Brown *Neuro-oncology* vol 23 (Suppl 6) abstr vi72 2021
Abstract *Neuro-Onc*
https://academic.oup.com/neuro-oncology/article/23/Supplement_6/vi72/6426987

1944 Adherence with Adjuvant Endocrine Therapy with or without Palbociclib in the PALLAS Trial (AFT-05)

Eileen Shinn, David Zahrieh, Angela DeMichele, Nick Zdenkowski, Julie Lemieux, Jun Mao, Vesna Bjelic-Radasic, Michelle Naughton, Georg Pfeiler, Karen Gelmon, Ingrid Mayer, Daniel Egle, Gabriele Zoppoli, Tiffany Traina, Miguel Martin Jiménez, Silvia Antolin Novoa, Tufia Haddad, Arlene Chan, Alistair Edward Ring, Antonio Wolff, Jose Juan Ponce Lorenzo, Dhanusha Sabanathan, Hal Burstein, Zbigniew Ireneusz Nowecki, Gunda Pristauz-Telsnigg, Adam Brufsky, Meritxell Bellet-Ezquerro, Theodoros Foukakis, Yelena Novik, Gabor Rubovszky, Karoline Muehlbacher, Otto Metzger, Theodora Goulioti, Ernest Law, Ann Partridge, Lisa Carey, Alex Zoroufy, Dominik Hlauschek, Christian Fesl, Erica Mayer, Michael Gnant *Cancer Res* vol 82 (suppl 4) P4-12-01 2022
Abstract *Health Outcomes*
https://aacrjournals.org/cancerres/article/82/4_Supplement/P4-12-01/681243/Abstract-P4-12-01-Adherer

1945 CpG Island Methylator Phenotype is Associated With Response to Adjuvant Irinotecan-Based Therapy for Stage 3 Colon Cancer

Stacey Shiovitz, Monica M. Bertagnolli, Lindsay A. Renfro, Eunmi Nam, Nathan R. Foster, Slavomir Dzieciatkowski, Yanxin Luo, Victoria Valinluck Lao, Raymond J. Monnat, Mary J. Emond, Nancy Maizels, Donna Niedzwiecki, Richard M. Goldberg, Leonard B. Saltz, Alan Venook, Robert S. Warren, William M. Grady *Gastroenterology* vol 147 (3) 637-645 2014
Manuscript *GI* <http://www.ncbi.nlm.nih.gov/pubmed/24859205>

1946 Feasibility of using an epigenetic marker of risk for lung cancer, methylation of p16, to promote smoking cessation among US veterans

Scott Shofer, Matthew Beyea, Sufeng Li, Lori A Bastian, Momen M Wahidi, Michael Kelley, Isaac M Lipkus *BMJ Open Respir Res* vol 1 (1) 2014
Manuscript *Prevention* <http://www.ncbi.nlm.nih.gov/pubmed/25478181>

1947 Six cycles of Doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: cancer and leukemia group B 40101

L. N. Shulman, C. T. Cirrincione, D. A. Berry, H. P. Becker, E. A. Perez, R. O'Regan, S. Martino, J. N. Atkins, E. Mayer, C. J. Schneider, G. Kimmick, L. Norton, H. Muss, E. P. Winer, C. Hudis *J Clin Oncol* vol 30 (33) 4071-4076 2012
Manuscript *Breast* <http://www.ncbi.nlm.nih.gov/pubmed/22826271>

1948 Four vs 6 Cycles of Doxorubicin and Cyclophosphamide (AC) or Paclitaxel (T) as Adjuvant Therapy for Breast Cancer in Women with 0-3 Positive Axillary Nodes: CALGB 40101 A 2x2 Factorial Phase III Trial: First Results Comparing 4 vs 6 Cycles of Therapy.

L. N. Shulman, C. T. Cirrincione, D. A. Berry, H. P. Becker, E. Perez, R. O'Regan, S. Martino, J. N. Atkins, C. Hudis, E. Winer 2010
Abstract *Breast*

1949 Comparison of doxorubicin and cyclophosphamide (AC) versus single-agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0-3 positive axillary nodes: CALGB 40101

L. Shulman, D. Berry, C. Cirrincione, H. Becker, E. Perez, R. O'Regan, S. Martino, C. L. Shapiro, S. J. Atkin, C. Schneider, G. Kimmick, H. Burstein, L. Norton, H. Muss, C. Hudis, E. Winer J Clin Oncol vol 31 (15 suppl) abstr 1007 2013

Abstract Breast

http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/1007?sid=9be34414-e040-4be0-b71e-0184

1950 Comparison of Doxorubicin and Cyclophosphamide Versus Single-Agent Paclitaxel As Adjuvant Therapy for Breast Cancer in Women With 0 to 3 Positive Axillary Nodes: CALGB 40101 (Alliance)

Lawrence N. Shulman, Donald A. Berry, Constance T. Cirrincione, Heather P. Becker, Edith A. Perez, Ruth O'Regan, Silvana Martino, Charles L. Shapiro, Charles J. Schneider, Gretchen Kimmick, Harold J. Burstein, Larry Norton, Hyman Muss, Clifford A. Hudis, Eric P. Winer J Clin Oncol vol 32 (22) 2311-2317 2014

Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/24934787>

1951 Randomized phase II study of two doses of pixantrone in patients with metastatic breast cancer, N1031 Alliance.

K. Sideras, A. Moreno-Aspitia, R. C. Tenglin, H. Liu, W. L. Lingle, M. M. Reinholz, K. C. Halling, B. Chen, G. Gross, R. B. Mowat, S. R. Dakhil, E. A. Perez J Clin Oncol vol 30 (15 suppl) abstr 1083 2012

Abstract Breast <http://meetinglibrary.asco.org/content/96940-114>

1952 North Central Cancer Treatment Group (NCCTG) N0537: Phase II Trial of VEGF-Trap in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and/or a Taxane

Kostandinos Sideras, Amylou C. Dueck, Timothy J. Hobday, Kendrith M. Rowland, Jacob B. Allred, Donald W. Northfelt, Wilma L. Lingle, Robert J. Behrens, Tom R. Fitch, Daniel A. Nikcevich, Edith A. Perez Clin Breast Cancer vol 12 (6) 387-391 2012

Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/23083501>

1953 Randomized Phase II Study of Two Doses of Pixantrone in Patients with Metastatic Breast Cancer (NCCTG N1031, Alliance)

Kostandinos Sideras, David W Hillman, Karthik Giridhar, Brenda F Ginos, Richard C Tenglin, Heshan Liu, Beiyun Chen, Winston Tan, Gerald G Gross, Rex B Mowat, Amylou C Dueck, Edith A Perez, Alvaro Moreno-Aspitia Oncologist vol 27 (5) 338-e368 2022

Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/35445723>

1954 Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant weekly paclitaxel followed by dose-dense AC on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance)

W. Sikov, D. Berry, C. Perou, B. Singh, C. Cirrincione, H. Burstein, C. Kuzma, T. Pluard, G. Somlo, E. Port, M. Golshan, J. Bellon, D. Collyar, O. Hahn, C. Hudis, E. Winer Cancer Res vol 73 (24 Suppl) Abstract nr S5-01 2013

Abstract Breast http://www.abstracts2view.com/sabcs13/view.php?nu=SABCS13L_458&terms=

1955 Randomized phase II trial of adding carboplatin and/or bevacizumab to neoadjuvant weekly paclitaxel and dose-dense AC in triple-negative breast cancer

W. Sikov, C. M. Perou, M. Golshan, D. Collyar, D. A. Berry, O. M. Hahn, B. Singh, C. A. Hudis, E. P. Winer J Clin Oncol vol 28 (15s) abstr TPS110 2010

Abstract Breast

http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/TPS110?sid=33bef702-6a74-44bd-8197-cb

1956 Impact of intrinsic subtype by PAM50 and other gene signatures on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC) after neoadjuvant chemotherapy

(NACT) +/- carboplatin (Cb) or bevacizumab (Bev): CALGB 40603/150709 (Alliance)

William M. Sikov, William T. Barry, Katherine A. Hoadley, Brandelyn N. Pitcher, Baljit Singh, Sara M Tolaney, Charles S Kuzma, Timothy J Pluard, George Somlo, Elisa R Port, Mehra Golshan, Donald A Berry, Olwen M Hahn, Lisa A Carey, Charles M. Perou, Clifford A Hudis, Eric P Winer *Cancer Res* vol 75 (suppl 9) S4-5 2015

Abstract Breast http://cancerres.aacrjournals.org/content/75/9_Supplement/S4-05

1957 Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)

William M. Sikov, Donald A. Berry, Charles M. Perou, Baljit Singh, Constance T. Cirrincione, Sara M. Tolaney, Charles S. Kuzma, Timothy J. Pluard, George Somlo, Elisa R. Port, Mehra Golshan, Jennifer R. Bellon, Deborah Collyar, Olwen M. Hahn, Lisa A. Carey, Clifford A. Hudis, Eric P. Winer *J Clin Oncol* vol 33 (1) 13-21 2015

Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/25092775>

1958 Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast cancer: outcomes from CALGB 40603 (Alliance)

William M Sikov, Donald A Berry, Charles M Perou, Baljit Singh, Constance T Cirrincione, Sara M Tolaney, Charles S Kuzma, Timothy J Pluard, George Somlo, Elisa R Port, Mehra Golshan, Jennifer R Bellon, Deborah Collyar, Olwen M Hahn, Lisa A Carey, Clifford A Hudis, Eric P Winer *Cancer Res* vol 76 (4 Suppl) S2-05 2016

Abstract Breast http://cancerres.aacrjournals.org/content/76/4_Supplement/S2-05.short

1959 CALGB/Alliance 40603: Long-term outcomes (LTOs) after neoadjuvant chemotherapy (NACT) (+/- carboplatin (Cb) and bevacizumab (Bev)) in triple-negative breast cancer (TNBC)

William M Sikov, Mei-Yin C Polley, Erin L Twohy, Charles M Perou, Baljit Singh, Donald A Berry, Sara M Tolaney, George Somlo, Elisa R Port, Cynthia Ma, Charles Kuzma, Eleftherios Mamounas, Mehra Golshan, Jennifer R Bellon, Deborah Collyar, Olwen M Hahn, Clifford A Hudis, Eric P Winer, Ann Partridge, Lisa A Carey *J Clin Oncol* vol 37 (15 suppl) 591 2019

Abstract Breast <https://meetinglibrary.asco.org/record/175572/abstract>

1960 Executive function in rural older adult smokers: influence of depression and nicotine dependence (NCT02510716)

Nikolas J. Silva, Cherie Conley, Shawn McClintock, Devon Noonan *Annals of Behavioral Medicine* vol 52 (Supplement 1) 377 (B321) 2018

Abstract Disparities

https://watermark.silverchair.com/kay013.pdf?token=AQECAHi208BE49Ooan9kKhW_Ercy7Dm3ZL_9

1961 Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B.

Lewis R Silverman, Erin P Demakos, Bercedis L Peterson, Alice B Kornblith, Jimmie C Holland, Rosalie Odchimar-Reissig, Richard M Stone, Douglas Nelson, Bayard L Powell, Carlos M DeCastro, John Ellerton, Richard A Larson, Charles A Schiffer, James F Holland *J Clin Oncol* vol 20 (10) 2429-40 2002

Manuscript Leukemia <http://www.ncbi.nlm.nih.gov/pubmed/12011120>

1962 A Phase II Trial Exploring the Success of Cryoablation Therapy in the Treatment of Invasive Breast Carcinoma: Results from ACOSOG (Alliance) Z1072

Rache M. Simmons, Karla V. Ballman, Charles Cox, Ned Carp, Jennifer Sabol, Rosa F. Hwang, Deanna Attai, Michael Sabel, David Nathanson, Andrew Kenler, Linsey Gold, Cary Kaufman, Linda Han, Aaron Bleznak, J. Stanley Smith, Dennis Holmes, Bruno Fornage, Carisa Le-Petross, Syed Hoda,

1963 A Phase II Trial Exploring the Success of Cryoablation Therapy in the Treatment of Invasive Breast Carcinoma: Results From ACOSOG (Alliance) Z1072

Rache Simmons, Karla Ballman, Charles Cox, Ned Carp, Jennifer Sabol, Rosa Hwang, Deanna Attai, Michael Sabel, David Nathanson, Andrew Kenler, Linsey Gold, Cary Kaufman, Linda Han, Aaron Bleznak, J. Stanley Smith, Dennis Holmes, Lorraine Tafra, Marla Dudak, Susan Weinberg, Michael Kinney, Bruno Fornage, Carisa Le-Petross, Syed Hoda, Thomas Buchholz, Janice Cormier, Wendy Lindeman, Linda McCall, Mark Watson, Bettye Green, Kelly Hunt Ann Surg Oncol vol 21 (2, suppl) 6 2014

Abstract Breast https://www.breastsurgeons.org/docs2014/2014_Official_Proceedings.pdf

1964 Normative data and clinically significant effect sizes for single-item numerical linear analogue self-assessment (LASA) scales.

Jasvinder A Singh, Dona E Locke, Daniel Satele, Suneetha Puttabasavaiah, Jan C. Buckner, Jeff A. Sloan J Clin Oncol vol 32 (suppl; abstr e17619) 2014

Abstract Health Outcomes NCCTG-95-20-53, NCCTG-95-46-51, NCCTG-95-24-52, NCCTG-95-92-04, NCCTG 97-02-02, NCCTG-964251, NCCTG-98-24-52, NCCTG-98-72-51, NCCTG-98-72-52, NCCTG-959257, NCCTG-989251, NCCTG-969256, NCCTG-971151, NCCTG-979251, NCCTG-979253 http://abstracts.asco.org/144/AbstView_144_129911.html

1965 Normative data and clinically significant effect sizes for single-item numerical linear analogue self-assessment (LASA) scales

Jasvinder A Singh, Daniel Satele, Suneetha Pattabasavaiah, Jan C Buckner, Jeff A Sloan Health Qual Life Outcomes vol 12 2014

Manuscript Health Outcomes NCCTG-95-20-53, NCCTG-95-46-51, NCCTG-95-92-04, NCCTG-95-24-52, NCCTG 97-02-02, NCCTG-964251, NCCTG-97-24-51, NCCTG-98-24-52, NCCTG-98-72-51, NCCTG-959257, NCCTG-98-72-52, NCCTG-969256, NCCTG-989251, NCCTG-971151, NCCTG-979251, NCCTG-979253 <http://www.ncbi.nlm.nih.gov/pubmed/25519478>

1966 Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance)

Preet Paul Singh, Qian Shi, Nathan R. Foster, Axel Grothey, Suresh G. Nair, Emily Chan, Anthony F. Shields, Richard M. Goldberg, Sharlene Gill, Morton S. Kahlenberg, Frank A. Sinicrope, Daniel J. Sargent, Steven R. Alberts Oncologist vol 21 (12) 1509-1521 2016

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/27881709>

1967 Relationship between Metformin use and Recurrence and Survival in Patients (pts) with Resected Stage III Colon Cancer (CC) Receiving Adjuvant Chemotherapy: Results from NCCTG N0147 (Alliance)

Preet Paul Singh, Qian Shi, Nathan Foster, Axel Grothey, Suresh Nair, Emily Chan, Anthony Frank Shields, Richard M. Goldberg, Sharlene Gill, Morton S. Kahlenberg, Frank A. Sinicrope, Daniel J. Sargent, Steven R. Alberts J Clin Oncol vol 33 (suppl) abstr 3531 2015

Abstract GI <http://meetinglibrary.asco.org/content/144132-156>

1968 Association of reduced intraepithelial CD3+/regulatory T-cell ratio with poor outcome in human colon cancers

F. A. Sinicrope, R. L. Rego, N. R. Foster, D. J. Sargent, S. M. Ansell, E. D. Kwon J Clin Oncol vol 26 (15s) abstr 11023 2008

Abstract GI http://hwmaint.meeting.ascopubs.org/cgi/content/abstract/26/15_suppl/11023

- 1969 Mutations in the proapoptotic BAX gene are associated with defective DNA mismatch repair and altered tumor growth rates in human colon cancers**
F. A. Sinicrope, R. L. Rego, A. J. French, N. R. Foster, D. J. Sargent, H. Windschitl, M. J. O'Connell, S. N. Thibodeau J Clin Oncol vol 25 (18s) abstr 10529 2007
Abstract GI
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID
- 1970 Prognostic impact of body-mass index upon cancer recurrence and survival in stage III colon cancer patients treated in adjuvant therapy trials**
F. Sinicrope, N. R. Foster, D. J. Sargent, S. Alberts, M. O'Connell J Clin Oncol vol 27 (15s) abstr 11088 2009
Abstract GI
<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/11088?sid=a57ac56b-2d39-4d5d-9c63-a772322>
- 1971 Evaluation of recurrence rate,time-to-recurrence, and hepatic metastases in patients with colon cancers with defective DNA mismatch repair.**
F. Sinicrope, N. R. Foster, D. J. Sargent, S. N. Thibodeau, S. Galliger, M. J. Moore, D. Tu
Gastrointestinal Cancers Symposium abstr 330 2010
Abstract GI
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=72&abstractID
- 1972 DNA Mismatch Repair Status and Site of Tumor Recurrence in Stage II and III Colon Cancers Treated in 5-Fluorouracil-Based Adjuvant Therapy Trials.**
F. Sinicrope, N. Foster, D. Sargent, S. Gallinger, P. Benatti, S. Marsoni, G. Monges, R. Labianca, M. O'Connell, C. Allegra J Clin Oncol vol 28 (15s) abstr 3519 2010
Abstract GI
http://meeting.ascopubs.org/gca?gca=ascomtg%3B28%2F15_suppl%2F3519&allch=&submit=Go
- 1973 Body mass index (BMI) as a prognostic and predictive factor in stage II/III colon cancer: An analysis of the ACCENT database**
F. Sinicrope, N. Foster, G. Yothers, A. Benson, D. Haller, J. Seitz, R. Labianca, J. Benedetti, R. Goldberg, A. De Gramont, D. Sargent J Clin Oncol vol 29 (15s) abstr e21126 2011
Abstract GI
http://meeting.ascopubs.org/gca?allch=&submit=Go&gca=ascomtg%3B29%2F15_suppl%2Fe21126
- 1974 Randomized Trial of FOLFOX Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair or Microsatellite Instability (ATOMIC, Alliance A021502)**
FA Sinicrope, F-S Ou, Q Shi, A Nixon, Kabir Mody, Alex LeVasseur, Amylou Dueck, Asha Dhanarajan, Christopher Lie, Deirdre Cohen, Federico Innocenti, Robert Behrens, Walter Peters, DJ Sargent, N Sommers, E O'Reilly, J Meyerhardt J Clin Oncol vol 35 (15 suppl) abstr TPS3630 2017
Abstract GI http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.TPS3630
- 1975 Prognostic Variables in Low and High Risk Stage III Colon Cancers Treated in Two Adjuvant Chemotherapy Trials**
Frank A. Sinicrope, Sakti Chakrabarti, Pierre Laurent-Puig, Luke Huebner, Thomas C. Smyrk, Josep Tabernero, Enrico Mini, Richard M. Goldberg, Aziz Zaanani, Gunnar Folprecht, Jean Luc Van Laethem, Karine Le Malicot, Qian Shi, Steven R. Alberts, Julien Taieb Eur J Cancer vol 144 101-12 2021
Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/33341444>
- 1976 Obesity Is an Independent Prognostic Variable in Colon Cancer Survivors**
Frank A. Sinicrope, Nathan R. Foster, Daniel J. Sargent, Michael J. O'Connell, Cathryn Rankin Clin

1977 DNA Mismatch Repair Status and Colon Cancer Recurrence and Survival in Clinical Trials of 5-Fluorouracil-Based Adjuvant Therapy

Frank A. Sinicrope, Nathan R. Foster, Stephen N. Thibodeau, Silvia Marsoni, Genevieve Monges, Roberto Labianca, Greg Yothers, Carmen Allegra, Malcolm J. Moore, Steven Gallinger, Daniel J. Sargent J Natl Cancer Inst vol 103 (11) 863-875 2011

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/21597022>

1978 Association of Obesity With DNA Mismatch Repair Status and Clinical Outcome in Patients With Stage II or III Colon Carcinoma Participating in NCCTG and NSABP Adjuvant Chemotherapy Trials

Frank A. Sinicrope, Nathan R. Foster, Harry H. Yoon, Thomas C. Smyrk, George P. Kim, Carmen J. Allegra, Greg Yothers, Daniel A. Nikcevich, Daniel J. Sargent J Clin Oncol vol 30 (4) 406-412 2012

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/22203756>

1979 Body Mass Index at Diagnosis and Survival Among Colon Cancer Patients Enrolled in Clinical Trials of Adjuvant Chemotherapy

Frank A. Sinicrope, Nathan R. Foster, Greg Yothers, Al Benson, Jean Francois Seitz, Roberto Labianca, Richard M. Goldberg, Aimery DeGramont, Michael J. O'Connell, Daniel J. Sargent Cancer vol 119 (8) 1528-1536 2013

Manuscript GI NCCTG-78-48-52, NCCTG-87-46-51, NCCTG-89-46-51, NCCTG-91-46-53, NCCTG-N0441 <http://www.ncbi.nlm.nih.gov/pubmed/23310947>

1980 Relative Contribution of Clinical and Molecular Features to Outcome Within Low and High Risk T and N Groups in Patients with Stage III Colon Cancers (Alliance)

Frank A. Sinicrope, Luke Huebner, Pierre Laurent-Puig, Thomas C. Smyrk, Josep Tabernero, Enrico Mini, Richard M. Goldberg, Gunnar Folprecht, Jean Luc Van Laethem, Karine Le Malicot, Qian Shi, Steven R. Alberts, Julien Taieb JCO vol 37 (no. 15_suppl) 3520 2019

Abstract Correl Sci NOS https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.3520

1981 Prognostic impact of KRAS and BRAFV600E mutations stratified by tumor site in resected stage III colon cancer patients treated with adjuvant mFOLFOX6 with or without cetuximab: NCCTG N0147 (Alliance)

Frank A. Sinicrope, Michelle R. Mahoney, Thomas C. Smyrk, Stephen N. Thibodeau, Richard M. Goldberg, Daniel J. Sargent, Garth D. Nelson, Steven R. Alberts J Clin Oncol vol 31 (15_suppl) 3523 2013

Abstract Correl Sci NOS https://ascopubs.org/doi/abs/10.1200/jco.2013.31.15_suppl.3523

1982 Prognostic impact of BRAF and KRAS mutations and their relationship to DNA mismatch repair (MMR) status in 2,686 stage III colon cancer patients (pts) treated in a phase III study of adjuvant FOLFOX +/- cetuximab: NCCTG N0147.

Frank A. Sinicrope, Michelle R. Mahoney, Thomas C. Smyrk, Stephen N. Thibodeau, Richard M. Goldberg, Daniel J. Sargent, Garth D. Nelson, Steven R. Alberts J Clin Oncol vol 30 (15_suppl) 3514-3514 2012

Abstract Correl Sci NOS https://ascopubs.org/doi/abs/10.1200/jco.2012.30.15_suppl.3514

1983 Prognostic Impact of Deficient DNA Mismatch Repair in Patients With Stage III Colon Cancer From a Randomized Trial of FOLFOX-Based Adjuvant Chemotherapy

Frank A. Sinicrope, Michelle R. Mahoney, Thomas C. Smyrk, Stephen N. Thibodeau, Robert S. Warren, Monica M. Bertagnolli, Garth D. Nelson, Richard M. Goldberg, Daniel J. Sargent, Steven R. Alberts J Clin Oncol vol 31 (29) 3664-72 2013

1984 Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance)

Frank A. Sinicrope, Michelle R. Mahoney, Harry H. Yoon, Thomas C. Smyrk, Stephen N. Thibodeau, Richard M. Goldberg, Garth D. Nelson, Daniel J. Sargent, Steven R. Alberts Clin Cancer Res vol 21 (23) 5294-5304 2015

Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/26187617>

1985 Prognostic Impact of Bim, Puma, and Noxa Expression in Human Colon Carcinomas

Frank A. Sinicrope, Rafaela L. Rego, Kenji Okumura, Nathan R. Foster, Michael J. O'Connell, Daniel J. Sargent, Harold E. Windschitl Clin Cancer Res vol 14 (18) 5810-5818 2008

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/18794091>

1986 Association of DNA Mismatch Repair and Mutations in BRAF and KRAS with Survival after Recurrence in Stage III Colon Cancers from Phase III Adjuvant Chemotherapy Trials

Frank A. Sinicrope, Qian Shi, Carmen J. Allegra, Thomas C. Smyrk, Stephen N. Thibodeau, Richard M. Goldberg, Jeffrey P. Meyers, Kay L. Pogue-Geile, Greg Yothers, Daniel J. Sargent, Steven R. Alberts JAMA Oncol vol 3 (4) 472-80 2017

Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/28006055>

1987 Molecular markers and survival after recurrence in stage III colon cancers from NCCTG N0147 and NSABP C-08 adjuvant chemotherapy trials

Frank A. Sinicrope, Qian Shi, Carmen Joseph Allegra, Thomas C. Smyrk, Stephen N. Thibodeau, Richard M. Goldberg, Jeffrey P. Meyers, Greg Yothers, Daniel J. Sargent, Steven R. Alberts J Clin Oncol vol 34 (suppl) abstr 3600 2016

Abstract Correl Sci NOS <http://meetinglibrary.asco.org/content/169815-176>

1988 Immunoscore Is Prognostic in Low-Risk and High-Risk Stage III Colon Carcinomas Treated With Adjuvant Infusional Fluorouracil, Leucovorin, and Oxaliplatin in a Phase III Trial

Frank A. Sinicrope, Qian Shi, Aurelie Catteau, Graham M. Poage, Tyler J. Zemla, Bernhard Mlecnik, Al B. Benson, Sharlene Gill, Richard M. Goldberg, Morton S. Kahlenberg, Suresh G. Nair, Anthony F. Shields, Thomas C. Smyrk, Jerome Galon, Steven R. Alberts JCO Precis Oncol vol 6 2022

Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/35952316>

1989 Immunoscore provides prognostic information in low (T1-3N1) and high risk (T4 or N2) subsets of stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance)

Frank A. Sinicrope, Qian Shi, Fabienne Hermitte, Erica N. Heying, Al B. Benson, Sharlene Gill, Richard M. Goldberg, Morton S. Kahlenberg, Suresh G. Nair, Anthony F. Shields, Daniel J. Sargent, Jérôme Galon, Steven R. Alberts J Clin Oncol vol 36 (suppl 4S) abstr 614 2018

Abstract Correl Sci NOS <https://meetinglibrary.asco.org/record/155684/abstract>

1990 Prognostic utility of immune markers and validation of Immunoscore in stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance)

Frank A. Sinicrope, Qian Shi, Fabienne Hermitte, Erica N. Heying, Al B. Benson, Sharlene Gill, Richard M. Goldberg, Morton S. Kahlenberg, Suresh G. Nair, Anthony F. Shields, Daniel J. Sargent, Jérôme Galon, Steven R. Alberts Annals of Oncology vol 28 (suppl_3) 153 2017

Abstract Correl Sci NOS

<https://academic.oup.com/annonc/article-lookup/doi/10.1093/annonc/mdx302.009>

1991 Association of an immunoscore with survival of stage III colon cancer (CC) patients treated

with adjuvant FOLFOX (Alliance N0147)

Frank A. Sinicrope, Qian Shi, Fabienne Hermitte, Erica Heying, Al Bowen Benson III, Sharlene Gill, Richard M. Goldberg, Morton Kahlenberg, Suresh Nair, Anthony Shields, Dan Sargent, Jerome Galon, Steven R. Alberts J Clin Oncol vol 35 (15 suppl) abstr 3579 2017
Abstract Correl Sci NOS http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.3579

1992 Validation of tumor infiltrating lymphocytes (TIL) and tumor budding as predictors of prognosis in patients with stage III colon cancers treated in a FOLFOX-based adjuvant therapy trial: NCCTG N0147 (Alliance)

Frank A. Sinicrope, Qian Shi, Hee Eun Lee, Nathan R. Foster, Steven R. Alberts, Thomas C. Smyrk J Clin Oncol vol 36 (suppl) abstr 3583 2018
Abstract Correl Sci NOS <https://meetinglibrary.asco.org/record/159055/abstract>

1993 Analysis of serum vitamin D levels and prognosis in stage III colon carcinoma patients treated with adjuvant FOLFOX+/- cetuximab chemotherapy (NCCTG N0147) (Alliance)

Frank A. Sinicrope, Qian Shi, Thomas C. Smyrk, Richard M. Goldberg, Erica N Heying, Steven J. Cohen, Sharlene Gill, Morton S. Kahlenberg, Suresh Nair, Anthony Frank Shields, Daniel J. Sargent, Balkrishna N. Jahagirdar, Michael N. Pollak, Steven R. Alberts J Clin Oncol vol 35 (15 suppl) abstr 3516 2017
Abstract Correl Sci NOS http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.3516

1994 Association of Adiponectin with Tumor Infiltrating Lymphocytes in Patients with Stage III Colon Cancer Treated in an Adjuvant Chemotherapy Trial (NCCTG N0147, Alliance)

Frank A. Sinicrope, Qian Shi, Thomas C. Smyrk, Richard M. Goldberg, Erica N Heying, Steven J. Cohen, Sharlene Gill, Dan Sha, Zhaohui Jin, Morton S. Kahlenberg, Suresh Nair, Anthony F. Shields, Balkrishna N. Jahagirdar, Nathan R. Foster, Michael N. Pollak, Steven R. Alberts J Clin Oncol vol 39 (suppl 15) 3591 2021
Abstract Correl Sci NOS <https://meetinglibrary.asco.org/record/196495/abstract>

1995 Molecular Markers Identify Subtypes of Stage III Colon Cancer Associated with Patient Outcomes

Frank A. Sinicrope, Qian Shi, Thomas C. Smyrk, Stephen N. Thibodeau, Rodrigo Dienstmann, Justin Guinney, Brian M. Bot, Sabine Tejpar, Mauro Delorenzi, Richard M. Goldberg, Michelle Mahoney, Daniel J. Sargent, Steven R. Alberts Gastroenterology vol 148 (1) 88-99 2015
Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/25305506>

1996 Molecular subtyping of colon cancers and distinct prognostic groups [NCCTG N0147 (Alliance)].

Frank A. Sinicrope, Qian Shi, Stephen N. Thibodeau, Richard M. Goldberg, Daniel J. Sargent, Steven R. Alberts J Clin Oncol vol 32 (5s) (suppl; abstr 3512) 2014
Abstract Correl Sci NOS http://abstracts.asco.org/144/AbstView_144_133603.html

1997 Association Of Tumor Infiltrating Lymphocytes (Tils) With Molecular Subtype And Prognosis In Stage III Colon Cancers From A FOLFOX-Based Adjuvant Chemotherapy Trial: NCCTG N0147 (Alliance)

Frank A. Sinicrope, Thomas C. Smyrk, Nathan R. Foster, Jeffrey P. Meyers, Stephen N. Thibodeau, Richard M. Goldberg, Qian Shi, Daniel J. Sargent, Steven R. Alberts J Clin Oncol vol 34 (suppl) abstr 3518 2016
Abstract Correl Sci NOS <http://meetinglibrary.asco.org/content/170078-176>

1998 Mutation-Specific Antibody Detects Mutant BRAFV600E Protein Expression in Human Colon Carcinomas

Frank A. Sinicrope, Thomas C. Smyrk, David Tougeron, Stephen N. Thibodeau, Shalini Singh, Andrea

Muranyi, Kandavel Shanmugam, Thomas M. Grogan, Steven R. Alberts, Qian Shi *Cancer* vol 119 (15) 2765-2770 2013

Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/23657789>

1999 Overall survival result and outcomes by KRAS, BRAF, and DNA mismatch repair in relation to primary tumor site in colon cancers from a randomized trial of adjuvant chemotherapy: NCCTG (Alliance) N0147.

Frank A. Sinicrope, Harry H. Yoon, Michelle R. Mahoney, Garth D. Nelson, Stephen N. Thibodeau, Richard M. Goldberg, Daniel J. Sargent, Steven R. Alberts *J Clin Oncol* vol 32 (15_suppl) 3525 2014

Abstract Correl Sci NOS

<http://meeting.ascopubs.org/cgi/content/abstrhttp://meetinglibrary.asco.org/content/133798-144>

2000 A low intraepithelial effector (CD3+):regulatory (FoxP3+) T-cell ratio predicts adverse outcome of human colon carcinoma

Frank A Sinicrope, Rafaela L Rego, Stephen M Ansell, Keith L Knutson, Nathan R Foster, Daniel J Sargent *Gastroenterology* vol 137 (4) 1270-1279 2009

Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/19577568>

2001 Contribution of Immunoscore and Molecular Features to Survival Prediction in Stage III Colon Cancer

Frank A Sinicrope, Qian Shi, Fabienne Hermitte, Tyler J Zemla, Bernhard Mlecnik, Al B Benson, Sharlene Gill, Richard M Goldberg, Morton S Kahlenberg, Suresh G Nair, Anthony F Shields, Thomas C Smyrk, Jerome Galon, Steven R Alberts *JNCI Cancer Spectr* vol 4 (3) 2020

Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/32455336>

2002 Association of Adiponectin and Vitamin D With Tumor Infiltrating Lymphocytes and Survival in Stage III Colon Cancer

Frank A Sinicrope, Qian Shi, Thomas C Smyrk, Richard M Goldberg, Steven J Cohen, Sharlene Gill, Morton S Kahlenberg, Suresh Nair, Anthony F Shield, Balkrishna N Jahagirdar, Sawyer B Jacobson, Nathan R Foster, Michael N Pollak, Steven R Alberts *JNCI Cancer Spectr* vol 5 (5) 2021

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/34485815>

2003 Model-based prediction of defective DNA mismatch repair using clinicopathological variables in sporadic colon cancer patients

Frank Sinicrope, N.R. Foster, D.J. Sargent, S.N. Thibodeau, T.C. Smyrk, M.J. O'Connell *Cancer* vol 116 (7) 1691-1698 2010

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/20186699>

2004 Repeated Measures Analyses of Dermatitis Symptom Evolution in Breast Cancer Patients Receiving Radiotherapy in a Phase 3 Randomized Trial of Mometasone Furoate vs Placebo (N06C4 [Alliance])

Terence T. Sio, Pamela J. Atherton, Brandon J Birkhead, David J. Schwartz, Jeff A. Sloan, Drew K. Seisler, James A. Martenson, Charles L. Loprinzi, Patricia C. Griffin, Roscoe F. Morton, Jon C. Anders, Thomas J. Stoffel, Robert E. Haselow, Rex B. Mowat, Michelle A. Neben Wittich, James D. Bearden, Robert C. Miller *Support Care Cancer* vol 24 (9) 3847-3855 2016

Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/27075674>

2005 Daily Lisinopril vs Placebo for Prevention of Chemoradiation-Induced Pulmonary Distress in Patients With Lung Cancer (Alliance MC1221): A Pilot Double-Blind Randomized Trial

Terence T. Sio, Pamela J. Atherton, Levi D. Pederson, W. Ken Zhen, Robert W. Mutter, Yolanda I. Garces, Daniel J. Ma, James L. Leenstra, Jean-Claude M. Rwigema, Shaker Dakhil, James D. Bearden, Sonja J. van der Veen, Apar K. Ganti, Steven E. Schild, Robert C. Miller *Int J Radiat Oncol Biol Phys*

2006 A pilot, randomized trial of daily lisinopril vs placebo to prevent radiation-induced pulmonary distress (Alliance MC1221)

Terence T. Sio, Pamela J. Atherton, W. Ken Zhen, Yolanda I. Garces, Daniel J. Ma, Apar Ganti, Schild, Robert C. Miller 2017

Abstract Symptom Inter https://library.iaslc.org/search-speaker?search_speaker=54829

2007 N-Acetylcysteine Rinse for Thick Secretion and Mucositis of Head and Neck Chemoradiotherapy (Alliance MC13C2): A Double-Blind Randomized Clinical Trial

Terence T. Sio, Miran J. Blanchard, Paul J. Novotny, Samir H. Patel, Jean-Claude M. Rwigema, Levi D. Pederson, Lisa A. McGee, Mauricio E. Gamez, Grant R. Seeger, James A. Martenson, Yvonne Grover, Michelle A. Neben Wittich, Yolanda I. Garces, Robert L. Foote, Robert C. Miller, Michele Y. Halyard Mayo Clin Proc vol 94 (9) 1814-24 2019

Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/31405750>

2008 Effect of Doxepin Mouthwash or Diphenhydramine-Lidocaine-Antacid Mouthwash vs Placebo on Radiotherapy-Related Oral Mucositis Pain

Terence T. Sio, Jennifer G. Le-Rademacher, James L. Leenstra, Charles L. Loprinzi, Grant Rine, Amarinthia Curtis, Anurag K. Singh, James A. Martenson, Paul J. Novotny, Angelina D. Tan, Rui Qin, Stephen J. Ko, Paul L. Reiter, Robert C. Miller JAMA vol 321 (15) 1481-90 2019

Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/30990550>

2009 A patient-level pooled analysis of the prognostic significance of baseline fatigue for overall survival (OS) among 3,915 patients participating in 43 North Central Cancer Treatment Group (NCCTG) and Mayo Clinic Cancer Center (MC) oncology clinical trials.

J. A. Sloan, H. Liu, D. J. Sargent, D. Satele, P. L. Schaefer, M. Y. Halyard, A. Grothey, Y. I. Garces, P. D. Brown, C. L. Loprinzi, J. C. Buckner J Clin Oncol vol 27 (15s) abstract 9599 2009

Abstract Health Outcomes

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID

2010 Was it worth it (WIWI)? patient satisfaction with clinical trial participation: Results from North Central Cancer Treatment Group (NCCTG) Phase III Trial N0147

J. A. Sloan, M. R. Mahoney, D. J. Sargent, J. M. Hubbard, H. Liu, E. M. Basch, A. F. Shields, E. Chan, R. M. Goldberg, S. Gill, M. S. Kahlenberg, S. R. Alberts J Clin Oncol vol 29 (suppl) abstr 6122 2011

Abstract Health Outcomes

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID

2011 Calibration of Quality-Adjusted Life Years (QALYS) For Oncology Clinical Trials (OCT).

J. A. Sloan, P. J. Novotny, D. J. Sargent, P. Decker ISOQOL abstr 187/1783 2010

Abstract GI <http://www.springerlink.com/content/5203321j83123k3p/fulltext.pdf>

2012 Clinically Significant Effect Sizes for Survival and Response Endpoints Using the 1/2 Standard Deviation Rule.

J. A. Sloan, P. J. Novotny, D. J. Sargent, P. Decker, R. Qin Qual Life Res vol 19 (40) abstr 1772 2010

Abstract GI <http://www.springerlink.com/content/5203321j83123k3p/fulltext.pdf>

2013 Relationship between genetic markers and quality of life (QOL) in stage III colon cancer (CC) patients (pts) prior to adjuvant treatment (N0147).

J. A. Sloan, Q. Shi, A. Lee, R. B. Diasio, E. S. Pavey, D. J. Sargent, R. M. Goldberg, F. A. Sinicrope,

M. R. Mahoney, S. R. Alberts J Clin Oncol vol 30 (15 suppl) abstr 3617 2012
Abstract Health Outcomes http://meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/3617

- 2014 Tumor burden is not related to quality of life in patients with metastatic colorectal cancer**
J. Sloan, A. Grothey, E. Green, X. Zhao, M. Campbell, D. Szydlo, D. Sargent, R. Goldberg J Clin Oncol vol 26 (suppl) abstr 4017 2008
Abstract GI
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID
- 2015 Calibration of quality-adjusted life years (QALYs) for oncology clinical trials (OCT)**
J. Sloan, P. Novotny, D. Sargent, P. A. Decker, R. Marks, H. Nelson J Clin Oncol vol 28 (15s) abstr 6108 2010
Abstract Respiratory
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID
- 2016 Expansion of the Wilson & Cleary Theoretical Model to Incorporate Genetic Influences on Quality of Life**
J Sloan, M Sprangers 2010
Abstract Health Outcomes
<http://download.springer.com/static/pdf/235/art%253A10.1007%252Fs11136-010-9766-6.pdf?originUrl=>
- 2017 Lessons from Large Scale Collection of Patient Reported Outcomes: Implications for Big Data Aggregation and Analytics**
Jeff A. Sloan, Michele Halyard, Issam El Naqa, Charles Mayo Int J Radiat Oncol Biol Phys vol 95 (3) 922-929 2016
Manuscript Health Outcomes NCCTG-N9741, NCCTG-89-20-52
<http://www.ncbi.nlm.nih.gov/pubmed/27302508>
- 2018 Prognostic significance of baseline fatigue for overall survival: A patient-level meta-analysis of 43 oncology clinical trials with 3915 patients**
Jeff A. Sloan, H. Liu, D.V. Satele, S. Puttabasavaiah, J. S. Kaur, J. Hubbard, A. Dueck, P. J. Stella, Jasvinder A. Singh Trends Cancer Res vol 12 97-110 2017
Manuscript Health Outcomes <http://www.ncbi.nlm.nih.gov/pubmed/31213748>
- 2019 Combining survival and toxicity effect sizes from clinical trials into an interpretable, quality-adjusted survival effect size estimate of treatment efficacy.**
Jeff A. Sloan, Brittny Major, Paul J. Novotny, Axel Grothey, Randolph Marks, Daniel J. Sargent, Amylou C. Dueck J Clin Oncol vol 32 (15_suppl) 6630 2014
Abstract Symptom Inter http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/6630
- 2020 Calibration of Quality-Adjusted Life Years for Oncology Clinical Trials**
Jeff A. Sloan, Daniel J. Sargent, Paul J. Novotny, Paul A. Decker, Randolph S. Marks, Heidi Nelson J Pain Symptom Manage vol 47 (6) 1091-1099.e3 2014
Manuscript Health Outcomes <http://www.ncbi.nlm.nih.gov/pubmed/24246787>
- 2021 BRAF V600 Mutation Detection in Plasma Cell-Free DNA: NCCTG N0879 (Alliance)**
Jessica A. Slostad, Minetta C. Liu, Jacob B. Allred, Lori A. Erickson, Kandelaria M. Rumilla, Matthew S. Block, Michael Keppen, David King, Svetomir N. Markovic, Robert R. McWilliams Mayo Clin Proc Innov Qual Outcomes vol 5 (6) 1012-20 2021
Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/34703985>
- 2022 Cell Free DNA BRAF Mutation V600 Plasma Detection in Melanoma (Alliance) NCCTG N0879**

Jessica Slostad, Jake Allred, Svetomir Markovic, Lori Erickson, Kandelaria Rumilla, Minetta Liu, Matthew Block, Robert McWilliams Pigment Cell & Melanoma Research vol 31 (1) 208 2018
Abstract Correl Sci NOS <https://onlinelibrary.wiley.com/doi/epdf/10.1111/pcmr.12656>

2023 The impact of prior therapy with ketoconazole (keto) on clinical outcomes after subsequent docetaxel treatment in metastatic castration-resistant prostate cancer (mCRPC) patients: Results from a randomized phase III trial (CALGB 90401).

E. J. Small, S. Halabi, M. A. Carducci, C. J. Ryan, D. J. George, J. F. Mahoney, W. M. Stadler, M. J. Morris, P. Kantoff, J. P. Monk, W. K. Kelly J Clin Oncol vol 30 (15 suppl) abstr 4667 2012
Abstract GU <http://meetinglibrary.asco.org/content/100283-114>

2024 Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).

Eric J Small, Susan Halabi, Nancy A Dawson, Walter M Stadler, Brian I Rini, Joel Picus, Preston Gable, Frank M Torti, Ellen Kaplan, Nicholas J Vogelzang J Clin Oncol vol 22 (6) 1025-33 2004
Manuscript GU <http://www.ncbi.nlm.nih.gov/pubmed/15020604>

2025 The reliability, validity, and sensitivity of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-chemotherapy-induced Peripheral Neuropathy (QLQ-CIPN-20).

E. M. L. Smith, Yang, J., T. Banerjee, C. Loprinzi, G. Cavaletti, C. Bridges, R. Haupt, G. Kanzawa, R. Knoerl, D. Lee-Ekblad, N. Prasertsri 2016
Abstract Symptom Inter NCCTG-N06CA, CI-PeriNomS, NCCTG-N08C1, NCCTG-N08CA, NCCTG-N08CB <https://www.mnrs.org/annual-conference/general-information>

2026 Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial

E. M. Smith, H. Pang, C. Cirrincione, S. Fleishman, E. D. Paskett, T. Ahles, L. R. Bressler, C. E. Fadul, C. Knox, N. Le-Lindqwister, P. B. Gilman, C. L. Shapiro JAMA vol 309 (13) 1359-1367 2013
Manuscript Onc Nursing <http://www.ncbi.nlm.nih.gov/pubmed/23549581>

2027 CALGB 170601: A phase III double blind trial of duloxetine to treat painful chemotherapy-induced peripheral neuropathy (CIPN)

Ellen M. Lavoie Smith, Herbert Pang, Constance Cirrincione, Stewart Barry Fleishman, Electra D. Paskett, Camilo E. Fadul, Chetaye Knox, Charles L. Shapiro, Paul Gilman J Clin Oncol vol 30 (18 suppl) abstr CRA9013 2012
Abstract Onc Nursing
http://meeting.ascopubs.org/cgi/content/abstract/30/18_suppl/CRA9013?sid=4920c7ed-8051-473c-82f7-

2028 Rasch model-based testing of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy (QLQ-CIPN20) using Alliance for Clinical Trials in Oncology (Alliance) A151408 study data

Ellen M. Lavoie Smith, Noah Zanzville, Grace Kanzawa-Lee, Clare Donohoe, Celia Bridges, Charles Loprinzi, Jennifer Le-Rademacher, James J. Yang Support Care Cancer vol 27 (7) 2599-2608 2019
Manuscript Symptom Inter NCCTG-N06CA, NCCTG-N08C1, NCCTG-N08CA, NCCTG-N08CB
<http://www.ncbi.nlm.nih.gov/pubmed/30460399>

2029 Efficacy and safety of zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: Results of CALGB 90202 (Alliance)

M. R. Smith, S. Halabi, C. J. Ryan, W. M. Stadler, A. Hussain, N. J. Vogelzang, R. J. Hauke, B. L. Sanford, E. J. Small J Clin Oncol vol 31 (suppl 6) abstr 27 2013
Abstract GU <http://meetinglibrary.asco.org/content/107592-134>

- 2030 Randomized Controlled Trial of Early Zoledronic Acid in Men With Castration-Sensitive Prostate Cancer and Bone Metastases: Results of CALGB 90202 (Alliance)**
Matthew R. Smith, Susan Halabi, Charles J. Ryan, Arif Hussain, Nicholas Vogelzang, Walter Stadler, Ralph J. Hauke, J. Paul Monk, Philip Saylor, Nirmala Bhoopalam, Fred Saad, Ben Sanford, W. Kevin Kelly, Michael Morris, Eric J. Small J Clin Oncol vol 32 (11) 1143-1150 2014
Manuscript GU <http://www.ncbi.nlm.nih.gov/pubmed/24590644>
- 2031 Incidence of Brain Metastasis as First Event in Patients with Esophageal Carcinoma: A Report from Three Prospective Alliance Clinical Trials**
Ron S. Smith, Nathan R. Foster, Aminah Jatoui, Stephan D. Thomé, Robert C. Miller J Gastrointest Cancer 2022
Manuscript GI NCCTG-N0044, NCCTG-N044E, NCCTG-N0342
<http://www.ncbi.nlm.nih.gov/pubmed/36251211>
- 2032 Dosimetric evaluation of radiation exposure during I-125 vicryl mesh implants: implications for ACOSOG z4032.**
Ryan P Smith, Matthew Schuchert, Krishna Komanduri, Steven Burton, Dwight E Heron, James D Luketich, Thomas d'Amato, Rodney Landreneau Ann Surg Oncol vol 14 (12) 3610-3 2007
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/17909906>
- 2033 Galiximab, an anti-CD80 primatized monoclonal antibody, in relapsed Hodgkin lymphoma (HL): Final results of CALGB 50602**
S. M. Smith, N. L. Bartlett, J. L. Johnson, S. Jung, H. Schoder, K. T. Egan, B. D. Cheson J Clin Oncol vol 28 (15s) abstr 8039 2010
Abstract Lymphoma
http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/8039?sid=d3b2c0e6-7ab7-420f-a807-6259
- 2034 Recombinant interferon-2b added to oral cyclophosphamide either as induction or maintenance in treatment-naïve follicular lymphoma: Final Analysis of CALGB 8691**
SM Smith, J Johnson, BD Cheson, G Canellos, G Petroni, M Oken, D Duggan, D Hurd, JP Gockerman, B Parker, J Prchal, BA Peterson Leuk Lymphoma vol 50 (10) 1606-1617 2009
Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/19626540>
- 2035 Unexpected and serious toxicity observed with combined idelalisib, lenalidomide and rituximab in relapsed/refractory B cell lymphomas: Alliance A051201 and A051202**
Sonali M. Smith, Brandelyn N. Pitcher, Sin-Ho Jung, Nancy L. Bartlett, Nina Wagner-Johnston, Steven I. Park, Kristy L. Richards, Amanda F. Cashen, Bruce D. Cheson, John P. Leonard Blood vol 124 (21) Abstr 3091 2014
Abstract Lymphoma Alliance-A051201, Alliance-A051202
<http://www.bloodjournal.org/content/124/21/3091>
- 2036 Safety and Tolerability of Idelalisib, Lenalidomide, and Rituximab in Relapsed and Refractory Lymphoma: Alliance A051201 and A051202 Phase I Trials**
Sonali M. Smith, Brandelyn N. Pitcher, Sin-Ho Jung, Nancy L. Bartlett, Nina Wagner-Johnston, Steven I. Park, Kristy L. Richards, Amanda F. Cashen, Anthony Jaslowski, Scott E. Smith, Bruce D. Cheson, Eric Hsi, John P. Leonard Lancet Haematol vol 4 (4) e176-82 2017
Manuscript Lymphoma Alliance-A051201, Alliance-A051202
<http://www.ncbi.nlm.nih.gov/pubmed/28314699>
- 2037 The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance)**
Sonali M. Smith, Heiko Schöder, Jeffrey L. Johnson, Sin-Ho Jung, Nancy L. Bartlett, Bruce D. Cheson

2038 Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.

Sonali M Smith, David Grinblatt, Jeffrey L Johnson, Donna Niedzwiecki, David Rizzieri, Nancy L Bartlett, Bruce D Cheson *Br J Haematol* vol 140 (3) 313-9 2008
Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/18217897>

2039 Detection of the BRAFV600E protein in human colon carcinomas by a mutation-specific antibody

T. C. Smyrk, D. Tougeron, S. N. Thibodeau, S. Singh, A. Muranyi, K. Shanmugam, T. M. Grogan, S. R. Alberts, Q. Shi, F. A. Sinicrope *J Clin Oncol* vol 31 (15 suppl) abstr 3576 2013
Abstract Correl Sci NOS <http://meetinglibrary.asco.org/content/112943-132>

2040 Racial Differences in Survival and Response to Therapy in Patients with Metastatic Colorectal Cancer: A Secondary Analysis of CALGB/SWOG 80405 (Alliance A151931)

Rebecca A. Snyder, Jun He, Jennifer Le-Rademacher, Fang-Shu Ou, Andrew B. Dodge, Tyler J. Zemla, Electra D. Paskett, George J. Chang, Federico Innocenti, Charles Blanke, Heinz-Josef Lenz, Blase N. Polite, Alan P. Venook *Cancer* vol 127 (20) 3801-3808 2021
Manuscript Disparities CALGB-80405 <http://www.ncbi.nlm.nih.gov/pubmed/34374082>

2041 Patient-reported Adverse Events During Neoadjuvant Therapy in a Phase 2 Borderline Resectable Pancreatic Cancer Clinical Trial (Alliance A021501).

Rebecca A Snyder, Amylou C Dueck, Briant Fruth, Qian Shi, Joleen M Hubbard, Joseph M Herman, Eileen M O'Reilly, Matthew H G Katz *Ann Surg* vol 278 (4) 598-608 2023
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/37334719>

2042 Overall survival (OS) of comparing 3 vs 6 months of adjuvant (adjuv) oxaliplatin-based therapy for patients (pts) with stage III colon cancer (CC): Updated results from the IDEA (International Duration Evaluation of Adjuv chemotherapy) collaboration

Alberto F. Sobrero, Andre Thierry, Jeffrey A. Meyerhardt, Axel Grothey, Timothy Iveson, Takayuki Yoshino, John Souglakos, Jeffrey P. Meyers, Roberto Labianca, Mark Saunders, Dewi Vemerey, Takeharu Yamanaka, Ioannis Boukovinas, Eiji Oki, Vassilis Gerogoulis, Valter Torri, Andrea Harkin, Julien Taieb, Anthony F. Shields, Qian Shi *J Clin Oncol* vol 38 (15_suppl) 4004 2020
Abstract GI CALGB-80702 https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.4004

2043 Sunitinib (S) switch maintenance in advanced non-small cell lung cancer (NSCLC): An ALLIANCE (CALGB 30607), randomized, placebo-controlled phase III trial.

Mark A. Socinski, Xiaofei F. Wang, Maria Quintos Baggstrom, Lin Gu, Thomas E. Stinchcombe, Martin J. Edelman, Sherman Baker JR, Heather Dorothy Manuel, Jeffrey Crawford, Everett E. Vokes *J Clin Oncol* vol 32 (5s) (suppl; abstr 8040) 2014
Abstract Respiratory http://abstracts.asco.org/144/AbstView_144_128285.html

2044 Switch Maintenance with Sunitinib (S) in Advanced Non-Small Cell Lung Cancer (NSCLC): An Alliance (CALGB 30607), Randomized, Placebo-controlled Phase III Trial

Mark A. Socinski, Xiaofei F. Wang, Maria Quintos Baggstrom, Lin Gu, Thomas E. Stinchcombe, Martin J. Edelman, Sherman Baker, Heather Dorothy Manuel, Jeffrey Crawford, Everett E. Vokes *Int J Radiat Oncol Biol Phys* vol 90 (5) abstr S1 2014
Abstract Respiratory <http://www.redjournal.org/article/S0360-3016%2814%2903704-3/abstract>

2045 Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer:

CALGB 30105.

Mark A Socinski, A William Blackstock, Jeffrey A Bogart, Xiaofei Wang, Michael Munley, Julian Rosenman, Lin Gu, Gregory A Masters, Peter Ungaro, Arthur Sleeper, Mark Green, Antonius A Miller, Everett E Vokes *J Clin Oncol* vol 26 (15) 2457-63 2008
Manuscript *Respiratory* <http://www.ncbi.nlm.nih.gov/pubmed/18487565>

2046 Biomarkers for Risk Stratification in Patients with Previously Untreated Follicular Lymphoma Receiving Anti-CD20-Based Biologic Therapy

Aliyah R. Sohani, Matthew J. Maurer, Sharmila Giri, Brandelyn Pitcher, Amy Chadburn, Jonathan W. Said, Nancy L. Bartlett, Myron S. Czuczman, Peter Martin, Cara A. Rosenbaum, Sin-Ho Jung, John P. Leonard, Bruce D. Cheson, Eric D. Hsi *Am J Surg Pathol* vol 45 (3) 384-93 2021
Manuscript *Correl Sci NOS* CALGB-50402, CALGB-50701, CALGB-50803, CALGB-50901
<http://www.ncbi.nlm.nih.gov/pubmed/33136585>

2047 Interfollicular CD10 Expression and Follicular PD1 Tumor-infiltrating lymphocytes as biologic risk factors in patients with previously untreated follicular lymphoma receiving rituximab-based biologic therapy: An Alliance correlative science study (CALGB 50901, 50402, 50701, 50803, 50401)

Aliyah R. Sohani, Brandy Pitcher, Amy Chadburn, Jonathan Said, Peter Martin, Myron S. Czuczman, Nancy Bartlett, Cara Rosenbaum, John P. Leonard, Bruce D. Cheson, Eric D. Hsi *Blood* vol 126 (23) abstr 334 2015
Abstract *Correl Sci NOS* CALGB-50401, CALGB-50402, CALGB-50701, CALGB-50803, CALGB-50901 <http://www.bloodjournal.org/content/126/23/334>

2048 Management of recurrent prostate cancer after radiotherapy: Results from CALGB 9687, a contemporary prospective multi-institutional salvage radical prostatectomy series

M. H. Sokoloff, G. D. Steinberg, S. Halabi, B. L. Sanford, J. A. Eastham, J. L. Mohler, P. J. Walther, P. R. Carroll, N. J. Vogelzang, E. J. Small *J Urol* vol 179 (4) 647 2008
Abstract *GU*
http://ac.els-cdn.com/S0022534708618923/1-s2.0-S0022534708618923-main.pdf?_tid=d5a3de1c-449a-1

2049 The impact of initial fludarabine therapy on transformation to Richter syndrome or prolymphocytic leukemia in patients with chronic lymphocytic leukemia: analysis of an intergroup trial (CALGB 9011).

Melhem Solh, Kanti R Rai, Bercedis L Peterson, Jonathan E Kolitz, Frederick R Appelbaum, Martin S Tallman, Andrew Belch, Richard A Larson, Vicki A Morrison *Leuk Lymphoma* vol 54 (2) 252-4 2013
Manuscript *Leukemia* <http://www.ncbi.nlm.nih.gov/pubmed/22897733>

2050 Utilizing cultural and ethnic variables in a survey to identify individuals at high risk for gastric cancer

I. Solsky, M. Parides, C. Schechter, B. Rapkin, H. In *J Clin Oncol* vol 37 (Suppl 4) abstr 23 2019
Abstract *Disparities* https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.4_suppl.23

2051 Cultural and ethnic variables improve a survey's ability to identify individuals at high risk for gastric cancer

Ian Solsky, Michael Parides, Clyde Schechter, Bruce Rapkin, Haejin In *Annals of Surgical Oncology* vol 26 (Supplement 1) S192-S193 2019
Abstract *Disparities* <https://link.springer.com/content/pdf/10.1245/s10434-019-07174-5.pdf>

2052 Development of a Personalized mHealth Program for Cancer Symptom and Complication Management.

Lixin Song, Eno Idiagbonya, Kevin Su, Juliet Idiagbonya *Stud Health Technol Inform* vol 270 1255-6 2020

- 2053 Marine omega-3 fatty acid intake and survival of stage III colon cancer according to tumor molecular markers in NCCTG Phase III trial N0147 (Alliance)**
Mingyang Song, Fang-Shu Ou, Tyler J. Zemla, Mark A. Hull, Qian Shi, Paul J. Limburg, Steven R. Alberts, Frank A. Sinicrope, Edward L. Giovannucci, Erin L Van Blarigan, Jeffrey A. Meyerhardt, Andrew T. Chan *Int J Cancer* vol 145 (2) 380-9 2019
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/30623420>
- 2054 Postdiagnosis marine omega-3 fatty acid intake and survival of stage III colon cancer in North Central Cancer Treatment Group phase III trial N0147 (Alliance)**
Mingyang Song, Fang-Shu Ou, Tyler J. Zemla, Qian Shi, Paul J. Limburg, Steven R. Alberts, Edward L. Giovannucci, Jeffrey A. Meyerhardt, Andrew T. Chan *Gastroenterology* vol 154 (6) S-787-S-788 2018
Abstract GI [https://www.gastrojournal.org/article/S0016-5085\(18\)32712-4/pdf](https://www.gastrojournal.org/article/S0016-5085(18)32712-4/pdf)
- 2055 A Pooled Analysis to the Prognosis and Predictive value of EGFR mutation on Survival in Patients with KRAS wild-type Lung Adenocarcinoma.**
Jean-Charles Soria, Elisabeth Brambilla, Gwénaél Le Teuff, Ming S. Tsao, Pasi A. Janne, Pierre Hainaut, Miquel Taron, Robert A. Kratzke, Frances A. Shepherd, Jean-Pierre Pignon *J Thorac Oncol* vol 6 (6) S617 2011
Abstract Respiratory <http://journals.lww.com/jto/Citation/2011/06001/Abstracts.1.aspx>
- 2056 Assessing the Impact of a Cooperative Group Trial on Breast Cancer Care in the Medicare Population**
Pamela R. Soulos, James B. Yu, Kenneth B. Roberts, Ann C. Raldow, Jeph Herrin, Jessica B. Long, Cary P. Gross *J Clin Oncol* vol 30 (14) 1601-1607 2012
Manuscript Older Adult <http://www.ncbi.nlm.nih.gov/pubmed/22393088>
- 2057 Effects of age, immune landscape, and response to trastuzumab (H) in HER-2 positive (HER2+) breast cancer in NCCTG (Alliance)-N9831.**
Aixa Elena Soyano, Daniel Serie, Afshin Mashadi-Hosseini, Sarah Warren, Gerardo Colon-Otero, Keith L. Knutson, Edith A. Perez, Alvaro Moreno-Aspitia, E Aubrey Thompson, Saranya Chumsri *JCO* vol 35 (no. 15_suppl) 530 2017
Abstract Breast
http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.530#affiliationsContainer
- 2058 Which patient will feel down, which will be happy? The need to study the genetic disposition of emotional states**
Mirjam A. G. Sprangers, Meike Bartels, Ruut Veenhoven, Frank Baas, Nicholas G. Martin, Miriam Mosing, Benjamin Movsas, Mary E. Ropka, Gen Shinozaki, Dick Swaab *Qual Life Res* vol 19 (10) 1429-1437 2010
Manuscript Health Outcomes <http://www.ncbi.nlm.nih.gov/pubmed/20419396>
- 2059 Scientific imperatives, clinical implications, and theoretical underpinnings for the investigation of the relationship between genetic variables and patient-reported quality-of-life outcomes**
Mirjam A. G. Sprangers, Jeff A. Sloan, Andrea Barsevick, Cynthia Chauhan, Amylou C. Dueck, Hein Raat, Quiling Shi, Cornelis J. F. Van Noorden *Qual Life Res* vol 19 (10) 1395-403 2010
Manuscript Health Outcomes <http://www.ncbi.nlm.nih.gov/pubmed/20945161>
- 2060 Outcomes for Patients with Residual Stage II/III Breast Cancer Following Neoadjuvant Chemotherapy (AFT-01)**
TJ Stankowski-Drengler, JR Schumacher, B Hanlon, D Livingston-Rosanoff, K Vande Walle, CC

2061 A Survey of Survivors

Stark, Nancy Appl Clin Trials vol 16 (7) 48-50,52,54. 2007
Manuscript Health Outcomes

2062 Current Utilization and Surgical Efficacy of Laparoscopic Colectomy in Colon Cancer

Robert P Sticca, Steven R Alberts, Michelle R Mahoney, Daniel J Sargent, Lisa M Finstuen, Garth D Nelson, Timothy M Husted, Jan Franko, Charles D Goldman, Barbara A Pockaj J Am Coll Surg vol 217 (1) 56-63 2013
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/23623224>

2063 Treatment outcomes of different prognostic groups of patients on cancer and leukemia group B trial 39801: induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for unresectable stage III non-small cell lung cancer

T. E. Stinchcombe, L. Hodgson, J. E. Herndon 2nd, M. J. Kelley, M. G. Cicchetti, N. Ramnath, H. B. Niell, J. N. Atkins, W. Akerley, M. R. Green, E. E. Vokes, Cancer, B. Leukemia Group J Thorac Oncol vol 4 (9) 1117-1125 2009
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/19652624>

2064 Clinical factors predictive of overall survival (OS) and the identification of prognostic groups in patients (pts) with unresectable stage III non-small cell lung cancer (NSCLC) treated with chemoradiotherapy on Cancer and Leukemia and Group B trial (CALGB) 39801

T. E. Stinchcombe, L. Hodgson, J. E. Herndon 2nd, M. J. Kelley, M. Cicchetti, N. Ramnath, H. B. Niell, J. N. Atkins, M. R. Green, E. E. Vokes J Clin Oncol vol 27 (15) abstr 7535 2009
Abstract Respiratory
<http://meeting.ascopubs.org/gca?allch=&submit=Go&gca=ascomtg%3B27%2F15S%2F7535>

2065 An analysis of the prevalence of HER2 and KRAS mutations, and ALK rearrangements and clinical outcomes in Cancer and Leukemia Group B [CALGB (Alliance)] trial 30406 in advanced non-small cell lung cancer (NSCLC)

T. E. Stinchcombe, L. M. Sholl, X. Wang, L. Gu, M. A. Socinski, S. J. Rodig, M. Capelletti, J. Crawford, M. J. Edelman, M. L. A. Villalona-Calero, R. Kratzke, E. E. Vokes, V. A. Miller, P. A. Janne J Clin Oncol vol 31 (15 suppl) abstr 8039 2013
Abstract Respiratory
http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/8039?sid=7a0ce0eb-b5ee-4fdc-a77f-71be7

2066 Risk factors for distant recurrence and brain metastases observed on American College of Surgical Oncology Group trial Z0030: Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) Non- Small Cell Lung Cancer (NSCLC)

Thomas E. Stinchcombe, Paul A. Decker, Gail E. Darling, Mark S. Allen, Joe B. Putnam Jr J Thorac Oncol vol 4 (9 suppl 1) abstr PD12.11.16 2009
Abstract Respiratory [http://www.jto.org/article/S1556-0864\(15\)33608-X/fulltext](http://www.jto.org/article/S1556-0864(15)33608-X/fulltext)

2067 Phase II trial of paclitaxel and cisplatin in patients with extensive stage small cell lung cancer: Cancer and Leukemia Group B trial 9430

Thomas E. Stinchcombe, Ann M. Mauer, Lydia D. Hodgson, James E. Herndon, Thomas J. Lynch, Mark. R. Green, Everett E. Vokes J Thorac Oncol vol 3 (11) 1301-1307 2008
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/18978566>

2068 Prognostic significance of initial clinical and molecular genetic features of acute promyelocytic

leukemia (APL): Results from the North American Intergroup Trial, C9710

W. Stock, B. K. Moser, B. L. Powell, F. Appelbaum, M. Tallman, R. A. Larson, J. Feusner, C. D. Bloomfield, C. Willman, R. Gallagher J Clin Oncol vol 25 (18s) abstr 7016 2007
Abstract Leuk Corr Sci CALGB-9710, CALGB-8461, CALGB-9665
http://meeting.ascopubs.org/cgi/content/short/25/18_suppl/7016

2069 High incidence of FLT3 mutations in adults with Acute Promyelocytic Leukemia (APL): Correlation with diagnostic features and treatment outcome (CALGB 9710)

W. Stock, K. Najib, B. K. Moser, N. Holowka, B. L. Powell, K. Gulati, C. D. Bloomfield, R. A. Larson, D. A. Sher J Clin Oncol vol 26 (suppl) abstr 7002 2008
Abstract Leuk Corr Sci CALGB-9710, CALGB-9665
http://meeting.ascopubs.org/cgi/content/short/26/15_suppl/7002

2070 Alemtuzumab can be Incorporated Into Front-Line Therapy of Adult Acute Lymphoblastic Leukemia (ALL): Final Phase I Results of a Cancer and Leukemia Group B Study (CALGB 10102)

W. Stock, B. Sanford, G. Lozanski, R. Vij, J. C. Byrd, B. L. Powell, M. Wetzler, D. Sher, C. Edwards, M. Kelly, S. Richards, C. Sung, G. Malnassy, E. Hoke, C. D. Bloomfield, R. A. Larson Blood vol 114 (22) 345-345 2009
Abstract Leukemia <http://www.bloodjournal.org/content/114/22/838.full>

2071 An inherited genetic variant in CEP72 promoter predisposes to vincristine-induced peripheral neuropathy in adults with acute lymphoblastic leukemia

Wendy Stock, Barthelemy Diouf, Kristine R. Crews, Deqing Pei, Cheng Cheng, Kristina Laumann, Sumithra J. Mandrekar, Selina Luger, Anjali Advani, Richard M. Stone, Richard A. Larson, William E. Evans Clin Pharmacol Ther vol 101 (3) 391-5 2017
Manuscript Leukemia CALGB-10102, CALGB-10403, CALGB-19802, CALGB-9862
<http://www.ncbi.nlm.nih.gov/pubmed/27618250>

2072 Dose Intensification of Daunorubicin and Cytarabine during Treatment of Adult Acute Lymphoblastic Leukemia: Results of Cancer and Leukemia Group B Study 19802

Wendy Stock, Jeffrey L. Johnson, Richard M. Stone, Jonathan E. Kolitz, Bayard L. Powell, Meir Wetzler, Peter Westervelt, Guido Marcucci, Daniel J. DeAngelo, James W. Vardiman, Diane McDonnell, Krzysztof Mrózek, Clara D. Bloomfield, Richard A. Larson Cancer vol 119 (1) 90-98 2013
Manuscript Leukemia <http://www.ncbi.nlm.nih.gov/pubmed/22744771>

2073 What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies

Wendy Stock, Mei La, Ben Sanford, Clara D. Bloomfield, James W. Vardiman, Paul Gaynon, Richard A. Larson, James Nachman Blood vol 112 (5) 1646-54 2008
Manuscript Leukemia CALGB-8811, CALGB-9331, CALGB-19802, CALGB-8461, CALGB-9111, CALGB-9511 <http://www.ncbi.nlm.nih.gov/pubmed/18502832>

2074 A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403

Wendy Stock, Selina M. Luger, Anjali S. Advani, Jun Yin, Richard C. Harvey, Charles G. Mullighan, Cheryl L. Willman, Noreen Fulton, Kristina M. Laumann, Greg Malnassy, Elisabeth Paietta, Edy Parker, Susan Geyer, Krzysztof Mrózek, Clara D. Bloomfield, Ben Sanford, Guido Marcucci, Michaela Liedtke, David F. Claxton, Matthew C. Foster, Jeffrey A. Bogart, John C. Greco, Frederick R. Appelbaum, Harry Erba, Mark R. Litzow, Martin S. Tallman, Richard M. Stone, Richard A. Larson Blood vol 133 (14) 1548-59 2019
Manuscript Leukemia <http://www.ncbi.nlm.nih.gov/pubmed/30658992>

2075 Favorable outcomes for adolescents and young adults (AYA) with Acute Lymphoblastic Leukemia (ALL): Early results of US Intergroup trial CALGB 10403 (Alliance)

Wendy Stock, Selina Luger, Anjali Advani, Susan Geyer, Richard Harvey, Charles Mullighan, Cheryl Willman, Edy Parker, Kristina Laumann, Ben Sanford, Guido Marcucci, Elizabeth Paietta, Martin S. Tallman, Frederick R. Appelbaum, Harry P. Erba, Mark Litzow, Richard M. Stone, Richard A. Larson
Blood vol 124 (21) abstr 796 2014
Abstract Leukemia CALGB-10403 <http://www.bloodjournal.org/content/124/21/796>

2076 CALGB 10603 (RATIFY): A randomized phase III study of induction (daunorubicin/cytarabine) and consolidation (high-dose cytarabine) chemotherapy combined with midostaurin or placebo in treatment-naïve patients with FLT3 mutated AML

R. M. Stone, H. Dohner, G. Ehninger, M. Villeneuve, T. Teasdale, J. D. Virkus, L. R. Bressler, M. M. Seiler, G. Marcucci, R. A. Larson J Clin Oncol vol 29 (supplement) abstr TPS199 2011
Abstract Leukemia
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID

2077 Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

Richard M. Stone, Sumithra J. Mandrekar, Ben L. Sanford, Kristina Laumann, Susan Geyer, Clara D. Bloomfield, Christian Thiede, Thomas W. Prior, Konstanze Döhner, Guido Marcucci, Francesco Lo-Coco, Rebecca B. Klisovic, Andrew Wei, Jorge Sierra, Miguel A. Sanz, Joseph M. Brandwein, Theo de Witte, Dietger Niederwieser, Frederick R. Appelbaum, Bruno C. Medeiros, Martin S. Tallman, Jürgen Krauter, Richard F. Schlenk, Arnold Ganser, Hubert Serve, Gerhard Ehninger, Sergio Amadori, Richard A. Larson, Hartmut Döhner N Engl J Med vol 377 (5) 454-464 2017
Manuscript Leukemia <http://www.ncbi.nlm.nih.gov/pubmed/28644114>

2078 The Addition of Midostaurin to Standard Chemotherapy Decreases Cumulative Incidence of Relapse (CIR) in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603 / RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with FLT3 Mutations

Richard M. Stone, Sumithra Mandrekar, Ben L Sanford, Susan Geyer, Clara D. Bloomfield, Konstanze Dohner, Christian Thiede, Guido Marcucci, Francesco Lo-Coco, Rebecca B. Klisovic, Andrew Wei, Jorge Sierra, Miguel A. Sanz, Joseph M. Brandwein, Theo de Witte, Dietger Niederwieser, Frederick R. Appelbaum, Bruno C. Medeiros, Martin S. Tallman, Jürgen Krauter, *Richard F. Schlenk, Arnold Ganser, Hubert Serve, Gerhard Ehninger, Sergio Amadori, Hartmut Dohner, Richard A. Larson Blood vol 130 (Suppl 1) 2580 2017
Abstract Leukemia http://www.bloodjournal.org/content/130/Suppl_1/2580

2079 Midostaurin v Placebo plus Daunorubicin/Cytarabine Induction, High-dose Cytarabine Consolidation and Maintenance Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients (pts) age 18-60 with FLT3 mutations: An International Prospective Randomized Placebo-Controlled Double-Blind Trial (CALGB 10603 [Alliance])

Richard M. Stone, Sumithra Mandrekar, Ben L Sanford, Susan Geyer, Clara D. Bloomfield, Konstanze Dohner, Christian Thiede, Guido Marcucci, Francesco Lo-Coco, Rebecca B. Klisovic, Andrew Wei, Jorge Sierra, Miguel A. Sanz, Joseph M. Brandwein, Theo de Witte, Dietger Niederwieser, Frederick R. Appelbaum, Bruno C. Medeiros, Martin S Tallman, Jürgen Krauter, Richard F. Schlenk, Arnold Ganser, Hubert Serve, Gerhard Ehninger, Sergio Amadori, Richard A. Larson, Hartmut Dohner Blood vol 126 (23) 6 2015
Abstract Leukemia <http://www.bloodjournal.org/content/126/23/6.abstract>

2080 High Dose Cytarabine plus Gemtuzumab Ozogamicin for Patients with Relapsed or Refractory Acute Myeloid Leukemia: Cancer and Leukemia Group B Study 19902

Richard M. Stone, Barry Moser, Ben Sanford, Philip Schulman, Jonathan E. Kolitz, Steven Allen,

Wendy Stock, Ilene Galinsky, Ravi Vij, Guido Marcucci, David Hurd, Richard A. Larson *Leuk Res* vol 35 (3) 329-333 2011
Manuscript *Leukemia* <http://www.ncbi.nlm.nih.gov/pubmed/20688393>

2081 A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804.

Richard M Stone, Kathleen A Donohue, Wendy Stock, Vera Hars, Charles A Linker, Thomas Shea, Daniel J Deangelo, Guido Marcucci, Clara D Bloomfield, Richard A Larson *Cancer Chemother Pharmacol* vol 63 (5) 859-64 2009
Manuscript *Leukemia* <http://www.ncbi.nlm.nih.gov/pubmed/18670778>

2082 Doxorubicin, vinblastine and gemcitabine (AVG), a novel regimen excluding bleomycin for the treatment of early stage Hodgkin Lymphoma (HL): Results of CALGB 50203

D. J. Straus, A. S. Lacasce, M. E. Juweid, L. Kostakoglu, N. C. Hall, J. L. Johnson, S. Jung, G. P. Canellos, L. Schwartz, B. D. Cheson *Blood* vol 110 (11) abstr 214 2007
Abstract *Lymphoma* http://www.abstracts2view.com/hem07/view.php?nu=HEM07L1_1040&terms

2083 Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET

David J. Straus, Jeffrey L. Johnson, Ann S. LaCasce, Nancy L. Bartlett, Lale Kostakoglu, Eric D. Hsi, Heiko Schöder, Nathan C. Hall, Sin-Ho Jung, George P. Canellos, Lawrence H. Schwartz, Ronald W. Takvorian, Malik E. Juweid, Bruce D. Cheson *Blood* vol 117 (20) 5314-5320 2011
Manuscript *Lymphoma* <http://www.ncbi.nlm.nih.gov/pubmed/21355087>

2084 CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET

David J. Straus, Sin-Ho Jung, Brandelyn Pitcher, Lale Kostakoglu, John C. Grecula, Eric D. Hsi, Heiko Schöder, Leslie L. Popplewell, Julie E. Chang, Craig H. Moskowitz, Nina Wagner-Johnston, John P. Leonard, Jonathan W. Friedberg, Brad S. Kahl, Bruce D. Cheson, Nancy L. Bartlett *Blood* vol 132 (10) 1013-21 2018
Manuscript *Lymphoma* <http://www.ncbi.nlm.nih.gov/pubmed/30049811>

2085 Initial results of US Intergroup Trial of Response-Adapted Chemotherapy Based on PET for Non-Bulky Stage I and II Hodgkin Lymphoma (HL) (CALGB/Alliance 50604)

David J. Straus, Brandelyn N. Pitcher, Lale Kostakoglu, John C. Grecula, Eric Hsi, Heiko Schöder, Sin-Ho Jung, Leslie L. Popplewell, John P. Leonard, Jonathan W. Friedberg, Brad S. Kahl, Bruce D. Cheson, Nancy L. Bartlett *Blood* vol 126 (23) abstr 578 2015
Abstract *Lymphoma* <http://www.bloodjournal.org/content/126/23/578?sso-checked=true>

2086 Adjuvant chemotherapy (AC) in stage IB non-small cell lung cancer (NSCLC): Long-term follow-up of Cancer and Leukemia Group B (CALGB) 9633

G. M. Strauss, X. Wang, M. A. Maddaus, D. W. Johnstone, E. A. Johnson, D. H. Harpole, H. Gillenwater, L. Gu, D. J. Sugarbaker, M. R. Green, S. L. Graziano, R. A. Kratzke, R. L. Schilsky, J. Crawford, E. E. Vokes *J Clin Oncol* vol 29 (15s) abstr 7015 2011
Abstract *Respiratory* http://meeting.ascopubs.org/cgi/content/abstract/29/15_suppl/7015?sid=350a6f5a-3df6-4aa5-8dc3-8f6da

2087 Adjuvant Paclitaxel Plus Carboplatin Compared With Observation in Stage IB Non-Small-Cell Lung Cancer: CALGB 9633 With the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups

Gary M. Strauss, James E. Herndon, Michael A. Maddaus, David W. Johnstone, Elizabeth A. Johnson, David H. Harpole, Heidi H. Gillenwater, Dorothy M. Watson, David J. Sugarbaker, Richard L. Schilsky, Everett E. Vokes, Mark R. Green *J Clin Oncol* vol 26 (31) 5043-5051 2008

2088 Individual Item Analysis of Quality of Life Assessments Related to Laparoscopic-assisted Colectomy in the COST Trial 93-46-53 (INT 0146)

C. H. Stucky, B. A. Pockaj, P. A. Novotny, J. A. Sloan, D. J. Sargent, M. J. O'Connell, R. W. Beart Jr, J. Skibber, H. Nelson, J. C. Weeks *Ann Surg Oncol* vol 17 (Supplement 1) S36 abstr 93 2010
Abstract GI <http://link.springer.com/content/pdf/10.1245%2Fs10434-009-0903-9>

2089 Long-Term Follow-Up and Individual Item Analysis of Quality of Life Assessments Related to Laparoscopic-Assisted Colectomy in the COST Trial 93-46-53 (INT 0146)

Chee-Chee H. Stucky, Barbara A. Pockaj, Paul J. Novotny, Jeff A. Sloan, Daniel J. Sargent, Michael J. O'Connell, Robert W. Beart, John M. Skibber, Heidi Nelson, Jane C. Weeks *Ann Surg Oncol* vol 18 (9) 2422-2431 2011
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/21452066>

2090 Long-term surgical outcomes of 1018 patients with early stage NSCLC in ACOSOG Z0030 trial

S. Su, W. J. Scott, M. S. Allen, G. E. Darling, P. A. Decker, R. J. McKenna Jr, R. J. Landreneau, D. R. Jones, R. I. Incullet, B. F. Meyers 2013
Abstract Respiratory <http://www.aats.org/annualmeeting/Program-Books/2013/LB6.cgi>

2091 Patterns of survival and recurrence after surgical treatment of early stage non-small cell lung carcinoma in the ACOSOG Z0030 (Alliance) trial

Stacey Su, Walter J Scott, Mark S Allen, Gail E Darling, Paul A Decker, Robert J McKenna, Bryan F Meyers *J Thorac Cardiovasc Surg* vol 147 (2) 747-52: Discussion 752-3 2014
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/24290575>

2092 Genome-Wide Meta-Analyses Identifies Novel Taxane-Induced Peripheral Neuropathy Associated Loci

L E Sucheston-Campbell, A I Clay-Gilmour, W E Barlow, G T Budd, D O Stram, C A Haiman, X Sheng, L Yan, G Zirpoli, S Yao, C Jiang, K Owzar, D Hershman, K S Albain, D F Hayes, H C Moore, T J Hobday, J A Stewart, A Rizvi, C Isaacs, Muhammad Salim, J R Gralow, G N Hortobagyi, R B Livingston, D L Kroetz, C B Ambrosone *Pharmacogenet Genomics* vol 28 (2) 49-55 2018
Manuscript PPP CALGB-40101, SWOG-S0221 <http://www.ncbi.nlm.nih.gov/pubmed/29278617>

2093 Benefit of adjuvant trastuzumab in breast cancer patients with focal HER2 amplified clones: Data from N9831 Intergroup Adjuvant Trial

W. R. Sukov, D. V. Miller, A. C. Dueck, K. S. Tenner, R. B. Jenkins, P. A. Kaufman, N. E. Davidson, S. R. Dakhil, S. Martino, V. Roy, E. A. Perez *J Clin Oncol* vol 27 (15) abst 520 2009
Abstract Breast
<http://meeting.ascopubs.org/gca?allch=&submit=Go&gca=ascomtg%3B27%2F15S%2F520>

2094 Episodic future thinking: A behavioral intervention to promote weight loss in breast cancer survivors.

Jasmine S Sukumar, Jennifer Vaughn, Jeffrey Stein, Patrick Schnell, Preeti Khetarpal Sudheendra, Ashley Pariser, Margaret Elena Gatti-Mays, Nicole Olivia Williams, Mathew Amprayil Cherian, Daniel G. Stover, Robert Wesolowski, Bhuvanewari Ramaswamy, Maryam B. Lustberg, Sagar D. Sardesai *J Clin Oncol* vol 40 (16_suppl) TPS12139-TPS12139 2022
Abstract Prevention https://ascopubs.org/doi/pdf/10.1200/JCO.2022.40.16_suppl.TPS12139

2095 Evaluation of sensitivity to endocrine therapy index (SET2,3) for response to neoadjuvant endocrine therapy and longer-term breast cancer patient outcomes (Alliance Z1031)

Vera J. Suman, Lili Du, Tanya Hoskin, Meenakshi Anurag, Cynthia Ma, Isabelle Bedrosian, Kelly K.

Hunt, Matthew J. Ellis, W. Fraser Symmans Clin Cancer Res vol 28 (15) 3287-95 2022
Manuscript Correl Sci NOS ACOSOG-Z1031 <http://www.ncbi.nlm.nih.gov/pubmed/35653124>

2096 The ALTERNATE trial: assessing a biomarker driven strategy for the treatment of post-menopausal women with ER+/Her2 invasive breast cancer

Vera Jean Suman, Matthew J. Ellis, Cynthia X. Ma Chin Clin Oncol vol 4 (3) 34 2015
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/26408301>

2097 Molecular features of prostate cancer post-neoadjuvant therapy in the Phase 3 CALGB 90203 trial.

Takayuki Sumiyoshi, Xiaofei Wang, Evan W Warner, Andrea Sboner, Matti Annala, Michael Sigouros, Kevin Beja, Kei Mizuno, Shengyu Ku, Ladan Fazli, James Eastham, Mary-Ellen Taplin, Jeffrey Simko, Susan Halabi, Michael J Morris, Martin E Gleave, Alexander W Wyatt, Himisha Beltran J Natl Cancer Inst 2023
Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/37676819>

2098 Estimation of historical control rate for a single arm de-escalation study - Application to the POSITIVE trial.

Zhuoxin Sun, Samuel M Niman, Olivia Pagani, Ann H Partridge, Hatem A Azim Jr, Fedro A Peccatori, Monica Ruggeri, Angelo Di Leo, Marco Colleoni, Richard D Gelber, Meredith M Regan Breast vol 53 1-7 2020
Manuscript Symptom Inter IBSCG 48-14 <http://www.ncbi.nlm.nih.gov/pubmed/32535486>

2099 Results of CALGB 39802: feasibility of video-assisted thoracic surgery (VATS) lobectomy for early stage lung cancer

S. J. Swanson, J. Herndon 2nd, A. D'Amico, T. Demmy, R. Mckenna, M. Green, D. Sugarbaker Proc Am Soc Clin Oncol vol 21 abstr 1158 2002
Abstract Respiratory
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=16&abstractID

2100 Video-assisted thoracic surgery lobectomy: report of CALGB 39802--a prospective, multi-institution feasibility study.

Scott J Swanson, James E Herndon, Thomas A D'Amico, Todd L Demmy, Robert J McKenna, Mark R Green, David J Sugarbaker J Clin Oncol vol 25 (31) 4993-7 2007
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/17971599>

2101 Evaluation of the sensitivity to endocrine therapy index (SET2,3) for response to neoadjuvant endocrine therapy (NET) and subsequent prognosis. (Alliance)

W. Fraser Symmans, Lili Du, Tanya Hoskin, Meenakshi Anurag, Cynthia Ma, Isabelle Bedrosian, Kelly Hunt, Matthew Ellis, Vera J Suman. J Clin Oncol vol 39 (no. 15_suppl) 580 2021
Abstract Correl Sci NOS https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.580

2102 Evaluation of methylated DCR1 as a biomarker for response to adjuvant irinotecan-based therapy in stage III colon cancer: cancer and leukaemia Group B 89803 (Alliance)

Lynn Symonds, Ming Yu, YuHong Zhang, Fang-Shu Ou, Tyler J. Zemla, Kelly Carter, Monica Bertagnolli, Federico Innocenti, Linda JW Bosch, Gerrit A Meijer, Beatriz Carvalho, William M. Grady, Stacey A. Cohen Epigenetics vol 17 (12) 1715-25 2022
Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/35412430>

2103 Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer

Julien Taieb, Karine Le Malicot, Qian Shi, Frédérique Penault-Llorca, Olivier Bouché, Josep Tabernero, Enrico Mini, Richard M. Goldberg, Gunnar Folprecht, Jean Luc Van Laethem, Daniel J. Sargent, Steven R. Alberts, Jean Francois Emile, Pierre Laurent Puig, Frank A. Sinicrope J Natl

2104 Prognostic value of BRAF V600E and KRAS exon 2 mutations in microsatellite stable (MSS), stage III colon cancers (CC) from patients (pts) treated with adjuvant FOLFOX+/- cetuximab: A pooled analysis of 3934 pts from the PETACC8 and N0147 trials

Julien Taieb, Karine Le Malicot, Frederique Madeleine Penault-Llorca, Olivier Bouche, Qian Shi, Stephen N. Thibodeau, Josep Tabernero, Enrico Mini, Richard M. Goldberg, Gunnar Folprecht, Jean-Luc Van Laethem, Daniel J. Sargent, Steven R. Alberts, Pierre Laurent-Puig, Frank A. Sinicrope
J Clin Oncol vol 33 (suppl) abstr 3507 2015

Abstract Correl Sci NOS http://ascopubs.org/doi/abs/10.1200/jco.2015.33.15_suppl.3507

2105 Frequency and impact of grade three or four toxicities of novel agents on outcomes of older patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma (alliance A151611)

Michael Tallarico, Jared C. Foster, Drew Seisler, Jacqueline M. Lafky, Arti Hurria, Aminah Jatoi, Harvey J. Cohen, Hyman B. Muss, Nancy Bartlett, Bruce D. Cheson, Sin-Ho Jung, John P. Leonard, John C. Byrd, Chadi Nabhan J Geriatr Oncol vol 9 (4) 321-28 2018

Manuscript Older Adult <http://www.ncbi.nlm.nih.gov/pubmed/29673807>

2106 Toxicities and related outcomes of elderly patients (65 years) with hematologic malignancies in the contemporary era (Alliance A151611)

Michael Tallarico, Jared Foster, Drew Seisler, Jacqueline M. Lafky, Arti Hurria, Aminah Jatoi, Harvey J. Cohen, Hyman B. Muss, Nancy Bartlett, Bruce D. Cheson, Sin-Ho Chung, John Byrd, John P. Leonard, Chadi Nabhan Blood vol 128 (22) abstr 536 2016

Abstract Older Adult CALGB-10101, CALGB-10404, CALGB-10501, CALGB-19805, CALGB-19901, CALGB-50002, CALGB-50103, CALGB-50201, CALGB-50401, CALGB-50402, CALGB-50501, CALGB-50602, CALGB-50701, CALGB-50803

<http://www.bloodjournal.org/content/128/22/536>

2107 Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group

M. S. Tallman, H. T. Kim, P. Montesinos, F. R. Appelbaum, J. De La Serna, J. M. Bennett, G. Deben, C. D. Bloomfield, J. Gonzalez, J. H. Feusner, M. Gonzalez, R. Gallagher, J. D. Miguel, R. A. Larson, G. Milone, E. Paietta, C. Rayon, J. M. Rowe, C. Rivas, C. A. Schiffer, E. Vellenga, L. Shepherd, J. L. Slack, P. H. Wiernik, C. L. Willman, M. A. Sanz Blood vol 116 (25) 5650-5659 2010

Manuscript Leukemia <http://www.ncbi.nlm.nih.gov/pubmed/20858857>

2108 QOL and Survival Comparisons by Race in Oncology Clinical Trials

AD Tan, PJ Novotny, JS Kaur, JC Buckner, RB Mowat, E Paskett, JA Sloan J Cancer Clin Oncol vol 2 (1) 2016

Manuscript Disparities NCCTG-N0621, NCCTG-N0691

<http://www.ncbi.nlm.nih.gov/pubmed/28691116>

2109 N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial.

W W Tan, D W Hillman, M Salim, D W Northfelt, D M Anderson, P J Stella, R Niedringhaus, A M Bernath, S S Gamini, F Palmieri, E A Perez Ann Oncol vol 21 (3) 493-7 2010

Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/19625343>

2110 N0539 phase II trial of fulvestrant and bevacizumab in patients with metastatic breast cancer previously treated with an aromatase inhibitor: a North Central Cancer Treatment Group (now Alliance) trial

W. W. Tan, A. C. Dueck, P. Flynn, P. Steen, D. Anderson, K. Rowland Jr, D. Northfelt, E. A. Perez
Ann Oncol vol 10 (24) 2548-54 2013
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/23798616>

2111 N0539 Phase II Trial of Fulvestrant and Bevacizumab in Patients with Metastatic Breast Cancer Previously Treated with an Aromatase Inhibitor: A North Central Cancer Treatment Group Trial.

W. W. Tan, A. C. Dueck, P. Flynn, P. Steen, D. Anderson, K. Rowland Jr, D. Northfelt, W. Lingle, J. Copland, E. A. Perez Cancer Res vol 69 (24 suppl 3) abstr 738S 2009
Abstract Breast http://cancerres.aacrjournals.org/content/69/24_Supplement/4096

2112 Phase I study of panobinostat (LBH589) and letrozole in post-menopausal women with metastatic breast cancer.

W. Tan, J. Allred, A. Moreno-Aspitia, D. Northfelt, J. Ingle, E. A. Perez J Clin Oncol vol 30 (15 suppl) abstr e13501 2012
Abstract Breast <http://meetinglibrary.asco.org/content/95426-114>

2113 N0337: Phase II study of capecitabine in combination with vinorelbine and trastuzumab for the first or second treatment of HER2+metastatic breast cancer

W. Tan, J. Allred, M. Salim, P. Flynn, J. W. Kugler, P. J. Stella, M. Wiesenfeld, A. M. Bernath Jr, T. R. Fitch, E. A. Perez J Clin Oncol vol 27 (15) abstr 120 2009
Abstract Breast
<http://meeting.ascopubs.org/gca?allch=&submit=Go&gca=ascomtg%3B27%2F15S%2F1020>

2114 Phase I study of panobinostat (LBH589) and letrozole in post-menopausal metastatic breast cancer patients

Winston W. Tan, Jacob B. Allred, Alvaro Moreno-Aspitia, Donald W. Northfelt, James N. Ingle, Matthew P. Goetz, Edith A. Perez Clin Breast Cancer vol 16 (2) 82-86 2016
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/26774555>

2115 Phase II Interventional Study (N0337) of Capecitabine in Combination With Vinorelbine and Trastuzumab for First- or Second-Line Treatment of HER2-Positive Metastatic Breast Cancer: A North Central Cancer Treatment Group Trial

Winston W. Tan, Jacob B. Allred, Muhammad Salim, Patrick Flynn, Paul A. S. Fishkin, Philip J. Stella, Martin Wiesenfeld, Albert M. Bernath, Tom R. Fitch, Edith A. Perez Clin Breast Cancer vol 12 (2) 81-86 2012
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/22444716>

2116 Integrated Analysis of Multidimensional Genomic Data on CALGB 40601 (Alliance), a Randomized Neoadjuvant Phase III Trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-Positive Breast Cancer

Maki Tanioka, Chen Fan, Lisa A. Carey, Terry Hyslop, Brandelyn Pitcher, Joel S. Parker, Katie Hoadley, N. Lynn Henry, Sara Toloney, Chau Dang, Ian E. Krop, Lyndsay Harris, Donald A. Berry, Elaine Mardis, Charles M. Perou, Eric P Winer, Clifford A Hudis Cancer Res vol 77 (4 suppl) Abstract nr S3-05 2017
Abstract Sequencing http://cancerres.aacrjournals.org/content/77/4_Supplement/S3-05

2117 Integrated analysis of RNA and DNA from the phase III trial CALGB 40601 identifies predictors of response to trastuzumab-based neoadjuvant chemotherapy in HER2-positive breast cancer

Maki Tanioka, Cheng Fan, Joel S Parker, Katherine A Hoadley, Zhiyuan Hu, Yan Li, Terry M Hyslop, Brandelyn N Pitcher, Matthew G Soloway, Patricia A Spears, Lynn N Henry, Sara Toloney, Chau T Dang, Ian E Krop, Lyndsay N Harris, Donald A Berry, Elaine R Mardis, Eric P Winer, Clifford A Hudis, Lisa A Carey, Charles M Perou Clin Cancer Res vol 24 (21) 5292-304 2018

2118 Transient state change, but not permanent subtype change, after HER2-targeted therapy for HER2-positive breast cancer (Alliance)

Maki Tanioka, Joel S Parker, Lynn N Henry, Sara Tolaney, Chau Dang, Ian E Krop, Lyndsay Harris, David Hillman, Mei Polley, Donald A Berry, Eric P Winer, Lisa A Carey, Charles M Perou *Cancer Res* vol 79 (4 Suppl) Abstract nr P3-08-04 2019
Abstract Correl Sci NOS http://cancerres.aacrjournals.org/content/79/4_Supplement/P3-08-04

2119 A prognostic model integrating clinical information and gene expression signatures in phase III neoadjuvant trial CALGB 40601(Alliance).

Maki Tanioka, Joel S Parker, Lynn N Henry, Sara Tolaney, Chau Dang, Ian E Krop, Lyndsay Harris, David Hillman, Mei Polley, Donald A Berry, Eric P Winer, Lisa A Carey, Charles M Perou *Ann Oncol* vol 29 (suppl_7) abstr SPS-3 2018
Abstract Breast <https://www.sciencedirect.com/science/article/pii/S0923753419329370>

2120 A phase I/randomized phase II study of MLN0128 vs. Pazopanib in patients with locally advanced/unresectable and/or metastatic sarcoma: Alliance A091304

William Tap, Michelle Mahoney, Elise Horvath, Anthony Jazlowski, Gary Schwartz *J Clin Oncol* vol 34 (suppl) abstr TPS11073 2016
Abstract Experimental <http://meetinglibrary.asco.org/content/170721-176>

2121 Multisite, Randomized Trial of Early Integrated Palliative and Oncology Care in Patients with Advanced Lung and Gastrointestinal Cancer: Alliance A221303

Jennifer S. Temel, Jeff Sloan, Tyler Zemla, Joseph A. Greer, Vicki A. Jackson, Areej El-Jawahri, Mihir Kamdar, Arif Kamal, Craig D. Blinderman, Jacob Strand, Dylan Zylla, Christopher Daugherty, Muhammad Furqan, Jennifer Obel, Mohammad Razaq, Eric J. Roeland, Charles Loprinzi *J Palliat Med* vol 23 (7) 922-9 2020
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/32031887>

2122 Phase III Trial of Trimodality Therapy With Cisplatin, Fluorouracil, Radiotherapy, and Surgery Compared With Surgery Alone for Esophageal Cancer: CALGB 9781

Joel Tepper, Mark J. Krasna, Donna Niedzwiecki, Donna Hollis, Carolyn E. Reed, Richard Goldberg, Krystyna Kiel, Christopher Willett, David Sugarbaker, Robert Mayer *J Clin Oncol* vol 26 (7) 1086-1092 2008
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/18309943>

2123 Use of Remote Symptom Monitoring with Breast Cancer Survivors using Patient Reported Outcome Measures in mychart

S. Terstriep, J. Wacker, C. Quinlan Horner, E. Basch, K. Pochardt *JCO* vol 37 (15_suppl) e23125 2019
Abstract CCDD https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.e23125

2124 Use of Remote Symptom Monitoring with Breast Cancer Survivors using Patient Reported Outcome Measures through Epic Mychart.

Shelby A. Terstriep, James Wacker, Charissa Quinlan, Kiara Pochardt, Ethan M. Basch *J Clin Oncol* vol 37 (suppl 27) abstr 208 2019
Abstract CCDD https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.27_suppl.208

2125 A novel approach of longitudinal adverse event evaluation in oncology clinical trials: the Toxicity over Time (ToxT) analysis of clinical trials N9741 and 979254 (Alliance)

Gita Thanarajasingam, Pamela J. Atherton, Paul J. Novotny, Charles L. Loprinzi, Jeff A. Sloan, Axel Grothey *Lancet Oncol* vol 17 (5) 663-670 2016

2126 Beyond maximum grade: A novel, longitudinal toxicity over time (ToxT) adverse event analysis of lenalidomide in follicular lymphoma in Alliance A151617

Gita Thanarajasingam, Amylou Dueck, Paul J. Novotny, Thomas E. Witzig, Thomas M. Habermann, Grzegorz S. Nowakowski, Christopher R. Flowers, Nancy L. Bartlett, Kristie A. Blum, Brandelyn N. Pitcher, Sin-Ho Jung, Pamela J. Atherton, Angelina Tan, Jeff A. Sloan, John P. Leonard Hematol Oncol vol 35 (S2) 213-5 2017
Abstract Health Outcomes CALGB-50401
http://onlinelibrary.wiley.com/doi/10.1002/hon.2438_78/full

2127 Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in CALGB 50401 (Alliance)

Gita Thanarajasingam, John P. Leonard, Thomas E. Witzig, Thomas M. Habermann, Kristie A. Blum, Nancy L. Bartlett, Christopher R. Flowers, Brandelyn N. Pitcher, Sin-Ho Jung, Pamela J. Atherton, Angelina Tan, Paul J. Novotny, Amylou C. Dueck Lancet Haematol vol 7 (6) e490-e497 2020
Manuscript Health Outcomes CALGB-50401 <http://www.ncbi.nlm.nih.gov/pubmed/32470440>

2128 The high prevalence of FLT3-ITD mutations is associated with the poor outcome in adult patients with t(6;9)(p23;q34) positive AML - Results of an international metaanalysis

C. Thiede, C. D. Bloomfield, F. Lo Coco, S. Frohling, W. Hiddemann, J. Krauter, M. Schaich, S. P. Whitman, G. Saglio, K. Dohner, K. Spiekermann, S. Schnittger, A. Ganser, G. Heil, T. Buchner, H. Dohner, R. A. Larson, G. Ehninger Blood vol 110 (11) 234A-234A 2007
Abstract Leuk Corr Sci CALGB-19808, CALGB-8461, CALGB-9621, CALGB-9665
<http://www.bloodjournal.org/content/110/11/761?sso-checked=true>

2129 The high prevalence of FLT3-ITD mutations is associated with the poor outcome in adult patients with t(6;9)(p23;q34) positive AML: Results of an international metaanalysis

C. Thiede, C. D. Bloomfield, F. Lo Coco, S. Frohling, W. Hiddemann, J. Krauter, M. Schaich, S. P. Whitman, G. Saglio, K. Dohner, K. Spiekermann, S. Schnittger, A. Ganser, G. Heil, T. Buchner, H. Dohner, R. A. Larson, G. Ehninger Onkologie vol 30 (suppl 3) 113 (abstr 214) 2007
Abstract Leuk Corr Sci CALGB-8461, CALGB-9665
<http://content.karger.com/ProdukteDB/produkte.asp?Aktion=Ausgabe&Ausgabe=233773&ProduktNr=2>

2130 FLT3 mutation assay laboratory cross validation: results from the CALGB 10603/RATIFY(Alliance) trial in patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML)

Christian Thiede, Thomas Prior, Francesco Lo Coco, Jürgen Krauter, Eva Barragan, Josep Nomdedeu, Joop H. Jansen, Andrew Wei, Weiqiang Zhao, Xiaohong Li, Celine Pallaud, Eva Tiecke, Richard Larson, Clara D. Bloomfield, Hartmut Döhner, Gerhard Ehninger, Richard Stone, Konstanze Döhner Blood vol 132 (Suppl) 2800 2018
Abstract Leukemia
http://www.bloodjournal.org/content/132/Suppl_1/2800.abstract?sso-checked=true

2131 Translational correlates, including outcome for patients (pts) with ER-/PR-/HER2- (triple negative (TNeg)) disease from N0234, a phase II trial of gemcitabine and erlotinib for pts with previously treated metastatic breast cancer (MBC)

S. Thome, T. Hobday, D. Hillman, M. Aubry, W. Lingle, M. Reinholz, D. Graham, P. Flynn, A. Moreno, E. Perez J Clin Oncol vol 25 (18s) abstr 1071 2007
Abstract Breast http://meeting.ascopubs.org/cgi/content/short/25/18_suppl/1071

2132 Impact of Adjuvant Trastuzumab on Local-regional Failure Rates in the NCCTG N9831

(Alliance) Study

Cameron S. Thorpe, Carlos E. Vargas, Amylou C. Dueck, Kathleen S. Tenner, Edith A. Perez, E. Shelley Hwang, Michele Y. Halyard, Thomas M. Pisansky, Nancy E. Davidson, Silvana Martino, Barbara A. Pockaj International Journal of Radiation Oncology • Biology • Physics vol 105 (1 Supplement) S9-S10 2019
Abstract Breast [https://www.redjournal.org/article/S0360-3016\(19\)31232-5/fulltext](https://www.redjournal.org/article/S0360-3016(19)31232-5/fulltext)

2133 Decision Aids for Localized Prostate Cancer in Diverse Minority Men: Primary Outcome Results from a Multi-Centered Cancer Care Delivery Trial (Alliance A191402CD)

Jon C. Tilburt, David Zahrieh, Joel E. Pacyna, Daniel G. Petereit, Judith S. Kaur, Bruce D. Rapkin, Robert L. Grubb, George J. Chang, Michael J. Morris, Evan Z. Kovac, Kara N. Babaian, Jeff A. Sloan, Ethan M. Basch, Elizabeth S. Peil, Amylou C. Dueck, Paul J. Novotny, Electra D. Paskett, Jan C. Buckner, Daniel D. Joyce, Victor M. Montori, Dominick L. Frosch, Robert J. Volk, Simon P. Kim Cancer vol 128 (6) 1242-51 2022
Manuscript Disparities <http://www.ncbi.nlm.nih.gov/pubmed/34890060>

2134 Decision Aids for Localized Prostate Cancer: Outcomes from an Alliance Research Base Cancer Care Delivery Research (CCDR) Protocol - A191402CD

Jon Charles Tilburt, Joel E Pacyna, Daniel G. Petereit, Judith Salmon Kaur, Bruce D. Rapkin, Robert Grubb, George J. Chang, Michael J. Morris, Evan Kovac, Jeff A. Sloan, Ethan M. Basch, Elizabeth M. Storrick, David Zahrieh, Amylou C. Dueck, Electra D. Paskett, Jan C. Buckner, Victor Montori, Domnick L Frosch, Robert Joseph Volk, Simon P. Kim J Clin Oncol vol 38 (15_suppl) e24176 2020
Abstract CCDR https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.e24176

2135 Long-term Decisional Regret for Minority Men Diagnosed with Prostate Cancer: Results from a Multi-Centered Randomized Clinical Trial of Decision Aids (Alliance)

Jon Tilburt, Joe Pacyna, George Chang, Amylou Dueck, Robert Grubb, Judith Kaur, Michael Morris, Paul Novotny, Electra Paskett, Daniel Petereit, Bruce Rapkin, Jeff Sloan, Elizabeth Storrick, David Zahrieh, Dominick Frosch, Victor Montori, Robert Volk, Ethan Basch, Jan Buckner, Kelly Parsons, Kara Babaian, Evan Kovac, Simon Kim J Urol vol 206 (3) e48 2021
Abstract CCDR <https://www.auajournals.org/doi/10.1097/JU.0000000000001967.12>

2136 Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia

Michael H. Tomasson, Zhifu Xiang, Richard Walgren, Yu Zhao, Yumi Kasai, Tracie Miner, Rhonda E. Ries, Olga Lubman, Daved H. Fremont, Michael D. McLellan, Jacqueline E. Payton, Peter Westervelt, John F. DiPersio, Daniel C. Link, Matthew J. Walter, Timothy A. Graubert, Mark Watson, Jack Baty, Sharon Heath, William D. Shannon, Rakesh Nagarajan, Clara D. Bloomfield, Elaine R. Mardis, Richard K. Wilson, Timothy J. Ley Blood vol 111 (9) 4797-4808 2008
Manuscript Leuk Corr Sci CALGB-19808, CALGB-9621, CALGB-9665
<http://www.ncbi.nlm.nih.gov/pubmed/18270328>

2137 Is local review of positron emission tomography scans sufficient in diffuse large Bcell lymphoma clinical trials? A CALGB 50303 analysis

Pallawi Torka, Levi D. Pederson, Michael V. Knopp, David Poon, Jun Zhang, Brad S. Kahl, Howard R. Higley, Gary Kelloff, Jonathan W. Friedberg, Lawrence H. Schwartz, Wyndham H. Wilson, John P. Leonard, Nancy L. Bartlett, Heiko Schöder, Amy S. Ruppert Cancer Med vol 12 (7) 8211-7 2023
Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/36799072>

2138 Phase IB Study of Sorafenib and Evofosfamide in Patients with Advanced Hepatocellular and Renal Cell Carcinomas (NCCTG N1153, Alliance)

Nguyen H Tran, Nathan R Foster, Amit Mahipal, Thomas Byrne, Joleen Hubbard, Alvin Silva, Kabir Mody, Steven Alberts, Mitesh J. Borad Invest New Drugs vol 39 (4) 1072-80 2021

2139 Optimizing whole brain radiotherapy dose and fractionation: Results from a prospective phase III trial (Alliance)

Daniel M. Trifiletti, Karla V. Ballman, Paul D. Brown, S. Keith Anderson, Xiomara W. Carrero, Jane H. Cerhan, Anthony C. Whitton, Jeffrey Greenspoon, Ian F. Parney, Nadia N. Laack, Jonathan B. Ashman, Jean-Paul Bahary, Costas G. Hajipanayis, James J. Urbanic, Fred G. Barker II, Elana Farace, Deepak Khuntia, Caterina Giannini, Jan C Buckner, Evanthia Galanis, David Roberge *International Journal of Radiation Oncology • Biology • Physics* vol 105 (1 Supplement) S10 2019
Abstract Neuro-Onc [https://www.redjournal.org/article/S0360-3016\(19\)31233-7/fulltext](https://www.redjournal.org/article/S0360-3016(19)31233-7/fulltext)

2140 Optimizing Whole Brain Radiation Therapy Dose and Fractionation: Results From a Prospective Phase 3 Trial (NCCTG N107C [Alliance]/CEC.3).

Daniel M Trifiletti, Karla V Ballman, Paul D Brown, S Keith Anderson, Xiomara W Carrero, Jane H Cerhan, Anthony C Whitton, Jeffrey Greenspoon, Ian F Parney, Nadia N Laack, Jonathan B Ashman, Jean-Paul Bahary, Costas G Hadjipanayis, James J Urbanic, Fred G Barker II, Elana Farace, Deepak Khuntia, Caterina Giannini, Jan C Buckner, Evanthia Galanis, David Roberge *Int J Radiat Oncol Biol Phys* vol 106 (2) 255-60 2020
Manuscript Neuro-Onc <http://www.ncbi.nlm.nih.gov/pubmed/31654784>

2141 LACE-Bio Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation in Completely Resected Non-Small Cell Lung Cancer (NSCLC)

M. S. Tsao, P. Hainaut, A. Bourredjem, P. A. Janne, J.-P. Pignon, J.-Y. Douillard, J.-C. Soria, L. Seymour, F. A. Shepherd *Ann Oncol* vol 21 (supplement 8) viii63 2010
Abstract Respiratory
<http://oncologypro.esmo.org/meeting-resources/meeting-abstracts/european-society-for-medical-oncolog>

2142 PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer

M.-S. Tsao, G. Le Teuff, F. A. Shepherd, C. Landais, P. Hainaut, M. Filipits, R. Pirker, T. Le Chevalier, S. Graziano, R. Kratzke, J.-C. Soria, J.-P. Pignon, L. Seymour, E. Brambilla *Ann Oncol* vol 28 (4) 882-9 2017
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/28137741>

2143 Subtype Classification of Lung Adenocarcinoma Predicts Benefit From Adjuvant Chemotherapy in Patients Undergoing Complete Resection

Ming-Sound Tsao, Sophie Marguet, Gwénaél Le Teuff, Sylvie Lantuejoul, Frances A. Shepherd, Lesley Seymour, Robert Kratzke, Stephen L. Graziano, Helmut H. Popper, Rafael Rosell, Jean-Yves Douillard, Thierry Le-Chevalier, Jean-Pierre Pignon, Jean-Charles Soria, Elisabeth M. Brambilla *J Clin Oncol* vol 33 (30) 3439-3446 2015
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/25918286>

2144 Postoperative surveillance recommendations for early-stage colon cancer based on results from the clinical outcomes of surgical therapy trial

V. L. Tsikitis, K. Malireddy, E. A. Green, B. Christensen, R. Whelan, J. Hyder, D. Lauter, P. Marcello, S. Larach, D. Sargent, H. Nelson *J Clin Oncol* vol 27 (15s Supplement) abstr 4013 2009
Abstract GI NCCTG-934651, CALGB-9396
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID

2145 Postoperative Surveillance Recommendations for Early Stage Colon Cancer Based on Results From the Clinical Outcomes of Surgical Therapy Trial

Vassiliki L. Tsikitis, Kishore Malireddy, Erin A. Green, Brent Christensen, Richard Whelan, Jace Hyder, Peter Marcello, Sergio Larach, David Lauter, Daniel J. Sargent, Heidi Nelson *J Clin Oncol* vol

2146 Barriers and Facilitators to the Implementation of a Web-Based Decision Aid in Surgery Clinics (Alliance A231701CD)

Jennifer L. Tucholka, Jessica R. Schumacher, Patricia McNamara, Angelina Tan, David Zahrieh, Selina Chow, Catherine R. Breuer, Grace McKinney, Heather B. Neuman 2022

Abstract CCDR

<https://academyhealth.confex.com/academyhealth/2022di/meetingapp.cgi/Search/0?sort=Relevance&size>

2147 Use of baseline quality of life (QOL) as compared with performance status (PS) as prognostic factors for overall survival (OS) in patients with metastatic colorectal cancer (mCRC)

J. Turja, A. Grothey, D. Sargent, D. Szydlo, X. Zhao, M. Campbell, R. Goldberg, J. Sloan J Clin Oncol vol 26 (suppl) abstr 4016 2008

Abstract GI

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID

2148 Phase II evaluation of gefitinib in patients with newly diagnosed grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group study N0074 1

Joon H. Uhm, Karla V. Ballman, Wenting Wu, Caterina Giannini, JC Krauss, Jan C. Buckner, C.D James, Bernd W. Scheithauer, Robert J. Behrens, Patrick J. Flynn, Paul L. Schaefer, Shaker R. Dakhill, Kurt A. Jaeckle Int J Radiat Oncol Biol Phys vol 80 (2) 347-353 2011

Manuscript Neuro-Onc <http://www.ncbi.nlm.nih.gov/pubmed/20510539>

2149 A Phase I Study of Rituximab, Lenalidomide, and Ibrutinib in Previously Untreated Follicular Lymphoma

C. Ujjani, B. D. Cheson, S.-H. Jung Hematol Oncol vol 31 (S1) 271-278 2013

Abstract Lymphoma <http://onlinelibrary.wiley.com/doi/10.1002/hon.2084/full>

2150 Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103

Chaitra S. Ujjani, Sin-Ho Jung, Brandelyn Pitcher, Peter Martin, Steven I. Park, Kristie A. Blum, Sonali M. Smith, Myron Czuczman, Matthew S. Davids, Ellis Levine, Lionel D. Lewis, Scott E. Smith, Nancy L. Bartlett, John P. Leonard, Bruce D. Cheson Blood vol 128 (21) 2510-2516 2016

Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/27697771>

2151 Phase I Study of Rituximab, Lenalidomide, and Ibrutinib in Previously Untreated Follicular Lymphoma (Alliance 051103)

Chaitra Ujjani, Sin-Ho Jung, Brandelyn Pitcher, Peter Martin, Steven I. Park, Kristie Blum, Sonali Smith, Matthew S. Davids, Myron Czuczman, John P. Leonard, Bruce D. Cheson Blood vol 126 (23) abstr 471 2015

Abstract Lymphoma <http://www.bloodjournal.org/content/126/23/471>

2152 Phase I Study of Accelerated Hypofractionated Radiotherapy with Concurrent Chemotherapy for Stage III Non-Small-Cell Lung Cancer: CALGB 31102 (Alliance)

James J. Urbanic, Xiaofei Wang, Jeffrey A. Bogart, Thomas E. Stinchcombe, Lydia Hodgson, Steven E. Schild, Lyudmila Bazhenova, Olwen Hahn, Ravi Salgia, Everett E. Vokes Int J Radiat Oncol Biol Phys vol 101 (1) 177-185 2018

Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/29487024>

2153 Phase I Study of Accelerated Hypofractionated Radiotherapy with Concurrent Chemotherapy for Stage III Non-Small-Cell Lung Cancer: CALGB 31102 (Alliance)

James J Urbanic, Jeffrey A Bogart, Thomas Stinchcombe, Xiaofei Wang, Lydia Hodgson, Steven

Schild, Lyudmila Bahzenova, Ravi Salgia, Everett Vokes Int J Radiat Oncol Biol Phys vol 93 (3 suppl) S86 2015

Abstract Respiratory <http://www.redjournal.org/article/S0360-3016%2815%2900938-4/fulltext>

2154 Allogeneic Hematopoietic Cell Transplantation (HCT) vs. Non-HCT Consolidation Therapies in Acute Myeloid Leukemia (AML) Patients 60-75 Years of Age in First Complete Remission (CR1): An Alliance (A151509), SWOG, ECOG and CIBMTR Study

Celalettin Ustun, Jennifer G Le-Rademacher, Hailin Wang, Megan Othus, Zhuoxin Sun, Brittny Major, Mei-Jie Zhang, Jacqueline M. Lafky, Selina Chow, Krzysztof Mrozek, Eyal Attar, Clara D. Bloomfield, Larry Cripe, Richard A. Larson, Guido Marcucci, Gail J. Roboz, Geoffrey Uy, Richard Stone, Aminah Jatoi, Thomas Shea, Marcos de Lima, James Foran, Brenda M. Sandmaier, Mark Litzow, Harry P Erba, Arti Hurria, Daniel Weisdorf, Andrew Artz Blood vol 132 (suppl 1) 2170 2018

Abstract Leukemia Alliance-A151509, CALGB-100103

http://www.bloodjournal.org/content/132/Suppl_1/2170

2155 Allogeneic Hematopoietic Cell Transplantation Compared to Chemotherapy Consolidation in older Acute Myeloid Leukemia (AML) Patients 60–75 Years in First Complete Remission (CR1): An Alliance (A151509), SWOG, ECOG-ACRIN and CIBMTR Study

Celalettin Ustun, Jennifer Le-Rademacher, Hai-Lin Wang, Megan Othus, Zhuoxin Sun, Brittny Major, Mei-Jie Zhang, Elizabeth Storrack, Jacqueline M Lafky, Selina Chow, Krzysztof Mrózek, Eyal C. Attar, Such Nand, Clara D. Bloomfield, Larry D. Cripe, Martin S. Tallman, Frederick Appelbaum, Richard A. Larson, Guido Marcucci, Gail J. Roboz, Geoffrey L. Uy, Richard M. Stone, Aminah Jatoi, Thomas C. Shea, Marcos de Lima, James M. Foran, Brenda M. Sandmaier, Mark R. Litzow, Harry P. Erba, Arti Hurria, Daniel J. Weisdorf, Andrew S. Artz Leukemia vol 33 (11) 2599-2609 2019
Manuscript Older Adult CALGB-10502, CALGB-10801, CALGB-11001, CALGB-11002, ECOG-E3999, SWOG-S0432, SWOG-S0703 <http://www.ncbi.nlm.nih.gov/pubmed/31073153>

2156 A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001

Geoffrey L. Uy, Sumithra J. Mandrekar, Kristina Laumann, Guido Marcucci, Weiqiang Zhao, Mark J. Levis, Heidi D. Klepin, Maria R. Baer, Bayard L. Powell, Peter Westervelt, Daniel J. DeAngelo, Wendy Stock, Ben Sanford, William G. Blum, Clara D. Bloomfield, Richard M. Stone, Richard A. Larson Blood Adv vol 1 (5) 331-340 2017

Manuscript Leukemia <http://www.ncbi.nlm.nih.gov/pubmed/29034366>

2157 Addition of Sorafenib to Chemotherapy Improves the Overall Survival of Older Adults With FLT3-ITD Mutated AML (Alliance C11001).

Geoffrey L. Uy, Sumithra Mandrekar, Kristina Laumann, Ben Sanford, Guido Marcucci, Weiqiang Zhao, Mark Levis, Heidi D. Klepin, Bayard L. Powell, Maria R. Baer, Wendy Stock, John Byrd, Richard M. Stone, Richard A. Larson Blood vol 126 (23) 319 2015

Abstract Leukemia <http://www.bloodjournal.org/content/126/23/319.abstract>

2158 Initial Results Of a Phase II Trial Of Sorafenib Plus Standard Induction In Older Adults With Mutant FLT3 Acute Myeloid Leukemia (AML) (Alliance trial C11001)

Geoffrey L. Uy, Ben Sanford, Guido Marcucci, Weiqiang Zhao, Susan Geyer, Heidi D. Klepin, Bayard L. Powell, Maria R. Baer, Wendy Stock, Richard M. Stone, Richard A. Larson Blood vol 122 (21) Abstract 2653 2013

Abstract Leukemia <http://www.bloodjournal.org/content/122/21/2653.abstract?sso-checked=true>

2159 Alliance A041701 - A randomized phase 2/3 study of conventional chemotherapy +/- uproleselan (GMI-1271) in older adults with acute myeloid leukemia receiving intensive induction chemotherapy

Geoffrey L. Uy, Vivien Yin, Heidi Klepin, Shira Dinner, Anthony Jaslowski, Steven A. Strickland, Jane L. Liesveld, John C. Byrd, Richard M. Stone Blood vol 134 (Supplement 1) abstract 1366 2019
Abstract Leukemia
https://ashpublications.org/blood/article/134/Supplement_1/1366/427436/Alliance-A041701-a-Randomiz

2160 Mammographic Breast Density Response to Aromatase Inhibition

Celine M. Vachon, Vera J. Suman, Kathleen R. Brandt, Matthew L. Kosel, Aman U. Buzdar, Janet E. Olson, Fang-Fang Wu, Lynn M. Flickinger, Giske Ursin, Catherine R. Elliott, Lois Shepherd, Richard M. Weinshilboum, Paul E. Goss, James N. Ingle Clin Cancer Res vol 19 (8) 2144-53 2013
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/23468058>

2161 Marine -3 Polyunsaturated Fatty Acid and Fish Intake after Colon Cancer Diagnosis and Survival: CALGB 89803 (Alliance)

Erin L. Van Blarigan, Charles S. Fuchs, Donna Niedzwiecki, Xing Ye, Sui Zhang, Mingyang Song, Leonard B. Saltz, Robert J. Mayer, Rex B. Mowat, Renaud Whittom, Alexander Hantel, Al Benson III, Daniel Atienza, Michael Messino, Hedy Kindler, Alan Venook, Shuji Ogino, Edward L. Giovannucci, Jeffrey A. Meyerhardt Cancer Epidemiol Biomarkers Prev vol 27 (4) 438-45 2018
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/29358223>

2162 Association of Survival With Adherence to the American Cancer Society Nutrition and Physical Activity Guidelines for Cancer Survivors After Colon Cancer Diagnosis

Erin L. Van Blarigan, Charles S. Fuchs, Donna Niedzwiecki, Sui Zhang, Leonard B. Saltz, Robert J. Mayer, Rex B. Mowat, Renaud Whittom, Alexander Hantel, Al Benson III, Daniel Atienza, Michael Messino, Hedy Kindler, Alan Venook, Shuji Ogino, Edward L. Giovannucci, Kimmie Ng, Jeffrey A. Meyerhardt JAMA Oncol vol 4 (6) 783-790 2018
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/29710284>

2163 Dietary fat in relation to all-cause mortality and cancer progression and death among people with metastatic colorectal cancer: data from CALGB 80405 (Alliance)/SWOG 80405

Erin L. Van Blarigan, Chao Ma, Fang-Shu Ou, Tiffany M. Bainter, Alan P. Venook, Kimmie Ng, Donna Niedzwiecki, Edward Giovannucci, Heinz-Josef Lenz, Blase N. Polite, Howard S. Hochster, Richard M. Goldberg, Robert J. Mayer, Charles D. Blanke, Eileen M. O'Reilly, Kristen K. Ciombor, Jeffrey A. Meyerhardt Int J Cancer vol 152 (2) 123-36 2023
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/35904874>

2164 Dietary fat intake in relation to overall and progression-free survival among people with advanced or metastatic colorectal cancer: data from CALGB 80405 (Alliance)

Erin L. Van Blarigan, Chao Ma, Fang-Shu Ou, Alan Venook, Kimmie Ng, Donna Niedzwiecki, Edward Giovannucci, Heinz-Josef Lenz, Federico Innocenti, James E. Shaw, Blase N. Polite, Howard S. Hochster, Richard M. Goldberg, Robert J. Mayer, Charles D. Blanke, Eileen M. O'Reilly, Charles S. Fuchs, Jeffrey A. Meyerhardt J Clin Oncol vol 39 (no. 15_suppl) 3588 2021
Abstract GI <https://meetinglibrary.asco.org/record/196452/abstract>

2165 Associations Between Unprocessed Red Meat and Processed Meat With Risk of Recurrence and Mortality in Patients With Stage III Colon Cancer

Erin L. Van Blarigan, Fang-Shu Ou, Tiffany M. Bainter, Charles S. Fuchs, Donna Niedzwiecki, Sui Zhang, Leonard B. Saltz, Robert J. Mayer, Alexander Hantel, Al B. Benson, Daniel Atienza, Michael Messino, Hedy L. Kindler, Alan P. Venook, Shuji Ogino, Hanna K. Sanoff, Edward L. Giovannucci, Kimmie Ng, Jeffrey A. Meyerhardt JAMA Netw Open vol 5 (2) 2022
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/35191970>

2166 Dietary fat intake after colon cancer diagnosis in relation to cancer recurrence and survival: CALGB 89803 (Alliance)

Erin L. Van Blarigan, Fang-Shu Ou, Donna Niedzwiecki, Sui Zhang, Charles S. Fuchs, Leonard Saltz, Robert J Mayer, Alan Venook, Shuji Ogino, Mingyang Song, Al Benson, Alexander Hantel, James N Atkins, Edward L. Giovannucci, Jeffrey A. Meyerhardt *Cancer Epidemiol Biomarkers Prev* vol 27 (10) 1227-30 2018

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/30038051>

2167 Association of Diet Quality With Survival Among People With Metastatic Colorectal Cancer in the Cancer and Leukemia B and Southwest Oncology Group 80405 Trial

Erin L. Van Blarigan, Sui Zhang, Fang-Shu Ou, Alan Venlo, Kimmie Ng, Chloe Atreya, Katherine Van Loon, Donna Niedzwiecki, Edward Giovannucci, Eric G. Wolfe, Heinz-Josef Lenz, Federico Innocenti, Bert H. O'Neil, James E. Shaw, Blase N. Polite, Howard S. Hochster, James N. Atkins, Richard M. Goldberg, Robert J. Mayer, Charles D. Blanke, Eileen M. O'Reilly, Charles S. Fuchs, Jeffrey A. Meyerhardt *JAMA Netw Open* vol 3 (10) e2023500 2020

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/33125497>

2168 Diet quality and survival in metastatic colorectal cancer (CRC): data from CALGB/SWOG 80405 (Alliance)

Erin L. Van Blarigan, Sui Zhang, Fang-Shu Ou, Alan Venook, Kimmie Ng, Chloe Atreya, Donna Niedzwiecki, Edward Giovannucci, Federico Innocenti, Heinz-Josef Lenz, Bert H. O'Neil, James E. Shaw, Blase N. Polite, Howard S. Hochster, James N. Atkins, Richard M. Goldberg, Robert J. Mayer, Charles D. Blanke, Eileen O'Reilly, Charles S. Fuchs, Jeffrey A. Meyerhardt 2019

Abstract GI

2169 Long-chain omega-3 fatty acid and fish intake after colon cancer diagnosis and disease-free, recurrence-free, and overall survival CALGB 89803 (Alliance)

Erin L Van Blarigan, Charles S. Fuchs, Donna Niedzwiecki, Xing Ye, Sui Zhang, Mingyang Song, Leonard B. Saltz, Robert J. Mayer, Rex B. Mowat, Renaud Whittom, Alexander Hantel, Al Benson, Daniel Atienza, Michael Messino, Hedy Kindler, Alan Venook, Shuji Ogino, Walter C. Willett, Edward L. Giovannucci, Jeffrey A. Meyerhardt *J Clin Oncol* vol 35 (suppl 4S) abstr 585 2017

Abstract GI http://abstracts.asco.org/195/AbstView_195_176704.html

2170 American Cancer Society (ACS) Nutrition and Physical Activity Guidelines after colon cancer diagnosis and disease-free (DFS), recurrence-free (RFS), and overall survival (OS) in CALGB 89803 (Alliance)

Erin L Van Blarigan, Charles S. Fuchs, Donna Niedzwiecki, Xing Ye, Sui Zhang, Mingyang Song, Leonard B. Saltz, Robert J. Mayer, Rex B. Mowat, Renaud Whittom, Alexander Hantel, Al Benson, Daniel Atienza, Michael Messino, Hedy Kindler, Alan Venook, Shuji Ogino, Walter C. Willett, Edward L. Giovannucci, Jeffrey A. Meyerhardt *J Clin Oncol* vol 35 (15 suppl) 10006 2017

Abstract GI http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.10006

2171 25-hydroxyvitamin D levels and survival in patients with advanced pancreatic cancer (APC): Findings from CALGB 80303

K. Van Loon, K. Owzar, C. Jiang, H. L. Kindler, M. F. Mulcahy, D. Niedzwiecki, E. M. O'Reilly, C. S. Fuchs, F. Innocenti, A. P. Venook *J Clin Oncol* vol 31 (15 suppl) abstr 4022 2013

Abstract GI

http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/4022?sid=8c179369-c78a-4495-9e6b-4195

2172 Comparison of dietary and lifestyle habits among stage III and metastatic colorectal cancer patients

K. Van Loon, D. S. Wigler, D. Niedzwiecki, D. R. Hollis, A. P. Venook, C. S. Fuchs, C. Blanke, L. B. Saltz, R. M. Goldberg, J. A. Meyerhardt *J Clin Oncol* vol 29 (15s) abstr e14026 2011

Abstract GI CALGB-80405, CALGB-89803

http://meeting.ascopubs.org/cgi/content/abstract/29/15_suppl/e14026?sid=4d819d7d-7fdb-4c16-9ecb-58

- 2173 Comparison of Dietary and Lifestyle Habits Among Stage III and Metastatic Colorectal Cancer Patients: Findings from CALGB 89803 and CALGB 80405**
K. Van Loon, D. Wigler, D. Niedzwiecki, A. P. Venook, C. Fuchs, C. Blanke, L. Saltz, R. M. Goldberg, J. A. Meyerhardt Clin Colorectal Cancer vol 12 (2) 95-102 2013
Manuscript GI CALGB-89803, CALGB-80405 <http://www.ncbi.nlm.nih.gov/pubmed/23317558>
- 2174 Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer?: A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab**
Katherine Van Loon, Anne M. Espinoza, David R. Fogelman, Robert A. Wolff, Milind M. Javle, Renuka V. Iyer, Vincent J. Picozzi, Ludmila Katherine Martin, Tanios Bekaii-Saab, Margaret A. Tempero, Nathan R. Foster, George P. Kim, Andrew H. Ko Pancreas vol 43 (3) 343-349 2014
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/24622062>
- 2175 25-Hydroxyvitamin D Levels and Survival in Advanced Pancreatic Cancer: Findings From CALGB 80303 (Alliance)**
Katherine Van Loon, Kouros Owzar, Chen Jiang, Hedy L. Kindler, Mary F. Mulcahy, Donna Niedzwiecki, Eileen M. O'Reilly, Charles Fuchs, Federico Innocenti, Alan P. Venook J Natl Cancer Inst vol 106 (8) 2014
Manuscript GI CALGB-80303 <http://www.ncbi.nlm.nih.gov/pubmed/25099612>
- 2176 Disparities in Older Adult Accrual to Cancer Trials: Analysis from the Alliance for Clinical Trials in Oncology (A151736)**
Noam A. VanderWalde, Travis Dockter, Daniel V. Wakefield, Daniel Satele, Jeff Sloan, Reshma Jaggi, Stuart M. Lichtman, Rachel A. Freedman, Jacqueline M. Lafky, Hyman Muss, Harvey Jay Cohen, Jennifer Le-Rademacher, Aminah Jatoi J Geriatr Oncol vol 13 (1) 20-6 2022
Manuscript Older Adult <http://www.ncbi.nlm.nih.gov/pubmed/34364834>
- 2177 Modeling Accrual of Older Adults to Cancer Clinical Trials: (Alliance A151736)**
Noam VanderWalde, Daniel Wakefield, Daniel Satele, Travis Dockter, Jeff Sloan, Reshma Jaggi, Stuart Lichtman, Rachel A. Freedman, Jacqueline Lafky, Hyman Muss, Harvey Cohen, Arti Hurria, Aminah Jatoi, Jennifer Le-Rademacher J Clin Oncol vol 37 (15 suppl) e18132 2019
Abstract Older Adult <https://meetinglibrary.asco.org/record/173120/abstract>
- 2178 Modeling Accrual of Older Adults to Cancer Clinical Trials: (Alliance A151736)**
Noam VanderWalde, Daniel Wakefield, Daniel Satele, Travis Dockter, Jeff Sloan, Reshma Jaggi, Stuart Lichtman, Rachel A. Freedman, Jacqueline Lafky, Hyman Muss, Harvey Cohen, Arti Hurria, Aminah Jatoi, Jennifer Le-Rademacher J Geriatr Oncol vol 10 (6, suppl 1) abstr S46 2019
Abstract Older Adult [https://www.geriatriconcology.net/article/S1879-4068\(19\)31193-2/fulltext](https://www.geriatriconcology.net/article/S1879-4068(19)31193-2/fulltext)
- 2179 Impact of Adjuvant Trastuzumab on Locoregional Failure Rates in the Randomized Clinical Trial: NCCTG N9831 (Alliance) Study**
Carlos E. Vargas, Cameron S. Thorpe, Amylou C. Dueck, Kathleen S. Tenner, Nancy E. Davidson, Silvana Martino, Thomas M. Pisansky, E. Shelley Hwang, Michele Y. Halyard, Barbara A. Pockaj, Edith A. Perez Cancer vol 126 (24) 5239-46 2020
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/32931029>
- 2180 Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission**
Sumithira Vasu, Jessica Kohlschmidt, Krzysztof Mrózek, Ann-Kathrin Eisfeld, Deedra Nicolet, Lisa J. Sterling, Heiko Becker, Klaus H. Metzeler, Dimitrios Papaioannou, Bayard L. Powell, Jonathan E. Kowitz, Joseph O. Moore, Maria R. Baer, Gail J. Roboz, Richard M. Stone, John C. Byrd, Andrew J.

Carroll, Clara D. Bloomfield Blood Adv vol 2 (13) 1645-50 2018
Manuscript Leukemia CALGB-8221, CALGB-8461, CALGB-8525, CALGB-8721, CALGB-8821,
CALGB-9022, CALGB-19808, CALGB-8923, CALGB-9222, CALGB-9420, CALGB-9621,
CALGB-9720 <http://www.ncbi.nlm.nih.gov/pubmed/29991495>

2181 Lymph node analysis in esophageal resection: American College of Surgeons Oncology Group Z0060 trial.

Nirmal K Veeramachaneni, Jennifer B Zoole, Paul A Decker, Joe B Putnam, Bryan F Meyers Ann
Thorac Surg vol 86 (2) 418-21; discussion 421 2008
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/18640307>

2182 Validation of a 12-gene colon cancer recurrence score (RS) in stage II colon cancer (CC) patients (pts) from CALGB 9581

A. P. Venook, D. Niedzwiecki, M. Lopatin, M. Lee, P. N. Friedman, W. L. Frankel, K. Clark-Langone,
C. Yoshizawa, C. Millward, S. Shak, R. M. Goldberg, N. Mahmoud, R. L. Schilsky, M. M. Bertagnolli
J Clin Oncol vol 29 (suppl) abstr 3518 2011

Abstract GI

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID

2183 Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) ± cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALGB 80203 preliminary results

A. Venook, D. Niedzwiecki, D. Hollis, S. Sutherland, R. Goldberg, S. Alberts, A. Benson, J. Wade, R.
Schilsky, R. Mayer J Clin Oncol vol 24 (18s) abstr. 3509 2006

Abstract GI <http://www.ncbi.nlm.nih.gov/pubmed/27953330>

2184 CALGB/SWOG 80405: Analysis of patients undergoing surgery as part of treatment strategy

A. Venook, D. Niedzwiecki, H. Lenz, M. Mahoney, F. Innocenti, B. O'Neil, H. Hochster, R. Goldberg,
R. Schilsky, R. Mayer, B. Polite, J. Atkins, J. Shaw, M. Bertagnolli, C. Blanke Ann Oncol vol 25
(suppl 4) abstr LBA10 2014

Abstract GI http://annonc.oxfordjournals.org/content/25/suppl_4/mdu438.8.short

2185 CALGB/SWOG 80405: Phase III Trial of Irinotecan/5-FU/Leucovorin (FOLFIRI) or Oxaliplatin/5-FU/Leucovorin (mFOLFOX6) with Bevacizumab (BV) or Cetuximab (CET) for Patients (PTS) with KRAS Wild-Type (WT) Untreated Metastatic Adenocarcinoma of the colon

A. Venook, D. Niedzwiecki, H.J. Lenz, F. Innocenti, M.R. Mahoney, B. O'Neil, J. Shaw, B. Polite, H.
Hochster, J. Atkins, R. Goldberg, R. Mayer, R. Schilsky, M. Bertagnolli, C. Blanke, Cancer and
Leukemia Group B, SWOG, ECOG Ann Oncol vol 25 (supple 2) ii112-ii113 2014

Abstract GI http://annonc.oxfordjournals.org/content/25/suppl_2/ii112.2.full

2186 Impact of primary (1°) tumor location on overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB / SWOG 80405 (Alliance)

Alan P. Venook, Donna Niedzwiecki, Federico Innocenti, Briant Fruth, Claire Greene, Bert H. O'Neil,
James Edward Shaw, Blase N. Polite, Howard S. Hochster, Charles David Blanke, Richard M.
Goldberg, Richard L. Schilsky, Robert J. Mayer, Monica M. Bertagnolli, Heinz-Josef Lenz J Clin
Oncol vol 34 (suppl) abstr 3504 2016

Abstract GI <http://meetinglibrary.asco.org/content/161936-176>

2187 Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer

Alan P. Venook, Donna Niedzwiecki, Heinz-Josef Lenz, Federico Innocenti, Briant Fruth, Jeffrey A.
Meyerhardt, Deborah Schrag, Claire Greene, Bert H. O'Neil, James Norman Atkins, Scott Berry, Blase
N. Polite, Eileen M. O'Reilly, Richard M. Goldberg, Howard S. Hochster, Richard L. Schilsky, Monica

M. Bertagnolli, Anthony B. El-Khoueiry, Peter Watson, Al B. Benson, Daniel L. Mulkerin, Robert J. Mayer, Charles Blanke JAMA vol 317 (23) 2392-401 2017
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/28632865>

2188 CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC).

Alan P. Venook, Donna Niedzwiecki, Heinz-Josef Lenz, Federico Innocenti, Michelle R. Mahoney, Bert H. O'Neil, James Edward Shaw, Blase N. Polite, Howard S. Hochster, James Norman Atkins, Richard M. Goldberg, Robert J. Mayer, Richard L. Schilsky, Monica M. Bertagnolli, Charles David Blanke J Clin Oncol vol 32 (15_suppl) LBA3 2014
Abstract GI http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/LBA3

2189 Biologic Determinants of Tumor Recurrence in Stage II Colon Cancer: Validation Study of the 12-Gene Recurrence Score in Cancer and Leukemia Group B (CALGB) 9581

Alan P. Venook, Donna Niedzwiecki, Margarita Lopatin, Xing Ye, Mark Lee, Paula N. Friedman, Wendy Frankel, Kim Clark-Langone, Carl Millward, Steven Shak, Richard M. Goldberg, Najjia N. Mahmoud, Robert S. Warren, Richard L. Schilsky, Monica M. Bertagnolli J Clin Oncol vol 31 (14) 1775-1781 2013
Manuscript GI CALGB-9581, CALGB-150705 <http://www.ncbi.nlm.nih.gov/pubmed/23530100>

2190 Primary (1°) tumor location as an independent prognostic marker from molecular features for overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB / SWOG 80405 (Alliance)

Alan P. Venook, Fang-Shu Ou, Federico Innocenti, Howard S. Hochster, Donna Niedzwiecki, Richard Goldberg, Robert Mayer, Monica Bertagnolli, Tyler Zemla, Charles David Blanke, Xueping Qu, Omar Kabbarah, Heinz-Josef Lenz J Clin Oncol vol 35 (15 suppl) abstr 3503 2017
Abstract GI http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.3503

2191 Phase II Study of Everolimus in Metastatic Malignant Melanoma (NCCTGN0377, Alliance)

Jesus Vera Aguilera, Ravi D. Rao, Jacob B. Allred, Vera J. Suman, Harold E. Windschitl, Judith S. Kaur, William J. Maples, Val J. Lowe, Edward T. Creagan, Lori A. Erickson, Svetomir Markovic Oncologist vol 23 (8) 887-e94 2018
Manuscript Experimental <http://www.ncbi.nlm.nih.gov/pubmed/29666297>

2192 Receptor Activator of Nuclear Factor Kappa B (RANK) Expression in Primary Breast Cancer Correlates with Recurrence Free Survival and Development of Bone Metastases in I-SPY1 (CALGB 150007/150012; ACRIN 6657)

Neelima Vidula, Christina Yau, Jiali Li, Laura J. Esserman, Hope S. Rugo Breast Cancer Res Treat vol 165 (1) 129-38 2017
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/28577080>

2193 Androgen receptor gene expression in primary breast cancer

Neelima Vidula, Christina Yau, Denise Wolf, Hope S. Rugo NPJ Breast Cancer vol 5 2019
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/31840050>

2194 CALGB 100801 (Alliance): A phase II multi-center study of the addition of azacitidine (AZA) following allogeneic transplantation using a targeted busulfan based conditioning regimen for high risk myelodysplasia (MDS) and older patients with acute myeloid leukemia (AML)

Ravi Vij, Vera Hars, William Blum, Tsiporah Shore, Aaron Rapoport, Thomas Shea, Eva Hoke, Richard Stone, Paula Friedman, Kouros Owzar, Steven Devine Bone Marrow Transplantation vol 50 (S1) abstr P640 2015
Abstract Transplant <http://viewer.zmags.com/publication/b0929dae#/b0929dae/450>

2195 CALGB 100801 (Alliance): A phase II multi-center NCI cooperative group study of the addition of azacitidine (AZA) to reduced-intensity conditioning (RIC) allogeneic transplantation for high risk myelodysplasia (MDS) and older patients with acute myeloid leukemia (AML): Results of a busulfan test dose strategy

Ravi Vij, Vera Hars, Thomas Shea, Eva Hoke, William Blum, Richard Stone, Mark Ratain, Kouros Owzar, Steven Devine Blood vol 124 (21) abstr 543 2014
Abstract Transplant <http://www.bloodjournal.org/content/124/21/543>

2196 A phase II multi-center study of the addition of azacitidine to reduced-intensity conditioning allogeneic transplantation for high-risk myelodysplasia (and older patients with acute myeloid leukemia): CALGB 100801 (Alliance)

Ravi Vij, Jennifer Le-Rademacher, Kristina Laumann, Vera Hars, Kouros Owzar, Tsiporah Shore, Sumithira Vasu, Amanda Cashen, Luis Isola, Thomas Shea, Margarida DeMagalhaes-Silverman, David Hurd, Kenneth Meehan, Frank Beardell, Steven Devine Biol Blood Marrow Transplant vol 25 (10) 1984-92 2019
Manuscript Transplant <http://www.ncbi.nlm.nih.gov/pubmed/31212080>

2197 Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B.

Everett E Vokes, James E Herndon, Michael J Kelley, M Giulia Cicchetti, Nithya Ramnath, Harvey Neill, James N Atkins, Dorothy M Watson, Wallace Akerley, Mark R Green J Clin Oncol vol 25 (13) 1698-704 2007
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/17404369>

2198 Daratumumab + Lenalidomide, Bortezomib & Dexamethasone Improves Depth of Response in Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN AFT-29

Peter M. Voorhees, Jonathan L. Kaufman, Jacob Laubach, Douglas W. Sborov, Brandi Reeves, Cesar Rodriguez, Ajai Chari, Rebecca Silbermann, Luciano J. Costa, Larry D. Anderson Jr, Jr, Nitya Nathwani, Nina Shah, Yvonne A. Efebera, Caitlin Costello, Andrzej Jakubowiak, Tanya M. Wildes, Robert Z. Orlowski, Kenneth H. Shain, Andrew J. Cowan, Sean Murphy, Yana Lutska, Huiling Pei, Jon Ukropec, Jessica Vermeulen, Carla de Boer, Daniela Hoehn, Thomas S. Lin, Paul G. Richardson 546-547 2019
Abstract Myeloma
http://imw2019boston.org/images/Abstracts/17th_IMW_Abstract_Book_FINAL_V2.pdf

2199 Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial

Peter M. Voorhees, Jonathan L. Kaufman, Jacob Laubach, Douglas W. Sborov, Brandi Reeves, Cesar Rodriguez, Ajai Chari, Rebecca Silbermann, Luciano J. Costa, Larry D. Anderson Jr, Nitya Nathwani, Nina Shah, Yvonne A. Efebera, Sarah A. Holstein, Caitlin Costello, Andrzej Jakubowiak, Tanya M. Wildes, Robert Z. Orlowski, Kenneth H. Shain, Andrew J. Cowan, Sean Murphy, Yana Lutska, Huiling Pei, Jon Ukropec, Jessica Vermeulen, Carla de Boer, Daniela Hoehn, Thomas S. Lin, Paul G. Richardson Blood vol 136 (8) 936-945 2020
Manuscript Myeloma <http://www.ncbi.nlm.nih.gov/pubmed/32325490>

2200 Depth of response to daratumumab (DARA), lenalidomide, bortezomib, and dexamethasone (RVD) improves over time in patients (pts) with transplant-eligible newly diagnosed multiple myeloma (NDMM): GRIFFIN study update (AFT-29)

Peter M. Voorhees, Jonathan L. Kaufman, Jacob Laubach, Douglas W. Sborov, Brandi Reeves, Cesar Rodriguez, Ajai Chari, Rebecca Silbermann, Luciano J. Costa, Larry D. Anderson, Jr, Nitya Nathwani, Nina Shah, Yvonne A. Efebera, Caitlin Costello, Andrzej Jakubowiak, Tanya M. Wildes, Robert Z.

Orlowski, Kenneth H. Shain, Andrew J. Cowan, Sean Murphy, Yana Lutska, Huiling Pei, Jon Ukropec, Jessica Vermeulen, Carla de Boer, Daniela Hoehn, Thomas S. Lin, Paul G. Richardson Blood vol 134 (Supplement_1) 691 2019

Abstract Myeloma

https://ashpublications.org/blood/article/134/Supplement_1/691/426395/Depth-of-Response-to-Daratum

2201 Interim safety analysis of a phase 2 randomized study of daratumumab (dara), lenalidomide (r), bortezomib (v), and dexamethasone (d; dararvd) vs. rvd in patients (pts) with newly diagnosed multiple myeloma (mm) eligible for highdose therapy (hdt) and autologous stem cell transplantation (asct)

Peter M. Voorhees, Michael Morris, Luciano J. Costa, Reeves Brandi, Nitya Nathwani, Cesar Rodriguez, Yana Lutska, Laura Hydutsky, Huiling Pei, Jon Ukropec, Ming Qi, Thomas Lin, Paul G Richardson Blood vol 130 (suppl 1) 1879 2017

Abstract Myeloma http://www.bloodjournal.org/content/130/Suppl_1/1879?sso-checked=true

2202 Alliance A061202. A phase I/II study of pomalidomide, dexamethasone and ixazomib versus pomalidomide and dexamethasone for patients with multiple myeloma refractory to lenalidomide and proteasome inhibitor based therapy: Phase I results.

Peter M. Voorhees, Flora Mulkey, Hani Hassoun, Claudia E. Paba-Prada, Yvonne Efebera, Eva Hoke, Guadalupe Aquino, Destin Carlisle, Vera Suman, Paul G. Richardson Blood vol 126 (23) abstr 375 2015

Abstract Myeloma <http://www.bloodjournal.org/content/126/23/375>

2203 Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study

Peter M. Voorhees, Robert Z. Orlowski, Flora Mulkey, Peter Watson, Susan Geyer, Ben L. Sanford, Elizabeth Bennett, Asher A. Chanan-Khan, Clara D. Bloomfield, Richard A. Larson Br J Haematol vol 171 (3) 373-377 2015

Manuscript Leukemia <http://www.ncbi.nlm.nih.gov/pubmed/26202857>

2204 Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFIN

Peter M. Voorhees, Cesar Rodriguez, Brandi Reeves, Nitya Nathwani, Luciano J. Costa, Yana Lutska, Padma Bobba, Daniela Hoehn, Huiling Pei, Jon Ukropec, Ming Qi, Thomas S. Lin, Paul G. Richardson Blood Adv vol 5 (4) 1092-6 2021

Manuscript Myeloma <http://www.ncbi.nlm.nih.gov/pubmed/33606004>

2205 Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Efficacy and Safety Analysis of the Safety Run-in Population of GRIFFIN (AFT-29)

Peter M. Voorhees, Cesar Rodriguez, Brandi Reeves, Nitya Nathwani, Luciano J Costa, Yana Lutska, Cynthia Haines, Daniela Hoehn, Huiling Pei, Jon Ukropec, Ming Qi, Thomas S Lin, Paul G Richardson Blood vol 35 (Supplement 1) 48-49 2020

Abstract Myeloma

<https://ashpublications.org/blood/article/136/Supplement%201/48/472928/Daratumumab-DARA-Plus-L>

2206 Efficacy and Updated Safety Analysis of a Safety Run-in Cohort from Griffin, a Phase 2 Randomized Study of Daratumumab (Dara), Bortezomib (V), Lenalidomide (R), and Dexamethasone (D; DaraVrd) Vs. Vrd in Patients (Pts) with Newly Diagnosed (ND) Multiple Myeloma (MM) Eligible for HighDose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT)

Peter M. Voorhees, Cesar Rodriguez, Brandi Reeves, Nitya Nathwani, Luciano J Costa, Yana Lutska, Daniela Hoehn, Huiling Pei, Jon Ukropec, Ming Qi, Thomas Lin, Paul Richardson Blood vol 132

(suppl 1) 151 2018

Abstract Myeloma http://www.bloodjournal.org/content/132/Suppl_1/151

2207 A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202)

Peter M. Voorhees, Vera J. Suman, Sascha A. Tuchman, Jacob P. Laubach, Hani Hassoun, Yvonne A. Efebera, Flora Mulkey, Misty Bova-Solem, Katelyn Santo, Destin Carlisle, Philip L. McCarthy, Paul G. Richardson Am J Hematol vol 96 (12) 1595-1603 2021

Manuscript Myeloma <http://www.ncbi.nlm.nih.gov/pubmed/34559902>

2208 Depth of Response to Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone Improves Over Time in Patients With Transplant-Eligible Newly Diagnosed Multiple Myeloma: GRIFFIN Study Update

Peter M Voorhees, Jonathan L Kaufman, Jacob Laubach, Douglas W Sborov, Brandi Reeves, Cesar Rodriguez, Ajai Chari, Rebecca Silbermann, Luciano J Costa, Larry D Jr Anderson, Nitya Nathwani, Nina Shah, Yvonne A Efebera, Caitlin Costello, Andrzej Jakubowiak, Tanya M Wildes, Robert Z Orłowski, Kenneth H Shain, Andrew J Cowan, Sean Murphy, Yana Lutska, Huiling Pei, Jon Ukropec, Jessica Vermeulen, Carla de Boer, Daniela Hoehn, Thomas S Lin, Paul G Richardson Bone Marrow Transplantation vol 55 p 127, abstr O120 2020

Abstract Myeloma <https://www.nature.com/articles/s41409-020-01119-3.pdf>

2209 Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial.

Peter M Voorhees, Douglas W Sborov, Jacob Laubach, Jonathan L Kaufman, Brandi Reeves, Cesar Rodriguez, Ajai Chari, Rebecca Silbermann, Luciano J Costa, Larry D Anderson, Nitya Nathwani, Nina Shah, Naresh Bumma, Yvonne A Efebera, Sarah A Holstein, Caitlin Costello, Andrzej Jakubowiak, Tanya M Wildes, Robert Z Orłowski, Kenneth H Shain, Andrew J Cowan, Shira Dinner, Huiling Pei, Annelore Cortoos, Sharmila Patel, Thomas S Lin, Saad Z Usmani, Paul G Richardson Lancet Haematol 2023

Manuscript Myeloma <http://www.ncbi.nlm.nih.gov/pubmed/37708911>

2210 Addition of ixazomib to pomalidomide-dexamethasone improves progression-free survival for myeloma patients progressing on frontline lenalidomide: results of the randomized alliance study A061202

Peter Voorhees, Vera Suman, Yvonne Efebera, Noopur Raje, Sascha Tuchman, Cesar Rodriguez, Katelyn Santo, Misty Bova-Solem, Destin Carlisle, Saad Usmani, Phil McCarthy, Paul Richardson Clinical Lymphoma, Myeloma & Leukemia vol 22 (Supplement 1) P-282 2022

Abstract Myeloma

https://www.myelomasociety.org/wp-content/uploads/2022/09/IMS2022-supplement_v3_25-07-2022-00

2211 The Addition of Ixazomib (IXA) to Pomalidomide (POM) and Dexamethasone (DEX) Improves Progression-Free Survival (PFS) for Multiple Myeloma (MM) Patients (Pts) Progressing on Lenalidomide (LEN) as Part of 1st Line Therapy: Results of the Randomized Phase II Alliance Study A061202

Peter Voorhees, Vera Suman, Yvonne Efebera, Noopur Raje, Sascha Tuchman, Cesar Rodriguez, Katelyn Santo, Misty Bova-Solem, Destin Carlisle, Saad Usmani, Phil McCarthy, Paul Richardson Hemasphere vol 6 (suppl) 858-9 2022

Abstract Myeloma <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429562/>

2212 Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial

Maria Teresa Voso, Richard A. Larson, Dan Jones, Guido Marcucci, Thomas Prior, Jürgen Krauter,

Michael Heuser, Serena Lavorgna, Josep Nomdedeu, Susan M. Geyer, Alison Walker, Andrew H. Wei, Jorge Sierra, Miguel A. Sanz, Joseph M. Brandwein, Theo M. de Witte, Joop H. Jansen, Dietger Niederwieser, Frederick R. Appelbaum, Bruno C. Medeiros, Martin S. Tallman, Richard F. Schlenk, Arnold Ganser, Sergio Amadori, Yuan Cheng, YinMiao Chen, Celine Pallaud, Ling Du, Alfonso Picocchi, Gerhard Ehninger, John Byrd, Christian Thiede, Konstanze Döhner, Richard M. Stone, Hartmut Döhner, Clara D. Bloomfield, Francesco Lo-Coco *Blood Adv* vol 4 (19) 4945-54 2020
Manuscript *Leukemia* <http://www.ncbi.nlm.nih.gov/pubmed/33049054>

2213 RATIFY: Prognostic impact of FLT3 tyrosine kinase domain (TKD) and NPM1 mutation status in patients with newly diagnosed acute myeloid leukemia (AML) treated with midostaurin or placebo plus standard chemotherapy (Alliance)

Maria Teresa Voso, Richard A. Larson, Thomas W Prior, Guido Marcucci, Dan Jones, Jürgen Krauter, Michael Heuser, Serena Lavorgna, Josep Noedeu, Kristine Laumann, Susan M. Geyer, Rebecca B. Klisovic, Andrew Wei, Jorge Sierra, Miguel A. Sanz, Joseph M. Brandwein, T. M. M de Witte, Joop H. Jansen, Dietger Niederwieser, Frederick R. Appelbaum, Bruno C. Medeiros, Martin S. Tallman, Richard F. Schlenk, Arnold Ganser, Hubert Serve, Gerhard Ehninger, Sergio Amadori, Yuan Cheng, Insa Gathmann, Eva Tiecke, Christian Thiede, Konstanze Döhner, Hartmut Döhner, Richard M. Stone, Clara D. Bloomfield, Francesco Lo-Coco *Blood* vol 132 (Suppl 1) 2668 2018
Abstract *Leukemia* http://www.bloodjournal.org/content/132/Suppl_1/2668?sso-checked=true

2214 Ratify (Alliance 10603): Prognostic Impact of FLT3 Tyrosine Kinase Domain (TKD) and NPM1 Mutation Status in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Treated with Midostaurin Plus Standard Chemotherapy

Maria Teresa Voso, Richard A. Larson, Thomas W Prior, Guido Marcucci, Dan Jones, Jürgen Krauter, Michael Heuser, Serena Lavorgna, Josep Nomdedeu, Susan M. Geyer, Rebecca B. Klisovic, Andrew Wei, Jorge Sierra, Miguel A. Sanz, Joseph M. Brandwein, T. M. M de Witte, Joop H. Jansen, Dietger Niederwieser, Frederick R. Appelbaum, Bruno C Medeiros, Martin S. Tallman, Richard F. Schlenk, Arnold Ganser, Sergio Amadori, Yuan Cheng, YinMiao Chen, Eva Tiecke, Christian Thiede, Konstanze Döhner, Hartmut Döhner, Richard M. Stone, Clara D. Bloomfield, Francesco Lo-Coco. *HemaSphere* vol 3 (Issue) 79-80 2019
Abstract *Leukemia*
https://journals.lww.com/hemasphere/Fulltext/2019/06001/RATIFY__PROGNOSTIC_IMPACT_OF_FI

2215 Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34640 Patients in the ACCENT Database

Anna D Wagner, Axel Grothey, Thierry Andre, Jesse G Dixon, Norman Wolmark, Daniel G Haller, Carmen J Allegra, Aimery de Gramont, Eric VanCutsem, Steven R Alberts, Thomas J George, Michael J O'Connell, Christopher Twelves, Julien Taieb, Leonard B Saltz, Charles D Blanke, Edoardo Francini, Rachel Kerr, Greg Yothers, Jean F Seitz, Silvia Marsoni, Richard M Goldberg, Qian Shi *J Natl Cancer Inst* vol 113 (4) 400-7 2020
Manuscript *GI* <http://www.ncbi.nlm.nih.gov/pubmed/32835356>

2216 5-year Follow-up of a Randomized Controlled Trial of Immediate versus Delayed Zoledronic Acid for Prevention of Bone Loss in Postmenopausal Women with Breast Cancer Starting Letrozole after Tamoxifen: N03CC (Alliance)

Nina D. Wagner-Johnston, Jeff A. Sloan, Heshan Liu, Ann E. Kearns, Stephanie L. Hines, Suneetha Puttabasavaiah, Shaker R. Dakhil, Jacqueline M. Lafky, Edith A. Perez, Charles L. Loprinzi *Cancer* vol 121 (15) 2537-2543 2015
Manuscript *Symptom Inter* <http://www.ncbi.nlm.nih.gov/pubmed/25930719>

2217 New Recurrent Balanced Translocations in Acute Myeloid Leukemia and Myelodysplastic Syndromes: Cancer and Leukemia Group B (CALGB) 8461

A. Walker, K. Mrózek, J. Kohlschmidt, K. W. Rao, M. J. Pettenati, L. J. Sterling, G. Marcucci, A. J.

2218 Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance)

Alison R. Walker, Guido Marcucci, Jun Yin, William Blum, Wendy Stock, Jessica Kohlschmidt, Krzysztof Mrózek, Andrew J. Carroll, Ann-Kathrin Einfeld, Eunice S. Wang, Sawyer Jacobson, Jonathan E. Kolitz, Mohan Thakuri, Grek Sutamtewagul, Ravi Vij, Robert K. Stuart, John C. Byrd, Clara D. Bloomfield, Richard M. Stone, Richard A. Larson Blood Adv vol 5 (13) 2775-87 2021
Manuscript Leukemia <http://www.ncbi.nlm.nih.gov/pubmed/34251414>

2219 No evidence for microsatellite instability in acute myeloid leukemia

Christopher J. Walker, Ann-Kathrin Einfeld, Luke K. Genutis, Maryam Bainazar, Jessica Kohlschmidt, Krzysztof Mrózek, Andrew J. Carroll, Jonathan E. Kolitz, Bayard L. Powell, Eunice S. Wang, Richard M. Stone, Ralf Bundschuh, Albert de la Chapelle, Clara D. Bloomfield Leukemia vol 31 (6) 1474-6 2017
Manuscript Leuk Corr Sci CALGB-20202, CALGB-8461, CALGB-9665
<http://www.ncbi.nlm.nih.gov/pubmed/28336936>

2220 Uniparental Disomies (UPD) of Chromosome 13q Is Associated with Shorter Disease-Free Survival in Adult Patients (Pts) with De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML)

Christopher J. Walker, Ann-Kathrin Einfeld, Jessica Kohlschmidt, Krzysztof Mrózek, Deedra Nicolet, James S. Blachly, Christopher Oakes, Shelley Orwick, Bayard Powell, Jonathan Kolitz, Chi Song, Andrew J. Carroll, Richard M. Stone, Albert De La Chapelle, John C. Byrd, Clara D. Bloomfield Blood vol 132 (Suppl 1) 2777 2018
Abstract Leuk Corr Sci CALGB-8461, CALGB-20202
http://www.bloodjournal.org/content/132/Suppl_1/2777.abstract

2221 Distinct Gene Expression Profiles and Mutations Are Associated with Disease Relapse after Achievement of Complete Remission (CR) in Adult Patients younger than 60 years with de novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) (Alliance)

Christopher J. Walker, Ann-Kathrin Einfeld, Hatice Gulcin Ozer, Jessica Kohlschmidt, Deedra Nicolet, Krzysztof Mrózek, Dimitrios Papaioannou, Luke K. Genutis, Bayard L. Powell, Geoffrey L. Uy, Jonathan E. Kolitz, Andrew J. Carroll, Richard M. Stone, Ramiro Garzon, John C. Byrd, Albert De La Chapelle, Clara D. Bloomfield Blood vol 134 (Supplemental_1) 1247 2019
Abstract Leuk Corr Sci CALGB-20202, CALGB-8461, CALGB-9665
https://ashpublications.org/blood/article/134/Supplement_1/1247/426892/Distinct-Gene-Expression-Prof

2222 Genetic Characterization and Prognostic Relevance of Acquired Uniparental Disomies in Cytogenetically Normal Acute Myeloid Leukemia

Christopher J. Walker, Jessica Kohlschmidt, Ann-Kathrin Einfeld, Krzysztof Mrózek, Sandya Liyanarachchi, Chi Song, Deedra Nicolet, James S. Blachly, Marius Bill, Dimitrios Papaioannou, Christopher C. Oakes, Brain Giacomelli, Luke K. Genutis, Sophia E. Maharry, Shelley Orwick, Kellie J. Archer, Bayard L. Powell, Jonathan E. Kolitz, Geoffrey L. Uy, Eunice S. Wang, Andrew J. Carroll, Richard M. Stone, John C. Byrd, Albert de la Chapelle, Clara D. Bloomfield Clin Cancer Res vol 25 (21) 6524-6531 2019
Manuscript Leuk Corr Sci CALGB-8721, CALGB-10201, CALGB-10502, CALGB-10503, CALGB-10603, CALGB-19808, CALGB-20202, CALGB-8461, CALGB-8525, CALGB-8821, CALGB-8923, CALGB-9022, CALGB-9222, CALGB-9420, CALGB-9621, CALGB-9665, CALGB-9720 <http://www.ncbi.nlm.nih.gov/pubmed/31375516>

2223 Gene expression signature predicts relapse in adult patients with cytogenetically normal acute

myeloid leukemia

Christopher J. Walker, Krzysztof Mrózek, Hatice Gulcin Ozer, Deedra Nicolet, Jessica Kohlschmidt, Dimitrios Papaioannou, Luke K. Genutis, Marius Bill, Bayard L. Powell, Geoffrey L. Uy, Jonathan E. Kolitz, Andrew J. Carroll, Richard M. Stone, Ramiro Garzon, John C. Byrd, Ann-Kathrin Einfeld, Albert de la Chapelle, Clara D. Bloomfield *Blood Adv* vol 5 (5) 1474-82 2021
Manuscript *Leuk Corr Sci* CALGB-8525, CALGB-8721, CALGB-10503, CALGB-10603, CALGB-19808, CALGB-9222, CALGB-9621 <http://www.ncbi.nlm.nih.gov/pubmed/33683341>

2224 Genome-wide association study (GWAS) identifies a significant acute myeloid leukemia (AML) susceptibility locus near BICRA (Alliance)

Christopher J. Walker, Christopher C. Oakes, Luke K. Genutis, Brian Giacobelli, Sandya Liyanarachchi, Deedra Nicolet, Ann-Kathrin Einfeld, Markus Scholz, Pamela Brock, Jessica Kohlschmidt, Krzysztof Mrózek, Marius Bill, Andrew J. Carroll, Jonathan E. Kolitz, Bayard L. Powell, Eunice S. Wang, Dietger W. Niederwieser, Richard M. Stone, John C. Byrd, Sebastian Schwind, Albert De La Chapelle, Clara D. Bloomfield *Blood* vol 132 (Suppl 1) 85 2018
Abstract *Leuk Corr Sci* CALGB-8461, CALGB-20202
http://www.bloodjournal.org/content/132/Suppl_1/85.abstract?sso-checked=true

2225 Genome-wide association study identifies an acute myeloid leukemia susceptibility locus near BICRA

Christopher J. Walker, Christopher C. Oakes, Luke K. Genutis, Brian Giacobelli, Sandya Liyanarachchi, Deedra Nicolet, Ann-Kathrin Einfeld, Markus Scholz, Pamela Brock, Jessica Kohlschmidt, Krzysztof Mrózek, Marius Bill, Andrew J. Carroll, Jonathan E. Kolitz, Bayard L. Powell, Eunice S. Wang, Dietger W. Niederwieser, Richard M. Stone, John C. Byrd, Sebastian Schwind, Albert de la Chapelle, Clara D. Bloomfield *Leukemia* vol 33 (3) 771-5 2019
Manuscript *Leuk Corr Sci* CALGB-8461, CALGB-9665, CALGB-20202
<http://www.ncbi.nlm.nih.gov/pubmed/30291333>

2226 Meta-Analysis of Genome-Wide Association Studies of Acute Myeloid Leukemia (AML) Patients Identifies Loci Associated with Risk of 11q23/KMT2A-Translocated and Core-Binding Factor (CBF) AML (Alliance).

Christopher J. Walker, Junke Wang, Alyssa I. Clay-Gilmour, Krzysztof Mrózek, Deedra Nicolet, Christopher C. Oakes, Jessica Kohlschmidt, Bayard L. Powell, Jonathan E. Kolitz, Andrew Carroll, Ezgi Karaesmen, Abbas Rizvi, Qianqian Zhu, Li Yan, Leah Preus, Song Liu, Yiwen Wang, Daniel O. Stram, Loreall Pooler, Xin Sheng, Christopher Haiman, David Van Den Berg, Amy Webb, Guy Brock, Stephen Spellman, Marcelo Pasquini, Philip McCarthy, James Allan, Friedrich Stölzel, Kenan Onel, Richard M. Stone, Ramiro Garzon, Clara D. Bloomfield, John C. Byrd, Albert de la Chapelle, Terri Hahn, Ann-Kathrin Einfeld, Lara Sucheston-Campbell *Blood* vol 136 (Supplement 1) 29-30 2020
Abstract *PPP* CALGB-20202, CALGB-8461, CALGB-9665
<https://ashpublications.org/blood/article/136/Supplement%201/29/471743/Meta-Analysis-of-Genome-W>

2227 Impact of a multi-disciplinary patient education session on accrual to a difficult clinical trial: the Toronto experience with the surgical prostatectomy versus interstitial radiation intervention trial.

Kris Wallace, Neil Fleshner, Michael Jewett, Joan Basiuk, Juanita Crook *J Clin Oncol* vol 24 (25) 4158-62 2006
Manuscript *GU* <http://www.ncbi.nlm.nih.gov/pubmed/16943531>

2228 High resolution array-based CGH and SNP studies of AML genomes

M. J. Walter, R. Ries, X. Li, W. Shannon, J. Payton, J. Books, C. Bloomfield, K. Mrozek, A. Ruppert, J. Dipersio, D. Link, M. Tomasson, T. Graubert, P. Westervelt, M. Watson, S. Heath, J. Baty, J. Armstrong, E. Mardis, R. Wilson, R. Selzer, T. Richmond, J. Kitzman, P. Eis, T. Ley *Blood* vol 110 (11) 40A-40A 2007
Abstract *Leuk Corr Sci* CALGB-8461, CALGB-9665

2229 Acquired copy number alterations in adult acute myeloid leukemia genomes

Matthew J. Walter, Jacqueline E. Payton, Rhonda E. Ries, William D. Shannon, Hrishikesh Deshmukh, Yu Zhao, Jack Baty, Sharon Heath, Peter Westervelt, Mark A. Watson, Michael H. Tomasson, Rakesh Nagarajan, Brian P. O'Gara, Clara D. Bloomfield, Krzysztof Mrózek, Rebecca R. Selzer, Todd A. Richmond, Jacob Kitzman, Joel Geoghegan, Peggy S. Eis, Rachel Maupin, Robert S. Fulton, Michael McLellan, Richard K. Wilson, Elaine R. Mardis, Daniel C. Link, Timothy A. Graubert, John F. DiPersio, Timothy J. Ley Proc Natl Acad Sci USA vol 106 (31) 12950-12955 2009
Manuscript Leuk Corr Sci <http://www.ncbi.nlm.nih.gov/pubmed/19651600>

2230 Plasma 25-Hydroxyvitamin D Levels and Survival in Stage III Colon Cancer: Findings from CALGB/SWOG 80702 (Alliance).

Qiao-Li Wang, Chao Ma, Chen Yuan, Qian Shi, Brian M Wolpin, Yin Zhang, Charles S Fuchs, Jeffrey Meyer, Tyler Zemla, En Cheng, Priya Kumthekar, Katherine A Guthrie, Felix Couture, Philip Kuebler, Pankaj Kumar, Benjamin Tan, Smitha Krishnamurthi, Richard M Goldberg, Alan Venook, Charles Blanke, Anthony F Shields, Eileen M O'Reilly, Jeffrey A Meyerhardt, Kimmie Ng Clin Cancer Res vol 29 (14) 2621-30 2023
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/37289007>

2231 A Phase II Study of Carboplatin, Etoposide and Exisulind in Patients with Extensive Stage Small Cell Lung Cancer: CALGB 30104

X. F. Wang, R. Govindan, J. E. Herndon 2nd, R. C. Barrier, D. Watson, R. Florence, E. E. Vokes, M. R. Green J Clin Oncol vol 23 (16s) abst 7161 2005
Abstract Respiratory
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=34&abstractID

2232 Vatalanib population pharmacokinetics in patients with myelodysplastic syndrome: CALGB 10105 (Alliance)

X Wang, K. Owzar, P. Gupta, R. A. Larson, F. Mulkey, A. A. Miller, L. D. Lewis, D. Hurd, R. Vij, M. J. Ratain, D. Murry Clin Pharmacol Ther vol 93 (S82-S82) 2013
Abstract PPP <http://www.nature.com/clpt/journal/v93/n1s/index.html#Abstracts-of-Papers>

2233 Validation of Survival Prognostic Models for Non-Small-Cell Lung Cancer in Stage- and Age-specific Groups

Xiaofei Wang, Lin Gu, Ying Zhang, Daniel J. Sargent, William Richards, Apar Kishor Ganti, Jeffery Crawford, Harvey Jay Cohen, Thomas Stinchcombe, Everett Vokes, Herbert Pang Lung Cancer vol 90 (2) 281-287 2015
Manuscript Respiratory CALGB-8834, CALGB-8836, CALGB-8931, CALGB-8932, CALGB-9132, CALGB-9532, CALGB-140202, CALGB-140203, CALGB-30203, CALGB-30303, CALGB-30402, CALGB-30406, CALGB-30506, CALGB-30704, CALGB-39802, CALGB-39809, CALGB-39904, CALGB-9238, CALGB-9335, CALGB-9633, CALGB-9730, CALGB-9731, CALGB-9761,
Comprehensive <http://www.ncbi.nlm.nih.gov/pubmed/26319317>

2234 Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials

Xiaofei Wang, Xiaoyi Wang, Lydia Hodgson, Stephen L. George, Daniel J. Sargent, Nate R. Foster, Apar Kishor Ganti, Thomas E. Stinchcombe, Jeffrey Crawford, Robert Kratzke, Alex A. Adjei, Hedy L. Kindler, Everett E. Vokes, Herbert Pang Oncologist vol 22 (2) 189-198 2017
Manuscript Respiratory CALGB-8435, CALGB-8638, CALGB-8833, CALGB-8933, CALGB-9031, CALGB-30101, CALGB-30107, CALGB-30307, CALGB-30601, CALGB-39807, CALGB-9131, CALGB-9234, CALGB-9530, CALGB-9631, CALGB-9733, NCCTG-N0021, NCCTG-N0623

<http://www.ncbi.nlm.nih.gov/pubmed/28188257>

2235 Vatalanib population pharmacokinetics in patients with myelodysplastic syndrome: CALGB 10105 (Alliance)

Xiaofeng Wang, Kouros Owzar, Pankaj Gupta, Richard A Larson, Flora Mulkey, Antonius A Miller, Lionel D Lewis, David Hurd, Ravi Vij, Mark J Ratain, Daryl J Murry *Br J Clin Pharmacol* vol 78 (5) 1005-13 2014

Manuscript PPP <http://www.ncbi.nlm.nih.gov/pubmed/24838014>

2236 Cholesterol-lowering Intervention Decreases mTOR Complex 2 Signaling and Enhances Antitumor Immunity

Yanping Wang, Sungyong You, Shengchen Su, Austin Yeon, Eric M. Lo, Sungjin Kim, James L. Mohler, Michael R. Freeman, Hyung L. Kim *Clin Cancer Res* vol 28 (2) 414-24 2022

Manuscript Prevention <http://www.ncbi.nlm.nih.gov/pubmed/34728526>

2237 Impact of Race, Ethnicity and BMI on Achievement of Pathologic Complete Response Following Neoadjuvant Chemotherapy for Breast Cancer: A Pooled Analysis of Four Prospective Alliance Clinical Trials (A151426)

Erica T. Warner, Karla V. Ballman, Carrie Strand, Judy Boughey, Aman U. Buzdar, Lisa A. Carey, William M. Sikov, H. Partridge *Breast Cancer Res Treat* vol 159 (1) 109-118 2016

Manuscript Disparities ACOSOG-Z1041, ACOSOG-Z1071, CALGB-40601, CALGB-40603
<http://www.ncbi.nlm.nih.gov/pubmed/27449492>

2238 Age, Race, BMI and Pathologic Complete Response Following Neoadjuvant Chemotherapy: An Analysis of Four Alliance Clinical Trials

Erica T. Warner, Karla V. Ballman, Carrie Strand, Ann H. Partridge *J Clin Oncol* vol 33 (suppl 285) 33 2015

Abstract Disparities ACOSOG-Z1031, ACOSOG-Z1041, CALGB-40601, CALGB-40603
<http://meetinglibrary.asco.org/content/155240-163>

2239 A novel interaction of genotype, gender and adjuvant treatment in survival after resection of stage III colon cancer: Results of CALGB 89803

R. S. Warren, C. E. Atreya, D. Niedzwiecki, R. J. Mayer, R. M. Goldberg, C. C. Compton, V. K. Weinberg, M. M. Bertagnolli *J Clin Oncol* vol 30 (4s) abstr 452 2012

Abstract GI <http://meetinglibrary.asco.org/content/88492-115>

2240 Association of TP53 Mutational Status and Gender with Survival After Adjuvant Treatment for Stage III Colon Cancer: Results of CALGB 89803

Robert S. Warren, Chloe E. Atreya, Donna Niedzwiecki, Vivian K. Weinberg, David B. Donner, Robert J. Mayer, Richard M. Goldberg, Carolyn C. Compton, Marlene B. Zuraek, Cynthia Ye, Leonard B. Saltz, Monica M. Bertagnolli *Clin Cancer Res* vol 19 (20) 5777-5787 2013

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/23983256>

2241 Economic analysis of the Clinical Outcomes of Surgical Therapy (COST) trial comparing laparoscopically-assisted colectomy (LAC) with open colectomy (OC) for colon cancer.

J. Weeks, H. Nelson, D. Romanus, K. Long, D. Sargent *J Clin Oncol* vol 26 (15s) abstr 6502 2008

Abstract Health Outcomes INT-0146, NCCTG-93-46-55, CALGB-9396
http://www.abstract.asco.org/AbstView_55_34994.html

2242 Perioperative gemcitabine + erlotinib plus pancreaticoduodenectomy for resectable pancreatic adenocarcinoma: ACOSOG Z5041 (Alliance) phase II trial

Alice C. Wei, Fang-Shu Ou, Qian Shi, Xiomara Carrero, Eileen M. O'Reilly, Jeffrey Meyerhardt, Robert A. Wolff, Hedy L. Kindler, Douglas B. Evans, Vikram Deshpande, Joseph Misdraji, Eric

Tamm, Dushyant Sahani, Malcolm Moore, Elliot Newman, Nipun Merchant, Jordan Berlin, Laura W. Goff, Peter Pisters, Mitchell C. Posner *Ann Surg Oncol* vol 26 (13) 4489-97 2019
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/31418130>

2243 A phase II study of pre- and post-operative gemcitabine and erlotinib plus pancreaticoduodenectomy (PD) for patients with resectable pancreatic ductal adenocarcinoma (PDAC): ACOSOG/ Alliance Z5041 Trial

Alice Chia-chi Wei, Fang-Shu Ou, Qian Shi, Eileen Mary O'Reilly, Jeffrey A. Meyerhardt, Robert A. Wolff, Hedy L. Kindler, Douglas B. Evans, Vikram Deshpande, Joseph Misdraji, Eric P. Tamm, Dushyant Sahani, Malcolm J. Moore, Elliot Newman, Nipun B. Merchant, Jordan Berlin, Laura Williams Goff, Peter W. T. Pisters, Mitchell C. Posner *J Clin Oncol* vol 36 (15_suppl) 4112 2018
Abstract GI http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.4112

2244 Factors associated with nodal pathologic complete response among breast cancer patients treated with neoadjuvant chemotherapy: results of CALGB 40601 (HER2+) and 40603 (triple-negative) (Alliance)

Anna Weiss, Jordan Campbell, Karla V. Ballman, William M. Sikov, Lisa A. Carey, E. Shelley Hwang, Matthew M. Poppe, Ann H. Partridge, David W. Ollila, Mehra Golshan *Ann Surg Oncol* vol 28 (11) 5960-71 2021
Manuscript Breast CALGB-40601, CALGB-40603 <http://www.ncbi.nlm.nih.gov/pubmed/33821344>

2245 Factors associated with residual nodal disease among breast cancer patients treated with neoadjuvant chemotherapy: Results of CALGB 40601 (HER2-positive) and 40603 (triple negative) (Alliance)

Anna Weiss, Jordan Campbell, Karla Ballman, William Sikov, Lisa Carey, Shelley Hwang, Matthew Poppe, Ann Partridge, David Ollila, Mehra Golshan *Ann Surg Oncol* vol 20 (Suppl 1) p S9 2021
Abstract Breast CALGB-40601, CALGB-40603
<https://link.springer.com/content/pdf/10.1245/s10434-021-09682-9.pdf>

2246 Dissemination and implementation of a fertility preservation decision aid website for women with cancer: recommendations from ten experts in the field

June Weston, Aubri Hoffman, Sukhkamal Campbell, Laura Crocker, Deborah Holman, Robert Volk *Journal of Assisted Reproduction and Genetics* vol 37 987–1015 2020
Abstract CCDD <https://link.springer.com/article/10.1007%2Fs10815-020-01754-1#article-info>

2247 Autologous stem cell transplantation (SCT) following sequential chemotherapy and imatinib for adults with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) - CALGB study 10001

M. Wetzler, W. Stock, K. A. Donohue, K. Owzar, D. A. Sher, E. E. Hoke, J. M. Mccarty, W. G. Blum, B. L. Powell, C. D. Bloomfield, C. A. Linker, R. A. Larson *Blood* vol 110 (11) 843A-844A 2007
Abstract Leukemia CALGB-10001, CALGB-8461, CALGB-9665, CALGB-9862
http://www.abstracts2view.com/hem07/view.php?nu=HEM07L1_1631

2248 Imatinib and Autologous Stem Cell Transplantation for Philadelphia Positive Acute Lymphoblastic Leukemia (Ph+ ALL) – CALGB study 10001

M. Wetzler, W. Stock, C. Linker, R. A. Larson *Ann Hematol* vol 87 (Suppl 1) S92-S93 2008
Abstract Leukemia <http://www.springerlink.com/content/u34p00527070m826/fulltext.pdf>

2249 Autologous Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Achieves Outcomes Similar to Allogeneic Transplantation - Results of CALGB 10001 (Alliance)

M. Wetzler, D. Watson, W. Stock, K. Owzar, G. Koval, E. Hoke, J. M. Mccarty, W. Blum, B. L. Powell, G. Marcucci, C. D. Bloomfield, C. Linker, R. A. Larson *Blood* vol 120 (21) -816 2012

2250 Feasibility of administering oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia – Cancer and leukemia group B study 10107

Meir Wetzler, Kathleen A. Donohue, Olatoyosi M. Odenike, Eric J. Feldman, David D. Hurd, Richard M. Stone, Peter Westerfelt, Clara D. Bloomfield, Richard A. Larson *Leuk Lymphoma* vol 49 (7) 1274-1278 2008

Manuscript *Leukemia* <http://www.ncbi.nlm.nih.gov/pubmed/18452072>

2251 Intensive induction is effective in selected octogenarian acute myeloid leukemia patients: prognostic significance of karyotype and selected molecular markers used in the European LeukemiaNet classification

Meir Wetzler, Krzysztof Mrózek, Jessica Kohlschmidt, Hervé Dombret, Hartmut Döhner, Sylvain Pilorge, Utz Krug, Andrew J. Carroll, Richard A. Larson, Guido Marcucci, Wolfgang Hiddemann, Thomas Büchner, Clara D. Bloomfield *Haematologica* vol 99 (2) 308-313 2014

Manuscript *Leuk Corr Sci CALGB-8221, CALGB-8525, CALGB-9720, CALGB-10201, CALGB-8923* <http://www.ncbi.nlm.nih.gov/pubmed/24097631>

2252 Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511

Meir Wetzler, Ben L. Sanford, Joanne Kurtzberg, Divino DeOliveira, Stanley R. Frankel, Bayard L. Powell, Jonathan E. Kolitz, Clara D. Bloomfield, Richard A. Larson *Blood* vol 109 (10) 4164-4167 2007

Manuscript *Leuk Corr Sci CALGB-8461, CALGB-9511* <http://www.ncbi.nlm.nih.gov/pubmed/17264295>

2253 Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance)

Meir Wetzler, Dorothy Watson, Wendy Stock, Gregory Koval, Flora A. Mulkey, Eva E. Hoke, John M. McCarty, William G. Blum, Bayard L. Powell, Guido Marcucci, Clara D. Bloomfield, Charles A. Linker, Richard A. Larson *Haematologica* vol 99 (1) 111-115 2014

Manuscript *Leukemia* <http://www.ncbi.nlm.nih.gov/pubmed/24077846>

2254 Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of paclitaxel-induced sensory peripheral neuropathy

Heather E. Wheeler, Eric R. Gamazon, Claudia Wing, Uchenna O. Njiaju, Chidiamara Njoku, R. Michael Baldwin, Kouros Owzar, Chen Jiang, Dorothy Watson, Ivo Shterev, Michiaki Kubo, Hitoshi Zembutsu, Eric Winer, Clifford Hudis, Lawrence N. Shulman, Yusuke Nakamura, Mark J. Ratain, Deanna L. Kroetz, Nancy J. Cox, M. Eileen Dolan *Clin Cancer Res* vol 19 (2) 491-499 2013

Manuscript *PPP* <http://www.ncbi.nlm.nih.gov/pubmed/23204130>

2255 Adverse Prognostic Impact of FLT3 Internal Tandem Duplication (ITD) Is Age-Associated in Older ≥ 60 Years (Y) De Novo cytogenetically Normal Acute Myeloid Leukemia (CN-AML) Patients (Pts): a Cancer and Leukemia Group B (CALGB) Study

S. P. Whitman, K. Maharry, M. D. Radmacher, K. Mrozek, D. Margeson, K. B. Holland, H. Becker, Y. Z. Wu, S. Schwind, M. R. Baer, B. L. Powell, R. M. Stone, A. J. Carroll, R. A. Larson, M. A. Caligiuri, G. Marcucci, C. D. Bloomfield *Blood* vol 114 (22) 631-632 2009

Abstract *Leuk Corr Sci CALGB-10201, CALGB-20202, CALGB-8461, CALGB-9720* <http://www.bloodjournal.org/content/114/22/1579>

2256 Improved clinical outcome of cytogenetically normal acute myeloid leukemia patients with the MLL partial tandem duplication: A Cancer and Leukemia Group B (CALGB) study

S. P. Whitman, A. S. Ruppert, G. Marcucci, K. A. Mrozek, P. Paschka, C. Langer, C. D. Baldus, J. Wen, T. Vukosavljevic, B. L. Powell, A. J. Carroll, M. A. Caligiuri, J. E. Kolitz, R. A. Larson, C. D. Bloomfield *Cancer Res* vol 67 abstr 2439 2007
Abstract *Leuk Corr Sci* CALGB-19808, CALGB-20502, CALGB-8461, CALGB-9621, CALGB-9665, CALGB-9769
http://cancerres.aacrjournals.org/content/67/9_Supplement/2439.abstract?sid=00413711-0287-4de7-a621

2257 FLT3 D835/I836 mutations predict worse disease-free survival (DFS) in younger adults with cytogenetically normal acute myeloid leukemia (CN AML) without FLT3 internal tandem duplications (ITD): A Cancer and Leukemia Group B (CALGB) study

S. P. Whitman, A. S. Ruppert, M. D. Radmacher, K. A. Mrozek, P. Paschka, J. E. Kolitz, R. A. Larson, M. A. Caligiuri, G. Marcucci, C. D. Bloomfield *J Clin Oncol* vol 25 (18s) 10532 2007
Abstract *Leuk Corr Sci* CALGB-19808, CALGB-20502, CALGB-8461, CALGB-9621, CALGB-9665
http://meeting.ascopubs.org/gca?gca=ascomtg%3B25%2F18_suppl%2F10532&allch=&submit=Go

2258 Adverse Prognostic Impact of GAS6 Expression in De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) (CALGB 8461, 9665, 20202; Alliance)

S. Whitman, J. Kohlschmidt, K. Maharry, D. Nicolet, S. Schwind, H. Becker, K. H. Metzeler, K. Mrozek, J. H. Mendler, Ann-Kathrin Einfeld, S. Volinia, B. L. Powell, T. H. Carter, J. E. Kolitz, R. M. Stone, I.-K. Park, M. A. Caligiuri, G. Marcucci, C. D. Bloomfield *Blood* vol 120 (21) -1293 2012
Abstract *Leuk Corr Sci* CALGB-8461, CALGB-9665, CALGB-20202
<http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;120/21/1293>

2259 The MLL partial tandem duplication in adults aged 60 years and older with de novo cytogenetically normal acute myeloid leukemia

SP Whitman, MA Caligiuri, K Maharry, MD Radmacher, J Kohlschmidt, H Becker, K Mrózek, Y-Z Wu, S Schwind, KH Metzeler, JH Mendler, J Wen, MR Baer, BL Powell, TH Carter, JE Kolitz, M Wetzler, AJ Carroll, RA Larson, G Marcucci, CD Bloomfield *Leukemia* vol 26 (7) 1713-1717 2012
Manuscript *Leuk Corr Sci* CALGB-10201, CALGB-8525, CALGB-8923, CALGB-9420, CALGB-9720 <http://www.ncbi.nlm.nih.gov/pubmed/22382894>

2260 DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication

Susan P. Whitman, Björn Hackanson, Sandya Liyanarachchi, Shujun Liu, Laura J. Rush, Kati Maharry, Dean Margeson, Ramana Davuluri, Jing Wen, Tatiana Witte, Li Yu, Chunhui Liu, Clara D. Bloomfield, Guido Marcucci, Christoph Plass, Michael A. Caligiuri *Blood* vol 112 (5) 2013-2016 2008
Manuscript *Leuk Corr Sci* CALGB-20502, CALGB-9665, CALGB-9769
<http://www.ncbi.nlm.nih.gov/pubmed/18566324>

2261 GAS6 expression identifies high-risk adult AML patients: potential implications for therapy

Susan P. Whitman, Jessica Kohlschmidt, Kati Maharry, Stefano Volinia, Krzysztof Mrózek, Deedra Nicolet, Sebastian Schwind, Heiko Becker, Klaus H. Metzeler, Jason H. Mendler, Ann-Kathrin Einfeld, Andrew J. Carroll, Bayard L. Powell, Thomas H. Carter, Maria R. Baer, Jonathan E. Kolitz, Il-Kyoo Park, Richard M. Stone, Michael A. Caligiuri, Guido Marcucci, Clara D. Bloomfield *Leukemia* vol 28 (6) 1252-1258 2014
Manuscript *Leuk Corr Sci* CALGB-8525, CALGB-8923, CALGB-9420, CALGB-9621, CALGB-9720, CALGB-10201, CALGB-19808 <http://www.ncbi.nlm.nih.gov/pubmed/24326683>

2262 FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

Susan P. Whitman, Kati Maharry, Michael D. Radmacher, Heiko Becker, Krzysztof Mrózek, Dean Margeson, Kelsi B. Holland, Yue-Zhong Wu, Sebastian Schwind, Klaus H. Metzeler, Jing Wen, Maria R. Baer, Bayard L. Powell, Thomas H. Carter, Jonathan E. Kolitz, Meir Wetzler, Joseph O. Moore, Richard M. Stone, Andrew J. Carroll, Richard A. Larson, Michael A. Caligiuri, Guido Marcucci, Clara D. Bloomfield *Blood* vol 116 (18) 3622-3626 2010
Manuscript *Leuk Corr Sci* CALGB-8461, CALGB-8525, CALGB-10201, CALGB-8923, CALGB-9420, CALGB-9720 <http://www.ncbi.nlm.nih.gov/pubmed/20656931>

2263 Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study

Susan P. Whitman, Amy S. Ruppert, Guido Marcucci, Krzysztof Mrózek, Peter Paschka, Christian Langer, Claudia D. Baldus, Jing Wen, Tamara Vukosavljevic, Bayard L. Powell, Andrew J. Carroll, Jonathan E. Kolitz, Richard A. Larson, Michael A. Caligiuri, Clara D. Bloomfield *Blood* vol 109 (12) 5164-5167 2007
Manuscript *Leuk Corr Sci* CALGB-19808, CALGB-20502, CALGB-8461, CALGB-9621, CALGB-9665, CALGB-9769 <http://www.ncbi.nlm.nih.gov/pubmed/17341662>

2264 FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications

Susan P. Whitman, Amy S. Ruppert, Michael D. Radmacher, Krzysztof Mrózek, Peter Paschka, Christian Langer, Claudia D. Baldus, Jing Wen, Frederick Racker, Bayard L. Powell, Jonathan E. Kolitz, Richard A. Larson, Michael A. Caligiuri, Guido Marcucci, Clara D. Bloomfield *Blood* vol 111 (3) 1552-1559 2008
Manuscript *Leuk Corr Sci* CALGB-19808, CALGB-20502, CALGB-8461, CALGB-9621, CALGB-9665 <http://www.ncbi.nlm.nih.gov/pubmed/17940205>

2265 Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: Analysis from CALGB 10403 and the CIBMTR

Matthew J. Wieduwilt, Wendy Stock, Anjali Advani, Selina Luger, Richard A. Larson, Martin Tallman, Frederick Appelbaum, Mei-Jie Zhang, Khalid Bo-Subait, Hai-Lin Wang, Vijaya Raj Bhatt, Bhagirathbhai Dholaria, Mary Eapen, Mehdi Hamadani, Omer Jamy, Tim Prestidge, Michael Pulsipher, David Ritchie, David Rizzieri, Akshay Sharma, Pere Barba, Brenda M. Sandmaier, Marcos de Lima, Partow Kebriaei, Mark Litzow, Wael Saber, Daniel Weisdorf *Leukemia* vol 35 (7) 2076-85 2021
Manuscript *Leukemia* <http://www.ncbi.nlm.nih.gov/pubmed/33785862>

2266 A phase II study of dasatinib and dexamethasone as primary therapy followed by hematopoietic cell transplantation for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: CALGB Study 10701 (Alliance)

Matthew J. Wieduwilt, Jun Yin, Meir Wetzler, Geoff Uy, Bayard L. Powell, Jonathan Kolitz, Michaela Liedtke, Wendy Stock, Jan H. Beumer, Ryan J. Mattison, Alese Halvorson, Steven Devine, Scott Smith, Richard M. Stone, Richard A. Larson *Blood* vol 128 (22) abstr 2782 2016
Abstract *Leukemia* <http://www.bloodjournal.org/content/128/22/2782>

2267 A phase II study of dasatinib and dexamethasone as primary therapy followed by transplantation for adults with newly diagnosed PH/BCR-ABL1-positive acute lymphoblastic leukemia: Final results of Alliance/CALGB study 10701

Matthew J. Wieduwilt, Jun Yin, Meir Wetzler, Geoff Uy, Bayard L. Powell, Jonathan Kolitz, Michaela Liedtke, Wendy Stock, Jan H. Beumer, Ryan J. Mattison, Elizabeth Storricks, Steven Devine, Scott Smith, Richard M. Stone, Richard A. Larson *Blood* vol 132 (suppl 1) abstr 309 2018
Abstract *Leukemia* http://www.bloodjournal.org/content/132/Suppl_1/309

- 2268 Dasatinib and dexamethasone followed by hematopoietic cell transplantation for adults with Ph-positive ALL**
Matthew J. Wieduwilt, Jun Yin, Meir Wetzler, Geoffrey L. Uy, Bayard L. Powell, Jonathan E. Kolitz, Michaela Liedtke, Wendy Stock, Jan H. Beumer, Ryan J. Mattison, Elizabeth Storricks, Susan M. Christner, Lionel D. Lewis, Steven Devine, Richard M. Stone, Richard A. Larson *Blood Adv* vol 5 (22) 4691-4700 2021
Manuscript *Leukemia* <http://www.ncbi.nlm.nih.gov/pubmed/34492682>
- 2269 Influence of molecular alterations on site-specific (SS) time to recurrence (TTR) following adjuvant therapy in resected colon cancer (CC)**
Ryan E. Wilcox, Qian Shi, Frank A. Sinicrope, Daniel J. Sargent, Nathan R. Foster, Jeffrey P. Meyers, Richard M. Goldberg, Suresh Nair, Anthony F. Shields, Emily Chan, Sharlene Gill, Morton S. Kahlenberg, Steven R. Alberts *J Clin Oncol* vol 33 (suppl) abstr 3590 2015
Abstract *Correl Sci NOS*
http://hwmaint.meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/3590
- 2270 Adherence to the National Quality Forum (NQF) Breast Cancer Measures Within Cancer Clinical Trials: A Review From ACOSOG Z0010**
Lee G. Wilke, Karla V. Ballman, Linda M. McCall, Armando E. Giuliano, Pat W. Whitworth, Peter W. Blumencranz, Douglas S. Reintgen, William E. Burak, A. Marilyn Leitch, Kelly K. Hunt *Ann Surg Oncol* vol 17 (8) 1989-1994 2010
Manuscript *Breast* <http://www.ncbi.nlm.nih.gov/pubmed/20309640>
- 2271 A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype**
W. H. Wilson, S. H. Jung, P. Porcu, D. Hurd, J. Johnson, S. E. Martin, M. Czuczman, R. Lai, J. Said, A. Chadburn, D. Jones, K. Dunleavy, G. Canellos, A. D. Zelenetz, B. D. Cheson, E. D. Hsi
Haematologica vol 97 (5) 758-765 2012
Manuscript *Lymphoma* <http://www.ncbi.nlm.nih.gov/pubmed/22133772>
- 2272 Multi-center study of dose-adjusted EPOCH-Rin untreated diffuse large B-cell lymphoma: CALGB 50103**
W. H. Wilson, A. D. Zelenetz, D. Niedzwiecki, D. D. Hurd, S. E. Martin, M. S. Czuczman, J. L. Johnson, G. P. Canellos, B. D. Cheson *Ann Oncol* vol 19 (suppl 4) 146-147 abstr206 2008
Abstract *Lymphoma* http://annonc.oxfordjournals.org/content/19/suppl_4/iv141.full.pdf+html
- 2273 Phase III randomized study of R-CHOP versus DA-EPOCH-R and molecular analysis of untreated diffuse large B-cell lymphoma: Alliance/CALGB 50303**
Wyndham H. Wilson, Sin-Ho Jung, Brandelyn Pitcher, Eric Hsi, Jonathan Friedberg, Bruce D. Cheson, Nancy Bartlett, Scott E. Smith, Nina Wagner Johnston, Brad S. Kahl, Louis Staudt, Kristie Blum, Jeremy Abramson, Oliver W. Press, Richard I. Fisher, Kristy Richards, Heiko Schoder, Julie Chang, Andrew Zelenetz, John P. Leonard *Blood* vol 128 (22) abstr 469 2016
Abstract *Lymphoma* <http://www.bloodjournal.org/content/128/22/469>
- 2274 Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: Cancer and Leukemia Group B trial 9342.**
Eric P Winer, Donald A Berry, Susan Woolf, David Duggan, Alice Kornblith, Lyndsay N Harris, Richard A Michaelson, Jeffrey A Kirshner, Gini F Fleming, Michael C Perry, Mark L Graham, Stewart A Sharp, Roger Keresztes, I Craig Henderson, Clifford Hudis, Hyman Muss, Larry Norton *J Clin Oncol* vol 22 (11) 2061-8 2004
Manuscript *Breast* <http://www.ncbi.nlm.nih.gov/pubmed/15169793>

- 2275 High rate of event-free survival at 24 months with everolimus/RCHOP for untreated diffuse large B-cell lymphoma: updated results from NCCTG N1085 (Alliance)**
T E Witzig, B LaPlant, T M Habermann, E McPhail, D J Inwards, I N Micallef, J P Colgan, G S Nowakowski, S M Ansell, P B Johnston *Blood Cancer J* vol 7 (6) e576- 2017
Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/28649983>
- 2276 Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: A phase II trial in the North Central Cancer Treatment Group**
Thomas E. Witzig, Susan M. Geyer, Paul J. Kurtin, Joseph P. Colgan, David J. Inwards, Ivana N. M. Micallef, Betsy R. LaPlant, John C. Michalak, Muhammad Salim, Robert J. Dalton, Dennis F. Moore, Craig B. Reeder *Leuk Lymphoma* vol 49 (6) 1074-1080 2008
Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/18569634>
- 2277 Patient-specific integrative pathway analysis using PARADIGM identifies key activities in I-SPY 1 breast cancer patients (CALGB 150007/150012; ACRIN 6657)**
D. Wolf, C. Yau, S. Benz, C. Vaske, J. Stuart, R. Roy, A. Olshen, A. Boudreau, D. Haussler, J. W. Gray, P. Spellman, S. E. Davis, N. Hylton, L. Van't Veer, L. J. Esserman *Cancer Res* vol 71 (24 suppl) 179s (abstr p171-106-109) 2011
Abstract *Correl Sci NOS ACRIN-6657, CALGB-150007*
http://cancerres.aacrjournals.org/content/71/24_Supplement/P1-06-09
- 2278 Gene expression changes associated with response to neoadjuvant chemotherapy are observed early in treatment: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)**
D. Wolf, C. Yau, M. Magbanua, A. Boudreau, S. Davis, C. Haqq, J. Park, L. Esserman, L. Van't Veer *Cancer Res* vol 72 (24 suppl) Abstract nr P2-05-01 2012
Abstract *Correl Sci NOS CALGB-150007, CALGB-150012*
http://cancerres.aacrjournals.org/cgi/content/short/72/24_MeetingAbstracts/P2-05-01?rss=1
- 2279 The relationship between numbness, tingling, and shooting/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, N06CA**
S. L. Wolf, D. L. Barton, R. Qin, E. J. Wos, J. A. Sloan, H. Liu, N. K. Aaronson, D. V. Satele, B. I. Mattar, N. B. Green, C. L. Loprinzi *Support Care Cancer* vol 20 (3) 625-632 2012
Manuscript *Health Outcomes* <http://www.ncbi.nlm.nih.gov/pubmed/21479990>
- 2280 Relationship of sensory symptoms and motor function in patients with chemotherapy-induced peripheral neuropathy (CIPN) utilizing the EORTC QLQ CIPN20: NCCTG study N06CA**
S. L. Wolf, R. Qin, D. L. Barton, J. A. Sloan, H. Liu, N. K. Aaronson, D. V. Satele, N. B. Green, B. I. Mattar, C. L. Loprinzi *J Clin Oncol* vol 27 (15s) abstr 9587 2009
Abstract *Health Outcomes*
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID
- 2281 Evaluation of a urea/lactic acid-based topical keratolytic agent (ULABTKA) for prevention of capecitabine-induced hand and foot syndrome (HFS): NCCTG trial N05C5**
S. L. Wolf, R. Qin, S. P. Menon, K. M. Rowland Jr, J. W. Kugler, P. J. Flynn, D. Christian, D. Satele, J. L. Berenberg, C. L. Loprinzi *J Clin Oncol* vol 28 (15s) abstr 9017 2010
Abstract *Symptom Inter*
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID
- 2282 Placebo-Controlled Trial to Determine the Effectiveness of a Urea/Lactic Acid-Based Topical Keratolytic Agent for Prevention of Capecitabine-Induced Hand-Foot Syndrome: North Central Cancer Treatment Group Study N05C5**
Sherry L. Wolf, Rui Qin, Smitha P. Menon, Kendrith M. Rowland, Sachdev Thomas, Robert Delaune,

- 2283 Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer**
Brian M. Wolpin, Cosmeri Rizzato, Peter Kraft, Charles Kooperberg, Gloria M. Petersen, Zhaoming Wang, Alan A. Arslan, Laura Beane-Freeman, Paige M. Bracci, Julie Buring, Federico Canzian, Eric J. Duell, Steven Gallinger, Graham G. Giles, Gary E. Goodman, Phyllis J. Goodman, Eric J. Jacobs, Aruna Kamineni, Alison P. Klein, Laurence N. Kolonel, Matthew H. Kulke, Donghui Li, N ria Malats, Sara H. Olson, Harvey A. Risch, Howard D. Sesso, Kala Visvanathan, Emily White, Wei Zheng, Christian C. Abnet, Demetrius Albanes, Gabriella Andreotti, Melissa A. Austin, Richard Barfield, Daniela Basso, Sonja I. Berndt, Marie-Christine Boutron-Ruault, Michelle Brotzman, Markus W. B chler, H. Bas Bueno-de-Mesquita, Peter Bugert, Laurie Burdette, Daniele Campa, Neil E. Caporaso, Gabriele Capurso, Charles Chung, Michelle Cotterchio, Eithne Costello, Joanne Elena, Niccola Funel, J. Michael Gaziano, Nathalia A. Giese, Edward L. Giovannucci, Michael Goggins, Megan J. Gorman, Myron Gross, Christopher A. Haiman, Manal Hassan, Kathy J. Helzlsouer, Brian E. Henderson, Elizabeth A. Holly, Nan Hu, David J. Hunter, Federico Innocenti, Mazda Jenab, Rudolf Kaaks, Timothy J. Key, Kay-Tee Khaw, Eric A. Klein, Manolis Kogevinas, Vittorio Krogh, Juozas Kupcinskis, Robert C. Kurtz, Andrea LaCroix, Maria T. Landi, Stefano Landi, Loic Le Marchand, Andrea Mambrini, Satu Mannisto, Roger L. Milne, Yusuke Nakamura, Ann L. Oberg, Kouros Owzar, Alpa V. Patel, Petra H. M. Peeters, Ulrike Peters, Raffaele Pezzilli, Ada Piepoli, Miquel Porta, Francisco X. Real, Elio Riboli, Nathaniel Rothman, Aldo Scarpa, Xiao-Ou Shu, Debra T. Silverman, Pavel Soucek, Malin Sund, Renata Talar-Wojnarowska, Philip R. Taylor, George E. Theodoropoulos, Mark Thornquist, Anne Tj nneland, Geoffrey S. Tobias, Dimitrios Trichopoulos, Pavel Vodicka, Jean Wactawski-Wende, Nicolas Wentzensen, Chen Wu, Herbert Yu, Kai Yu, Anne Zeleniuch-Jacquotte, Robert Hoover, Patricia Hartge, Charles Fuchs, Stephen J. Chanock, Rachael S. Stolzenberg-Solomon, Laufey T. Amundadottir Nat Genet vol 46 (9) 994-1000 2014
Manuscript PPP <http://www.ncbi.nlm.nih.gov/pubmed/25086665>
- 2284 Expanding Beyond Maximum Grade: Chemotherapy Toxicity over Time by Age and Performance Status in Advanced NonSmall Cell Lung Cancer in CALGB 9730 (Alliance A151729)**
Melisa L. Wong, Junheng Gao, Gita Thanarajasingam, Jeff A. Sloan, Amylou C. Dueck, Paul J. Novotny, Aminah Jatoi, Arti Hurria, Louise C. Walter, Christine Miaskowski, Harvey J. Cohen, William A. Wood, Josephine L. Feliciano, Thomas E. Stinchcombe, Xiaofei Wang Oncologist vol 26 (3) e435-e444 2021
Manuscript Older Adult CALGB-9730 <http://www.ncbi.nlm.nih.gov/pubmed/32951293>
- 2285 Comparison of chemotherapy toxicity over time according to age and performance status in patients with advanced non-small cell lung cancer: a toxicity over time analysis of CALGB 9730 (Alliance A151729)**
Melisa L. Wong, Junheng Gao, Gita Thanarajasingam, Jeff A. Sloan, Amylou C. Dueck, Paul J. Novotny, Aminah Jatoi, Arti Hurria, William A. Wood, Josephine L. Feliciano, Louise C. Walter, Christine Miaskowski, Thomas E. Stinchcombe, Xiaofei Wang J Geriatr Oncol vol 9 (6S1) S76-S77 2018
Abstract Older Adult
<https://www.sciencedirect.com/science/article/pii/S1879406818304375?via%3Dihub>
- 2286 Cost Implications of New Treatments for Advanced Colorectal Cancer**
Yu-Ning Wong, Neal J. Meropol, William Speier, Daniel Sargent, Richard M. Goldberg, J. Robert Beck Cancer vol 115 (10) 2081-2091 2009
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/19309745>
- 2287 A randomized phase II trial of vitamin D vs placebo in premenopausal women: CALGB 70806**

M. E. Wood, F. Kinglsey, A. B. Ambaye, L. Yee, S. J. Jung, J. R. Marshall, E. Paskett *Cancer Res* vol 71 (24 suppl) 613s (abstr OT612-604-601) 2011
Abstract Prevention http://cancerres.aacrjournals.org/content/71/24_Supplement/OT2-04-01

2288 Change in mammographic density with metformin use: A companion study to NCIC study MA.32.

Marie E. Wood, Rui Qin, Huong T. Le-Petross, E Shelley Hwang, Jennifer A. Ligibel, Ingrid A. Mayer, James Roger Marshall, Pamela Jean Goodwin *J Clin Oncol* vol 31 (15 suppl) abstr TPS1608 2013
Abstract Breast http://ascopubs.org/doi/abs/10.1200/jco.2013.31.15_suppl.tps1608

2289 The Influence of Vitamin D on Mammographic Density: Results from CALGB 70806 (Alliance) a Randomized Clinical Trial.

Marie E Wood, Heshan Liu, Elizabeth Storrick, David Zahrieh, H Carisa Le-Petross, Sin-Ho Jung, Patricia Zekan, M Margaret Kemeny, Jayne R Charlamb, Lili X Wang, Gary W Unzeitig, Candace S Johnson, Judy E Garber, James R Marshall, Isabelle Bedrosian *Cancer Prev Res (Phila)* vol 14 (7) 753-62 2021
Manuscript Prevention <http://www.ncbi.nlm.nih.gov/pubmed/33849913>

2290 Influence of vitamin D (Vit D) on mammographic density (MD) and insulin like growth factor 1 (IGF1): results of CALGB (Alliance) 70806

Marie Wood, Drew K. Seisler, Meng-Kang Hsieh, Despina Kontos, Abiy Ambaye, Huong T. Le-Petross, Sin-Ho Jung, Heshan Liu, Patricia Zekan, Lucien Cardinal, Jayne Charlamb, Lili X. Wang, Gary W. Unzeitig, Judy Garber, James Marshall *J Clin Oncol* vol 36 (15_suppl) 1549 2018
Abstract Prevention https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.1549

2291 Objective Measures of Performance Status in Cancer: A pilot Alliance study

WA Wood, X Tan, NS Grover, A Stover, A Kannappan, Burkes R Carr, P, TC Shea, A Artz, SM Devine, J Ligibel, AV Bennett, EM Basch *J Clin Oncol* vol 36 (30_suppl) abstr 284 2018
Abstract Disparities http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.30_suppl.284

2292 The Pathways fertility preservation decision aid website for women with cancer: development and field testing.

Terri L Woodard, Aubri S Hoffman, Laura A Covarrubias, Deborah Holman, Leslie Schover, Andrea Bradford, Derek B Hoffman, Aakrati Mathur, Jerah Thomas, Robert J Volk *J Cancer Surviv* vol 12 (1) 101-14 2018
Manuscript CCDR <http://www.ncbi.nlm.nih.gov/pubmed/29034438>

2293 Pathways: patient-centred decision counselling for women at risk of cancer-related infertility: a protocol for a comparative effectiveness cluster randomised trial

Terri Lynn Woodard, Aubri S Hoffman, Laura C Crocker, Deborah A Holman, Derek B Hoffman, Jusheng Ma, Roland L Bassett, Viola B Leal, Robert J Volk *BMJ Open* vol 8 (2) e019994. 2018
Manuscript CCDR <http://www.ncbi.nlm.nih.gov/pubmed/29467138>

2294 Outcome of Adolescents and Young Adults with Acute Myeloid Leukemia Treated on COG Trials Compared to CALGB and SWOG Trials

William G. Woods, Anna R.K. Franklin, Todd A. Alonzo, Robert B. Gerbing, Kathleen A. Donohue, Megan Othus, John Horan, Frederick R. Appelbaum, Elihu H. Estey, Clara D. Bloomfield, Richard A. Larson *Cancer* vol 119 (23) 4170-9 2013
Manuscript Leukemia CALGB-8525, CALGB-9022, CALGB-9222, CALGB-9621, CALGB-19808, CALGB-8461 <http://www.ncbi.nlm.nih.gov/pubmed/24104597>

2295 Impact of Age on Outcomes Following Initial Therapy with Various Chemotherapy and

Chemoimmunotherapy Regimens in Patients with Chronic Lymphocytic Leukemia (CLL): Results of CALGB Studies

J. A. Woyach, A. S. Ruppert, B. Peterson, K. R. Rai, T. S. Lin, F. R. Appelbaum, M. S. Tallman, A. R. Belch, R. A. Larson, J. C. Byrd *Blood* vol 118 (21) 134 2011
Abstract *Leukemia* CALGB-9011, CALGB-10101, CALGB-9712
<http://ash.confex.com/ash/2011/webprogram/Paper43135.html>

2296 Treatment with fludarabine and rituximab produces extended remissions and survival in chronic lymphocytic leukemia (CLL) without increased risk of second malignancy: Long-term follow up of CALGB study 9712

J. Woyach, N. A. Heerema, A. Stark, B. L. Peterson, J. G. Gribben, V. A. Morrison, K. R. Rai, R. A. Larson, J. C. Byrd *Blood* vol 114 (22) abstr 539 2009
Abstract *Leukemia*
<http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;114/22/539?maxtoshow=&hits=10&R>

2297 Chemoimmunotherapy With Fludarabine and Rituximab Produces Extended Overall Survival and Progression-Free Survival in Chronic Lymphocytic Leukemia: Long-Term Follow-Up of CALGB Study 9712

Jennifer A. Woyach, Amy S. Ruppert, Nyla A. Heerema, Bercedis L. Peterson, John G. Gribben, Vicki A. Morrison, Kanti R. Rai, Richard A. Larson, John C. Byrd *J Clin Oncol* vol 29 (10) 1349-1355 2011
Manuscript *Leukemia* <http://www.ncbi.nlm.nih.gov/pubmed/21321292>

2298 Long term results of Alliance A041202 show continued advantage of ibrutinib-based regimens compared with bendamustine plus rituximab chemoimmunotherapy

Jennifer A. Woyach, Amy S. Ruppert, Nyla Heerema, Weiqiang Zhao, Allison M Booth, Wei Ding, Nancy L. Bartlett, Danielle M Brander, Paul M Barr, Kerry A Rogers, Sameer Parikh, Steven Coutre, Arti Hurria, Gerard Lozanski, Sreenivasa Nattam, Richard A. Larson, Harry Erba, Mark Litzow, Carolyn Owen, James Atkins, Jeremy Abramson, Jennifer Brown, Rich Little, Scott E. Smith, Richard M. Stone, Sumithra Mandrekar, John C. Byrd *Blood* vol 138 (Supplement 1) 639 2021
Abstract *Leukemia* <https://www.sciencedirect.com/science/article/pii/S0006497121026306>

2299 Ibrutinib alone or in combination with rituximab produces superior progression free survival compared with bendamustine plus rituximab in untreated older patients with chronic lymphocytic leukemia: Results of Alliance A041202

Jennifer A. Woyach, Amy S. Ruppert, Nyla Heerema, Weiqiang Zhao, Allison M Booth, Wei Ding, Nancy Bartlett, Danielle M Brander, Paul M Barr, Kerry A Rogers, Sameer Parikh, Steven Coutre, Arti Hurria, Gerard Lozanski, Sreenivasa Nattam, Richard A. Larson, Harry Erba, Mark Litzow, Carolyn Owen, James Atkins, Jeremy Abramson, Richard M. Stone, Sumithra Mandrekar, John C. Byrd *Blood* vol 132 (Suppl 1) 6 2018
Abstract *Leukemia* http://www.bloodjournal.org/content/132/Suppl_1/6.abstract?sso-checked=true

2300 Alliance A041702: A randomized phase III study of ibrutinib plus obinutuzumab versus ibrutinib plus venetoclax and obinutuzumab in untreated older patients (70 years of age) with chronic lymphocytic leukemia (CLL)

Jennifer A. Woyach, Amy S. Ruppert, Gabriela Perez, Allison Booth, Diane Feldman, Elie Dib, Aminah Jatoi, Jennifer Le-Rademacher, Nyla Heerema, Gerard Lozanski, Richard Little, Wei Ding, Richard Stone, Sumithra Mandrekar, John C Byrd *Blood* vol 134 (Supplement 1) abstr 642 CLL 2019
Abstract *Leukemia*
https://ashpublications.org/blood/search-results?page=1&q=a041702&fl_SiteID=1000001&fl_IssueNo=

2301 Alliance A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus

Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)

Jennifer A. Woyach, Amy S. Ruppert, Gabriela Perez, Allison Booth, Diane Feldman, Elie Dib, Aminah Jatoi, Jennifer Le-Rademacher, Nyla Heerema, Gerard Lozanski, Richard Little, Brian Hill, Wei Ding, Richard Stone, Sumithra Mandrekar, John C Byrd Blood vol 138 (Supplement 1) 3728 2021

Abstract Leukemia <https://www.sciencedirect.com/science/article/pii/S0006497121056482>

2302 Impact of Age on Outcomes After Initial Therapy With Chemotherapy and Different Chemoimmunotherapy Regimens in Patients With Chronic Lymphocytic Leukemia: Results of Sequential Cancer and Leukemia Group B Studies

Jennifer A. Woyach, Amy S. Ruppert, Kanti Rai, Thomas S. Lin, Susan Geyer, Jonathan Kolitz, Frederick R. Appelbaum, Martin S. Tallman, Andrew R. Belch, Vicki A. Morrison, Richard A. Larson, John C. Byrd J Clin Oncol vol 31 (4) 440-7 2013

Manuscript Leukemia CALGB-9011, CALGB-9712, CALGB-19901, CALGB-10101
<http://www.ncbi.nlm.nih.gov/pubmed/23233702>

2303 Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.

Jennifer A Woyach, Amy S Ruppert, Nyla A Heerema, Weiqiang Zhao, Allison M Booth, Wei Ding, Nancy L Bartlett, Danielle M Brander, Paul M Barr, Kerry A Rogers, Sameer A Parikh, Steven Coutre, Arti Hurria, Jennifer R Brown, Gerard Lozanski, James S Blachly, Hatice G Ozer, Brittny Major-Elechi, Briant Fruth, Sreenivasa Nattam, Richard A Larson, Harry Erba, Mark Litzow, Carolyn Owen, Charles Kuzma, Jeremy S Abramson, Richard F Little, Scott E Smith, Richard M Stone, Sumithra J Mandrekar, John C Byrd N Engl J Med vol 379 (26) 2517-28 2018

Manuscript Leukemia <http://www.ncbi.nlm.nih.gov/pubmed/30501481>

2304 Deletions in HSP110 T17 and Patient Prognosis in Stage III Microsatellite Instable (MSI) Colon Cancers: Findings from CALGB 89803 and NCCTG N0147.

Christina Wu, Qian Shi, Jerneja Tomsic, Jeffrey Meyers, Wendy L. Frankel, Cynthia Timmers, Leonard B. Saltz, Steven R. Alberts, Daniel J. Sargent, Heather Hampel, Albert De La Chapelle, Richard M. Goldberg J Clin Oncol vol 34 (suppl) abstr 315148 2016

Abstract Correl Sci NOS CALGB-89803, NCCTG-N0147
<http://meetinglibrary.asco.org/content/164224-176>

2305 Relationship between overall survival and progression-free survival for recent NCCTG glioblastoma multiforme trials

W. Wu, E. Galanis, J. C. Buckner, K. A. Jaeckle, D. J. Sargent J Clin Oncol vol 30 (15 suppl) abstr 2004 2012

Abstract Neuro-Onc http://meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/2004

2306 Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma

Wenting Wu, Kathleen R. Lamborn, Jan C. Buckner, Paul J. Novotny, Susan M. Chang, Judith R. O'Fallon, Kurt A. Jaeckle, Michael D. Prados Neuro Oncol vol 12 (2) 164-172 2010

Manuscript Neuro-Onc <http://www.ncbi.nlm.nih.gov/pubmed/20150383>

2307 Discovery of a new phosphoHER2+/FISH- molecular subtype of human breast cancer by functional pathway mapping

J. Wulfkuhle, M. Pierobon, J. Laird, V. Espina, L. Liotta, L. J. Esserman, E. Petricoin J Clin Oncol vol 25 (15s) abstr 11009 2009

Abstract Correl Sci NOS <http://meetinglibrary.asco.org/content/32961-65>

2308 Protein pathway activation mapping of I-SPY 1 biopsy specimens identifies new network focused drug targets for patients with HR+/HER2- tumors

J. Wulfkuhle, C. Yau, R. Gallagher, D. Wolf, V. Calvert, V. Espina, J. Illi, Q. Wu, M. Boe, Y. Yan, L. Liotta, L. Van't Veer, L. Esserman, E. Petricoin *Cancer Res* vol 72 (24 suppl) Abstract nr P3-04-02 2012
Abstract Correl Sci NOS CALGB-150007, CALGB-150012
http://cancerres.aacrjournals.org/content/72/24_Supplement/P3-04-02

2309 Molecular analysis of HER2 signaling in human breast cancer by functional protein pathway activation mapping

Julia D. Wulfkuhle, Daniela Berg, Claudia Wolff, Rupert Langer, Kai Tran, Julie Illi, Virginia Espina, Mariaelena Pierobon, Jianghong Deng, Angela DeMichele, Axel Walch, Holger Bronger, Ingrid Becker, Christine Waldhör, Heinz Höfler, Laura Esserman, Lance A. Liotta, Karl-Friedrich Becker, Emanuel F. Petricoin *Clin Cancer Res* vol 18 (23) 6426-6435 2012
Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/23045247>

2310 Dual VEGF inhibition with sorafenib and bevacizumab as salvage therapy in metastatic colorectal cancer: results of the phase II North Central Cancer Treatment Group study N054C (Alliance)

Hao Xie, Jacqueline M. Lafky, Bruce W. Morlan, Philip J. Stella, Shaker R. Dakhil, Gerald G. Gross, William S. Loui, Joleen M. Hubbard, Steven R. Alberts, Axel Grothey *Ther Adv Med Oncol* vol 12 1758835920910913 2020
Manuscript GI <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066587>

2311 Morphological Appearance of Radiofrequency Ablated Stage IA NSCLC in Medically Inoperable Patients as Related to Recurrence: Results from the ACOSOG Z4033 (Alliance Trial)

Lillian Xiong, Erica Alexander, Shauna Hillman, Angelina Tan, Grayson Baird, Hiran Fernando, Damian Dupuy 2015
Abstract Respiratory <http://archive.rsna.org/2015/15008022.html>

2312 Identifying strong instrumental variables for pleiotropic assessment in Mendelian randomization: CALGB/SWOG 80405 (Alliance)

Akram Yazdani, Heinz-Josef Lenz, Gianluigi Pillonetto, Raul Mendez-Giraldez, Monica M Bertagnolli, Alan P Venook, Mark J Ratain, Naim Rashid, Benjamin G Vincent, Xueping Qu, Yujia Wen, William F Symmans, Andrew B Nixon, Michael Kosorok, Charles M Perou, Federico Innocenti 2022
Abstract PPP <https://www.ashg.org/wp-content/uploads/2022/09/ASHG2022-PosterAbstracts.pdf>

2313 Treatment-specific gene regulatory pathways in colorectal cancer patients (Alliance)

Akram Yazdani, Heinz-Josef Lenz, Xueping Qu, Monica M Bertagnolli, Alan P. Venook, Federico Innocenti 2021
Abstract Correl Sci NOS
<https://www.ashg.org/wp-content/uploads/2022/01/2021-ASHG-Meeting-Abstracts.pdf>

2314 Tumor and germline markers for gemcitabine sensitivity in pancreatic cancer

S. Yee, E. Collisson, S. Gysin, K. Owzar, C. Jiang, E. Jorgenson, J. Paquette, T. Tokuyasu, P. Matsson, F. Innocenti, M. J. Ratain, M. McMahon, A. Ko, M. A. Tempero, K. M. Giacomini 2009
Abstract PPP

2315 Event-free survival as a surrogate endpoint for overall survival in previously untreated acute myeloid leukemia: An individual patient-level analysis of multiple randomized trials (Alliance A151614)

Jun Yin, Betsy LaPlant, Elizabeth Storricks, Geoffrey L. Uy, Guido Marcucci, Hugo F. Fernandez, Zhuoxin Sun, Frederick R. Appelbaum, Megan Othus, Williams G. Blum, Stephen H. Petersdorf, Richard A. Larson, Richard M. Stone, Sumithra J. Mandrekar *Blood* vol 132 (Suppl 1) 1386 2018

2316 Evaluation of event-free survival as a robust end point in untreated acute myeloid leukemia (Alliance A151614)

Jun Yin, Betsy LaPlant, Geoffrey L. Uy, Guido Marcucci, William Blum, Richard A. Larson, Richard M. Stone, Sumithra J. Mandrekar *Blood Adv* vol 3 (11) 1714-21 2019

Manuscript Leukemia CALGB-10201, CALGB-10503, CALGB-10603, CALGB-10801, CALGB-11001 <http://www.ncbi.nlm.nih.gov/pubmed/31171508>

2317 Impact of the Timing of Complete Remission and Transplantation on Estimates of Event-Free Survival in Acute Myeloid Leukemia

Jun Yin, Betsy R. Laplant, Geoffrey L. Uy, Guido Marcucci, William Blum, Richard A. Larson, Richard M. Stone, Sumithra Mandrekar *JAMA Oncol* vol 128 214 2016

Abstract Leukemia CALGB-10201, CALGB-10503, CALGB-10603, CALGB-10801, CALGB-11001 <http://www.bloodjournal.org/content/128/22/214>

2318 Radiofrequency Ablation of Medically Inoperable Stage IA Non–Small Cell Lung Cancer: Are Early Posttreatment PET Findings Predictive of Treatment Outcome?

Don C. Yoo, Damian E. Dupuy, Shauna L. Hillman, Hiran C. Fernando, William S. Rilling, Jo-Anne O. Shepard, Barry A. Siegel *AJR Am J Roentgenol* vol 197 (2) 334-340 2011

Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/21785078>

2319 Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (Alliance)

H. H. Yoon, N. R. Foster, J. P. Meyers, P. D. Steen, D. W. Visscher, R. Pillai, D. M. Prow, C. M. Reynolds, B. T. Marchello, R. B. Mowat, B. I. Mattar, C. Erlichman, M. P. Goetz *Ann Oncol* vol 27 (2) 339-344 2016

Manuscript Experimental <http://www.ncbi.nlm.nih.gov/pubmed/26578722>

2320 Prognostic impact of specific KRAS mutations in codon 12 and 13 in 2,165 BRAF-wildtype colon cancers: Results from NCCTG N0147 (Alliance)

H. H. Yoon, D. Tougeron, M. R. Mahoney, Q. Shi, D. J. Sargent, S. N. Thibodeau, F. A. Sinicrope, S. R. Alberts *European Journal of Cancer* vol 49 abstract 2160 2013

Abstract Correl Sci NOS

<http://eccamsterdam2013.ecco-org.eu/Scientific-Programme/Searchable-Programme.aspx#anchorScpr>

2321 Racial differences in KRAS/BRAF mutation rates and survival in colon cancer (NCCTG N0147 [Alliance]).

Harry H. Yoon, Qian Shi, Steven R. Alberts, Richard M. Goldberg, Stephen N. Thibodeau, Daniel J. Sargent, Frank A. Sinicrope *J Clin Oncol* vol 32 (15_suppl) 3536 2014

Abstract GI http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/3536

2322 Racial Differences in BRAF/KRAS Mutation Rates and Survival in Stage III Colon Cancer Patients

Harry H. Yoon, Qian Shi, Steven R. Alberts, Richard M. Goldberg, Stephen N. Thibodeau, Daniel J. Sargent, Frank A. Sinicrope *J Natl Cancer Inst* vol 107 (10) 2015

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/26160882>

2323 Inter-tumoral heterogeneity of CD3+ and CD8+ T-cell densities in the microenvironment of DNA mismatch repair-deficient colon cancers: implications for prognosis

Harry H. Yoon, Qian Shi, Erica N. Heying, Andrea Muranyi, Joerg Bredno, Faith Ough, Azita

Djalilvand, June Clements, Rebecca Bowermaster, Wen-Wei Liu, Michael Barnes, Steven R. Alberts,

2324 CD3+ and CD8+ tumor-infiltrating lymphocyte (TIL) densities prognostically stratify DNA mismatch repair-deficient (dMMR) colon cancer patients (pts): NCCTG N0147 (Alliance)

Harry H. Yoon, Qian Shi, Erica N. Heying, Andrea Muranyi, Faith Ough, Azita Djalilvand, June Clements, Rebecca Bowermaster, Wen-Wei Liu, Michael Barnes, Steven R. Alberts, Kandavel Shanmugam, Frank A. Sinicrope J Clin Oncol vol 36 (Suppl) abstr 3598 2018

Abstract Correl Sci NOS <https://meetinglibrary.asco.org/record/158879/abstract>

2325 KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild type stage III colon cancers from an adjuvant chemotherapy trial (N0147 Alliance)

Harry H. Yoon, David Tougeron, Qian Shi, Steven R. Alberts, Michelle R. Mahoney, Garth D. Nelson, Suresh G. Nair, Stephen N. Thibodeau, Richard M. Goldberg, Daniel J. Sargent, Frank A. Sinicrope Clin Cancer Res vol 20 (11) 3033-3043 2014

Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/24687927>

2326 Induction versus no induction chemotherapy before neoadjuvant chemoradiotherapy and surgery in oesophageal adenocarcinoma: a multicentre randomised phase II trial (NCCTG N0849 [Alliance]).

Harry H Yoon, Fang-Shu Ou, Gamini S Soori, Qian Shi, Dennis A Wigle, Robert P Sticca, Robert Clell Miller, James L Leenstra, Patrick J Peller, Brenda Ginos, Erica Heying, Tsung-Teh Wu, Timothy F Drevyanko, Stephen Ko, Bassam Ibrahim Mattar, Daniel A Nikcevich, Robert J Behrens, Maged F Khalil, George P Kim, Steven R Alberts Eur J Cancer vol 150 214-23 2021

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/33934058>

2327 Outcomes in white (W) patients (pts) and those of African (A) descent receiving adjuvant therapy for colon cancer (CC)

G. Yothers, A. W. Blackstock, N. Wolmark, R. M. Goldberg, M. J. O'Connell, J. Benedetti, J. Dignam, D. J. Sargent J Clin Oncol vol 25 (18s) abstr 4017 2007

Abstract GI CALGB-89803, NCCTG-N0441

http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID=3

2328 Outcomes Among Black Patients With Stage II and III Colon Cancer Receiving Chemotherapy: An Analysis of ACCENT Adjuvant Trials

Greg Yothers, Daniel J. Sargent, Norman Wolmark, Richard M. Goldberg, Michael J. O'Connell, Jacqueline K. Benedetti, Leonard B. Saltz, James J. Dignam, A. William Blackstock J Natl Cancer Inst vol 103 (20) 1498-1506 2011

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/21997132>

2329 Influence of genetic variation in the vitamin D pathway on plasma 25-hydroxyvitamin D3 levels and survival among patients with metastatic colorectal cancer

Chen Yuan, Lindsay Renfro, Pratibha B. Ambadwar, Fang-Shu Ou, Howard L. McLeod, Federico Innocenti, Jeffrey A. Meyerhardt, Brian M. Wolpin, Richard M. Goldberg, Axel Grothey, Charles S. Fuchs, Kimmie Ng Cancer Causes Control vol 30 (7) 757-65 2019

Manuscript PPP <http://www.ncbi.nlm.nih.gov/pubmed/31104167>

2330 Plasma 25-Hydroxyvitamin D Levels and Survival in Patients with Advanced or Metastatic Colorectal Cancer: Findings from CALGB/SWOG 80405 (Alliance)

Chen Yuan, Kaori Sato, Bruce W. Hollis, Sui Zhang, Donna Niedzwiecki, Fang-Shu Ou, I-Wen Chang, Bert H. O'Neil, Federico Innocenti, Heinz-Josef Lenz, Charles D. Blanke, Richard M.

Goldberg, Alan P. Venook, Robert J. Mayer, Charles S. Fuchs, Jeffrey A. Meyerhardt, Kimmie Ng Clin Cancer Res vol 25 (24) 7497-505 2019

2331 Clinical Outcomes in Patients With Colon Cancer With Microsatellite Instability of Sporadic or Familial Origin Treated With Adjuvant FOLFOX With or Without Cetuximab: A Pooled Analysis of the PETACC8 and N0147 Trials

Aziz Zaanan, Qian Shi, Julien Taieb, Steven R. Alberts, Jeffrey P. Meyers, Thomas C. Smyrk, Catherine Julie, Ayman Zawadi, Josep Taberero, Enrico Mini, Richard M. Goldberg, Gunnar Folprecht, Jean Luc Van Laethem, Karine Le Malicot, Daniel J. Sargent, Pierre Laurent-Puig, Frank A. Sinicrope JCO Precis Oncol vol 4 2020
Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/32923882>

2332 Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy

Aziz Zaanan, Qian Shi, Julien Taieb, Steven R. Alberts, Jeffrey P. Meyers, Thomas C. Smyrk, Catherine Julie, Ayman Zawadi, Josep Taberero, Enrico Mini, Richard M. Goldberg, Gunnar Folprecht, Jean Luc Van Laethem, Karine Le Malicot, Daniel J. Sargent, Pierre Laurent-Puig, Frank A. Sinicrope JAMA Oncol vol 4 (3) 379-83 2018
Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/28983557>

2333 Is the predictive and prognostic impact of sporadic and familial microsatellite instable stage III colon cancer different? A pooled analysis of the PETACC8 and NCCTG N0147 (Alliance) trials

Aziz Zaanan, Qian Shi, Julien Taieb, Steven R. Alberts, Jeffrey P. Meyers, Thomas C. Smyrk, Catherine Julie, Ayman Zawadi, Josep Taberero, Enrico Mini, Richard M. Goldberg, Gunnar Folprecht, Jean Luc Van Laethem, Karine Le Malicot, Daniel J. Sargent, Pierre Laurent-Puig, Frank A. Sinicrope J Clin Oncol vol 37 (no. 15_suppl) 3583 2019
Abstract Correl Sci NOS https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.3583

2334 Analysis of DNA mismatch repair (MMR) and clinical outcome in stage III colon cancers from patients treated with adjuvant FOLFOX + cetuximab in the PETACC8 and N0147 adjuvant trials.

Aziz Zaanan, Qian Shi, Julien Taieb, Steven R. Alberts, Thomas C. Smyrk, Catherine Julié, Ayman Zawadi, Josep Taberero, Enrico Mini, Richard M. Goldberg, Gunnar Folprecht, Jean L. Van Laethem, Karine Le Malicot, Daniel J. Sargent, Pierre Laurent-Puig, Frank A. Sinicrope J Clin Oncol vol 33 (suppl) abstr 3506 2015
Abstract Correl Sci NOS <http://meetinglibrary.asco.org/content/146390-156>

2335 Successes and lessons learned in database development for national multi-site cancer care delivery research trials: the Alliance for Clinical Trials in Oncology experience

David Zahrieh, Shauna L. Hillman, Angelina D. Tan, Jennifer L. Frank, Travis Dockter, Bobbi Jo Meyers, Cassie L. Cherevko, Elizabeth S. Peil, Shaylene McCue, Oudom Kour, Heather J. Gunn, Heather B. Neuman, George J. Chang, Electra D. Paskett, Sumithra J. Mandrekar, Amylou C. Dueck Trials vol 23 (1) 645 2022
Manuscript SDMC NOS Alliance-A191402CD, Alliance-A231601CD, Alliance-A231602CD, Alliance-A231701CD, Alliance-A231901CD <http://www.ncbi.nlm.nih.gov/pubmed/35945621>

2336 Temporal, Location- and Symptom-Specific Likelihood of Patient-Reported Sensory Symptoms Related to Oxaliplatin-Induced Peripheral Neuropathy (OIPN) in Patients Receiving Oxaliplatin for Three Months

David Zahrieh, Daniel Satele, Ellen M. Lavoie Smith, Charles L. Loprinzi, Jennifer Le-Rademacher Cancers (Basel) vol 14 (5) 1212 2022
Manuscript SDMC NOS NCCTG-N08CB, MC11C4
<http://www.ncbi.nlm.nih.gov/pubmed/35267520>

2337 PDIGREE: An adaptive phase 3 trial of PD-inhibitor nivolumab and Ipilimumab (IPI-NIVO)

with VEGF TKI cabozantinib (CABO) in metastatic untreated RENal Cell CancEr (Alliance A031704)

Tian Zhang, Karla Ballman, Atish Choudhury, Ronald C. Chen, Colleen Watt, Yujia Wen, Ardaman Shergill, Tyler Zemla, Hamid Emamekhoo, Ulka Vaishampayan, Michael J. Morris, Daniel J. George, Toni K. Choueiri J Clin Oncol vol 39 (6_suppl) TPS366 2021

Abstract GU https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.6_suppl.TPS366

2338 PDIGREE: An adaptive phase 3 trial of PD-inhibitor nivolumab and Ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated RENal Cell CancEr (Alliance A031704)

Tian Zhang, Karla Ballman, Atish Choudhury, Ronald C. Chen, Colleen Watt, Yujia Wen, Ardaman Shergill, Tyler Zemla, Hamid Emamekhoo, Ulka Vaishampayan, Michael J. Morris, Daniel J. George, Toni K. Choueiri J Clin Oncol vol 38 (15_suppl) TPS5100 2020

Abstract GU https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.TPS5100

2339 PDIGREE: An adaptive phase 3 trial of PD-inhibitor nivolumab and Ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated RENal Cell CancEr (Alliance A031704)

Tian Zhang, Karla Ballman, Atish Choudhury, Ronald C. Chen, Colleen Watt, Yujia Wen, Tyler Zemla, Hamid Emamekhoo, Shilpa Gupta, Michael J. Morris, Daniel J. George, Toni K. Choueiri J Clin Oncol vol 37 (suppl) abstr TPS4596 2019

Abstract GU https://abstracts.asco.org/239/AbstView_239_257269.html

2340 PDIGREE: An adaptive phase 3 trial of PD-inhibitor nivolumab and Ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated RENal Cell CancEr (Alliance A031704)

Tian Zhang, Karla Ballman, Atish Choudhury, Ronald C. Chen, Colleen Watt, Yujia Wen, Tyler Zemla, Hamid Emamekhoo, Shilpa Gupta, Michael J. Morris, Daniel J. George, Toni K. Choueiri J Clin Oncol vol 39 (no. 6_suppl) TPS4596 2020

Abstract GU https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.TPS4596

2341 Predictive value of MAOB gene expression for targeted therapy in patients (pts) with metastatic colorectal cancer (mCRC) enrolled in CALGB/SWOG 80405 (Alliance)

Wu Zhang, Joshua Millstein, Yan Yang, Fang-Shu Ou, Federico Innocenti, Hiroyuki Arai, Shivani Soni, Sandra Algaze, Priya Jayachandran, Monica M. Bertagnolli, Howard S. Hochster, Donna Niedzwiecki, Richard M. Goldberg, Robert J. Mayer, Charles D. Blanke, Alan P. Venook, Omar Kabbarah, Francesca Battaglin, Heinz-Josef Lenz J Clin Oncol vol 40 (16_suppl) 3580-3580 2022

Abstract PPP CALGB-80405 https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.3580

2342 A Phase I/II Study of Bortezomib in Combination with Paclitaxel, Carboplatin and Concurrent Thoracic Radiation Therapy for Non-Small Cell Lung Cancer: NCCTG-N0321

Yujie Zhao, Nathan R. Foster, Jeffrey P. Meyers, Sachdev P. Thomas, Donald W. Northfelt, Kendrith M. Rowland, Bassam I. Mattar, David B. Johnson, Julian R. Molina, Sumithra J. Mandrekar, Steven E. Schild, James D. Bearden, Marie-Christine Aubry, Alex A. Adjei J Thorac Oncol vol 10 (1) 172-180 2015

Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/25247339>

2343 Venlafaxine to prevent oxaliplatin-induced neuropathy?: A pilot randomized placebo-controlled trial.

Collin Thomas Zimmerman, Pamela J. Atherton, Deirdre R. Pachman, Drew K. Seisler, Nina D. Wagner-Johnston, Shaker R. Dakhil, Jacqueline M. Lafky, Rui Qin, Axel Grothey, Charles L. Loprinzi J Clin Oncol vol 33 (suppl 15) e20734 2015

Abstract Symptom Inter <http://meetinglibrary.asco.org/content/143704-156>

2344 Venlafaxine to Prevent Oxaliplatin-Induced Neuropathy? A Pilot Randomized Placebo Controlled Trial

Collin Zimmerman, Pam Atherton, Deirdre Pachman, Drew Seisler, Nina Wagner-Johnston, Shaker

Dakhil, Jacqueline M Lafky, Rui Qin, Axel Grothey, Charles L Loprinzi Support Care Cancer vol 23 (suppl 1) S152 (abstract 112-106-P) 2015
Abstract Symptom Inter http://mascc2015.kenes.com/Documents/10.1007_s00520-015-2712-y.pdf

2345 MC11C4: a pilot randomized, placebo-controlled, double-blind study of venlafaxine to prevent oxaliplatin-induced neuropathy

Collin Zimmerman, Pamela J. Atherton, Deirdre Pachman, Drew Seisler, Nina Wagner-Johnston, Shaker Dakhil, Jacqueline M. Lafky, Rui Qin, Axel Grothey, Charles L. Loprinzi Support Care Cancer vol 24 (3) 1071-1078 2016
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/26248652>

2346 A Pooled Analysis of the Cardiac Events in the Trastuzumab Adjuvant Trials

Evandro de Azambuja, Noam Ponde, Marion Procter, Priya Rastogi, Reena Cecchini, Matteo Lambertini, Karla Ballman, Alvaro Moreno Aspitia, Dimitrios Zardavas, Lise Roca, Richard D. Gelber, Martine Piccart-Gebhart, Thomas Suter Breast Cancer Res Treat vol 179 (1) 161-71 2020
Manuscript Breast NCCTG-N9831 <http://www.ncbi.nlm.nih.gov/pubmed/31605311>

2347 Association Between Disease-Free Survival and Overall Survival When Survival Is Prolonged After Recurrence in Patients Receiving Cytotoxic Adjuvant Therapy for Colon Cancer: Simulations Based on the 20,800 Patient ACCENT Data Set

Aimery de Gramont, Joleen Hubbard, Qian Shi, Michael J. O'Connell, Marc Buyse, Jacqueline Benedetti, Brian Bot, Chris O'Callaghan, Greg Yothers, Richard M. Goldberg, Charles D. Blanke, Al Benson, Qiqi Deng, Steven R. Alberts, Thierry Andre, Norman Wolmark, Axel Grothey, Daniel Sargent J Clin Oncol vol 28 (3) 460-465 2010
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/20008641>